FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU Li, G
   Millard, SP
   Peskind, ER
   Zhang, J
   Yu, CE
   Leverenz, JB
   Mayer, C
   Shofer, JS
   Raskind, MA
   Quinn, JF
   Galasko, DR
   Montine, TJ
AF Li, Ge
   Millard, Steven P.
   Peskind, Elaine R.
   Zhang, Jing
   Yu, Chang-En
   Leverenz, James B.
   Mayer, Cynthia
   Shofer, Jane S.
   Raskind, Murray A.
   Quinn, Joseph F.
   Galasko, Douglas R.
   Montine, Thomas J.
TI Cross-Sectional and Longitudinal Relationships Between Cerebrospinal
   Fluid Biomarkers and Cognitive Function in People Without Cognitive
   Impairment From Across the Adult Life Span
SO JAMA NEUROLOGY
LA English
DT Article
ID ALZHEIMERS-DISEASE; OLDER-ADULTS; FOLLOW-UP; IN-VIVO; DECLINE; BRAIN;
   DEMENTIA; MODELS; MATTER; RATIO
AB IMPORTANCE Age-related cognitive decline among older individuals with normal cognition is a complex trait that potentially derives from processes of aging, inherited vulnerabilities, environmental factors, and common latent diseases that can progress to cause dementia, such as Alzheimer disease and vascular brain injury.
   OBJECTIVE To use cerebrospinal fluid (CSF) biomarkers to gain insight into this complex trait.
   DESIGN, SETTING, AND PARTICIPANTS Secondary analyses of an academic multicenter cross-sectional (n = 315) and longitudinal (n = 158) study of 5 neuropsychological tests (Immediate Recall, Delayed Recall, Trail Making Test Parts A and B, and Category Fluency) in cognitively normal individuals aged 21 to 100 years.
   MAIN OUTCOMES AND MEASURES To investigate the association of these cognitive function test results with age, sex, educational level, inheritance of the epsilon 4 allele of the apolipoprotein E gene, and CSF concentrations of beta-amyloid 42 (A beta 42) and tau (biomarkers of Alzheimer disease) as well as F-2-isoprostanes (measures of free radical injury).
   RESULTS Age and educational level were broadly predictive of cross-sectional cognitive performance; of the genetic and CSF measures, only greater CSF F-2-isoprostane concentration was significantly associated with poorer executive function (adjusted R-2 <= 0.31). Longitudinal measures of cognitive abilities, except Category Fluency, also were associated broadly with age; of the genetic and CSF measures, only lower baseline CSF A beta 42 concentration was associated with longitudinal measures of immediate and delayed recall (marginal R-2 <= 0.31).
   CONCLUSIONS AND RELEVANCE Our results suggest that age and educational level accounted for a substantial minority of variance in cross-sectional or longitudinal cognitive test performance in this large group of cognitively normal adults. Latent Alzheimer disease and other diseases that produce free radical injury, such as vascular brain injury, accounted for a small amount of variation in cognitive test performance across the adult human life span. Additional genetic and environmental factors likely contribute substantially to age-related cognitive decline.
C1 [Li, Ge; Peskind, Elaine R.; Leverenz, James B.; Shofer, Jane S.; Raskind, Murray A.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
   [Millard, Steven P.; Peskind, Elaine R.; Mayer, Cynthia; Raskind, Murray A.] VA Puget Sound Hlth Care Syst, Vet Affairs VA Northwest Network Mental Illness R, Seattle, WA USA.
   [Zhang, Jing; Montine, Thomas J.] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA.
   [Yu, Chang-En] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA.
   [Yu, Chang-En] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA.
   [Leverenz, James B.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA.
   [Quinn, Joseph F.] Oregon Hlth & Sci Univ, Sch Med, Dept Neurol, Portland, OR 97201 USA.
   [Quinn, Joseph F.] VA Parkinsons Dis Res Educ & Clin Ctr, Portland, OR USA.
   [Galasko, Douglas R.] Univ Calif San Diego, Sch Med, Dept Neurosci, La Jolla, CA 92093 USA.
RP Montine, TJ (reprint author), Univ Washington, Sch Med, Dept Pathol, POB 357470, Seattle, WA 98195 USA.
EM tmontine@uw.edu
FU National Institutes of Health [AG023185, AG031892, AG05131, AG05136,
   AG08017, AG033693, U01-NS082137]; Department of Veterans Affairs; Oregon
   Clinical and Translational Research Institute [UL1TR000128]; Jane and
   Lee Seidman Fund; Nancy and Buster Alvord Endowment
FX This work was supported by National Institutes of Health grants
   AG023185, AG031892, AG05131, AG05136, AG08017, AG033693, and
   U01-NS082137; the Department of Veterans Affairs; the Oregon Clinical
   and Translational Research Institute grant UL1TR000128; the Jane and Lee
   Seidman Fund; and the Nancy and Buster Alvord Endowment.
NR 46
TC 12
Z9 12
U1 1
U2 7
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6149
EI 2168-6157
J9 JAMA NEUROL
JI JAMA Neurol.
PD JUN
PY 2014
VL 71
IS 6
BP 742
EP 751
DI 10.1001/jamaneurol.2014.445
PG 10
WC Clinical Neurology
SC Neurosciences & Neurology
GA AN3IF
UT WOS:000340479800012
PM 24756381
ER

PT J
AU Possis, E
   Bui, T
   Gavian, M
   Leskela, J
   Linardatos, E
   Loughlin, J
   Strom, T
AF Possis, Elizabeth
   Bui, Thao
   Gavian, Margaret
   Leskela, Jennie
   Linardatos, Effie
   Loughlin, Jennifer
   Strom, Thad
TI Driving Difficulties Among Military Veterans: Clinical Needs and Current
   Intervention Status
SO MILITARY MEDICINE
LA English
DT Review
ID POSTTRAUMATIC-STRESS-DISORDER; VEHICLE ACCIDENT SURVIVORS; MENTAL-HEALTH
   PROBLEMS; RISK-TAKING BEHAVIORS; SENSATION-SEEKING;
   RESIDENTIAL-TREATMENT; VIETNAM VETERANS; ERA VETERANS; US VETERANS;
   GULF-WAR
AB Military personnel deployed to Iraq and Afghanistan often develop mental health difficulties, which may manifest as problematic driving behavior. Veterans may be more likely to engage in risky driving and to subsequently be involved in motor vehicle accidents and fatalities. This article reviews literature on driving difficulties among military veterans and evaluates available research on the potential pathways that underlie risky driving behavior. Current interventions for problematic driving behaviors are considered, and the necessity of modifying these interventions to address the unique difficulties encountered by military veterans is highlighted. The review concludes with a discussion of clinical implications of these findings and identification of possible avenues for future research and intervention.
C1 [Possis, Elizabeth; Leskela, Jennie; Strom, Thad] Minneapolis Vet Affairs Hlth Care Syst, Minneapolis, MN 55417 USA.
   [Bui, Thao] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
   [Gavian, Margaret] North Mem Med Ctr, Psychiat Partial Hosp Program, Robbinsdale, MN 55422 USA.
   [Linardatos, Effie] Geisel Sch Med Dartmouth, Dept Psychiat, Lebanon, NH 03756 USA.
   [Loughlin, Jennifer] Barrow Neurol Inst, Phoenix, AZ 85013 USA.
RP Possis, E (reprint author), Minneapolis Vet Affairs Hlth Care Syst, One Vet Dr 116A, Minneapolis, MN 55417 USA.
NR 58
TC 5
Z9 5
U1 1
U2 2
PU ASSOC MILITARY SURG US
PI BETHESDA
PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA
SN 0026-4075
EI 1930-613X
J9 MIL MED
JI Milit. Med.
PD JUN
PY 2014
VL 179
IS 6
BP 633
EP 639
DI 10.7205/MlLMED-D-13-00327
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA AN7UM
UT WOS:000340806500008
PM 24902130
ER

PT J
AU Chan, K
   Hernandez, L
   Yang, HD
   Goetz, MB
AF Chan, Kee
   Hernandez, Leilani
   Yang, Heidi
   Goetz, Matthew Bidwell
TI Comparative Cost Analysis of Clinical Reminder for HIV Testing at the
   Veterans Affairs Healthcare System
SO VALUE IN HEALTH
LA English
DT Article
DE AIDS; cost analysis; Veterans Affairs Healthcare System
ID STRATEGIES; SETTINGS; STATEMENT; RECEIPT; TRIAL
AB Objective: To estimate the cost and health outcomes associated with a new HIV testing strategy that utilizes routine-based clinical reminders. Methods: We conducted an economic analysis of 1) traditional pretest/post-test counseling; 2) counseling and a new clinical reminders system; and 3) only clinical reminder in the veterans' health care system. A payer perspective decision model was conducted to calculate the 1-year budget impact of three HIV testing strategies. Parameter values were obtained from the literature, including patients' probability of accepting test, and costs associated with HIV testing procedures. Deidentified patient data, including total population screened and number of new HIV cases, were collected from one clinic in Los Angeles, California, from August 2004 to December 2011. Annual total costs and costs per new case were calculated on the basis of parameter values and patient data Sensitivity analyses were conducted to evaluate the robustness of the critical variable on costs. Results: The total cost of the clinical reminder system with pretest counseling was $81,726 over 1 year compared with $109,208 for traditional HIV testing. Under a clinical reminder system with no pretest counseling, the number of HIV tests performed and the number of new diagnoses increased for that year. In addition, cost per new diagnoses was the lowest. Conclusions: The clinical reminder system can reduce the cost per cases identified and promote better performance of HIV testing compared with traditional HIV testing. The fundamental decision model can be used for hospital facilities outside the Veteran Affairs adopting a similar program for improving the HIV testing rate.
C1 [Chan, Kee; Hernandez, Leilani; Yang, Heidi] Boston Univ, Sargent Coll, Coll Hlth & Rehabil Sci, Dept Hlth Sci, Boston, MA 02215 USA.
   [Chan, Kee] Ctr Hlth Qual & Econ Res, Bedford, MA USA.
   [Goetz, Matthew Bidwell] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Infect Dis Sect, Los Angeles, CA 90095 USA.
   [Goetz, Matthew Bidwell] VA Greater Los Angeles Healthcare Syst, Dept Med, Infect Dis Sect, Los Angeles, CA USA.
RP Chan, K (reprint author), Boston Univ, Sargent Coll, Coll Hlth & Rehabil Sci, 635 Commonwealth Ave, Boston, MA 02215 USA.
EM keechan@bu.edu
OI Goetz, Matthew/0000-0003-4542-992X
NR 14
TC 1
Z9 1
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1098-3015
EI 1524-4733
J9 VALUE HEALTH
JI Value Health
PD JUN
PY 2014
VL 17
IS 4
BP 334
EP 339
DI 10.1016/j.jval.2014.03.001
PG 6
WC Economics; Health Care Sciences & Services; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA AO1ON
UT WOS:000341082900005
PM 24968992
ER

PT J
AU Mendez, MF
   Shapira, JS
AF Mendez, Mario F.
   Shapira, Jill S.
TI Kissing or "Osculation" in Frontotemporal Dementia
SO JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES
LA English
DT Article
ID KLUVER-BUCY-SYNDROME; TEMPORAL-LOBE EPILEPSY
AB The authors investigated the neuropsychiatry of kissing in frontotemporal dementia. Among 15 patients, two had compulsive social kissing, bitemporal involvement, and Kluver-Bucy symptoms, and four pursued kissing with sexually disinhibited behavior. Future research should clarify the neuropsychiatric significance of kissing behavior.
C1 [Mendez, Mario F.; Shapira, Jill S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90089 USA.
   [Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehavioral Sci, Los Angeles, CA USA.
   [Mendez, Mario F.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Mendez, MF (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90089 USA.
EM mmendez@ucla.edu
FU NIA [R01AG034499-03]
FX Supported by NIA grant # R01AG034499-03.
NR 12
TC 0
Z9 0
U1 0
U2 6
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 0895-0172
EI 1545-7222
J9 J NEUROPSYCH CLIN N
JI J. Neuropsychiatr. Clin. Neurosci.
PD SUM
PY 2014
VL 26
IS 3
BP 258
EP 261
PG 4
WC Clinical Neurology; Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA AN3ML
UT WOS:000340492100044
PM 24922478
ER

PT J
AU Byrd, JK
   Smith, KJ
   de Almeida, JR
   Albergotti, WG
   Davis, KS
   Kim, SW
   Johnson, JT
   Ferris, RL
   Duvvuri, U
AF Byrd, J. Kenneth
   Smith, Kenneth J.
   de Almeida, John R.
   Albergotti, W. Greer
   Davis, Kara S.
   Kim, Seungwon W.
   Johnson, Jonas T.
   Ferris, Robert L.
   Duvvuri, Umamaheswar
TI Transoral Robotic Surgery and the Unknown Primary: A Cost-Effectiveness
   Analysis
SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY
LA English
DT Article
DE transoral robotic surgery; TORS; occult primary; cost-effectiveness
   analysis
ID SQUAMOUS-CELL CARCINOMA; LYMPH-NODE METASTASES; PRIMARY TUMORS; RADICAL
   PROSTATECTOMY; EXTRACAPSULAR SPREAD; NECK; HEAD; TECHNOLOGY; MANAGEMENT;
   PARADIGM
AB Objective. To evaluate the cost-effectiveness of transoral robotic surgery (TORS) for the diagnosis and treatment of cervical unknown primary squamous cell carcinoma (CUP).
   Study Design. Case series with chart review.
   Setting. Tertiary academic hospital.
   Subjects and Methods. A retrospective chart review was performed on patients with new occult primary squamous cell carcinoma of the head and neck with nondiagnostic imaging and/or endoscopy who were treated with TORS at a tertiary hospital between 2009 and 2012. Direct costs were obtained from the hospital's billing system, and national data were used for inpatient hospital costs and physician fees. The proportion of tumors found in 3 strategies was used as effectiveness to calculate the incremental cost-effectiveness ratio.
   Results. In total, 206 head and neck robotic cases were performed at our institution between December 2009 and December 2012. Three surgeons performed TORS on 22 patients for occult primary squamous cell carcinoma. The primary tumor was located in 19 of 22 patients (86.4%). The incremental cost-effectiveness ratio for sequential and simultaneous examination under anesthesia with tonsillectomy (EUA) and TORS base of tongue resection was $8619 and $5774 per additional primary identified, respectively.
   Conclusion. Sequential EUA followed by TORS is associated with an incremental cost-effectiveness ratio of $8619 compared with traditional EUA alone. Bilateral base of tongue resection should be considered in the workup of these patients, particularly if the palatine tonsils have already been removed.
C1 [Byrd, J. Kenneth; Albergotti, W. Greer; Davis, Kara S.; Kim, Seungwon W.; Johnson, Jonas T.; Ferris, Robert L.; Duvvuri, Umamaheswar] Univ Pittsburgh, Med Ctr, Dept Otolaryngol, Pittsburgh, PA 15213 USA.
   [Smith, Kenneth J.] Univ Pittsburgh, Med Ctr, Dept Med, Pittsburgh, PA 15213 USA.
   [de Almeida, John R.] Univ Toronto, Dept Otolaryngol Head & Neck Surg, Toronto, ON, Canada.
   [Duvvuri, Umamaheswar] VA Pittsburgh Hlth Syst, Pittsburgh, PA USA.
RP Byrd, JK (reprint author), Univ Pittsburgh, Med Ctr, Dept Otolaryngol, 200 Lothrop St,Suite 500, Pittsburgh, PA 15213 USA.
EM byrdjk@upmc.edu
FU Department of Veterans Affairs
FX This work was supported in part by funds from the Department of Veterans
   Affairs; this work does not reflect the views of the U.S. government or
   the Department of Veterans Affairs.
NR 22
TC 17
Z9 17
U1 0
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0194-5998
EI 1097-6817
J9 OTOLARYNG HEAD NECK
JI Otolaryngol. Head Neck Surg.
PD JUN
PY 2014
VL 150
IS 6
BP 976
EP 982
DI 10.1177/0194599814525746
PG 7
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA AN2YC
UT WOS:000340451000014
PM 24618502
ER

PT J
AU Morgenroth, DC
   Medverd, JR
   Seyedali, M
   Czerniecki, JM
AF Morgenroth, David C.
   Medverd, Jonathan R.
   Seyedali, Mahyo
   Czerniecki, Joseph M.
TI The relationship between knee joint loading rate during walking and
   degenerative changes on magnetic resonance imaging
SO CLINICAL BIOMECHANICS
LA English
DT Article
DE Osteoarthritis; Knee; Gait
ID TRANS-TIBIAL AMPUTATION; ADDUCTION MOMENT; TIBIOFEMORAL OSTEOARTHRITIS;
   DISEASE SEVERITY; IN-VITRO; CARTILAGE; GAIT; BONE; IMPACT; STRENGTH
AB Background: While animal study and cadaveric study have demonstrated an association between knee joint loading rate and joint degeneration, the relationship between knee joint loading rate during walking and osteoarthritis has not yet been sufficiently studied in humans.
   Methods: Twenty-eight participants (14 transfemoral amputees and 14 age and body mass matched controls) underwent knee MRI with subsequent assessment using the semiquantitative Whole-Organ Magnetic Resonance Image Score. Each subject also underwent gait analysis in order to determine knee adduction moment loading rate, peak, and impulse and an exploratory measure, knee adduction moment rate * magnitude.
   Findings; Significant correlations were found between medial tibiofemoral joint degeneration and knee adduction moment peak (slope = 0.42 [SE 0.20]; P = .037), loading rate (slope = 12.3 [SE 3.2]; P = .0004), and rate * magnitude (slope = 437 [SE 100]; P < .0001). These relationships continued to be significant after adjusting for body mass or subject type. The relationship between medial knee semiquantitative MRI score and knee adduction moment loading rate and rate * magnitude continued to be significant even after adjusting for peak moment (P < .0001), however, the relationship between medial knee semiquantitative MRI score and peak moment was no longer significant after adjusting for either loading rate or rate * magnitude (P > .2 in both cases).
   Interpretation; This study suggests an independent relationship between knee adduction moment loading rate and medial tibiofemoral joint degeneration. Our results support the hypothesis that rate of loading, represented by the knee adduction moment loading rate, is strongly associated with medial tibiofemoral joint degeneration independent of knee adduction moment peak and impulse. Published by Elsevier Ltd.
C1 [Morgenroth, David C.; Seyedali, Mahyo; Czerniecki, Joseph M.] VAPSHCS, Dept Vet Affairs, Rehabil Res & Dev Ctr Excellence, Seattle, WA USA.
   [Medverd, Jonathan R.] VAPSHCS, Dept Vet Affairs, Dept Radiol, Seattle, WA USA.
   [Morgenroth, David C.; Czerniecki, Joseph M.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA.
   [Medverd, Jonathan R.] Univ Washington, Dept Radiol, Seattle, WA 98195 USA.
RP Morgenroth, DC (reprint author), VA Puget Sound Hlth Care Syst, RCS 117,1660 S Columbian Way, Seattle, WA 98108 USA.
EM dmorgen@uw.edu
FU U.S. Department of Veterans Affairs, Office of Research and Development
   (RRD Center) [A4843C]; National Institutes of Health (NIH) [K12
   HD001097]
FX This material is based on work supported in part by the U.S. Department
   of Veterans Affairs, Office of Research and Development (RR&D Center
   Grant A4843C). Additionally, David Morgenroth's work on this project was
   supported by the National Institutes of Health (NIH grant K12 HD001097).
   None of the authors have any conflicts of interest related to this work.
   The content is solely the responsibility of the authors and does not
   necessarily represent the official views of the National Institutes of
   Health.
NR 43
TC 7
Z9 7
U1 0
U2 9
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0268-0033
EI 1879-1271
J9 CLIN BIOMECH
JI Clin. Biomech.
PD JUN
PY 2014
VL 29
IS 6
BP 664
EP 670
DI 10.1016/j.clinbiomech.2014.04.008
PG 7
WC Engineering, Biomedical; Orthopedics; Sport Sciences
SC Engineering; Orthopedics; Sport Sciences
GA AN1KH
UT WOS:000340340700010
PM 24820134
ER

PT J
AU Soltis, K
   Acierno, R
   Gros, DF
   Yoder, M
   Tuerk, PW
AF Soltis, Kathryn
   Acierno, Ron
   Gros, Daniel F.
   Yoder, Matthew
   Tuerk, Peter W.
TI Post-Traumatic Stress Disorder: Ethical and Legal Relevance to the
   Criminal Justice System
SO JOURNAL OF LAW MEDICINE & ETHICS
LA English
DT Article
ID NATIONAL COMORBIDITY SURVEY; INTERNATIONAL CONSENSUS GROUP;
   COGNITIVE-PROCESSING THERAPY; MENTAL-HEALTH-SERVICES; PROLONGED
   EXPOSURE; PSYCHIATRIC-DISORDERS; MILITARY PERSONNEL; RISK-FACTORS; US
   VETERANS; GULF-WAR
C1 [Soltis, Kathryn] Med Univ S Carolina, Natl Crime Victims Res & Treatment Ctr, Charleston, SC 29425 USA.
   [Acierno, Ron; Tuerk, Peter W.] Ralph H Johnson VA Med Ctr, PTSD Clin Team, Charleston, SC USA.
   [Acierno, Ron] Med Univ S Carolina, Coll Nursing, Charleston, SC USA.
   [Gros, Daniel F.] Ralph H Johnson VAMC, Mental Hlth Primary Care Integrat Program, Charleston, SC USA.
   [Gros, Daniel F.; Yoder, Matthew; Tuerk, Peter W.] MUSC, Dept Psychiat & Behav Sci, Charleston, SC USA.
   [Yoder, Matthew] Ralph H Johnson Vet Affairs Med Ctr, Posttraumat Stress Clin, Charleston, SC USA.
   [Tuerk, Peter W.] APA Accredited MUSC VA Psychol Internship Program, Charleston, SC USA.
RP Soltis, K (reprint author), Med Univ S Carolina, Natl Crime Victims Res & Treatment Ctr, Charleston, SC 29425 USA.
NR 81
TC 2
Z9 2
U1 1
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1073-1105
EI 1748-720X
J9 J LAW MED ETHICS
JI J. Law Med. Ethics
PD SUM
PY 2014
VL 42
IS 2
SI SI
BP 147
EP 154
DI 10.1111/jlme.12130
PG 8
WC Ethics; Law; Medical Ethics; Medicine, Legal
SC Social Sciences - Other Topics; Government & Law; Medical Ethics; Legal
   Medicine
GA AM2XI
UT WOS:000339714400006
PM 25040378
ER

PT J
AU Hamner, MB
AF Hamner, Mark B.
TI The Role of PTSD in Adjudicating Violent Crimes
SO JOURNAL OF LAW MEDICINE & ETHICS
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; DOMESTIC VIOLENCE; ABUSE; PREVALENCE;
   VICTIMS
C1 [Hamner, Mark B.] Med Univ S Carolina, Charleston, SC 29425 USA.
   [Hamner, Mark B.] Ralph H Johnson VA Med Ctr, PTSD Clin, Charleston, SC USA.
   [Hamner, Mark B.] Amer Psychiat Assoc, Washington, DC 20005 USA.
RP Hamner, MB (reprint author), Med Univ S Carolina, Charleston, SC 29425 USA.
NR 19
TC 2
Z9 2
U1 1
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1073-1105
EI 1748-720X
J9 J LAW MED ETHICS
JI J. Law Med. Ethics
PD SUM
PY 2014
VL 42
IS 2
SI SI
BP 155
EP 160
DI 10.1111/jlme.12131
PG 6
WC Ethics; Law; Medical Ethics; Medicine, Legal
SC Social Sciences - Other Topics; Government & Law; Medical Ethics; Legal
   Medicine
GA AM2XI
UT WOS:000339714400007
PM 25040379
ER

PT J
AU Wangelin, BC
   Tuerk, PW
AF Wangelin, Bethany C.
   Tuerk, Peter W.
TI PTSD in Active Combat Soldiers: To Treat or Not to Treat
SO JOURNAL OF LAW MEDICINE & ETHICS
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; PROLONGED EXPOSURE THERAPY; OPERATION
   IRAQI FREEDOM; NATIONAL-GUARD SOLDIERS; HEALTH TREATMENT-SEEKING;
   MENTAL-HEALTH; PSYCHOLOGICAL SYMPTOMS; MARITAL SATISFACTION; TREATMENT
   SERVICES; VIETNAM VETERANS
C1 [Wangelin, Bethany C.; Tuerk, Peter W.] Ralph H Johnson VA Med Ctr, PTSD Clin Team, Charleston, SC 29401 USA.
   [Tuerk, Peter W.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC USA.
   [Tuerk, Peter W.] APA Accredited MUSC VA Psychol Internship Program, Charleston, SC USA.
RP Wangelin, BC (reprint author), Ralph H Johnson VA Med Ctr, PTSD Clin Team, Charleston, SC 29401 USA.
NR 81
TC 2
Z9 2
U1 1
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1073-1105
EI 1748-720X
J9 J LAW MED ETHICS
JI J. Law Med. Ethics
PD SUM
PY 2014
VL 42
IS 2
SI SI
BP 161
EP 170
DI 10.1111/jlme.12132
PG 10
WC Ethics; Law; Medical Ethics; Medicine, Legal
SC Social Sciences - Other Topics; Government & Law; Medical Ethics; Legal
   Medicine
GA AM2XI
UT WOS:000339714400008
PM 25040380
ER

PT J
AU Thase, ME
AF Thase, Michael E.
TI Combining Cognitive Therapy and Pharmacotherapy for Depressive
   Disorders: A Review of Recent Developments
SO INTERNATIONAL JOURNAL OF COGNITIVE THERAPY
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; BEHAVIORAL-ANALYSIS SYSTEM; MAJOR
   DEPRESSION; RECURRENT DEPRESSION; BIPOLAR DISORDER; CHRONIC FORMS;
   PSYCHOTHERAPY; MEDICATION; PREVENTION; NEFAZODONE
AB Cognitive Behavior Therapy (CBT) and pharmacotherapy, including antidepressants for depressive disorders and mood stabilizers for bipolar disorders, are effective and widely disseminated treatments that often are considered the first line of therapy for these common, yet potentially disabling conditions. Given the imperfect and often unpredictable effects of these treatments, as well as the obvious differences in the aspects of depressive syndromes that they target, there has been a longstanding and widespread belief that these strategies will have additive effects. After 30-plus years of research-and slow progress-it now seems reasonably clear that CBT and pharmacotherapy have a partially additive benefit for patients with depressive disorders; this effect is proposed to be largely explained by improving outcomes for patients who are less responsive to one or both of the monotherapies. This article summarizes the research literature, including newer studies that examining differential impact on neural circuits and the metabolic activity of relevant brain regions.
C1 [Thase, Michael E.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Thase, Michael E.] Univ Penn, Med Ctr, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
RP Thase, ME (reprint author), 3535 Market St,Suite 670, Philadelphia, PA 19104 USA.
EM thase@mail.med.upenn.edu
NR 38
TC 1
Z9 1
U1 1
U2 23
PU GUILFORD PUBLICATIONS INC
PI NEW YORK
PA 72 SPRING STREET, NEW YORK, NY 10012 USA
SN 1937-1209
EI 1937-1217
J9 INT J COGN THER
JI Int. J. Cogn. Ther.
PD JUN
PY 2014
VL 7
IS 2
BP 108
EP 121
PG 14
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA AM1NI
UT WOS:000339612800002
ER

PT J
AU Doran, KM
   Curry, LA
   Vashi, AA
   Platis, S
   Rowe, M
   Gang, M
   Vaca, FE
AF Doran, Kelly M.
   Curry, Leslie A.
   Vashi, Anita A.
   Platis, Stephanie
   Rowe, Michael
   Gang, Maureen
   Vaca, Federico E.
TI "Rewarding and Challenging at the Same Time": Emergency Medicine
   Residents' Experiences Caring for Patients Who Are Homeless
SO ACADEMIC EMERGENCY MEDICINE
LA English
DT Article
ID SAFETY-NET EMERGENCY; STUDENTS ATTITUDES; CARE; PEOPLE; URBAN;
   POPULATION; DEPARTMENTS; INTERVENTION; PHYSICIANS; LEARNERS
AB Objectives: The objectives were to examine how emergency medicine (EM) residents learn to care for patients in the emergency department (ED) who are homeless and how providing care for patients who are homeless influences residents' education and professional development as emergency physicians.
   Methods: We conducted in-depth, one-on-one interviews with EM residents from two programs. A random sample of residents stratified by training year was selected from each site. Interviews were digitally recorded and professionally transcribed. A team of researchers with diverse content-relevant expertise reviewed transcripts independently and applied codes to text segments using a grounded theory approach. The team met regularly to reconcile differences in code interpretations. Data collection and analysis occurred iteratively, and interviews continued until theoretical saturation was achieved.
   Results: Three recurring themes emerged from 23 resident interviews. First, residents learn unique aspects of EM by caring for patients who are homeless. This learning encompasses both specific knowledge and skills (e. g., disease processes infrequently seen in other populations) and professional development as an emergency physician (e. g., the core value of service in EM). Second, residents learn how to care for patients who are homeless through experience and informal teaching rather than through a formal curriculum. Residents noted little formal curricular time dedicated to homelessness and instead learned during clinical shifts through personal experience and by observing more senior physicians. One unique method of learning was through stories of "misses," in which patients who were homeless had bad outcomes. Third, caring for patients who are homeless affects residents emotionally in complex, multifaceted ways. Emotions were dominated by feelings of frustration. This frustration was often related to feelings of futility in truly helping homeless patients, particularly for patients who were frequent visitors to the ED and who had concomitant alcohol dependence.
   Conclusions: Caring for ED patients who are homeless is an important part of EM residency training. Our findings suggest the need for increased formal curricular time dedicated to the unique medical and social challenges inherent in treating patients who are homeless, as well as enhanced support and resources to improve the ability of residents to care for this vulnerable population. Future research is needed to determine if such interventions improve EM resident education and, ultimately, result in improved care for ED patients who are homeless. (C) 2014 by the Society for Academic Emergency Medicine
C1 [Doran, Kelly M.; Vashi, Anita A.] Yale Univ, Sch Med, Robert Wood Johnson Fdn Clin Scholars Program, New Haven, CT USA.
   [Doran, Kelly M.; Vashi, Anita A.] US Dept Vet Affairs, New Haven, CT USA.
   [Doran, Kelly M.; Vashi, Anita A.; Vaca, Federico E.] Yale Univ, Sch Med, Dept Emergency Med, New Haven, CT USA.
   [Curry, Leslie A.; Platis, Stephanie] Yale Univ, Sch Publ Hlth, New Haven, CT USA.
   [Curry, Leslie A.] Yale Univ, Sch Med, Robert Wood Johnson Fdn RWJF Clin Scholars Progra, New Haven, CT USA.
   [Rowe, Michael] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA.
   [Doran, Kelly M.; Gang, Maureen] NYU, Bellevue Hosp Ctr, Sch Med, Dept Emergency Med, New York, NY 10016 USA.
RP Doran, KM (reprint author), NYU, Bellevue Hosp Ctr, Sch Med, Dept Emergency Med, New York, NY 10016 USA.
EM kelly.doran@nyumc.org
FU RWJF; U.S. Department of Veterans Affairs through the RWJF Clinical
   Scholars Program
FX Financial support for this study was received from the RWJF and the U.S.
   Department of Veterans Affairs through the RWJF Clinical Scholars
   Program. The funder had no role in the study conduct or presentation of
   the results.
NR 44
TC 1
Z9 1
U1 1
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1069-6563
EI 1553-2712
J9 ACAD EMERG MED
JI Acad. Emerg. Med.
PD JUN
PY 2014
VL 21
IS 6
BP 673
EP 679
DI 10.1111/acem.12388
PG 7
WC Emergency Medicine
SC Emergency Medicine
GA AL5GR
UT WOS:000339162200009
PM 25039552
ER

PT J
AU Myaskovsky, L
   Pleis, J
   Dew, M
   Switzer, G
   Shapiro, R
AF Myaskovsky, L.
   Pleis, J.
   Dew, M.
   Switzer, G.
   Shapiro, R.
TI Race, Experience of Discrimination, and Other Non-Medical Factors
   Predict Differences in Acceptance for Kidney Transplantation.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Myaskovsky, L.; Pleis, J.; Switzer, G.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
   [Myaskovsky, L.; Pleis, J.; Dew, M.; Switzer, G.; Shapiro, R.] Univ Pittsburgh, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA B1197
BP 827
EP 827
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033303588
ER

PT J
AU Myaskovsky, L
   Pleis, J
   Ramkumar, M
   Langone, A
   Saha, S
   Thomas, C
AF Myaskovsky, L.
   Pleis, J.
   Ramkumar, M.
   Langone, A.
   Saha, S.
   Thomas, C.
TI Fewer Race Disparities in the National VA Kidney Transplant Program.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Myaskovsky, L.; Pleis, J.; Ramkumar, M.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
   [Myaskovsky, L.; Pleis, J.; Ramkumar, M.] Univ Pittsburgh, Pittsburgh, PA USA.
   [Langone, A.] VA Tennessee Valley Healthcare Syst, Nashville, TN USA.
   [Saha, S.] Portland VA Med Ctr, Portland, OR 97239 USA.
   [Thomas, C.] Iowa City VA Healthcare Syst, Iowa City, IA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA B1196
BP 827
EP 827
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033303587
ER

PT J
AU Stein, DJ
   McLaughlin, KA
   Koenen, KC
   Atwoli, L
   Friedman, MJ
   Hill, ED
   Maercker, A
   Petukhova, M
   Shahly, V
   van Ommeren, M
   Alonso, J
   Borges, G
   de Girolamo, G
   de Jonge, P
   Demyttenaere, K
   Florescu, S
   Karam, EG
   Kawakami, N
   Matschinger, H
   Okoliyski, M
   Posada-Villa, J
   Scott, KM
   Viana, MC
   Kessler, RC
AF Stein, Dan J.
   McLaughlin, Katie A.
   Koenen, Karestan C.
   Atwoli, Lukoye
   Friedman, Matthew J.
   Hill, Eric D.
   Maercker, Andreas
   Petukhova, Maria
   Shahly, Victoria
   van Ommeren, Mark
   Alonso, Jordi
   Borges, Guilherme
   de Girolamo, Giovanni
   de Jonge, Peter
   Demyttenaere, Koen
   Florescu, Silvia
   Karam, Elie G.
   Kawakami, Norito
   Matschinger, Herbert
   Okoliyski, Michail
   Posada-Villa, Jose
   Scott, Kate M.
   Viana, Maria Carmen
   Kessler, Ronald C.
TI DSM-5 AND ICD-11 DEFINITIONS OF POSTTRAUMATIC STRESS DISORDER:
   INVESTIGATING "NARROW" AND "BROAD" APPROACHES
SO DEPRESSION AND ANXIETY
LA English
DT Article
DE Posttraumatic stress disorder; World Mental Health Surveys;
   epidemiology; nosology; DSM-IV; DSM-5; ICD-10; ICD-11
ID CLINICAL-SIGNIFICANCE CRITERION; CONFIRMATORY FACTOR-ANALYSIS;
   MENTAL-HEALTH; FRIEDMAN 2013; PTSD; SYMPTOMS; IMPACT; CLASSIFICATION;
   COMORBIDITY; PROPOSALS
AB Background: The development of the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) and ICD-11 has led to reconsideration of diagnostic criteria for posttraumatic stress disorder (PTSD). The World Mental Health (WMH) Surveys allow investigation of the implications of the changing criteria compared to DSM-IV and ICD-10. Methods: WMH Surveys in 13 countries asked respondents to enumerate all their lifetime traumatic events (TEs) and randomly selected one TE per respondent for PTSD assessment. DSM-IV and ICD-10 PTSD were assessed for the 23,936 respondents who reported lifetime TEs in these surveys with the fully structured Composite International Diagnostic Interview (CIDI). DSM-5 and proposed ICD-11 criteria were approximated. Associations of the different criteria sets with indicators of clinical severity (distress-impairment, suicidality, comorbid fear-distress disorders, PTSD symptom duration) were examined to investigate the implications of using the different systems. Results: A total of 5.6% of respondents met criteria for "broadly defined" PTSD (i.e., full criteria in at least one diagnostic system), with prevalence ranging from 3.0% with DSM-5 to 4.4% with ICD-10. Only one-third of broadly defined cases met criteria in all four systems and another one third in only one system (narrowly defined cases). Between-system differences in indicators of clinical severity suggest that ICD-10 criteria are least strict and DSM-IV criteria most strict. The more striking result, though, is that significantly elevated indicators of clinical significance were found even for narrowly defined cases for each of the four diagnostic systems. Conclusions: These results argue for a broad definition of PTSD defined by any one of the different systems to capture all clinically significant cases of PTSD in future studies. Depression and Anxiety 31: 494-505, 2014. (C) 2014 Wiley Periodicals, Inc.
C1 [Stein, Dan J.] Univ Cape Town, Dept Psychiat & Mental Hlth, ZA-7925 Cape Town, South Africa.
   [McLaughlin, Katie A.] Univ Washington, Dept Psychol, Seattle, WA 98195 USA.
   [Koenen, Karestan C.] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA.
   [Atwoli, Lukoye] Moi Univ, Dept Psychiat, Eldoret, Kenya.
   [Friedman, Matthew J.] US Dept Vet Affairs, Natl Ctr PTSD, VA Med Ctr, White River Jct, VT USA.
   [Hill, Eric D.; Petukhova, Maria; Kessler, Ronald C.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA.
   [Maercker, Andreas; Shahly, Victoria] Univ Zurich, Dept Psychol, Div Psychopathol, CH-8006 Zurich, Switzerland.
   [van Ommeren, Mark] WHO, Dept Mental Hlth & Subst Abuse, CH-1211 Geneva, Switzerland.
   [Alonso, Jordi] Hosp Mar, IMIM, Hlth Serv Res Unit, Barcelona, Spain.
   [Alonso, Jordi] CIBER Epidemol & Salud Publ CIBERESP, Barcelona, Spain.
   [Borges, Guilherme] Natl Inst Psychiat Mexico, Dept Epidemiol Res, Div Epidemiol & Psychosocial Res, Mexico City, DF, Mexico.
   [Borges, Guilherme] Metropolitan Autonomous Univ, Mexico City, DF, Mexico.
   [de Girolamo, Giovanni] IRCCS Ctr S Giovanni Dio Fatebenefratelli, Brescia, Italy.
   [de Jonge, Peter] Univ Groningen, Univ Med Ctr Groningen, Dept Psychiat PdJ, NL-9713 AV Groningen, Netherlands.
   [Demyttenaere, Koen] Univ Hosp Gasthuisberg, Dept Psychiat, Leuven, Belgium.
   [Florescu, Silvia] Natl Sch Publ Hlth Management & Profess Dev, Hlth Serv Res & Evaluat Ctr, Bucharest, Romania.
   [Karam, Elie G.] Balamand Univ, St George Hosp Univ Med Ctr, Fac Med, IDRAAC,MIND, Beirut, Lebanon.
   [Kawakami, Norito] Univ Tokyo, Sch Publ Hlth, Dept Mental Hlth, Tokyo, Japan.
   [Matschinger, Herbert] Univ Leipzig, Inst Social Med Occupat Hlth & Publ Hlth, Publ Hlth Res Unit HM, D-04109 Leipzig, Germany.
   [Okoliyski, Michail] Minist Hlth, Natl Ctr Publ Hlth & Anal, Dept Mental Hlth, Sofia, Bulgaria.
   [Posada-Villa, Jose] Pontificia Univ Javeriana, Inst Colombiano Sistema Nervioso, Bogota, Colombia.
   [Scott, Kate M.] Univ Otago, Dept Psychol Med, Dunedin, New Zealand.
   [Viana, Maria Carmen] Univ Fed Espirito Santo, Dept Social Med, Vitoria, Brazil.
RP Stein, DJ (reprint author), Univ Cape Town, Groote Schuur Hosp, Dept Psychiat, J2,Anzio Rd, ZA-7925 Cape Town, South Africa.
EM dan.stein@uct.ac.za
RI Stein, Dan/A-1752-2008; Alonso, Jordi/A-5514-2010
OI Stein, Dan/0000-0001-7218-7810; Alonso, Jordi/0000-0001-8627-9636;
   Borges, Guilherme/0000-0002-3269-0507; Atwoli,
   Lukoye/0000-0001-7710-9723; McLaughlin, Katie/0000-0002-1362-2410
FU United States National Institute of Mental Health [R01MH070884]; John D.
   and Catherine T. MacArthur Foundation; Pfizer Foundation; US Public
   Health Service [R13-MH066849, R01-MH069864, R01-MH092526, R01-DA016558];
   Fogarty International Center [FIRCA R03-TW006481]; Pan American Health
   Organization; Eli Lilly & Company Foundation; Ortho-McNeil
   Pharmaceutical, Inc.; GlaxoSmithKline; Bristol-Myers Squibb; Shire
   Pharmaceuticals; State of Sao Paulo Research Foundation (FAPESP)
   [03/00204-3]; European Commission [QLG5-1999-01042, SANCO 2004123];
   Piedmont Region; Fondo de Investigacion Sanitaria; Instituto de Salud
   Carlos III [FIS 00/0028, CIBER CB06/02/0046, RETICS RD06/0011 REM-TAP];
   Ministerio de Ciencia y Tecnologia, Spain [SAF 2000-158-CE]; Departament
   de Salut, Generalitat de Catalunya; Japan Ministry of Health, Labour and
   Welfare [H13-SHOGAI-023, H14-TOKUBETSU-026, H16-KOKORO-013]; National
   Institute of Health/Fogarty International Center [R03 TW006481-01];
   Astra Zeneca; Hikma Pharm; Janssen Cilag; MSD; Novartis; Sanofi Aventis;
   Servier; National Institute of Psychiatry Ramon de la Fuente [INPRFMDIES
   4280]; National Council on Science and Technology [CONACyT-G30544-H];
   Health & Social Care Research & Development Division; Champalimaud
   Foundation; Gulbenkian Foundation; Foundation for Science and Technology
   (FCT); Ministry of Health; Ministry of Public Health; National Institute
   of Mental Health (NIMH) [U01-MH60220]
FX Contract grant sponsor: United States National Institute of Mental
   Health; Contract grant number: R01MH070884; Contract grant sponsor: John
   D. and Catherine T. MacArthur Foundation; Contract grant sponsor: The
   Pfizer Foundation; Contract grant sponsor: The US Public Health Service;
   Contract grant numbers: R13-MH066849, R01-MH069864, R01-MH092526, and
   R01-DA016558; Contract grant sponsor: Fogarty International Center;
   Contract grant number: FIRCA R03-TW006481; Contract grant sponsor: The
   Pan American Health Organization; Contract grant sponsor: the Eli Lilly
   & Company Foundation; Contract grant sponsor: Ortho-McNeil
   Pharmaceutical, Inc.; Contract grant sponsor: GlaxoSmithKline; Contract
   grant sponsor: Bristol-Myers Squibb; Contract grant sponsor: Shire
   Pharmaceuticals; Contract grant sponsor: State of Sao Paulo Research
   Foundation (FAPESP) Thematic Project; Contract grant number: 03/00204-3;
   Contract grant sponsor: European Commission; Contract grant numbers:
   QLG5-1999-01042 and SANCO 2004123; Contract grant sponsor: The Piedmont
   Region; Contract grant sponsor: Fondo de Investigacion Sanitaria;
   Contract grant sponsor: Instituto de Salud Carlos III; Contract grant
   number: FIS 00/0028; Contract grant sponsor: Ministerio de Ciencia y
   Tecnologia, Spain; Contract grant number: SAF 2000-158-CE; Contract
   grant sponsor: Departament de Salut, Generalitat de Catalunya; Contract
   grant sponsor: Instituto de Salud Carlos III; Contract grant numbers:
   CIBER CB06/02/0046 and RETICS RD06/0011 REM-TAP; Contract grant sponsor:
   Japan Ministry of Health, Labour and Welfare; Contract grant numbers:
   H13-SHOGAI-023, H14-TOKUBETSU-026, and H16-KOKORO-013; Contract grant
   sponsor: National Institute of Health/Fogarty International Center;
   Contract grant number: R03 TW006481-01; Contract grant sponsor: Astra
   Zeneca; Contract grant sponsor: Hikma Pharm; Contract grant sponsor:
   Janssen Cilag; Contract grant sponsor: MSD; Contract grant sponsor:
   Novartis; Contract grant sponsor: Sanofi Aventis; Contract grant
   sponsor: Servier; Contract grant sponsor: The National Institute of
   Psychiatry Ramon de la Fuente; Contract grant number: INPRFMDIES 4280;
   Contract grant sponsor: National Council on Science and Technology;
   Contract grant number: CONACyT-G30544-H; Contract grant sponsor: Health
   & Social Care Research & Development Division; Contract grant sponsor:
   Champalimaud Foundation; Contract grant sponsor: Gulbenkian Foundation;
   Contract grant sponsor: Foundation for Science and Technology (FCT);
   Contract grant sponsor: Ministry of Health; Contract grant sponsor:
   Ministry of Public Health (former Ministry of Health); Contract grant
   sponsor: National Institute of Mental Health (NIMH); Contract grant
   number: U01-MH60220.
NR 40
TC 32
Z9 32
U1 1
U2 37
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1091-4269
EI 1520-6394
J9 DEPRESS ANXIETY
JI Depress. Anxiety
PD JUN
PY 2014
VL 31
IS 6
BP 494
EP 505
DI 10.1002/da.22279
PG 12
WC Psychology, Clinical; Psychiatry; Psychology
SC Psychology; Psychiatry
GA AL3XZ
UT WOS:000339066600005
PM 24894802
ER

PT J
AU Glick, AR
   Khan, IA
   Sher, L
AF Glick, Amy R.
   Khan, Imran A.
   Sher, Leo
TI Treatment of Antipsychotic-Induced Sialorrhea
SO PSYCHIATRIC ANNALS
LA English
DT Editorial Material
ID CLOZAPINE-INDUCED SIALORRHEA; STRATEGIES
C1 [Glick, Amy R.; Sher, Leo] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
   [Khan, Imran A.; Sher, Leo] James J Peters VA Med Ctr, New York, NY USA.
RP Glick, AR (reprint author), Icahn Sch Med Mt Sinai, One Gustave L Levy Pl, New York, NY 10029 USA.
EM amy.glick@mountsinai.org
NR 10
TC 0
Z9 0
U1 0
U2 3
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 0048-5713
EI 1938-2456
J9 PSYCHIAT ANN
JI Psychiatr. Ann.
PD JUN
PY 2014
VL 44
IS 6
BP 267
EP 269
DI 10.3928/00485713-20140609-02
PG 3
WC Psychiatry
SC Psychiatry
GA AL0PB
UT WOS:000338827700002
ER

PT J
AU Varghese, M
   Ho, L
   Wang, J
   Zhao, W
   Levine, S
   Ono, K
   Mannino, S
   Pasinetti, GM
AF Varghese, Merina
   Ho, Lap
   Wang, Jun
   Zhao, Wei
   Levine, Samara
   Ono, Kenjiro
   Mannino, Salvatore
   Pasinetti, Giulio Maria
TI Green coffee as a novel agent for Alzheimer's disease prevention by
   attenuating diabetes
SO TRANSLATIONAL NEUROSCIENCE
LA English
DT Article
DE Coffee; Alzheimer's disease; Diabetes; Diabetes type 2; Brain; Energy
   metabolism
ID INDUCED INSULIN-RESISTANCE; AMYLOID-BETA LEVELS; COGNITIVE IMPAIRMENT;
   DECAFFEINATED COFFEE; CHLOROGENIC ACID; MOUSE MODEL; CAFFEINE; MICE;
   RISK; CONSUMPTION
AB Diabetes type 2, caused mainly by insulin resistance, is growing in incidence worldwide. In addition to being a major public health concern, type 2 diabetes is also a risk factor for dementia, including Alzheimer's disease type dementia. Coffee consumption is reported to have protective effects in both diabetes and Alzheimer's disease. We review here the reported beneficial effects of coffee in both disease conditions and the previously identified active ingredients of coffee. Furthermore, we revisit our recent findings of improved glucose utilization in the periphery and in the brain in a mouse model of high-fat diet induced type 2 diabetes after treatment with a decaffeinated green coffee preparation. Overall, consumption of coffee appears to improve diabetes and reduce the risk of dementia, although future studies are required to further identify the active components and the type of coffee that is most effective in addressing these conditions.
C1 [Varghese, Merina; Ho, Lap; Wang, Jun; Zhao, Wei; Levine, Samara; Pasinetti, Giulio Maria] Mt Sinai Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA.
   [Ho, Lap; Wang, Jun; Zhao, Wei; Pasinetti, Giulio Maria] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY 10468 USA.
   [Ono, Kenjiro] Kanazawa Univ, Grad Sch Med Sci, Dept Neurol & Neurobiol & Aging, Kanazawa, Ishikawa 9209640, Japan.
   [Mannino, Salvatore] Osped Alzano, Geriatr Output Unit, Bergamo, Italy.
RP Varghese, M (reprint author), Mt Sinai Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA.
EM giulio.pasinetti@mssm.edu
OI Varghese, Merina/0000-0002-1517-3903
NR 44
TC 3
Z9 3
U1 3
U2 20
PU DE GRUYTER OPEN LTD
PI WARSAW
PA SOLIPSKA 14A-1, 02-482 WARSAW, POLAND
SN 2081-3856
EI 2081-6936
J9 TRANSL NEUROSCI
JI Transl. Neurosci.
PD JUN
PY 2014
VL 5
IS 2
BP 111
EP 116
DI 10.2478/s13380-014-0213-y
PG 6
WC Neurosciences
SC Neurosciences & Neurology
GA AK8AV
UT WOS:000338650400001
ER

PT J
AU Scott, JC
   Pietrzak, RH
   Southwick, SM
   Jordan, J
   Silliker, N
   Brandt, CA
   Haskell, SG
AF Scott, J. Cobb
   Pietrzak, Robert H.
   Southwick, Steven M.
   Jordan, Jessica
   Silliker, Norman
   Brandt, Cynthia A.
   Haskell, Sally G.
TI Military Sexual Trauma Interacts With Combat Exposure to Increase Risk
   for Posttraumatic Stress Symptomatology in Female Iraq and Afghanistan
   Veterans
SO JOURNAL OF CLINICAL PSYCHIATRY
LA English
DT Article
ID MALE VIETNAM VETERANS; MENTAL-HEALTH; GENDER-DIFFERENCES; NATIONAL
   SAMPLE; WOMEN VETERANS; CHILD-ABUSE; LIFE EVENTS; GULF-WAR; DISORDER;
   SYMPTOMS
AB Objective: Sexual trauma during military service is increasingly recognized as a substantial public health problem and is associated with detrimental effects on veteran mental health. In this study, we examined associations between childhood trauma, military sexual trauma (MST), combat exposure, and military-related posttraumatic stress symptomatology (PTSS) in the Women Veterans Cohort Study (WVCS), a community-based sample of veterans who served in the recent conflicts in Iraq and Afghanistan.
   Method: From July 2008 to December 2011, 365 female veterans completed a survey that assessed combat exposure, military sexual trauma, military-related PTSS (assessed using the PTSD [posttraumatic stress disorder] Checklist-Military Version), and demographic, life history, and other psychopathology variables.
   Results: High rates of childhood trauma (59.7%) and MST (sexual assault = 14.7%; sexual harassment = 34.8%) were observed in this sample. A hierarchical regression revealed that active duty status, childhood trauma, combat exposure, and MST were independently associated with increased severity of military-related PTSS (Ps < .05). Moreover, a significant interaction emerged between MST and combat exposure in predicting military-related PTSS (P = .030), suggesting that the relationship between combat exposure and PTSS was altered by MST status. Specifically, under conditions of high combat exposure, female veterans with MST had significantly higher PTSS compared to female veterans without MST.
   Conclusions: Taken together, results suggest that exposure to multiple traumas during military service may have synergistic effects on posttraumatic stress symptoms in female veterans. Moreover, our findings highlight the importance of prevention efforts to protect female veterans from the detrimental effects of MST, particularly those who are exposed to high levels of combat. (C) Copyright 2014 Physicians Postgraduate Press, Inc.
C1 [Scott, J. Cobb; Pietrzak, Robert H.; Southwick, Steven M.; Jordan, Jessica] VA Connecticut Healthcare Syst, Clin Neurosci Div, Natl Ctr Posttraumat Stress Disorder, West Haven, CT USA.
   [Scott, J. Cobb; Pietrzak, Robert H.; Southwick, Steven M.; Jordan, Jessica] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA.
   [Scott, J. Cobb] Philadelphia VA Med Ctr, Vet Integrated Serv Network VISN, Mental Illness Res Educ & Clin Ctr MIRECC 4, Philadelphia, PA 19104 USA.
   [Silliker, Norman; Brandt, Cynthia A.; Haskell, Sally G.] VA Connecticut Healthcare Syst, West Haven, CT USA.
   [Brandt, Cynthia A.] Dept Emergency Med, New Haven, CT USA.
   [Brandt, Cynthia A.] Yale Ctr Med Informat, New Haven, CT USA.
   [Haskell, Sally G.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA.
RP Scott, JC (reprint author), Philadelphia VA Med Ctr, MIRECC 116,3900 Woodland Ave, Philadelphia, PA 19104 USA.
EM scott1@mail.med.upenn.edu
FU Veterans Administration (VA) Health Services Research and Development
   Service (HSRD) [DHI07-065]; Clinical Neurosciences Division of the
   National Center for Posttraumatic Stress Disorder; VA Clinical Science &
   Research Developmental Award [IK2 CX000772]
FX Funding for this study was provided by Veterans Administration (VA)
   Health Services Research and Development Service (HSR&D) grant
   #DHI07-065 to Drs Haskell and Brandt. Preparation of this report was
   also supported in part by the Clinical Neurosciences Division of the
   National Center for Posttraumatic Stress Disorder and a VA Clinical
   Science & Research Developmental Award (IK2 CX000772) to Dr Scott.
NR 64
TC 12
Z9 12
U1 3
U2 29
PU PHYSICIANS POSTGRADUATE PRESS
PI MEMPHIS
PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA
SN 0160-6689
EI 1555-2101
J9 J CLIN PSYCHIAT
JI J. Clin. Psychiatry
PD JUN
PY 2014
VL 75
IS 6
BP 637
EP 643
DI 10.4088/JCP.13m08808
PG 7
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA AK5IO
UT WOS:000338458200015
ER

PT J
AU Kagan, VE
   Kapralov, AA
   St Croix, CM
   Watkins, SC
   Kisin, ER
   Kotchey, GP
   Balasubramanian, K
   Vlasova, II
   Yu, J
   Kim, K
   Seo, W
   MallampaIli, RK
   Star, A
   Shvedova, AA
AF Kagan, Valerian E.
   Kapralov, Alexandr A.
   St Croix, Claudette M.
   Watkins, Simon C.
   Kisin, Elena R.
   Kotchey, Gregg P.
   Balasubramanian, Krishnakumar
   Vlasova, Irina I.
   Yu, Jaesok
   Kim, Kang
   Seo, Wanji
   MallampaIli, Rama K.
   Star, Alexander
   Shvedova, Anna A.
TI Lung Macrophages "Digest" Carbon Nanotubes Using a
   Superoxide/Peroxynitrite Oxidative Pathway
SO ACS NANO
LA English
DT Article
DE single-walled carbon nanotubes; peroxynitrite; biodegradation; lung
ID DARK-FIELD MICROSCOPY; IN-VIVO; NITRIC-OXIDE; PULMONARY INFLAMMATION;
   REACTIVE OXYGEN; PEROXYNITRITE; CELLS; NANOPARTICLES; NANOMATERIALS;
   NEUTROPHILS
AB In contrast to short-lived neutrophils, macrophages display persistent presence in the lung of animals after pulmonary exposure to carbon nanotubes. While effective in the clearance of bacterial pathogens and injured host cells, the ability of macrophages to "digest" carbonaceous nanoparticles has not been documented. Here, we used chemical, biochemical, and cell and animal models and demonstrated oxidative biodegradation of oxidatively functionalized single-walled carbon nanotubes via superoxide/NO* -> peroxynitrite-driven oxidative pathways of activated macrophages facilitating clearance of nanoparticles from the lung.
C1 [Kagan, Valerian E.; Kapralov, Alexandr A.; Balasubramanian, Krishnakumar; Vlasova, Irina I.] Univ Pittsburgh, Ctr Free Rad & Antioxidant Hlth, Pittsburgh, PA 15260 USA.
   [MallampaIli, Rama K.] Univ Pittsburgh, Acute Lung Injury Ctr Excellence, Pittsburgh, PA USA.
   [Kagan, Valerian E.; Kapralov, Alexandr A.; St Croix, Claudette M.; Balasubramanian, Krishnakumar; Vlasova, Irina I.] Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA USA.
   [Watkins, Simon C.] Univ Pittsburgh, Dept Physiol & Cell Biol, Pittsburgh, PA USA.
   [Kotchey, Gregg P.; Seo, Wanji; Star, Alexander] Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15260 USA.
   [Yu, Jaesok; Kim, Kang; MallampaIli, Rama K.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.
   [MallampaIli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA USA.
   [Shvedova, Anna A.] NIOSH, Pathol & Physiol Res Branch, Hlth Effects Lab Div, Morgantown, WV USA.
   [Vlasova, Irina I.] Res Inst Physicochem Med, Moscow 119495, Russia.
RP Kagan, VE (reprint author), Univ Pittsburgh, Ctr Free Rad & Antioxidant Hlth, Pittsburgh, PA 15260 USA.
EM kagan@pitt.edu
OI Kapralov, Oleksandr/0000-0002-3006-916X
FU National Institute for Occupational Safety and Health (NIOSH)
   [OH008282]; National Institutes of Health, NIEHS [R01ES019304,
   U19AI068021, PO1HL114453]; RFBR [12-04-01293]; EPA STAR Graduate
   Fellowship [FP-91713801]
FX This work was supported by the National Institute for Occupational
   Safety and Health (NIOSH), OH008282, and National Institutes of Health,
   NIEHS R01ES019304, U19AI068021, PO1HL114453, and RFBR 12-04-01293.
   G.P.K. acknowledges an EPA STAR Graduate Fellowship, FP-91713801.
NR 50
TC 46
Z9 46
U1 0
U2 26
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936-0851
EI 1936-086X
J9 ACS NANO
JI ACS Nano
PD JUN
PY 2014
VL 8
IS 6
BP 5610
EP 5621
DI 10.1021/nn406484b
PG 12
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA AK0FV
UT WOS:000338089200025
PM 24871084
ER

PT J
AU Shore, S
   Carey, EP
   Turakhia, MP
   Jackevicius, CA
   Cunningham, F
   Pilote, L
   Bradley, SM
   Maddox, TM
   Grunwald, GK
   Baron, AE
   Rumsfeld, JS
   Varosy, PD
   Schneider, PM
   Marzec, LN
   Ho, PM
AF Shore, Supriya
   Carey, Evan P.
   Turakhia, Mintu P.
   Jackevicius, Cynthia A.
   Cunningham, Fran
   Pilote, Louise
   Bradley, Steven M.
   Maddox, Thomas M.
   Grunwald, Gary K.
   Baron, Anna E.
   Rumsfeld, John S.
   Varosy, Paul D.
   Schneider, Preston M.
   Marzec, Lucas N.
   Ho, P. Michael
TI Adherence to dabigatran therapy and longitudinal patient outcomes:
   Insights from the Veterans Health Administration
SO AMERICAN HEART JOURNAL
LA English
DT Article
ID ATRIAL-FIBRILLATION; ANTITHROMBOTIC TREATMENT; MEDICATION ADHERENCE;
   CLINICAL-PRACTICE; WARFARIN; ANTICOAGULATION; ETEXILATE; CARE;
   UNDERTREATMENT; CHALLENGES
AB Background Dabigatran is a novel oral anti-coagulant (NOAC) that reduces risk of stroke in patients with non-valvular atrial fibrillation (NVAF). It does not require routine monitoring with laboratory testing which may have an adverse impact on adherence. We aimed to describe adherence to dabigatran in the first year after initiation and assess the association between non-adherence to dabigatran and clinical outcomes in a large integrated healthcare system.
   Methods We studied a national cohort of 5,376 patients with NVAF, initiated on dabigatran between October-2010 and September-2012 at all Veterans Affairs hospitals. Adherence to dabigatran was calculated as proportion of days covered (PDC) and association between PDC and outcomes was assessed using standard regression techniques.
   Results Mean age of the study cohort was 71.3 +/- 9.7 years; 98.3% were men and mean CHADS(2) score was 2.4 +/- 1.2 (mean CHA(2)DS(2)VASc score 3.2 +/- 1.4). Median PDC was 94% (IQR 76%-100%; mean PDC 84% +/- 22%) over a median follow-up of 244 days (IQR 140-351). A total of 1,494 (27.8%) patients had a PDC <80% and were classified as non-adherent. After multivariable adjustment, lower adherence was associated with increased risk for combined all-cause mortality and stroke (HR 1.13, 95% CI 1.07-1.19 per 10% decrease in PDC). Adherence to dabigatran was not associated with non-fatal bleeding or myocardial infarction.
   Conclusions In the year after initiation, adherence to dabigatran for a majority of patients is very good. However, 28% of patients in our cohort had poor adherence. Furthermore, lower adherence to dabigatran was associated with increased adverse outcomes. Concerted efforts are needed to optimize adherence to NOACs.
C1 [Shore, Supriya; Carey, Evan P.; Bradley, Steven M.; Maddox, Thomas M.; Grunwald, Gary K.; Rumsfeld, John S.; Varosy, Paul D.; Schneider, Preston M.; Marzec, Lucas N.; Ho, P. Michael] Vet Affairs Eastern Colorado Hlth Care Syst, Denver, CO USA.
   [Shore, Supriya; Bradley, Steven M.; Maddox, Thomas M.; Rumsfeld, John S.; Varosy, Paul D.; Schneider, Preston M.; Marzec, Lucas N.; Ho, P. Michael] Univ Colorado, Sch Med, Aurora, CO USA.
   [Shore, Supriya; Carey, Evan P.; Bradley, Steven M.; Maddox, Thomas M.; Rumsfeld, John S.; Varosy, Paul D.; Schneider, Preston M.; Marzec, Lucas N.; Ho, P. Michael] Colorado Cardiovasc Outcomes Res Consortium, Denver, CO USA.
   [Carey, Evan P.; Grunwald, Gary K.; Baron, Anna E.] Univ Colorado, Sch Publ Hlth, Aurora, CO USA.
   [Turakhia, Mintu P.] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA.
   [Turakhia, Mintu P.] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
   [Jackevicius, Cynthia A.] Vet Affairs Greater Angeles Hlth Care Syst, Los Angeles, CA USA.
   [Jackevicius, Cynthia A.] Western Univ Hlth Sci, Pomona, CA USA.
   [Cunningham, Fran] US Dept Vet Affairs, Pharm Benefits Management Serv, Hines, IL USA.
   [Cunningham, Fran] Ctr Medicat Safety, Hines, IL USA.
   [Pilote, Louise] McGill Univ, Ctr Hlth, Montreal, PQ, Canada.
RP Ho, PM (reprint author), VA Eastern Colorado Hlth Care Syst, Cardiol Sect, 111B,1055 Clermont St, Denver, CO 80220 USA.
EM michael.ho@va.gov
FU NHLBI NIH HHS [T32 HL007822]
NR 28
TC 49
Z9 49
U1 0
U2 11
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-8703
EI 1097-5330
J9 AM HEART J
JI Am. Heart J.
PD JUN
PY 2014
VL 167
IS 6
BP 810
EP 817
DI 10.1016/j.ahj.2014.03.023
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AK3US
UT WOS:000338350800009
PM 24890529
ER

PT J
AU Sacks, GD
   Diggs, BS
   Hadjizacharia, P
   Green, D
   Salim, A
   Malinoski, DJ
AF Sacks, Greg D.
   Diggs, Brian S.
   Hadjizacharia, Pantelis
   Green, Donald
   Salim, Ali
   Malinoski, Darren J.
TI Reducing the rate of catheter-associated bloodstream infections in a
   surgical intensive care unit using the Institute for Healthcare
   Improvement central line bundle
SO AMERICAN JOURNAL OF SURGERY
LA English
DT Article
DE Catheter-associated line infections; Infection control; Central venous
   catheters; Quality improvement; Healthcare cost; Checklist
ID PRACTICE GUIDELINES; PREVENTION; QUALITY
AB BACKGROUND: Central line-associated bloodstream infections (CLABSIs) are a significant source of morbidity and mortality. This study sought to determine whether implementation of the Institute for Healthcare Improvement (IHI) Central Line Bundle would reduce the incidence of CLABSIs.
   METHODS: The IHI Central Line Bundle was implemented in a surgical intensive care unit. Patient demographics and the rate of CLABSIs per 1,000 catheter days were compared between the pre- and postintervention groups. Contemporaneous infection rates in an adjacent ICU were measured.
   RESULTS: Baseline demographics were similar between the pre- and postintervention groups. The rate of CLABSIs per catheter days decreased from 19/3,784 to 3/1,870 after implementation of the IHI Bundle (1.60 vs 5.02 CLABSIs per 1,000 catheter days; rate ratio .32 [.08 to .99, P < .05]). There was no significant change in CLABSIs in the control ICU.
   CONCLUSIONS: Implementation of the IHI Central Line Bundle reduced the incidence of CLABSIs in our SICU by 68%, preventing 12 CLABSIs, 2.5 deaths, and saving $198,600 annually. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Sacks, Greg D.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA.
   [Diggs, Brian S.; Malinoski, Darren J.] Oregon Hlth & Sci Univ, Dept Surg, Portland, OR 97201 USA.
   [Hadjizacharia, Pantelis; Green, Donald] Univ Arizona, Dept Surg, Tucson, AZ USA.
   [Salim, Ali] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA.
   [Malinoski, Darren J.] Portland VA Med Ctr, Sect Surg Crit Care, Portland, OR USA.
RP Malinoski, DJ (reprint author), Oregon Hlth & Sci Univ, Dept Surg, Portland, OR 97201 USA.
EM darren.malinoski@va.gov
NR 24
TC 15
Z9 16
U1 0
U2 8
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9610
EI 1879-1883
J9 AM J SURG
JI Am. J. Surg.
PD JUN
PY 2014
VL 207
IS 6
BP 817
EP 823
DI 10.1016/j.amjsurg.2013.08.041
PG 7
WC Surgery
SC Surgery
GA AK5BY
UT WOS:000338440100003
PM 24576582
ER

PT J
AU Donnelly, J
   Wang, H
   Locke, J
   Mannon, R
   Baddley, J
AF Donnelly, J.
   Wang, H.
   Locke, J.
   Mannon, R.
   Baddley, J.
TI Healthcare Facility-Associated Clostridium difficile Infection in Solid
   Organ Transplant Recipients
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Donnelly, J.; Wang, H.] Univ Alabama Birmingham, Dept Emergency Med, Birmingham, AL USA.
   [Locke, J.] Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA.
   [Mannon, R.; Baddley, J.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
   [Baddley, J.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA D2397
BP 772
EP 772
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033303405
ER

PT J
AU Hebert, PL
   Liu, CF
   Wong, ES
   Hernandez, SE
   Batten, A
   Lo, S
   Lemon, JM
   Conrad, DA
   Grembowski, D
   Nelson, K
   Fihn, SD
AF Hebert, Paul L.
   Liu, Chuan-Fen
   Wong, Edwin S.
   Hernandez, Susan E.
   Batten, Adam
   Lo, Sophie
   Lemon, Jaclyn M.
   Conrad, Douglas A.
   Grembowski, David
   Nelson, Karin
   Fihn, Stephan D.
TI Patient-Centered Medical Home Initiative Produced Modest Economic
   Results For Veterans Health Administration, 2010-12
SO HEALTH AFFAIRS
LA English
DT Article
ID PRIMARY-CARE; COST SAVINGS; GROWTH; ACCESS
AB In 2010 the Veterans Health Administration (VHA) began a nationwide initiative called Patient Aligned Care Teams (PACT) that reorganized care at all VHA primary care clinics in accordance with the patient-centered medical home model. We analyzed data for fiscal years 2003-12 to assess how trends in health care use and costs changed after the implementation of PACT. We found that PACT was associated with modest increases in primary care visits and with modest decreases in both hospitalizations for ambulatory care-sensitive conditions and outpatient visits with mental health specialists. We estimated that these changes avoided $596 million in costs, compared to the investment in PACT of $774 million, for a potential net loss of $178 million in the study period. Although PACT has not generated a positive return, it is still maturing, and trends in costs and use are favorable. Adopting patient-centered care does not appear to have been a major financial risk for the VHA.
C1 [Hebert, Paul L.] VA Puget Sound Hlth Care Syst, Vet Affairs VA Hlth Serv Res & Dev Ctr Vet Ctr, Value Driven Hlth, Seattle, WA 98108 USA.
   [Hebert, Paul L.; Liu, Chuan-Fen; Hernandez, Susan E.] Univ Washington, Dept Hlth Serv, Sch Publ Hlth, Seattle, WA 98195 USA.
   [Liu, Chuan-Fen; Wong, Edwin S.; Batten, Adam; Nelson, Karin] Value Driven Hlth, VA Hlth Serv Res & Dev Ctr Vet Ctr, Seattle, WA USA.
   [Lo, Sophie] Vet Hlth Adm Off Analyt & Business Intelligence, Bedford, MA USA.
   [Lemon, Jaclyn M.] Univ Washington, Sch Med, Seattle, WA 98195 USA.
   [Conrad, Douglas A.] Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA.
   [Grembowski, David] Univ Washington, Seattle, WA 98195 USA.
   [Nelson, Karin; Fihn, Stephan D.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA.
   [Fihn, Stephan D.] VA Puget Sound Hlth Care Syst, VHA Off Analyt & Business Intelligence, Seattle, WA USA.
RP Hebert, PL (reprint author), VA Puget Sound Hlth Care Syst, Vet Affairs VA Hlth Serv Res & Dev Ctr Vet Ctr, Value Driven Hlth, Seattle, WA 98108 USA.
EM paul.hebert2@va.gov
FU Veterans Health Administration (VHA) Patient Centered Medical Home
   Demonstration Laboratory Coordination Center [XVA-61-041]; VHA Health
   Services Research and Development Career Development Award [CDA 13-024]
FX This research was presented at the Society of General Internal Medicine
   Annual Meeting, Denver, Colorado, April 23, 2013; and the AcademyHealth
   Annual Research Meeting, Baltimore, Maryland, June 23, 2013. This work
   was funded by the Veterans Health Administration (VHA) Patient Centered
   Medical Home Demonstration Laboratory Coordination Center (Grant No.
   XVA-61-041). Edwin Wong is supported by a VHA Health Services Research
   and Development Career Development Award (Grant No. CDA 13-024). The
   views expressed herein are those of the authors and do not necessary
   represent the views of the Department of Veterans Affairs or other
   affiliated institutions.
NR 21
TC 13
Z9 13
U1 1
U2 3
PU PROJECT HOPE
PI BETHESDA
PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA
SN 0278-2715
J9 HEALTH AFFAIR
JI Health Aff.
PD JUN
PY 2014
VL 33
IS 6
BP 980
EP 987
DI 10.1377/hlthaff.2013.0893
PG 8
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA AK1PL
UT WOS:000338187200009
PM 24889947
ER

PT J
AU Walling, AM
   Dy, SM
AF Walling, Anne M.
   Dy, Sydney M.
TI The Importance of a Comprehensive, Patient-Centered Approach to
   End-of-Life Care
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Editorial Material
ID DISCUSSIONS; PREFERENCES; OUTCOMES
C1 [Walling, Anne M.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA.
   [Walling, Anne M.] Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA.
   [Dy, Sydney M.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA.
   [Dy, Sydney M.] Johns Hopkins Kimmel Canc Ctr, Harry J Duffey Family Pain & Palliat Care Program, Baltimore, MD USA.
RP Dy, SM (reprint author), Rm 609,624 N Broadway, Baltimore, MD 21205 USA.
EM sdy@jhsph.edu
FU NCATS NIH HHS [KL2 TR000122, UL1 TR000124, KL2TR000122]
NR 14
TC 1
Z9 1
U1 3
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2014
VL 29
IS 6
BP 822
EP 823
DI 10.1007/s11606-013-2757-x
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AK1VS
UT WOS:000338206600002
PM 24420868
ER

PT J
AU Bailey, FA
   Williams, BR
   Woodby, LL
   Goode, PS
   Redden, DT
   Houston, TK
   Granstaff, US
   Johnson, TM
   Pennypacker, LC
   Haddock, KS
   Painter, JM
   Spencer, JM
   Hartney, T
   Burgio, KL
AF Bailey, F. Amos
   Williams, Beverly R.
   Woodby, Lesa L.
   Goode, Patricia S.
   Redden, David T.
   Houston, Thomas K.
   Granstaff, U. Shanette
   Johnson, Theodore M., II
   Pennypacker, Leslye C.
   Haddock, K. Sue
   Painter, John M.
   Spencer, Jessie M.
   Hartney, Thomas
   Burgio, Kathryn L.
TI Intervention to Improve Care at Life's End in Inpatient Settings: The
   BEACON Trial
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE palliative care; end-of-life care; palliative medicine; hospice;
   inpatient
ID ILL CANCER-PATIENTS; SMALL-SAMPLE ADJUSTMENTS; PALLIATIVE CARE; OF-LIFE;
   INTENSIVE-CARE; PAIN MANAGEMENT; HOSPICE CARE; LAST HOURS; DEATH;
   OPPORTUNITIES
AB BACKGROUND: Widespread implementation of palliative care treatment plans could reduce suffering in the last days of life by adopting best practices of traditionally home-based hospice care in inpatient settings.
   OBJECTIVE: To evaluate the effectiveness of a multi-modal intervention strategy to improve processes of end-of-life care in inpatient settings.
   DESIGN: Implementation trial with an intervention staggered across hospitals using a multiple-baseline, stepped wedge design.
   PARTICIPANTS: Six Veterans Affairs Medical Centers (VAMCs).
   INTERVENTION: Staff training was targeted to all hospital providers and focused on identifying actively dying patients and implementing best practices from home-based hospice care, supported with an electronic order set and paper-based educational tools.
   MAIN MEASURES: Several processes of care were identified as quality endpoints for end-of-life care (last 7 days) and abstracted from electronic medical records of veterans who died before or after intervention (n=6,066). Primary endpoints were proportion with an order for opioid pain medication at time of death, do-not-resuscitate order, location of death, nasogastric tube, intravenous line infusing, and physical restraints. Secondary endpoints were administration of opioids, order/administration of antipsychotics, benzodiazepines, and scopolamine (for death rattle); sublingual administration; advance directives; palliative care consultations; and pastoral care services. Generalized estimating equations were conducted adjusting for longitudinal trends.
   KEY RESULTS: Significant intervention effects were observed for orders for opioid pain medication (OR: 1.39), antipsychotic medications (OR: 1.98), benzodiazepines (OR: 1.39), death rattle medications (OR: 2.77), sublingual administration (OR: 4.12), nasogastric tubes (OR: 0.71), and advance directives (OR: 1.47). Intervention effects were not significant for location of death, do-not-resuscitate orders, intravenous lines, or restraints.
   CONCLUSIONS: This broadly targeted intervention strategy led to modest but statistically significant changes in several processes of care, indicating its potential for widespread dissemination to improve end-of-life care for thousands of patients who die each year in inpatient settings. (C) Society of General Internal Medicine 2014
C1 [Bailey, F. Amos; Williams, Beverly R.; Woodby, Lesa L.; Goode, Patricia S.; Redden, David T.; Granstaff, U. Shanette; Burgio, Kathryn L.] Birmingham Atlanta Geriatr Res Educ & Clin Ctr GR, Dept Vet Affairs, Birmingham, AL USA.
   [Bailey, F. Amos; Williams, Beverly R.; Woodby, Lesa L.; Goode, Patricia S.; Redden, David T.; Granstaff, U. Shanette; Burgio, Kathryn L.] Univ Alabama Birmingham, Birmingham, AL USA.
   [Houston, Thomas K.] US Dept Vet Affairs, VA eHlth Qual Enhancement Res Initiat, Bedford, MA USA.
   [Houston, Thomas K.] Univ Massachusetts Med Sch, Worcester, MA USA.
   [Johnson, Theodore M., II] Birmingham Atlanta Geriatr Res Educ & Clin Ctr GR, Decatur, GA USA.
   [Johnson, Theodore M., II] Emory Univ, Atlanta, GA 30322 USA.
   [Pennypacker, Leslye C.] Malcom Randall VA Med Ctr, Gainesville, FL USA.
   [Haddock, K. Sue] William Jennings Bryan Dorn VA Med Ctr, Columbia, SC USA.
   [Painter, John M.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
   [Spencer, Jessie M.] GV Sonny Montgomery VA Med Ctr, Jackson, MS USA.
   [Hartney, Thomas] Charlie Norwood VA Med Ctr, Augusta, GA USA.
RP Burgio, KL (reprint author), Birmingham VA Med Ctr, Birmingham Atlanta Geriatr Res Educ & Clin Ctr, 11G,700 South 19th St, Birmingham, AL 35233 USA.
EM kburgio@uabmc.edu
FU Department of Veterans Affairs, Veterans Health Administration, Office
   of Research and Development, Health Services Research and Development
   Service [IIR 03-126]
FX This research was supported by a Merit Review grant from the Department
   of Veterans Affairs, Veterans Health Administration, Office of Research
   and Development, Health Services Research and Development Service (IIR
   03-126 "Intervention to Improve Care at Life's End in VA Medical
   Centers;" PI: KL Burgio, Co-PI: FA Bailey). The funding source had no
   role in the design and conduct of the study; collection, management,
   analysis, and interpretation of the data; preparation, review, or
   approval of the manuscript.
NR 62
TC 15
Z9 15
U1 1
U2 12
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2014
VL 29
IS 6
BP 836
EP 843
DI 10.1007/s11606-013-2724-6
PG 8
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AK1VS
UT WOS:000338206600008
PM 24449032
ER

PT J
AU Wald, HL
   Leykum, LK
   Mattison, MLP
   Vasilevskis, EE
   Meltzer, DO
AF Wald, Heidi L.
   Leykum, Luci K.
   Mattison, Melissa L. P.
   Vasilevskis, Eduard E.
   Meltzer, David O.
TI Road Map to a Patient-Centered Research Agenda at the Intersection of
   Hospital Medicine and Geriatric Medicine
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE geriatrics; hospitals; hospitalists; patient-centered care; research
ID OLDER PATIENTS; CARE; ADULTS
AB As the United States ages, the patient population in acute care hospitals is increasingly older and more medically complex. Despite evidence of a high burden of disease, high costs, and often poor outcomes of care, there is limited understanding of the presentation, diagnostic strategies, and management of acute illness in older adults. In this paper, we present a strategy for the development of a research agenda at the intersection of hospital and geriatric medicine. This approach is informed by the Patient-Centered Outcomes Research Institute (PCORI) framework for identification and prioritization of research areas, emphasizing input from patients and caregivers. The framework's four components are: 1) Topic generation, 2) Gap Analysis in Systematic Review, 3) Value of information (VOI) analysis, and 4) Peer Review. An inclusive process for topic generation requiring the systematic engagement of multiple stakeholders, especially patients, is emphasized. In subsequent steps, researchers and stakeholders prioritize research topics in order to identify areas that optimize patient-centeredness, population impact, impact on clinical decision making, ease of implementation, and durability. Finally, next steps for dissemination of the research agenda and evaluation of the impact of the patient-centered research prioritization process are described. (C) Society of General Internal Medicine 2014
C1 [Wald, Heidi L.] Univ Colorado Sch Med, Div Hlth Care Policy & Res, Aurora, CO USA.
   [Leykum, Luci K.] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
   [Mattison, Melissa L. P.] Beth Israel Deaconess Med Ctr, Boston, MA USA.
   [Mattison, Melissa L. P.] Harvard Univ, Sch Med, Boston, MA USA.
   [Vasilevskis, Eduard E.] Vanderbilt Univ, Div Gen Internal Med & Publ Hlth, Sect Hosp Med, Nashville, TN 37235 USA.
   [Vasilevskis, Eduard E.] Vanderbilt Univ, Ctr Qual Aging, Nashville, TN 37235 USA.
   [Vasilevskis, Eduard E.] GRECC, Nashville, TN USA.
   [Meltzer, David O.] Univ Chicago, Chicago, IL 60637 USA.
RP Wald, HL (reprint author), Div Hlth Care Policy & Res, Dept Med, Campus Box F480 13199 E Moniview Blvd,Suite 400, Aurora, CO 80024 USA.
EM Heidi.wald@ucdenver.edu
RI Meltzer, David/C-2926-2009
OI Meltzer, David/0000-0003-2790-7393
FU American Association of Instructors of Medicine/Association of Specialty
   Providers; John A. Hartford Foundation; Paul Beeson Career Development
   Award in Aging (NIA) [5 K23 AG034544]; Rx Foundation; Department of
   Veterans Affairs, Veterans Health Administration, Health Services
   Research and Development Service [REA 05-129, CDA 07-022]; South Texas
   Veterans Health Care System; National Institute On Aging of the National
   Institutes of Health [K23AG040157]; Veterans Affairs Clinical Research
   Center of Excellence; Geriatric Research, Education and Clinical Center
   (GRECC)
FX This work was supported by the American Association of Instructors of
   Medicine/Association of Specialty Providers, and the John A. Hartford
   Foundation. Dr. Wald is supported by a Paul Beeson Career Development
   Award in Aging (NIA 5 K23 AG034544). Dr. Mattison acknowledges the
   support of Rx Foundation. This work was also supported by the Department
   of Veterans Affairs, Veterans Health Administration, Health Services
   Research and Development Service (REA 05-129, CDA 07-022). Investigator
   salary support (to Dr. Leykum) is provided through this funding, and
   through the South Texas Veterans Health Care System. Dr. Vasilevskis was
   supported by the National Institute On Aging of the National Institutes
   of Health (K23AG040157) and the Veterans Affairs Clinical Research
   Center of Excellence, and the Geriatric Research, Education and Clinical
   Center (GRECC).
NR 23
TC 5
Z9 5
U1 1
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2014
VL 29
IS 6
BP 926
EP 931
DI 10.1007/s11606-014-2777-1
PG 6
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AK1VS
UT WOS:000338206600023
PM 24557516
ER

PT J
AU Arbaje, AI
   Kansagara, DL
   Salanitro, AH
   Englander, HL
   Kripalani, S
   Jencks, SF
   Lindquist, LA
AF Arbaje, Alicia I.
   Kansagara, Devan L.
   Salanitro, Amanda H.
   Englander, Honora L.
   Kripalani, Sunil
   Jencks, Stephen F.
   Lindquist, Lee A.
TI Regardless of Age: Incorporating Principles from Geriatric Medicine to
   Improve Care Transitions for Patients with Complex Needs
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE care transitions; geriatrics; utilization; healthcare delivery;
   vulnerable populations
ID CONGESTIVE-HEART-FAILURE; OLDER-ADULTS; HOSPITAL READMISSION;
   RANDOMIZED-TRIAL; RISK; INTERVENTION; CAREGIVERS; SETTINGS;
   REHOSPITALIZATIONS; DEMENTIA
AB With its focus on holistic approaches to patient care, caregiver support, and delivery system redesign, geriatrics has advanced our understanding of optimal care during transitions. This article provides a framework for incorporating geriatrics principles into care transition activities by discussing the following elements: (1) identifying factors that make transitions more complex, (2) engaging care "receivers" and tailoring home care to meet patient needs, (3) building "recovery plans" into transitional care, (4) predicting and avoiding preventable readmissions, and (5) adopting a palliative approach, when appropriate, that optimizes patient and family goals of care. The article concludes with a discussion of practical aspects of designing, implementing, and evaluating care transitions programs for those with complex care needs, as well as implications for public policy. (C) Society of General Internal Medicine 2014
C1 [Arbaje, Alicia I.] Johns Hopkins Univ, Dept Med, Div Geriatr Med & Gerontol, Baltimore, MD 21224 USA.
   [Kansagara, Devan L.] Oregon Hlth & Sci Univ, Sect Gen Internal Med, Portland VA Med Ctr, Portland, OR 97201 USA.
   [Salanitro, Amanda H.] Vanderbilt Univ Sch Med, Nashville, TN USA.
   [Englander, Honora L.] Oregon Hlth & Sci Univ, Div Hosp Med, Portland, OR 97201 USA.
   [Kripalani, Sunil] Vanderbilt Univ Sch Med, Div Gen Internal Med & Publ Hlth, Sect Hosp Med, Nashville, TN USA.
   [Jencks, Stephen F.] Healthcare Safety & Qual, Baltimore, MD USA.
   [Lindquist, Lee A.] Northwestern Univ Feinberg Sch Med, Sect Gen Internal Med & Geriatr, Dept Med, Chicago, IL USA.
RP Arbaje, AI (reprint author), Johns Hopkins Univ, Dept Med, Div Geriatr Med & Gerontol, Mason F Lord Bldg,Ctr Tower,5200 Eastern Ave,7th, Baltimore, MD 21224 USA.
EM aarbaje@jhmi.edu
FU Association of Specialty Professors
FX The Association of Specialty Professors provided funding for the
   conceptualization of priority areas for publication, of which this
   manuscript is one. The views expressed in this article are those of the
   authors and do not necessarily reflect the position or policy of the
   Department of Veterans Affairs or the United States government.
NR 49
TC 4
Z9 4
U1 3
U2 11
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2014
VL 29
IS 6
BP 932
EP 939
DI 10.1007/s11606-013-2729-1
PG 8
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AK1VS
UT WOS:000338206600024
PM 24557511
ER

PT J
AU Chiovaro, JC
   Gaggar, A
AF Chiovaro, Joseph C.
   Gaggar, Anuj
TI Crystalline Bone Marrow in Systemic Oxalosis
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Editorial Material
ID PRIMARY HYPEROXALURIA
C1 [Chiovaro, Joseph C.] Portland VA Med Ctr, Portland, OR USA.
   [Chiovaro, Joseph C.] Oregon Hlth & Sci Univ, Portland, OR 97239 USA.
   [Gaggar, Anuj] Univ Calif San Francisco, San Francisco, CA 94143 USA.
RP Chiovaro, JC (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, Dept Med, 3710 Southwest US Vet Hosp Rd, Portland, OR 97239 USA.
EM jchiovaro@gmail.com
NR 3
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2014
VL 29
IS 6
BP 961
EP 961
DI 10.1007/s11606-013-2618-7
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AK1VS
UT WOS:000338206600028
PM 24078429
ER

PT J
AU Cardo, LF
   Coto, E
   Ribacoba, R
   Mata, IF
   Moris, G
   Menendez, M
   Alvarez, V
AF Cardo, Lucia F.
   Coto, Eliecer
   Ribacoba, Rene
   Mata, Ignacio F.
   Moris, German
   Menendez, Manuel
   Alvarez, Victoria
TI The screening of the 3 ' UTR sequence of LRRK2 identified an association
   between the rs66737902 polymorphism and Parkinson's disease
SO JOURNAL OF HUMAN GENETICS
LA English
DT Article
DE DNA polymorphisms; genetic risk; LRRK2 gene; microRNAs; Parkinson's
   disease
ID MUTATION; VARIANTS; BRAIN; SNCA; GENE
AB Mutations in the leucine-rich repeat kinase 2 gene (LRRK2) are the most common genetic determinants of familial and sporadic Parkinson's disease (PD). Most of the mutational screenings analyzed the exon-coding sequence. Our aim was to determine whether LRRK2 3' untranslated region (UTR) variants were associated with the risk of developing PD in a large cohort of patients (n = 743) and controls (n = 523) from Spain. We identified a total of 12 3'UTR variants (two new). Single-nucleotide polymorphism (SNP) rs66737902 C allele was overrepresented in patients (P = 0.005; odds ratio = 1.47). This SNP was in linkage disequilibrium with the p.R1441G mutation, but the association remained significant among mutation-negative cases. We found a significant lower level of the LRRK2 transcript in the Substantia nigra (SN) of PD postmortem donors (n = 9) who were rs66737902 C carriers (P = 0.01). This SNP was predicted to affect a binding site for miR-138-2-3p. We showed that this microRNA was expressed in all the SN samples. In conclusion, we found a significant association between SNP rs66737902 and the risk of developing PD. This effect on PD risk could be explained by differences in LRRK2 transcript levels between the two alleles.
C1 [Cardo, Lucia F.; Coto, Eliecer; Alvarez, Victoria] Hosp Univ Cent Asturias, Genet Mol Lab Med, Oviedo 33006, Spain.
   [Coto, Eliecer] Univ Oviedo, Dept Med, Oviedo, Spain.
   [Ribacoba, Rene; Moris, German; Menendez, Manuel] Hosp Univ Cent Asturias & Alvarez Buylla Mieres, Asturias, Spain.
   [Mata, Ignacio F.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA.
   [Mata, Ignacio F.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA.
RP Alvarez, V (reprint author), Hosp Univ Cent Asturias, Genet Mol Lab Med, Oviedo 33006, Spain.
EM victoria.alvarez@sespa.princast.es
FU 'Fundacion Parkinson Asturias'; 'Obra Social Cajastur'; Spanish 'Fondo
   de Investigaciones Sanitarias-Fondos FEDER' European Union [FIS
   11/0093]; FICYT-Principado de Asturias
FX We thank Dr Claire Troakes and the London Neurodegenerative Diseases
   Brain Bank for supplying all post mortem brain samples. We also thank
   the 'Fundacion Parkinson Asturias' and 'Obra Social Cajastur' for their
   support. This work was supported by grants from the Spanish 'Fondo de
   Investigaciones Sanitarias-Fondos FEDER' European Union (FIS 11/0093).
   LFC is a predoctoral fellowship from FICYT-Principado de Asturias.
NR 17
TC 2
Z9 2
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1434-5161
EI 1435-232X
J9 J HUM GENET
JI J. Hum. Genet.
PD JUN
PY 2014
VL 59
IS 6
BP 346
EP 348
DI 10.1038/jhg.2014.26
PG 3
WC Genetics & Heredity
SC Genetics & Heredity
GA AK1PC
UT WOS:000338186000010
PM 24758914
ER

PT J
AU Joseph, NT
   Kamarck, TW
   Muldoon, MF
   Manuck, SB
AF Joseph, Nataria Tennille
   Kamarck, Thomas W.
   Muldoon, Matthew F.
   Manuck, Stephen B.
TI Daily Marital Interaction Quality and Carotid Artery Intima-Medial
   Thickness in Healthy Middle-Aged Adults
SO PSYCHOSOMATIC MEDICINE
LA English
DT Article
DE marital quality; marital interaction; ecological momentary assessment;
   intima-media thickness; cardiovascular disease
ID CORONARY-HEART-DISEASE; BLOOD-PRESSURE; CARDIOVASCULAR-DISEASE;
   DAILY-LIFE; WOMEN; RISK; ASSOCIATION; STRESS; SAMPLE; PROGRESSION
AB Objective: To examine the association between marital interaction quality during daily life and subclinical cardiovascular disease (CVD). Studies have shown that marital status and quality of marriage are associated with cardiovascular health. However, little is known about the role of marital interaction quality during daily life in contributing to these effects. Methods: The sample consisted of 281 healthy, employed middle-aged adults who were married or living with a partner in a marital-like relationship (mean age = 42.0 years, 88% white, 52% men). Marital interaction quality was assessed using hourly real-time ecological momentary assessments for 4 days, with participants rating their current or recent partner interactions on positive and negative characteristics (e. g., agreeableness and conflict). Carotid artery intima-medial thickness (IMT) was assessed using ultrasound imaging. Results: Adjusting for demographics, positive marital interaction was inversely associated with IMT (b = -0.02, F(1,275) = 9.18, p = .002), and negative marital interaction was positively associated with IMT (b = 0.02 F(1,275) = 10.29, p = .001). These associations were not accounted for by behavioral and biological CVD risk factors and were consistent across age, sex, race, and education. The associations were also independent of marital interaction frequency, nonmarital social interaction quality, and personality factors. Global reports of marital quality, in contrast, were not associated with IMT. Conclusions: Marital quality as measured during real-time interactions between partners was associated with subclinical CVD in healthy middle-aged adults. This study supports the use of real-time social interaction assessment for characterizing links between social relationships and cardiovascular health.
C1 [Joseph, Nataria Tennille] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA.
   [Kamarck, Thomas W.] Univ Pittsburgh, Dept Psychiat & Psychol, Pittsburgh, PA USA.
   [Muldoon, Matthew F.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.
   [Manuck, Stephen B.] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA.
RP Joseph, NT (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM nataria.joseph@va.gov
FU National Institutes of Health [P01 HL040962, T32 HL007560]; VA Office of
   Academic Affiliations' Women's Health Fellowship Program
FX This research was supported by National Institutes of Health Grants P01
   HL040962 awarded to Drs. Manuck, Kamarck, and Muldoon and T32 HL007560
   (fellowship) awarded to Dr. Joseph. Dr. Joseph is currently supported by
   the VA Office of Academic Affiliations' Women's Health Fellowship
   Program. The authors have no conflicts of interest to disclose.
NR 49
TC 11
Z9 11
U1 1
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0033-3174
EI 1534-7796
J9 PSYCHOSOM MED
JI Psychosom. Med.
PD JUN
PY 2014
VL 76
IS 5
BP 347
EP 354
DI 10.1097/PSY.0000000000000071
PG 8
WC Psychiatry; Psychology; Psychology, Multidisciplinary
SC Psychiatry; Psychology
GA AK0TQ
UT WOS:000338128800004
PM 24915293
ER

PT J
AU Bera, A
   Das, F
   Ghosh-Choudhury, N
   Li, XN
   Pal, S
   Gorin, Y
   Kasinath, BS
   Abboud, HE
   Choudhury, GG
AF Bera, Amit
   Das, Falguni
   Ghosh-Choudhury, Nandini
   Li, Xiaonan
   Pal, Sanjay
   Gorin, Yves
   Kasinath, Balakuntalam S.
   Abboud, Hanna E.
   Choudhury, Goutam Ghosh
TI A positive feedback loop involving Erk5 and Akt turns on mesangial cell
   proliferation in response to PDGF
SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
LA English
DT Article
DE Akt kinase; cell proliferation; MAP kinase; receptor tyrosine kinase;
   renal physiology
ID METANEPHRIC MESENCHYMAL CELLS; ACTIVATED PROTEIN-KINASE; INDUCED
   DNA-SYNTHESIS; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; CYCLIN D1;
   TRANSGENIC MICE; EXPRESSION; RECEPTOR; GLOMERULONEPHRITIS
AB Platelet-derived growth factor BB and its receptor (PDGFR beta) play a pivotal role in the development of renal glomerular mesangial cells. Their roles in increased mesangial cell proliferation during mesangioproliferative glomerulonephritis have long been noted, but the operating logic of signaling mechanisms regulating these changes remains poorly understood. We examined the role of a recently identified MAPK, Erk5, in this process. PDGF increased the activating phosphorylation of Erk5 and tyrosine phosphorylation of proteins in a time-dependent manner. A pharmacologic inhibitor of Erk5, XMD8-92, abrogated PDGF-induced DNA synthesis and mesangial cell proliferation. Similarly, expression of dominant negative Erk5 or siRNAs against Erk5 blocked PDGF-stimulated DNA synthesis and proliferation. Inhibition of Erk5 attenuated expression of cyclin D1 mRNA and protein, resulting in suppression of CDK4-mediated phosphorylation of the tumor suppressor protein pRb. Expression of cyclin D1 or CDK4 prevented the dominant negative Erk5-or siErk5 mediated inhibition of DNA synthesis and mesangial cell proliferation induced by PDGF. We have previously shown that phosphatidylinositol 3-kinase (PI3-kinase) contributes to PDGF-induced proliferation of mesangial cells. Inhibition of PI3-kinase blocked PDGF-induced phosphorylation of Erk5. Since PI3-kinase acts through Akt, we determined the role of Erk5 on Akt phosphorylation. XMD8-92, dominant negative Erk5, and siErk5 inhibited phosphorylation of Akt by PDGF. Interestingly, we found inhibition of PDGF-induced Erk5 phosphorylation by a pharmacological inhibitor of Akt kinase and kinase dead Akt in mesangial cells. Thus our data unfold the presence of a positive feedback microcircuit between Erk5 and Akt downstream of PI3-kinase nodal point for PDGF-induced mesangial cell proliferation.
C1 [Ghosh-Choudhury, Nandini; Kasinath, Balakuntalam S.; Abboud, Hanna E.; Choudhury, Goutam Ghosh] South Texas Vet Hlth Care Syst, Vet Adm Res Serv, San Antonio, TX USA.
   [Ghosh-Choudhury, Nandini] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
   [Bera, Amit; Das, Falguni; Li, Xiaonan; Pal, Sanjay; Gorin, Yves; Kasinath, Balakuntalam S.; Abboud, Hanna E.; Choudhury, Goutam Ghosh] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
   [Choudhury, Goutam Ghosh] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA.
RP Choudhury, GG (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
EM choudhuryg@uthscsa.edu
FU Veterans Affairs Service Merit Review [5I01BX000926]; National Institute
   of Diabetes and Digestive and Kidney Diseases [RO1-DK-50190]; National
   Institutes of Health and Veterans Affairs Research Service grants;
   Cancer Therapy and Research Center at San Antonio; Veterans Affairs
   Research Service Merit Review grant; Veterans Affairs Senior Research
   Career Scientist Award
FX The results described in this manuscript are the work supported by
   Veterans Affairs Service Merit Review Grant 5I01BX000926 and National
   Institute of Diabetes and Digestive and Kidney Diseases Grant
   RO1-DK-50190 (to G. G. Choudhury). G. G. Choudhury is a recipient of
   Veterans Affairs Senior Research Career Scientist Award. B. S. Kasinath,
   Y. Gorin, and H. E. Abboud are supported by National Institutes of
   Health and Veterans Affairs Research Service grants (B. S. Kasinath and
   H. E. Abboud). N. Ghosh-Choudhury is supported by Veterans Affairs
   Research Service Merit Review grant and a pilot grant from Cancer
   Therapy and Research Center at San Antonio.
NR 45
TC 7
Z9 7
U1 0
U2 4
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6143
EI 1522-1563
J9 AM J PHYSIOL-CELL PH
JI Am. J. Physiol.-Cell Physiol.
PD JUN
PY 2014
VL 306
IS 11
BP C1089
EP C1100
DI 10.1152/ajpcell.00387.2013
PG 12
WC Cell Biology; Physiology
SC Cell Biology; Physiology
GA AJ7SL
UT WOS:000337897300012
PM 24740537
ER

PT J
AU Huang, LW
   Lipschutz, JH
AF Huang, Liwei
   Lipschutz, Joshua H.
TI Cilia and Polycystic Kidney Disease, Kith and Kin
SO BIRTH DEFECTS RESEARCH PART C-EMBRYO TODAY-REVIEWS
LA English
DT Review
DE polycystic kidney disease; cilia; planar cell polarity; exocyst
ID PLANAR CELL POLARITY; LEFT-RIGHT AXIS; SMOOTH-MUSCLE-CELLS;
   INTRAFLAGELLAR TRANSPORT; EPITHELIAL-CELLS; CYSTIC KIDNEY; RENAL CILIA;
   INTRACELLULAR CALCIUM; PRIMARY CILIOGENESIS; MEMBRANE-PROTEIN
AB In the past decade, cilia have been found to play important roles in renal cystogenesis. Many genes, such as PKD1 and PKD2 which, when mutated, cause autosomal dominant polycystic kidney disease (ADPKD), have been found to localize to primary cilia. The cilium functions as a sensor to transmit extracellular signals into the cell. Abnormal cilia structure and function are associated with the development of polyscystic kidney disease (PKD). Cilia assembly includes centriole migration to the apical surface of the cell, ciliary vesicle docking and fusion with the cell membrane at the intended site of cilium outgrowth, and microtubule growth from the basal body. This review summarizes the most recent advances in cilia and PKD research, with special emphasis on the mechanisms of cytoplasmic and intraciliary protein transport during ciliogenesis. (C) 2014 Wiley Periodicals, Inc.
C1 Eastern Virginia Med Sch, Dept Med, Norfolk, VA 23501 USA.
   Philadelphia Vet Affairs Med Ctr, Dept Med, Philadelphia, PA USA.
   Univ Penn, Dept Med, Philadelphia, PA 19104 USA.
RP Huang, LW (reprint author), Lewis Hall Rm 2124,740 W Olney Rd, Norfolk, VA 23501 USA.
EM huangle@evms.edu
FU Veterans Affairs (Merit Award); NIH [DK093625, 5P30 DK047757-18]
FX Supported by a grant from the Veterans Affairs (Merit Award to J.H.L.),
   and NIH (DK093625 to L. H., and 5P30 DK047757-18 pilot award to J.H.L.).
NR 96
TC 3
Z9 4
U1 1
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1542-975X
EI 1542-9768
J9 BIRTH DEFECTS RES C
JI Birth Defects Res. Part C-Embryo Today-Rev.
PD JUN
PY 2014
VL 102
IS 2
BP 174
EP 185
DI 10.1002/bdrc.21066
PG 12
WC Developmental Biology; Reproductive Biology
SC Developmental Biology; Reproductive Biology
GA AJ8PG
UT WOS:000337967700005
PM 24898006
ER

PT J
AU Clark, DG
   Kapur, P
   Geldmacher, DS
   Brockington, JC
   Harrell, L
   DeRamus, TP
   Blanton, PD
   Lokken, K
   Nicholas, AP
   Marson, DC
AF Clark, D. G.
   Kapur, P.
   Geldmacher, D. S.
   Brockington, J. C.
   Harrell, L.
   DeRamus, T. P.
   Blanton, P. D.
   Lokken, K.
   Nicholas, A. P.
   Marson, D. C.
TI Latent information in fluency lists predicts functional decline in
   persons at risk for Alzheimer disease
SO CORTEX
LA English
DT Article
DE Alzheimer's disease; Cognitive neuropsychology; Dementia; MCI (mild
   cognitive impairment); Machine learning; Random forests
ID MILD COGNITIVE IMPAIRMENT; VERBAL FLUENCY; FINANCIAL ABILITIES;
   CONVERSION; DEMENTIA; DIAGNOSIS; CAPACITY; INFERIOR; ATROPHY
AB Objective: We constructed random forest classifiers employing either the traditional method of scoring semantic fluency word lists or new methods. These classifiers were then compared in terms of their ability to diagnose Alzheimer disease (AD) or to prognosticate among individuals along the continuum from cognitively normal (CN) through mild cognitive impairment (MCI) to AD.
   Method: Semantic fluency lists from 44 cognitively normal elderly individuals, 80 MCI patients, and 41 AD patients were transcribed into electronic text files and scored by four methods: traditional raw scores, clustering and switching scores, "generalized" versions of clustering and switching, and a method based on independent components analysis (ICA). Random forest classifiers based on raw scores were compared to "augmented" classifiers that incorporated newer scoring methods. Outcome variables included AD diagnosis at baseline, MCI conversion, increase in Clinical Dementia Rating-Sum of Boxes (CDR-SOB) score, or decrease in Financial Capacity Instrument (FCI) score. Receiver operating characteristic (ROC) curves were constructed for each classifier and the area under the curve (AUC) was calculated. We compared AUC between raw and augmented classifiers using Delong's test and assessed validity and reliability of the augmented classifier.
   Results: Augmented classifiers outperformed classifiers based on raw scores for the outcome measures AD diagnosis (AUC .97 vs .95), MCI conversion (AUC .91 vs .77), CDR-SOB increase (AUC .90 vs .79), and FCI decrease (AUC .89 vs .72). Measures of validity and stability over time support the use of the method.
   Conclusion: Latent information in semantic fluency word lists is useful for predicting cognitive and functional decline among elderly individuals at increased risk for developing AD. Modem machine learning methods may incorporate latent information to enhance the diagnostic value of semantic fluency raw scores. These methods could yield information valuable for patient care and clinical trial design with a relatively small investment of time and money. Published by Elsevier Ltd.
C1 [Clark, D. G.; Blanton, P. D.; Lokken, K.; Nicholas, A. P.] Birmingham VA Med Ctr, Birmingham, AL 35233 USA.
   [Clark, D. G.; Geldmacher, D. S.; Brockington, J. C.; Harrell, L.; Nicholas, A. P.; Marson, D. C.] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL USA.
   [Kapur, P.] Georgia Hlth Sci Univ, Dept Biomed Sci, Augusta, GA USA.
   [DeRamus, T. P.] Univ Alabama Birmingham, Dept Psychol & Behav Neurosci, Birmingham, AL USA.
RP Clark, DG (reprint author), 1720,7th Ave South,SC 620C, Birmingham, AL 35294 USA.
EM dgclark@uab.edu
FU Department of Veterans Affairs, Veterans Health Administration,
   Rehabilitation Research and Development Service [E6553W]; Alzheimer's
   Disease Research Center (Marson, PI) [2R01 AG021927, 1P50 AG16582]
FX The research reported here was supported by the Department of Veterans
   Affairs, Veterans Health Administration, Rehabilitation Research and
   Development Service (E6553W, PI David Clark, Department of Neurology).
   In addition, the work was supported by grants 2R01 AG021927 (Marson, PI)
   and 1P50 AG16582 (Alzheimer's Disease Research Center) (Marson, PI).
NR 57
TC 3
Z9 3
U1 0
U2 13
PU ELSEVIER MASSON
PI MILANO
PA VIA PALEOCAPA 7, 20121 MILANO, ITALY
SN 0010-9452
EI 1973-8102
J9 CORTEX
JI Cortex
PD JUN
PY 2014
VL 55
SI SI
BP 202
EP 218
DI 10.1016/j.cortex.2013.12.013
PG 17
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA AJ5ZY
UT WOS:000337770700017
PM 24556551
ER

PT J
AU Bakaeen, FG
   Reda, DJ
   Gelijns, AC
   Cornwell, L
   Omer, S
   Al Jurdi, R
   Kougias, P
   Anaya, D
   Berger, DH
   Huang, GD
AF Bakaeen, Faisal G.
   Reda, Domenic J.
   Gelijns, Annetine C.
   Cornwell, Lorraine
   Omer, Shuab
   Al Jurdi, Rayan
   Kougias, Panos
   Anaya, Daniel
   Berger, David H.
   Huang, Grant D.
TI Department of Veterans Affairs Cooperative Studies Program Network of
   Dedicated Enrollment Sites Implications for Surgical Trials
SO JAMA SURGERY
LA English
DT Article
ID PERCUTANEOUS CORONARY INTERVENTION; OUTCOMES RESEARCH-INSTITUTE;
   ARTERY-BYPASS SURGERY; RANDOMIZED-TRIAL; VALVE-REPLACEMENT; ON-PUMP;
   REPAIR
AB IMPORTANCE Surgical clinical trials have played a critical role in shaping clinical practice, yet their launch and conduct remain challenging. Innovative approaches to carrying out such studies can not only help transform how trials produce definitive evidence but also move the field toward increased participation in trials.
   OBJECTIVE To review a recently launched pilot program aimed at enhancing patient enrollment and improving surgical trial operations at individual sites and nationally.
   SETTING AND PARTICIPANTS After a solicitation to create a national network focused on making the conduct of clinical trials more efficient, 10 Department of Veterans Affairs (VA) sites were selected. These sites, collectively called the Cooperative Studies Program (CSP) Network of Dedicated Enrollment Sites (NODES), were evaluated with regard to their previous participation in CSP multisite trials, the strength of the local clinical research environment, and presentation of innovative plans to coordinate and enhance the operations of local CSP studies and share best practices with other centers. Node accountability was also emphasized and involved metrics that tracked productivity and efficiency.
   RESULTS Building from available CSP experience in a range of clinical trials, including ones involving surgical interventions, NODES provides VA surgeons with resources for facilitating timely study initiation, determining patient availability, and addressing enrollment barriers. Such resources are particularly important for surgical studies, which often face challenges in patient recruitment and retention. In addition, NODES can maintain qualified and trained personnel at sites to support surgeons with limited time to fulfill the numerous administrative and regulatory responsibilities that often fall to the investigators.
   CONCLUSIONS AND RELEVANCE The VA's approach to enhancing trial efficiency may reinvigorate interest in surgical trials by offering a redesigned cooperative framework that builds on a core of high-yield sites and could mitigate traditional limitations of surgical trials.
C1 [Bakaeen, Faisal G.; Cornwell, Lorraine; Omer, Shuab; Kougias, Panos; Anaya, Daniel; Berger, David H.] Baylor Coll Med, Michael E DeBakey VA Med Ctr, Dept Surg, Houston, TX 77030 USA.
   [Bakaeen, Faisal G.] Texas Heart Inst, Dept Cardiovasc Surg, Houston, TX 77025 USA.
   [Reda, Domenic J.; Huang, Grant D.] US Dept Vet Affairs, Cooperat Studies Program Cent Off, Washington, DC USA.
   [Gelijns, Annetine C.] Mt Sinai Sch Med, Dept Hlth Evidence & Policy, New York, NY USA.
   [Al Jurdi, Rayan] Michael E DeBakey VA Med Ctr, Houston, TX USA.
RP Bakaeen, FG (reprint author), Michael E DeBakey VA Med Ctr, Div Cardiothorac Surg, Mail Stop OCL 112,2002 Holcombe Blvd, Houston, TX 77030 USA.
EM fbakaeen@bcm.edu
FU Department of Veterans Affairs Cooperative Studies Program
FX This work was supported by the Department of Veterans Affairs
   Cooperative Studies Program.
NR 25
TC 2
Z9 2
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6254
EI 2168-6262
J9 JAMA SURG
JI JAMA Surg.
PD JUN
PY 2014
VL 149
IS 6
BP 507
EP 513
DI 10.1001/jamasurg.2013.4150
PG 7
WC Surgery
SC Surgery
GA AJ7WB
UT WOS:000337909900005
PM 24647851
ER

PT J
AU Imel, ZE
   Baldwin, SA
   Baer, JS
   Hartzler, B
   Dunn, C
   Rosengren, DB
   Atkins, DC
AF Imel, Zac E.
   Baldwin, Scott A.
   Baer, John S.
   Hartzler, Bryan
   Dunn, Chris
   Rosengren, David B.
   Atkins, David C.
TI Evaluating Therapist Adherence in Motivational Interviewing by Comparing
   Performance With Standardized and Real Patients
SO JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY
LA English
DT Article
DE motivational interviewing; therapist adherence; mixed models;
   standardized patients
ID ALLIANCE-OUTCOME CORRELATION; COMPETENCE; CLINICIAN; DEPENDABILITY;
   VARIABILITY; ASSESSMENTS; SESSIONS; BEHAVIOR; LARGER; THINK
AB Objective: The goal of measuring therapist adherence is to determine whether a therapist can perform a given treatment. Yet, the evaluation of therapist behaviors in most clinical trials is limited. Typically, randomized trials have few therapists and minimize therapist variability through training and supervision. Furthermore, therapist adherence is confounded with uncontrolled differences in patients across therapists. Consequently, the extent to which adherence measures capture differences in actual therapist adherence versus other sources of variance is unclear. Method: We estimated intra-class correlations (ICCs) for therapist adherence in sessions with real and standardized patients (RPs and SPs), using ratings from a motivational interviewing (MI) dissemination trial (Baer et al., 2009) in which 189 therapists recorded 826 sessions with both patient types. We also examined the correlations of therapist adherence between SP and RP sessions, and the reliability of therapist level adherence scores with generalizability coefficients (GCs). Results: ICCs for therapist adherence were generally large (average ICC for SPs = .44; average ICC for RPs = .40), meaning that a given therapist's adherence scores were quite similar across sessions. Both ICCs and GCs were larger for SP sessions compared to RPs on global measures of MI adherence, such as Empathy and MI Spirit. Correlations between therapist adherence with real and standardized patients were moderate to large on 3 of 5 adherence measures. Conclusion: Differences in therapist-level adherence ratings were substantial, and standardized patients have promise as tools to evaluate therapist behavior.
C1 [Imel, Zac E.] Univ Utah, Dept Educ Psychol, Salt Lake City, UT 84112 USA.
   [Baldwin, Scott A.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA.
   [Baer, John S.] Univ Washington, Dept Psychol, Seattle, WA 98195 USA.
   [Baer, John S.] VA Puget Sound Healthcare Syst, CESATE, Seattle, WA USA.
   [Hartzler, Bryan] Univ Washington, Alcohol Drug Abuse Inst, Seattle, WA 98195 USA.
   [Dunn, Chris; Atkins, David C.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
   [Rosengren, David B.] Prevent Res Inst, Lexington, KY USA.
RP Imel, ZE (reprint author), Univ Utah, Dept Educ Psychol, 1705 Campus Ctr Dr,Room 327, Salt Lake City, UT 84112 USA.
EM zac.imel@utah.edu
RI Baldwin, Scott/G-4021-2017
OI Baldwin, Scott/0000-0003-3428-0437; imel, zachary/0000-0001-9645-7184;
   Atkins, David/0000-0002-5781-9880
FU NIAAA NIH HHS [R01 AA018673, R01/AA018673]; NIDA NIH HHS [R01/DA016360,
   R34 DA034860, R34/DA034860, U10 DA013714]
NR 28
TC 13
Z9 13
U1 2
U2 8
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0022-006X
EI 1939-2117
J9 J CONSULT CLIN PSYCH
JI J. Consult. Clin. Psychol.
PD JUN
PY 2014
VL 82
IS 3
BP 472
EP 481
DI 10.1037/a0036158
PG 10
WC Psychology, Clinical
SC Psychology
GA AJ7SF
UT WOS:000337896700009
PM 24588405
ER

PT J
AU Watts, LT
   Long, JA
   Chemello, J
   Van Koughnet, S
   Fernandez, A
   Huang, SL
   Shen, Q
   Duong, TQ
AF Watts, Lora Talley
   Long, Justin Alexander
   Chemello, Jonathan
   Van Koughnet, Samantha
   Fernandez, Angelica
   Huang, Shiliang
   Shen, Qiang
   Duong, Timothy Q.
TI Methylene Blue Is Neuroprotective against Mild Traumatic Brain Injury
SO JOURNAL OF NEUROTRAUMA
LA English
DT Article
DE antioxidant; mitochondria; MRI; oxidative stress; vasogenic edema
ID SPINAL-CORD-INJURY; CYCLOSPORINE-A; NEURONAL DEGENERATION;
   OXYGEN-CONSUMPTION; CEREBRAL-ISCHEMIA; REACTIVE GLIOSIS; FLUORO-JADE;
   MECHANISMS; GENERATION; PERFUSION
AB Traumatic brain injury (TBI) is a leading cause of death and disability worldwide. Methylene blue (MB) has known energy-enhancing and antioxidant properties. This study tested the hypothesis that MB treatment reduces lesion volume and behavioral deficits in a rat model of mild TBI. In a randomized double-blinded design, animals received either MB (n = 5) or vehicle (n = 6) after TBI. Studies were performed on 0, 1, 2, 7, and 14 days following an impact to the primary forelimb somatosensory cortex. MRI lesion was not apparent 1 h after TBI, became apparent 3 h after TBI, and peaked at 2 days for both groups. The MB-treated animals showed significantly smaller MRI lesion volume than the vehicle-treated animals at all time points studied. The MB-treated animals exhibited significantly improved scores on forelimb placement asymmetry and foot fault tests than did the vehicle-treated animals at all time points studied. Smaller numbers of dark-stained Nissl cells and Fluoro-Jade (R) positive cells were observed in the MB-treated group than in vehicle-treated animals 14 days post-TBI. In conclusion, MB treatment minimized lesion volume, behavioral deficits, and neuronal degeneration following mild TBI. MB is already approved by the United States Food and Drug Administration (FDA) to treat a number of indications, likely expediting future clinical trials in TBI.
C1 [Watts, Lora Talley; Long, Justin Alexander; Chemello, Jonathan; Van Koughnet, Samantha; Fernandez, Angelica; Huang, Shiliang; Shen, Qiang; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA.
   [Watts, Lora Talley] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
   [Watts, Lora Talley; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Neurol, San Antonio, TX 78229 USA.
   [Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA.
   [Duong, Timothy Q.] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM wattsl@uthscsa.edu; duongt@uthscsa.edu
NR 45
TC 15
Z9 16
U1 0
U2 9
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0897-7151
EI 1557-9042
J9 J NEUROTRAUM
JI J. Neurotrauma
PD JUN 1
PY 2014
VL 31
IS 11
BP 1063
EP 1071
DI 10.1089/neu.2013.3193
PG 9
WC Critical Care Medicine; Clinical Neurology; Neurosciences
SC General & Internal Medicine; Neurosciences & Neurology
GA AJ7RS
UT WOS:000337895300009
ER

PT J
AU Scheiner, DL
   Keilp, J
   Mindt, MR
   Burke, AK
   Oquendo, MA
   Mann, JJ
AF Scheiner, Diane L.
   Keilp, John
   Mindt, Monica Rivera
   Burke, Ainsley K.
   Oquendo, Maria A.
   Mann, J. John
TI Verbal Learning Deficits in Posttraumatic Stress Disorder and Depression
SO JOURNAL OF TRAUMATIC STRESS
LA English
DT Article
ID PSYCHIATRIC-DISORDERS; HOLOCAUST SURVIVORS; MEMORY PERFORMANCE; SUICIDE
   ATTEMPTERS; MAJOR DEPRESSION; COMBAT VETERANS; PTSD; ATTENTION;
   COMORBIDITY; DYSFUNCTION
AB Verbal learning and memory deficits are frequently reported in posttraumatic stress disorder (PTSD), but may be a product of its psychiatric comorbidities, especially major depressive disorder (MDD). To evaluate this hypothesis, 25 medication-free patients with PTSD and comorbid MDD were compared to 148 medication-free patients with equally severe MDD alone and to 96 nonpatients on a measure of verbal learning and memory. Additional measures of attention, working memory, and executive function were administered to evaluate their contribution to verbal memory impairment. Patients with comorbid PTSD and MDD demonstrated the greatest deficit in verbal learning compared to both MDD patients and nonpatients (omnibus effect sizes ranged d = 0.41 to 0.50), one that was not accounted for by other cognitive deficits. Findings suggest that a current diagnosis of PTSD makes a contribution to verbal learning deficits beyond the effect of depression alone.
C1 [Scheiner, Diane L.; Mindt, Monica Rivera] Fordham Univ, Dept Psychol, Bronx, NY 10458 USA.
   [Keilp, John; Burke, Ainsley K.; Oquendo, Maria A.; Mann, J. John] Columbia Univ, Dept Psychiat, New York, NY USA.
   [Keilp, John; Burke, Ainsley K.; Oquendo, Maria A.; Mann, J. John] New York State Psychiat Inst & Hosp, Div Mol Imaging & Neuropathol, New York, NY 10032 USA.
RP Scheiner, DL (reprint author), West Los Angeles Healthcare Ctr, VA Greater Los Angeles Healthcare Syst, Psychol Dept 116B, Bldg 256,Room 204,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM dscheiner@fordham.edu
FU NIMH NIH HHS [5P50 MH-62185, MH-62155]
NR 55
TC 2
Z9 2
U1 3
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0894-9867
EI 1573-6598
J9 J TRAUMA STRESS
JI J. Trauma Stress
PD JUN
PY 2014
VL 27
IS 3
BP 291
EP 298
DI 10.1002/jts.21921
PG 8
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA AJ8JM
UT WOS:000337949300006
PM 24850268
ER

PT J
AU Price, M
   Davidson, TM
   Ruggiero, KJ
   Acierno, R
   Resnick, HS
AF Price, Matthew
   Davidson, Tatiana M.
   Ruggiero, Kenneth J.
   Acierno, Ron
   Resnick, Heidi S.
TI Predictors of Using Mental Health Services After Sexual Assault
SO JOURNAL OF TRAUMATIC STRESS
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; NATIONAL COMORBIDITY SURVEY; RAPE
   MEDICAL-CARE; SUBSTANCE USE; EARLY INTERVENTION; TREATMENT-SEEKING;
   TRAUMATIC INJURY; RECENT VICTIMS; UNITED-STATES; HELP-SEEKING
AB Sexual assault increases the risk for psychopathology. Despite the availability of effective interventions, relatively few victims who need treatment receive care in the months following an assault. Prior work identified several factors associated with utilizing care, including ethnicity, insurance, and posttraumatic stress disorder (PTSD) symptoms. Few studies, however, have examined predictors of treatment utilization prospectively from the time of assault. The present study hypothesized that White racial status, younger age, being partnered, having health insurance, having previously received mental health treatment, and having more PTSD and depression symptoms would predict utilization of care in the 6 months postassault. This was examined in a sample of 266 female sexual assault victims with an average age of 26.2 years, of whom 62.0% were White and 38.0% were African American assessed at 1.5 and 6 months postassault. Available information on utilizing care varied across assessments (1.5 months, n = 214; 3 months, n = 126; 6 months, n = 204). Significant predictors included having previously received mental health treatment (OR = 4.09), 1 day depressive symptoms (OR = 1.06), and having private insurance (OR = 2.24) or Medicaid (OR = 2.19). Alcohol abuse and prior mental health care were associated with a substantial increase in treatment utilization (OR = 4.07). The findings highlight the need to help victims at risk obtain treatment after sexual assault.
C1 [Price, Matthew] Univ Vermont, Dept Psychol, Burlington, VT 05405 USA.
   [Davidson, Tatiana M.; Ruggiero, Kenneth J.; Acierno, Ron; Resnick, Heidi S.] Med Univ S Carolina, Natl Crime Victims Ctr, Charleston, SC 29425 USA.
   [Ruggiero, Kenneth J.; Acierno, Ron] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
RP Resnick, HS (reprint author), Med Univ S Carolina, Natl Crime Victims Ctr, Natl Crime Victims Res & Treatment Ctr, 67 President St, Charleston, SC 29425 USA.
EM resnickh@musc.edu
FU NIDA NIH HHS [R01 DA023099, R01 DA011158, R01DA023099, R01DA11158]; NIMH
   NIH HHS [T32 MH018869, T32MH018869]
NR 54
TC 10
Z9 10
U1 5
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0894-9867
EI 1573-6598
J9 J TRAUMA STRESS
JI J. Trauma Stress
PD JUN
PY 2014
VL 27
IS 3
BP 331
EP 337
DI 10.1002/jts.21915
PG 7
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA AJ8JM
UT WOS:000337949300011
PM 24852357
ER

PT J
AU Tang, Y
   Gellad, WF
   Men, A
   Donohue, JM
AF Tang, Yan
   Gellad, Walid F.
   Men, Aiju
   Donohue, Julie M.
TI Impact of Medicare Part D Plan Features on Use of Generic Drugs
SO MEDICAL CARE
LA English
DT Article
DE Medicare Part D; cost-sharing; prior authorization; step therapy;
   generic drugs
ID D BENEFICIARIES; HEART-FAILURE; ADHERENCE; COST; COPAYMENT; PHYSICIAN;
   PERCEPTIONS; PROGRAM; CHOICE
AB Background:Little is known about how Medicare Part D plan features influence choice of generic versus brand drugs.Objectives:To examine the association between Part D plan features and generic medication use.Methods:Data from a 2009 random sample of 1.6 million fee-for-service, Part D enrollees aged 65 years and above, who were not dually eligible or receiving low-income subsidies, were used to examine the association between plan features (generic cost-sharing, difference in brand and generic copay, prior authorization, step therapy) and choice of generic antidepressants, antidiabetics, and statins. Logistic regression models accounting for plan-level clustering were adjusted for sociodemographic and health status.Results:Generic cost-sharing ranged from $0 to $9 for antidepressants and statins, and from $0 to $8 for antidiabetics (across 5th-95th percentiles). Brand-generic cost-sharing differences were smallest for statins (5th-95th percentiles: $16-$37) and largest for antidepressants ($16-$64) across plans. Beneficiaries with higher generic cost-sharing had lower generic use [adjusted odds ratio (OR)=0.97, 95% confidence interval (CI), 0.95-0.98 for antidepressants; OR=0.97, 95% CI, 0.96-0.98 for antidiabetics; OR=0.94, 95% CI, 0.92-0.95 for statins]. Larger brand-generic cost-sharing differences and prior authorization were significantly associated with greater generic use in all categories. Plans could increase generic use by 5-12 percentage points by reducing generic cost-sharing from the 75th ($7) to 25th percentiles ($4-$5), increasing brand-generic cost-sharing differences from the 25th ($25-$26) to 75th ($32-$33) percentiles, and using prior authorization and step therapy.Conclusions:Cost-sharing features and utilization management tools were significantly associated with generic use in 3 commonly used medication categories.
C1 [Tang, Yan; Men, Aiju; Donohue, Julie M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA 15261 USA.
   [Gellad, Walid F.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
   [Gellad, Walid F.] Univ Pittsburgh, Div Gen Med, Pittsburgh, PA 15261 USA.
   [Gellad, Walid F.] Univ Pittsburgh, Ctr Pharmaceut Policy & Prescribing, Pittsburgh, PA 15261 USA.
   [Gellad, Walid F.] RAND Hlth, Pittsburgh, PA USA.
RP Tang, Y (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, 130 DeSoto St,Crabtree Hall A663, Pittsburgh, PA 15261 USA.
EM yat11@pitt.edu
OI Donohue, Julie/0000-0003-2418-6017
FU RAND-University of Pittsburgh Health Initiative (RUPHI); Clinical and
   Translational Science Institute at the University of Pittsburgh;
   National Institutes of Health (NIH) Clinical and Translational Science
   Award (CTSA) program [UL1RR024153, UL1TR000005]; VA HSR&D Career
   Development Award [CDA09-207]
FX Supported by a pilot grant funded by both RAND-University of Pittsburgh
   Health Initiative (RUPHI) and the Clinical and Translational Science
   Institute at the University of Pittsburgh, which is supported by the
   National Institutes of Health (NIH) Clinical and Translational Science
   Award (CTSA) program (grants UL1RR024153 and UL1TR000005). W. F. G. is
   additionally supported by a VA HSR&D Career Development Award
   (CDA09-207).
NR 46
TC 1
Z9 1
U1 1
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7079
EI 1537-1948
J9 MED CARE
JI Med. Care
PD JUN
PY 2014
VL 52
IS 6
BP 541
EP 548
DI 10.1097/MLR.0000000000000142
PG 8
WC Health Care Sciences & Services; Health Policy & Services; Public,
   Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
GA AJ5LK
UT WOS:000337723900012
PM 24824538
ER

PT J
AU Byrne, T
   Fargo, JD
   Montgomery, AE
   Munley, E
   Culhane, DP
AF Byrne, Thomas
   Fargo, Jamison D.
   Montgomery, Ann Elizabeth
   Munley, Ellen
   Culhane, Dennis P.
TI The Relationship between Community Investment in Permanent Supportive
   Housing and Chronic Homelessness
SO SOCIAL SERVICE REVIEW
LA English
DT Article
ID NEW-YORK-CITY; MENTAL-ILLNESS; RENT CONTROL; COST-EFFECTIVENESS;
   HEALTH-CARE; SERVICE USE; PHILADELPHIA; PROGRAM; ADULTS; INDIVIDUALS
AB In recent years, permanent supportive housing (PSH) has emerged as the preferred intervention for addressing chronic homelessness in the United States. However, almost all prior studies examining the effectiveness of PSH have been conducted at the individual level, with only minimal attempts to empirically test the relationship between PSH and chronic homelessness at the community level. This study uses longitudinal data collected by the US Department of Housing and Urban Development (HUD) and several other sources to model the relationship between measures of community investment in PSH and rates of chronic homelessness. The results show modest negative associations between increased investment in PSH and rates of chronic homelessness over time. We discuss the implications of these findings for ongoing efforts to address chronic homelessness and future research.
C1 [Byrne, Thomas; Culhane, Dennis P.] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA.
   [Byrne, Thomas; Fargo, Jamison D.; Montgomery, Ann Elizabeth; Munley, Ellen; Culhane, Dennis P.] US Dept Vet Affairs, Washington, DC USA.
   [Fargo, Jamison D.] Utah State Univ, Logan, UT 84322 USA.
RP Byrne, T (reprint author), Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA.
NR 54
TC 6
Z9 6
U1 5
U2 29
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0037-7961
EI 1537-5404
J9 SOC SERV REV
JI Soc. Serv. Rev.
PD JUN
PY 2014
VL 88
IS 2
BP 234
EP 263
DI 10.1086/676142
PG 30
WC Social Work
SC Social Work
GA AJ5QV
UT WOS:000337741600002
ER

PT J
AU Brahmbhatt, R
   Carter, SA
   Hicks, SC
   Berger, DH
   Liang, MK
AF Brahmbhatt, Reshma
   Carter, Stacey A.
   Hicks, Stephanie C.
   Berger, David H.
   Liang, Mike K.
TI Identifying Risk Factors for Surgical Site Complications after
   Laparoscopic Ventral Hernia Repair: Evaluation of the Ventral Hernia
   Working Group Grading System
SO SURGICAL INFECTIONS
LA English
DT Article
ID INCISIONAL HERNIA; WOUND-INFECTION; MESH; HERNIORRHAPHY; METAANALYSIS;
   RECURRENCE; OUTCOMES
AB Background: In 2010, the Ventral Hernia Working Group (VHWG) published a grading system to assess the risk of surgical site complications in patients undergoing ventral hernia repair. This study evaluated the predictive value of the VHWG classification for the surgical outcomes of laparoscopic ventral hernia repair (LVHR) and identified independent factors associated with surgical site infection (SSI) and surgical site occurrence (SSO). Methods: A retrospective review was performed of all patients who underwent LVHR over a 10-year period at two institutions. The U.S. Centers for Disease Control and Prevention definition of SSI and the VHWG definition of SSO were used. Univariable analysis was performed using the Student t-test, analysis of variance, chi-square test, or Fisher exact test, as appropriate. Multivariable analysis was used to identify independent factors associated with SSI and SSO. Results: Differences in American Society of Anesthesiologists class, body mass index, diabetes mellitus, chronic obstructive pulmonary disease, tobacco use, hernia type, prior abdominal surgery, prior ventral hernia repair, hernia size, and total infections were identified by grade. There was no difference in SSI or SSO by grade. Multivariable analysis revealed institution and number of prior abdominal operations to be associated with SSI. Institution, prostate disease, and prior ventral hernia repair were associated with SSO. Conclusions: The VHWG classification was unable to predict SSI and SSO and may not be applicable in LVHR. This study identified independent factors associated with SSI and SSO in LVHR. Although further study is warranted to validate these results, the factors presented may be a useful tool to stratify patient risk of SSI and SSO with LVHR.
C1 [Brahmbhatt, Reshma; Carter, Stacey A.; Berger, David H.; Liang, Mike K.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Michael E DeBakey Dept Surg, Houston, TX 77030 USA.
   [Hicks, Stephanie C.] Rice Univ, Dept Stat, Houston, TX 77251 USA.
RP Liang, MK (reprint author), Michael E DeBakey VAMC, 2002 Holcombe Blvd,OCL 112, Houston, TX 77030 USA.
EM ml3@bcm.edu
RI Liang, Mike/L-8493-2015
OI Liang, Mike/0000-0001-7063-7291; Hicks, Stephanie/0000-0002-7858-0231
FU Lifecell; KCI; Acell
FX R.B., S.A.C., S.C.H., and D.H.B. declare no competing financial
   interests. M. K. L. has held research grants from Lifecell and
   unrestricted education grants from Lifecell, KCI, and Acell.
NR 40
TC 7
Z9 7
U1 0
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1096-2964
EI 1557-8674
J9 SURG INFECT
JI Surg. Infect.
PD JUN
PY 2014
VL 15
IS 3
BP 187
EP 193
DI 10.1089/sur.2012.179
PG 7
WC Infectious Diseases; Surgery
SC Infectious Diseases; Surgery
GA AJ9EI
UT WOS:000338009600006
PM 24773169
ER

PT J
AU Miller, RA
   Harrison, DE
   Astle, CM
   Fernandez, E
   Flurkey, K
   Han, M
   Javors, MA
   Li, XN
   Nadon, NL
   Nelson, JF
   Pletcher, S
   Salmon, AB
   Sharp, ZD
   Van Roekel, S
   Winkleman, L
   Strong, R
AF Miller, Richard A.
   Harrison, David E.
   Astle, Clinton M.
   Fernandez, Elizabeth
   Flurkey, Kevin
   Han, Melissa
   Javors, Martin A.
   Li, Xinna
   Nadon, Nancy L.
   Nelson, James F.
   Pletcher, Scott
   Salmon, Adam B.
   Sharp, Zelton Dave
   Van Roekel, Sabrina
   Winkleman, Lynn
   Strong, Randy
TI Rapamycin-mediated lifespan increase in mice is dose and sex dependent
   and metabolically distinct from dietary restriction
SO AGING CELL
LA English
DT Article
DE aging; caloric restriction; glucose; IGF-1; insulin; longevity; mouse;
   mTOR; rapamycin; xenobiotic metabolism
ID GENETICALLY HETEROGENEOUS MICE; INTERVENTIONS TESTING PROGRAM; AMES
   DWARF MICE; INSULIN SENSITIVITY; EXTENSION; LONGEVITY; TOR; RESISTANCE;
   PATHWAY; GENES
AB Rapamycin, an inhibitor of mTOR kinase, increased median lifespan of genetically heterogeneous mice by 23% (males) to 26% (females) when tested at a dose threefold higher than that used in our previous studies; maximal longevity was also increased in both sexes. Rapamycin increased lifespan more in females than in males at each dose evaluated, perhaps reflecting sexual dimorphism in blood levels of this drug. Some of the endocrine and metabolic changes seen in diet-restricted mice are not seen in mice exposed to rapamycin, and the pattern of expression of hepatic genes involved in xenobiotic metabolism is also quite distinct in rapamycin-treated and diet-restricted mice, suggesting that these two interventions for extending mouse lifespan differ in many respects.
C1 [Miller, Richard A.; Han, Melissa; Li, Xinna; Van Roekel, Sabrina; Winkleman, Lynn] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA.
   [Miller, Richard A.; Han, Melissa; Li, Xinna; Pletcher, Scott; Van Roekel, Sabrina; Winkleman, Lynn] Univ Michigan, Geriatr Ctr, Ann Arbor, MI 48109 USA.
   [Harrison, David E.; Astle, Clinton M.; Flurkey, Kevin] Jackson Lab, Bar Harbor, ME 04609 USA.
   [Fernandez, Elizabeth; Strong, Randy] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA.
   [Fernandez, Elizabeth; Strong, Randy] South Texas Vet Hlth Care Syst, Res Serv, San Antonio, TX 78229 USA.
   [Javors, Martin A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA.
   [Nadon, Nancy L.] NIA, Div Aging Biol, Bethesda, MD 20892 USA.
   [Nelson, James F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA.
   [Nelson, James F.; Salmon, Adam B.; Sharp, Zelton Dave; Strong, Randy] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA.
   [Pletcher, Scott] Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA.
   [Sharp, Zelton Dave] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78245 USA.
RP Miller, RA (reprint author), Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA.
EM millerr@umich.edu
FU NIH [AG022303, AG031736, AG022307, AG013319, AG022308, CA034196];
   Department of Veterans Affairs
FX This work was supported by NIH grants AG022303, AG031736 (RAM),
   AG022307, AG013319 (RS), and AG022308 (DEH), with important facilities
   supported by CA034196 (DEH) and the Department of Veterans Affairs (RS),
   We thank Lili Deng and Andrzej Galecki for statistical assistance, Jeff
   Halter for comments on an early draft of the paper, and Lisa Burmeister,
   Vivian Diaz, Nelson Durgin, Vicki Ingalls, Amanda Keedle, and Pam J
   Krason for technical assistance.
NR 46
TC 107
Z9 109
U1 2
U2 19
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1474-9718
EI 1474-9726
J9 AGING CELL
JI Aging Cell
PD JUN
PY 2014
VL 13
IS 3
BP 468
EP 477
DI 10.1111/acel.12194
PG 10
WC Cell Biology; Geriatrics & Gerontology
SC Cell Biology; Geriatrics & Gerontology
GA AJ2VV
UT WOS:000337523400009
PM 24341993
ER

PT J
AU Buck, KJ
   Iancu, OD
   Walter, NAR
AF Buck, K. J.
   Iancu, O. D.
   Walter, N. A. R.
TI QUANTITIATIVE TRAIT LOCUS (QTL), GENE EXPRESSION AND COEXPRESSION
   NETWORK ANALYSES IDENTIFY A ROLE FOR OXIDATIVE PHOSPHORYLATION IN
   ETHANOL WITHDRAWAL
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism
   (RSA) / 17th Congress of the
   International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA)
CY JUN 21-25, 2014
CL Bellevue, WA
SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism
C1 Portland VA Med Ctr, Dept Behav Neurosci, Portland, OR 97239 USA.
   Portland VA Med Ctr, Portland Alcohol Res Ctr, Portland, OR 97239 USA.
   Oregon Hlth & Sci Univ, Portland, OR 97239 USA.
NR 0
TC 0
Z9 0
U1 1
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2014
VL 38
SU 1
SI SI
MA 0011
BP 3A
EP 3A
PG 1
WC Substance Abuse
SC Substance Abuse
GA AJ2VX
UT WOS:000337523700012
ER

PT J
AU Williams, EC
   Lapham, GT
   Lee, AK
   Richards, JE
   Berger, DB
   Ludman, E
   Bradley, KA
AF Williams, E. C.
   Lapham, G. T.
   Lee, A. K.
   Richards, J. E.
   Berger, D. B.
   Ludman, E.
   Bradley, K. A.
TI READINESS TO CHANGE AND SEVERITY OF UNHEALTHY ALCOHOL USE AMONG PRIMARY
   CARE PATIENTS RECRUITED TO A TRIAL OF COLLABORATIVE CARE
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism
   (RSA) / 17th Congress of the
   International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA)
CY JUN 21-25, 2014
CL Bellevue, WA
SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism
C1 [Williams, E. C.] VA Puget Sound HSR&D COIN, Seattle, WA USA.
   [Williams, E. C.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
   [Lapham, G. T.; Lee, A. K.; Richards, J. E.; Ludman, E.; Bradley, K. A.] Grp Hlth Res Inst, Seattle, WA USA.
   [Berger, D. B.] VA Puget Sound, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2014
VL 38
SU 1
SI SI
MA 0226
BP 57A
EP 57A
PG 1
WC Substance Abuse
SC Substance Abuse
GA AJ2VX
UT WOS:000337523700227
ER

PT J
AU Hawkins, EJ
   Lapham, GT
   Lee, AK
   Kivlahan, DR
   Berger, BD
   Hebert, PL
   Saxon, AJ
   Bradley, KA
AF Hawkins, E. J.
   Lapham, G. T.
   Lee, A. K.
   Kivlahan, D. R.
   Berger, B. D.
   Hebert, P. L.
   Saxon, A. J.
   Bradley, K. A.
TI PREVALENCE AND COMORBIDITY OF PTSD AMONG HEAVY DRINKERS ENROLLED IN A
   COLLABORATIVE CARE TRIAL FOR ALCOHOL USE DISORDERS IN VA PRIMARY CARE
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism
   (RSA) / 17th Congress of the
   International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA)
CY JUN 21-25, 2014
CL Bellevue, WA
SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism
C1 Grp Hlth Res Inst, Seattle, WA 98101 USA.
   VA Puget Sound Hlth Care Syst, Seattle, WA 98118 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2014
VL 38
SU 1
SI SI
MA 0252
BP 63A
EP 63A
PG 1
WC Substance Abuse
SC Substance Abuse
GA AJ2VX
UT WOS:000337523700253
ER

PT J
AU Bradley, KA
   Lapham, GT
   Richards, J
   Merrill, JO
   Williams, EC
   Lee, AK
   Holden, E
   Chavez, LJ
   Kivlahan, DR
AF Bradley, K. A.
   Lapham, G. T.
   Richards, J.
   Merrill, J. O.
   Williams, E. C.
   Lee, A. K.
   Holden, E.
   Chavez, L. J.
   Kivlahan, D. R.
TI THE PREVALENCE OF DSM-IV VERSUS DSM-5 ALCOHOL USE DISORDERS (AUD) IN
   PRIMARY CARE PATIENTS AT HIGH RISK FOR AUD IN THE CHOICE TRIAL
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism
   (RSA) / 17th Congress of the
   International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA)
CY JUN 21-25, 2014
CL Bellevue, WA
SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism
C1 Univ Washington, VA Puget Sound, HSR&D COIN & Gen Med Serv, Grp Hlth Res Inst,Dept Med, Seattle, WA 98195 USA.
   Univ Washington, VA Puget Sound, HSR&D COIN & Gen Med Serv, Grp Hlth Res Inst,Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
   Univ Washington, VA Puget Sound, HSR&D COIN & Gen Med Serv, Grp Hlth Res Inst,Dept Hlth Serv, Seattle, WA 98195 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2014
VL 38
SU 1
SI SI
MA 0493
BP 124A
EP 124A
PG 1
WC Substance Abuse
SC Substance Abuse
GA AJ2VX
UT WOS:000337523700494
ER

PT J
AU Pennington, DL
   Lasher, BA
   Herbst, E
   Schrodek, E
   Hong, E
   Waldrop, A
   Heinz, A
   Williams, C
   Abrams, G
   Neylan, TC
   Seal, K
   Carney, C
   Besterman, A
   Batki, SL
AF Pennington, D. L.
   Lasher, B. A.
   Herbst, E.
   Schrodek, E.
   Hong, E.
   Waldrop, A.
   Heinz, A.
   Williams, C.
   Abrams, G.
   Neylan, T. C.
   Seal, K.
   Carney, C.
   Besterman, A.
   Batki, S. L.
TI COGNITION AND SELF-REGULATION IN VETERANS WITH ALCOHOL USE DISORDER,
   PTSD AND TBI: BASELINE SUBJECT CHARACTERISTICS IN TOPIRAMATE TREATMENT
   TRIALS
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism
   (RSA) / 17th Congress of the
   International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA)
CY JUN 21-25, 2014
CL Bellevue, WA
SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism
C1 [Pennington, D. L.; Lasher, B. A.; Herbst, E.; Schrodek, E.; Hong, E.; Waldrop, A.; Heinz, A.; Williams, C.; Abrams, G.; Neylan, T. C.; Seal, K.; Carney, C.; Besterman, A.; Batki, S. L.] UCSF Dept Psychiat, Addict Res Program, San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
NR 0
TC 0
Z9 0
U1 2
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2014
VL 38
SU 1
SI SI
MA 0547
BP 137A
EP 137A
PG 1
WC Substance Abuse
SC Substance Abuse
GA AJ2VX
UT WOS:000337523700548
ER

PT J
AU Gubner, NR
   Phillips, TJ
AF Gubner, N. R.
   Phillips, T. J.
TI EFFECTS OF VARENICLINE ON THE EXPRESSION OF ETHANOL-INDUCED LOCOMOTOR
   SENSITIZATION, A MOUSE MODEL OF NEUROADAPTATION
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism
   (RSA) / 17th Congress of the
   International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA)
CY JUN 21-25, 2014
CL Bellevue, WA
SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism
C1 [Gubner, N. R.; Phillips, T. J.] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland Alcohol Res Ctr, Dept Behav Neurosci, Portland, OR 97239 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2014
VL 38
SU 1
SI SI
MA 0622
BP 156A
EP 156A
PG 1
WC Substance Abuse
SC Substance Abuse
GA AJ2VX
UT WOS:000337523700623
ER

PT J
AU Krenek, M
   Simpson, TL
AF Krenek, M.
   Simpson, T. L.
TI DEGREE OF CORRESPONDENCE BETWEEN DAILY MONITORING AND RETROSPECTIVE
   RECALL OF ALCOHOL USE AMONG INDIVIDUALS WITH COMORBID AUD AND PTSD
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism
   (RSA) / 17th Congress of the
   International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA)
CY JUN 21-25, 2014
CL Bellevue, WA
SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism
C1 [Krenek, M.; Simpson, T. L.] VA Puget Sound Healthcare Syst, Seattle Div, Seattle, WA 98108 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2014
VL 38
SU 1
SI SI
MA 0823
BP 206A
EP 206A
PG 1
WC Substance Abuse
SC Substance Abuse
GA AJ2VX
UT WOS:000337523701023
ER

PT J
AU Collins, SE
   Duncan, MH
   Smart, BF
   Saxon, AJ
   Malone, DK
   Jackson, TR
   Ries, RK
AF Collins, S. E.
   Duncan, M. H.
   Smart, B. F.
   Saxon, A. J.
   Malone, D. K.
   Jackson, T. R.
   Ries, R. K.
TI A PILOT STUDY OF EXTENDED-RELEASE NALTREXONE AND HARM REDUCTION
   COUNSELING FOR CHRONICALLY HOMELESS PEOPLE WITH ALCOHOL DEPENDENCE
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism
   (RSA) / 17th Congress of the
   International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA)
CY JUN 21-25, 2014
CL Bellevue, WA
SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism
C1 [Collins, S. E.; Duncan, M. H.; Smart, B. F.; Ries, R. K.] Univ Washington, Seattle, WA 98195 USA.
   [Saxon, A. J.] VA Puget Sound, Seattle, WA 98108 USA.
   [Malone, D. K.] DESC, Seattle, WA 98104 USA.
   [Jackson, T. R.] Evergreen Treatment Serv, Seattle, WA 98134 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2014
VL 38
SU 1
SI SI
MA 0850
BP 213A
EP 213A
PG 1
WC Substance Abuse
SC Substance Abuse
GA AJ2VX
UT WOS:000337523701050
ER

PT J
AU Batki, SL
   Pennington, DL
   Lasher, BA
   Herbst, E
   Schrodek, E
   Hong, E
   Waldrop, A
   Heinz, A
   Williams, C
   Abrams, G
   Neylan, TC
   Seal, K
   Carney, C
   Besterman, A
AF Batki, S. L.
   Pennington, D. L.
   Lasher, B. A.
   Herbst, E.
   Schrodek, E.
   Hong, E.
   Waldrop, A.
   Heinz, A.
   Williams, C.
   Abrams, G.
   Neylan, T. C.
   Seal, K.
   Carney, C.
   Besterman, A.
TI ALCOHOL USE DISORDER AND PTSD SEVERITY IN VETERANS WITH AND WITHOUT
   COMORBID TBI: BASELINE SUBJECT CHARACTERISTICS IN TOPIRAMATE TREATMENT
   TRIALS
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism
   (RSA) / 17th Congress of the
   International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA)
CY JUN 21-25, 2014
CL Bellevue, WA
SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism
C1 [Batki, S. L.; Pennington, D. L.; Lasher, B. A.; Herbst, E.; Schrodek, E.; Hong, E.; Waldrop, A.; Heinz, A.; Williams, C.; Abrams, G.; Neylan, T. C.; Seal, K.; Carney, C.; Besterman, A.] Univ Calif San Francisco, Dept Psychiat, Addict Res Program, San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2014
VL 38
SU 1
SI SI
MA 0855
BP 214A
EP 214A
PG 1
WC Substance Abuse
SC Substance Abuse
GA AJ2VX
UT WOS:000337523701055
ER

PT J
AU Barkley-Levenson, AM
   Crabbe, JC
AF Barkley-Levenson, A. M.
   Crabbe, J. C.
TI NEUROPEPTIDE Y AND BINGE-LIKE DRINKING IN HIGH DRINKING IN THE DARK
   SELECTED MICE
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism
   (RSA) / 17th Congress of the
   International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA)
CY JUN 21-25, 2014
CL Bellevue, WA
SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism
C1 Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland Alcohol Res Ctr, Portland, OR 97239 USA.
   Portland VA Med Ctr, Portland, OR 97239 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2014
VL 38
SU 1
SI SI
MA 0896
BP 224A
EP 224A
PG 1
WC Substance Abuse
SC Substance Abuse
GA AJ2VX
UT WOS:000337523701096
ER

PT J
AU Wilhelm, CJ
   Beard, DR
   Hashimoto, JG
   Roberts, ML
   Loftis, JM
   Wiren, KM
AF Wilhelm, C. J.
   Beard, D. R.
   Hashimoto, J. G.
   Roberts, M. L.
   Loftis, J. M.
   Wiren, K. M.
TI DISTINCT GLUCOCORTICOID SIGNALING ASSOCIATED WITH ETHANOL-INDUCED
   INFLAMMOTOXICITY
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism
   (RSA) / 17th Congress of the
   International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA)
CY JUN 21-25, 2014
CL Bellevue, WA
SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism
C1 Portland VA Med Ctr, Res Serv, Portland, OR 97239 USA.
   Oregon Hlth & Sci Univ, Portland, OR 97239 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2014
VL 38
SU 1
SI SI
MA 0991
BP 248A
EP 248A
PG 1
WC Substance Abuse
SC Substance Abuse
GA AJ2VX
UT WOS:000337523701191
ER

PT J
AU McGinnis, K
   Tate, J
   Bryant, K
   Fiellin, D
   Justice, A
AF McGinnis, K.
   Tate, J.
   Bryant, K.
   Fiellin, D.
   Justice, A.
TI SENSITIVITY TO ALCOHOL INTOXICATION EFFECTS BY HIV STATUS AND TREATMENT
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism
   (RSA) / 17th Congress of the
   International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA)
CY JUN 21-25, 2014
CL Bellevue, WA
SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism
C1 VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
   CT VA Healthcare Syst, Vet Aging Cohort Study, West Haven, CT USA.
   Yale Univ, New Haven, CT USA.
   NIAAA, Bethesda, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2014
VL 38
SU 1
SI SI
MA 1131
BP 283A
EP 283A
PG 1
WC Substance Abuse
SC Substance Abuse
GA AJ2VX
UT WOS:000337523701330
ER

PT J
AU Barkley-Levenson, AM
   Crabbe, JC
AF Barkley-Levenson, A. M.
   Crabbe, J. C.
TI BEHAVIORAL AND MOLECULAR CHARACTERISTICS OF MICE 'AT-RISK' FOR
   BINGE-LIKE DRINKING
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism
   (RSA) / 17th Congress of the
   International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA)
CY JUN 21-25, 2014
CL Bellevue, WA
SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism
C1 Oregon Hlth & Sci Univ, Portland Alcohol Res Ctr, Dept Behav Neurosci, Portland, OR 97239 USA.
   Portland VA Med Ctr, Portland, OR 97239 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2014
VL 38
SU 1
SI SI
MA 247
BP 354A
EP 354A
PG 1
WC Substance Abuse
SC Substance Abuse
GA AJ2VX
UT WOS:000337523701614
ER

PT J
AU Rasmussen, DD
   Beckwith, LE
   Kincaid, CL
   Froehlich, JC
AF Rasmussen, Dennis D.
   Beckwith, Lauren E.
   Kincaid, Carrie L.
   Froehlich, Janice C.
TI Combining the 1-Adrenergic Receptor Antagonist, Prazosin, with the
   -Adrenergic Receptor Antagonist, Propranolol, Reduces Alcohol Drinking
   More Effectively Than Either Drug Alone
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Article
DE Propranolol; Prazosin; Alcoholism Treatment; Noradrenergic
ID PREFERRING P RATS; DEPENDENCE; ETHANOL; WITHDRAWAL; PREFERENCE
AB Background Evidence suggests that activation of the noradrenergic system may contribute to alcohol drinking in animals and humans. Our previous studies demonstrated that blocking 1-adrenergic receptors with the antagonist, prazosin, decreased alcohol drinking in rats under various conditions. As noradrenergic activation is also regulated by -adrenergic receptors, we now examine the effects of the -adrenergic receptor antagonist, propranolol, alone or in combination with prazosin, on alcohol drinking in rats selectively bred for high voluntary alcohol intake and alcohol preference (P line). Methods Two studies were conducted with male P rats. In study 1, rats were allowed to become alcohol-dependent during 14weeks of ad libitum access to food, water, and 20% alcohol, and the effect of propranolol (5 to 15mg/kg, intraperitoneally [IP]) and prazosin (1 to 2mg/kg, IP) on alcohol intake during withdrawal was assessed. In study 2, the effect of propranolol (5mg/kg, IP) and prazosin (2mg/kg, IP) on alcohol intake following prolonged imposed abstinence was assessed. Results Alcohol drinking following propranolol treatment was variable, but the combination of propranolol+prazosin consistently suppressed alcohol drinking during both alcohol withdrawal and following prolonged imposed abstinence, and the combination of these 2 drugs was more effective than was treatment with either drug alone. Conclusions Treatment with prazosin+propranolol, or a combination of other centrally active 1- and -adrenergic receptor antagonists, may assist in preventing alcohol relapse in some individuals.
C1 [Rasmussen, Dennis D.] VISN 20 Mental Illness Res Educ & Clin Ctr, Seattle, WA USA.
   [Rasmussen, Dennis D.; Beckwith, Lauren E.; Kincaid, Carrie L.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
   [Rasmussen, Dennis D.; Beckwith, Lauren E.; Kincaid, Carrie L.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
   [Froehlich, Janice C.] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA.
RP Rasmussen, DD (reprint author), VA Puget Sound Hlth Care Syst, Med Ctr, MIRECC 116, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM drasmuss@u.washington.edu
FU NIH [R01 AA018604, P20 AA017839, AA018604, P60 AA007611, R24 AA15512]
FX This material is based on work supported in part by resources from the
   VA Puget Sound Health Care System, the VA VISN 20 Mental Illness
   Research, Education and Clinical Center (MIRECC), and by NIH grants R01
   AA018604, P20 AA017839 (DDR) and AA018604, P60 AA007611 (JCF). P rats
   were provided by the Alcohol Research Resource Center supported by NIH
   grant R24 AA15512.
NR 28
TC 8
Z9 8
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2014
VL 38
IS 6
BP 1532
EP 1539
DI 10.1111/acer.12441
PG 8
WC Substance Abuse
SC Substance Abuse
GA AJ2SI
UT WOS:000337511400006
PM 24891220
ER

PT J
AU Medici, V
   Schroeder, DI
   Woods, R
   LaSalle, JM
   Geng, YZ
   Shibata, NM
   Peerson, J
   Hodzic, E
   Dayal, S
   Tsukamoto, H
   Kharbanda, KK
   Tillman, B
   French, SW
   Halsted, CH
AF Medici, Valentina
   Schroeder, Diane I.
   Woods, Rima
   LaSalle, Janine M.
   Geng, Yongzhi
   Shibata, Noreene M.
   Peerson, Janet
   Hodzic, Emir
   Dayal, Sanjana
   Tsukamoto, Hidekazu
   Kharbanda, Kusum K.
   Tillman, Brittany
   French, Samuel W.
   Halsted, Charles H.
TI Methylation and Gene Expression Responses to Ethanol Feeding and Betaine
   Supplementation in the Cystathionine Beta Synthase-Deficient Mouse
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Article
DE Alcohol; S-Adenosylmethionine; S-Adenosylhomocysteine; Cystathionine
   Beta Synthase; DNA Methylation
ID ALCOHOLIC LIVER-DISEASE; ENDOPLASMIC-RETICULUM STRESS; NITRIC-OXIDE
   SYNTHASE; GLOBAL DNA METHYLATION; MICROPIGS FED ETHANOL; ALPHA
   PPAR-ALPHA; METHIONINE METABOLISM; EPIGENETIC REGULATION; MICE; INJURY
AB Background Alcoholic steatohepatitis (ASH) is caused in part by the effects of ethanol (EtOH) on hepatic methionine metabolism. Methods To investigate the phenotypic and epigenetic consequences of altered methionine metabolism in this disease, we studied the effects of 4-week intragastric EtOH feeding with and without the methyl donor betaine in cystathionine beta synthase (CS) heterozygous C57BL/6J mice. Results The histopathology of early ASH was induced by EtOH feeding and prevented by betaine supplementation, while EtOH feeding reduced and betaine supplementation maintained the hepatic methylation ratio of the universal methyl donor S-adenosylmethionine (SAM) to the methyltransferase inhibitor S-adenosylhomocysteine (SAH). MethylC-seq genomic sequencing of heterozygous liver samples from each diet group found 2 to 4% reduced methylation in gene bodies, but not promoter regions of all autosomes of EtOH-fed mice, each of which were normalized in samples from mice fed the betaine-supplemented diet. The transcript levels of nitric oxide synthase (Nos2) and DNA methyltransferase 1 (Dnmt1) were increased, while those of peroxisome proliferator receptor- (Ppar) were reduced in EtOH-fed mice, and each was normalized in mice fed the betaine-supplemented diet. DNA pyrosequencing of CS heterozygous samples found reduced methylation in a gene body of Nos2 by EtOH feeding that was restored by betaine supplementation and was correlated inversely with its expression and positively with SAM/SAH ratios. Conclusions The present study has demonstrated relationships among EtOH induction of ASH with aberrant methionine metabolism that was associated with gene body DNA hypomethylation in all autosomes and was prevented by betaine supplementation. The data imply that EtOH-induced changes in selected gene transcript levels and hypomethylation in gene bodies during the induction of ASH are a result of altered methionine metabolism that can be reversed through dietary supplementation of methyl donors.
C1 [Medici, Valentina; Geng, Yongzhi; Shibata, Noreene M.; Halsted, Charles H.] Univ Calif Davis, Dept Internal Med, Sacramento, CA 95817 USA.
   [Schroeder, Diane I.; Woods, Rima; LaSalle, Janine M.] Univ Calif Davis, Dept Med Microbiol & Immunol, Genome Ctr, Sacramento, CA 95817 USA.
   Univ Calif Davis, MIND Inst, Sacramento, CA 95817 USA.
   [Peerson, Janet] Univ Calif Davis, Dept Nutr, Sacramento, CA 95817 USA.
   [Hodzic, Emir] Univ Calif Davis, Sch Vet Med, Real Time PCR & Res Diagnost Facil, Sacramento, CA 95817 USA.
   [Dayal, Sanjana] Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA.
   [Tsukamoto, Hidekazu] Univ So Calif, Keck Sch Med, Southern Calif Res Ctr ALPD & Cirrhosis, Los Angeles, CA 90033 USA.
   [Tsukamoto, Hidekazu] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA.
   [Kharbanda, Kusum K.] Vet Affairs Nebraska Western Iowa Hlth Care Syst, Res Serv, Omaha, NE USA.
   [Tillman, Brittany; French, Samuel W.] Harbor UCLA Med Ctr, Dept Pathol, Torrance, CA 90509 USA.
RP Medici, V (reprint author), Univ Calif Davis, Div Gastroenterol & Hepatol, Dept Internal Med, 4150 5 St,Suite 3500, Sacramento, CA 95817 USA.
EM valentina.medici@ucdmc.ucdavis.edu
RI Schroeder, Diane/I-2200-2015
OI Schroeder, Diane/0000-0003-2282-9912; LaSalle,
   Janine/0000-0002-3480-2031
FU National Institutes of Health [K08DK084111, R03AA020577-01, P50AA11991];
   Southern California Research Center for ALPD and Cirrhosis; Morphology
   Core [P50AA11991]; Department of Veterans Affairs, Office of Research
   and Development [BX001155]; Liver Center [P30 DK026743]; Division of
   Gastroenterology and Hepatology at UC Davis;  [R01ES021707]
FX This research was supported by National Institutes of Health grant
   numbers K08DK084111 (to VM), R03AA020577-01 (to CHH), P50AA11991
   Southern California Research Center for ALPD and Cirrhosis (to HT),
   P50AA11991 Morphology Core (to SWF), R01ES021707 (to JML and DIS), and
   by a Biomedical Laboratory Research and Development National Merit
   Review grant BX001155 from the Department of Veterans Affairs, Office of
   Research and Development (to KKK). VM is a member of the University of
   California San Francisco Liver Center (Liver Center grant number P30
   DK026743) and received funds from the Division of Gastroenterology and
   Hepatology at UC Davis. The content is the sole responsibility of the
   authors and does not necessarily represent the official views of the
   National Institutes of Health.
NR 49
TC 7
Z9 7
U1 1
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2014
VL 38
IS 6
BP 1540
EP 1549
DI 10.1111/acer.12405
PG 10
WC Substance Abuse
SC Substance Abuse
GA AJ2SI
UT WOS:000337511400007
PM 24730561
ER

PT J
AU Glass, JE
   Williams, EC
   Bucholz, KK
AF Glass, Joseph E.
   Williams, Emily C.
   Bucholz, Kathleen K.
TI Psychiatric Comorbidity and Perceived Alcohol Stigma in a Nationally
   Representative Sample of Individuals with DSM-5 Alcohol Use Disorder
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Article
DE Perceived Stigma; Alcoholism Stigma; Alcohol; Psychiatric Disorders;
   Latent Class Analysis
ID SUBSTANCE USE DISORDERS; LABELING THEORY APPROACH; LATENT CLASS
   ANALYSIS; DRUG-USE DISORDERS; UNITED-STATES; EPIDEMIOLOGIC SURVEY;
   MENTAL-DISORDERS; SEXUAL MINORITY; HEALTH; CONSEQUENCES
AB Background Alcohol use disorder (AUD) is among the most stigmatized health conditions and is frequently comorbid with mood, anxiety, and drug use disorders. Theoretical frameworks have conceptualized stigma-related stress as a predictor of psychiatric disorders. We described profiles of psychiatric comorbidity among people with AUD and compared levels of perceived alcohol stigma across profiles. Methods Cross-sectional data were analyzed from a general population sample of U.S. adults with past-year DSM-5 AUD (n=3,368) from the National Epidemiologic Survey on Alcohol and Related Conditions, which was collected from 2001 to 2005. Empirically derived psychiatric comorbidity profiles were established with latent class analysis, and mean levels of perceived alcohol stigma were compared across the latent classes while adjusting for sociodemographic characteristics and AUD severity. Results Four classes of psychiatric comorbidity emerged within this AUD sample, including those with: (i) high comorbidity, reflecting internalizing (i.e., mood and anxiety disorders) and externalizing (i.e., antisocial personality and drug use disorders) disorders; (ii) externalizing comorbidity; (iii) internalizing comorbidity; and (iv) no comorbidity. Perceived alcohol stigma was significantly higher in those with internalizing comorbidity (but not those with high comorbidity) as compared to those with no comorbidity or externalizing comorbidity. Conclusions Perceived stigma, as manifested by anticipations of social rejection and discrimination, may increase risk of internalizing psychiatric comorbidity. Alternatively, internalizing psychiatric comorbidity could sensitize affected individuals to perceive more negative attitudes toward them. Future research is needed to understand causal and bidirectional associations between alcohol stigma and psychiatric comorbidity.
C1 [Glass, Joseph E.] Univ Wisconsin, Sch Social Work, Madison, WI 53706 USA.
   [Williams, Emily C.] VA Puget Sound Hlth Care Syst, Denver Seattle Ctr Innovat Vet Ctr & Value Driven, Hlth Serv Res & Dev, Seattle, WA USA.
   [Williams, Emily C.] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA.
   [Bucholz, Kathleen K.] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA.
   [Bucholz, Kathleen K.] Washington Univ, Sch Med, Midwest Alcoholism Res Ctr, St Louis, MO USA.
RP Glass, JE (reprint author), Univ Wisconsin, Sch Social Work, 1350 Univ Ave, Madison, WI 53706 USA.
EM jglass2@wisc.edu
FU National Institutes of Health under Ruth L. Kirschstein National
   Research Service [5T32 DA015035, 1F31AA021034]; VA Health Services
   Research Development [CDA 12-276]; National Institute of Mental Health
   [R25 MH080916-01A2]; Department of Veterans Affairs, Health Services
   Research & Development Service, Quality Enhancement Research Initiative
   (QUERI); National Institute on Alcohol Abuse and Alcoholism; National
   Institute on Drug Abuse of the National Institute of Health
   [R01AA012460, P60AA011998, U01AA008401, R01AA017915, R01AA01 7444,
   R21AA020018, R01DA014363]
FX We are grateful to Sean D. Kristjannson for consultations on the
   statistical analysis and the feedback that he provided on this work. Dr.
   Glass received support to conduct this project from the National
   Institutes of Health under Ruth L. Kirschstein National Research Service
   Awards 5T32 DA015035 and 1F31AA021034. Dr. Williams is supported by a
   Career Development Award from VA Health Services Research & Development
   (CDA 12-276) and is an investigator with the Implementation Research
   Institute (IRI) at the George Warren Brown School of Social Work at
   Washington University in St. Louis. IRI is supported through an award
   from the National Institute of Mental Health (R25 MH080916-01A2) and the
   Department of Veterans Affairs, Health Services Research & Development
   Service, Quality Enhancement Research Initiative (QUERI). For the
   research reported in this publication, KKB was supported by the National
   Institute on Alcohol Abuse and Alcoholism and the National Institute on
   Drug Abuse of the National Institute of Health under award numbers
   R01AA012460, P60AA011998, U01AA008401, R01AA017915, R01AA01 7444,
   R21AA020018, and R01DA014363.
NR 50
TC 6
Z9 6
U1 4
U2 14
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2014
VL 38
IS 6
BP 1697
EP 1705
DI 10.1111/acer.12422
PG 9
WC Substance Abuse
SC Substance Abuse
GA AJ2SI
UT WOS:000337511400025
PM 24848495
ER

PT J
AU Schmidt, TP
   Pennington, DL
   Durazzo, TC
   Meyerhoff, DJ
AF Schmidt, Thomas P.
   Pennington, David L.
   Durazzo, Timothy C.
   Meyerhoff, Dieter J.
TI Postural Stability in Cigarette Smokers and During Abstinence from
   Alcohol
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Article
DE Ataxia; Balance; Postural Stability; Alcohol Dependence; Cigarette
   Smoking; Abstinence
ID CROSS-SECTIONAL ANALYSIS; GRAY-MATTER VOLUMES; SHORT-TERM RECOVERY;
   ATAXIA TEST BATTERY; NEUROCOGNITIVE RECOVERY; NICOTINE DEPENDENCE;
   MAGNETIC-RESONANCE; GAIT DISTURBANCES; MAJOR DEPRESSION; BRAIN STRUCTURE
AB Background Static postural instability is common in alcohol-dependent individuals (ALC). Chronic alcohol consumption has deleterious effects on the neural and perceptual systems subserving postural stability. However, little is known about the effects of chronic cigarette smoking on postural stability and its changes during abstinence from alcohol. Methods A modified Fregly ataxia battery was administered to a total of 115 smoking (sALC) and nonsmoking ALC (nsALC) and to 71 smoking (sCON) and nonsmoking light/nondrinking controls (nsCON). Subgroups of abstinent ALC were assessed at 3 time points (TPs; approximately 1, 5, 34weeks of abstinence from alcohol); a subset of nsCON was retested at 40weeks. We tested whether cigarette smoking affects postural stability in CON and in ALC during extended abstinence from alcohol, and we used linear mixed effects modeling to measure change across TPs within ALC. Results Chronic smoking was associated with reduced performance on the Sharpened Romberg eyes-closed task in abstinent ALC at all 3 TPs and in CON. The test performance of nsALC increased significantly between 1 and 32weeks of abstinence, whereas the corresponding increases for sALC between 1 and 35weeks were nonsignificant. With long-term abstinence from alcohol, nsALC recovered into the range of nsCON and sALC recovered into the range of sCON. Static postural stability decreased with age and correlated with smoking variables but not with drinking measures. Conclusions Chronic smoking was associated with reduced static postural stability with eyes closed and with lower increases of postural stability during abstinence from alcohol. Smoking cessation in alcohol dependence treatment may facilitate recovery from static postural instability during abstinence.
C1 [Schmidt, Thomas P.; Pennington, David L.; Durazzo, Timothy C.; Meyerhoff, Dieter J.] San Francisco VA Med Ctr, CIND, San Francisco, CA 94121 USA.
   [Schmidt, Thomas P.; Pennington, David L.; Durazzo, Timothy C.; Meyerhoff, Dieter J.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA.
RP Schmidt, TP (reprint author), San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis 114M, 4150 Clement St, San Francisco, CA 94121 USA.
EM thomas.schmidt@ucsf.edu
FU National Institutes of Health [AA10788, DA24136]
FX This work was supported by grants from the National Institutes of Health
   [AA10788 to DJM.; DA24136 to TCD] administered by the Northern
   California Institute for Research and Education, and by the use of
   resources and facilities at the San Francisco Veterans Administration
   Medical Center. We thank Mary Rebecca Young, Kathleen Altieri, Ricky
   Chen, and Drs. Peter Banys, Steven Batki, and Ellen Herbst of the
   Veterans Administration Substance Abuse Day Hospital, and Dr. David
   Pating, Karen Moise, and their colleagues at the Kaiser Permanente
   Chemical Dependency Recovery Program in San Francisco for their valuable
   assistance in recruiting participants. We also wish to extend our
   gratitude to the study participants, who made this research possible.
NR 54
TC 1
Z9 1
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2014
VL 38
IS 6
BP 1753
EP 1760
DI 10.1111/acer.12409
PG 8
WC Substance Abuse
SC Substance Abuse
GA AJ2SI
UT WOS:000337511400032
PM 24721012
ER

PT J
AU Harvey, PD
   Siever, LJ
   Huang, GD
   Muralidhar, S
   Zhao, HY
   Miller, P
   Aslan, M
   Mane, S
   McNamara, M
   Gleason, T
   Brophy, M
   Przygodszki, R
   O'Leary, TJ
   Gaziano, M
   Concato, J
AF Harvey, Philip D.
   Siever, Larry J.
   Huang, Grant D.
   Muralidhar, Sumitra
   Zhao, Hongyu
   Miller, Perry
   Aslan, Mihaela
   Mane, Shrikant
   McNamara, Margaret
   Gleason, Theresa
   Brophy, Mary
   Przygodszki, Ronald
   O'Leary, Timothy J.
   Gaziano, Michael
   Concato, John
TI The Genetics of Functional Disability in Schizophrenia and Bipolar
   Illness: Methods and Initial Results for VA Cooperative Study #572
SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS
LA English
DT Article
DE schizophrenia; bipolar; genetics; neurocognition; disability
ID CONSENSUS COGNITIVE BATTERY; MENTAL-ILLNESS; UNITED-STATES; I DISORDER;
   CONSORTIUM; ENDOPHENOTYPES; IMPAIRMENT; PREDICTION; STABILITY; CANDIDATE
AB Given the prominence of cognitive impairments and disability associated with schizophrenia and bipolar disorder, substantial interest has arisen in identifying determinants of the diseases and their features. Genetic variation has been linked to skills that underlie disability ("functional capacity" or FC), highlighting need for understanding of these relationships. We describe the design and methods of a large, multisite, observational study focusing on the genetics of functional disability in schizophrenia and bipolar disorder, presenting initial data on recruitment, and characterization of the sample. Known as Veterans Affairs (VA) Cooperative Studies Program (CSP)#572, this study is recruiting, diagnosing, and assessing U.S. Veterans with either schizophrenia or bipolar I disorder. Assessments include neuropsychological (NP) testing, FC, suicidality, and co-morbid conditions such as posttraumatic stress disorder (PTSD). A sample of "psychiatrically healthy" Veterans from another project serves as a comparison group. An interim total of 8,140 participants (42.1% schizophrenia) have been recruited and assessed as of September 30, 2013, with 9 months of enrollment remaining and with a target sample size of 9,500. Veterans with schizophrenia were more likely to never have married, whereas lifetime PTSD and suicidality were more common in the bipolar veterans. Performance on the FC measures and NP tests was consistent with previous results, with mean t-scores of 35 (-1.5 SD) for schizophrenia and 41 (-0.9 SD) for the bipolar Veterans. This large population is representative of previous studies in terms of patient performance and co-morbidities. Subsequent genomic analyses will examine the genomic correlates of performance-based measures. Published 2014. This article is a U.S. Government work and is in the public domain in the USA.
C1 [Harvey, Philip D.] Bruce W Carter Miami Vet Affairs VA Med Ctr, Miami, FL USA.
   [Harvey, Philip D.] Univ Miami, Sch Med, Miami, FL 33136 USA.
   [Siever, Larry J.; McNamara, Margaret] James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
   [Siever, Larry J.; McNamara, Margaret] Mt Sinai Sch Med, New York, NY USA.
   [Huang, Grant D.; Muralidhar, Sumitra; Gleason, Theresa; Przygodszki, Ronald; O'Leary, Timothy J.] Vet Hlth Adm, Off Res & Dev, Washington, DC USA.
   [Zhao, Hongyu; Miller, Perry; Aslan, Mihaela; Concato, John] VA Connecticut Healthcare Syst, CERC, West Haven, CT USA.
   [Zhao, Hongyu; Miller, Perry; Aslan, Mihaela; Mane, Shrikant; Concato, John] Yale Univ, Sch Med, New Haven, CT USA.
   [Brophy, Mary; Gaziano, Michael] MAVERIC, Jamaica Plain, MA USA.
   [Brophy, Mary] Boston Univ, Sch Med, Boston, MA 02118 USA.
   [Gaziano, Michael] Harvard Univ, Boston, MA 02115 USA.
RP Harvey, PD (reprint author), Univ Miami, Miller Sch Med, 1120 NW 14th St,Suite 1450, Miami, FL 33136 USA.
EM pharvey@med.miami.edu
OI Przygodzki, Ronald/0000-0002-1238-262X
FU Department of Veterans Affairs Cooperative Studies Program
FX Grant sponsor: Department of Veterans Affairs Cooperative Studies
   Program.
NR 36
TC 10
Z9 10
U1 8
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1552-4841
EI 1552-485X
J9 AM J MED GENET B
JI Am. J. Med. Genet. B
PD JUN
PY 2014
VL 165
IS 4
BP 381
EP 389
DI 10.1002/ajmg.b.32242
PG 9
WC Genetics & Heredity; Psychiatry
SC Genetics & Heredity; Psychiatry
GA AJ4UX
UT WOS:000337674600012
PM 24798943
ER

PT J
AU Molnar, AO
   Parikh, CR
   Coca, SG
   Thiessen-Philbrook, H
   Koyner, JL
   Shlipak, MG
   Myers, ML
   Garg, AX
AF Molnar, Amber O.
   Parikh, Chirag R.
   Coca, Steven G.
   Thiessen-Philbrook, Heather
   Koyner, Jay L.
   Shlipak, Michael G.
   Myers, Mary Lee
   Garg, Amit X.
CA TRIBE-AKI Consortium
TI Association Between Preoperative Statin Use and Acute Kidney Injury
   Biomarkers in Cardiac Surgical Procedures
SO ANNALS OF THORACIC SURGERY
LA English
DT Article
ID ACUTE-RENAL-FAILURE; ISCHEMIA-REPERFUSION INJURY; URINARY BIOMARKERS;
   SURGERY; THERAPY; RISK; OUTCOMES; BYPASS; PRAVASTATIN; DEFINITION
AB Background. Acute kidney injury (AKI) is a serious complication of cardiac operations for which there remains no specific therapy. Animal data and several observational studies suggest that statins prevent AKI, but the results are not conclusive, and many studies are retrospective in nature.
   Methods. We conducted a multicenter prospective cohort study of 625 adult patients undergoing elective cardiac operations. All patients were taking statins and were grouped according to whether statins were continued or held in the 24 hours before operation. The primary outcome was AKI as defined by a doubling of serum creatinine or dialysis. The secondary outcome was the peak level of several kidney injury biomarkers. The results were adjusted for demographic and clinical factors.
   Results. Continuing(vs holding) a statin before operation was not associated with a lower risk of AKI, as defined by a doubling of serum creatinine or dialysis (adjusted relative risk [RR] 1.09; 95% confidence interval [CI] 0.44, 2.70). However, continuing a statin was associated with a lower risk of elevation of the following AKI biomarkers: urine interleukin-18, urine neutrophil gelatinase-associated lipocalin, urine kidney injury molecule-1, and plasma neutrophil gelatinase-associated lipocalin (adjusted RR 0.34; 95% CI 0.18, 0.62), (adjusted RR 0.41; 95% CI 0.22, 0.76), (adjusted RR 0.37; 95% CI 0.20, 0.76), (adjusted RR 0.62; 95% CI 0.39, 0.98), respectively.
   Conclusions. Statins may prevent kidney injury after cardiac operations, as evidenced by lower levels of kidney injury biomarkers. (c) 2014 by The Society of Thoracic Surgeons
C1 Univ Ottawa, Dept Med, Div Nephrol, Ottawa, ON, Canada.
   Yale Univ, Sch Med, Nephrol Sect, Vet Affairs CT Healthcare Syst, New Haven, CT USA.
   Yale Univ, Program Appl Translat Res, New Haven, CT USA.
   Vet Affairs Med Ctr, Dept Med, West Haven, CT USA.
   Univ Western Ontario, Dept Med, Div Nephrol, London, ON, Canada.
   Univ Chicago, Pritzker Sch Med, Dept Med, Nephrol Sect, Chicago, IL 60637 USA.
   Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Div Gen Internal Med, San Francisco, CA 94143 USA.
   Univ Western Ontario, Div Cardiac Surg, London, ON, Canada.
   McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada.
   Univ Western Ontario, Dept Epidemiol & Biostat, London, ON, Canada.
   Inst Clin Evaluat Sci, Toronto, ON, Canada.
RP Parikh, CR (reprint author), Yale Univ, Nephrol Sect, 950 Campbell Ave,Mail Code 151B,Bldg 35 A,Rm 219, West Haven, CT 06516 USA.
EM chirag.parikh@yale.edu
FU NIH [RO1HL085757, K24DK090203]; TRIBE-AKI Consortium; National
   Institutes of Health [K23DK080132, R01DK096549, R01HL085757]; Acute
   Kidney Injury (ASSESS-AKI) Consortium [U01DK082185]
FX This study was supported by the NIH grant RO1HL085757 (CRP) to fund the
   TRIBE-AKI Consortium to study novel biomarkers of acute kidney injury in
   cardiac surgery. S.G.C. is supported by National Institutes of Health
   Grants K23DK080132, R01DK096549, and R01HL085757. C.R.P. is also
   supported by NIH grant K24DK090203. S.G.C., A.X.G., and C.R.P. are also
   members of the NIH-sponsored ASsess, Serial Evaluation, and Subsequent
   Sequelae in Acute Kidney Injury (ASSESS-AKI) Consortium (U01DK082185).
   The urine biomarker assays were donated by Abbott Diagnostics (IL-18 and
   NGAL) and Sekisui Diagnostics, LLC (KIM-1 and L-FABP). The granting
   agencies, Abbott Diagnostics and Sekisui Diagnostics, Inc, did not
   participate in the design and conduct of the study; collection,
   management, analysis, and interpretation of the data; and preparation,
   review, or approval of the manuscript.
NR 40
TC 17
Z9 17
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
EI 1552-6259
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD JUN
PY 2014
VL 97
IS 6
BP 2081
EP 2088
DI 10.1016/j.athoracsur.2014.02.033
PG 9
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA AI9KT
UT WOS:000337252200032
PM 24725831
ER

PT J
AU Domsic, RT
   Nihtyanova, SI
   Wisniewski, SR
   Fine, MJ
   Lucas, M
   Kwoh, CK
   Denton, CP
   Medsger, TA
AF Domsic, Robyn T.
   Nihtyanova, Svetlana I.
   Wisniewski, Stephen R.
   Fine, Michael J.
   Lucas, Mary
   Kwoh, C. Kent
   Denton, Christopher P.
   Medsger, Thomas A., Jr.
TI Derivation and Validation of a Prediction Rule for Two-Year Mortality in
   Early Diffuse Cutaneous Systemic Sclerosis
SO ARTHRITIS & RHEUMATOLOGY
LA English
DT Article
ID CLINICAL-PREDICTION; SCLERODERMA; SURVIVAL; FEATURES; DEATH; EMPHASIS;
   DISEASE; COHORT; MODEL
AB Objective. Systemic sclerosis (SSc) is associated with a reduction in life expectancy, but there are no validated prognostic models for determining short-term mortality. The objective of this study was to derive and validate a prediction rule for 2-year mortality in patients with early diffuse cutaneous SSc (dcSSc).
   Methods. We studied a prospectively enrolled cohort of 387 US Caucasian patients with early dcSSc (<2 years from the appearance of the first symptom), randomly divided into a derivation cohort (n = 260) and a validation cohort (n = 127). Predefined baseline predictor variables were analyzed in a stepwise multi-variable logistic regression model in order to identify factors independently associated with 2-year all-cause mortality using a cutoff of P < 0.05. We rounded the beta values to the nearest integer and summed the points assigned to each variable in order to stratify patients into low-risk, moderate-risk, and high-risk groups. We then applied this rule to an external validation cohort of 110 Caucasian patients with early dcSSc from a single UK center and compared stratum-specific mortality using chi-square statistics.
   Results. Four independent predictor variables (with assigned integer values) comprised the model: age at first visit (points allotted: -1, 0, or 1), skin thickness progression rate (points allotted: 0 or 1), gastrointestinal tract severity (points allotted: 0, 1, or 2), and anemia (points allotted: 0 or 2). The prediction model performed well, with no significant differences between the derivation cohort and the US or UK validation cohorts in the low-risk and moderate-risk groups.
   Conclusion. We derived a 4-variable prediction rule that can be used to stratify patients with early dcSSc into groups by risk of 2-year mortality, and we validated that prediction rule in US and UK cohorts.
C1 [Domsic, Robyn T.; Wisniewski, Stephen R.; Fine, Michael J.; Lucas, Mary; Kwoh, C. Kent; Medsger, Thomas A., Jr.] Univ Pittsburgh, Pittsburgh, PA 15261 USA.
   [Nihtyanova, Svetlana I.; Denton, Christopher P.] UCL, Sch Med, Royal Free Hosp, London W1N 8AA, England.
   [Fine, Michael J.; Kwoh, C. Kent] Vet Affairs Pittsburgh Healthcare, Vet Affairs Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
RP Domsic, RT (reprint author), Univ Pittsburgh, S724 Biomed Sci Tower,3500 Terrace St, Pittsburgh, PA 15261 USA.
EM rtd4@pitt.edu
OI Wisniewski, Stephen/0000-0002-3877-9860
FU NIH (from the National Institute of Arthritis and Musculoskeletal and
   Skin Diseases) [K23-AR-057845]
FX Dr. Domsic's work was supported by the NIH (grant K23-AR-057845 from the
   National Institute of Arthritis and Musculoskeletal and Skin Diseases).
NR 34
TC 9
Z9 9
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2326-5191
EI 2326-5205
J9 ARTHRITIS RHEUMATOL
JI Arthritis Rheumatol.
PD JUN
PY 2014
VL 66
IS 6
BP 1616
EP 1624
DI 10.1002/art.38381
PG 9
WC Rheumatology
SC Rheumatology
GA AJ0SL
UT WOS:000337366200024
PM 24470430
ER

PT J
AU Sher, L
   Braquehais, MD
AF Sher, Leo
   Dolores Braquehais, Maria
TI Suicidal behavior in military veterans and health care professionals
SO AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY
LA English
DT Letter
ID MORTALITY
C1 [Sher, Leo] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.
   [Sher, Leo] James J Peters Vet Adm, Med Ctr, New York, NY USA.
   [Dolores Braquehais, Maria] Galatea Fdn, Coll Metges Barcelona, Galatea Clin, Integral Care Program Sick Doctors, Barcelona, Spain.
   [Dolores Braquehais, Maria] Univ Autonoma Barcelona, Vail dHebron Univ Hosp, Dept Psychiat & Legal Med, CIBERSAM, E-08193 Barcelona, Spain.
RP Sher, L (reprint author), Icahn Sch Med Mt Sinai, James J Peters Vet Adm, Med Ctr, 130 West Kingsbridge Rd, Bronx, NY 10468 USA.
EM DrLeoSher@gmail.com
NR 3
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0004-8674
EI 1440-1614
J9 AUST NZ J PSYCHIAT
JI Aust. N. Z. J. Psych.
PD JUN
PY 2014
VL 48
IS 6
BP 589
EP 589
DI 10.1177/0004867413517761
PG 1
WC Psychiatry
SC Psychiatry
GA AJ4RE
UT WOS:000337662700020
PM 24366856
ER

PT J
AU Wiener, RS
   Ouellette, DR
   Diamond, E
   Fan, VS
   Maurer, JR
   Mularski, RA
   Peters, JI
   Halpern, SD
AF Wiener, Renda Soylemez
   Ouellette, Daniel R.
   Diamond, Edward
   Fan, Vincent S.
   Maurer, Janet R.
   Mularski, Richard A.
   Peters, Jay I.
   Halpern, Scott D.
TI An Official American Thoracic Society/American College of Chest
   Physicians Policy Statement
SO CHEST
LA English
DT Article
ID PULMONARY ARTERIAL-HYPERTENSION; CLINICAL-PRACTICE GUIDELINES; SYSTOLIC
   HEART-FAILURE; LUNG-CANCER DIAGNOSIS; COMPUTED-TOMOGRAPHY; PATIENT
   COMMUNICATION; EMERGENCY-DEPARTMENT; EXERCISE CAPACITY;
   DECISION-ANALYSIS; CONTROLLED-TRIAL
AB The American Board of Internal Medicine Foundation's Choosing Wisely campaign aims to curb health-care costs and improve patient care by soliciting lists from medical societies of the top five tests or treatments in their specialty that are used too frequently and inappropriately. The American Thoracic Society (ATS) and American College of Chest Physicians created a joint task force, which produced a top five list for adult pulmonary medicine. Our top five recommendations, which were approved by the executive committees of the ATS and American College of Chest Physicians and published by Choosing Wisely in October 2013, are as follows: (1) Do not perform CT scan surveillance for evaluation of indeterminate pulmonary nodules at more frequent intervals or for a longer period of time than recommended by established guidelines; (2) do not routinely offer pharmacologic treatment with advanced vasoactive agents approved only for the management of pulmonary arterial hypertension to patients with pulmonary hypertension resulting from left heart disease or hypoxemic lung diseases (groups II or III pulmonary hypertension); (3) for patients recently discharged on supplemental home oxygen following hospitalization for an acute illness, do not renew the prescription without assessing the patient for ongoing hypoxemia; (4) do not perform chest CT angiography to evaluate for possible pulmonary embolism in patients with a low clinical probability and negative results of a highly sensitive D-dimer assay; (5) do not perform CT scan screening for lung cancer among patients at low risk for lung cancer. We hope pulmonologists will use these recommendations to stimulate frank discussions with patients about when these tests and treatments are indicated-and when they are not.
C1 [Wiener, Renda Soylemez] Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02118 USA.
   [Wiener, Renda Soylemez] Edith Nourse Rogers Mem Vet Hosp, Ctr Healthcare Org & Implementat Res, Bedford, MA USA.
   [Wiener, Renda Soylemez] Dartmouth Inst Hlth Policy & Clin Practice, Hanover, NH USA.
   [Ouellette, Daniel R.] Henry Ford Hlth Syst, Detroit, MI USA.
   [Diamond, Edward] Suburban Lung Associates, Elk Grove Village, IL USA.
   [Fan, Vincent S.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
   [Fan, Vincent S.] Univ Washington, Dept Med, Seattle, WA USA.
   [Maurer, Janet R.] Univ Arizona, Coll Med, Dept Med, Phoenix, AZ USA.
   [Maurer, Janet R.] Magellan Hlth Serv Inc, Natl Imaging Associates, Qual Improvement & Compliance, Phoenix, AZ USA.
   [Mularski, Richard A.] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA.
   [Mularski, Richard A.] Northwest Permanente PC, Dept Pulm Crit Care Med, Portland, OR USA.
   [Mularski, Richard A.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA.
   [Peters, Jay I.] UT Hlth Sci Ctr, San Antonio, TX USA.
   [Peters, Jay I.] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
   [Halpern, Scott D.] Univ Penn, Dept Med, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA.
   [Halpern, Scott D.] Univ Penn, Dept Biostat & Epidemiol, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA.
   [Halpern, Scott D.] Univ Penn, Dept Med Eth & Hlth Policy, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA.
   [Halpern, Scott D.] Univ Penn, Leonard Davis Inst, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA.
RP Wiener, RS (reprint author), Ctr Pulm, 72 E Concord St,R-304, Boston, MA 02118 USA.
EM rwiener@bu.edu
OI Wiener, Renda/0000-0001-7712-2135
FU NCI NIH HHS [K07 CA138772]
NR 79
TC 13
Z9 14
U1 0
U2 6
PU AMER COLL CHEST PHYSICIANS
PI GLENVIEW
PA 2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA
SN 0012-3692
J9 CHEST
JI Chest
PD JUN
PY 2014
VL 145
IS 6
BP 1383
EP 1391
DI 10.1378/chest.14-0670
PG 9
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA AJ0OV
UT WOS:000337355600032
PM 24889436
ER

PT J
AU Fan, VS
   Meek, PM
AF Fan, Vincent S.
   Meek, Paula M.
TI Anxiety, Depression, and Cognitive Impairment in Patients with Chronic
   Respiratory Disease
SO CLINICS IN CHEST MEDICINE
LA English
DT Article
DE Anxiety; Depression; Cognitive impairment; Chronic respiratory disease
ID OBSTRUCTIVE PULMONARY-DISEASE; RANDOMIZED CONTROLLED-TRIAL;
   QUALITY-OF-LIFE; STATE WORRY QUESTIONNAIRE; WORKING-MEMORY; COPD
   PATIENTS; PRIMARY-CARE; PSYCHOMETRIC PROPERTIES; REHABILITATION PROGRAM;
   ARTERIAL-HYPERTENSION
AB In this article, the prevalence of depression, anxiety, and cognitive impairment in persons with chronic obstructive pulmonary disease, and the impact of these psychological and cognitive factors on clinical outcomes in COPD is reviewed. Methods for screening and identification of these conditions in COPD are described. The extent to which depression, anxiety or cognitive impairment limit or modify the effectiveness of pulmonary rehabilitation, and whether pulmonary rehabilitation may ameliorate these psychological and cognitive impairments are discussed.
C1 [Fan, Vincent S.] Univ Washington, Dept Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98105 USA.
   [Meek, Paula M.] Univ Colorado, Coll Nursing, Boulder, CO 80309 USA.
RP Fan, VS (reprint author), Univ Washington, Dept Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98105 USA.
EM Vincent.fan@va.gov
NR 85
TC 5
Z9 5
U1 2
U2 23
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-5231
EI 1557-8216
J9 CLIN CHEST MED
JI Clin. Chest Med.
PD JUN
PY 2014
VL 35
IS 2
BP 399
EP +
DI 10.1016/j.ccm.2014.02.012
PG 12
WC Respiratory System
SC Respiratory System
GA AJ5ZL
UT WOS:000337769400013
PM 24874134
ER

PT J
AU Tripathy, D
   Clement, SC
   Schwenke, DC
   Banerji, M
   Bray, GA
   Buchanan, TA
   Gastaldelli, A
   Henry, RR
   Kitabchi, AE
   Mudaliar, S
   Ratner, RE
   Stentz, FB
   Musi, N
   Reaven, PD
   DeFronzo, RA
AF Tripathy, Devjit
   Clement, Stephen C.
   Schwenke, Dawn C.
   Banerji, MaryAnn
   Bray, George A.
   Buchanan, Thomas A.
   Gastaldelli, Amalia
   Henry, Robert R.
   Kitabchi, Abbas E.
   Mudaliar, Sunder
   Ratner, Robert E.
   Stentz, Frankie B.
   Musi, Nicolas
   Reaven, Peter D.
   DeFronzo, Ralph A.
TI Baseline Adiponectin Levels Do Not Influence the Response to
   Pioglitazone in ACT NOW
SO DIABETES CARE
LA English
DT Article
ID TYPE-2 DIABETES-MELLITUS; ACTIVATED PROTEIN-KINASE; PPAR-GAMMA AGONISTS;
   INSULIN SENSITIVITY; GLUCOSE; RESISTANCE; EXPRESSION; PREVENTION;
   OXIDATION; INDEX
AB OBJECTIVE
   Plasma adiponectin levels are reduced in type 2 diabetes mellitus (T2DM) and other insulin-resistant states. We examined whether plasma adiponectin levels at baseline and after pioglitazone treatment in impaired glucose tolerance (IGT) subjects were associated with improved insulin sensitivity (Si) and glucose tolerance status.
   RESEARCH DESIGN AND METHODS
   A total of 602 high-risk IGT subjects in ACT NOW were randomized to receive pioglitazone or placebo with a median follow-up of 2.4 years.
   RESULTS
   Pioglitazone reduced IGT conversion to diabetes by 72% in association with improved n-cell function by 64% (insulin secretion/insulin resistance index) and increased tissue sensitivity by 88% (Matsuda index). In pioglitazone-treated subjects, plasma adiponectin concentration increased threefold from 13 +/- 0.5 to 38 +/- 2.5 mu g/mL (P < 0.001) and was strongly correlated with the improvement in SI (r = 0.436, P < 0.001) and modestly correlated with glucose area under the curve during oral glucose tolerance test (r = 0.238, P < 0.005) and insulin secretion/insulin resistance index (r = 0.306, P < 0.005). The increase in adiponectin was a strong predictor of reversion to normal glucose tolerance and prevention of T2DM. In the placebo group, plasma adiponectin did not change and was not correlated with changes in glucose levels. There was an inverse association between baseline plasma adiponectin concentration and progression to diabetes in the placebo group but not in the pioglitazone group.
   CONCLUSIONS
   Baseline adiponectin does not predict the response to pioglitazone. The increase in plasma adiponectin concentration after pioglitazone therapy in IGT subjects is strongly related to improved glucose tolerance status and enhanced tissue sensitivity to insulin.
C1 [Tripathy, Devjit; Musi, Nicolas; DeFronzo, Ralph A.] Texas Diabet Inst, San Antonio, TX 78207 USA.
   [Tripathy, Devjit; Gastaldelli, Amalia; Musi, Nicolas; DeFronzo, Ralph A.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
   [Tripathy, Devjit; Musi, Nicolas; DeFronzo, Ralph A.] South Texas VA Hlth Care Syst, Audie L Murphy Hosp, San Antonio, TX USA.
   [Clement, Stephen C.] Georgetown Univ, Div Endocrinol & Metab, Washington, DC USA.
   [Schwenke, Dawn C.; Reaven, Peter D.] Phoenix VA Hlth Care Syst, Phoenix, AZ USA.
   [Schwenke, Dawn C.] Arizona State Univ, Coll Nursing & Hlth Innovat, Phoenix, AZ USA.
   [Banerji, MaryAnn] SUNY Hlth Sci Ctr, Brooklyn, NY USA.
   [Bray, George A.] Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70803 USA.
   [Buchanan, Thomas A.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA.
   [Gastaldelli, Amalia] CNR, Inst Clin Physiol, Cardiometab Risk Unit, I-56100 Pisa, Italy.
   [Henry, Robert R.; Mudaliar, Sunder] VA San Diego Healthcare Syst, San Diego, CA USA.
   [Henry, Robert R.; Mudaliar, Sunder] Univ Calif San Diego, San Diego, CA 92103 USA.
   [Kitabchi, Abbas E.; Stentz, Frankie B.] Univ Tennessee, Div Endocrinol Diabet & Metab, Memphis, TN USA.
   [Ratner, Robert E.] Medstar Res Inst, Hyattsville, MD USA.
RP DeFronzo, RA (reprint author), Texas Diabet Inst, San Antonio, TX 78207 USA.
EM albarado@uthscsa.edu
RI Gastaldelli, Amalia/H-3319-2014
OI Gastaldelli, Amalia/0000-0003-2594-1651
FU General Clinical Research Center at the University of Tennessee Health
   Science Center, Clinical and Translational Science Award [M01-RR-00221,
   UL1-TR-000130]; South Texas Veterans Health Care System-Audie Murphy
   Division; Veterans Administration Health Care System
FX This study was supported in part by General Clinical Research Center
   grant M01-RR-00221 at the University of Tennessee Health Science Center,
   Clinical and Translational Science Award grant UL1-TR-000130 to the
   University of Southern California, and the South Texas Veterans Health
   Care System-Audie Murphy Division. Part (five-eighths) of R.A.D.'s
   salary is supported by the Veterans Administration Health Care System.
   Takeda Pharmaceuticals North America provided the study drug.
NR 22
TC 2
Z9 2
U1 0
U2 3
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
EI 1935-5548
J9 DIABETES CARE
JI Diabetes Care
PD JUN
PY 2014
VL 37
IS 6
BP 1706
EP 1711
DI 10.2337/dc13-1745
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA AJ5RX
UT WOS:000337746100048
PM 24705615
ER

PT J
AU Mentz, RJ
   Cotter, G
   Cleland, JGF
   Stevens, SR
   Chiswell, K
   Davison, BA
   Teerlink, JR
   Metra, M
   Voors, AA
   Grinfeld, L
   Ruda, M
   Mareev, V
   Lotan, C
   Bloomfield, DM
   Fiuzat, M
   Givertz, MM
   Ponikowski, P
   Massie, BM
   O'Connor, CM
AF Mentz, Robert J.
   Cotter, Gad
   Cleland, John G. F.
   Stevens, Susanna R.
   Chiswell, Karen
   Davison, Beth A.
   Teerlink, John R.
   Metra, Marco
   Voors, Adriaan A.
   Grinfeld, Liliana
   Ruda, Mikhail
   Mareev, Viacheslav
   Lotan, Chaim
   Bloomfield, Daniel M.
   Fiuzat, Mona
   Givertz, Michael M.
   Ponikowski, Piotr
   Massie, Barry M.
   O'Connor, Christopher M.
TI International differences in clinical characteristics, management, and
   outcomes in acute heart failure patients: better short-term outcomes in
   patients enrolled in Eastern Europe and Russia in the PROTECT trial
SO EUROPEAN JOURNAL OF HEART FAILURE
LA English
DT Article
DE Acute heart failure; Length of stay; Trial; Regional differences; Global
   variation; Outcomes
ID ACUTE MYOCARDIAL-INFARCTION; QUALITY-OF-CARE; VASOPRESSIN ANTAGONISM;
   HOSPITAL READMISSION; EVEREST EFFICACY; SURVEY PROGRAM; RATES; SURVIVAL;
   TRENDS; HF
AB AimsThe implications of geographical variation are unknown following adjustment for hospital length of stay (LOS) in heart failure (HF) trials that included patients whether or not they had systolic dysfunction. We investigated regional differences in an international acute HF trial.
   Methods and resultsThe PROTECT trial investigated 2033 patients with acute HF and renal dysfunction hospitalized at 173 sites in 17 countries with randomization to rolofylline or placebo. We grouped enrolling countries into six regions. Baseline characteristics, in-hospital management, and outcomes were explored by region. The primary study outcome was 60-day mortality or cardiovascular/renal hospitalization. Secondary outcomes included 180-day mortality. Of 2033 patients, 33% were from Eastern Europe, 19% from Western Europe, 16% from Israel, 15% from North America, 14% from Russia, and 3% from Argentina. Marked differences in baseline characteristics, HF phenotype, in-hospital diuretic and vasodilator strategies, and LOS were observed by region. LOS was shortest in North America and Israel (median 5 days) and longest in Russia (median 15 days). Regional event rates varied significantly. Following multivariable adjustment, region was an independent predictor of the risk of mortality/hospitalization at 60 days, with the lowest risk in Russia (hazard ratio 0.39, 95% confidence interval 0.23-0.64 vs. Western Europe) due to lower rehospitalization; mortality differences were attenuated by 180 days.
   ConclusionsIn an international HF trial, there were differences in baseline characteristics, treatments, LOS, and rehospitalization amongst regions, but little difference in longer term mortality. Rehospitalization differences exist independent of LOS. This analysis may help inform future trial design and should be externally validated.
C1 [Mentz, Robert J.; Fiuzat, Mona; O'Connor, Christopher M.] Duke Univ, Durham, NC 27710 USA.
   [Cotter, Gad; Davison, Beth A.] Momentum Res Inc, Durham, NC USA.
   [Cleland, John G. F.] Univ Hull, Kingston Upon Hull, Yorks, England.
   [Stevens, Susanna R.; Chiswell, Karen] Duke Clin Res Inst, Durham, NC USA.
   [Teerlink, John R.; Massie, Barry M.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Teerlink, John R.; Massie, Barry M.] San Francisco VA Med Ctr, San Francisco, CA USA.
   [Metra, Marco] Univ Brescia, Brescia, Italy.
   [Voors, Adriaan A.] Univ Groningen, Groningen, Netherlands.
   [Grinfeld, Liliana] Univ Buenos Aires, Buenos Aires, DF, Argentina.
   [Ruda, Mikhail] Cardiol Res Ctr, Moscow 121552, Russia.
   [Mareev, Viacheslav] Russian Acad Med Sci, Cardiol Sci Ctr, Inst Clin Cardiol, Moscow, Russia.
   [Lotan, Chaim] Hadassah Med Org Ein Karem, Jerusalem, Israel.
   [Bloomfield, Daniel M.] Merck Res Labs, Rahway, NJ USA.
   [Givertz, Michael M.] Brigham & Womens Hosp, Boston, MA 02115 USA.
   [Ponikowski, Piotr] Med Univ, Clin Mil Hosp, Wroclaw, Poland.
RP Mentz, RJ (reprint author), Duke Univ, Med Ctr, 2301 Erwin Rd, Durham, NC 27710 USA.
EM robert.mentz@duke.edu
RI Ponikowski, Piotr/O-6454-2015
OI Ponikowski, Piotr/0000-0002-3391-7064; Mareev, Vyacheslav
   Yurievich/0000-0002-7285-2048; Metra, Marco/0000-0001-6691-8568;
   Davison, Beth/0000-0003-2374-6449; Cleland, John/0000-0002-1471-7016
FU NIGMS NIH HHS [T32 GM086330]
NR 26
TC 27
Z9 27
U1 0
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1388-9842
EI 1879-0844
J9 EUR J HEART FAIL
JI Eur. J. Heart Fail.
PD JUN
PY 2014
VL 16
IS 6
BP 614
EP 624
DI 10.1002/ejhf.92
PG 11
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AJ2FG
UT WOS:000337470400006
PM 24771609
ER

PT J
AU Jhund, PS
   Claggett, B
   Packer, M
   Zile, MR
   Voors, AA
   Pieske, B
   Lefkowitz, M
   Shi, V
   Bransford, T
   McMurray, JJV
   Solomon, SD
AF Jhund, Pardeep S.
   Claggett, Brian
   Packer, Milton
   Zile, Michael R.
   Voors, Adriaan A.
   Pieske, Burkert
   Lefkowitz, Martin
   Shi, Victor
   Bransford, Toni
   McMurray, John J. V.
   Solomon, Scott D.
TI Independence of the blood pressure lowering effect and efficacy of the
   angiotensin receptor neprilysin inhibitor, LCZ696, in patients with
   heart failure with preserved ejection fraction: an analysis of the
   PARAMOUNT trial
SO EUROPEAN JOURNAL OF HEART FAILURE
LA English
DT Article
DE Blood pressure; Heart failure; Neprilysin inhibitor; NT-proBNP;
   Preserved ejection fraction
ID RANDOMIZED CONTROLLED-TRIAL; ATRIAL-NATRIURETIC-PEPTIDE; DIASTOLIC
   FUNCTION; CONVERTING ENZYME; RAT; OMAPATRILAT; MORTALITY; DIAGNOSIS
AB AimsThe first in class angiotensin receptor neprilysin inhibitor, LCZ696 has been shown to reduce levels of N-terminal pro-brain natriuretic peptide (NT-proBNP), reduce left atrial size and improve New York Heart Association (NYHA) class in patients with heart failure with preserved ejection fraction (HFpEF). We examined whether the effects of LCZ696 were independent of systolic blood pressure (SBP) lowering.
   Methods and resultsIn the Prospective comparison of ARNi (angiotensin receptor neprilysin inhibitor) with ARB (angiotensin receptor blocker) on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) trial 301 patients were randomly assigned to LCZ696 or valsartan. We examined the relationship between SBP lowering and LCZ696 on NT-proBNP level, left atrial size, NYHA class and estimated glomerular filtration rate (eGFR). By 12weeks blood pressure was reduced by 9mmHg (SD 15)/5mmHg (SD 11) in patients receiving LCZ696 in comparison with 3mmHg (SD 17)/2mmHg (SD 12) in those receiving valsartan. The change in NT-proBNP was poorly correlated with change in SBP (LCZ696, r=0.17, P=0.06; valsartan, r=0.05, P=0.58) After adjustment for change in SBP, the ratio of change in NT-proBNP at 12weeks for LCZ696 vs. valsartan was 0.76 (95% CI 0.63-0.93, P=0.008), and similar to the ratio not adjusting for SBP (0.76, 95% CI 0.63-0.92, P=0.006); P for interaction was 0.38). Similarly, reduction in left atrial volume index at 36weeks, improvement in NYHA class and eGFR were all independent of the change in SBP.
   ConclusionIn patients with HFpEF, the effect of the angiotensin receptor neprilysin inhibitor LCZ696 on NT-proBNP, left atrial volume, functional class, and eGFR was independent of reduction in SBP.
C1 [Jhund, Pardeep S.; Claggett, Brian; Solomon, Scott D.] Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA.
   [Jhund, Pardeep S.; McMurray, John J. V.] Univ Glasgow, BHF Glasgow Cardiovasc Res Ctr, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland.
   [Packer, Milton] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA.
   [Zile, Michael R.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
   [Zile, Michael R.] Med Univ S Carolina, Charleston, SC 29425 USA.
   [Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands.
   [Pieske, Burkert] Med Univ Graz, Dept Cardiol, Graz, Austria.
   [Lefkowitz, Martin; Shi, Victor; Bransford, Toni] Novartis Pharmaceut, E Hanover, NJ USA.
RP Solomon, SD (reprint author), Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA.
EM ssolomon@rics.bwh.harvard.edu
OI Jhund, Pardeep/0000-0003-4306-5317; mcmurray, john/0000-0002-6317-3975
NR 22
TC 27
Z9 30
U1 0
U2 14
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1388-9842
EI 1879-0844
J9 EUR J HEART FAIL
JI Eur. J. Heart Fail.
PD JUN
PY 2014
VL 16
IS 6
BP 671
EP 677
DI 10.1002/ejhf.76
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AJ2FG
UT WOS:000337470400013
PM 24692284
ER

PT J
AU Schmittdiel, JA
   Dyer, W
   Uratsu, C
   Magid, DJ
   O'Connor, PJ
   Beck, A
   Butler, M
   Ho, MP
   Vazquez-Benitez, G
   Adams, AS
AF Schmittdiel, Julie A.
   Dyer, Wendy
   Uratsu, Connie
   Magid, David J.
   O'Connor, Patrick J.
   Beck, Arne
   Butler, Melissa
   Ho, Michael P.
   Vazquez-Benitez, Gabriela
   Adams, Alyce S.
TI Initial Persistence With Antihypertensive Therapies Is Associated With
   Depression Treatment Persistence, But Not Depression
SO JOURNAL OF CLINICAL HYPERTENSION
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; MEDICATION ADHERENCE; UNITED-STATES;
   HYPERTENSIVE PATIENTS; SYSTEM FACTORS; HEART-DISEASE; BLACK-MEN;
   PREVALENCE; SYMPTOMS; TRENDS
AB The purpose of this study was to examine the relationship between the presence of clinical depression and persistence to drug therapy treatment for depression with early nonpersistence to antihypertensive therapies in a large, diverse cohort of newly treated hypertension patients. Using a hypertension registry at Kaiser Permanente Northern California, the authors conducted a retrospective cohort study of 44,167 adults (18years and older) with hypertension who were new users of antihypertensive therapy in 2008. We used multivariate logistic regression analysis to model the relationships between the presence of clinical depression and early nonpersistence (defined as failing to refill the first prescription within 90days after the end of the first fill days' supply) to antihypertensive therapies, controlling for sociodemographic and clinical risk factors. Within the group of 1484 patients who had evidence of clinical depression in the 12months prior to the initiation of antihypertensive therapy, the authors examined the relationship between drug therapy treatment for depression and 6-month persistence with antidepressant therapy with early nonpersistence with antihypertensive therapies. No association was found between the presence of clinical depression and early nonpersistence to antihypertensive therapies after adjustment for individual demographic and clinical characteristics and neighborhood-level socioeconomic status. However, among the subset of 1484 patients with documented evidence of clinical depression in the 12months prior to the initiation of antihypertensive therapy, being prescribed and persistence with antidepressant therapy was strongly associated with lower odds of early nonpersistence to antihypertensive medications (odds ratio, 0.64; confidence interval, 0.42-0.96). In an integrated delivery system, the authors found that treatment for depression was associated with higher levels of antihypertensive persistence. Improving quality of depression care in patients with comorbid hypertension may be an important strategy in decreasing cardiovascular disease risk in these patients.
C1 [Schmittdiel, Julie A.; Dyer, Wendy; Uratsu, Connie; Adams, Alyce S.] Kaiser Permanente, Div Res, Oakland, CA 94612 USA.
   [Magid, David J.; Beck, Arne; Ho, Michael P.] Kaiser Permanente, Inst Res, Denver, CO USA.
   [Magid, David J.; Ho, Michael P.] Univ Colorado, Denver, CO 80202 USA.
   [O'Connor, Patrick J.; Vazquez-Benitez, Gabriela] HealthPartners Res Fdn, Minneapolis, MN USA.
   [Butler, Melissa] Kaiser Permanente, Ctr Hlth Res Southeast, Atlanta, GA USA.
   [Ho, Michael P.] Denver VA Med Ctr, Denver, CO USA.
RP Schmittdiel, JA (reprint author), Kaiser Permanente, Div Res, 2000 Broadway, Oakland, CA 94612 USA.
EM Julie.A.Schmittdiel@kp.org
FU National Heart, Lung, and Blood Institute [3U19HL091179-04S1]; National
   Institute for Mental Health; Health Delivery Systems Center for Diabetes
   Translational Research - National Institute for Diabetes, Digestive and
   Kidney Diseases [P30DK092924]
FX This study was funded by [3U19HL091179-04S1] the National Heart, Lung,
   and Blood Institute and the National Institute for Mental Health as a
   supplement to the HMO Research Network Cardiovascular Disease Network.
   Additional support for Drs Adams, Schmittdiel, and OConnor was also
   provided by the Health Delivery Systems Center for Diabetes
   Translational Research [P30DK092924], funded by the National Institute
   for Diabetes, Digestive and Kidney Diseases. The funders had no role in
   the design or conduct of the study, data collection, management,
   analysis or interpretation, or in the preparation, review, or approval
   of this manuscript. The authors report no conflicts of interest. Dr
   Schmittdiel had full access to all the data in the study and takes
   responsibility for the integrity of the data and the accuracy of the
   data analysis.
NR 31
TC 2
Z9 2
U1 1
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1524-6175
EI 1751-7176
J9 J CLIN HYPERTENS
JI J. Clin. Hypertens.
PD JUN
PY 2014
VL 16
IS 6
BP 412
EP 417
DI 10.1111/jch.12300
PG 6
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA AJ3XE
UT WOS:000337600400007
PM 24716533
ER

PT J
AU Tang, VL
   Halm, EA
   Fine, MJ
   Johnson, CS
   Anzueto, A
   Mortensen, EM
AF Tang, Victoria L.
   Halm, Ethan A.
   Fine, Michael J.
   Johnson, Christopher S.
   Anzueto, Antonio
   Mortensen, Eric M.
TI Predictors of rehospitalization after admission for pneumonia in the
   veterans affairs healthcare system
SO JOURNAL OF HOSPITAL MEDICINE
LA English
DT Article
ID COMMUNITY-ACQUIRED PNEUMONIA; HOSPITAL ADMISSION; ELDERLY-PATIENTS;
   DISCHARGE; OUTCOMES; RISK; READMISSION; INSTABILITY; MORTALITY
AB INTRODUCTION Although some factors associated with rehospitalization after community-acquired pneumonia have been identified, other factors such as medical care utilization and medication usage have not been previously studied. We investigated novel predictors of rehospitalization in patients admitted with pneumonia. METHODS Using Department of Veteran Affairs (VA) administrative data from October 2001 to September 2007, we examined a cohort of patients 65 years old and older, who were hospitalized with pneumonia, in 150 VA acute care hospitals. The cohort was randomly split into derivation and validation samples, and then logistic regression models were used to identify and validate predictors of all-cause rehospitalization within 30 days. RESULTS Of the 45,134 subjects, 13% were rehospitalized within 30 days. No significant differences were noted between the derivation and validation cohorts. Factors associated with readmission included age, marital status, chronic renal disease, prior malignancy, nursing home residence, congestive heart failure, use of oral corticosteroids, number of emergency department visits a year prior, prior admission, number of outpatient clinic visits in a year prior, and length of hospital stay. The C statistics for the derivation and validation models were 0.615 and 0.613, respectively. CONCLUSIONS Factors associated with readmission were largely unrelated to the underlying pneumonia, but were related to demographics, comorbidities, healthcare utilization, and length of stay on index admission. Journal of Hospital Medicine 2014;9:379-383. 2014 Society of Hospital Medicine
C1 [Tang, Victoria L.; Johnson, Christopher S.; Mortensen, Eric M.] VA North Texas Hlth Care Syst, Div Gen Internal Med, Dallas, TX USA.
   [Tang, Victoria L.; Halm, Ethan A.; Johnson, Christopher S.; Mortensen, Eric M.] Univ Texas SW Med Ctr Dallas, Div Gen Internal Med, Dallas, TX 75390 USA.
   [Fine, Michael J.] Univ Pittsburgh, VA Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
   [Fine, Michael J.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
   [Fine, Michael J.] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA USA.
   [Anzueto, Antonio] South Texas Vet Hlth Care Syst, Div Pulm Dis & Crit Care Med, San Antonio, TX USA.
   [Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
RP Mortensen, EM (reprint author), Dallas VA Med Ctr, 111E,4500 South Lancaster, Dallas, TX 75216 USA.
EM eric.mortensen@UTSouthwestern.edu
OI Mortensen, Eric/0000-0002-3880-5563
FU National Institute of Nursing Research [R01NR010828]
FX The project described was supported by grant number R01NR010828 from the
   National Institute of Nursing Research. The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the National Institute of Nursing Research or the
   National Institutes of Health. This material is the result of work
   supported with resources and the use of facilities at the VA North Texas
   Health Care System. Funding agencies had no role in conducting the
   study, or role in the preparation, review, or approval of the
   manuscript. The views expressed in this article are those of the authors
   and do not necessarily represent the views of the Department of Veterans
   Affairs.
NR 18
TC 3
Z9 4
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1553-5592
EI 1553-5606
J9 J HOSP MED
JI J. Hosp. Med.
PD JUN
PY 2014
VL 9
IS 6
BP 379
EP 383
DI 10.1002/jhm.2184
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA AJ2VK
UT WOS:000337522100006
PM 24648401
ER

PT J
AU Lackey, AE
   Pandey, T
   Moshiri, M
   Lalwani, N
   Lall, C
   Bhargava, P
AF Lackey, Amanda E.
   Pandey, Tarun
   Moshiri, Mariam
   Lalwani, Neeraj
   Lall, Chandana
   Bhargava, Puneet
TI Productivity, Part 2: Cloud Storage, Remote Meeting Tools,
   Screencasting, Speech Recognition Software, Password Managers, and
   Online Data Backup
SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY
LA English
DT Article
DE Productivity; cloud applications; collaboration
ID RADIOLOGY EDUCATION 2.0-ON; CUSP
AB It is an opportune time for radiologists to focus on personal productivity. The ever increasing reliance on computers and the Internet has significantly changed the way we work. Myriad software applications are available to help us improve our personal efficiency. In this article, the authors discuss some tools that help improve collaboration and personal productivity, maximize e-learning, and protect valuable digital data.
C1 [Lackey, Amanda E.; Pandey, Tarun] Univ Arkansas Med Sci, Dept Radiol, Little Rock, AR 72205 USA.
   [Moshiri, Mariam; Lalwani, Neeraj] Univ Washington, Sch Med, Dept Radiol, Seattle, WA 98195 USA.
   [Lall, Chandana] Univ Calif Irvine, Orange, CA 92668 USA.
   [Bhargava, Puneet] Univ Washington, Dept Radiol, Seattle, WA 98195 USA.
   [Bhargava, Puneet] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
RP Bhargava, P (reprint author), Univ Washington, Mail Box 358280,S-114 Radiol,1660 S Columbian Way, Seattle, WA 98108 USA.
EM bhargp@uw.edu
RI Lalwani, Neeraj/A-3490-2011
OI Lalwani, Neeraj/0000-0001-5514-2805; Bhargava,
   Puneet/0000-0002-3849-9666
NR 27
TC 1
Z9 1
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1546-1440
J9 J AM COLL RADIOL
JI J. Am. Coll. Radiol.
PD JUN
PY 2014
VL 11
IS 6
BP 580
EP 588
DI 10.1016/j.jacr.2013.11.021
PG 9
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA AJ0HJ
UT WOS:000337331000011
PM 24674716
ER

PT J
AU Germino, JC
   Rapp, EJ
   Hippe, DS
   Shah, AC
   McFall, ME
   Bhargava, P
AF Germino, Jessica C.
   Rapp, Elliot J.
   Hippe, Daniel S.
   Shah, Anura C.
   McFall, Miles E.
   Bhargava, Puneet
TI Assessing and Optimizing Imaging of Patients with Posttraumatic Stress
   Disorder
SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY
LA English
DT Editorial Material
ID CLAUSTROPHOBIA; ANXIETY; EXPERIENCES
C1 [Germino, Jessica C.; Rapp, Elliot J.; Hippe, Daniel S.] Univ Washington, Dept Radiol, Seattle, WA 98108 USA.
   [Shah, Anura C.] Vet Affairs Puget Sound Hlth Care Syst, Seattle Div, Dept Prevent & Management Disrupt Behav, Seattle, WA USA.
   [McFall, Miles E.] Vet Affairs Puget Sound Hlth Care Syst, Seattle Div, Seattle, WA USA.
   [McFall, Miles E.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98108 USA.
   [Bhargava, Puneet] Univ Washington, Dept Radiol, Seattle, WA 98108 USA.
   [Bhargava, Puneet] VA Puget Hlth Care Syst, Seattle, WA 98108 USA.
RP Bhargava, P (reprint author), Univ Washington, S-114 RAD,1660 S Columbian Way,Mail Box 358280, Seattle, WA 98108 USA.
EM bhargp@uw.edu
OI Bhargava, Puneet/0000-0002-3849-9666
NR 14
TC 1
Z9 1
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1546-1440
J9 J AM COLL RADIOL
JI J. Am. Coll. Radiol.
PD JUN
PY 2014
VL 11
IS 6
BP 629
EP 631
DI 10.1016/j.jacr.2013.10.020
PG 3
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA AJ0HJ
UT WOS:000337331000020
PM 24613448
ER

PT J
AU Makam, AN
   Boscardin, WJ
   Mao, YH
   Steinman, MA
AF Makam, Anil N.
   Boscardin, W. John
   Mao, Yinghui
   Steinman, Michael A.
TI Risk of Thiazide-Induced Metabolic Adverse Events in Older Adults
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE aged; adverse effects; sodium chloride symporter inhibitors;
   hypertension; outcome assessment (health care)
ID INDUCED HYPONATREMIA; BLOOD-PRESSURE; SYSTOLIC HYPERTENSION;
   CARDIOVASCULAR EVENTS; ELDERLY PROGRAM; CLINICAL-TRIALS; DRUG-REACTIONS;
   DIURETICS; OUTCOMES; METAANALYSIS
AB Objectives To evaluate the risk and predictors of thiazide-induced adverse events (AEs) in multimorbid older adults in real-world clinical settings. Design Observational cohort study. Setting National Veterans Affairs data from 2007 to 2008. Participants Veterans aged 65 and older newly prescribed a thiazide (N=1,060) compared with propensity-matched nonusers of antihypertensive medications (N=1,060). Measurements The primary outcome was a composite of metabolic AEs defined as sodium less than 135mEq/L, potassium less than 3.5mEq/L, or a decrease in the estimated glomerular filtration rate (eGFR) of more than 25% from the baseline rate. Secondary outcomes included sev-ere AEs (sodium <130mEq/L, potassium <3.0mEq/L, or a decrease in eGFR of more than 50%). Results Over 9months of follow-up, 14.3% of new thiazide users developed an AE, compared with 6.0% of nonusers (number needed to harm (NNH) 12, 95% confidence interval (CI)=9-17, P<.001); 1.8% of new users developed a severe AE, compared with 0.6% of nonusers (NNH=82, P=.008), and 3.8% of new users had an emergency department visit or hospitalization with an AE, compared with 2.0% of nonusers (NNH=56, P=.02). Risk of AEs did not vary according to age, but having five or more comorbidities was associated with 3.0 times the odds (95% CI=1.4-6.2) of developing an AE as having one comorbidity (hypertension). Low-normal and unmeasured baseline sodium and potassium values were among the strongest predictors of hyponatremia and hypokalemia, respectively. Only 42% of thiazide users had laboratory monitoring within 90days after initiation. Conclusion Thiazide-induced AEs are common in older adults. Greater attention should be paid to potential complications in prescribing thiazides to older adults, including closer laboratory monitoring before and after initiation of thiazides.
C1 [Makam, Anil N.] Univ Texas SW Med Ctr Dallas, Div Gen Internal Med, Dallas, TX 75390 USA.
   [Boscardin, W. John; Mao, Yinghui; Steinman, Michael A.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Div Geriatr, San Francisco, CA USA.
   [Boscardin, W. John] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
RP Makam, AN (reprint author), 5323 Harry Hines Blvd,Mail Code 9169, Dallas, TX 75390 USA.
EM anil.makam@utsouthwestern.edu
OI Makam, Anil/0000-0001-7072-9946
FU National Institute on Aging (NIA) [K23-AG030999, RC1-AG036377]; federal
   training grant from the National Research Service Award
   [T32HP19025-07-00]
FX Conflict of Interest: This study was supported by Grants K23-AG030999
   and RC1-AG036377 from the National Institute on Aging (NIA). Dr. Makam's
   work on this project was completed while he was a primary care research
   fellow at the University of California at San Francisco, funded by a
   federal training grant from the National Research Service Award
   (T32HP19025-07-00).
NR 36
TC 7
Z9 7
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD JUN
PY 2014
VL 62
IS 6
BP 1039
EP 1045
DI 10.1111/jgs.12839
PG 7
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA AJ4EJ
UT WOS:000337624300005
PM 24823661
ER

PT J
AU Weiner, DK
   Morone, NE
   Spallek, H
   Karp, JF
   Schneider, M
   Washburn, C
   Dziabiak, MP
   Hennon, JG
   Elnicki, DM
AF Weiner, Debra K.
   Morone, Natalia E.
   Spallek, Heiko
   Karp, Jordan F.
   Schneider, Michael
   Washburn, Carol
   Dziabiak, Michael P.
   Hennon, John G.
   Elnicki, D. Michael
CA Univ Pittsburgh Ctr Excellence Pai
TI E-Learning Module on Chronic Low Back Pain in Older Adults: Evidence of
   Effect on Medical Student Objective Structured Clinical Examination
   Performance
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE medical student education; older adults; low back pain; objective
   structured clinical examination
ID EDUCATION; CARE; COMPETENCE; OUTCOMES
AB The Institute of Medicine has highlighted the urgent need to close undergraduate and graduate educational gaps in treating pain. Chronic low back pain (CLBP) is one of the most common pain conditions, and older adults are particularly vulnerable to potential morbidities associated with misinformed treatment. An e-learning case-based interactive module was developed at the University of Pittsburgh Center of Excellence in Pain Education, one of 12 National Institutes of Health-designated centers, to teach students important principles for evaluating and managing CLBP in older adults. A team of six experts in education, information technology, pain management, and geriatrics developed the module. Teaching focused on common errors, interactivity, and expert modeling and feedback. The module mimicked a patient encounter using a standardized patient (the older adult with CLBP) and a pain expert (the patient provider). Twenty-eight medical students were not exposed to the module (Group 1) and 27 were exposed (Group 2). Their clinical skills in evaluating CLBP were assessed using an objective structured clinical examination (OSCE). Mean scores were 62.0 +/- 8.6 for Group 1 and 79.5 +/- 10.4 for Group 2 (P<.001). Using an OSCE pass-fail cutoff score of 60%, 17 of 28 Group 1 students (60.7%) and 26 of 27 Group 2 students (96.3%) passed. The CLBP OSCE was one of 10 OSCE stations in which students were tested at the end of a Combined Ambulatory Medicine and Pediatrics Clerkship. There were no between-group differences in performance on eight of the other nine OSCE stations. This module significantly improved medical student clinical skills in evaluating CLBP. Additional research is needed to ascertain the effect of e-learning modules on more-advanced learners and on improving the care of older adults with CLBP.
C1 [Weiner, Debra K.; Morone, Natalia E.; Hennon, John G.] Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA.
   [Weiner, Debra K.] Univ Pittsburgh, Dept Med, Div Geriatr Med, Pittsburgh, PA USA.
   [Weiner, Debra K.; Karp, Jordan F.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA.
   [Weiner, Debra K.; Karp, Jordan F.] Univ Pittsburgh, Dept Anesthesiol, Pittsburgh, PA USA.
   [Weiner, Debra K.; Morone, Natalia E.; Karp, Jordan F.] Univ Pittsburgh, Clin & Translat Sci Inst, Pittsburgh, PA USA.
   [Morone, Natalia E.; Dziabiak, Michael P.; Elnicki, D. Michael] Univ Pittsburgh, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA.
   [Spallek, Heiko] Univ Pittsburgh, Sch Dent Med, Dept Dent Publ Hlth, Pittsburgh, PA USA.
   [Schneider, Michael] Univ Pittsburgh, Sch Hlth & Rehabil Sci, Pittsburgh, PA USA.
   [Washburn, Carol] Univ Pittsburgh, Ctr Instruct Dev & Distance Educ, Pittsburgh, PA USA.
   [Hennon, John G.] Univ Pittsburgh, Univ Ctr Social & Urban Res, Pittsburgh, PA USA.
RP Weiner, DK (reprint author), Suite 500,3471 Fifth Ave, Pittsburgh, PA 15213 USA.
EM dweiner@pitt.edu
OI Spallek, Heiko/0000-0001-6865-4818; Schneider,
   MIchael/0000-0001-7190-3379
FU Altarum Institute; NIH Pain Consortium [HHSN271201100111U]
FX Conflict of Interest: The editor in chief has reviewed the conflict of
   interest checklist provided by the authors and has determined that the
   authors have no financial or any-other kind of personal conflicts with
   this paper. This work was supported by funding awarded to Centers of
   Excellence in Pain Education by the Altarum Institute, which received
   funding from the NIH Pain Consortium (HHSN271201100111U). Dr. Karp has
   received medication supplies from Pfizer and Reckitt Benckiser for
   investigator-initiated trials. The contents of this report do not
   necessarily represent the views of the Department of Veterans Affairs OF
   the U.S. government.
NR 29
TC 1
Z9 1
U1 1
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD JUN
PY 2014
VL 62
IS 6
BP 1161
EP 1167
DI 10.1111/jgs.12871
PG 7
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA AJ4EJ
UT WOS:000337624300023
PM 24833496
ER

PT J
AU Moody, SY
   Newsom, EM
   Covinsky, KE
AF Moody, Sandra Y.
   Newsom, Edwina M.
   Covinsky, Kenneth E.
TI Determinants of Perceived Emotional Recovery and Perceived Change in
   Health After a Disaster
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Letter
ID HURRICANE KATRINA; STORM
C1 [Moody, Sandra Y.; Covinsky, Kenneth E.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA 94117 USA.
   [Moody, Sandra Y.; Covinsky, Kenneth E.] San Francisco VA Med Ctr, San Francisco, CA USA.
   [Moody, Sandra Y.] Kameda Med Ctr, Kamogawa, Japan.
   [Newsom, Edwina M.] Univ Calif San Francisco, Inst Hlth & Aging, San Francisco, CA USA.
RP Moody, SY (reprint author), Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA 94117 USA.
FU NCATS NIH HHS [UL1 TR000004]; NCRR NIH HHS [UL1 RR024131]; NIA NIH HHS
   [5R01AG28621, R01 AG028621]
NR 10
TC 0
Z9 0
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD JUN
PY 2014
VL 62
IS 6
BP 1189
EP 1191
DI 10.1111/jgs.12852
PG 3
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA AJ4EJ
UT WOS:000337624300031
PM 24925556
ER

PT J
AU Stankovic, I
   Krismer, F
   Jesic, A
   Antonini, A
   Benke, T
   Brown, RG
   Burn, DJ
   Holton, JL
   Kaufmann, H
   Kostic, VS
   Ling, H
   Meissner, WG
   Poewe, W
   Semnic, M
   Seppi, K
   Takeda, A
   Weintraub, D
   Wenning, GK
AF Stankovic, Iva
   Krismer, Florian
   Jesic, Aleksandar
   Antonini, Angelo
   Benke, Thomas
   Brown, Richard G.
   Burn, David J.
   Holton, Janice L.
   Kaufmann, Horacio
   Kostic, Vladimir S.
   Ling, Helen
   Meissner, Wassilios G.
   Poewe, Werner
   Semnic, Marija
   Seppi, Klaus
   Takeda, Atsushi
   Weintraub, Daniel
   Wenning, Gregor K.
CA Movement Disorders Soc MSA MODIMSA
TI Cognitive Impairment in Multiple System Atrophy: A Position Statement by
   the Neuropsychology Task Force of the MDS Multiple System Atrophy
   (MODIMSA) Study Group
SO MOVEMENT DISORDERS
LA English
DT Article
DE cognition; multiple system atrophy; neuropsychology
ID PROGRESSIVE SUPRANUCLEAR PALSY; VOXEL-BASED MORPHOMETRY; IDIOPATHIC
   PARKINSONS-DISEASE; BRAIN GLUCOSE-METABOLISM; CEREBELLAR TYPE;
   STRIATONIGRAL DEGENERATION; FRONTAL-LOBE; OLIVOPONTOCEREBELLAR ATROPHY;
   DEPRESSIVE SYMPTOMS; CLINICAL-PARAMETERS
AB Consensus diagnostic criteria for multiple system atrophy consider dementia as a nonsupporting feature, despite emerging evidence demonstrating that cognitive impairments are an integral part of the disease. Cognitive disturbances in multiple system atrophy occur across a wide spectrum from mild single domain deficits to impairments in multiple domains and even to frank dementia in some cases. Frontal-executive dysfunction is the most common presentation, while memory and visuospatial functions also may be impaired. Imaging and neuropathological findings support the concept that cognitive impairments in MSA originate from striatofrontal deafferentation, with additional contributions from intrinsic cortical degeneration and cerebellar pathology. Based on a comprehensive evidencebased review, the authors propose future avenues of research that ultimately may lead to diagnostic criteria for cognitive impairment and dementia associated with multiple system atrophy. (C) 2014 International Parkinson and Movement Disorder Society
C1 [Stankovic, Iva; Kostic, Vladimir S.] Univ Belgrade, Sch Med, Clin Ctr Serbia, Neurol Clin, Belgrade, Serbia.
   [Krismer, Florian; Benke, Thomas; Poewe, Werner; Seppi, Klaus; Wenning, Gregor K.] Med Univ Innsbruck, Dept Neurol, A-6020 Innsbruck, Austria.
   [Jesic, Aleksandar; Semnic, Marija] Univ Novi Sad, Neurol Clin, Clin Ctr Vojvodina, Sch Med Novi Sad, Novi Sad 21000, Serbia.
   [Antonini, Angelo] IRCCS, Fdn Osped San Camillo, Dept Parkinsons Dis, Venice, Italy.
   [Brown, Richard G.] Kings Coll London, Inst Psychiat, Dept Psychol, London WC2R 2LS, England.
   [Burn, David J.] Newcastle Univ, Inst Ageing & Hlth, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
   [Holton, Janice L.; Ling, Helen] UCL, Inst Neurol, Queen Sq Brain Bank Neurol Disorders, London, England.
   [Kaufmann, Horacio] NYU, Langone Med Ctr, Dysautonomia Ctr, New York, NY USA.
   [Meissner, Wassilios G.] Univ Bordeaux, Inst Malad Neurodegenerat, Bordeaux, France.
   [Takeda, Atsushi] Sendai Nishitaga Hosp, Natl Hosp Org, Dept Neurol, Sendai, Miyagi, Japan.
   [Weintraub, Daniel] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Weintraub, Daniel] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA USA.
RP Wenning, GK (reprint author), Med Univ Innsbruck, Dept Neurol, Anichstr 35, A-6020 Innsbruck, Austria.
EM gregor.wenning@i-med.ac.at
RI Ling, Helen/J-3751-2013; Brown, Richard/A-9599-2010; Meissner,
   Wassilios/C-7817-2015
OI Brown, Richard/0000-0001-9021-0172; Meissner,
   Wassilios/0000-0003-2172-7527; Kaufmann, Horacio/0000-0002-1851-9981
FU Austrian Science Fund (FWF) [F04404-B19]; National Institute for Health
   Research (NIHR) Mental Health Biomedical Research Centre; Dementia
   Biomedical Research Unit at South London, and Maudsley NHS Foundation
   Trust and King's College London; Reta Lila Weston Institute for
   Neurological Studies; Multiple System Atrophy Trust; National Institute
   for Health Research University College London Hospitals Biomedical
   Research Centre
FX This study was supported by funds of the Austrian Science Fund (FWF):
   F04404-B19. Dr. Brown acknowledges support from the National Institute
   for Health Research (NIHR) Mental Health Biomedical Research Centre and
   Dementia Biomedical Research Unit at South London, and Maudsley NHS
   Foundation Trust and King's College London. The views expressed are
   those of the author and not necessarily those of the NHS, the NIHR or
   the Department of Health. Dr. Holton is supported by the Reta Lila
   Weston Institute for Neurological Studies and the Multiple System
   Atrophy Trust. Part of the study was supported by the National Institute
   for Health Research University College London Hospitals Biomedical
   Research Centre.
NR 80
TC 31
Z9 31
U1 1
U2 13
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0885-3185
EI 1531-8257
J9 MOVEMENT DISORD
JI Mov. Disord.
PD JUN
PY 2014
VL 29
IS 7
BP 857
EP 867
DI 10.1002/mds.25880
PG 11
WC Clinical Neurology
SC Neurosciences & Neurology
GA AJ4TZ
UT WOS:000337670600007
PM 24753321
ER

PT J
AU Achey, M
   Aldred, JL
   Aljehani, N
   Bloem, BR
   Biglan, KM
   Chan, P
   Cubo, E
   Dorsey, ER
   Goetz, CG
   Guttman, M
   Hassan, A
   Khandhar, SM
   Mari, Z
   Spindler, M
   Tanner, CM
   van den Haak, P
   Walker, R
   Wilkinson, JR
AF Achey, Meredith
   Aldred, Jason L.
   Aljehani, Noha
   Bloem, Bastiaan R.
   Biglan, Kevin M.
   Chan, Piu
   Cubo, Esther
   Dorsey, E. Ray
   Goetz, Christopher G.
   Guttman, Mark
   Hassan, Anhar
   Khandhar, Suketu M.
   Mari, Zoltan
   Spindler, Meredith
   Tanner, Caroline M.
   van den Haak, Pieter
   Walker, Richard
   Wilkinson, Jayne R.
CA Int Parkinson Movement Disorder
TI The Past, Present, and Future of Telemedicine for Parkinson's Disease
SO MOVEMENT DISORDERS
LA English
DT Article
DE telemedicine; Parkinson's disease
ID NURSING-HOME RESIDENTS; RANDOMIZED CONTROLLED-TRIAL; SEDENTARY PATIENTS;
   PHYSICAL-ACTIVITY; CLINICAL-TRIALS; UNITED-STATES; HEALTH-CARE;
   PREVALENCE; HISTORY; PEOPLE
AB Travel distance, growing disability, and uneven distribution of doctors limit access to care for most Parkinson's disease (PD) patients worldwide. Telemedicine, the use of telecommunications technology to deliver care at a distance, can help overcome these barriers. In this report, we describe the past, present, and likely future applications of telemedicine to PD. Historically, telemedicine has relied on expensive equipment to connect single patients to a specialist in pilot programs in wealthy nations. As the cost of video conferencing has plummeted, these efforts have expanded in scale and scope, now reaching larger parts of the world and extending the focus from care to training of remote providers. Policy, especially limited reimbursement, currently hinders the growth and adoption of these new care models. As these policies change and technology advances and spreads, the following will likely develop: integrated care networks that connect patients to a wide range of providers; education programs that support patients and health care providers; and new research applications that include remote monitoring and remote visits. Together, these developments will enable more individuals with PD to connect to care, increase access to expertise for patients and providers, and allow more-extensive, less-expensive participation in research. (C) 2014 International Parkinson and Movement Disorder Society
C1 [Achey, Meredith; Dorsey, E. Ray] Univ Rochester, Med Ctr, Ctr Human Expt Therapeut, Rochester, NY 14642 USA.
   [Aldred, Jason L.] Northwest Neurol PLLC, Spokane, WA USA.
   [Aljehani, Noha; Mari, Zoltan] Johns Hopkins Med, Dept Neurol, Baltimore, MD USA.
   [Bloem, Bastiaan R.; van den Haak, Pieter] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Neurol, Nijmegen, Netherlands.
   [Biglan, Kevin M.; Dorsey, E. Ray] Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA.
   [Chan, Piu] Capital Med Univ, Dept Neurol & Neurobiol, Xuanwu Hosp,Beijing Inst Brain Disorders, Beijing Key Lab Parkinsons Dis,Parkinsons Dis Ctr, Beijing, Peoples R China.
   [Cubo, Esther] Univ Hosp, Dept Neurol, Burgos, Spain.
   [Goetz, Christopher G.] Rush Univ, Med Ctr, Chicago, IL 60612 USA.
   [Guttman, Mark] Univ Toronto, Div Neurol, Ctr Movement Disorders, Markham, ON, Canada.
   [Hassan, Anhar] Mayo Clin, Dept Neurol, Rochester, MN USA.
   [Khandhar, Suketu M.] Kaiser Permanente, Movement Disorders Program, Raleigh, NC USA.
   [Spindler, Meredith; Wilkinson, Jayne R.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA.
   [Tanner, Caroline M.] Univ Calif San Francisco, Parkinsons Dis Res Educ & Clin Ctr, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA.
   [Tanner, Caroline M.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
   [Walker, Richard] North Tyneside Gen Hosp, Dept Med, North Shields, Tyne & Wear, England.
   [Wilkinson, Jayne R.] Dept Vet Affairs, Dept Neurol, Philadelphia, PA USA.
RP Dorsey, ER (reprint author), Univ Rochester, Med Ctr, Ctr Human Expt Therapeut, 265 Crittenden Blvd,CU 420694, Rochester, NY 14642 USA.
EM ray.dorsey@chet.rochester.edu
RI Bloem, B.R./H-8013-2014
FU Davis Phinney Foundation; Great Lakes NeuroTechnologies; Michael J. Fox
   Foundation; Patient-Centered Outcomes Research Institute
FX Dr. Biglan has telemedicine research-related grants with the Davis
   Phinney Foundation, Great Lakes NeuroTechnologies, Michael J. Fox
   Foundation, and the Patient-Centered Outcomes Research Institute and has
   filed a patent related to telemedicine and neurology. Dr. Dorsey has
   telemedicine research-related grants with the Davis Phinney Foundation,
   Great Lakes NeuroTechnologies, Michael J. Fox Foundation, and the
   Patient-Centered Outcomes Research Institute, is a member of the medical
   advisory board for, and has stock options in, Grand Rounds (an online
   second opinion service), is an unpaid advisor to SBR Health and Vidyo,
   and has filed a patent related to telemedicine and neurology. Dr. Goetz
   is an officer of the International Parkinson and Movement Disorder
   Society (MDS) that supports this program. Dr. Tanner is a coinvestigator
   on telemedicine research-related grants with the Davis Phinney
   Foundation, the Patient-Centered Outcomes Research Institute, and the
   MDS.
NR 89
TC 22
Z9 22
U1 3
U2 24
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0885-3185
EI 1531-8257
J9 MOVEMENT DISORD
JI Mov. Disord.
PD JUN
PY 2014
VL 29
IS 7
BP 871
EP 883
DI 10.1002/mds.25903
PG 13
WC Clinical Neurology
SC Neurosciences & Neurology
GA AJ4TZ
UT WOS:000337670600011
PM 24838316
ER

PT J
AU Huerta, CI
   Sarkar, PR
   Duong, TQ
   Laird, AR
   Fox, PT
AF Huerta, Claudia I.
   Sarkar, Pooja R.
   Duong, Timothy Q.
   Laird, Angela R.
   Fox, Peter T.
TI Neural Bases of Food Perception: Coordinate-Based Meta-Analyses of
   Neuroimaging Studies in Multiple Modalities
SO OBESITY
LA English
DT Article
ID ALE METAANALYSIS; FUNCTIONAL MRI; BRAIN; ACTIVATION; ADDICTION; CALORIE;
   OBESITY; INSULA; CUES
AB Objective: The purpose of this study was to compare the results of the three food-cue paradigms most commonly used for functional neuroimaging studies to determine: i) commonalities and differences in the neural response patterns by paradigm and ii) the relative robustness and reliability of responses to each paradigm.
   Methods: Functional magnetic resonance imaging studies using standardized stereotactic coordinates to report brain responses to food cues were identified using online databases. Studies were grouped by food-cue modality as: i) tastes (8 studies); ii) odors (8 studies); and, iii) images (11 studies). Activation likelihood estimation was used to identify statistically reliable regional responses within each stimulation paradigm.
   Results: Brain response distributions were distinctly different for the three stimulation modalities, corresponding to known differences in location of the respective primary and associative cortices. Visual stimulation induced the most robust and extensive responses. The left anterior insula was the only brain region reliably responding to all three stimulus categories.
   Conclusions: These findings suggest visual food-cue paradigm as promising candidate for imaging studies addressing the neural substrate of therapeutic interventions.
C1 [Huerta, Claudia I.; Sarkar, Pooja R.; Fox, Peter T.] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA.
   [Huerta, Claudia I.; Sarkar, Pooja R.; Duong, Timothy Q.; Fox, Peter T.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA.
   [Duong, Timothy Q.; Laird, Angela R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA.
   [Laird, Angela R.] Florida Int Univ, Dept Phys, Miami, FL 33199 USA.
   [Fox, Peter T.] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Huerta, CI (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA.
EM fox@uthscsa.edu
RI Fox, Peter/B-4725-2010
OI Fox, Peter/0000-0002-0465-2028
FU  [R01 MH074457]
FX This study was funded by R01 MH074457 (PTF and ARL, PIs).
NR 40
TC 10
Z9 10
U1 0
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1930-7381
EI 1930-739X
J9 OBESITY
JI Obesity
PD JUN
PY 2014
VL 22
IS 6
BP 1439
EP 1446
DI 10.1002/oby.20659
PG 8
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA AJ3AM
UT WOS:000337537000009
PM 24174404
ER

PT J
AU Huddle, TS
   Kertesz, SG
   Nash, RR
AF Huddle, Thomas S.
   Kertesz, Stefan G.
   Nash, Ryan R.
TI Health Care Institutions Should Not Exclude Smokers From Employment
SO ACADEMIC MEDICINE
LA English
DT Article
ID SMOKING; WORKPLACE
AB Some health care institutions, including academic health centers, have adopted policies excluding smokers from employment. Claims advanced on behalf of these policies include financial savings from reduced health costs and absenteeism as well as advantages consonant with their message of healthy living. The authors suggest that the institutional savings from these policies are speculative and unproven. Also, in settings where large medical schools operate, it is likely to be the poor, including members of minority groups, who, under an employee smoker ban, will lose the opportunity to work for an employer that offers health insurance and other benefits. In response to the incentives created by such bans, some will quit smoking, but most will not. Thus, at the community level, employee smoker bans are more likely to be harmful than beneficial.
   Although private businesses may rightly choose not to hire smokers in the 19 states where such policies are legal, health care institutions, including academic health centers, should consider hiring choices in light of the values they profess. The traditional values of medicine include service to all persons in need, even when illness results from addiction or unsafe behavior. Secular academic communities require a shared dedication to discovery without requiring strict conformity of private behavior or belief. The authors conclude that for health care institutions, policies of hiring smokers and helping them to quit are both prudent and expressive of the norms of medical care, such as inclusion, compassion, and fellowship, that academic health professionals seek to honor.
C1 [Huddle, Thomas S.; Kertesz, Stefan G.] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA.
   [Huddle, Thomas S.] Univ Alabama Birmingham, Birmingham VA Med Ctr, Birmingham, AL USA.
   [Kertesz, Stefan G.] Birmingham VA Med Ctr, Birmingham, AL USA.
   [Nash, Ryan R.] Ohio State Univ, Ctr Bioeth, Columbus, OH 43210 USA.
RP Huddle, TS (reprint author), FOT 720,1530 3rd Ave S, Birmingham, AL 35294 USA.
EM thuddle@uab.edu
OI Kertesz, Stefan/0000-0001-6101-8421
NR 24
TC 3
Z9 3
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-2446
EI 1938-808X
J9 ACAD MED
JI Acad. Med.
PD JUN
PY 2014
VL 89
IS 6
BP 843
EP 847
DI 10.1097/ACM.0000000000000247
PG 5
WC Education, Scientific Disciplines; Health Care Sciences & Services
SC Education & Educational Research; Health Care Sciences & Services
GA AI8NU
UT WOS:000337176300012
PM 24871233
ER

PT J
AU Momplaisir, F
   Yehia, BR
   Harhay, MO
   Fetzer, B
   Brady, KA
   Long, JA
AF Momplaisir, Florence
   Yehia, Baligh R.
   Harhay, Michael O.
   Fetzer, Bradley
   Brady, Kathleen A.
   Long, Judith A.
TI HIV Testing Trends: Southeastern Pennsylvania, 2002-2010
SO AIDS PATIENT CARE AND STDS
LA English
DT Article
ID FOR-DISEASE-CONTROL; EMERGENCY-DEPARTMENT; ANTIRETROVIRAL THERAPY;
   UNITED-STATES; CLINICAL GUIDELINES; PREVALENCE AREA; SEXUAL HISTORY;
   CARE; PREVENTION; PROGRAM
AB There are limited data on HIV testing trends after 2006 when the Centers for Disease Control and Prevention (CDC) introduced opt-out HIV testing with the aims of identifying HIV-infected persons early and linking them to care. We used data from the Southeastern Pennsylvania Household Health Survey between 2002 and 2010 to evaluate HIV testing over time. 50,698 adult (>= 18 years) survey respondents were included. HIV testing increased after the CDC recommendations: 42.1% of survey respondents received testing at least once in 2002 versus 51.4% in 2010, p < 0.001. Testing trends increased among all demographic groups, but existing differences in testing before 2006 persisted after that year as follows: younger patients, racial/ethnic minorities, patients on Medicaid were all more likely to get tested than their counterparts. Blacks and patients seeking care in community health centers had the fastest rise in HIV testing. The probability of HIV testing in Blacks was 0.56 (95% CI 0.54-0.60) in 2002 and increased to 0.73 (0.70-0.76) by 2010. Patients seeking care in community health centers had a probability of HIV testing of 0.57 (0.47-0.66) in 2002, which increased to 0.69 (0.60-0.77) by 2010. In comparison, patients in private clinics had an HIV testing probability of 0.40 (0.360.43) in 2002 compared to 0.47 (0.40-0.54) in 2010. HIV testing is increasing, particularly among ethnic minorities and in community health centers. However, testing remains to be improved in that setting and across all clinic types.
C1 [Momplaisir, Florence] Temple Univ Hosp & Med Sch, Infect Dis Sect, Philadelphia, PA 19140 USA.
   [Yehia, Baligh R.] Univ Penn, Div Infect Dis, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Harhay, Michael O.; Fetzer, Bradley; Long, Judith A.] Univ Penn, Div Gen Internal Med, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Brady, Kathleen A.] Philadelphia Dept Publ Hlth, Philadelphia, PA USA.
   [Long, Judith A.] Philadelphia VA Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
RP Momplaisir, F (reprint author), Temple Univ Hosp & Med Sch, Suite 501,3401 North Broad St, Philadelphia, PA 19140 USA.
EM Florence.Momplaisir@tuhs.temple.edu
OI Harhay, Michael/0000-0002-0553-674X
FU NIMH NIH HHS [K23 MH097647]
NR 48
TC 4
Z9 4
U1 1
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1087-2914
EI 1557-7449
J9 AIDS PATIENT CARE ST
JI Aids Patient Care STDS
PD JUN
PY 2014
VL 28
IS 6
BP 303
EP 310
DI 10.1089/apc.2014.0044
PG 8
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA AI9CG
UT WOS:000337224700005
PM 24742326
ER

PT J
AU Ndiaye, MA
   Nihal, M
   Wood, GS
   Ahmad, N
AF Ndiaye, Mary A.
   Nihal, Minakshi
   Wood, Gary S.
   Ahmad, Nihal
TI Skin, Reactive Oxygen Species, and Circadian Clocks
SO ANTIOXIDANTS & REDOX SIGNALING
LA English
DT Review
ID SLEEP-WAKE CYCLES; OXIDATIVE STRESS; VITAMIN-A; DNA-DAMAGE;
   SIGNAL-TRANSDUCTION; RETINOIC ACID; EPIDERMAL-KERATINOCYTES;
   MELATONINERGIC SYSTEMS; EPITHELIAL-CELLS; BARRIER FUNCTION
AB Significance: Skin, a complex organ and the body's first line of defense against environmental insults, plays a critical role in maintaining homeostasis in an organism. This balance is maintained through a complex network of cellular machinery and signaling events, including those regulating oxidative stress and circadian rhythms. These regulatory mechanisms have developed integral systems to protect skin cells and to signal to the rest of the body in the event of internal and environmental stresses. Recent Advances: Interestingly, several signaling pathways and many bioactive molecules have been found to be involved and even important in the regulation of oxidative stress and circadian rhythms, especially in the skin. It is becoming increasingly evident that these two regulatory systems may, in fact, be interconnected in the regulation of homeostasis. Important examples of molecules that connect the two systems include serotonin, melatonin, vitamin D, and vitamin A. Critical Issues: Excessive reactive oxygen species and/or dysregulation of antioxidant system and circadian rhythms can cause critical errors in maintaining proper barrier function and skin health, as well as overall homeostasis. Unfortunately, the modern lifestyle seems to contribute to increasing alterations in redox balance and circadian rhythms, thereby posing a critical problem for normal functioning of the living system. Future Directions: Since the oxidative stress and circadian rhythm systems seem to have areas of overlap, future research needs to be focused on defining the interactions between these two important systems. This may be especially important in the skin where both systems play critical roles in protecting the whole body.
C1 [Ndiaye, Mary A.; Nihal, Minakshi; Wood, Gary S.; Ahmad, Nihal] Univ Wisconsin, Dept Dermatol, Madison, WI 53706 USA.
   [Wood, Gary S.; Ahmad, Nihal] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA.
RP Ahmad, N (reprint author), Univ Wisconsin, Dept Dermatol, Med Sci Ctr, Room 423 1300 Univ Ave, Madison, WI 53706 USA.
EM nahmad@wisc.edu
FU NIH [R01AR059130, R01CA176748]; VA Merit Review Award [1I01BX001008]
FX This work was partly supported by funding to N.A. from the NIH
   (R01AR059130 and R01CA176748) and VA Merit Review Award (1I01BX001008).
NR 123
TC 5
Z9 6
U1 4
U2 22
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1523-0864
EI 1557-7716
J9 ANTIOXID REDOX SIGN
JI Antioxid. Redox Signal.
PD JUN
PY 2014
VL 20
IS 18
BP 2982
EP 2996
DI 10.1089/ars.2013.5645
PG 15
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA AI8LN
UT WOS:000337167100008
PM 24111846
ER

PT J
AU Barron, DS
   Tandon, N
   Lancaster, JL
   Fox, PT
AF Barron, Daniel S.
   Tandon, Nitin
   Lancaster, Jack L.
   Fox, Peter T.
TI Thalamic structural connectivity in medial temporal lobe epilepsy
SO EPILEPSIA
LA English
DT Article
DE Hippocampal sclerosis; Magnetic resonance imaging; Diffusion-weighted
   imaging; Thalamic connectivity
ID DEEP BRAIN-STIMULATION; SEGMENTATION; PULVINAR; SEIZURES; NUCLEUS
AB The thalamus has been implicated in various stages of medial temporal lobe epilepsy (MTLE) seizure evolution. The relative density and functional significance (in epileptogenesis) of thalamic projections to MTL subregions, however, remains to be determined. This study used structural and diffusion magnetic resonance imaging (MRI) to evaluate thalamic connection density with distinct MTL subregions in terms of location and volume. Nineteen MTLE patients with unilateral hippocampal sclerosis (HS; 12 right; 10 female) were compared to 19 age-matched controls. Five regions of interest (ROIs) per hemisphere were created in native space: thalamus, amygdala, entorhinal cortex, hippocampus, and parahippocampus. Separate probabilistic tractography analyses were performed between the thalamus and each ipsilateral MTL subregion (four per hemisphere). Individual connectivity profiles and regional volumes were assessed. The medial pulvinar consistently showed the highest connection density with the hippocampus in healthy controls and in MTLE patients. Decreased thalamic connected volume was observed for thalamohippocampal pathways in patients with MTLE, and indicates pathway-specific deafferentation. Regional hippocampal and thalamic atrophy was also observed, indicating gray and white matter loss in the thalamohippocampal pathway. Consistent localization of dense medial pulvinar (PuM) connectivity with the hippocampus suggests chronic PuM stimulation could modulate the MTLE seizure network. Decreased thalamic connected volume is a promising biomarker for epileptogenesis that merits longitudinal validation.
C1 [Barron, Daniel S.; Lancaster, Jack L.; Fox, Peter T.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA.
   [Barron, Daniel S.] Yale Univ, Sch Med, New Haven, CT 06510 USA.
   [Tandon, Nitin] Univ Texas Hlth Sci Ctr Houston, Dept Neurosurg, Houston, TX 77030 USA.
   [Lancaster, Jack L.; Fox, Peter T.] Univ Texas Hlth Sci Ctr Houston, Dept Radiol, Houston, TX 77030 USA.
   [Fox, Peter T.] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
   [Fox, Peter T.] Univ Hong Kong, State Key Lab Brain & Cognit Sci, Hong Kong, Peoples R China.
   [Fox, Peter T.] Univ Texas Hlth Sci Ctr San Antonio, Dept Neurol, San Antonio, TX 78229 USA.
RP Barron, DS (reprint author), Yale Univ, Sch Med, 367 Cedar St, New Haven, CT 06510 USA.
EM daniel.s.barron@yale.edu
RI Fox, Peter/B-4725-2010
OI Fox, Peter/0000-0002-0465-2028
FU  [1F31 NS083160-01];  [RO1 MH074457]
FX The authors thank Jose E. Cavazos (UTHSC-SA, edits), Kristin S. Budde
   (UTHSC-SA, edits), Vatche G. Baboyan (UTHSC-H, data transfer), and the
   patients who participated in this study. The authors also thank the
   anonymous reviewers for their time and helpful directives. This study
   was funded by 1F31 NS083160-01 (D.S.B.) and RO1 MH074457 (P.T.F.).
NR 16
TC 14
Z9 15
U1 0
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0013-9580
EI 1528-1167
J9 EPILEPSIA
JI Epilepsia
PD JUN
PY 2014
VL 55
IS 6
BP e50
EP e55
DI 10.1111/epi.12637
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA AJ4DE
UT WOS:000337620200001
PM 24802969
ER

PT J
AU Deyo, RA
   Dworkin, SF
   Amtmann, D
   Andersson, G
   Borenstein, D
   Carragee, E
   Carrino, J
   Chou, R
   Cook, K
   DeLitto, A
   Goertz, C
   Khalsa, P
   Loeser, J
   Mackey, S
   Panagis, J
   Rainville, J
   Tosteson, T
   Turk, D
   Von Korff, M
   Weinertt, DK
AF Deyo, Richard A.
   Dworkin, Samuel F.
   Amtmann, Dagmar
   Andersson, Gunnar
   Borenstein, David
   Carragee, Eugene
   Carrino, John
   Chou, Roger
   Cook, Karon
   DeLitto, Anthony
   Goertz, Christine
   Khalsa, Partap
   Loeser, John
   Mackey, Sean
   Panagis, James
   Rainville, James
   Tosteson, Tor
   Turk, Dennis
   Von Korff, Michael
   Weinertt, Debra K.
TI Report of the NIH Task Force on Research Standards for Chronic Low Back
   Pain
SO JOURNAL OF PAIN
LA English
DT Article
DE Low back pain; chronic low back pain; research standards; minimum
   dataset; NIH Task Force
ID CLINICAL-PRACTICE GUIDELINE; DEFINING CHRONIC PAIN; INFORMATION-SYSTEM
   PROMIS; FUNCTION ITEM BANK; QUALITY-OF-LIFE; PRIMARY-CARE; PROGNOSTIC
   APPROACH; SCREENING TOOL; START BACK; OUTCOME MEASURES
AB Despite rapidly increasing intervention, functional disability due to chronic low back pain (cLBP) has increased in recent decades. We often cannot identify mechanisms to explain the major negative impact cLBP has on patients' lives. Such cLBP is often termed non-specific and may be due to multiple biologic and behavioral etiologies. Researchers use varied inclusion criteria, definitions, baseline assessments, and outcome measures, which impede comparisons and consensus. Therefore, NIH Pain Consortium charged a Research Task Force (RTF) to draft standards for research on cLBP. The resulting multidisciplinary panel recommended using 2 questions to define cLBP; cLBP by its impact (defined by pain intensity, pain interference, and physical function); use of a minimum dataset to describe research participants (drawing heavily on the PROMIS methodology); reporting "responder analyses" in addition to mean outcome scores; and suggestions for future research and dissemination. The Pain Consortium has approved the recommendations, which investigators should incorporate into NIH grant proposals. The RTF believes that these recommendations will advance the field, help to resolve controversies, and facilitate future research addressing the genomic, neurologic, and other mechanistic substrates of chronic low back pain. We expect that the RTF recommendations will become a dynamic document and undergo continual improvement.
   Perspective: A task force was convened by the NIH Pain Consortium with the goal of developing research standards for chronic low back pain. The results included recommendations for definitions, a minimum dataset, reporting outcomes, and future research. Greater consistency in reporting should facilitate comparisons among studies and the development of phenotypes. (C) 2014 by the American Pain Society. Published by Elsevier Inc. All rights reserved
C1 [Deyo, Richard A.; Chou, Roger] Oregon Hlth & Sci Univ, Portland, OR 97239 USA.
   [Dworkin, Samuel F.; Amtmann, Dagmar; Loeser, John; Turk, Dennis] Univ Washington, Seattle, WA 98195 USA.
   [Andersson, Gunnar] Rush Univ, Med Ctr, Chicago, IL 60612 USA.
   [Borenstein, David] George Washington Univ, Washington, DC USA.
   [Carragee, Eugene; Mackey, Sean] Stanford Univ, Stanford, CA 94305 USA.
   [Carrino, John] Johns Hopkins Univ, Baltimore, MD USA.
   [Cook, Karon] Northwestern Univ, Evanston, IL USA.
   [DeLitto, Anthony; Weinertt, Debra K.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
   [DeLitto, Anthony; Weinertt, Debra K.] Univ Pittsburgh, Pittsburgh, PA USA.
   [Goertz, Christine] Palmer Coll Chiropract, Davenport, IA USA.
   [Khalsa, Partap] Natl Ctr Complementary & Alternat Med, Bethesda, MD USA.
   [Panagis, James] NIAMSD, Bethesda, MD 20892 USA.
   [Rainville, James] New England Baptist Hosp, Roxbury Crossing, MA USA.
   [Tosteson, Tor] Dartmouth Coll, Hanover, NH USA.
   [Von Korff, Michael] Grp Hlth Res Inst, Seattle, WA USA.
RP Deyo, RA (reprint author), Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
EM deyor@ohsu.edu
FU National Center for Complementary and Alternative Medicine; National
   Institute for Arthritis, Musculoskeletal, and Skin Diseases
FX This study was supported by the National Center for Complementary and
   Alternative Medicine and the National Institute for Arthritis,
   Musculoskeletal, and Skin Diseases.
NR 127
TC 31
Z9 31
U1 9
U2 18
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 1526-5900
J9 J PAIN
JI J. Pain
PD JUN
PY 2014
VL 15
IS 6
BP 569
EP 585
DI 10.1016/j.jpain.2014.03.005
PG 17
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA AJ0HM
UT WOS:000337331400001
PM 24787228
ER

PT J
AU Sobel, JD
   Vartanian, SM
   Gasper, WJ
   Grenon, M
   Rapp, JH
   Hiramoto, JS
   Chuter, TA
   Reilly, LM
AF Sobel, Julia D.
   Vartanian, Shant M.
   Gasper, Warren J.
   Grenon, Marlene
   Rapp, Joseph H.
   Hiramoto, Jade S.
   Chuter, Timothy A.
   Reilly, Linda M.
TI Factors Associated With Spinal Cord Ischemia After Multibranched
   Endovascular Thoracoabdominal Aneurysm Repair
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Meeting Abstract
CT Vascular Annual Meeting of the Society-for-Vascular-Surgery
CY JUN 05-07, 2014
CL Boston, MA
SP Soc Vasc Surg
C1 [Sobel, Julia D.; Vartanian, Shant M.; Gasper, Warren J.; Hiramoto, Jade S.; Chuter, Timothy A.; Reilly, Linda M.] Univ Calif San Francisco, Div Vasc & Endovasc Surg, San Francisco, CA 94143 USA.
   [Grenon, Marlene; Rapp, Joseph H.] San Francisco VA Med Ctr, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD JUN
PY 2014
VL 59
IS 6
SU S
BP 22S
EP 23S
PG 2
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA AI9ND
UT WOS:000337258400046
ER

PT J
AU Ozaki, CK
   Hamdan, AD
   Barshes, NR
   Wyers, MC
   Hevelone, ND
   Belkin, M
   Nguyen, LL
AF Ozaki, C. K.
   Hamdan, Allen D.
   Barshes, Neal R.
   Wyers, Mark C.
   Hevelone, Nathanael D.
   Belkin, Michael
   Nguyen, Louis L.
TI Prospective, Randomized, Multi-Institutional Clinical Trial of a Silver
   Alginate Dressing to Reduce Lower Extremity Vascular Surgery Wound
   Complications
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Meeting Abstract
CT Vascular Annual Meeting of the Society-for-Vascular-Surgery
CY JUN 05-07, 2014
CL Boston, MA
SP Soc Vasc Surg
C1 [Ozaki, C. K.; Hevelone, Nathanael D.; Belkin, Michael; Nguyen, Louis L.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
   [Hamdan, Allen D.; Wyers, Mark C.] Harvard Univ, Beth Israel Deaconess Med Ctr, Medidcal Sch, Boston, MA 02215 USA.
   [Barshes, Neal R.] Baylor Coll Med, Michael E Debakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD JUN
PY 2014
VL 59
IS 6
SU S
BP 31S
EP 31S
PG 1
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA AI9ND
UT WOS:000337258400063
ER

PT J
AU Azarbal, AF
   Harris, S
   Mitchell, E
   Liem, TK
   Landry, GJ
   Edwards, J
   McLafferty, R
   Moneta, GL
AF Azarbal, Amir F.
   Harris, Sheena
   Mitchell, Erica
   Liem, Timothy K.
   Landry, Gregory J.
   Edwards, James
   McLafferty, Robert
   Moneta, Gregory L.
TI Nasal Methacillin-Resistant Staphylococcus aureus Colonization Is
   Associated With a Higher Postoperative Infection Rate After Major Lower
   Extremity Amputation
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Meeting Abstract
CT Vascular Annual Meeting of the Society-for-Vascular-Surgery
CY JUN 05-07, 2014
CL Boston, MA
SP Soc Vasc Surg
C1 [Azarbal, Amir F.; Edwards, James; McLafferty, Robert] Portland VA Med Ctr, Portland, OR USA.
   [Harris, Sheena; Mitchell, Erica; Liem, Timothy K.; Landry, Gregory J.; Moneta, Gregory L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD JUN
PY 2014
VL 59
IS 6
SU S
BP 72S
EP 72S
PG 1
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA AI9ND
UT WOS:000337258400150
ER

PT J
AU Landry, GJ
   Yarmosh, A
   Shukla, B
   Azarbal, AF
   Liem, TK
   Mitchell, E
   McLafferty, R
   Moneta, GL
AF Landry, Gregory J.
   Yarmosh, Alla
   Shukla, Bhavesh
   Azarbal, Amir F.
   Liem, Timothy K.
   Mitchell, Erica
   McLafferty, Robert
   Moneta, Gregory L.
TI Current Status of Symptomatic Nonatherosclerotic Mesenteric Vascular
   Disease
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Meeting Abstract
CT Vascular Annual Meeting of the Society-for-Vascular-Surgery
CY JUN 05-07, 2014
CL Boston, MA
SP Soc Vasc Surg
C1 [Landry, Gregory J.; Yarmosh, Alla; Shukla, Bhavesh; Liem, Timothy K.; Mitchell, Erica; Moneta, Gregory L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
   [Azarbal, Amir F.; McLafferty, Robert] Portland VA Med Ctr, Portland, OR USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD JUN
PY 2014
VL 59
IS 6
SU S
BP 105S
EP 105S
PG 1
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA AI9ND
UT WOS:000337258400219
ER

PT J
AU Kaatz, A
   Carnes, M
AF Kaatz, Anna
   Carnes, Molly
TI Stuck in the Out-Group: Jennifer Can't Grow Up, Jane's Invisible, and
   Janet's Over the Hill
SO JOURNAL OF WOMENS HEALTH
LA English
DT Editorial Material
ID WOMEN; STEREOTYPES; SPECIALTY; MEDICINE; CULTURE; FEMALE; SCHOOL; SEX
AB Fifty years after Title IX, women remain sparsely represented in high ranks and leadership in academic medicine. Although men and women enter the career pipeline at similar rates, academic medicine does not equivalently advance them. Currently, women account for 32% of associate professors, 20% of full professors, 14% of department chairs, and 11% of deans at U. S. medical schools-far from the near sex parity seen in medical students since the 1990s. Over 30 years of research confirms that gender stereotypes can operate to disadvantage women in review processes and consequently bar their advancement in domains like science and medicine. The authors present three vignettes to illustrate how gender stereotypes can also operate to disadvantage women in social interactions by positioning them in the "out-group" for many career-advancing opportunities. The authors argue that policies alone will not achieve gender equity in the academic medicine workforce. Addressing stereotype-based gender bias is critical for the future of academic medicine. Interventions that treat gender bias as a remediable habit show promise in promoting gender equity and transforming institutional culture to achieve the full participation of women at all career stages. A critical step is to recognize when gender stereotyped assumptions are influencing judgments and decision making in ourselves and others, challenge them as unjust, and deliberately practice replacing them with accurate and objective data.
C1 [Kaatz, Anna; Carnes, Molly] Univ Wisconsin, Ctr Womens Hlth Res, Madison, WI 53715 USA.
   [Carnes, Molly] Univ Wisconsin, Dept Med, Madison, WI 53715 USA.
   [Carnes, Molly] Univ Wisconsin, Dept Psychiat, Madison, WI 53715 USA.
   [Carnes, Molly] Univ Wisconsin, Dept Ind & Syst Engn, Madison, WI 53715 USA.
   [Carnes, Molly] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA.
RP Carnes, M (reprint author), Univ Wisconsin, Ctr Womens Hlth Res, 700 Regent St,Suite 301, Madison, WI 53715 USA.
EM mlcarnes@wisc.edu
FU NIGMS NIH HHS [R01 GM111002, R25 GM083252]
NR 27
TC 11
Z9 11
U1 3
U2 15
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-9996
EI 1931-843X
J9 J WOMENS HEALTH
JI J. Womens Health
PD JUN
PY 2014
VL 23
IS 6
BP 481
EP 484
DI 10.1089/jwh.2014.4766
PG 4
WC Public, Environmental & Occupational Health; Medicine, General &
   Internal; Obstetrics & Gynecology; Women's Studies
SC Public, Environmental & Occupational Health; General & Internal
   Medicine; Obstetrics & Gynecology; Women's Studies
GA AI9BT
UT WOS:000337222700001
PM 24844292
ER

PT J
AU Guo, FJ
   Moellering, DR
   Garvey, WT
AF Guo, Fangjian
   Moellering, Douglas R.
   Garvey, W. Timothy
TI Use of HbA1c for Diagnoses of Diabetes and Prediabetes: Comparison with
   Diagnoses Based on Fasting and 2-Hr Glucose Values and Effects of
   Gender, Race, and Age
SO METABOLIC SYNDROME AND RELATED DISORDERS
LA English
DT Article
ID LIFE-STYLE; PREVENTION PROGRAM; HEMOGLOBIN A(1C); TOLERANCE; ADULTS;
   A1C; PREVALENCE; TRIAL; CLASSIFICATION; MANAGEMENT
AB Background: Glycated hemoglobin (HbA1c) has been advocated for the diagnosis of diabetes and prediabetes. Its performance has been commonly assessed in corroboration with elevated fasting plasma glucose (FPG), but not the combination of FPG and 2-hr glucose values. This study assesses receiver operating characteristics (ROC) curves of HbA1c pertaining to the diagnoses of prediabetes and diabetes by FPG and/or 2-hr glucose, and the effects of age, gender, and race.
   Methods: We assessed the utility of HbA1c for diagnosing diabetes and prediabetes among 5395 adults without known diabetes from the National Health and Nutrition Examination Survey (NHANES) 2005-2010.
   Results: Current cutoffs of HbA1c for diabetes (6.5%) or prediabetes (5.7%) exhibited low sensitivity (0.249 and 0.354, respectively) and high specificity in identifying patients diagnosed using both FPG and 2-hr glucose, resulting in large false-negative rates (75.1% and 64.9%). Misdiagnosis rates increased with age and in non-Hispanic whites and Mexican Americans. When HbA1c was combined with FPG for diagnoses, the false-negative rate remained high for diabetes (45.7%), but was reduced for prediabetes (9.2%).
   Conclusions: When assessed against diagnoses using both FPG and 2-hr glucose, HbA1c had low sensitivity and high specificity for identifying diabetes and prediabetes, which varied as a function of age and race. Regarding recently released American Diabetes Association (ADA) and joint European guidelines, it is important to consider that HbA1c values below 6.5% and 5.7% do not reliably exclude the presence of diabetes and prediabetes, respectively. Overall, the data argue for greater use of oral glucose tolerance tests (OGTTs) and both FPG and 2-hr glucose values for diagnosis of diabetes and prediabetes.
C1 [Guo, Fangjian; Moellering, Douglas R.; Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35233 USA.
   [Garvey, W. Timothy] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
RP Guo, FJ (reprint author), Univ Alabama Birmingham, Dept Nutr Sci, Webb 241,1675 Univ Blvd, Birmingham, AL 35233 USA.
EM ilovedd@uab.edu; garveyt@uab.edu
RI Guo, Fangjian/B-7705-2015
OI Guo, Fangjian/0000-0003-3729-2724
FU Merit Review program of the Department of Veterans Affairs, National
   Institutes of Health [DK-038765, DK-083562]; UAB Diabetes Research
   Center [P30-DK079626]
FX We gratefully acknowledge our funding resources, including the Merit
   Review program of the Department of Veterans Affairs, National
   Institutes of Health (DK-038765 and DK-083562), and the UAB Diabetes
   Research Center (P30-DK079626). All data used in this study were
   collected by the National Center for Health Statistics Centers for
   Disease Control and Prevention.
NR 35
TC 16
Z9 18
U1 3
U2 18
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-4196
EI 1557-8518
J9 METAB SYNDR RELAT D
JI Metab. Syndr. Relat. Disord.
PD JUN
PY 2014
VL 12
IS 5
BP 258
EP 268
DI 10.1089/met.2013.0128
PG 11
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA AI9JV
UT WOS:000337249800003
PM 24512556
ER

PT J
AU Genta, RM
   Sonnenberg, A
AF Genta, Robert M.
   Sonnenberg, Amnon
TI Big data in gastroenterology research
SO NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY
LA English
DT Article
ID INFLAMMATORY-BOWEL-DISEASE; PEPTIC-ULCER DISEASE; HELICOBACTER-PYLORI;
   HOSPITAL ADMISSION; BARRETTS-ESOPHAGUS; SURVEILLANCE; RISK; PREVALENCE;
   ENDOSCOPY; MORTALITY
AB In epidemiological research, large datasets are essential to reliably capture small variations among comparative groups or detect new unsuspected associations. Although large databases of web-search information, social media, airline traffic and telephone records are already widely used to capture social trends, large databases in medical research are just emerging. With the universal use of electronic medical records underway, vast amounts of health-related information will become available for biomedical research. Accepting such new research tools-based on the analysis of large pre-existing datasets rather than hypothesis-driven, in-depth prospective study-will require a new mindset in clinical research, as data might be `messy' and only associations, but not causality, can be detected. In spite of such limitations, the utilization of these new resources for medical research harbours great potential for advancing knowledge about digestive diseases.
C1 [Genta, Robert M.] Univ Texas SW Med Ctr Dallas, Med Ctr, Dallas, TX 75390 USA.
   [Genta, Robert M.] Mirace Life Sci, Miraca Life Sci Res Inst, Irving, TX 75039 USA.
   [Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97239 USA.
RP Genta, RM (reprint author), Univ Texas SW Med Ctr Dallas, Med Ctr, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.
EM robert.genta@utsouthwestern.edu
NR 39
TC 8
Z9 8
U1 1
U2 24
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1759-5045
EI 1759-5053
J9 NAT REV GASTRO HEPAT
JI Nat. Rev. Gastroenterol. Hepatol.
PD JUN
PY 2014
VL 11
IS 6
DI 10.1038/nrgastro.2014.18
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AI9DX
UT WOS:000337230500009
PM 24594912
ER

PT J
AU Axon, RN
   Penney, FT
   Kyle, TR
   Zapka, J
   Marsden, J
   Zhao, YM
   Mauldin, PD
   Moran, WP
AF Axon, Robert N.
   Penney, Fletcher T.
   Kyle, Thomas R.
   Zapka, Jane
   Marsden, Justin
   Zhao, Yumin
   Mauldin, Patrick D.
   Moran, William P.
TI A Hospital Discharge Summary Quality Improvement Program Featuring
   Individual and Team-based Feedback and Academic Detailing
SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES
LA English
DT Article
DE Care transitions; Hospital discharge; Discharge summary; Quality
   improvement
ID PRIMARY-CARE PHYSICIANS; INTERNAL-MEDICINE; VULNERABLE ELDERS;
   AFTER-DISCHARGE; RE-AIM; COMMUNICATION; PERFORMANCE
AB Background: Discharge summaries are an important component of hospital care transitions typically completed by interns in teaching hospitals. However, these documents are often not completed in a timely fashion or do not include pertinent details of hospitalization. This report outlines the development and impact of a curriculum intervention to improve the quality of discharge summaries by interns and residents in Internal Medicine. A previous study demonstrated that a discharge summary curriculum featuring individualized feedback was associated with improved summary quality, but few subsequent studies have described implementation of similar curricula. No information exists on the utility of other strategies such as team-based feedback or academic detailing. Methods: Study participants were 96 Internal Medicine intern and resident physicians at an academic medical center-based training program. A comprehensive evidence-based discharge summary quality improvement program was developed and implemented that featured a discharge summary template to facilitate summary preparation, individual feedback, team-based feedback, academic detailing and an objective discharge summary evaluation instrument. Results: The discharge summary evaluation instrument had moderate interrater reliability (kappa = 0.72). Discharge summary scores improved from mean score of 70% to 82% (P = 0.05). Interns and residents participating in this program also reported increased confidence in producing and critiquing summaries. Conclusions: A comprehensive discharge summary curriculum can be feasibly implemented within the context of a residency program. Team-based feedback and academic detailing may serve to reinforce individual feedback and extend program reach.
C1 [Axon, Robert N.] Ralph H Johnson Vet Affairs Med Ctr, Ctr Dis Prevent & Hlth Intervent Div Populat, Charleston, SC 29425 USA.
   [Axon, Robert N.; Penney, Fletcher T.; Kyle, Thomas R.; Marsden, Justin; Zhao, Yumin; Mauldin, Patrick D.; Moran, William P.] Med Univ S Carolina, Div Gen Internal Med & Geriatr, Charleston, SC 29425 USA.
   [Zapka, Jane] Med Univ S Carolina, Div Biostat & Epidemiol, Charleston, SC 29425 USA.
   [Mauldin, Patrick D.] South Carolina Coll Pharm, Charleston, SC USA.
RP Axon, RN (reprint author), Ralph H Johnson Vet Affairs Med Ctr, Ctr Dis Prevent & Hlth Intervent Div Populat, 135 Rutledge Ave,MSC 591, Charleston, SC 29425 USA.
EM axon@musc.edu
FU Donald W. Reynolds Foundation; Medical University of South Carolina
   (MUSC)
FX This study was supported by a grant from the Donald W. Reynolds
   Foundation entitled "Aging Q<SUP>3</SUP>: Quality Education, Quality
   Care, and Quality of Life" and matching funds provided by the Medical
   University of South Carolina (MUSC).
NR 22
TC 7
Z9 7
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0002-9629
EI 1538-2990
J9 AM J MED SCI
JI Am. J. Med. Sci.
PD JUN
PY 2014
VL 347
IS 6
BP 472
EP 477
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA AI5IG
UT WOS:000336898500009
PM 24845304
ER

PT J
AU Boyer-Guittaut, M
   Poillet, L
   Liang, QL
   Bole-Richard, E
   Ouyang, XS
   Benavides, GA
   Chakrama, FZ
   Fraichard, A
   Darley-Usmar, VM
   Despouy, G
   Jouvenot, M
   Delage-Mourroux, R
   Zhang, JH
AF Boyer-Guittaut, Michael
   Poillet, Laura
   Liang, Qiuli
   Bole-Richard, Elodie
   Ouyang, Xiaosen
   Benavides, Gloria A.
   Chakrama, Fatima-Zahra
   Fraichard, Annick
   Darley-Usmar, Victor M.
   Despouy, Gilles
   Jouvenot, Michele
   Delage-Mourroux, Regis
   Zhang, Jianhua
TI The role of GABARAPL1/GEC1 in autophagic flux and mitochondrial quality
   control in MDA-MB-436 breast cancer cells
SO AUTOPHAGY
LA English
DT Article
DE autophagy; breast cancer; GABARAP; GABARAPL1; GEC1; LAMP1; LC3;
   lysosome; MDA-MB-436; mitochondria; mitophagy
ID CENTRAL-NERVOUS-SYSTEM; OXIDATIVE STRESS; PARKINSONS-DISEASE;
   MESSENGER-RNAS; GLYCOGEN-METABOLISM; GABA(A) RECEPTOR; GENE-EXPRESSION;
   SMOKE EXPOSURE; PROTEIN; GEC1
AB GABARAPL1/GEC1 is an early estrogen-induced gene which encodes a protein highly conserved from C. elegans to humans. Overexpressed GABARAPL1 interacts with GABA A or kappa opioid receptors, associates with autophagic vesicles, and inhibits breast cancer cell proliferation. However, the function of endogenous GABARAPL1 has not been extensively studied. We hypothesized that GABARAPL1 is required for maintaining normal autophagic flux, and plays an important role in regulating cellular bioenergetics and metabolism. To test this hypothesis, we knocked down GABARAPL1 expression in the breast cancer MDA-MB-436 cell line by shRNA. Decreased expression of GABARAPL1 activated procancer responses of the MDA-MB-436 cells including increased proliferation, colony formation, and invasion. In addition, cells with decreased expression of GABARAPL1 exhibited attenuated autophagic flux and a decreased number of lysosomes. Moreover, decreased GABARAPL1 expression led to cellular bioenergetic changes including increased basal oxygen consumption rate, increased intracellular ATP, increased total glutathione, and an accumulation of damaged mitochondria. Taken together, our results demonstrate that GABARAPL1 plays an important role in cell proliferation, invasion, and autophagic flux, as well as in mitochondrial homeostasis and cellular metabolic programs.
C1 [Boyer-Guittaut, Michael; Poillet, Laura; Bole-Richard, Elodie; Chakrama, Fatima-Zahra; Fraichard, Annick; Despouy, Gilles; Jouvenot, Michele; Delage-Mourroux, Regis] Univ Franche Comte, Lab Biochim, Estrogenes Express Genique & Pathol Syst Nerveux, F-25030 Besancon, France.
   [Boyer-Guittaut, Michael; Liang, Qiuli; Ouyang, Xiaosen; Benavides, Gloria A.; Darley-Usmar, Victor M.; Zhang, Jianhua] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
   [Boyer-Guittaut, Michael; Liang, Qiuli; Ouyang, Xiaosen; Benavides, Gloria A.; Darley-Usmar, Victor M.; Zhang, Jianhua] Univ Alabama Birmingham, Ctr Free Rad Biol, Birmingham, AL USA.
   [Ouyang, Xiaosen; Zhang, Jianhua] Birmingham VA Med Ctr, Dept Vet Affairs, Birmingham, AL USA.
RP Zhang, JH (reprint author), Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
EM michael.boyer-guittaut@univ-fcomte.fr; zhanja@uab.edu
OI Zhang, Jianhua/0000-0002-2128-9574
FU Universite of Franche-Comte; Region de Franche-Comte; VA merit award;
   RDCC-APCC core (NIH P30 grant) [P30 AR48311];  [NIHR01-NS064090]
FX Michael Boyer-Guittaut would like to thank his colleagues from the
   EA3922 team, Jacques Bahi, president of the Universite of Franche-Comte,
   Abderrazzak Kadmiri, director of UFR-ST of the Universite of
   Franche-Comte and the Universite of Franche-Comte for their support
   during this research project performed at the University of Alabama in
   Birmingham, AL, USA. Laura Poillet is supported by a fellowship of the
   Region de Franche-Comte. The authors acknowledge funding from the
   following sources: Dr Jianhua Zhang was supported by NIHR01-NS064090 and
   a VA merit award. Flow cytometry was supported by RDCC-APCC core (NIH
   P30 grant #P30 AR48311). The authors would like to thank Enid F Keyser
   (UAB Flow cytometry core, Birmingham, AL) for her technical help using
   the LSR-II Becton Dickinson flow cytometer. Authors are grateful to
   Jianhua Zhang's and Victor M Darley-Usmar's laboratory members for their
   technical help, advice, and critical reviewing of this manuscript.
NR 64
TC 15
Z9 15
U1 1
U2 16
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1554-8627
EI 1554-8635
J9 AUTOPHAGY
JI Autophagy
PD JUN
PY 2014
VL 10
IS 6
BP 986
EP 1003
DI 10.4161/auto.28390
PG 18
WC Cell Biology
SC Cell Biology
GA AI6GT
UT WOS:000336970800004
PM 24879149
ER

PT J
AU Ali, A
   Ku, JH
   Suhler, EB
   Choi, D
   Rosenbaum, JT
AF Ali, Amro
   Ku, Jennifer H.
   Suhler, Eric B.
   Choi, Dongseok
   Rosenbaum, James T.
TI The course of retinal vasculitis
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SYSTEMIC ASSOCIATIONS; MULTIPLE-SCLEROSIS; DISEASE; CORTICOSTEROIDS;
   PERIPHLEBITIS; EFFICACY
AB Aims To determine if characteristics of retinal vasculitis correlate with ocular complications, or the response to different lines of treatment.
   Materials and methods We performed a computerised database analysis of 56 patients evaluated for uveitis at the Casey Eye Institute from September 1985 until May 2010. All patients had non-infectious retinal vasculitis and at least 1 year of follow-up.
   Results Although occlusive vasculitis was rare, retinal neovascularisation occurred much more commonly in the occlusive vasculitis subgroup than among the nonocclusive vasculitis subgroup (p<0.01). Epiretinal membrane (ERM) was found more commonly in the retinal vasculitis patients who presented with cotton wool spots and intraretinal haemorrhage compared to retinal vasculitis patients who presented with sheathing noted on clinical examination (p<0.01). Smoking was significantly related to vision loss. Age at presentation below 40 years correlated with therapy beyond oral corticosteroids
   Conclusions The heterogeneity of retinal vasculitis should be considered in providing prognostic information. Neovascularisation occurs more commonly in occlusive retinal vasculitis, and ERM is diagnosed more frequently in conjunction with cotton wool spots and intraretinal haemorrhage rather than just vascular sheathing. Cigarette use predicts visual loss and patients who are relatively young often receive treatment beyond oral corticosteroids.
C1 [Ali, Amro; Ku, Jennifer H.; Suhler, Eric B.; Rosenbaum, James T.] Oregon Hlth & Sci Univ, Dept Ophthalmol, Portland, OR 97239 USA.
   [Ku, Jennifer H.; Suhler, Eric B.; Choi, Dongseok] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97239 USA.
   [Suhler, Eric B.] Portland VA Med Ctr, Portland, OR USA.
   [Rosenbaum, James T.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97239 USA.
   [Rosenbaum, James T.] Legacy Hlth Syst, Devers Eye Inst, Portland, OR USA.
RP Ku, JH (reprint author), Oregon Hlth & Sci Univ, Dept Ophthalmol, Mailcode CEI,3375 Terwilliger blvd, Portland, OR 97239 USA.
EM kuj@ohsu.edu
FU Research to Prevent Blindness, through National Eye Institute; Stan and
   Madelle Rosenfeld Family Trust the William and Mary Bauman Foundation
FX This work was supported by Research to Prevent Blindness, through a core
   grant from the National Eye Institute, and by funds from the Stan and
   Madelle Rosenfeld Family Trust the William and Mary Bauman Foundation.
NR 26
TC 3
Z9 3
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUN
PY 2014
VL 98
IS 6
BP 785
EP 789
DI 10.1136/bjophthalmol-2013-303443
PG 5
WC Ophthalmology
SC Ophthalmology
GA AI6JI
UT WOS:000336979100017
PM 24511084
ER

PT J
AU Edrey, YH
   Salmon, AB
AF Edrey, Yael H.
   Salmon, Adam B.
TI Revisiting an age-old question regarding oxidative stress
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Review
DE Aging; Life span; Longevity; Age-related disease; Mouse models; Free
   radicals
ID METHIONINE-SULFOXIDE-REDUCTASE; MANGANESE SUPEROXIDE-DISMUTASE;
   REPLICATIVE LIFE-SPAN; TRANSGENIC MICE; MUSCLE ATROPHY;
   INSULIN-RESISTANCE; MITOCHONDRIAL-FUNCTION; ALZHEIMERS-DISEASE; KNOCKOUT
   MOUSE; IN-VIVO
AB Significant advances in maintaining health;throughout life can be made through a clear understanding of the fundamental mechanisms that regulate aging. The Oxidative Stress Theory of Aging (OSTA) is probably the most well studied mechanistic theory of aging and suggests that the rate of aging is controlled by accumulation of oxidative damage. To directly test the OSTA, aging has been measured in several lines of mice with genetic alterations in the expression of enzymatic antioxidants. Under its strictest interpretation, these studies do not support the OSTA, as modulation of antioxidant expression does not generally affect mouse life span. However, the incidence of many age-related diseases and pathologies is altered in these models, suggesting that oxidative stress does significantly influence some aspects of the aging process. Further, oxidative stress may affect aging in disparate patterns among tissues or under various environmental conditions. In this review, we summarize the current literature regarding aging in antioxidant mutant mice and offer several interpretations of their support of the OSTA. Published by Elsevier Inc.
C1 [Edrey, Yael H.; Salmon, Adam B.] Sam & Ann Barshop Inst Longev & Aging Studies & S, San Antonio, TX 78229 USA.
   [Salmon, Adam B.] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA.
   [Salmon, Adam B.] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78229 USA.
RP Salmon, AB (reprint author), South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, 15355 Lambda Dr, San Antonio, TX 78245 USA.
EM salmona@uthscsa.edu
FU Geriatric Research, Education and Clinical Center of the South Texas
   Veterans Health Care Systems; San Antonio Nathan Shock Center [NIA 5P30
   AG013319-19]; San Antonio Area Foundation
FX The authors thank Arlan Richardson, Holly Van Remmen, and Yuji Ikeno for
   discussions that led to the compilation of this review and their
   yeoman's work over the past 15+ years in regard to testing the OSTA
   under the criteria above. This work was supported by the Geriatric
   Research, Education and Clinical Center of the South Texas Veterans
   Health Care Systems, a pilot grant from the San Antonio Nathan Shock
   Center (NIA 5P30 AG013319-19), and a Biomedical Research Grant from the
   San Antonio Area Foundation.
NR 128
TC 24
Z9 24
U1 1
U2 30
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0891-5849
EI 1873-4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD JUN
PY 2014
VL 71
BP 368
EP 378
DI 10.1016/j.freeradbiomed.2014.03.038
PG 11
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA AI5FP
UT WOS:000336891100033
PM 24704971
ER

PT J
AU Morris, DL
   Fernando, MMA
   Taylor, KE
   Chung, SA
   Nititham, J
   Alarcon-Riquelme, ME
   Barcelloss, LF
   Behrens, TW
   Cotsapas, C
   Gaffney, PM
   Graham, RR
   Pons-Estel, BA
   Gregersen, PK
   Harley, JB
   Hauser, SL
   Hom, G
   Langefeld, CD
   Noble, JA
   Rioux, JD
   Seldin, MF
   Vyse, TJ
   Criswell, LA
AF Morris, D. L.
   Fernando, M. M. A.
   Taylor, K. E.
   Chung, S. A.
   Nititham, J.
   Alarcon-Riquelme, M. E.
   Barcelloss, L. F.
   Behrens, T. W.
   Cotsapas, C.
   Gaffney, P. M.
   Graham, R. R.
   Pons-Estel, B. A.
   Gregersen, P. K.
   Harley, J. B.
   Hauser, S. L.
   Hom, G.
   Langefeld, C. D.
   Noble, J. A.
   Rioux, J. D.
   Seldin, M. F.
   Vyse, T. J.
   Criswell, L. A.
CA Syst Lupus Erythematosus Genet Con
TI MHC associations with clinical and autoantibody manifestations in
   European SLE
SO GENES AND IMMUNITY
LA English
DT Article
DE Sub-phenotype analysis; MHC; meta-analysis; genetics; systemic lupus
   erythematosus; Europeans
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; GENOME-WIDE ASSOCIATION; RO SS-A;
   SUSCEPTIBILITY VARIANTS; RHEUMATOID-ARTHRITIS; LOCI; MODEL; DISEASES;
   REGION
AB Systemic lupus erythematosus (SLE) is a clinically heterogeneous disease affecting multiple organ systems and characterized by autoantibody formation to nuclear components. Although genetic variation within the major histocompatibility complex (MHC) is associated with SLE, its role in the development of clinical manifestations and autoantibody production is not well defined. We conducted a meta-analysis- of four independent European SLE case collections for associations between SLE sub-phenotypes and MHC single-nucleotide polymorphism genotypes, human leukocyte antigen (HLA) alleles and variant HLA amino acids. Of the 11 American College of Rheumatology criteria and 7 autoantibody sub-phenotypes examined, anti-Ro/SSA and anti-La/SSB antibody subsets exhibited the highest number and most statistically significant associations. HLA-DRB1*03:01 was significantly associated with both sub-phenotypes. We found evidence of associations independent of MHC class II variants in the anti-Ro subset alone. Conditional analyses showed that anti-Ro and anti-La subsets are independently associated with HLA-DRB1*0301, and that the HLA-DRB1*03:01 association with SLE is largely but not completely driven by the association of this allele with these sub-phenotypes. Our results provide strong evidence for a multilevel risk model for HLA-DRB1*03:01 in SLE, where the association with anti-Ro and anti-La antibody-positive SLE is much stronger than SLE without these autoantibodies.
C1 [Morris, D. L.; Fernando, M. M. A.; Vyse, T. J.] Guys Hosp, Kings Coll London, Sch Med, Dept Med & Mol Genet, London SE1 9RT, England.
   [Taylor, K. E.; Chung, S. A.; Nititham, J.] Univ Calif San Francisco, Dept Med, Rosalind Russell Med Res Ctr Arthrit, San Francisco, CA USA.
   [Alarcon-Riquelme, M. E.] Pfizer Univ Granada Junta de Andalucia, Ctr Genom & Invest Oncol, GENYO, Dept Human DNA Variabil, Granada, Spain.
   [Alarcon-Riquelme, M. E.; Gaffney, P. M.] Oklahoma Med Res Fdn, Arthrit & Clin Immunol Program, Oklahoma City, OK 73104 USA.
   [Barcelloss, L. F.] Univ Calif Berkeley, Sch Publ Hlth, Div Epidemiol, Genet Epidemiol & Genom Lab, Berkeley, CA 94720 USA.
   [Behrens, T. W.; Graham, R. R.; Hom, G.] Genentech Inc, Immunol Biomarkers Grp, San Francisco, CA USA.
   [Cotsapas, C.] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06520 USA.
   [Pons-Estel, B. A.] Hosp Prov Rosario, Rheumatol Serv, Rosario, Argentina.
   [Gregersen, P. K.] North Shore LIJ Hlth Syst, Feinstein Inst Med Res, Robert S Boas Ctr Genom & Human Genet, Manhasset, NY USA.
   [Harley, J. B.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA.
   [Harley, J. B.] US Dept Vet Affairs, Med Ctr, Cincinnati, OH USA.
   [Hauser, S. L.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
   [Langefeld, C. D.] Wake Forest Univ Hlth Sci, Dept Biostat Sci, Wake Forest, NC USA.
   [Noble, J. A.] Childrens Hosp, Oakland Res Inst, Oakland, CA 94609 USA.
   [Rioux, J. D.] Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada.
   [Rioux, J. D.] Montreal Heart Inst, Res Ctr, Montreal, PQ H1T 1C8, Canada.
   [Seldin, M. F.] Univ Calif Davis, Davis, CA 95616 USA.
RP Morris, DL (reprint author), Guys Hosp, Kings Coll London, Sch Med, Dept Med & Mol Genet, London SE1 9RT, England.
EM david.l.morris@kcl.ac.uk
RI Rioux, John/A-9599-2015
OI Rioux, John/0000-0001-7560-8326; Alarcon Riquelme, Marta
   Eugenia/0000-0002-7632-4154; Cotsapas, Chris/0000-0002-7772-5910
FU Swedish Research Council, lnstituto de Salud Carlos III [PI12/02558];
   FEDER; EU; BIOLUPUS RNP; European Science Foundation; American College
   of Rheumatology Rheumatology Research Foundation Physician Scientist
   Development Award; National Institutes of Health; National Center for
   Advancing Translational Sciences through UCSF-CTSI [KL2TR000143];
   Clinician Scientist Fellowship [18239]; DLM [17761/PI TJV]; Swedish
   Research Council and Instituto de Salud Carlos III [PS09/00129]; FEDER
   funds of the European Union; Consejeria de Salud de Andalucia [PI0012];
   National Institutes of Allergy and Infectious Diseases [AI067152];
   Wellcome Trust Case-Control Consortium [076113, 085475]; NIH [AR052300,
   AR02175, AR22804, AR42460, AI024717, AI083194, AR62277, AI082714,
   AI53747, AI31584, DE15223, RR20143, PR094002, AI62629, AR48940, AR19084,
   AR043274, AI063274, AI40076, AR052125, HG006828, AR048929, AR049084]
FX We thank the original study participants and their families for their
   contributions to this research, along with clinical colleagues who
   facilitated data collection. We thank Alexander Dilthey for his advice
   during the HLA imputation. We also thank the investigators of IMAGEN
   (John D Rioux, Philippe Goyette, Timothy J Vyse, Lennart Hammarstrom,
   Michelle MA Fernando, Todd Green, Philip L De Jager, Sylvain Foisy,
   Joanne Wang, Paul IW de Bakker, Stephen Leslie, Gilean McVean, Leonid
   Padyukov, Lars Alfredsson, Vito Annese, David A Hafler, Qiang
   Pan-Hammarstrom, Ritva Matell, Stephen J Sawcer, Alastair D Compston,
   Bruce AC Cree, Daniel B Mirel, Mark J Daly, Tim W Behrens, Lars
   Klareskog, Peter K Gregersen, Jorge R Oksenberg and Stephen L Hauser).;
   A full list of the investigators who contributed to the generation of
   the Wellcome Trust Case-Control Consortium data is available from the
   WTCCC website (see Web Resources).; This study was founded by Swedish
   Research Council, lnstituto de Salud Carlos III (PI12/02558) partly
   financed by FEDER funds of the EU, and the BIOLUPUS RNP funded by the
   European Science Foundation to MEA-R; American College of Rheumatology
   Rheumatology Research Foundation Physician Scientist Development Award
   and National Institutes of Health, National Center for Advancing
   Translational Sciences through UCSF-CTSI Grant KL2TR000143 to SAC.;
   Arthritis Research UK funded a Clinician Scientist Fellowship for MMAF
   (ref 18239) and the Arthritis Research UK funded DLM under (ref 17761/PI
   TJV). MEA-R was funded by the Swedish Research Council and Instituto de
   Salud Carlos III grant number PS09/00129 cofinanced through FEDER funds
   of the European Union and the Consejeria de Salud de Andalucia PI0012.;
   The IMAGEN consortium was supported by Grant AI067152 from the National
   Institutes of Allergy and Infectious Diseases.; Funding for the Wellcome
   Trust Case-Control Consortium project was provided by the Wellcome Trust
   under award 076113 and 085475.; Cord blood samples were collected by V L
   Nimgaonkar's group at the University of Pittsburgh, as part of a
   multi-institutional collaborative research project with J Smoller, MD
   DSc and P Sklar, MD PhD. (Massachusetts General Hospital; grant MH
   63420).; Support for the Illumina MHC Panel study was provided by the
   NIH (AR052300, AR02175, AR22804, AR62277, AR42460, AI024717, AI083194,
   AR62277, AI082714, AI53747, AI31584, DE15223, RR20143, PR094002,
   AI62629, AR48940, AR19084, AR043274, AI063274, AI40076, AR052125,
   HG006828, AR048929, and AR049084), research grants from the US
   Department of Veterans Affairs, US Department of Defense (PR094002),
   American College of Rheumatology, Alliance for Lupus Research,
   Rheuminations, the Lupus Foundation of Minnesota and the Mary Kirkland
   Center for Lupus Research. This study was performed in part in the
   General Clinical Research Center, Moffitt Hospital, University of
   California San Francisco, with funds provided by the National Center for
   Research Resources, 5 M01 RR-00079, US Public Health Service.
NR 26
TC 18
Z9 19
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-4879
EI 1476-5470
J9 GENES IMMUN
JI Genes Immun.
PD JUN
PY 2014
VL 15
IS 4
BP 210
EP 217
DI 10.1038/gene.2014.6
PG 8
WC Genetics & Heredity; Immunology
SC Genetics & Heredity; Immunology
GA AI5CT
UT WOS:000336883700002
PM 24598797
ER

PT J
AU Kroenke, K
AF Kroenke, Kurt
TI Are the Harms of False-Positive Screening Test Results Minimal or
   Meaningful?
SO JAMA INTERNAL MEDICINE
LA English
DT Editorial Material
C1 [Kroenke, Kurt] US Dept Vet Affairs, Ctr Hlth Informat & Commun, Hlth Serv Res & Dev, Indianapolis, IN USA.
   [Kroenke, Kurt] Regenstrief Inst Inc, Indianapolis, IN 46202 USA.
   [Kroenke, Kurt] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA.
RP Kroenke, K (reprint author), Regenstrief Inst Inc, 1050 Wishard Blvd,Fifth Floor, Indianapolis, IN 46202 USA.
EM kkroenke@regenstrief.org
NR 8
TC 1
Z9 1
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD JUN
PY 2014
VL 174
IS 6
BP 961
EP 963
DI 10.1001/jamainternmed.2014.160
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA AI4OA
UT WOS:000336843500032
PM 24756378
ER

PT J
AU Wiener, RS
   Gould, MK
   Slatore, CG
   Fincke, BG
   Schwartz, LM
   Woloshin, S
AF Wiener, Renda Soylemez
   Gould, Michael K.
   Slatore, Christopher G.
   Fincke, Benjamin G.
   Schwartz, Lisa M.
   Woloshin, Steven
TI Resource Use and Guideline Concordance in Evaluation of Pulmonary
   Nodules for Cancer Too Much and Too Little Care
SO JAMA INTERNAL MEDICINE
LA English
DT Article
ID FLEISCHNER SOCIETY GUIDELINES; LUNG-CANCER; MANAGEMENT; RADIOLOGISTS;
   CT; COMPLICATIONS; STATEMENT; ADHERENCE; BIOPSY; FRANCE
AB IMPORTANCE Pulmonary nodules are common, and more will be found with implementation of lung cancer screening. How potentially malignant pulmonary nodules are evaluated may affect patient outcomes, health care costs, and effectiveness of lung cancer screening programs. Guidelines for evaluating pulmonary nodules for cancer exist, but little is known about how nodules are evaluated in the usual care setting.
   OBJECTIVE To characterize nodule evaluation and concordance with guidelines.
   DESIGN, SETTING, AND PARTICIPANTS A retrospective cohort study was conducted including detailed review of medical records from pulmonary nodule detection through evaluation completion, cancer diagnosis, or study end (December 31, 2012). The participants included 300 adults with pulmonary nodules from 15 Veterans Affairs hospitals.
   MAIN OUTCOMES AND MEASURES Resources used for evaluation at any Veterans Affairs facility and guideline-concordant evaluation served as the main outcomes.
   RESULTS Twenty-seven of 300 patients (9.0%) with pulmonary nodules ultimately received a diagnosis of lung cancer: 1 of 57 (1.8%) with a nodule of 4 mm or less, 4 of 134 (3.0%) with a nodule of 5 to 8 mm, and 22 of 109 (20.2%) with a nodule larger than 8 mm. Nodule evaluation entailed 1044 imaging studies, 147 consultations, 76 biopsies, 13 resections, and 21 hospitalizations. Radiographic surveillance (n = 277) lasted a median of 13 months but ranged from less than 0.5 months to 8.5 years. Forty-six patients underwent invasive procedures (range per patient, 1-4): 41.3%(19 patients) did not have cancer and 17.4% (8) experienced complications, including 1 death. Notably, 15 of the 300 (5.0%) received no purposeful evaluation and had no obvious reason for deferral, seemingly "falling through the cracks." Among 197 patients with a nodule detected after release of the Fleischner Society guidelines, 44.7% received care inconsistent with guidelines (17.8% overevaluation, 26.9% underevaluation). In multivariable analyses, the strongest predictor of guideline-inconsistent care was inappropriate radiologist recommendations (overevaluation relative risk, 4.6 [95% CI, 2.3-9.2]; underevaluation, 4.3 [2.7-6.8]). Other systems factors associated with underevaluation included receiving care at more than 1 facility (2.0 [1.5-2.7]) and nodule detection during an inpatient or preoperative visit (1.6 [1.1-2.5]).
   CONCLUSIONS AND RELEVANCE Pulmonary nodule evaluation is often inconsistent with guidelines, including cases with no workup and others with prolonged surveillance or unneeded procedures that may cause harm. Systems to improve quality (eg, aligning radiologist recommendations with guidelines and facilitating communication across providers) are needed before lung cancer screening is widely implemented.
C1 [Wiener, Renda Soylemez; Fincke, Benjamin G.] Edith Nourse Rogers Mem Vet Hosp, Ctr Healthcare Org & Implementat Res, Bedford, MA 01730 USA.
   [Wiener, Renda Soylemez] Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02118 USA.
   [Wiener, Renda Soylemez; Schwartz, Lisa M.; Woloshin, Steven] Dartmouth Med Sch, Dartmouth Inst Hlth Policy & Clin Practice, Hanover, NH USA.
   [Gould, Michael K.] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA 91101 USA.
   [Slatore, Christopher G.] Portland VA Med Ctr, Hlth Serv Res & Dev, Portland, OR USA.
   [Slatore, Christopher G.] Oregon Hlth & Sci Univ, Div Pulm & Crit Care Med, Portland, OR 97201 USA.
   [Fincke, Benjamin G.] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA.
   [Schwartz, Lisa M.; Woloshin, Steven] Dept Vet Affairs, Vet Affairs Outcomes Grp, White River Jct, VT USA.
RP Wiener, RS (reprint author), Edith Nourse Rogers Mem Vet Hosp, Ctr Healthcare Org & Implementat Res, 200 Springs Rd,Bldg 70 Mail Code 152, Bedford, MA 01730 USA.
EM rwiener@bu.edu
OI Wiener, Renda/0000-0001-7712-2135; Slatore,
   Christopher/0000-0003-0958-8122
FU Veterans Affairs (VA) Health Services Research and Development (HSRD)
   [PPO 08-401]; White River Junction VA Medical Center; Edith Nourse
   Rogers Memorial Veterans Hospital; Portland VA Medical Center; National
   Cancer Institute [K07 CA138772]; VA HSR&D Career Development Award
FX This study was supported by the Veterans Affairs (VA) Health Services
   Research and Development (HSR&D) (PPO 08-401) and with resources from
   the White River Junction VA Medical Center, Edith Nourse Rogers Memorial
   Veterans Hospital, and Portland VA Medical Center. Dr Wiener is also
   supported by career development award K07 CA138772 from the National
   Cancer Institute, and Dr Slatore is supported by a VA HSR&D Career
   Development Award.
NR 37
TC 20
Z9 20
U1 1
U2 6
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD JUN
PY 2014
VL 174
IS 6
DI 10.1001/jamainternmed.2014.561
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA AI4OA
UT WOS:000336843500017
PM 24710850
ER

PT J
AU van Deursen, VM
   Edwards, C
   Cotter, G
   Davison, BA
   Damman, K
   Teerlink, JR
   Metra, M
   Felker, GM
   Ponikowski, P
   Unemori, E
   Severin, T
   Voors, AA
AF van Deursen, Vincent M.
   Edwards, Christopher
   Cotter, Gad
   Davison, Beth A.
   Damman, Kevin
   Teerlink, John R.
   Metra, Marco
   Felker, G. Michael
   Ponikowski, Piotr
   Unemori, Elaine
   Severin, Thomas
   Voors, Adriaan A.
TI Liver Function, In-Hospital, and Post-Discharge Clinical Outcome in
   Patients With Acute Heart Failure-Results From the Relaxin for the
   Treatment of Patients With Acute Heart Failure Study
SO JOURNAL OF CARDIAC FAILURE
LA English
DT Article
DE Liver function; acute decompensated heart failure; prognosis
ID FUNCTION TESTS; FUNCTION ABNORMALITIES; MORTALITY; PROGRAM
AB Background: Elevated plasma concentrations of liver function tests are prevalent in patients with chronic heart failure (HF). Little is known about liver function in patients with acute HF. We aimed to assess the prevalence and prognostic value of serial measurements of liver function tests in patients admitted with acute decompensated HF.
   Methods: We investigated liver function tests from all 234 patients from the Relaxin for the Treatment of Patients With Acute Heart Failure study at baseline and during hospitalization. The end points were worsening HF through day 5, 60-day mortality or rehospitalization, and 180-day mortality.
   Results: Mean age was 70 +/- 10 years, 56% were male, and most patients were in New York Heart Association functional class III/IV (73%). Abnormal liver function tests were frequently found. for alanine transaminase (ALT; 12%), aspartate transaminase (AST; 21%), alkaline phosphatase (12%), and total bilirubin (19%), and serum albumin (25%) and total protein (9%) were decreased. In-hospital changes were very small. On a continuous scale, baseline ALT and AST were associated with 180-day mortality (hazard ratios [HRs; per doubling] 1.52 [P = .030] and 1.97 [P = .013], respectively) and worsening HF through day 5 (HRs [per doubling] 1.72 [P = .005] and 1.95 [P = .008], respectively). Albumin was associated with 180-day mortality (HR 0.86; P = .001) but not with worsening HF (HR 0.95; P = .248). Total protein was associated with only worsening HF (HR 0.91; P = .004).
   Conclusions: Abnormal liver function tests are often present in patients with acute HF and are associated with an increased risk for mortality, rehospitalization, and in-hospital worsening HF.
C1 [van Deursen, Vincent M.; Damman, Kevin; Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands.
   [Edwards, Christopher; Cotter, Gad; Davison, Beth A.] Momentum Res, Durham, NC USA.
   [Teerlink, John R.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Cardiol Sect, San Francisco, CA 94143 USA.
   [Metra, Marco] Univ Brescia, Dept Expt & Appl Sci, Sect Cardiovasc Dis, Brescia, Italy.
   [Felker, G. Michael] Duke Univ, Duke Clin Res Inst, Durham, NC USA.
   [Ponikowski, Piotr] Med Univ, Dept Hlth Sci, Mil Hosp, Dept Cardiol, Wroclaw, Poland.
   [Unemori, Elaine] Corthera, San Mateo, CA USA.
   [Severin, Thomas] Novartis Pharmaceut, Basel, Switzerland.
RP Voors, AA (reprint author), Univ Med Ctr Groningen, Dept Cardiol, Hanzepl 1, NL-9700 RB Groningen, Netherlands.
EM a.a.voors@umcg.nl
RI Ponikowski, Piotr/O-6454-2015
OI Ponikowski, Piotr/0000-0002-3391-7064; Davison,
   Beth/0000-0003-2374-6449; Metra, Marco/0000-0001-6691-8568
FU Corthera (a Novartis affiliate company); Amgen; Bayer; Corthera; Cardio3
   Bioscience; Cytokinetics; Merck; Novartis; Takeda; Teva; Trevena; Abbott
   Vascular; Medpace; Otsuka; Roche Diagnostics; BG Medicine; Medtronic; St
   Jude; National Heart, Lung, and Blood Institute; Abbott; PDL Biopharma;
   Alere; Cardio3 Biosciences; Celladon; Ceva; European Commission; Dutch
   Heart Foundation; Servier; Torrent; Vifor
FX The Pre-RELAX-AHF study is supported by Corthera (a Novartis affiliate
   company). Mr Edwards and Drs Cotter and Davison are employees of
   Momentum Research, which has provided consulting and trial management
   services to Novacardia, Merck, Corthera, Novartis, Nile Therapeutics,
   Bioheart, Cardio3 Biosciences, Amgen, Celadon, Targegen, Trevena,
   Sorbent Therapeutics, and the National Institutes of Health. Dr Teerlink
   has received research grants or consulting fees from Amgen, Bayer,
   Corthera, Cardio3 Bioscience, Cytokinetics, Merck, Novartis, Takeda,
   Teva, and Trevena. Dr Metra has received consulting income from Abbott
   Vascular, Bayer, Corthera, and Novartis and travel support and honoraria
   from Servier and Novartis. Dr Felker has received consulting income from
   Novartis, Medpace, Amgen, Otsuka, Trevena, Roche Diagnostics, Merck, BG
   Medicine, Medtronic, and St Jude and grant funding from Amgen, Otsuka,
   Roche Diagnostics, and the National Heart, Lung, and Blood Institute. Dr
   Ponikowski has been a consultant for Astellas, Bayer, EKR Therapeutics,
   Johnson and Johnson, The Medicines Company, Medtronic, Novartis, Otsuka,
   Palatin Technologies, PDL Biopharma, Pericor Therapeutics, Sigma Tau,
   Solvay Pharmaceuticals, and Trevena; has received honoraria from Alere,
   Beckman-Coulter, Biogenidec, Corthera, Ikaria, Nile Therapeutics,
   Momentum Research, and Overcome; has received research support from
   Abbott, Merck and PDL Biopharma; and has received travel support from My
   Life and equipment support from Sonosite. Dr Unemori is employed by the
   sponsor, Corthera. Dr Severin is an employee and shareholder of Novartis
   Pharma. Dr Voors has received consultancy fees and/or research grants
   from Alere, Bayer, Cardio3 Biosciences, Celladon, Ceva, the European
   Commission, the Dutch Heart Foundation, Novartis, Servier, Torrent, and
   Vifor. Dr van Deursen no relationships relevant to the contents of this
   paper to disclose.
NR 18
TC 10
Z9 10
U1 0
U2 3
PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
PI PHILADELPHIA
PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA
SN 1071-9164
EI 1532-8414
J9 J CARD FAIL
JI J. Card. Fail.
PD JUN
PY 2014
VL 20
IS 6
BP 407
EP 413
DI 10.1016/j.cardfail.2014.03.003
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AI7LA
UT WOS:000337070900005
PM 24642379
ER

PT J
AU Kasinath, BS
AF Kasinath, Balakuntalam S.
TI Hydrogen sulfide to the rescue in obstructive kidney injury
SO KIDNEY INTERNATIONAL
LA English
DT Editorial Material
ID CYSTATHIONINE-GAMMA-LYASE; RENAL ISCHEMIA/REPERFUSION; CELLS
AB Hydrogen sulfide is a gasotransmitter with far-reaching effects on cell function. Studies show that, depending on the context, hydrogen sulfide can function as an ameliorative agent or as a mediator of kidney injury.
C1 [Kasinath, Balakuntalam S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
RP Kasinath, BS (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, MC7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM kasinath@uthscsa.edu
FU NIDDK NIH HHS [R01 DK077295]
NR 12
TC 6
Z9 6
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0085-2538
EI 1523-1755
J9 KIDNEY INT
JI Kidney Int.
PD JUN
PY 2014
VL 85
IS 6
BP 1255
EP 1258
DI 10.1038/ki.2013.529
PG 4
WC Urology & Nephrology
SC Urology & Nephrology
GA AI4FG
UT WOS:000336820500002
PM 24875544
ER

PT J
AU George, B
   Fan, QF
   Dlugos, CP
   Soofi, AA
   Zhang, JD
   Verma, R
   Park, TJ
   Wong, H
   Curran, T
   Nihalani, D
   Holzman, LB
AF George, Britta
   Fan, Qingfeng
   Dlugos, Christopher P.
   Soofi, Abdulsalam A.
   Zhang, Jidong
   Verma, Rakesh
   Park, Tae-Ju
   Wong, Hetty
   Curran, Tom
   Nihalani, Deepak
   Holzman, Lawrence B.
TI Crk1/2 and CrkL form a hetero-oligomer and functionally complement each
   other during podocyte morphogenesis
SO KIDNEY INTERNATIONAL
LA English
DT Article
DE cytoskeleton; nephrin; podocyte; signaling
ID ACTIN CYTOSKELETON; SLIT DIAPHRAGM; INTERCELLULAR JUNCTION; TRANSGENIC
   MICE; NEPHRIN; EXPRESSION; PROTEINS; GENE; PROMOTES; FAMILY
AB Activation of the slit diaphragm protein nephrin induces actin cytoskeletal remodeling, resulting in lamellipodia formation in podocytes in vitro in a phosphatidylinositol-3 kinase-, focal adhesion kinase-, Cas-, and Crk1/2-dependent fashion. In mice, podocyte-specific deletion of Crk1/2 prevents or attenuates foot process effacement in two models of podocyte injury. This suggests that cellular mechanisms governing lamellipodial protrusion in vitro are similar to those in vivo during foot process effacement. As Crk1/2-null mice developed and aged normally, we tested whether the Crk1/2 paralog, CrkL, functionally complements Crk1/2 in a podocyte-specific context. Podocyte-specific CrkL-null mice, like podocyte-specific Crk1/2-null mice, developed and aged normally but were protected from protamine sulfate-induced foot process effacement. Simultaneous podocyte-specific deletion of Crk1/2 and CrkL resulted in albuminuria detected by 6 weeks postpartum and associated with altered podocyte process architecture. Nephrin-induced lamellipodia formation in podocytes in vitro was CrkL-dependent. CrkL formed a hetero-oligomer with Crk2 and, like Crk2, was recruited to tyrosine phosphorylated nephrin. Thus, Crk1/2 and CrkL are physically linked, functionally complement each other during podocyte foot process spreading, and together are required for developing typical foot process architecture.
C1 [George, Britta; Fan, Qingfeng; Zhang, Jidong; Wong, Hetty; Nihalani, Deepak; Holzman, Lawrence B.] Univ Penn, Renal Electrolyte & Hypertens Div, Philadelphia, PA 19104 USA.
   [George, Britta; Dlugos, Christopher P.] Univ Klinikum Munster, Med Klin & Poliklin D, Munster, Germany.
   [Soofi, Abdulsalam A.; Verma, Rakesh] Univ Michigan, Div Nephrol, Ann Arbor, MI 48109 USA.
   [Park, Tae-Ju; Curran, Tom] Childrens Hosp Philadelphia, Res Inst, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
   [Holzman, Lawrence B.] Dept Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
RP Holzman, LB (reprint author), Univ Penn, Renal Electrolyte & Hypertens Div, 405 Clin Res Bldg,415 Curie Blvd, Philadelphia, PA 19104 USA.
EM lholzman@upenn.edu
RI Curran, Tom/D-7515-2011
OI Park, Taeju/0000-0003-3897-3994
FU NIDDK [DK080751]; Department of Veterans Affairs; Deutsche
   Forschungsgemeinschaft [GE 2158/1-1, GE 2158/3-1]; Pennsylvania
   Department of Health Cure Formulary [4100047628]
FX This work was supported by grants to LBH from the NIDDK (DK080751) and
   the Department of Veterans Affairs, and to BG from the Deutsche
   Forschungsgemeinschaft (GE 2158/1-1, GE 2158/3-1). This work was also
   supported by a Pennsylvania Department of Health Cure Formulary grant to
   TC (SAP #4100047628).
NR 32
TC 7
Z9 7
U1 1
U2 5
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0085-2538
EI 1523-1755
J9 KIDNEY INT
JI Kidney Int.
PD JUN
PY 2014
VL 85
IS 6
BP 1382
EP 1394
DI 10.1038/ki.2013.556
PG 13
WC Urology & Nephrology
SC Urology & Nephrology
GA AI4FG
UT WOS:000336820500020
PM 24499776
ER

PT J
AU Moonen, AJH
   Wijers, A
   Leentjens, AFG
   Christine, CW
   Factor, SA
   Juncos, J
   Lyness, JM
   Marsh, L
   Panisset, M
   Pfeiffer, R
   Rottenberg, D
   Ramos, CS
   Shulman, L
   Singer, C
   Slevin, J
   McDonald, W
   Auinger, P
   Richard, IH
AF Moonen, A. J. H.
   Wijers, A.
   Leentjens, A. F. G.
   Christine, C. W.
   Factor, S. A.
   Juncos, J.
   Lyness, J. M.
   Marsh, L.
   Panisset, M.
   Pfeiffer, R.
   Rottenberg, D.
   Ramos, C. Serrano
   Shulman, L.
   Singer, C.
   Slevin, J.
   McDonald, W.
   Auinger, P.
   Richard, I. H.
TI Severity of depression and anxiety are predictors of response to
   antidepressant treatment in Parkinson's disease
SO PARKINSONISM & RELATED DISORDERS
LA English
DT Article
DE Parkinson's disease; Depression; Clinical trials randomized controlled;
   Venlafaxine; Paroxetine
ID DATABASE; PLACEBO
AB Background: Antidepressants have appeared to be more effective than placebo treatment in treating depressive syndromes in patients with Parkinson's disease (PD). Objective: To identify factors that predict improvement in depressive symptoms during antidepressant treatment in depressed PD patients.
   Methods: A secondary analysis was performed on the dataset of the Randomized Placebo-controlled Study of Antidepressants in PD (SAD-PD), in which 76 patients received active treatment with either paroxetine or venlafaxine extended release (XR), and 39 patients received placebo treatment. Backward stepwise regression analyses were conducted with change in 24-item Hamilton Depression Rating Scale (HAMD-24) score between assessments at baseline and week 12 as the main outcome measure, and sex, age, baseline HAMD-24 score, Unified Parkinson's Disease Rating Scale section III (UPDRS-III) score, Mini-Mental State Examination (MMSE), and the Clinical Anxiety Scale (CAS) as independent variables.
   Results: In both the active treatment and placebo groups, higher baseline HAMD-24 score and lower UPDRS-III score were associated with greater reduction in HAMD-24 score. Higher anxiety scores predicted less response in the active treatment group. Higher MMSE scores predicted greater response only in the placebo-treated group. Sex and age were no predictors of response.
   Conclusions: Higher pre-treatment depression scores and lower pre-treatment anxiety scores are the two most important predictors for improvement during antidepressant treatment in depressed PD patients, which is in line with those found in treatment studies of depressed non-PD patients. Furthermore, our results indicate the requirement for different or more intensive treatment for depressed PD patients with more severe anxiety symptoms. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Moonen, A. J. H.; Wijers, A.; Leentjens, A. F. G.] Maastricht Univ, Dept Psychiat, NL-6200 MD Maastricht, Netherlands.
   [Christine, C. W.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
   [Factor, S. A.; Juncos, J.] Emory Univ, Dept Neurol, Atlanta, GA USA.
   [McDonald, W.] Emory Univ, Dept Psychiat & Behav Sci, Atlanta, GA 30322 USA.
   [Marsh, L.] Michael E DeBakey Vet Adm Med Ctr, Houston, TX USA.
   [Marsh, L.] Baylor Coll Med, Dept Psychiat, Houston, TX 77030 USA.
   [Marsh, L.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA.
   [Panisset, M.] Univ Montreal, Dept Neurol, Montreal, PQ, Canada.
   [Pfeiffer, R.] Univ Tennessee, Dept Neurol, Hlth Sci Ctr, Memphis, TN USA.
   [Rottenberg, D.] Univ Minnesota, Dept Neurol, Minneapolis, MN 55455 USA.
   [Rottenberg, D.] Univ Minnesota, Dept Radiol, Minneapolis, MN 55455 USA.
   [Ramos, C. Serrano] Univ Puerto Rico, Sch Med, San Juan, PR 00936 USA.
   [Shulman, L.] Univ Maryland, Sch Med, Dept Neurol, Baltimore, MD 21201 USA.
   [Singer, C.] Univ Miami, Dept Neurol, Leonard M Miller Sch Med, Miami, FL USA.
   [Slevin, J.] Univ Kentucky, Coll Med, Dept Neurol, Lexington, KY USA.
   [Lyness, J. M.; Auinger, P.; Richard, I. H.] Univ Rochester, Sch Med & Dent, Rochester, NY USA.
RP Moonen, AJH (reprint author), Maastricht Univ, Dept Psychiat, POB 616, NL-6200 MD Maastricht, Netherlands.
EM anja.moonen@maastrichtuniversity.nl
FU National Institutes of Health/National Institute of Neurological
   Disorders and Stroke [R01 N5046487]; General Clinical Research Center at
   Johns Hopkins University School of Medicine (National Center for
   Research Resources/NIH) [M01-RR00052]
FX This study was funded by National Institutes of Health/National
   Institute of Neurological Disorders and Stroke grant R01 N5046487 and
   the General Clinical Research Center at Johns Hopkins University School
   of Medicine (National Center for Research Resources/NIH M01-RR00052).
   Wyeth Pharmaceuticals provided venlafaxine extended release and matching
   placebo. Glaxo-Smith-Kline provided paroxetine.
NR 10
TC 6
Z9 7
U1 0
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1353-8020
EI 1873-5126
J9 PARKINSONISM RELAT D
JI Parkinsonism Relat. Disord.
PD JUN
PY 2014
VL 20
IS 6
BP 644
EP 646
DI 10.1016/j.parkreldis.2014.02.025
PG 3
WC Clinical Neurology
SC Neurosciences & Neurology
GA AI5AN
UT WOS:000336877900016
PM 24679737
ER

PT J
AU Khodjaev, SD
   Teerlink, JR
   Malik, FI
AF Khodjaev, Soidjon D.
   Teerlink, John R.
   Malik, Fady I.
TI Novel drug mechanisms in development for heart failure
SO PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY
LA English
DT Review
DE BAY 94-8862; Heart failure; LCZ696; Omecamtiv mecarbil; Pharmacologic
   therapy; Serelaxin; TRV 027; Ularitide
ID CARDIAC MYOSIN ACTIVATOR; DOUBLE-BLIND; MINERALOCORTICOID RECEPTOR;
   OMECAMTIV-MECARBIL; NATRIURETIC PEPTIDES; CONTROLLED-TRIAL; HORMONE
   RELAXIN; BAY 94-8862; TASK-FORCE; URODILATIN
AB Heart failure therapy has seen many advances over the last 40 years and has rapidly expanded beyond diuretics and digoxin to include several new mechanisms of action and devices whose efficacy had been demonstrated in large clinical trials. The evidence for their use is thoroughly summarized and discussed in current heart failure treatment guidelines and is not the subject of this review. Despite these advances, the mortality and morbidity in heart failure patients is still substantial, and there remains a need to develop new heart failure therapies. Recognizing that advances in medical therapy are often driven by the introduction of drugs with novel mechanisms of action, here we provide an overview of investigative heart failure drugs with novel mechanisms of action that are the subject of ongoing clinical trials.
C1 [Khodjaev, Soidjon D.; Teerlink, John R.] San Francisco VA Med Ctr, Cardiol Sect, San Francisco, CA 94121 USA.
   [Khodjaev, Soidjon D.; Teerlink, John R.; Malik, Fady I.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA.
   [Malik, Fady I.] Cytokinet Inc, Res & Early Dev, San Francisco, CA USA.
RP Teerlink, JR (reprint author), San Francisco VA Med Ctr, Cardiol Sect, 111C,4150 Clement St, San Francisco, CA 94121 USA.
EM john.teerlink@ucsf.edu
NR 42
TC 0
Z9 0
U1 2
U2 15
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0031-6768
EI 1432-2013
J9 PFLUG ARCH EUR J PHY
JI Pflugers Arch.
PD JUN
PY 2014
VL 466
IS 6
BP 1219
EP 1225
DI 10.1007/s00424-014-1528-9
PG 7
WC Physiology
SC Physiology
GA AI4AO
UT WOS:000336807700018
PM 24793049
ER

PT J
AU Yang, ZR
   Wang, C
   Zhou, QX
   An, JL
   Hildebrandt, E
   Aleksandrov, LA
   Kappes, JC
   DeLucas, LJ
   Riordan, JR
   Urbatsch, IL
   Hunt, JF
   Brouillette, CG
AF Yang, Zhengrong
   Wang, Chi
   Zhou, Qingxian
   An, Jianli
   Hildebrandt, Ellen
   Aleksandrov, Luba A.
   Kappes, John C.
   DeLucas, Lawrence J.
   Riordan, John R.
   Urbatsch, Ina L.
   Hunt, John F.
   Brouillette, Christie G.
TI Membrane protein stability can be compromised by detergent interactions
   with the extramembranous soluble domains
SO PROTEIN SCIENCE
LA English
DT Review
DE CFTR; NBD1; DSC; CD; thermal unfolding; detergent interaction; membrane
   protein; extramembrane domain; soluble domain
ID TRANSMEMBRANE CONDUCTANCE REGULATOR; NUCLEOTIDE-BINDING DOMAIN;
   DIFFERENTIAL SCANNING CALORIMETRY; CYSTIC-FIBROSIS MUTATION;
   CYTOCHROME-C-OXIDASE; FULL-LENGTH CFTR; DELTA-F508 MUTATION; SURFACTANT
   INTERACTIONS; ESCHERICHIA-COLI; EFFICIENT PURIFICATION
AB Detergent interaction with extramembranous soluble domains (ESDs) is not commonly considered an important determinant of integral membrane protein (IMP) behavior during purification and crystallization, even though ESDs contribute to the stability of many IMPs. Here we demonstrate that some generally nondenaturing detergents critically destabilize a model ESD, the first nucleotide-binding domain (NBD1) from the human cystic fibrosis transmembrane conductance regulator (CFTR), a model IMP. Notably, the detergents show equivalent trends in their influence on the stability of isolated NBD1 and full-length CFTR. We used differential scanning calorimetry (DSC) and circular dichroism (CD) spectroscopy to monitor changes in NBD1 stability and secondary structure, respectively, during titration with a series of detergents. Their effective harshness in these assays mirrors that widely accepted for their interaction with IMPs, i.e., anionic>zwitterionic>nonionic. It is noteworthy that including lipids or nonionic detergents is shown to mitigate detergent harshness, as will limiting contact time. We infer three thermodynamic mechanisms from the observed thermal destabilization by monomer or micelle: (i) binding to the unfolded state with no change in the native structure (all detergent classes); (ii) native state binding that alters thermodynamic properties and perhaps conformation (nonionic detergents); and (iii) detergent binding that directly leads to denaturation of the native state (anionic and zwitterionic). These results demonstrate that the accepted model for the harshness of detergents applies to their interaction with an ESD. It is concluded that destabilization of extramembranous soluble domains by specific detergents will influence the stability of some IMPs during purification.
C1 [Yang, Zhengrong; Brouillette, Christie G.] Univ Alabama Birmingham, Dept Chem, Birmingham, AL 35294 USA.
   [Yang, Zhengrong; Zhou, Qingxian; An, Jianli; DeLucas, Lawrence J.; Brouillette, Christie G.] Univ Alabama Birmingham, Struct Biol Ctr, Birmingham, AL USA.
   [Wang, Chi; Hunt, John F.] Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.
   [Hildebrandt, Ellen; Urbatsch, Ina L.] Texas Tech Univ, Hlth Sci Ctr, Dept Cell Biol & Biochem, Lubbock, TX 79430 USA.
   [Aleksandrov, Luba A.; Riordan, John R.] Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC USA.
   [Aleksandrov, Luba A.; Riordan, John R.] Univ N Carolina, Cyst Fibrosis Treatment & Res Ctr, Chapel Hill, NC USA.
   [Kappes, John C.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
   [Kappes, John C.] Birmingham Vet Affairs Med Ctr, Res Serv, Birmingham, AL USA.
   [DeLucas, Lawrence J.] Univ Alabama Birmingham, Dept Optometry, Birmingham, AL USA.
   [Urbatsch, Ina L.] Texas Tech Univ, Hlth Sci Ctr, Ctr Membrane Prot Res, Lubbock, TX 79430 USA.
RP Brouillette, CG (reprint author), 1025 18th St South,234 CBSE, Birmingham, AL 35294 USA.
EM jfhunt@biology.columbia.edu; christie@uab.edu
FU CFFT; NIH [R01 DK051619, R0 1DK051870, P01 HL110873]; Shared Facility
   Program of the UAB Comprehensive Cancer Center [316851]
FX Grant sponsor: CFFT (to C. B., J.H., I. U., J.R., L. D., and J.K.).
   Grant sponsor: NIH R01 DK051619; R0 1DK051870; P01 HL110873 (to J.R.).
   Grant sponsor: Shared Facility Program of the UAB Comprehensive Cancer
   Center; Grant number: 316851.
NR 102
TC 12
Z9 12
U1 1
U2 28
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0961-8368
EI 1469-896X
J9 PROTEIN SCI
JI Protein Sci.
PD JUN
PY 2014
VL 23
IS 6
BP 769
EP 789
DI 10.1002/pro.2460
PG 21
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AI4NW
UT WOS:000336843100010
PM 24652590
ER

PT J
AU Davis, LA
   Whitfield, E
   Cannon, GW
   Wolff, RK
   Johnson, DS
   Reimold, AM
   Kerr, GS
   Richards, JS
   Mikuls, TR
   Caplan, L
AF Davis, Lisa A.
   Whitfield, Emily
   Cannon, Grant W.
   Wolff, Roger K.
   Johnson, Dannette S.
   Reimold, Andreas M.
   Kerr, Gail S.
   Richards, J. Steuart
   Mikuls, Ted R.
   Caplan, Liron
TI Association of rheumatoid arthritis susceptibility gene with lipid
   profiles in patients with rheumatoid arthritis
SO RHEUMATOLOGY
LA English
DT Article
DE arthritis; rheumatoid; polymorphism; single nucleotide; cholesterol;
   HDL; LDL; triglycerides
ID NF-KAPPA-B; DENSITY-LIPOPROTEIN CHOLESTEROL; CARDIOVASCULAR
   RISK-FACTORS; C-REL; DISEASE SUSCEPTIBILITY; MYOCARDIAL-INFARCTION;
   VASCULAR-DISEASE; NUCLEAR-FACTOR; POLYMORPHISM; TRANSCRIPTION
AB Objective. RA patients have an increased risk of cardiovascular (CV) disease, although the mechanisms are unclear. As RA and CV disease may be associated through lipid profiles, we examined whether single nucleotide polymorphisms (SNPs) associated with RA susceptibility were associated with low-density lipoprotein (LDL), high-density lipoprotein (HDL) and triglyceride (TG) levels in RA subjects.
   Methods. Patients (n = 763) enrolled in the Veterans Affairs RA registry who were not on hydroxymethyl-glutaryl-CoA reductase inhibitor were genotyped for human leukocyte antigen shared epitope (HLA-DRB1-SE) and SNPs in the following genes: CTLA-4 (cytotoxic T-lymphocyte antigen 4), IL-10, PTPN22 (protein tyrosine phosphatase, non-receptor type 22), REL (c-Rel), STAT4 (signal transducer and activator of transcription protein), TNF-alpha and TRAF1 (TNF receptor-associated factor 1). Other covariates included patient characteristics (age, gender, race, smoking status, education, BMI, modified Charlson-Deyo comorbidity index), CV characteristics (hypertension, diabetes, alcohol abuse), pharmacologic exposures (MTX, anti-TNF, glucocorticoids) and RA severity/activity markers (RA disease duration, mean DAS, CRP, RF positivity, anti-CCP positivity). Multivariate linear regression was performed to determine the factors associated with LDL, HDL and TG levels.
   Results. The REL SNP rs9309331 homozygous minor allele was associated with higher LDL levels. Caucasian race and increasing BMI were associated with lower HDL. Factors associated with higher TG were diabetes, Caucasian race and higher BMI.
   Conclusion. The REL SNP rs9309331 was associated with LDL levels in our study. This association is a possible explanation of the increased risk of RA patients for CV disease and requires further inquiry.
C1 [Davis, Lisa A.] Univ Colorado, Sch Med, Dept Med, Div Rheumatol,Denver Hlth Med Ctr, Denver, CO USA.
   [Whitfield, Emily; Caplan, Liron] Univ Colorado, Sch Med, Dept Med, Div Rheumatol,Denver Vet Affairs Med Ctr VAMC, Denver, CO USA.
   [Davis, Lisa A.; Caplan, Liron] Univ Colorado, Sch Med, Dept Med, Div Rheumatol, Denver, CO USA.
   [Whitfield, Emily] Denver VAMC, Dept Res, Div Care Coordinat, Denver, CO USA.
   [Cannon, Grant W.] George E Wahlen VAMC, Staff Acad Affiliat, Salt Lake City, UT USA.
   [Cannon, Grant W.] Univ Utah, Sch Med, Dept Med, Div Rheumatol, Salt Lake City, UT USA.
   [Wolff, Roger K.] Univ Utah, Sch Med, Dept Internal Med, Div Epidemiol, Salt Lake City, UT USA.
   [Johnson, Dannette S.] Jackson VAMC, Med Serv, Rheumatol Sect, Jackson, MS USA.
   [Johnson, Dannette S.] Univ Mississippi, Dept Internal Med, Div Rheumatol & Mol Immunol, Jackson, MS 39216 USA.
   [Reimold, Andreas M.] Dallas VAMC, Med Serv, Rheumatol Sect, Dallas, TX USA.
   [Reimold, Andreas M.] Univ Texas Dallas, SW Med Ctr, Dept Internal Med, Dallas, TX USA.
   [Kerr, Gail S.; Richards, J. Steuart] VAMC, Med Serv, Rheumatol Sect, Washington, DC USA.
   [Kerr, Gail S.; Richards, J. Steuart] Georgetown Univ, Dept Med, Div Rheumatol, Washington, DC USA.
   [Mikuls, Ted R.] Omaha VAMC, Med Serv, Rheumatol Sect, Omaha, NE USA.
   [Mikuls, Ted R.] Univ Nebraska Med Ctr, Nebraska Arthrit Outcomes Res Ctr, Omaha, NE USA.
RP Davis, LA (reprint author), Denver Hlth & Hosp Author, 777 Bannock St,MC 4000, Denver, CO 80204 USA.
EM lisa.davis@ucdenver.edu
FU Veterans Affairs Health Services Research and Development Grant [SHP
   08-172]; University of Colorado Denver, Division of Rheumatology;
   National Institutes of Health/National Institute of Arthritis and
   Musculoskeletal and Skin Diseases [T32 AR007534-24]; National Institutes
   of Health Loan Repayment Award; Rheumatology Research Foundation
   Rheumatology Scientist Development Award; Denver Health and Hospital
   Authority; University of Colorado; Colorado Clinical and Translational
   Science Institute; Veterans Affairs Health Services Research and
   Development Career Development Award [CDA 07-221]
FX This work, including the genotyping, was supported by a Veterans Affairs
   Health Services Research and Development Grant (SHP 08-172) and the
   University of Colorado Denver, Division of Rheumatology. L.D. received
   support from the National Institutes of Health/National Institute of
   Arthritis and Musculoskeletal and Skin Diseases (T32 AR007534-24),
   National Institutes of Health Loan Repayment Award, the Rheumatology
   Research Foundation Rheumatology Scientist Development Award, Denver
   Health and Hospital Authority, the University of Colorado and the
   Colorado Clinical and Translational Science Institute. L.C. received
   support from a Veterans Affairs Health Services Research and Development
   Career Development Award (CDA 07-221). The funding sources had no role
   in the design, collection, analysis, interpretation of data, writing of
   the report or decision to submit this article for publication. The views
   expressed in this article are those of the authors and do not
   necessarily reflect the position or policy of the Department of Veterans
   Affairs or US government. All investigators participating in this
   research had access to all data. We declare that we (and our spouses,
   partners and children under 18 years of age) have no financial or
   personal relationships with other people or organizations that could
   inappropriately influence (bias) this work, including employment,
   consultancies, stock ownership, honoraria, paid expert testimony,
   patents or patent applications and travel grants, within 5 years of
   beginning the work submitted.
NR 49
TC 6
Z9 6
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1462-0324
EI 1462-0332
J9 RHEUMATOLOGY
JI RHEUMATOLOGY
PD JUN
PY 2014
VL 53
IS 6
BP 1014
EP 1021
DI 10.1093/rheumatology/ket472
PG 8
WC Rheumatology
SC Rheumatology
GA AI6KJ
UT WOS:000336982600008
PM 24489016
ER

PT J
AU Kratz, M
   Marcovina, S
   Nelson, JE
   Yeh, MM
   Kowdley, KV
   Callahan, HS
   Song, XL
   Di, CZ
   Utzschneider, KM
AF Kratz, Mario
   Marcovina, Santica
   Nelson, James E.
   Yeh, Matthew M.
   Kowdley, Kris V.
   Callahan, Holly S.
   Song, Xiaoling
   Di, Chongzhi
   Utzschneider, Kristina M.
TI Dairy fat intake is associated with glucose tolerance, hepatic and
   systemic insulin sensitivity, and liver fat but not beta-cell function
   in humans
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
ID TRANS-PALMITOLEIC ACID; ADIPOSE-TISSUE; PLASMA; VALIDATION; BIOMARKERS;
   RESISTANCE; ADULTS; RISK
AB Background: Plasma phospholipid concentrations of trans-palmitoleic acid (trans-16: ln-7), a biomarker of dairy fat intake, are inversely associated with incident type 2 diabetes in 2 US cohorts.
   Objective: The objective was to investigate whether the intake of trans-16: ln-7 in particular, or dairy fat in general, is associated with glucose tolerance and key factors determining glucose tolerance.
   Design: A cross-sectional investigation was undertaken in 17 men and women with nonalcoholic fatty liver disease and 15 body mass index (BMI)- and age-matched controls. The concentrations of trans-16:1n 7 and 2 other biomarkers of dairy fat intake, 15:0 and 17:0, were measured in plasma phospholipids and free fatty acids (FFAs). Liver fat was estimated by computed tomography derived liver-spleen ratio. Intravenous-glucose-tolerance tests and oralglucose-tolerance test (OGTT) and hyperinsulinemic-euglycemic clamps were performed to assess beta-cell function and hepatic and systemic insulin sensitivity.
   Results: In multivariate analyses adjusted for age, sex, and BMI, phospholipid 17:0, phospholipid trans-16:1n-7, PIA 15:0, and FFA 17:0 were inversely associated with fasting plasma glucose, the area under the curve for glucose during an OGTT, and liver fat. Phospholipid trans-16:1n 7 was also positively associated with hepatic and systemic insulin sensitivity. None of the biomarkers were associated with beta-cell function. The associations between dairy fat intake and glucose tolerance were attenuated by adjusting for insulin sensitivity or liver fat, but strengthened by adjusting for beta-cell function.
   Conclusion: Although we cannot rule out reverse causation, these data support the hypothesis that dairy fat improves glucose tolerance, possibly through a mechanism involving improved hepatic and systemic insulin sensitivity and reduced liver fat. This trial was registered at clinicaltrials.gov as NCT01289639.
C1 [Kratz, Mario; Song, Xiaoling] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Canc Prevent Program, Seattle, WA 98109 USA.
   [Di, Chongzhi] Biostat Program, Seattle, WA 98109 USA.
   [Kratz, Mario; Utzschneider, Kristina M.] Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA.
   [Kratz, Mario] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
   [Yeh, Matthew M.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA.
   [Marcovina, Santica] Univ Washington, Northwest Lipid Res Labs, Seattle, WA 98195 USA.
   [Nelson, James E.; Kowdley, Kris V.] Virginia Mason Med Ctr, Benaroya Res Inst, Seattle, WA 98101 USA.
   [Callahan, Holly S.] Univ Washington, Inst Translat Hlth Sci, Seattle, WA 98195 USA.
   [Utzschneider, Kristina M.] VA Puget Sound Hlth Care Syst, Dept Med, Div Endocrinol, Seattle, WA USA.
RP Kratz, M (reprint author), Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Mail Stop M4-B402,1100 Fairview Ave North, Seattle, WA 98109 USA.
EM mkratz@fhcrc.org
FU US Department of Veterans Affairs, Office of Research and Development
   Medical Research Service; NIH [UL1RR025014, P30DK017047, P30DK035816,
   DK020579, RR000954, DK056341, T32DK007247, U01DK061728, K24DK002957,
   R21ES022332]
FX Supported by the US Department of Veterans Affairs, Office of Research
   and Development Medical Research Service, and NIH grant nos.
   UL1RR025014, P30DK017047, P30DK035816, DK020579, RR000954, DK056341,
   T32DK007247, U01DK061728, K24DK002957, and R21ES022332.
NR 20
TC 19
Z9 19
U1 1
U2 15
PU AMER SOC NUTRITION-ASN
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0002-9165
EI 1938-3207
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD JUN
PY 2014
VL 99
IS 6
BP 1385
EP 1396
DI 10.3945/ajcn.113.075457
PG 12
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA AH9NW
UT WOS:000336470100011
PM 24740208
ER

PT J
AU Turner, AP
   Williams, RM
   Norvell, DC
   Henderson, AW
   Hakimi, KN
   Blake, DJ
   Czerniecki, JM
AF Turner, Aaron P.
   Williams, Rhonda M.
   Norvell, Daniel C.
   Henderson, Alison W.
   Hakimi, Kevin N.
   Blake, Donna Jo
   Czerniecki, Joseph M.
TI Prevalence and 1-Year Course of Alcohol Misuse and Smoking in Persons
   with Lower Extremity Amputation as a Result of Peripheral Arterial
   Disease
SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION
LA English
DT Article
DE Smoking; Alcohol Misuse; Amputation; Prevalence; Social Support
ID SPINAL-CORD-INJURY; DISORDERS IDENTIFICATION TEST; TYPE-2
   DIABETES-MELLITUS; LOWER-LIMB AMPUTATION; 6.5-YEAR FOLLOW-UP;
   RISK-FACTORS; SOCIAL SUPPORT; MULTIPLE-SCLEROSIS; CIGARETTE-SMOKING;
   UNITED-STATES
AB Objective The aim of this study was to describe prevalence of alcohol misuse and smoking among individuals with amputations as a result of peripheral arterial disease before surgery and 12 mos after surgery, changes in these behaviors over time, and factors associated with change.
   Design This is a prospective cohort study of 75 veterans experiencing their first major unilateral amputation. Measures included demographic and general health information, Alcohol Use Disorders Identification Test, smoking behaviors, and social support.
   Results Sixteen percent of the participants reported engaging in alcohol misuse at presurgical baseline; and 13% at 12 mos after amputation. Thirty-seven percent of the participants were categorized as smokers at baseline; this number dropped to 29% at 12 mos after amputation. Among those who decreased drinking and quit smoking, there was a trend indicating greater social support.
   Conclusions The participants endorsed drinking and smoking behaviors at levels consistent with other types of disability and with veterans using the Veterans Health Administration for their health care. Even with a variety of health concerns, after amputation, most of the smokers and those engaging in alcohol misuse continued to smoke and drink at their preamputation rate. The presence of social support may encourage health behavior change and is an important area for future research and intervention.
C1 [Turner, Aaron P.; Williams, Rhonda M.; Henderson, Alison W.; Hakimi, Kevin N.; Czerniecki, Joseph M.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
   [Turner, Aaron P.; Williams, Rhonda M.; Hakimi, Kevin N.; Czerniecki, Joseph M.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA.
   [Norvell, Daniel C.] Spectrum Res Inc, Tacoma, WA USA.
   [Blake, Donna Jo] Denver VAMC, Denver, CO USA.
   [Blake, Donna Jo] Univ Colorado, Denver, CO 80202 USA.
RP Turner, AP (reprint author), VA Puget Sound Hlth Care Syst, RCS 117,1660 S Columbian Way, Seattle, WA 98108 USA.
OI Turner, Aaron/0000-0001-6897-8003
FU United States Department of Veterans Affairs, Office of Research and
   Development, Rehabilitation Research and Development [A41241, B4927W]
FX Supported by the United States Department of Veterans Affairs, Office of
   Research and Development, Rehabilitation Research and Development (Merit
   Review A41241, Joseph M. Czerniecki, PI, and Career Development Award
   B4927W, Aaron P. Turner, PI).
NR 78
TC 1
Z9 1
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0894-9115
EI 1537-7385
J9 AM J PHYS MED REHAB
JI Am. J. Phys. Med. Rehabil.
PD JUN
PY 2014
VL 93
IS 6
BP 493
EP 502
DI 10.1097/PHM.0000000000000055
PG 10
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA AI3FC
UT WOS:000336744900005
PM 24508927
ER

PT J
AU Lee, JXW
   Yusin, JS
   Randhawa, I
AF Lee, Joyce Xiang Wu
   Yusin, Joseph Stephen
   Randhawa, Inderpal
TI Properdin deficiency-associated bronchiectasis
SO ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
LA English
DT Letter
C1 [Lee, Joyce Xiang Wu; Yusin, Joseph Stephen] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Allergy & Immunol, Los Angeles, CA 90073 USA.
   [Randhawa, Inderpal] Long Beach Mem Med Ctr, Long Beach, CA USA.
RP Lee, JXW (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Dept Allergy & Immunol, Los Angeles, CA 90073 USA.
EM joycexianglee@gmail.com
NR 8
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1081-1206
EI 1534-4436
J9 ANN ALLERG ASTHMA IM
JI Ann. Allergy Asthma Immunol.
PD JUN
PY 2014
VL 112
IS 6
BP 557
EP 559
PG 6
WC Allergy; Immunology
SC Allergy; Immunology
GA AH9XJ
UT WOS:000336498400017
PM 24793003
ER

PT J
AU Carbone, LD
   Chin, AS
   Lee, TA
   Burns, SP
   Svircev, JN
   Hoenig, HM
   Bailey, L
   Weaver, FM
AF Carbone, Laura D.
   Chin, Amy S.
   Lee, Todd A.
   Burns, Stephen P.
   Svircev, Jelena N.
   Hoenig, Helen M.
   Bailey, Lauren
   Weaver, Frances M.
TI Thiazide Use Is Associated With Reduced Risk for Incident Lower
   Extremity Fractures in Men With Spinal Cord Injury
SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION
LA English
DT Article
DE Fractures, bone; Men; Rehabilitation; Spinal cord injuries; Thiazides
ID BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; HIP FRACTURE; OLDER-ADULTS;
   DIURETIC USE; VITAMIN-D; OSTEOPOROSIS; WORLDWIDE; VETERANS
AB Objective: To determine the association between thiazide use and lower extremity fractures in patients who are men with a spinal cord injury (SCI).
   Design: Cohort study from fiscal years 2002 to 2007.
   Setting: Medical centers.
   Participants: Men (N=6969) with an SCI from the Veterans Affairs (VA) Spinal Cord Dysfunction (SCD) Registry, including 1433 users of thiazides and 5536 nonusers of thiazides.
   Intervention: Thiazide use versus nonuse.
   Main Outcome Measure: Incident lower extremity fractures.
   Results: Among the men, 21% in the VA SCD Registry (fiscal years 2002-2007) included in these analyses used thiazide diuretics. There were 832 incident lower extremity fractures over the time period of this study: 110 fractures (7.7%) in 1433 thiazide users and 722 fractures (13%) in 5536 nonusers of thiazides. In unadjusted and adjusted models alike, thiazide use was associated with at least a one-quarter risk reduction in lower extremity fracture at any given point in time (unadjusted: hazard ratio (HR)=.75; 95% confidence interval (CI), .59-.94; adjusted: HR=.74; 95% CI, .58-.95).
   Conclusions: Thiazide use is common in men with SCI and is associated with a decreased likelihood for lower extremity fractures. (C) 2014 by the American Congress of Rehabilitation Medicine
C1 [Carbone, Laura D.] Charlie Norwood Vet Affairs Med Ctr, Augusta, GA USA.
   [Carbone, Laura D.] Georgia Regents Univ, Dept Med, Augusta, GA 30912 USA.
   [Chin, Amy S.; Lee, Todd A.; Bailey, Lauren; Weaver, Frances M.] Care of Hines EJ, Jr Vet Affairs Hosp, Hines, IL USA.
   [Lee, Todd A.; Bailey, Lauren] Univ Illinois, Chicago, IL USA.
   [Burns, Stephen P.; Svircev, Jelena N.] Vet Affairs Puget Sound, Spinal Cord Injury Serv, Seattle, WA USA.
   [Burns, Stephen P.; Svircev, Jelena N.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA.
   [Hoenig, Helen M.] Durham Vet Affairs Med Ctr, Durham, NC USA.
   [Weaver, Frances M.] Loyola Univ, Stritch Sch Med, Maywood, IL 60153 USA.
RP Carbone, LD (reprint author), Georgia Regents Univ, Dept Med, Sect Rheumatol & Immunol, 1120 15th St,BI 5086, Augusta, GA 30912 USA.
EM lcarbone@gru.edu
FU Department of Veterans Affairs, Veterans Health Administration, Health
   Services Research and Development [UR 08-033]
FX Supported by the Department of Veterans Affairs, Veterans Health
   Administration, Health Services Research and Development (grant no. UR
   08-033).
NR 38
TC 2
Z9 2
U1 2
U2 3
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0003-9993
EI 1532-821X
J9 ARCH PHYS MED REHAB
JI Arch. Phys. Med. Rehabil.
PD JUN
PY 2014
VL 95
IS 6
BP 1015
EP 1020
DI 10.1016/j.apmr.2013.12.013
PG 6
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA AI3OY
UT WOS:000336773000002
PM 24378805
ER

PT J
AU Sullivan-Singh, SJ
   Sawyer, K
   Ehde, DM
   Bell, KR
   Temkin, N
   Dikmen, S
   Williams, RM
   Hoffman, JM
AF Sullivan-Singh, Sarah J.
   Sawyer, Kathryn
   Ehde, Dawn M.
   Bell, Kathleen R.
   Temkin, Nancy
   Dikmen, Sureyya
   Williams, Rhonda M.
   Hoffman, Jeanne M.
TI Comorbidity of Pain and Depression Among Persons With Traumatic Brain
   Injury
SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION
LA English
DT Article
DE Brain injuries; Depression; Pain; Rehabilitation
ID CUT-POINTS; SEVERITY; DISORDERS; PREVALENCE; VALIDITY; OUTCOMES
AB Objective: To assess the prevalence of pain, depression, and comorbid pain and depression among a civilian sample of persons with traumatic brain injury (TBI).
   Design: Longitudinal survey design with 1-year follow-up.
   Setting: Inpatient rehabilitation and the community.
   Participants: Participants (N = 158) admitted to inpatient rehabilitation after moderate to severe TBI.
   Interventions: Not applicable.
   Main Outcome Measures: Depression was assessed with the Patient Health Questionnaire-9 (PHQ-9); pain was assessed with a numerical rating scale from 0 (no pain) to 10 (worst pain). Participants who reported average pain >= 4 were classified as having pain, and participants with PHQ-9 scores >= 10 were classified as depressed.
   Results: Both pain and depression were more prevalent at baseline assessment (pain: 70%; depression: 31%) than at year 1 (pain: 34%; depression: 22%). Comorbid pain and depression declined from 27% at baseline to 18% at year 1. Pain was significantly associated with depression at baseline (relative risk: 2.62, P = .003) and at year 1 (relative risk: 7.98, P<.001).
   Conclusions: Pain and depression are common and frequently co-occur in persons with TBI. Although their frequency declined over the first year after injury, the strength of their association increased. Assessment and treatment of both conditions simultaneously may lead to improved outcomes, both early after TBI and over time. (C) 2014 by the American Congress of Rehabilitation Medicine
C1 [Sullivan-Singh, Sarah J.; Sawyer, Kathryn; Ehde, Dawn M.; Bell, Kathleen R.; Temkin, Nancy; Dikmen, Sureyya; Williams, Rhonda M.; Hoffman, Jeanne M.] Univ Washington, Dept Rehabil Med, Sch Med, Seattle, WA 98104 USA.
   [Temkin, Nancy; Dikmen, Sureyya] Univ Washington, Dept Neurol Surg, Sch Med, Seattle, WA 98104 USA.
   [Temkin, Nancy] Univ Washington, Dept Biostat, Sch Med, Seattle, WA 98104 USA.
   [Dikmen, Sureyya] Univ Washington, Dept Psychiat & Biobehav Sci, Sch Med, Seattle, WA 98104 USA.
   [Williams, Rhonda M.] Vet Affairs Puget Sound Healthcare Syst, Rehabil Care Serv, Seattle, WA USA.
RP Sullivan-Singh, SJ (reprint author), Univ Washington, Dept Rehabil Med, Harborview Med Ctr, 325 Ninth Ave,Box 359612, Seattle, WA 98104 USA.
EM sarahsullivansingh@gmail.com
FU National Institute on Disability and Rehabilitation Research Traumatic
   Brain Injury Model Systems [H133A070032]; Department of Defense
   Congressionally Directed Medical Research Programs [W81XWH-12-2-0109]
FX Supported by the National Institute on Disability and Rehabilitation
   Research Traumatic Brain Injury Model Systems (grant no. H133A070032)
   and Department of Defense Congressionally Directed Medical Research
   Programs (grant no. W81XWH-12-2-0109).
NR 27
TC 11
Z9 11
U1 0
U2 5
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0003-9993
EI 1532-821X
J9 ARCH PHYS MED REHAB
JI Arch. Phys. Med. Rehabil.
PD JUN
PY 2014
VL 95
IS 6
BP 1100
EP 1105
DI 10.1016/j.apmr.2014.02.001
PG 6
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA AI3OY
UT WOS:000336773000014
PM 24561058
ER

PT J
AU Abern, MR
   Terris, MK
   Aronson, WJ
   Kane, CJ
   Amling, CL
   Cooperberg, MR
   Freedland, SJ
AF Abern, Michael R.
   Terris, Martha K.
   Aronson, William J.
   Kane, Christopher J.
   Amling, Christopher L.
   Cooperberg, Matthew R.
   Freedland, Stephen J.
TI The Impact of Pathologic Staging on the Long-Term Oncologic Outcomes of
   Patients With Clinically High-Risk Prostate Cancer
SO CANCER
LA English
DT Article
DE prostatic neoplasms; prostatectomy; treatment outcome; pathology
ID RADICAL PROSTATECTOMY; UNITED-STATES; MORTALITY; NOMOGRAM; SURVIVAL;
   DISEASE; NG/ML; MEN
AB BACKGROUNDIn the prostate-specific antigen (PSA) screening era, approximately 15% of US men still present with clinically high-risk prostate cancer (PC). However, high-risk PC may be downgraded/downstaged at radical prostatectomy (RP), making additional therapy unnecessary. The authors tested the oncologic outcomes in men with clinically high-risk disease stratified on RP pathology.
   METHODSA total of 611 men with high-risk PC (PSA level>20 ng/mL, biopsy Gleason sum [bGS]8, or clinical classification ofT3) underwent RP and pelvic lymphadenectomy between 1998 and 2011. Outcomes included biochemical disease recurrence (BCR), receipt of androgen deprivation therapy (ADT), metastases, and PC-specific and overall survival. RP pathology was classified as unfavorable (pathologic Gleason sum8, pathologic classification ofT3, or lymph node-positive disease), or favorable (no unfavorable features). Multivariable analyses tested oncologic outcomes stratified by pathologic classification.
   RESULTSOverall, 527 men had complete pathologic data and were included in the current analysis. Of the cohort, 206 of 527 men (39%) had favorable pathology. This finding was more common in men with only 1 clinical high-risk feature, and a lower body mass index, PSA level, bGS, and percentage positive biopsy cores. Favorable pathology was associated with decreased BCR (hazards ratio [HR], 0.34), metastases (HR, 0.17), and PC death (HR, 0.17). After a median follow-up of 82 months (range, 49 months-131 months), 193 of the 527 men (37%) received ADT, including only 35 of the 206 men with favorable pathology (17%). Unfavorable pathology was associated with early ( 5 years) but not late treatment with ADT.
   CONCLUSIONSIn a large cohort of men with high-risk PC who were managed with RP, 39% had favorable pathology and superior oncologic outcomes. Cancer 2014;120:1656-1662. (c) 2014 American Cancer Society.
C1 [Abern, Michael R.] Univ Illinois, Dept Urol, Chicago, IL 60612 USA.
   [Terris, Martha K.] Vet Affairs Med Ctr, Urol Sect, Augusta, GA USA.
   [Terris, Martha K.] Med Coll Georgia, Urol Sect, Augusta, GA 30912 USA.
   [Aronson, William J.] Vet Affairs Greater Los Angeles Healthcare Syst, Urol Sect, Dept Surg, Los Angeles, CA USA.
   [Aronson, William J.] Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA USA.
   [Kane, Christopher J.] Univ Calif San Diego, Div Urol, San Diego, CA 92103 USA.
   [Amling, Christopher L.] Oregon Hlth & Sci Univ, Dept Urol, Portland, OR USA.
   [Cooperberg, Matthew R.] Univ Calif San Francisco, Ctr Comprehens Canc, Dept Urol, San Francisco, CA 94143 USA.
   [Cooperberg, Matthew R.] Vet Affairs Med Ctr, Dept Surg, Urol Sect, San Francisco, CA 94121 USA.
   [Freedland, Stephen J.] Vet Affairs Med Ctr, Urol Sect, Durham, NC USA.
   [Freedland, Stephen J.] Duke Univ, Sch Med, Dept Surg, Div Urol Surg, Durham, NC USA.
RP Abern, MR (reprint author), Univ Illinois, Dept Urol, 820 S Wood St,Suite 515, Chicago, IL 60612 USA.
EM mabern1@uic.edu
OI Terris, Martha/0000-0002-3843-7270
NR 23
TC 10
Z9 11
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD JUN 1
PY 2014
VL 120
IS 11
BP 1656
EP 1662
DI 10.1002/cncr.28647
PG 7
WC Oncology
SC Oncology
GA AI1OE
UT WOS:000336619700014
PM 24647966
ER

PT J
AU O'Horo, JC
   Maki, DG
   Krupp, AE
   Safdar, N
AF O'Horo, John C.
   Maki, Dennis G.
   Krupp, Anna E.
   Safdar, Nasia
TI Arterial Catheters as a Source of Bloodstream Infection: A Systematic
   Review and Meta-Analysis
SO CRITICAL CARE MEDICINE
LA English
DT Article
DE arterial catheterization; catheter-related infections; critical care;
   meta-analysis; nosocomial infections; peripheral; prevalence
ID CRITICALLY-ILL PATIENTS; RANDOMIZED CONTROLLED-TRIAL; CENTRAL VENOUS
   CATHETERS; INTENSIVE-CARE UNITS; RADIAL-ARTERY; FEMORAL-ARTERY;
   CARDIAC-SURGERY; COLONIZATION; CANNULATION; SEPSIS
AB Objective: Catheter-related bloodstream infections are associated with significant costs and adverse consequences. Arterial catheters are commonly used in the critical care setting and are among the most heavily manipulated vascular access devices. We sought to evaluate the prevalence of arterial catheter-related bloodstream infection.
   Data Sources: PubMed, CinAHL, EMBASE, and Web of Science.
   Study Selection: Included studies reported prevalence rate of catheter-related bloodstream infection for arterial catheters used for critical illness or postoperative monitoring. For the purposes of this study, catheter-related bloodstream infection was defined as positive blood culture collected from an arterial catheter and from the periphery with the same organism in a patient demonstrating systemic signs of sepsis.
   Data Extraction: The study population, site of insertion, antiseptic preparation, catheter days, and prevalence of catheter-related bloodstream infection were abstracted. When data were not available, authors were contacted for further information.
   Data Synthesis: Forty-nine studies met criteria including 222 cases of arterial catheter-related bloodstream infection in 30,841 catheters. Pooled incidence was 3.40/1,000 catheters or 0.96/1,000 catheter days. Prevalence was considerably higher in the subgroup of studies that cultured all catheters (1.26/1,000 catheter days) compared with those studies that cultured only when the arterial catheter was suspected as the source for the catheter-related bloodstream infection (0.70/1,000 catheter days). Pooled data also found a significantly increased risk of infection for femoral site of insertion compared with radial artery for arterial catheter placement (relative risk, 1.93; 95% CI, 1.32-2.84; p = 0.001)
   Conclusions: Arterial catheters are an underrecognized cause of catheter-related bloodstream infection. Pooled incidence when catheters were systematically cultured and correlated to blood culture results indicated a substantial burden of arterial catheter-related bloodstream infection. Selection of a radial site over a femoral site will help reduce the risk of arterial catheter-related bloodstream infection. Future studies should evaluate technologies applied to preventing central venous catheter-related bloodstream infection to arterial catheters as well.
C1 [O'Horo, John C.] Mayo Clin, Div Pulm & Crit Care Med, Rochester, MN USA.
   [Maki, Dennis G.; Safdar, Nasia] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
   [Krupp, Anna E.; Safdar, Nasia] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Sect Infect Dis, Madison, WI USA.
   [Safdar, Nasia] Univ Wisconsin Hosp & Clin, Madison, WI 53792 USA.
RP Safdar, N (reprint author), UW Med Fdn Centennial Bldg,1685 Highland Ave, Madison, WI 53705 USA.
EM ns2@medicine.wisc.edu
RI O'Horo, John/N-8681-2013
OI O'Horo, John/0000-0002-0880-4498
NR 62
TC 25
Z9 26
U1 2
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0090-3493
EI 1530-0293
J9 CRIT CARE MED
JI Crit. Care Med.
PD JUN
PY 2014
VL 42
IS 6
BP 1334
EP 1339
DI 10.1097/CCM.0000000000000166
PG 6
WC Critical Care Medicine
SC General & Internal Medicine
GA AH6UM
UT WOS:000336266900016
PM 24413576
ER

PT J
AU Inoue, T
   Higashiyama, M
   Kaji, I
   Rudenkyy, S
   Higuchi, K
   Guth, PH
   Engel, E
   Kaunitz, JD
   Akiba, Y
AF Inoue, Takuya
   Higashiyama, Masaaki
   Kaji, Izumi
   Rudenkyy, Sergiy
   Higuchi, Kazuhide
   Guth, Paul H.
   Engel, Eli
   Kaunitz, Jonathan D.
   Akiba, Yasutada
TI Dipeptidyl Peptidase IV Inhibition Prevents the Formation and Promotes
   the Healing of Indomethacin-Induced Intestinal Ulcers in Rats
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Article
DE Glucagon-like peptide-2; NSAIDs; Taste receptor
ID GLUCAGON-LIKE PEPTIDE-2; SHORT-BOWEL SYNDROME; NONSTEROIDAL
   ANTIINFLAMMATORY DRUGS; GROWTH-FACTOR-I; INDUCED ENTEROPATHY; ENTERAL
   NUTRIENTS; BICARBONATE SECRETION; AMINO-ACID; BLOOD-LOSS; GLP-2
AB We studied the intestinotrophic hormone glucagon-like peptide-2 (GLP-2) as a possible therapy for non-steroidal anti-inflammatory drug (NSAID)-induced intestinal ulcers. Luminal nutrients release endogenous GLP-2 from enteroendocrine L cells. Since GLP-2 is degraded by dipeptidyl peptidase IV (DPPIV), we hypothesized that DPPIV inhibition combined with luminal administration of nutrients potentiates the effects of endogenous GLP-2 on intestinal injury.
   Intestinal injury was induced by indomethacin (10 mg/kg, sc) in fed rats. The long-acting DPPIV inhibitor K579 was given intragastrically (ig) or intraperitoneally (ip) before or after indomethacin treatment. l-Alanine (l-Ala) and inosine 5'-monophosphate (IMP) were co-administered ig after the treatment.
   Indomethacin treatment induced intestinal ulcers that gradually healed after treatment. Pretreatment with ig or ip K579 given at 1 mg/kg reduced total ulcer length, whereas K579 at 3 mg/kg had no effect. Exogenous GLP-2 also reduced intestinal ulcers. The preventive effect of K579 was dose-dependently inhibited by a GLP-2 receptor antagonist. Daily treatment with K579 (1 mg/kg), GLP-2, or l-Ala + IMP after indomethacin treatment reduced total ulcer length. Co-administration (ig) of K579 and l-Ala + IMP further accelerated intestinal ulcer healing.
   DPPIV inhibition and exogenous GLP-2 prevented the formation and promoted the healing of indomethacin-induced intestinal ulcers, although high-dose DPPIV inhibition reversed the preventive effect. Umami receptor agonists also enhanced the healing effects of the DPPIV inhibitor. The combination of DPPIV inhibition and luminal nutrient-induced GLP-2 release may be a useful therapeutic tool for the treatment of NSAIDs-induced intestinal ulcers.
C1 [Inoue, Takuya; Higashiyama, Masaaki; Kaji, Izumi; Kaunitz, Jonathan D.; Akiba, Yasutada] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA.
   [Inoue, Takuya; Higuchi, Kazuhide] Osaka Med Coll, Dept Internal Med 2, Osaka, Japan.
   [Rudenkyy, Sergiy; Guth, Paul H.; Kaunitz, Jonathan D.; Akiba, Yasutada] Greater Los Angles Vet Affairs Healthcare Syst, Los Angeles, CA USA.
   [Engel, Eli] Univ Calif Los Angeles, Dept Biomath, Los Angeles, CA USA.
   [Kaunitz, Jonathan D.; Akiba, Yasutada] Brentwood Biomed Res Inst, Los Angeles, CA 90073 USA.
   [Kaunitz, Jonathan D.] West Los Angeles VA Med Ctr, Los Angeles, CA 90073 USA.
RP Kaunitz, JD (reprint author), West Los Angeles VA Med Ctr, Bldg 114,Suite 217,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM jake@ucla.edu
FU Department of Veterans Affairs Merit Review Award, NIH-NIDDK [R01
   DK54221]; NIH-NIDDK [P30 DK0413]
FX We thank Coleen and Bea Palileo for their assistance with manuscript
   preparation. Supported by the Department of Veterans Affairs Merit
   Review Award, NIH-NIDDK R01 DK54221 (J. Kaunitz), and the animal core of
   NIH-NIDDK P30 DK0413 (J.E. Rozengurt).
NR 53
TC 12
Z9 12
U1 0
U2 7
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
EI 1573-2568
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD JUN
PY 2014
VL 59
IS 6
BP 1286
EP 1295
DI 10.1007/s10620-013-3001-6
PG 10
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AH8KF
UT WOS:000336386000031
PM 24379150
ER

PT J
AU Hildebrandt, T
   Shope, S
   Varangis, E
   Klein, D
   Pfaff, DW
   Yehuda, R
AF Hildebrandt, Tom
   Shope, Sydney
   Varangis, Eleanna
   Klein, Diane
   Pfaff, Donald W.
   Yehuda, Rachel
TI Exercise reinforcement, stress, and beta-endorphins: An initial
   examination of exercise in anabolic-androgenic steroid dependence
SO DRUG AND ALCOHOL DEPENDENCE
LA English
DT Article
DE Anabolic androgenic steroids; beta-endorphin; Cortisol; ACTH; Compulsive
   exercise; Drug dependence
ID HEAVY-RESISTANCE EXERCISE; HEALTHY-YOUNG MEN; ACUTE HORMONAL RESPONSES;
   GROWTH-FACTOR RESPONSES; RAT-BRAIN; NANDROLONE DECANOATE;
   ANOREXIA-NERVOSA; PLASMA-CORTISOL; DOSE-RESPONSE; MALE HAMSTERS
AB Background: Anabolic-androgenic steroids (AASs) are abused primarily in the context of intense exercise and for the purposes of increasing muscle mass as opposed to drug-induced euphoria. AASs also modulate the HPA axis and may increase the reinforcing value of exercise through changes to stress hormone and endorphin release. To test this hypothesis, 26 adult males drawn from a larger study on AAS use completed a progressive ratio task designed to examine the reinforcing value of exercise relative to financial reinforcer.
   Method: Sixteen experienced and current users (8 on-cycle, 8 off-cycle) and 10 controls matched on quantity x frequency of exercise, age, and education abstained from exercise for 24 h prior to testing and provided 24-h cortisol, plasma cortisol, ACTH, beta-endorphin samples, and measures of mood, compulsive exercise, and body image.
   Results: Between group differences indicated that on-cycle AAS users had the highest beta-endorphin levels, lowest cortisol levels, higher ACTH levels than controls. Conversely, off-cycle AAS users had the highest cortisol and ACTH levels, but the lowest beta-endorphin levels. Exercise value was positively correlated with beta-endorphin and symptoms of AAS dependence.
   Conclusion: The HPA response to AASs may explain why AASs are reinforcing in humans and exercise may play a key role in the development of AAS dependence. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
C1 [Hildebrandt, Tom; Shope, Sydney; Varangis, Eleanna; Yehuda, Rachel] Ichan Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.
   [Klein, Diane] NYU, Dept Psychiat, New York, NY 10016 USA.
   [Pfaff, Donald W.] Rockefeller Univ, New York, NY 10021 USA.
   [Yehuda, Rachel] James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
RP Hildebrandt, T (reprint author), Ichan Sch Med Mt Sinai, Eating & Weight Disorders Program, Dept Psychiat, One Gustave Levy Pl,Box 1230, New York, NY 10029 USA.
EM hildebtb@hotmail.com
OI Hildebrandt, Thomas/0000-0001-7054-9590
FU NIDA K23 grant [DA024043]
FX Funds for this study were provided by NIDA K23 grant DA024043 awarded to
   Dr. Hildebrandt. NIDA had no influence over the study design, execution
   of the project, interpretation or results, or manuscript preparation.
NR 58
TC 1
Z9 1
U1 0
U2 24
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0376-8716
EI 1879-0046
J9 DRUG ALCOHOL DEPEN
JI Drug Alcohol Depend.
PD JUN 1
PY 2014
VL 139
BP 86
EP 92
DI 10.1016/j.drugalcdep.2014.03.008
PG 7
WC Substance Abuse; Psychiatry
SC Substance Abuse; Psychiatry
GA AI2SI
UT WOS:000336708000012
PM 24690349
ER

PT J
AU Lin, F
   Roiland, R
   Heffner, K
   Johnson, M
   Chen, DG
   Mapstone, M
AF Lin, Feng
   Roiland, Rachel
   Heffner, Kathi
   Johnson, Melissa
   Chen, Ding-Geng (Din)
   Mapstone, Mark
TI Evaluation of objective and perceived mental fatigability in older
   adults with vascular risk
SO JOURNAL OF PSYCHOSOMATIC RESEARCH
LA English
DT Article
DE Mental fatigability; Executive control; History of mental activities;
   Reaction time
ID COGNITIVE FATIGUE; SUBSEQUENT SYMPTOMS; MULTIPLE-SCLEROSIS; SUBJECTIVE
   FATIGUE; NORMATIVE DATA; HEART-FAILURE; AGE; EDUCATION; SAMPLE; MEMORY
AB Objectives: Mental fatigability refers to the failure to sustain participation in tasks requiring mental effort Older adults with vascular risk are at particular risk for experiencing mental fatigability. The present study (1) tested a new way of measuring objective mental fatigability by examining its association with perceived mental fatigability; and (2) identified associated psychological, physiological, and situational predictors.
   Methods: A cross-sectional study was conducted with 49 community-dwelling participants aged 75 + years with vascular risk. A 20-minute fatigability-manipulation task was used to induce mental fatigability and develop objective and perceived mental fatigability measures. Objective fatigability was calculated by the change of reaction time over the course of the task. Perceived fatigability was calculated by the change of fatigue self-reported before and after the task. A set of potential psychological, physiological, and situational predictors were measured.
   Results: There was a significant increase in reaction time and self-reported fatigue to the fatigability manipulation task, indicating occurrence of objective and perceived mental fatigability. Reaction time and self-reported fatigue were moderately, but significantly correlated. Higher levels of executive control and having a history of more frequently engaging in mental activities were associated with lower objective mental fatigability. None of the examined factors were associated with perceived mental fatigability.
   Conclusion: Objective and perceived mental fatigability were sensitive to our fatigability-manipulation task. While these two measures were correlated, they were not associated with the same factors. These findings need to be validated in studies with a more heterogeneous sample and a greater variety of fatigability-manipulation tasks. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Lin, Feng; Johnson, Melissa; Chen, Ding-Geng (Din)] Univ Rochester, Sch Nursing, Rochester, NY 14642 USA.
   [Lin, Feng; Heffner, Kathi] Univ Rochester, Dept Psychiat, Sch Med & Dent, Rochester, NY 14642 USA.
   [Roiland, Rachel] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
   [Chen, Ding-Geng (Din)] Univ Rochester, Sch Med & Dent, Dept Biostat & Computat Biol, Rochester, NY 14642 USA.
   [Mapstone, Mark] Univ Rochester, Sch Med & Dent, Dept Neurol, Rochester, NY 14642 USA.
RP Lin, F (reprint author), Univ Rochester, Med Ctr, HWH 2w128,601 Elmwood Ave, Rochester, NY 14642 USA.
EM vankee_lin@urmc.rochester.edu
OI Heffner, Kathi/0000-0003-1095-1873
FU University of Rochester CTSA from the National Center for Advancing
   Translational Sciences of the National Institutes of Health [KL2
   TR000095]; Sigma Theta Tau International Small Grants
FX Data collection of the present project was supported by Sigma Theta Tau
   International Small Grants to F. Lin. The manuscript preparation was
   supported by the University of Rochester CTSA award number KL2 TR000095
   from the National Center for Advancing Translational Sciences of the
   National Institutes of Health to F. Lin. The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the National Institutes of Health.
NR 52
TC 0
Z9 0
U1 3
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0022-3999
EI 1879-1360
J9 J PSYCHOSOM RES
JI J. Psychosomat. Res.
PD JUN
PY 2014
VL 76
IS 6
BP 458
EP 464
DI 10.1016/j.jpsychores.2014.04.001
PG 7
WC Psychiatry
SC Psychiatry
GA AI1UA
UT WOS:000336639300004
PM 24840140
ER

PT J
AU Cox, K
   McAdams, DP
AF Cox, Keith
   McAdams, Dan P.
TI Meaning making during high and low point life story episodes predicts
   emotion regulation two years later: How the past informs the future
SO JOURNAL OF RESEARCH IN PERSONALITY
LA English
DT Article
DE Narrative identity; Emotion regulation; Emotional memory
ID AUTOBIOGRAPHICAL MEMORIES; ADOLESCENCE
AB Memory processes are commonly thought to relate to a host of personality systems. The current study specifies a particular way that memory relates to personality. Highly-valenced, identity-rich memories - high and low point episodes in the life story - were analyzed to see if aspects of these memories predicted self-reports of emotion regulation two years later. Meaning making in high and low points predicted emotion regulation. Moreover, valence mattered. Positive meaning making in high and low point stories predicted positive emotion regulation while negative meaning making in low point stories predicted negative emotion regulation. These relationships held while controlling for baseline extraversion, neuroticism, and memory word count. Limitations due to study design are discussed. Published by Elsevier Inc.
C1 [Cox, Keith] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
   [Cox, Keith] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC USA.
   [McAdams, Dan P.] Northwestern Univ, Dept Psychol, Evanston, IL 60208 USA.
   [McAdams, Dan P.] Sch Educ & Social Policy, Evanston, IL USA.
RP Cox, K (reprint author), Ralph H Johnson VA Med Ctr, Charleston, SC USA.
EM keith.cox@va.gov
NR 14
TC 13
Z9 13
U1 3
U2 13
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0092-6566
EI 1095-7251
J9 J RES PERS
JI J. Res. Pers.
PD JUN
PY 2014
VL 50
BP 66
EP 70
DI 10.1016/j.jrp.2014.03.004
PG 5
WC Psychology, Social
SC Psychology
GA AI2TA
UT WOS:000336709800009
ER

PT J
AU Bent, S
   Hendren, RL
   Zandi, T
   Law, K
   Choi, JE
   Widjaja, F
   Kalb, L
   Nestle, J
   Law, P
AF Bent, Stephen
   Hendren, Robert L.
   Zandi, Tara
   Law, Kiely
   Choi, Jae-Eun
   Widjaja, Felicia
   Kalb, Luther
   Nestle, Jay
   Law, Paul
TI Internet-Based, Randomized, Controlled Trial of Omega-3 Fatty Acids for
   Hyperactivity in Autism
SO JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY
LA English
DT Article
DE autism; nutritional supplement; alternative medicine; hyperactivity
ID PERVASIVE DEVELOPMENTAL DISORDERS; PLACEBO-CONTROLLED-TRIAL; SPECTRUM
   DISORDERS; PARENT REPORT; CHILDREN; METHYLPHENIDATE; SUPPLEMENTATION;
   IRRITABILITY; ARIPIPRAZOLE; RISPERIDONE
AB Objective: Preliminary evidence suggests that omega-3 fatty acids may reduce hyperactivity in children with autism spectrum disorder (ASD). We sought to examine the feasibility of a novel, Internet-based clinical trial design to evaluate the efficacy of this supplement. Method: E-mail invitations were sent to parents of children aged 5 to 8 years enrolled in the Interactive Autism Network. All study procedures, including screening, informed consent, and collection of outcome measures took place over the Internet. The primary Outcome measures were parent- and teacher-rated changes in hyperactivity on the Aberrant Behavior Checklist (ABC-H). Results: During the 6-week recruitment period, 57 children from 28 states satisfied all eligibility criteria and were randomly assigned to 1.3 grams of omega-3 fatty acids or an identical placebo daily for 6 weeks. Outcome assessments were obtained from all 57 participants and 57 teachers, and the study was completed in 3 months. Children in the omega-3 fatty acid group had a greater reduction in hyperactivity (-5.3 points) compared to the placebo group (-2.6 points), but the difference was not statistically significant (1.9-point greater improvement in the omega-3 group, 95% CI = -2.2 to 5.2). Adverse events were rare and not associated with omega-3 fatty acids. Participant feedback was positive. Conclusion: Internet-based, randomized controlled trials of therapies in children with ASD are feasible and may lead to marked reductions in the time and cost of completing trials. A larger sample size is required to definitively determine the efficacy of omega-3 fatty acids. Clinical trial registration information-Omega-3 Fatty Acids for Hyperactivity Treatment in Autism Spectrum Disorder; http://clinicaltrials.gov; NCT 01694667.
C1 [Bent, Stephen; Hendren, Robert L.; Choi, Jae-Eun; Widjaja, Felicia] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Zandi, Tara; Law, Kiely; Kalb, Luther; Nestle, Jay; Law, Paul] Kennedy Krieger Inst, Baltimore, MD USA.
RP Bent, S (reprint author), San Francisco VA Med Ctr, 111-A1,4150 Clement St, San Francisco, CA 94121 USA.
EM Stephen.Bent@ucsf.edu
FU Simons Foundation [SFARI 206484]; National Center for Research
   Resources; National Center for Advancing Translational Sciences,
   National Institutes of Health, through UCSF-CTSI [UL1 RR024131]
FX This work was supported by a grant from the Simons Foundation (SFARI
   206484, S.B.) and by the National Center for Research Resources and the
   National Center for Advancing Translational Sciences, National
   Institutes of Health, through UCSF-CTSI Grant Number UL1 RR024131.
NR 25
TC 10
Z9 11
U1 1
U2 25
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0890-8567
EI 1527-5418
J9 J AM ACAD CHILD PSY
JI J. Am. Acad. Child Adolesc. Psychiatr.
PD JUN
PY 2014
VL 53
IS 6
BP 658
EP 666
DI 10.1016/j.jaac.2014.01.018
PG 9
WC Psychology, Developmental; Pediatrics; Psychiatry
SC Psychology; Pediatrics; Psychiatry
GA AI0SO
UT WOS:000336560400009
PM 24839884
ER

PT J
AU Jesinkey, SR
   Funk, JA
   Stallons, LJ
   Wills, LP
   Megyesi, JK
   Beeson, CC
   Schnellmann, RG
AF Jesinkey, Sean R.
   Funk, Jason A.
   Stallons, L. Jay
   Wills, Lauren P.
   Megyesi, Judit K.
   Beeson, Craig C.
   Schnellmann, Rick G.
TI Formoterol Restores Mitochondrial and Renal Function after
   Ischemia-Reperfusion Injury
SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID ACUTE KIDNEY INJURY; OXIDANT INJURY; TRANSCRIPTIONAL COACTIVATOR;
   PROMOTES RECOVERY; PROXIMAL TUBULES; BIOGENESIS; PGC-1-ALPHA; DISEASE;
   EXPRESSION; REGULATOR
AB Mitochondrial biogenesis may be an adaptive response necessary for meeting the increased metabolic and energy demands during organ recovery after acute injury, and renal mitochondrial dysfunction has been implicated in the pathogenesis of AKI. We proposed that stimulation of mitochondria! biogenesis 24 hours after ischemia/reperfusion (I/R)-induced AKI, when renal dysfunction is maximal, would accelerate recovery of mitochondrial and renal function in mice. We recently showed that formoterol, a potent, highly specific, and long-acting beta(2)-adrenergic agonist, induces renal mitochondrial biogenesis in naive mice. Animals were subjected to sham or I/R-induced AKI, followed by once-daily intraperitoneal injection with vehicle or formoterol beginning 24 hours after surgery and continuing through 144 hours after surgery. Treatment with formoterol restored renal function, rescued renal tubules from injury, and diminished necrosis after I/R-induced AKI. Concomitantly, formoterol stimulated mitochondrial biogenesis and restored the expression and function of mitochondrial proteins. Taken together, these results provide proof of principle that a novel drug therapy to treat AKI, and potentially other acute organ failures, works by restoring mitochondrial function and accelerating the recovery of renal function after injury has occurred.
C1 [Jesinkey, Sean R.; Funk, Jason A.; Stallons, L. Jay; Wills, Lauren P.; Beeson, Craig C.; Schnellmann, Rick G.] Med Univ S Carolina, Ctr Cell Death Injury & Regenerat, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA.
   [Megyesi, Judit K.] Univ Arkansas Med Sci, Dept Med, Little Rock, AR 72205 USA.
   [Schnellmann, Rick G.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
RP Schnellmann, RG (reprint author), MUSC MSC 140,280 Calhoun St, Charleston, SC 29425 USA.
EM schnell@musc.edu
FU National Institutes of Health [R01 GM084147, T32 HL007260-35,
   F32DK098053, C06 RR015455, P20 GM103542-02, UL1 RR029882]; Biomedical
   Laboratory Research and Development Program of the Department of
   Veterans Affairs [BX-000851]; South Carolina Clinical and Translational
   Research Institute
FX This study was supported by the National Institutes of Health (R01
   GM084147 to R.G.S., T32 HL007260-35 to S.R.J and L.J.S., F32DK098053 to
   L.J.S., C06 RR015455 and SC COBRE in Oxidants, Redox Balance and Stress
   Signaling P20 GM103542-02), and by the Biomedical Laboratory Research
   and Development Program of the Department of Veterans Affairs
   (BX-000851). This publication was supported, in part, by the South
   Carolina Clinical and Translational Research Institute, with an academic
   home at the Medical University of South Carolina CTSA, and funded by the
   National Institutes of Health (UL1 RR029882).
NR 30
TC 20
Z9 20
U1 0
U2 5
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1046-6673
EI 1533-3450
J9 J AM SOC NEPHROL
JI J. Am. Soc. Nephrol.
PD JUN
PY 2014
VL 25
IS 6
BP 1157
EP 1162
DI 10.1681/ASN.2013090952
PG 6
WC Urology & Nephrology
SC Urology & Nephrology
GA AI0RS
UT WOS:000336558100007
PM 24511124
ER

PT J
AU Funk, JA
   Janech, MG
   Dillon, JC
   Bissler, JJ
   Siroky, BJ
   Bell, PD
AF Funk, Jason A.
   Janech, Michael G.
   Dillon, Joshua C.
   Bissler, John J.
   Siroky, Brian J.
   Bell, P. Darwin
TI Characterization of Renal Toxicity in Mice Administered the Marine
   Biotoxin Domoic Acid
SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID ACUTE KIDNEY INJURY; LIONS ZALOPHUS-CALIFORNIANUS; SEA LIONS; C-FOS;
   RECEPTOR ANTAGONIST; TISSUE DISTRIBUTION; SUBCLINICAL AKI;
   GENE-EXPRESSION; NMDA RECEPTORS; SHELLFISH
AB Domoic acid (DA), an excitatory amino acid produced by diatoms belonging to the genus Pseudo-nitzschia, is a glutamate analog responsible for the neurologic condition referred to as amnesic shellfish poisoning. To date, the renal effects of DA have been underappreciated, although renal filtration is the primary route of systemic elimination and the kidney expresses ionotropic glutamate receptors. To characterize the renal effects of DA, we administered either a neurotoxic dose of DA or doses below the recognized limit of toxicity to adult Sv128/Black Swiss mice. DA preferentially accumulated in the kidney and elicited marked renal vascular and tubular damage consistent with acute tubular necrosis, apoptosis, and renal tubular cell desquamation, with toxic vacuolization and mitochondrial swelling as hallmarks of the cellular damage. Doses >= 0.1 mg/kg DA elevated the renal injury biomarkers kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin, and doses >= 0.005 mg/kg induced the early response genes c-fos and junb. Coadministration of DA with the broad spectrum excitatory amino acid antagonist kynurenic acid inhibited induction of c-fos, junb, and neutrophil gelatinase-associated lipocalin. These findings suggest that the kidney may be susceptible to excitotoxic agonists, and renal effects should be considered when examining glutamate receptor activation. Additionally, these results indicate that DA is a potent nephrotoxicant, and potential renal toxicity may require consideration when determining safe levels for human exposure.
C1 [Funk, Jason A.; Janech, Michael G.; Dillon, Joshua C.; Bell, P. Darwin] Med Univ S Carolina, Div Nephrol, Dept Med, Charleston, SC 29425 USA.
   [Bissler, John J.; Siroky, Brian J.] Cincinnati Childrens Hosp Med Ctr, Div Nephrol & Hypertens, Cincinnati, OH 45229 USA.
   [Bell, P. Darwin] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
RP Bell, PD (reprint author), Med Univ S Carolina, 70 President St,DDB 514,MSC 629, Charleston, SC 29425 USA.
EM bellpd@musc.edu
OI Janech, Michael/0000-0002-3202-4811
FU National Institutes of Health/National Institute of Diabetes and
   Digestive and Kidney Diseases [T32DK007752]; Office of Naval Research
   [N000140810341]; Veterans Affairs Merit Grant [P30 DK074038]; Dialysis
   Clinic
FX J.A.F. was supported by National Institutes of Health/National Institute
   of Diabetes and Digestive and Kidney Diseases Training Grant T32DK007752
   in Renal Function and Disease. M.G.J. was supported by Office of Naval
   Research Award N000140810341. This study was supported by Veterans
   Affairs Merit Grant P30 DK074038 and funds from Dialysis Clinic (to
   P.D.B.).
NR 58
TC 8
Z9 8
U1 0
U2 14
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1046-6673
EI 1533-3450
J9 J AM SOC NEPHROL
JI J. Am. Soc. Nephrol.
PD JUN
PY 2014
VL 25
IS 6
BP 1187
EP 1197
DI 10.1681/ASN.2013080836
PG 11
WC Urology & Nephrology
SC Urology & Nephrology
GA AI0RS
UT WOS:000336558100010
PM 24511141
ER

PT J
AU Decramer, M
   Anzueto, A
   Kerwin, E
   Kaelin, T
   Richard, N
   Crater, G
   Tabberer, M
   Harris, S
   Church, A
AF Decramer, Marc
   Anzueto, Antonio
   Kerwin, Edward
   Kaelin, Thomas
   Richard, Nathalie
   Crater, Glenn
   Tabberer, Maggie
   Harris, Stephanie
   Church, Alison
TI Efficacy and safety of umeclidinium plus vilanterol versus tiotropium,
   vilanterol, or umeclidinium monotherapies over 24 weeks in patients with
   chronic obstructive pulmonary disease: results from two multicentre,
   blinded, randomised controlled trials
SO LANCET RESPIRATORY MEDICINE
LA English
DT Article
ID REFERENCE VALUES; COPD PATIENTS; DYSPNEA; SALMETEROL; BRONCHODILATION;
   QUESTIONNAIRE; INDACATEROL; SHORTNESS; SAMPLE; BREATH
AB Background Combination long-acting bronchodilator treatment might be more effective than long-acting bronchodilator monotherapy for the treatment of chronic obstructive pulmonary disease (COPD). We aimed to compare the efficacy and safety of umeclidinium (UMEC) plus vilanterol (VI) with tiotropium (TIO) monotherapy, UMEC monotherapy, or VI monotherapy in patients with moderate to very severe COPD.
   Methods In two multicentre, randomised, blinded, double-dummy, parallel-group, active-controlled trials, eligible patients (current or former smokers aged 40 years or older with an established clinical history of COPD) were randomly assigned in 1:1:1:1 ratio to UMEC 125 mu g plus VI 25 mu g, UMEC 62.5 mu g plus VI 25 mu g, TIO 18 mu g, and either VI 25 mu g (study 1) or UMEC 125 mu g (study 2). All study drugs were used once daily for 24 weeks. TIO was delivered via the HandiHaler inhaler and all other active treatments were delivered via the ELLIPTA dry powder inhaler. Random assignment (by a validated computer-based system) was done by centre and was not stratified. All patients and physicians were masked to assigned treatment during the studies. The primary efficacy endpoint of both studies was trough forced expiratory volume in 1 s (FEV1) on day 169, which was analysed in the intention-to-treat population. Both studies are registered with ClinicalTrials.gov, numbers NCT01316900 (study 1) and NCT01316913 (study 2).
   Findings 1141 participants were recruited in study 1, and 1191 in study 2. For study 1, after exclusions, 208, 209, 214, and 212 patients were included in the intention-to-treat analyses for TIO monotherapy, VI monotherapy, UMEC 125 mu g plus VI 25 mu g, and UMEC 62.5 mu g plus VI 25 mu g, respectively. For study 2, 215, 222, 215, and 217 patients were included in the intention-to-treat analyses for TIO monotherapy, UMEC monotherapy, UMEC 125 mu g plus VI 25 mu g, and UMEC 62.5 mu g plus VI 25 mu g, respectively. In both studies, we noted improvements in trough FEV1 on day 169 for both doses of UMEC plus VI compared with TIO monotherapy (study 1, UMEC 125 mu g plus VI 25 mu g: 0.088 L [95% CI 0.036 to 0.140; p=0.0010]; study 1, UMEC 62.5 mu g plus VI 25 mu g: 0.090 L [0.039 to 0.141; p=0.0006]; study 2, UMEC 125 mu g plus VI 25 mu g: 0.074 L [0.025 to 0.123; p=0.0031]; study 2, UMEC 62.5 mu g plus VI 25 mu g: 0.060 L [0.010 to 0.109; nominal p=0.0182]). Both doses of UMEC plus VI also improved trough FEV1 compared with VI monotherapy (UMEC 125 mu g plus VI 25 mu g: 0.088 L [0.036 to 0.140; p=0.0010]; UMEC 62.5 mu g plus VI 25 mu g: 0.090 L [0.039 to 0.142; p=0.0006], but not compared with UMEC 125 mu g monotherapy (UMEC 125 mu g plus VI 25 mu g: 0.037 L [-0.012 to 0.087; p=0.14]; UMEC 62.5 mu g plus VI 25 mu g: 0.022 L [-0.027 to 0.072; p=0.38]). All treatments produced improvements in dyspnoea and health-related quality of life; we noted no significant differences in symptoms, health status, or risk of exacerbation between UMEC plus VI and TIO. The most common on-treatment, severe-intensity adverse event in both studies was acute exacerbation of COPD (1-4 [<1-2%] patients across treatment groups in study 1 and 1-6 [<1-3%] patients in study 2). We recorded five to 15 (2-7%) on-treatment serious adverse events across treatment groups in study 1, and nine to 22 (4-10%) in study 2. We noted no substantial changes from baseline in vital signs, clinical laboratory findings, or electrocardiography findings in any of the treatment groups.
   Interpretation Combination treatment with once-daily UMEC plus VI improved lung function compared with VI monotherapy and TIO monotherapy in patients with COPD. Overall our results suggest that the combination of UMEC plus VI could be beneficial for the treatment of moderate to very severe COPD.
C1 [Decramer, Marc] Univ Louvain, Div Resp, Univ Hosp, B-3000 Louvain, Belgium.
   [Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
   [Anzueto, Antonio] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
   [Kerwin, Edward] Clin Res Inst Southern Oregon, Medford, OR USA.
   [Kaelin, Thomas] Lowcountry Lung & Crit Care, Charleston, SC USA.
   [Richard, Nathalie; Harris, Stephanie; Church, Alison] GlaxoSmithKline, Resp & Immunoinflammat, Res Triangle Pk, NC USA.
   [Crater, Glenn] Aerocrine, Clin Dev, Morrisville, NC USA.
   [Tabberer, Maggie] GlaxoSmithKline, Uxbridge, Middx, England.
RP Decramer, M (reprint author), Univ Louvain, Div Resp, Univ Hosp, B-3000 Louvain, Belgium.
EM marc.decramer@uzleuven.be
OI Crater, Glenn/0000-0002-1159-1323
FU GlaxoSmithKline
FX The work presented here, including the conduct of the study, data
   analysis, and data interpretation, was supported by GlaxoSmithKline.
   Editorial assistance in the preparation of the report was provided by
   David Griffiths (Fishawack Indicia, Knutsford, UK) and was funded by
   GlaxoSmithKline.
NR 34
TC 88
Z9 90
U1 0
U2 14
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2213-2600
J9 LANCET RESP MED
JI Lancet Resp. Med.
PD JUN
PY 2014
VL 2
IS 6
BP 472
EP 486
DI 10.1016/S2213-2600(14)70065-7
PG 15
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA AI2WA
UT WOS:000336717900018
PM 24835833
ER

PT J
AU Gelernter, J
   Sherva, R
   Koesterer, R
   Almasy, L
   Zhao, H
   Kranzler, HR
   Farrer, L
AF Gelernter, J.
   Sherva, R.
   Koesterer, R.
   Almasy, L.
   Zhao, H.
   Kranzler, H. R.
   Farrer, L.
TI Genome-wide association study of cocaine dependence and related traits:
   FAM53B identified as a risk gene
SO MOLECULAR PSYCHIATRY
LA English
DT Article
DE cocaine dependence; cocaine-induced paranoia; European-American and
   African-American populations; GWAS; population genetics
ID POPULATION-BASED SAMPLE; INDUCED PSYCHOSIS; INDUCED PARANOIA; LINKAGE
   SCAN; ABUSE; ALCOHOLISM; TWINS
AB We report a genome-wide association study (GWAS) for cocaine dependence (CD) in three sets of African-and European-American subjects (AAs and EAs, respectively) to identify pathways, genes and alleles important in CD risk. The discovery GWAS data set (n=5697 subjects) was genotyped using the Illumina OmniQuad microarray (8 90 000 analyzed single-nucleotide polymorphisms (SNPs)). Additional genotypes were imputed based on the 1000 Genomes reference panel. Top-ranked findings were evaluated by incorporating information from publicly available GWAS data from 4063 subjects. Then, the most significant GWAS SNPs were genotyped in 2549 independent subjects. We observed one genome-wide-significant (GWS) result: rs2629540 at the FAM53B (` family with sequence similarity 53, member B') locus. This was supported in both AAs and EAs; P-value (meta-analysis of all samples) 4.28 x 10(-8). The gene maps to the same chromosomal region as the maximum peak we observed in a previous linkage study. NCOR2 (nuclear receptor corepressor 2) SNP rs150954431 was associated with P = 1.19 x 10(-9) in the EA discovery sample. SNP rs2456778, which maps to CDK1 ('cyclin-dependent kinase 1'), was associated with cocaine-induced paranoia in AAs in the discovery sample only (P-4.68 x 10(-8)). This is the first study to identify risk variants for CD using GWAS. Our results implicate novel risk loci and provide insights into potential therapeutic and prevention strategies.
C1 [Gelernter, J.] Yale Univ, Sch Med, Dept Psychiat, Div Human Genet, New Haven, CT USA.
   [Gelernter, J.] VA CT Healthcare Ctr, Dept Psychiat, West Haven, CT USA.
   [Gelernter, J.; Zhao, H.] Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA.
   [Gelernter, J.] Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT USA.
   [Sherva, R.; Koesterer, R.; Farrer, L.] Boston Univ, Sch Med, Dept Med Biomed Genet, Boston, MA 02118 USA.
   [Almasy, L.] Texas Biomed Res Inst, Dept Genet, San Antonio, TX USA.
   [Zhao, H.] Yale Univ, Dept Biostat, Sch Publ Hlth, New Haven, CT USA.
   [Kranzler, H. R.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Kranzler, H. R.] Philadelphia VA Med Ctr, Dept Psychiat, Philadelphia, PA USA.
   [Farrer, L.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA.
   [Farrer, L.] Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA.
   [Farrer, L.] Boston Univ, Sch Med, Dept Genet & Genom, Boston, MA 02118 USA.
   [Farrer, L.] Boston Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Boston, MA 02215 USA.
RP Gelernter, J (reprint author), Yale Univ, Sch Med, Dept Psychiat, Div Human Genet, VA CT 116A2,950 Campbell Ave, West Haven, CT 06516 USA.
EM joel.gelernter@yale.edu
OI Farrer, Lindsay/0000-0001-5533-4225
FU National Institutes of Health [N01-HG-65403, RC2 DA028909, R01 DA12690,
   R01 DA12849, R01 DA18432, R01 AA11330, R01 AA017535]; VA Connecticut and
   Philadelphia VA MIRECCs; Study of Addiction: Genetics and Environment
   (SAGE) was provided through the NIH Genes, Environment and Health
   Initiative [U01 HG004422]; Collaborative Study on the Genetics of
   Alcoholism (COGA) [U10 AA008401]; Collaborative Genetic Study of
   Nicotine Dependence (COGEND) [P01 CA089392]; Family Study of Cocaine
   Dependence (FSCD) [R01 DA013423]; Johns Hopkins University Center for
   Inherited Disease Research; NIH GEI [U01HG004438]; National Institute on
   Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; NIH
   contract 'High throughput genotyping for studying the genetic
   contributions to human disease' [HHSN268200782096C]
FX We appreciate the work in recruitment and assessment provided at McLean
   Hospital by Roger Weiss at the Medical University of South Carolina by
   Kathleen Brady and Raymond Anton and at the University of Pennsylvania
   by David Oslin. Genotyping services for a part of our GWAS study were
   provided by the Center for Inherited Disease Research (CIDR) and Yale
   University (Center for Genome Analysis). CIDR is fully funded through a
   federal contract from the National Institutes of Health to The Johns
   Hopkins University (contract number N01-HG-65403). We are grateful to
   Ann Marie Lacobelle, Michelle Cucinelli, Christa Robinson and Greg
   Dalton-Kay for their excellent technical assistance, to the SSADDA
   interviewers, led by Yari Nunez and Michelle Slivinsky, who devoted
   substantial time and effort to phenotype the study sample and to John
   Farrell for database management assistance. This study was supported by
   National Institutes of Health Grants RC2 DA028909, R01 DA12690, R01
   DA12849, R01 DA18432, R01 AA11330, R01 AA017535 and the VA Connecticut
   and Philadelphia VA MIRECCs. The publicly available data sets used for
   the analyses described in this manuscript were obtained from dbGaP at
   http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs0
   00092.v1.p1 through dbGaP accession number phs000092.v1.p. Funding
   support for the Study of Addiction: Genetics and Environment (SAGE) was
   provided through the NIH Genes, Environment and Health Initiative (GEI;
   U01 HG004422). SAGE is one of the genome-wide association studies funded
   as part of the Gene Environment Association Studies (GENEVA) under GEI.
   Assistance with phenotype harmonization and genotype cleaning, as well
   as with general study coordination, was provided by the GENEVA
   Coordinating Center (U01 HG004446). Assistance with data cleaning was
   provided by the National Center for Biotechnology Information. Support
   for collection of data sets and samples was provided by the
   Collaborative Study on the Genetics of Alcoholism (COGA; U10 AA008401),
   the Collaborative Genetic Study of Nicotine Dependence (COGEND; P01
   CA089392) and the Family Study of Cocaine Dependence (FSCD; R01
   DA013423). Funding support for genotyping, which was performed at the
   Johns Hopkins University Center for Inherited Disease Research, was
   provided by the NIH GEI (U01HG004438), the National Institute on Alcohol
   Abuse and Alcoholism, the National Institute on Drug Abuse and the NIH
   contract 'High throughput genotyping for studying the genetic
   contributions to human disease' (HHSN268200782096C).
NR 31
TC 29
Z9 29
U1 1
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1359-4184
EI 1476-5578
J9 MOL PSYCHIATR
JI Mol. Psychiatr.
PD JUN
PY 2014
VL 19
IS 6
BP 717
EP 723
DI 10.1038/mp.2013.99
PG 7
WC Biochemistry & Molecular Biology; Neurosciences; Psychiatry
SC Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry
GA AI2BZ
UT WOS:000336663100014
PM 23958962
ER

PT J
AU Bludau, S
   Eickhoff, SB
   Mohlberg, H
   Caspers, S
   Laird, AR
   Fox, PT
   Schleicher, A
   Zilles, K
   Amunts, K
AF Bludau, S.
   Eickhoff, S. B.
   Mohlberg, H.
   Caspers, S.
   Laird, A. R.
   Fox, P. T.
   Schleicher, A.
   Zilles, K.
   Amunts, K.
TI Cytoarchitecture, probability maps and functions of the human frontal
   pole
SO NEUROIMAGE
LA English
DT Article
ID ROSTRAL PREFRONTAL CORTEX; HUMAN ORBITOFRONTAL CORTEX; HUMAN
   CEREBRAL-CORTEX; PRIMARY SOMATOSENSORY CORTEX; INTERINDIVIDUAL
   VARIABILITY; STEREOTAXIC SPACE; MICROSTRUCTURAL PARCELLATION;
   INTERSUBJECT VARIABILITY; QUANTITATIVE APPROACH; PROSPECTIVE MEMORY
AB The frontal pole has more expanded than any other part in the human brain as compared to our ancestors. It plays an important role for specifically human behavior and cognitive abilities, e.g. action selection (Kovach et al., 2012). Evidence about divergent functions of its medial and lateral part has been provided, both in the healthy brain and in psychiatric disorders. The anatomical correlates of such functional segregation, however, are still unknown due to a lack of stereotaxic, microstructural maps obtained in a representative sample of brains. Here we show that the human frontopolar cortex consists of two cytoarchitectonically and functionally distinct areas: lateral frontopolar area 1 (Fp1) and medial frontopolar area 2 (Fp2). Based on observer-independent mapping in serial, cell-body stained sections of 10 brains, three-dimensional, probabilistic maps of areas Fp1 and Fp2 were created. They show, for each position of the reference space, the probability with which each area was found in a particular voxel. Applying these maps as seed regions for a meta-analysis revealed that Fp1 and Fp2 differentially contribute to functional networks: Fp1 was involved in cognition, working memory and perception, whereas Fp2 was part of brain networks underlying affective processing and social cognition. The present study thus disclosed cortical correlates of a functional segregation of the human frontopolar cortex. The probabilistic maps provide a sound anatomical basis for interpreting neuroimaging data in the living human brain, and open new perspectives for analyzing structure-function relationships in the prefrontal cortex. The new data will also serve as a starting point for further comparative studies between human and non-human primate brains. This allows finding similarities and differences in the organizational principles of the frontal lobe during evolution as neurobiological basis for our behavior and cognitive abilities. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Bludau, S.; Eickhoff, S. B.; Mohlberg, H.; Caspers, S.; Schleicher, A.; Zilles, K.; Amunts, K.] Res Ctr Julich, Inst Neurosci & Med INM 1, D-52425 Julich, Germany.
   [Eickhoff, S. B.] Univ Dusseldorf, Inst Clin Neurosci & Med Psychol, D-40001 Dusseldorf, Germany.
   [Laird, A. R.; Fox, P. T.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA.
   [Laird, A. R.; Fox, P. T.] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA.
   [Fox, P. T.] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
   [Zilles, K.] RVVTH Univ Aachen, Dept Psychiat Psychotherapy & Psychosomat, D-52074 Aachen, Germany.
   [Zilles, K.; Amunts, K.] JARA, Juelich Aachen Res Alliance, Julich, Germany.
   [Amunts, K.] Univ Dusseldorf, C&O Vogt Inst Brain Res, D-40001 Dusseldorf, Germany.
   [Laird, A. R.] Florida Int Univ, Dept Phys, Miami, FL 33199 USA.
RP Bludau, S (reprint author), Res Ctr Julich, Inst Neurosci & Med INM 1, D-52425 Julich, Germany.
EM s.bludau@fz-juelich.de
RI Zilles, Karl/J-9704-2013; Fox, Peter/B-4725-2010; Caspers,
   Svenja/H-9346-2013; Eickhoff, Simon/K-2061-2013; Amunts,
   Katrin/I-3470-2013
OI Zilles, Karl/0000-0001-9296-9959; Fox, Peter/0000-0002-0465-2028;
   Caspers, Svenja/0000-0001-5083-4669; Eickhoff,
   Simon/0000-0001-6363-2759; Bludau, Sebastian/0000-0001-6173-9050;
   Zilles, Karl/0000-0002-4705-4175; Amunts, Katrin/0000-0001-5828-0867
FU BMBF [01GW0612]; Helmholtz Alliance for Mental Health in an Aging
   Society (HeIMA); Helmholtz Alliance on Systems Biology (Human Brain
   Model)
FX This study was supported by the BMBF (01GW0612, K.A.). Further funding
   was granted by the Helmholtz Alliance for Mental Health in an Aging
   Society (HeIMA; KA., K.Z.) and by the Helmholtz Alliance on Systems
   Biology (Human Brain Model; K.Z., S.B.E.). The authors thank Katerina
   Semendeferi for critical review of the manuscript and for helpful
   discussions.
NR 104
TC 44
Z9 44
U1 4
U2 20
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
EI 1095-9572
J9 NEUROIMAGE
JI Neuroimage
PD JUN
PY 2014
VL 93
SI SI
BP 260
EP 275
DI 10.1016/j.neuroimage.2013.05.052
PN 2
PG 16
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
   Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA AI0RG
UT WOS:000336556500012
PM 23702412
ER

PT J
AU Skaperdas, E
   Tuepker, A
   Nicolaidis, C
   Robb, JK
   Kansagara, D
   Hickam, DH
AF Skaperdas, Eleni
   Tuepker, Anais
   Nicolaidis, Christina
   Robb, Jessica K.
   Kansagara, Devan
   Hickam, David H.
TI Congestive heart failure self-management among US veterans: The role of
   personal and professional advocates
SO PATIENT EDUCATION AND COUNSELING
LA English
DT Article
DE Primary care redesign; Self-management; Qualitative research; Heart
   failure; Veterans; US
ID CONTROLLED-TRIAL; CARE MANAGEMENT; EXPERIENCES; ADHERENCE; PATIENT;
   PROGRAM; RISK
AB Objective: Understand patients' experiences with primary care services for congestive heart failure (CHF) and explore the relationship between health services and self-management.
   Methods: We conducted semi-structured interviews with thirty-nine patients with CHF receiving care at one Veterans Affairs Medical Center (VA). We analyzed data using thematic content analysis.
   Results: Participants acknowledged the importance of ongoing engagement in the plan of care for CHF. They attributed success in this effort to be greatly influenced by personal advocates. The advocates included both members of the healthcare team with whom they had a continuity relationship and friends or family members who assisted on a daily basis. Participants also identified psychological symptoms as a major barrier to carrying out self-care.
   Conclusion: Patients identify relationships with health care workers, help from family and friends, and mental health problems as major influences on the ability to manage their CHF.
   Practice implications: Efforts to optimize CHF self-management should attend to health system and psychosocial barriers to care. Published by Elsevier Ireland Ltd.
C1 [Skaperdas, Eleni; Tuepker, Anais; Robb, Jessica K.; Kansagara, Devan; Hickam, David H.] Vet Hlth Adm, Portland VA Med Ctr Hlth Serv Res & Dev, VISN PACT Demonstrat Lab 20, Portland, OR USA.
   [Tuepker, Anais; Kansagara, Devan] Oregon Hlth & Sci Univ, Dept Med, Div Gen Internal Med & Geriatr, Portland, OR 97201 USA.
   [Nicolaidis, Christina] Portland State Univ, Sch Social Work, Portland, OR 97207 USA.
   [Nicolaidis, Christina] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA.
   [Hickam, David H.] Patient Centered Outcomes Res Inst, Washington, DC USA.
RP Skaperdas, E (reprint author), Portland VA Med Ctr, Mailcode R&D63,POB 1034, Portland, OR 97207 USA.
EM eleni.skaperdas@va.gov
FU VA Office of Patient Care
FX We thank the Veterans, their family members, and close friends for
   sharing their experiences, and gratefully acknowledge the contribution
   of all members of the VISN 20 PACT Demonstration Lab. Funding for the
   PACT Demonstration Laboratory initiative is provided by the VA Office of
   Patient Care.
NR 28
TC 3
Z9 3
U1 1
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0738-3991
J9 PATIENT EDUC COUNS
JI Patient Educ. Couns.
PD JUN
PY 2014
VL 95
IS 3
BP 371
EP 377
DI 10.1016/j.pec.2014.03.002
PG 7
WC Public, Environmental & Occupational Health; Social Sciences,
   Interdisciplinary
SC Public, Environmental & Occupational Health; Social Sciences - Other
   Topics
GA AI3QD
UT WOS:000336776100011
PM 24666772
ER

PT J
AU Koenig, CJ
   Maguen, S
   Monroy, JD
   Mayott, L
   Seal, KH
AF Koenig, Christopher J.
   Maguen, Shira
   Monroy, Jose D.
   Mayott, Lindsay
   Seal, Karen H.
TI Facilitating culture-centered communication between health care
   providers and veterans transitioning from military deployment to
   civilian life
SO PATIENT EDUCATION AND COUNSELING
LA English
DT Article
DE Patient-centered care; Health communication; Culture; Post-deployment
   health; Readjustment experience; Military veterans; USA
ID POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; AFGHANISTAN
   VETERANS; MENTAL-HEALTH; DISCOURSE ANALYSIS; COMBAT VETERANS; IRAQ;
   HOME; BARRIERS; FAMILY
AB Objective: To describe returning veterans' transition experience from military to civilian life and to educate health care providers about culture-centered communication that promotes readjustment to civilian life.
   Methods: Qualitative, in-depth, semi-structured interviews with 17 male and 14 female Iraq and Afghanistan veterans were audio recorded, transcribed verbatim, and analyzed using Grounded Practical Theory.
   Results: Veterans described disorientation when returning to civilian life after deployment. Veterans' experiences resulted from an underlying tension between military and civilian identities consistent with reverse culture shock. Participants described challenges and strategies for managing readjustment stress across three domains: intrapersonal, professional/educational, and interpersonal.
   Conclusions: To provide patient-centered care to returning Iraq and Afghanistan veterans, health care providers must be attuned to medical, psychological, and social challenges of the readjustment experience, including reverse culture shock. Cultufe-centered communication may help veterans integrate positive aspects of military and civilian identities, which may promote full reintegration into civilian life.
   Practice implications: Health care providers may promote culture-centered interactions by asking veterans to reflect about their readjustment experiences. By actively eliciting challenges and helping veterans' to identify possible solutions, health care providers may help veterans integrate military and civilian identities through an increased therapeutic alliance and social support throughout the readjustment process. Published by Elsevier Ireland Ltd.
C1 [Koenig, Christopher J.; Maguen, Shira; Monroy, Jose D.; Mayott, Lindsay; Seal, Karen H.] San Francisco Vet Adm Med Ctr, San Francisco, CA 94121 USA.
   [Koenig, Christopher J.] Univ Calif San Francisco, Philip R Lee Inst Hlth Policy Studies, San Francisco, CA 94143 USA.
   [Maguen, Shira; Seal, Karen H.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
   [Koenig, Christopher J.; Mayott, Lindsay; Seal, Karen H.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
   [Monroy, Jose D.] San Francisco State Univ, Dept Psychol, San Francisco, CA 94132 USA.
RP Koenig, CJ (reprint author), San Francisco Vet Adm Med Ctr, Dept Med, 4150 Clement St,111-A1, San Francisco, CA 94121 USA.
EM Christopher.Koenig@va.gov
OI Koenig, Christopher J./0000-0003-0884-4120
FU Department of Defense [W81XWH-08-2-0106]
FX Department of Defense award W81XWH-08-2-0106 funded this study. The
   funders had no role in the design, data analysis, writing or approval of
   the manuscript.
NR 66
TC 5
Z9 5
U1 6
U2 32
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0738-3991
J9 PATIENT EDUC COUNS
JI Patient Educ. Couns.
PD JUN
PY 2014
VL 95
IS 3
BP 414
EP 420
DI 10.1016/j.pec.2014.03.016
PG 7
WC Public, Environmental & Occupational Health; Social Sciences,
   Interdisciplinary
SC Public, Environmental & Occupational Health; Social Sciences - Other
   Topics
GA AI3QD
UT WOS:000336776100017
PM 24742536
ER

PT J
AU Clarke, TK
   Crist, RC
   Ang, A
   Ambrose-Lanci, LM
   Lohoff, FW
   Saxon, AJ
   Ling, W
   Hillhouse, MP
   Bruce, RD
   Woody, G
   Berrettini, WH
AF Clarke, T-K
   Crist, R. C.
   Ang, A.
   Ambrose-Lanci, L. M.
   Lohoff, F. W.
   Saxon, A. J.
   Ling, W.
   Hillhouse, M. P.
   Bruce, R. D.
   Woody, G.
   Berrettini, W. H.
TI Genetic variation in OPRD1 and the response to treatment for opioid
   dependence with buprenorphine in European-American females
SO PHARMACOGENOMICS JOURNAL
LA English
DT Article
DE buprenorphine; females; methadone; opioids; OPRD1; pharmacogenetics
ID METHADONE-MAINTENANCE TREATMENT; RECEPTOR GENE; POSTOPERATIVE PAIN;
   GENDER-DIFFERENCES; OPIATE DEPENDENCE; RANDOMIZED-TRIAL;
   DRUG-DEPENDENCE; ABUSE TREATMENT; SEX-DIFFERENCES; ANALGESIA
AB Two commonly prescribed treatments for opioid addiction are methadone and buprenorphine. Although these drugs show some efficacy in treating opioid dependence, treatment response varies among individuals. It is likely that genetic factors have a role in determining treatment outcome. This study analyses the pharmacogenetic association of six polymorphisms in OPRD1, the gene encoding the delta-opioid receptor, on treatment outcome in 582 opioid addicted European Americans randomized to either methadone or buprenorphine/naloxone (Suboxone) over the course of a 24-week open-label clinical trial. Treatment outcome was assessed as the number of missed or opioid-positive urine drug screens over the 24 weeks. In the total sample, no single-nucleotide polymorphisms (SNPs) in OPRD1 were significantly associated with treatment outcome in either treatment arm. However, sex-specific analyses revealed two intronic SNPs (rs581111 and rs529520) that predicted treatment outcome in females treated with buprenorphine. Females with the AA or AG genotypes at rs581111 had significantly worse outcomes than those with the GG genotype when treated with buprenorphine (P=0.03, relative risk (RR) = 1.67, 95% confidence interval (CI) 1.06-2.1). For rs529520, females with the AA genotype had a significantly worse outcome than those with the CC genotype when (P=0.006, RR =2.15, 95% CI 1.3-2.29). No significant associations were detected in males. These findings suggest that rs581111 and rs52920 may be usefulwhen considering treatment options for female opioid addicts, however, confirmation in an independent sample is warranted.
C1 [Clarke, T-K; Crist, R. C.; Ambrose-Lanci, L. M.; Lohoff, F. W.; Berrettini, W. H.] Univ Penn, Sch Med, Translat Res Labs, Dept Psychiat,Ctr Neurobiol & Behav, Philadelphia, PA 19104 USA.
   [Ang, A.; Ling, W.; Hillhouse, M. P.] Univ Calif Los Angeles, Integrated Subst Abuse Programs, Los Angeles, CA USA.
   [Saxon, A. J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
   [Bruce, R. D.] Yale Univ, Sch Med, New Haven, CT USA.
   [Woody, G.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Woody, G.] Treatment Res Inst, Philadelphia, PA USA.
RP Clarke, TK (reprint author), Univ Penn, Sch Med, Translat Res Labs, Dept Psychiat,Ctr Neurobiol & Behav, 125 South 31st St,Room 2109, Philadelphia, PA 19104 USA.
EM ctoni@mail.med.upenn.edu
RI Lohoff, Falk/M-7951-2016
OI Clarke, Toni-Kim/0000-0002-7745-6351
FU National Institute on Drug Abuse through the Clinical Trials Network
   (CTN); Pacific Northwest Node [U10 DA01714]; Oregon Hawaii Node [U10
   DA013036]; California/Arizona Node [U10 DA015815]; New England Node [U10
   DA13038]; Delaware Valley Node [U10 DA13043]; Pacific Region Node [U10
   DA13045]; New York Node [U10 DA013046]; Center for Neurobiology and
   Behavior, Department of Psychiatry, University of Pennsylvania
   [T32MH014654]; NIDA [P20DA025995, P60DA05186]; Veterans Administration
   Mental Illness Research Education; Clinical Center MIRECC
FX Main START study funding came from the National Institute on Drug Abuse
   through the Clinical Trials Network (CTN) through a series of grants
   provided to each participating node: the Pacific Northwest Node (U10
   DA01714), the Oregon Hawaii Node (U10 DA013036), the California/Arizona
   Node (U10 DA015815), the New England Node (U10 DA13038), the Delaware
   Valley Node (U10 DA13043), the Pacific Region Node (U10 DA13045) and the
   New York Node (U10 DA013046). Dr Berrettini was also supported by the
   Delaware Valley Node (U10 DA13043). This work was supported by the
   Center for Neurobiology and Behavior, Department of Psychiatry,
   University of Pennsylvania, Training Program in Neuropsychopharmacology
   (T32MH014654, PI: I Lucki), NIDA grant P20DA025995 (PI: W Berrettini),
   the Veterans Administration Mental Illness Research Education and
   Clinical Center MIRECC) at the Philadelphia VAMC (David Oslin, MD, PI)
   and NIDA grant P60DA05186 (PI: Charles O'Brien).
NR 51
TC 8
Z9 9
U1 1
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1470-269X
EI 1473-1150
J9 PHARMACOGENOMICS J
JI Pharmacogenomics J.
PD JUN
PY 2014
VL 14
IS 3
BP 303
EP 308
DI 10.1038/tpj.2013.30
PG 6
WC Genetics & Heredity; Pharmacology & Pharmacy
SC Genetics & Heredity; Pharmacology & Pharmacy
GA AI0SK
UT WOS:000336560000015
PM 24126707
ER

PT J
AU Reynolds, CF
   Thomas, SB
   Morse, JQ
   Anderson, SJ
   Albert, S
   Dew, MA
   Begley, A
   Karp, JF
   Gildengers, A
   Butters, MA
   Stack, JA
   Kasckow, J
   Miller, MD
   Quinn, SC
AF Reynolds, Charles F., III
   Thomas, Stephen B.
   Morse, Jennifer Q.
   Anderson, Stewart J.
   Albert, Steven
   Dew, Mary Amanda
   Begley, Amy
   Karp, Jordan F.
   Gildengers, Ariel
   Butters, Meryl A.
   Stack, Jacqueline A.
   Kasckow, John
   Miller, Mark D.
   Quinn, Sandra C.
TI Early Intervention to Preempt Major Depression Among Older Black and
   White Adults
SO PSYCHIATRIC SERVICES
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; LATE-LIFE DEPRESSION; PROBLEM-SOLVING
   THERAPY; PRIMARY-CARE PATIENTS; PREVENTING DEPRESSION; GERIATRIC
   DEPRESSION; RISK-FACTORS; METAANALYSIS; INVENTORY; SYMPTOMS
AB Objective: The study objective was to assess the efficacy of problem-solving therapy for primary care (PST-PC) for preventing episodes of major depression and mitigating depressive symptoms of older black and white adults. The comparison group received dietary coaching. Methods: A total of 247 participants (90 blacks, 154 whites, and three Asians) with subsyndromal depressive symptoms were recruited into a randomized depression prevention trial that compared effects of individually delivered PST-PC and dietary coaching on time to major depressive episode and level of depressive symptoms (Beck Depression Inventory) over two years. Cumulative intervention time averaged 5.5-6.0 hours in each study arm. Results: The two groups did not differ significantly in time to major depressive episodes, and incidence of such episodes was low (blacks, N=8, 9%; whites, N=13, 8%), compared with published rates of 20%-25% over one year among persons with subsyndromal symptoms and receiving care as usual. Participants also showed a mean decrease of 4 points in depressive symptoms, sustained over two years. Despite greater burden of depression risk factors among blacks, no significant differences from whites were found in the primary outcome. Conclusions: Both PST-PC and dietary coaching are potentially effective in protecting older black and white adults with subsyndromal depressive symptoms from developing episodes of major depression over two years. Absent a control for concurrent usual care, this conclusion is preliminary. If confirmed, both interventions hold promise as scalable, safe, nonstigmatizing interventions for delaying or preventing episodes of major depression in the nation's increasingly diverse older population.
C1 [Reynolds, Charles F., III; Morse, Jennifer Q.; Dew, Mary Amanda; Begley, Amy; Karp, Jordan F.; Gildengers, Ariel; Butters, Meryl A.; Stack, Jacqueline A.; Kasckow, John; Miller, Mark D.] Univ Pittsburgh, Western Psychiat Inst & Clin, Dept Psychiat, Sch Med, Pittsburgh, PA 15213 USA.
   [Kasckow, John] Vet Affairs Pittsburgh Hlth Care Syst, Dept Behav Hlth, Pittsburgh, PA USA.
   [Thomas, Stephen B.; Quinn, Sandra C.] Univ Maryland, Ctr Hlth Equ, College Pk, MD 20742 USA.
   [Anderson, Stewart J.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA.
   [Albert, Steven] Univ Pittsburgh, Dept Behav & Community Hlth Sci, Pittsburgh, PA USA.
RP Reynolds, CF (reprint author), Univ Pittsburgh, Western Psychiat Inst & Clin, Dept Psychiat, Sch Med, Pittsburgh, PA 15213 USA.
EM reynoldscf@upmc.edu
OI Anderson, Stewart/0000-0001-8948-0650; Albert,
   Steven/0000-0001-6786-9956
FU National Institute of Mental Health [P60 MD000207, P30 MH090333,
   UL1RR024153, UL1TR000005]; National Institutes of Health; University of
   Pittsburgh Medical Center Endowment in Geriatric Psychiatry;
   Commonwealth of Pennsylvania; Bristol-Myers Squibb; Forest; Pfizer;
   Lilly; Robert Bosch Health Care, Inc.
FX This work was supported by grants P60 MD000207, P30 MH090333,
   UL1RR024153, and UL1TR000005 from the National Institute of Mental
   Health and National Institutes of Health, by the University of
   Pittsburgh Medical Center Endowment in Geriatric Psychiatry, and by the
   Commonwealth of Pennsylvania. This work is registered on
   ClinicalTrials.gov as NCT00326677.; Dr. Reynolds reports receiving
   pharmaceutical support for National Institutes of Health sponsored
   research studies from Bristol-Myers Squibb, Forest, Pfizer, and Lilly.
   He is the co-inventor of Psychometric Analysis of the Pittsburgh Sleep
   Quality Index (licensed intellectual property PRO10050447). Dr. Karp
   reports receipt of medication supplies from Pfizer and Reckitt Benckiser
   for investigator-initiated studies. Dr. Butters has received
   remuneration from GlaxoSmithKline for performing neuropsychological
   services. Dr. Kasckow has received assistance from Robert Bosch Health
   Care, Inc., for software-related costs for a research project. The other
   authors report no competing interests.
NR 37
TC 14
Z9 14
U1 1
U2 5
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1075-2730
EI 1557-9700
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD JUN
PY 2014
VL 65
IS 6
BP 765
EP 773
DI 10.1176/appi.ps.201300216
PG 9
WC Health Policy & Services; Public, Environmental & Occupational Health;
   Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health; Psychiatry
GA AI3RJ
UT WOS:000336779300009
PM 24632760
ER

PT J
AU El-Serag, HB
   Sweet, S
   Winchester, CC
   Dent, J
AF El-Serag, Hashem B.
   Sweet, Stephen
   Winchester, Christopher C.
   Dent, John
TI Update on the epidemiology of gastro-oesophageal reflux disease: a
   systematic review
SO GUT
LA English
DT Article
ID IRRITABLE-BOWEL-SYNDROME; QUALITY-OF-LIFE; RISK-FACTORS; CLINICAL
   SPECTRUM; GENERAL-POPULATION; BARRETTS-ESOPHAGUS; ADULT-POPULATION;
   PRIMARY-CARE; PREVALENCE; SYMPTOMS
AB Objective To update the findings of the 2005 systematic review of population-based studies assessing the epidemiology of gastro-oesophageal reflux disease (GERD).
   Design PubMed and Embase were screened for new references using the original search strings. Studies were required to be population-based, to include >= 200 individuals, to have response rates >= 50% and recall periods < 12 months. GERD was defined as heartburn and/or regurgitation on at least 1 day a week, or according to the Montreal definition, or diagnosed by a clinician. Temporal and geographic trends in disease prevalence were examined using a Poisson regression model.
   Results 16 studies of GERD epidemiology published since the original review were found to be suitable for inclusion (15 reporting prevalence and one reporting incidence), and were added to the 13 prevalence and two incidence studies found previously. The range of GERD prevalence estimates was 18.1%-27.8% in North America, 8.8%-25.9% in Europe, 2.5%-7.8% in East Asia, 8.7%-33.1% in the Middle East, 11.6% in Australia and 23.0% in South America. Incidence per 1000 person-years was approximately 5 in the overall UK and US populations, and 0.84 in paediatric patients aged 117 years in the UK. Evidence suggests an increase in GERD prevalence since 1995 (p<0.0001), particularly in North America and East Asia.
   Conclusions GERD is prevalent worldwide, and disease burden may be increasing. Prevalence estimates show considerable geographic variation, but only East Asia shows estimates consistently lower than 10%.
C1 [El-Serag, Hashem B.] Houston Vet Affairs Med Ctr 152, Sect Gastroenterol & Hepatol, Houston, TX USA.
   [Sweet, Stephen; Winchester, Christopher C.] Oxford PharmaGenesis, Res Evaluat Unit, Oxford, England.
   [Winchester, Christopher C.] Univ Aberdeen, Ctr Acad Primary Care, Aberdeen, Scotland.
   [Dent, John] Royal Adelaide Hosp, Dept Gastroenterol Hepatol & Gen Med, Adelaide, SA 5000, Australia.
RP El-Serag, HB (reprint author), Houston VA Med Ctr, Sect Gastroenterol & Hepatol, 2002 Holcombe Blvd 152, Houston, TX 77030 USA.
EM hasheme@bcm.edu
OI Winchester, Christopher/0000-0003-3267-3990
FU Texas Digestive Disease Center [NIH DK58338, NIDDK K24-04-107]; Houston
   VA Health Services R&D Center of Excellence [HFP90-020]; AstraZeneca
   R&D, Molndal, Sweden
FX This work was supported in part by Texas Digestive Disease Center grants
   NIH DK58338 and NIDDK K24-04-107 to Dr El-Serag and by the Houston VA
   Health Services R&D Center of Excellence (HFP90-020). The views
   expressed in this article are those of the author(s) and do not
   necessarily represent the views of the Department of Veterans Affairs.
   Stephen Sweet and Christopher C Winchester are employees of Oxford
   PharmaGenesis, which received funding from AstraZeneca R&D, Molndal,
   Sweden for its role in the preparation of this systematic review.
NR 49
TC 157
Z9 172
U1 1
U2 22
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0017-5749
EI 1468-3288
J9 GUT
JI Gut
PD JUN
PY 2014
VL 63
IS 6
BP 871
EP 880
DI 10.1136/gutjnl-2012-304269
PG 10
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AG4AB
UT WOS:000335360000006
PM 23853213
ER

PT J
AU Martin, JT
   Milby, AH
   Chiaro, JA
   Kim, DH
   Hebela, NM
   Smith, LJ
   Elliott, DM
   Mauck, RL
AF Martin, John T.
   Milby, Andrew H.
   Chiaro, Joseph A.
   Kim, Dong Hwa
   Hebela, Nader M.
   Smith, Lachlan J.
   Elliott, Dawn M.
   Mauck, Robert L.
TI Translation of an engineered nanofibrous disc-like angle-ply structure
   for intervertebral disc replacement in a small animal model
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Intervertebral disc; Tissue engineering; Electrospinning; Surgical
   model; External fixation
ID HUMAN LUMBAR DISC; LOW-BACK-PAIN; ANNULUS FIBROSUS; BIOMECHANICAL
   FUNCTION; DYNAMIC COMPRESSION; LOADING IMPROVES; NUCLEUS PULPOSUS;
   ANULUS FIBROSUS; NEEDLE PUNCTURE; SCAFFOLDS
AB Intervertebral disc degeneration has been implicated in the etiology of low back pain; however, the current surgical strategies for treating symptomatic disc disease are limited. A variety of materials have been developed to replace disc components, including the nucleus pulposus (NP), the annulus fibrosus (AF) and their combination into disc-like engineered constructs. We have previously shown that layers of electrospun poly(epsilon-caprolactone) scaffold, mimicking the hierarchical organization of the native AF, can achieve functional parity with native tissue. Likewise, we have combined these structures with cell-seeded hydrogels (as an NP replacement) to form disc-like angle-ply structures (DAPS). The objective of this study was to develop a model for the evaluation of DAPS in vivo. Through a series of studies, we developed a surgical approach to replace the rat caudal disc with an acellular DAPS and then stabilized the motion segment via external fixation. We then optimized cell infiltration into DAPS by including sacrificial poly(ethylene oxide) layers interspersed throughout the angle-ply structure. Our findings illustrate that DAPS are stable in the caudal spine, are infiltrated by cells from the pen-implant space and that infiltration is expedited by providing additional routes for cell migration. These findings establish a new in vivo platform in which to evaluate and optimize the design of functional disc replacements. (C) 2014 Acts Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Martin, John T.; Milby, Andrew H.; Chiaro, Joseph A.; Kim, Dong Hwa; Hebela, Nader M.; Smith, Lachlan J.; Mauck, Robert L.] Univ Penn, Dept Orthopaed Surg, McKay Orthopaed Res Lab, Philadelphia, PA 19104 USA.
   [Martin, John T.; Mauck, Robert L.] Univ Penn, Dept Mech Engn & Appl Mech, Philadelphia, PA 19104 USA.
   [Elliott, Dawn M.] Univ Delaware, Dept Biomed Engn, Newark, DE 19716 USA.
   [Mauck, Robert L.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA.
   [Martin, John T.; Milby, Andrew H.; Chiaro, Joseph A.; Hebela, Nader M.; Smith, Lachlan J.; Mauck, Robert L.] Philadelphia VA Med Ctr, Translat Musculoskeletal Res Ctr, Philadelphia, PA 19104 USA.
   [Smith, Lachlan J.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA.
RP Mauck, RL (reprint author), Univ Penn, Dept Orthopaed Surg, McKay Orthopaed Res Lab, 36th St & Hamilton Walk,424 Stemmler Hall, Philadelphia, PA 19104 USA.
EM lemauck@mail.med.upenn.edu
FU Department of Defense [OR090090]; Department of Veterans Affairs
   [I01RX000211]
FX We would like to thank the exceptional staff of the Philadelphia VA
   Medical Center Animal Research Facility: Debra Pawlowski, Jeffrey House
   and Pierina Deritis. In addition we would like to thank Deborah Gorth
   and Feini Qu (animal procedures), Alexei Adan (DAPS fabrication and
   histology), Subash Poudel (DAPS geometry and mechanical property
   measurements), Sophia Stylianos (fabrication of surgical equipment) and
   Dr. Thomas Schaer (sterilization facilities). This work was funded by
   the Department of Defense (Grant #OR090090) and the Department of
   Veterans Affairs (Grant # I01RX000211).
NR 49
TC 18
Z9 21
U1 5
U2 17
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742-7061
EI 1878-7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD JUN
PY 2014
VL 10
IS 6
BP 2473
EP 2481
DI 10.1016/j.actbio.2014.02.024
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA AH7WK
UT WOS:000336345900012
PM 24560621
ER

PT J
AU Scherzer, R
   Gandhi, M
   Estrella, MM
   Tien, PC
   Deeks, SG
   Grunfeld, C
   Peralta, CA
   Shlipak, MG
AF Scherzer, Rebecca
   Gandhi, Monica
   Estrella, Michelle M.
   Tien, Phyllis C.
   Deeks, Steven G.
   Grunfeld, Carl
   Peralta, Carmen A.
   Shlipak, Michael G.
TI A chronic kidney disease risk score to determine tenofovir safety in a
   prospective cohort of HIV-positive male veterans
SO AIDS
LA English
DT Article
DE chronic kidney disease; HIV; risk score; tenofovir
ID INFECTED PATIENTS; RANDOMIZED-TRIAL; RENAL-FAILURE; CYSTATIN-C; THERAPY;
   INDIVIDUALS; ALBUMINURIA; ASSOCIATION; DYSFUNCTION; EXPOSURE
AB Objective:Tenofovir disoproxil fumarate is a widely used antiretroviral for HIV infection that has been associated with an increased risk of chronic kidney disease (CKD). Our objective was to derive a scoring system to predict 5-year risk of developing CKD in HIV-infected individuals and to estimate difference in risk associated with tenofovir use.Design:We evaluated time to first occurrence of CKD (estimated glomerular filtration rate <60ml/min per 1.73m(2)) in 21590 HIV-infected men from the Veterans Health Administration initiating antiretroviral therapy from 1997 to 2010.Methods:We developed a point-based score using multivariable Cox regression models. Median follow-up was 6.3 years, during which 2059 CKD events occurred.Results:Dominant contributors to the CKD risk score were traditional kidney risk factors (age, glucose, SBP, hypertension, triglycerides, proteinuria); CD4(+) cell count was also a component, but not HIV RNA. The overall 5-year event rate was 7.7% in tenofovir users and 3.8% in nonusers [overall adjusted hazard ratio 2.0, 95% confidence interval (CI) 1.8-2.2]. There was a progressive increase in 5-year CKD risk, ranging from less than 1% (zero points) to 16% (9 points) in nonusers of tenofovir, and from 1.4 to 21.4% among tenofovir users. The estimated number-needed-to-harm (NNH) for tenofovir use ranged from 108 for those with zero points to 20 for persons with at least nine points. Among tenofovir users with at least 1 year exposure, NNH ranged from 68 (zero points) to five (9 points).Conclusion:The CKD risk score can be used to predict an HIV-infected individual's absolute risk of developing CKD over 5 years and may facilitate clinical decision-making around tenofovir use.
C1 [Scherzer, Rebecca; Gandhi, Monica; Tien, Phyllis C.; Deeks, Steven G.; Grunfeld, Carl; Peralta, Carmen A.; Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
   [Scherzer, Rebecca; Tien, Phyllis C.; Grunfeld, Carl; Peralta, Carmen A.; Shlipak, Michael G.] San Francisco VA Med Ctr, San Francisco, CA USA.
   [Gandhi, Monica; Deeks, Steven G.] San Francisco Gen Hosp, Posit Hlth Program, San Francisco, CA 94110 USA.
   [Estrella, Michelle M.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
RP Shlipak, MG (reprint author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
EM michael.shlipak@ucsf.edu
FU National Institutes of Health [K23DK080645-01A1, 1R03AG034871-01,
   K24AI069994, R01 DK066488-01, RO1 AI098472]; National Center for
   Research Resources [KL2 RR024130]; American Heart Association
   Established Investigator Award; VA Public Health Strategic Healthcare
   Group; Gilead; Merck; Bristol-Myers Squibb; Abbott; Gilead Sciences; EMD
   Serono; Theratechnologies
FX This work was supported by the National Institutes of Health
   [K23DK080645-01A1 (A. I. C.), 1R03AG034871-01 (A.I.C./M.G.S.),
   K24AI069994, R01 DK066488-01 (M.G.S./A.I.C.), RO1 AI098472 (M. G.)], the
   National Center for Research Resources [KL2 RR024130], the American
   Heart Association Established Investigator Award (M.G.S.) and the VA
   Public Health Strategic Healthcare Group, which were administered by the
   Northern California Institute for Research and Education, and with
   resources of the Veterans Affairs Medical Center, San Francisco,
   California. These funding sources had no involvement in the design or
   execution of this study. S. G. D. received grant support from Gilead and
   Merck, and honorarium for ad hoc consulting from Gilead and
   GlaxoSmithKline. C.G. has received prior research funding and/or
   honorarium from Merck, Bristol-Myers Squibb, Abbott, Gilead Sciences,
   EMD Serono and Theratechnologies.
NR 30
TC 9
Z9 9
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD JUN 1
PY 2014
VL 28
IS 9
BP 1289
EP 1295
DI 10.1097/QAD.0000000000000258
PG 7
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA AH2SX
UT WOS:000335972500006
PM 24922479
ER

PT J
AU Katz, IR
AF Katz, Ira R.
TI Mental Health Needs of Older Veterans
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Editorial Material
ID NATIONAL-HEALTH; RESILIENCE
C1 Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA.
RP Katz, IR (reprint author), Philadelphia VA Med Ctr, Univ & Woodland Aves, Philadelphia, PA 19104 USA.
EM Ira.Katz2@va.gov
NR 13
TC 1
Z9 1
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1064-7481
EI 1545-7214
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD JUN
PY 2014
VL 22
IS 6
BP 527
EP 530
DI 10.1016/j.jagp.2014.01.014
PG 4
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA AH4HG
UT WOS:000336087400001
PM 24821286
ER

PT J
AU Yeager, DE
   Magruder, KM
AF Yeager, Derik E.
   Magruder, Kathryn M.
TI PTSD Checklist Scoring Rules for Elderly Veterans Affairs Outpatients
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE PTSD; screening; elderly
ID POSTTRAUMATIC-STRESS-DISORDER; PREVALENCE
AB Objective: To assess the diagnostic performance of the PTSDChecklist (PCL) for three age groups (<50, 50-64, and >= 65 years). Methods: The PCL was compared with the Clinician Administered PTSD Scale, a gold standard for the diagnosis of post-traumatic stress disorder. Receiver operating characteristic curves and the corresponding area under the receiver operating characteristic curve (AUC) and measures of sensitivity and specificity were used to assess the performance of and to determine optimal cutscores for the PCL across the three groups. Analyses were based on 858 randomly selected primary care patients who participated in a study conducted at four Veterans Administration medical centers. Results: AUCs were high for all three age groups (87.55%-88.26%), and there were no significant differences in AUCs across age groups chi(2). Optimal cutscores, however, varied considerably: 24 for the oldest group, 34 for the middle group, and 43 for the youngest group. Conclusion: Recommend use of lower PCL cutscore for older Veterans Administration primary care patients.
C1 [Yeager, Derik E.; Magruder, Kathryn M.] Ralph H Johnson Vet Affairs Med Ctr, Mental Hlth Serv, Charleston, SC USA.
   [Yeager, Derik E.; Magruder, Kathryn M.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
RP Yeager, DE (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, 67 President St, Charleston, SC 29425 USA.
EM yeagerde@musc.edu
FU Department of Veterans Affairs; Veterans Health Administration; Office
   of Research and Development; Health Services Research and Development
   [VCR 99-010-2]; National Center for Research Resources [UL1TR000062]
FX Supported by the Department of Veterans Affairs, Veterans Health
   Administration, Office of Research and Development, and Health Services
   Research and Development (VCR 99-010-2). The views expressed in this
   report are those of the authors and do not necessarily reflect the
   position or policy of the Department of Veteran Affairs or the U.S.
   government.; Also supported by award number UL1TR000062 from the
   National Center for Research Resources. The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the National Center for Research Resources or the
   National Institutes of Health.
NR 13
TC 4
Z9 4
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1064-7481
EI 1545-7214
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD JUN
PY 2014
VL 22
IS 6
BP 545
EP 550
DI 10.1016/j.jagp.2013.03.009
PG 6
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA AH4HG
UT WOS:000336087400004
PM 24041524
ER

PT J
AU Covinsky, KE
   Cenzer, IS
   Yaffe, K
   O'Brien, S
   Blazer, DG
AF Covinsky, Kenneth E.
   Cenzer, Irena Stijacic
   Yaffe, Kristine
   O'Brien, Sarah
   Blazer, Dan G.
TI Dysphoria and Anhedonia as Risk Factors for Disability or Death in Older
   Persons: Implications for the Assessment of Geriatric Depression
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE Depression; anhedonia; activities of daily living; quality of life;
   health status
ID SUBTHRESHOLD DEPRESSION; FUNCTIONAL LIMITATIONS; VASCULAR DEPRESSION;
   COMMUNITY SAMPLE; ELDERLY PERSONS; LATER-LIFE; SYMPTOMS; ADULTS;
   MORTALITY; DIRECTIONS
AB Objectives: Either dysphoria (sadness) or anhedonia (loss of interest in usually pleasurable activities) is required for a diagnosis of major depression. Although major depression is a known risk factor for disability in older persons, few studies have examined the relationship between the two core symptoms of major depression and disability or mortality. Our objective was to examine the relationship between these two core symptoms and time to disability or death. Methods: In a longitudinal cohort study, we used the nationally representative Health and Retirement Study to examine this relationship in 11,353 persons older than 62 years (mean: 73 years) followed for up to 13 years. Dysphoria and anhedonia were assessed with the Short Form Composite International Diagnostic Interview. Our outcome measure was time to either death or increased disability, defined as the new need for help in a basic activity of daily living. We adjusted for a validated disability risk index and other confounders. Results: Compared with subjects without either dysphoria or anhedonia, the risk for disability or death was not elevated in elders with dysphoria without anhedonia (adjusted hazard ratio [HR]: 1.11; 95% confidence interval [CI]: 0.91-1.36). The risk was elevated in those with anhedonia without dysphoria (HR: 1.30; 95% CI: 1.06-1.60) and those with both anhedonia and dysphoria (HR: 1.28; 95% CI: 1.13-1.46). Conclusion: Our results highlight the need for clinicians to learn whether patients have lost interest in usually pleasurable activities, even if they deny sadness.
C1 [Covinsky, Kenneth E.; Cenzer, Irena Stijacic; O'Brien, Sarah] Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA.
   [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA.
   [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA.
   [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94121 USA.
   [Covinsky, Kenneth E.; Cenzer, Irena Stijacic; Yaffe, Kristine; O'Brien, Sarah] San Francisco VA Med Ctr, San Francisco, CA USA.
   [Blazer, Dan G.] Duke Univ, Dept Psychiat & Behav Sci, Durham, NC USA.
RP Covinsky, KE (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr 181G, 4150 Clement, San Francisco, CA 94121 USA.
EM ken.covinsky@ucsf.edu
FU National Institute on Aging [R01AG028481, K24AG029812]
FX Supported by grants R01AG028481 and K24AG029812 from the National
   Institute on Aging. The Health and Retirement Study is funded by the
   National Institute on Aging.
NR 34
TC 9
Z9 9
U1 5
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1064-7481
EI 1545-7214
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD JUN
PY 2014
VL 22
IS 6
BP 606
EP 613
DI 10.1016/j.jagp.2012.12.001
PG 8
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA AH4HG
UT WOS:000336087400011
PM 23602308
ER

PT J
AU Kim, J
   Won, JS
   Singh, AK
   Sharma, AK
   Singh, I
AF Kim, Jinsu
   Won, Je-Seong
   Singh, Avtar K.
   Sharma, Anand K.
   Singh, Inderjit
TI STAT3 Regulation by S-Nitrosylation: Implication for Inflammatory
   Disease
SO ANTIOXIDANTS & REDOX SIGNALING
LA English
DT Article
ID ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; MEDIATED RECEPTOR-BINDING;
   EPIDERMAL-GROWTH-FACTOR; BRAIN MICROGLIAL CELLS; NITRIC-OXIDE; JAK-STAT;
   TYROSINE PHOSPHORYLATION; SERINE PHOSPHORYLATION; NITROSO-GLUTATHIONE
AB Aims: S-nitrosylation and S-glutathionylation, redox-based modifications of protein thiols, are recently emerging as important signaling mechanisms. In this study, we assessed S-nitrosylation-based regulation of Janus-activated kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) pathway that plays critical roles in immune/inflammatory responses and tumorigenesis. Results: Our studies show that STAT3 in stimulated microglia underwent two distinct redox-dependent modifications, S-nitrosylation and S-glutathionylation. STAT3 S-nitrosylation was associated with inducible nitric oxide synthase (iNOS)-produced nitric oxide (NO) and S-nitrosoglutathione (GSNO), whereas S-glutathionylation of STAT3 was associated with cellular oxidative stress. NO produced by iNOS or treatment of microglia with exogenous GSNO inhibited STAT3 activation via inhibiting STAT3 phosphorylation (Tyr(705)). Consequently, the interleukin-6 (IL-6)-induced microglial proliferation and associated gene expressions were also reduced. In cell-free kinase assay using purified JAK2 and STAT3, STAT3 phosphorylation was inhibited by its selective preincubation with GSNO, but not by preincubation of JAK2 with GSNO, indicating that GSNO-mediated mechanisms inhibit STAT3 phosphorylation through S-nitrosylation of STAT3 rather than JAK2. In this study, we identified that Cys(259) was the target Cys residue of GSNO-mediated S-nitrosylation of STAT3. The replacement of Cys(259) residue with Ala abolished the inhibitory role of GSNO in IL-6-induced STAT3 phosphorylation and transactivation, suggesting the role of Cys(259) S-nitrosylation in STAT3 phosphorylation. Innovation: Microglial proliferation is regulated by NO via S-nitrosylation of STAT3 (Cys(259)) and inhibition of STAT3 (Tyr(705)) phosphorylation. Conclusion: Our results indicate the regulation of STAT3 by NO-based post-translational modification (S-nitrosylation). These findings have important implications for the development of new therapeutics targeting STAT3 for treating diseases associated with inflammatory/immune responses and abnormal cell proliferation, including cancer. Antioxid. Redox Signal. 20, 2514-2527.
C1 [Kim, Jinsu; Singh, Inderjit] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA.
   [Won, Je-Seong; Singh, Avtar K.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA.
   [Singh, Avtar K.] Ralph H Johnson Vet Adm Med Ctr, Pathol & Lab Med Serv, Charleston, SC USA.
   [Sharma, Anand K.; Singh, Inderjit] Med Univ S Carolina, Dept Radiat Oncol, Charleston, SC 29425 USA.
RP Singh, I (reprint author), Med Univ S Carolina, Dept Pediat, 173 Ashley Ave CRI 516, Charleston, SC 29425 USA.
EM singhi@musc.edu
FU NIH; VA [NS072511, BX001062, NS037766, BX001072]
FX This work was supported by grants from NIH and VA (NS072511, BX001062,
   NS037766 and BX001072). We also acknowledge Ms. Joyce Bryan and Ms.
   Chara Williams for their help in procurement of animals and supplies.
NR 60
TC 13
Z9 13
U1 1
U2 6
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1523-0864
EI 1557-7716
J9 ANTIOXID REDOX SIGN
JI Antioxid. Redox Signal.
PD JUN 1
PY 2014
VL 20
IS 16
BP 2514
EP 2527
DI 10.1089/ars.2013.5223
PG 14
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA AG9SM
UT WOS:000335760000003
PM 24063605
ER

PT J
AU Tyler, KL
AF Tyler, Kenneth L.
TI Current developments in understanding of West Nile virus central nervous
   system disease
SO CURRENT OPINION IN NEUROLOGY
LA English
DT Review
DE acute flaccid paralysis; antiviral therapy; encephalitis; meningitis;
   vaccine; West Nile virus
ID UNITED-STATES; T-CELLS; ANTIVIRAL RESPONSE; FLACCID PARALYSIS; CHIMERIC
   VACCINE; IMMUNE-RESPONSE; INFECTION; ENCEPHALITIS; PATHOGENESIS;
   OUTBREAK
AB Purpose of reviewWest Nile virus (WNV) is the most important cause of epidemic encephalitis in the United States. We review articles published in the last 18months related to the epidemiology, immunology, clinical features, and treatment of this disease.Recent findingsThere was a resurgence in WNV disease in the United States in 2012. The WNV strain now predominant in the United States (NA/WN02) differs from the initial emergent isolate in 1999 (NY99). However, differences in the genetics of currently circulating United States WNV strains do not explain variations in epidemic magnitude or disease severity. Innate and acquired immunity are critical in control of WNV, and in some cases pathways are central nervous system specific. The clinical features of infection are now well understood, although nonconfirmed observations of chronic viral excretion in urine remain controversial. There is no specific antiviral therapy for WNV, but studies of antivirals specific for other flaviviruses may identify agents with promise against WNV. Phase I and II human WNV vaccine clinical trials have established that well tolerated and immunogenic WNV vaccines can be developed.SummaryWNV remains an important public health problem. Although recent studies have significantly increased our understanding of host immune and genetic factors involved in control of WNV infection, no specific therapy is yet available. Development of a well tolerated, immunogenic, and effective vaccine against WNV is almost certainly feasible, but economic factors and the lack of predictability of the magnitude and location of outbreaks are problematic for designing phase III trials and ultimate licensure.
C1 [Tyler, Kenneth L.] Univ Colorado, Sch Med, Dept Neurol, Aurora, CO 80045 USA.
   [Tyler, Kenneth L.] Eastern Colorado Healthcare Syst, Denver Vet Affairs Med Ctr, Denver, CO USA.
RP Tyler, KL (reprint author), Univ Colorado, Sch Med, Dept Neurol, Mailstop B-182,12700 East 19th Ave, Aurora, CO 80045 USA.
EM ken.tyler@ucdenver.edu
OI Tyler, Kenneth/0000-0003-3294-5888
FU NINDS [1 R01 NS076512]; NIAID [1 R21 AI01064]; Department of Veterans
   Affairs (MERIT) [BX000963]
FX K.L.T. is supported by grants from the NINDS (1 R01 NS076512), NIAID (1
   R21 AI01064), and the Department of Veterans Affairs (MERIT Grant
   BX000963).
NR 64
TC 7
Z9 7
U1 1
U2 17
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1350-7540
EI 1473-6551
J9 CURR OPIN NEUROL
JI Curr. Opin. Neurol.
PD JUN
PY 2014
VL 27
IS 3
BP 342
EP 348
DI 10.1097/WCO.0000000000000088
PG 7
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA AH2QQ
UT WOS:000335966500013
PM 24722324
ER

PT J
AU Miller, PS
   Evangelista, LS
   Giger, JN
   Martinez-Maza, O
   Corvera-Tindel, T
   Magpantay, L
   Pena, G
   Doering, LV
AF Miller, Pamela S.
   Evangelista, Lorraine S.
   Giger, Joyce Newman
   Martinez-Maza, Otoniel
   Corvera-Tindel, Teresita
   Magpantay, Larry
   Pena, Guadalupe
   Doering, Lynn V.
TI Exhaustion, immuno-inflammation, and pathogen burden after cardiac
   surgery: An exploratory study
SO EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING
LA English
DT Article
DE vital exhaustion; inflammation; pathogen burden; Coronary heart disease;
   herpesviruses; cytokines
ID C-REACTIVE PROTEIN; CORONARY-ARTERY-DISEASE; ANTIINFLAMMATORY CYTOKINE
   INTERLEUKIN-10; BYPASS GRAFT-SURGERY; VITAL EXHAUSTION;
   MYOCARDIAL-INFARCTION; CARDIOVASCULAR EVENTS; SOCIOECONOMIC-STATUS;
   ADHESION MOLECULES; ANGINA-PECTORIS
AB Background: Exhaustion, a consequence of prolonged stress characterized by unusual fatigue, is associated with increased risk of cardiac morbidity and mortality. In patients recovering from coronary artery bypass (CABG), little is known about the relationship of 1) immune-mediated inflammation and resultant endothelial activation, and 2) cumulative exposure to infectious pathogens (pathogen burden (PB)) implicated in coronary atherosclerosis to exhaustion. Aim: The aim of this exploratory study was to investigate the association of PB, inflammatory markers (interleukin (IL)-6, IL-10) and a marker of endothelial activation (soluble intercellular adhesion molecule-1 (sICAM-1)) to exhaustion. Methods: One to two months post-CABG, 42 individuals who met inclusion criteria were assessed for exhaustion using the Maastricht Interview for Vital Exhaustion. Serum IgG antibodies to herpes simplex virus (HSV)-1, HSV-2, cytomegalovirus, Epstein Barr virus, and inflammatory and endothelial activation markers were measured by enzyme-linked immunosorbent assay. Pathogen burden was defined as the total number of seropositive exposures: low (0-1), moderate (2-3), and high (4). Results: Prevalence of exhaustion was 40.5%. Relative to non-exhausted patients, exhausted patients demonstrated a higher frequency of moderate PB (h=0.73, p=0.04) but lower frequency of high PB (h=1.05, p=0.03). Exhaustion showed a non-significant trend for positive correlations with IL-6 and sICAM-1 levels, and inverse relation to PB. In subgroup analysis, exhausted patients had stronger correlations with IL-6 and IL-6:IL-10 and a tendency towards higher serum IL-10 concentrations compared with their non-exhausted counterparts. Conclusion: This hypothesis-generating study provides preliminary evidence that elevated post-CABG exhaustion may be associated with PB, inflammation, and endothelial activation.
C1 [Miller, Pamela S.] Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA.
   [Miller, Pamela S.; Giger, Joyce Newman; Corvera-Tindel, Teresita; Doering, Lynn V.] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90024 USA.
   [Evangelista, Lorraine S.] Univ Calif Irvine, Program Nursing Sci, Irvine, CA USA.
   [Giger, Joyce Newman] Amer Univ Hlth Sci, Signal Hill, CA USA.
   [Martinez-Maza, Otoniel] Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA.
   [Martinez-Maza, Otoniel] Univ Calif Los Angeles, David Geffen Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90095 USA.
   [Corvera-Tindel, Teresita] Vet Affairs Greater Los Angeles Hlth Care Syst, Nursing Res Dept, Los Angeles, CA USA.
   [Magpantay, Larry; Pena, Guadalupe] Univ Calif Los Angeles, David Geffen Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90095 USA.
RP Miller, PS (reprint author), Univ Calif San Francisco, Sch Nursing, 2 Koret Way,N411Y,Box 0606, San Francisco, CA 94143 USA.
EM Pamela.Miller@ucsf.edu
RI Martinez-Maza, Otoniel/B-2667-2009
OI Martinez-Maza, Otoniel/0000-0003-1364-0675
FU American Academy of Nurse Practitioners Foundation; Sigma Theta Tau
   International; Veterans Affairs Pre-doctoral Nurse Fellowship; James B.
   Pendleton Charitable Trust; McCarthy Family Foundation
FX This work was supported by grants from the American Academy of Nurse
   Practitioners Foundation; Sigma Theta Tau International; and Veterans
   Affairs Pre-doctoral Nurse Fellowship. This work was carried out in the
   facilities of the UCLA AIDS Institute, which were supported, in part, by
   funds from the James B. Pendleton Charitable Trust and the McCarthy
   Family Foundation.
NR 45
TC 1
Z9 1
U1 0
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1474-5151
EI 1873-1953
J9 EUR J CARDIOVASC NUR
JI Eur. J. Cardiovasc. Nurs.
PD JUN
PY 2014
VL 13
IS 3
BP 211
EP 220
DI 10.1177/1474515113482805
PG 10
WC Cardiac & Cardiovascular Systems; Nursing
SC Cardiovascular System & Cardiology; Nursing
GA AG8RO
UT WOS:000335686100003
PM 23524631
ER

PT J
AU Labarere, J
   Renaud, B
   Fine, MJ
AF Labarere, Jose
   Renaud, Bertrand
   Fine, Michael J.
TI Erratum to: How to derive and validate clinical prediction models for
   use in intensive care medicine (vol 40, pg 513, 2014)
SO INTENSIVE CARE MEDICINE
LA English
DT Correction
C1 [Labarere, Jose] Univ Hosp, Qual Care Unit, F-38043 Grenoble, France.
   [Labarere, Jose] Univ Grenoble 1, CNRS, TIMC, UMR 5525, Grenoble, France.
   [Renaud, Bertrand] Cochin Hosp, AP HP, Emergency Dept, Paris, France.
   [Renaud, Bertrand] Hop Hotel Dieu, AP HP, Emergency Dept, F-75181 Paris, France.
   [Renaud, Bertrand] Fac Med Paris Descartes, Paris, France.
   [Fine, Michael J.] VA Pittsburgh Healthcare Syst, Vet Affairs Ctr Hlth Equity & Res Promot, Pittsburgh, PA USA.
   [Fine, Michael J.] Univ Pittsburgh, Med Ctr, Div Gen Internal Med, Pittsburgh, PA USA.
   [Labarere, Jose] UQEM, F-38043 Grenoble 9, France.
RP Labarere, J (reprint author), UQEM, Pavillon Taillefer,CHU BP217, F-38043 Grenoble 9, France.
EM JLabarere@chu-grenoble.fr
RI Labarere, Jose/N-1688-2014
NR 1
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0342-4642
EI 1432-1238
J9 INTENS CARE MED
JI Intensive Care Med.
PD JUN
PY 2014
VL 40
IS 6
BP 925
EP 925
DI 10.1007/s00134-014-3271-2
PG 1
WC Critical Care Medicine
SC General & Internal Medicine
GA AH6ZJ
UT WOS:000336281100033
ER

PT J
AU Goveas, JS
   Espeland, MA
   Hogan, PE
   Tindle, HA
   Shih, RA
   Kotchen, JM
   Robinson, JG
   Barnes, DE
   Resnick, SM
AF Goveas, Joseph S.
   Espeland, Mark A.
   Hogan, Patricia E.
   Tindle, Hilary A.
   Shih, Regina A.
   Kotchen, Jane M.
   Robinson, Jennifer G.
   Barnes, Deborah E.
   Resnick, Susan M.
TI Depressive Symptoms and Longitudinal Changes in Cognition: Women's
   Health Initiative Study of Cognitive Aging
SO JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY
LA English
DT Article
DE depression; cognitive decline; vascular risk factors; cardiovascular
   disease; women; dementia; depressive symptoms
ID LATE-LIFE DEPRESSION; APOLIPOPROTEIN-E GENOTYPE; PRIMARY-CARE PATIENTS;
   GERIATRIC DEPRESSION; VASCULAR DEPRESSION; POSTMENOPAUSAL WOMEN;
   ALZHEIMER-DISEASE; IMPAIRMENT; DEMENTIA; RISK
AB Elevated depressive symptoms (DS) are associated with incident mild cognitive impairment and probable dementia in postmenopausal women. We examined the association of elevated DS with domain-specific cognitive changes and the moderating role of cardiovascular risk factor severity and cardiovascular disease (CVD). A total of 2221 elderly women who participated in the Women's Health Initiative Study of Cognitive Aging were separated into those with (N = 204) and without (N = 2017) elevated DS. The DS and multidomain cognitive outcomes were measured annually for an average follow-up of 5.04 years. Women with elevated DS showed baseline multidomain cognitive deficits but longitudinal declines in global cognition only. Persistent DS was related to greater global cognition, verbal knowledge and fluency, and memory declines. Significant DS-CVD interactions were observed cross-sectionally (but not longitudinally) for figural memory and fine motor speed. Future studies should investigate the role of nonvascular mechanisms linking DS and cognitive decline.
C1 [Goveas, Joseph S.] Med Coll Wisconsin, Dept Psychiat & Behav Med, Milwaukee, WI 53226 USA.
   [Espeland, Mark A.; Hogan, Patricia E.] Wake Forest Univ Hlth Sci, Dept Biostat Sci, Winston Salem, NC USA.
   [Tindle, Hilary A.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.
   [Shih, Regina A.] RAND Corp, Arlington, VA USA.
   [Kotchen, Jane M.] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA.
   [Kotchen, Jane M.] Med Coll Wisconsin, Clin & Translat Sci Inst, Milwaukee, WI 53226 USA.
   [Robinson, Jennifer G.] Univ Iowa, Dept Epidemiol, Iowa City, IA USA.
   [Barnes, Deborah E.] Univ Calif San Francisco, Dept Psychiat & Epidemiol, San Francisco, CA 94143 USA.
   [Barnes, Deborah E.] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA.
   [Barnes, Deborah E.] San Francisco VA Med Ctr, Dept Psychiat, San Francisco, CA USA.
   [Resnick, Susan M.] NIA, Lab Behav Neurosci, Intramural Res Program, NIH, Baltimore, MD 21224 USA.
RP Goveas, JS (reprint author), Med Coll Wisconsin, Dept Psychiat, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.
EM jgoveas@mcw.edu
FU National Heart, Lung, and Blood Institute, National Institutes of
   Health, US Department of Health and Human Services [N01WH22110, 24152,
   32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118-32119, 32122,
   42107-26, 42129-32, 44221]; Department of Health and Human Services;
   National Institute on Aging [NO1-AG-1-2106]; Intramural Research
   Program, National Institute on Aging; National Institutes of Health;
   Alzheimer's Association [NIRG-11-204070]; Extendicare Foundation; Brain
   & Behavior Research Foundation (NARSAD); Wyeth Pharmaceuticals; Brain
   and Behavior Research Foundation (previously NARSAD) young investigator
   award
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: The
   Women's Health Initiative (WHI) program is funded by the National Heart,
   Lung, and Blood Institute, National Institutes of Health, US Department
   of Health and Human Services through contracts N01WH22110, 24152,
   32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118-32119, 32122,
   42107-26, 42129-32, and 44221. The WHI Study of Cognitive Aging (WHISCA)
   was supported by the Department of Health and Human Services and the
   National Institute on Aging (NO1-AG-1-2106). SMR is supported by the
   Intramural Research Program, National Institute on Aging, and National
   Institutes of Health. JSG is supported by the Alzheimer's Association
   New Investigator NIRG-11-204070 and Extendicare Foundation, and
   previously by Brain & Behavior Research Foundation (NARSAD) young
   investigator, and Research for a Healthier Tomorrow, a Component of the
   Advancing a Healthier Wisconsin Endowment at MCW. The Women's Health
   Initiative Memory Study was funded in part by Wyeth Pharmaceuticals as
   an ancillary study to the WHI. DB's contributions were supported in part
   by Brain and Behavior Research Foundation (previously NARSAD) young
   investigator award.
NR 46
TC 11
Z9 11
U1 3
U2 7
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0891-9887
EI 1552-5708
J9 J GERIATR PSYCH NEUR
JI J. Geriatr. Psychiatry Neurol.
PD JUN
PY 2014
VL 27
IS 2
BP 94
EP 102
DI 10.1177/0891988714522697
PG 9
WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry
SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry
GA AH6DG
UT WOS:000336220300004
PM 24584465
ER

PT J
AU Hay, RJ
   Johns, NE
   Williams, HC
   Bolliger, IW
   Dellavalle, RP
   Margolis, DJ
   Marks, R
   Naldi, L
   Weinstock, MA
   Wulf, SK
   Michaud, C
   Murray, CJL
   Naghavi, M
AF Hay, Roderick J.
   Johns, Nicole E.
   Williams, Hywel C.
   Bolliger, Ian W.
   Dellavalle, Robert P.
   Margolis, David J.
   Marks, Robin
   Naldi, Luigi
   Weinstock, Martin A.
   Wulf, Sarah K.
   Michaud, Catherine
   Murray, Christopher J. L.
   Naghavi, Mohsen
TI The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence
   and Impact of Skin Conditions
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Article
ID SYSTEMATIC ANALYSIS; DISABILITY WEIGHTS; COMMUNITY; SCABIES; ECZEMA;
   DERMATOLOGY; ETHIOPIA; CRITERIA
AB The Global Burden of Disease (GBD) Study 2010 estimated the GBD attributable to 15 categories of skin disease from 1990 to 2010 for 187 countries. For each of the following diseases, we performed systematic literature reviews and analyzed resulting data: eczema, psoriasis, acne vulgaris, pruritus, alopecia areata, decubitus ulcer, urticaria, scabies, fungal skin diseases, impetigo, abscess, and other bacterial skin diseases, cellulitis, viral warts, molluscum contagiosum, and non-melanoma skin cancer. We used disability estimates to determine nonfatal burden. Three skin conditions, fungal skin diseases, other skin and subcutaneous diseases, and acne were in the top 10 most prevalent diseases worldwide in 2010, and eight fell into the top 50; these additional five skin problems were pruritus, eczema, impetigo, scabies, and molluscum contagiosum. Collectively, skin conditions ranged from the 2nd to 11th leading cause of years lived with disability at the country level. At the global level, skin conditions were the fourth leading cause of nonfatal disease burden. Using more data than has been used previously, the burden due to these diseases is enormous in both high- and low-income countries. These results argue strongly to include skin disease prevention and treatment in future global health strategies as a matter of urgency.
C1 [Hay, Roderick J.] Int Fdn Dermatol, London W1T 5HQ, England.
   [Johns, Nicole E.; Bolliger, Ian W.; Wulf, Sarah K.; Murray, Christopher J. L.; Naghavi, Mohsen] Univ Washington, Inst Hlth Metr & Evaluat, Washington, DC USA.
   [Williams, Hywel C.] Univ Nottingham, Ctr Evidence Based Dermatol, Nottingham NG7 2RD, England.
   [Dellavalle, Robert P.] Denver VA Med Ctr, Dermatol Serv, Denver, CO USA.
   [Margolis, David J.] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
   [Margolis, David J.] Univ Penn, Dept Dermatol, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Marks, Robin] Skin & Canc Fdn, Melbourne, Vic, Australia.
   [Naldi, Luigi] Azienda Osped Papa Giovanni XXIII, Dept Dermatol, Bergamo, Italy.
   [Weinstock, Martin A.] Brown Univ, Div Dermatoepidemiol, Providence, RI 02912 USA.
   [Michaud, Catherine] China Med Board, Cambridge, MA USA.
RP Hay, RJ (reprint author), Int Fdn Dermatol, 4 Fitzroy Sq, London W1T 5HQ, England.
EM roderick.hay@ifd.org
RI Bolliger, Ian/C-4207-2016; Naldi, Luigi/K-6343-2016
OI Bolliger, Ian/0000-0001-8055-297X; Naldi, Luigi/0000-0002-3160-2835;
   Johns, Nicole/0000-0003-4513-4582
NR 29
TC 117
Z9 119
U1 47
U2 88
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
EI 1523-1747
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD JUN
PY 2014
VL 134
IS 6
BP 1527
EP 1534
DI 10.1038/jid.2013.446
PG 8
WC Dermatology
SC Dermatology
GA AH5TJ
UT WOS:000336193700010
PM 24166134
ER

PT J
AU Hage, FG
   Garcia, EV
AF Hage, Fadi G.
   Garcia, Ernest V.
TI The independent prognostic value of left ventricular dyssynchrony
SO JOURNAL OF NUCLEAR CARDIOLOGY
LA English
DT Editorial Material
ID PHASE-ANALYSIS; MECHANICAL DYSSYNCHRONY; CARDIOMYOPATHY; DEATH; ERA
C1 [Hage, Fadi G.] Univ Alabama Birmingham, Div Cardiovasc Dis, Birmingham, AL 35294 USA.
   [Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Cardiol Sect, Birmingham, AL USA.
   [Garcia, Ernest V.] Emory Univ, Dept Radiol & Imaging Sci, Atlanta, GA 30322 USA.
RP Hage, FG (reprint author), Univ Alabama Birmingham, Div Cardiovasc Dis, Lyons Harrison Res Bldg 314,1900 Univ BLVD, Birmingham, AL 35294 USA.
EM fadihage@uab.edu
OI Hage, Fadi/0000-0002-1397-4942
NR 18
TC 1
Z9 1
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1071-3581
EI 1532-6551
J9 J NUCL CARDIOL
JI J. Nucl. Cardiol.
PD JUN
PY 2014
VL 21
IS 3
BP 541
EP 543
DI 10.1007/s12350-014-9878-4
PG 3
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
   Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
   Medical Imaging
GA AH6YI
UT WOS:000336278000013
PM 24623398
ER

PT J
AU Erickson, MA
   Morofuji, Y
   Owen, JB
   Banks, WA
AF Erickson, Michelle A.
   Morofuji, Yoichi
   Owen, Joshua B.
   Banks, William A.
TI Rapid Transport of CCL11 across the Blood-Brain Barrier: Regional
   Variation and Importance of Blood Cells
SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
LA English
DT Article
ID MICROVASCULAR ENDOTHELIAL-CELLS; COGNITIVE FUNCTION; RAT-BRAIN; EOTAXIN;
   CAPILLARY; MOUSE; CHEMOKINE; RECEPTOR; PLASMA; NEUROGENESIS
AB Increased blood levels of the eotaxin chemokine C-C motif ligand 11 (CCL11) in aging were recently shown to negatively regulate adult hippocampal neurogenesis. How circulating CCL11 could affect the central nervous system (CNS) is not clear, but one possibility is that it can cross the blood-brain barrier (BBB). Here, we show that CCL11 undergoes bidirectional transport across the BBB. Transport of CCL11 from blood into whole brain (influx) showed biphasic kinetics, with a slow phase preceding a rapid phase of uptake. We found that the slow phase was explained by binding of CCL11 to cellular components in blood, whereas the rapid uptake phase was mediated by direct interactions with the BBB. CCL11, even at high doses, did not cause BBB disruption. All brain regions except striatum showed a delayed rapid-uptake phase. Striatum had only an early rapid-uptake phase, which was the fastest of any brain region. We also observed a slow but saturable transport system for CCL11 from brain to blood. C-C motif ligand 3 (CCR3), an important receptor for CCL11, did not facilitate CCL11 transport across the BBB, although high concentrations of a CCR3 inhibitor increased brain uptake without causing BBB disruption. Our results indicate that CCL11 in the circulation can access many regions of the brain outside of the neurogenic niche via transport across the BBB. This suggests that blood-borne CCL11 may have important physiologic functions in the CNS and implicates the BBB as an important regulator of physiologic versus pathologic effects of this chemokine.
C1 [Erickson, Michelle A.] Univ Penn, Dept Pathol, Sch Dent Med, Philadelphia, PA 19104 USA.
   [Erickson, Michelle A.; Morofuji, Yoichi; Owen, Joshua B.; Banks, William A.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA.
   [Erickson, Michelle A.; Morofuji, Yoichi; Owen, Joshua B.; Banks, William A.] Univ Washington, Sch Med, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA.
   [Owen, Joshua B.] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
   [Morofuji, Yoichi] Nagasaki Univ, Dept Neurosurg, Nagasaki 852, Japan.
RP Banks, WA (reprint author), Bldg 1,Rm 810A,1660 Columbian Way, Seattle, WA 98108 USA.
EM wabanks1@u.washington.edu
FU National Institutes of Health National Institute on Aging
   [R01-AG029839]; National Institutes of Health National Institute of
   Neurological Disorders and Stroke [R01NS051334]
FX This work was supported by the National Institutes of Health National
   Institute on Aging [Grant R01-AG029839]; and National Institutes of
   Health National Institute of Neurological Disorders and Stroke [Grant
   R01NS051334].
NR 42
TC 13
Z9 13
U1 0
U2 4
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0022-3565
EI 1521-0103
J9 J PHARMACOL EXP THER
JI J. Pharmacol. Exp. Ther.
PD JUN
PY 2014
VL 349
IS 3
BP 497
EP 507
DI 10.1124/jpet.114.213074
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA AH5GJ
UT WOS:000336156200014
PM 24706984
ER

PT J
AU Saunders, RS
   Fernandes-Taylor, S
   Kind, AJH
   Engelbert, TL
   Greenberg, CC
   Smith, MA
   Matsumura, JS
   Kent, KC
AF Saunders, Richard S.
   Fernandes-Taylor, Sara
   Kind, Amy J. H.
   Engelbert, Travis L.
   Greenberg, Caprice C.
   Smith, Maureen A.
   Matsumura, Jon S.
   Kent, K. Craig
TI Rehospitalization to primary versus different facilities following
   abdominal aortic aneurysm repair
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Article
ID RURAL PATIENTS; SURGERY; VOLUME; CARE; REGIONALIZATION; READMISSIONS;
   HOSPITALS; MORTALITY; RESECTION; FAILURE
AB Objective: Reducing readmissions represents a unique opportunity to improve care and reduce health care costs and is the focus of major payers. A large number of surgical patients are readmitted to hospitals other than where the primary surgery was performed, resulting in clinical decisions that do not incorporate the primary surgeon and potentially alter outcomes. This study characterizes readmission to primary vs different hospitals after abdominal aortic aneurysm (AAA) repair and examines the implications with regard to mortality and cost.
   Methods: Patients who underwent open or endovascular aneurysm repair for AAA were identified from the Centers for Medicare and Medicaid Services Chronic Conditions Warehouse, a random 5% national sample of Medicare beneficiaries from 2005 to 2009. Outcomes for patients who underwent AAA repair and were readmitted within 30 days of initial discharge were compared based on readmission location (primary vs different hospital).
   Results: A total of 885 patients underwent AAA repair and were readmitted within 30 days. Of these, 626 (70.7%) returned to the primary facility, and 259 (29.3%) returned to a different facility. Greater distance from patient residence to the primary hospital was the strongest predictor of readmission to a different facility. Patients living 50 to 100 miles from the primary hospital were more likely to be readmitted to a different hospital compared with patients living <10 miles away (odds ratio, 8.50; P < .001). Patients with diagnoses directly related to the surgery (eg, wound infection) were more likely to be readmitted to the primary hospital, whereas medical diagnoses (eg, pneumonia and congestive heart failure) were more likely to be treated at a different hospital. There was no statistically significant difference in mortality between patients readmitted to a different or the primary hospital. Median total 30-day payments were significantly lower at different vs primary hospitals (primary, $11,978 vs different, $11,168; P = .04).
   Conclusions: Readmission to a different facility after AAA repair is common and occurs more frequently than for the overall Medicare population. Patients travelling a greater distance for AAA repair are more likely to return to different vs the primary hospital when further care is required. For AAA repair, quality healthcare may be achieved at marginally lower cost and with greater patient convenience for selected readmissions at hospitals other than where the initial procedure was performed.
C1 [Saunders, Richard S.; Fernandes-Taylor, Sara; Engelbert, Travis L.; Greenberg, Caprice C.; Matsumura, Jon S.; Kent, K. Craig] Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin Surg Outcomes Res Program WiSOR, Dept Surg, Madison, WI USA.
   [Kind, Amy J. H.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Div Geriatr, Madison, WI USA.
   [Smith, Maureen A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI USA.
   [Smith, Maureen A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Family Med, Madison, WI USA.
   [Kind, Amy J. H.] William S Middleton Hosp, GRECC, US Dept Vet Affairs, Madison, WI USA.
RP Kent, KC (reprint author), H4 710 Clin Sci Ctr, 600 Highland Ave, Madison, WI 53792 USA.
EM kent@surgery.wisc.edu
FU Health Innovation Program; University of Wisconsin School of Medicine
   and Public Health from The Wisconsin Partnership Program;
   Community-Academic Partnerships core of the University of Wisconsin
   Institute for Clinical and Translational Research (UW ICTR) through the
   National Center for Advancing Translational Sciences (NCATS)
   [UL1TR000427]
FX This project was supported in part by the Health Innovation Program, the
   University of Wisconsin School of Medicine and Public Health from The
   Wisconsin Partnership Program, and the Community-Academic Partnerships
   core of the University of Wisconsin Institute for Clinical and
   Translational Research (UW ICTR) through the National Center for
   Advancing Translational Sciences (NCATS), grant UL1TR000427.
NR 27
TC 12
Z9 12
U1 0
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD JUN
PY 2014
VL 59
IS 6
BP 1502
EP +
DI 10.1016/j.jvs.2013.12.015
PG 11
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA AH8DH
UT WOS:000336363800004
PM 24491237
ER

PT J
AU Kougias, P
   Sharath, S
   Barshes, NR
   Lowery, B
   Garcia, A
   Pak, T
   Bechara, CF
   Pisimisis, G
AF Kougias, Panos
   Sharath, Sherene
   Barshes, Neal R.
   Lowery, Briauna
   Garcia, Andrea
   Pak, Taemee
   Bechara, Carlos F.
   Pisimisis, George
TI Impact of cumulative intravascular contrast exposure on renal function
   in patients with occlusive and aneurysmal vascular disease
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Article; Proceedings Paper
CT 38th Annual Spring Meeting of the Peripheral-Vascular-Surgery-Society
CY MAY 29, 2013
CL San Francisco, CA
SP Peripheral Vasc Surg Soc
ID GLOMERULAR-FILTRATION-RATE; CHRONIC KIDNEY-DISEASE; RISK-FACTORS;
   INDUCED NEPHROPATHY; PROXIMAL FIXATION; REPAIR; DYSFUNCTION;
   CONSEQUENCES; TERM
AB Objective: Patients with occlusive or aneurysmal vascular disease are repeatedly exposed to intravascular (IV) contrast for diagnostic or therapeutic purposes. We sought to determine the long-term impact of cumulative iodinated IV contrast exposure (CIVCE) on renal function; the latter was defined by means of National Kidney Foundation (NKF) criteria.
   Methods: We performed a longitudinal study of consecutive patients without renal insufficiency at baseline (NFK stage I or II) who underwent interventions for arterial occlusive or aneurysmal disease. We collected detailed data on any IV iodinated contrast exposure (including diagnostic or therapeutic angiography, cardiac catheterization, IV pyelography, computed tomography with IV contrast, computed tomographic angiography); medication exposure throughout the observation period; comorbidities; and demographics. The primary end point was the development of renal failure (RF) (defined as NFK stage 4 or 5). Analysis was performed with the use of a shared frailty model with clustering at the patient level.
   Results: Patients (n = 1274) had a mean follow-up of 5.8 (range, 2.2-14) years. In the multivariate model with RF as the dependent variable and after adjusting for the statistically significant covariates of baseline renal function (hazard ratio [HR], 0.95; P < .001), diabetes (HR, 1.8; P = .007), use of an angiotensin-converting enzyme inhibitor (HR, 0.63; P = .03), use of antiplatelets (HR, 0.5; P = .01), cumulative number of open vascular operations performed (HR, 1.2; P = .001), and congestive heart failure (HR, 3.2; P < .001), CIVCE remained an independent predictor for RF development (HR, 1.1; P < .001). In the multivariate survival analysis model and after adjusting for the statistically significant covariates of perioperative myocardial infarction (HR, 3.9; P < .001), age at entry in the cohort (HR, 1.05; P = .035), total number of open operations (HR, 1.51; P < .001), and serum albumin (HR, 0.47; P < .001), CIVCE was an independent predictor of death (HR, 1.07; P < .001).
   Conclusions: Cumulative IV contrast exposure is an independent predictor of RF and death in patients with occlusive and aneurysmal vascular disease.
C1 [Kougias, Panos; Sharath, Sherene; Barshes, Neal R.; Lowery, Briauna; Bechara, Carlos F.; Pisimisis, George] Michael E DeBakey VA Med Ctr, Dept Surg, Houston, TX USA.
   [Kougias, Panos; Barshes, Neal R.; Garcia, Andrea; Pak, Taemee; Bechara, Carlos F.; Pisimisis, George] Baylor Coll Med, Dept Surg, Houston, TX 77030 USA.
RP Kougias, P (reprint author), Houston VAMC, Dept Surg, 2002 Holcombe Blvd OCL 112, Houston, TX 77030 USA.
EM pkougias@bcm.edu
NR 17
TC 3
Z9 3
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD JUN
PY 2014
VL 59
IS 6
BP 1644
EP 1650
DI 10.1016/j.jvs.2013.12.039
PG 7
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA AH8DH
UT WOS:000336363800025
PM 24560864
ER

PT J
AU Lee, LC
   Ge, L
   Zhang, ZH
   Pease, M
   Nikolic, SD
   Mishra, R
   Ratcliffe, MB
   Guccione, JM
AF Lee, Lik Chuan
   Ge, Liang
   Zhang, Zhihong
   Pease, Matthew
   Nikolic, Serjan D.
   Mishra, Rakesh
   Ratcliffe, Mark B.
   Guccione, Julius M.
TI Patient-specific finite element modeling of the Cardiokinetix
   Parachute(A (R)) device: effects on left ventricular wall stress and
   function
SO MEDICAL & BIOLOGICAL ENGINEERING & COMPUTING
LA English
DT Article
DE Myocardial infarction; Remodeling; Finite element method; Surgical
   ventricular restoration
ID CHRONIC HEART-FAILURE; MYOCARDIAL-INFARCTION; MRI; RESTORATION;
   MECHANICS; ANEURYSM
AB The Parachute(A (R)) (Cardiokinetix, Inc., Menlo Park, California) is a catheter-based device intended to reverse left ventricular (LV) remodeling after antero-apical myocardial infarction. When deployed, the device partitions the LV into upper and lower chambers. To simulate its mechanical effects, we created a finite element LV model based on computed tomography (CT) images from a patient before and 6 months after Parachute(A (R)) implantation. Acute mechanical effects were determined by in silico device implantation (VIRTUAL-Parachute). Chronic effects of the device were determined by adjusting the diastolic and systolic material parameters to better match the 6-month post-implantation CT data and LV pressure data at end-diastole (ED) (POST-OP). Regional myofiber stress and pump function were calculated in each case. The principal finding is that VIRTUAL-Parachute was associated with a 61.2 % reduction in the lower chamber myofiber stress at ED. The POST-OP model was associated with a decrease in LV diastolic stiffness and a larger reduction in myofiber stress at the upper (27.1 %) and lower chamber (78.4 %) at ED. Myofiber stress at end-systole and stroke volume was little changed in the POST-OP case. These results suggest that the primary mechanism of Parachute(A (R)) is a reduction in ED myofiber stress, which may reverse eccentric post-infarct LV hypertrophy.
C1 [Lee, Lik Chuan; Ge, Liang; Ratcliffe, Mark B.; Guccione, Julius M.] Univ Calif San Francisco, Dept Surg, San Francisco, CA USA.
   [Lee, Lik Chuan; Ge, Liang; Ratcliffe, Mark B.; Guccione, Julius M.] Univ Calif San Francisco, Dept Bioengn, San Francisco, CA 94143 USA.
   [Lee, Lik Chuan; Ge, Liang; Zhang, Zhihong; Mishra, Rakesh; Ratcliffe, Mark B.; Guccione, Julius M.] San Francisco VA Med Ctr, Div Surg Serv 112, San Francisco, CA 94121 USA.
   [Pease, Matthew; Nikolic, Serjan D.] Cardiokinetix Inc, Menlo Pk, CA USA.
   [Mishra, Rakesh] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
RP Ratcliffe, MB (reprint author), San Francisco VA Med Ctr, Div Surg Serv 112, 4150 Clement St, San Francisco, CA 94121 USA.
EM mark.ratcliffe@va.gov
FU NIH [R01-HL-084431, R01-HL-077921, R01-HL-118627]
FX This study was supported by an unrestricted gift from Cardiokinetix and
   NIH grants R01-HL-084431 (Dr. Ratcliffe), R01-HL-077921 and
   R01-HL-118627 (Dr. Guccione).
NR 23
TC 15
Z9 17
U1 0
U2 4
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0140-0118
EI 1741-0444
J9 MED BIOL ENG COMPUT
JI Med. Biol. Eng. Comput.
PD JUN
PY 2014
VL 52
IS 6
BP 557
EP 566
DI 10.1007/s11517-014-1159-5
PG 10
WC Computer Science, Interdisciplinary Applications; Engineering,
   Biomedical; Mathematical & Computational Biology; Medical Informatics
SC Computer Science; Engineering; Mathematical & Computational Biology;
   Medical Informatics
GA AH8HO
UT WOS:000336378200005
PM 24793158
ER

PT J
AU Heatwole, C
   Bode, R
   Johnson, N
   Dekdebrun, J
   Dilek, N
   Heatwole, M
   Hilbert, JE
   Luebbe, E
   Martens, W
   Mcdermott, MP
   Rothrock, N
   Thornton, C
   Vickrey, BG
   Victorson, D
   Moxley, R
AF Heatwole, Chad
   Bode, Rita
   Johnson, Nicholas
   Dekdebrun, Jeanne
   Dilek, Nuran
   Heatwole, Mark
   Hilbert, James E.
   Luebbe, Elizabeth
   Martens, William
   Mcdermott, Michael P.
   Rothrock, Nan
   Thornton, Charles
   Vickrey, Barbara G.
   Victorson, David
   Moxley, Richard, III
TI MYOTONIC DYSTROPHY HEALTH INDEX: INITIAL EVALUATION OF A
   DISEASE-SPECIFIC OUTCOME MEASURE
SO MUSCLE & NERVE
LA English
DT Article
DE pain management; pain assessment; myotonic dystrophy type 1;
   facioscapulohumeral muscular dystrophy; rehabilitation
ID PATIENT-REPORTED OUTCOMES; QUALITY-OF-LIFE; MUSCULAR-DYSTROPHY; DRUG
   DEVELOPMENT; CTG REPEAT; PERSPECTIVE; VALIDITY; TYPE-1; TRIALS; GENE
AB Introduction: We examined the effects of pain site and intensity on function in patients with myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD) and chronic pain. Methods: Questionnaires assessing pain sites, pain extent (number of sites), pain intensity, and pain interference were completed by 182 individuals with DM1 (43%) or FSHD (57%) and chronic pain. Results: There was a positive association between pain extent and intensity with pain interference, and a negative association with psychological functioning in both DM1 and FSHD. Pain intensity at specific sites had differential impact beyond the effects of pain intensity alone. Head pain intensity independently affected psychological functioning, whereas leg, foot, hip, and knee pain contributed independently to the prediction of pain interference. Conclusions: Pain site and intensity differentially modulates the effect of chronic pain on function in DM1 and FSHD patients. Researchers and clinicians should consider these factors when assessing and treating pain. Muscle Nerve 49: 900-905, 2014
C1 [Heatwole, Chad; Dekdebrun, Jeanne; Dilek, Nuran; Hilbert, James E.; Luebbe, Elizabeth; Martens, William; Mcdermott, Michael P.; Thornton, Charles; Moxley, Richard, III] Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA.
   [Bode, Rita] Psychometr Consultant, Chicago, IL USA.
   [Johnson, Nicholas] Univ Utah, Dept Neurol, Salt Lake City, UT USA.
   [Mcdermott, Michael P.] Univ Rochester, Med Ctr, Dept Biostat & Computat Biol, Rochester, NY 14642 USA.
   [Rothrock, Nan; Victorson, David] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Vickrey, Barbara G.] Univ Calif Los Angeles, Med Ctr, David Geffen Sch Med, Los Angeles, CA 90024 USA.
   [Vickrey, Barbara G.] Greater Los Angeles VA HealthCare Syst, Los Angeles, CA USA.
RP Heatwole, C (reprint author), Univ Rochester, Med Ctr, Dept Neurol, 601 Elmwood Ave,Box 673, Rochester, NY 14642 USA.
EM chad_heatwole@urmc.rochester.edu
FU National Institute of Arthritis and Musculoskeletal and Skin Disorders
   [1K23AR055947]; Senator Paul D. Wellstone Muscular Dystrophy Cooperative
   Research Center [NINDS U54NS48843]; Muscular Dystrophy Association;
   Saunders Family Fund; University of Rochester CTSA award from the
   National Center for Research Resources [UL1 RR024160]; National Center
   for Advancing Translational Sciences of the National Institutes of
   Health
FX Partial support for this research was provided by the National Institute
   of Arthritis and Musculoskeletal and Skin Disorders (1K23AR055947), the
   Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center
   (NINDS U54NS48843), the Muscular Dystrophy Association, and the Saunders
   Family Fund. The project described in this publication was also
   supported by the University of Rochester CTSA award number UL1 RR024160
   from the National Center for Research Resources and the National Center
   for Advancing Translational Sciences of the National Institutes of
   Health. The content is solely the responsibility of the authors and does
   not necessarily represent the official views of the National Institutes
   of Health. Additional information regarding the MDHI is available at the
   Neuromuscular Institute of Quality-of-Life Studies and Outcome Measure
   Development website www.QOLINSTITUTE.com and MDHI licensing
   opportunities can be reviewed at: www.urmc.rochester.edu/techtransfer.
NR 27
TC 6
Z9 6
U1 2
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0148-639X
EI 1097-4598
J9 MUSCLE NERVE
JI Muscle Nerve
PD JUN
PY 2014
VL 49
IS 6
BP 906
EP 914
DI 10.1002/mus.24079
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA AH2MA
UT WOS:000335954400016
PM 24142420
ER

PT J
AU Peng, ZC
   Zhang, NH
   Chandra, D
   Homanics, GE
   Olsen, RW
   Houser, CR
AF Peng, Zechun
   Zhang, Nianhui
   Chandra, Dave
   Homanics, Gregg E.
   Olsen, Richard W.
   Houser, Carolyn R.
TI Altered Localization of the delta Subunit of the GABA(A) Receptor in the
   Thalamus of alpha 4 Subunit Knockout Mice
SO NEUROCHEMICAL RESEARCH
LA English
DT Article
DE Immunohistochemistry; Non-synaptic GABA receptors; Plasticity; Receptor
   trafficking; Tonic inhibition; Ventrobasal nucleus
ID TEMPORAL-LOBE EPILEPSY; AMINOBUTYRIC ACID(A) RECEPTORS; INTERMITTENT
   ETHANOL TREATMENT; CEREBELLAR GRANULE CELLS; ADULT-RAT BRAIN; TONIC
   INHIBITION; PHARMACOLOGICAL CHARACTERIZATION; IMMUNOCYTOCHEMICAL
   DISTRIBUTION; ENDOPLASMIC-RETICULUM; BEHAVIORAL-RESPONSES
AB The alpha 4 subunit of the GABA(A) receptor (GABA(A)R) is highly expressed in the thalamus where receptors containing the alpha 4 and delta subunits are major mediators of tonic inhibition. The alpha 4 subunit also exhibits considerable plasticity in a number of physiological and pathological conditions, raising questions about the expression of remaining GABA(A)R subunits when the alpha 4 subunit is absent. Immunohistochemical studies of an alpha 4 subunit knockout (KO) mouse revealed a substantial decrease in delta subunit expression in the ventrobasal nucleus of the thalamus as well as other forebrain regions where the alpha 4 subunit is normally expressed. In contrast, several subunits associated primarily with phasic inhibition, including the alpha 1 and gamma 2 subunits, were moderately increased. Intracellular localization of the delta subunit was also altered. While delta subunit labeling was decreased within the neuropil, some labeling remained in the cell bodies of many neurons in the ventrobasal nucleus. Confocal microscopy demonstrated co-localization of this labeling with an endoplasmic reticulum marker, and electron microscopy demonstrated increased immunogold labeling near the endoplasmic reticulum in the alpha 4 KO mouse. These results emphasize the strong partnership of the delta and alpha 4 subunit in the thalamus and suggest that the alpha 4 subunit of the GABA(A)R plays a critical role in trafficking of the delta subunit to the neuronal surface. The findings also suggest that previously observed reductions in tonic inhibition in the alpha 4 subunit KO mouse are likely to be related to alterations in delta subunit expression, in addition to loss of the alpha 4 subunit.
C1 [Peng, Zechun; Zhang, Nianhui; Houser, Carolyn R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA.
   [Chandra, Dave; Homanics, Gregg E.] Univ Pittsburgh, Dept Anesthesiol & Pharmacol & Chem Biol, Pittsburgh, PA USA.
   [Olsen, Richard W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA.
   [Houser, Carolyn R.] VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA.
RP Houser, CR (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, CHS 73-235, Los Angeles, CA 90095 USA.
EM houser@mednet.ucla.edu
FU National Institutes of Health [NS075245, AA14022, AA13004, AA007680];
   Veterans Affairs Medical Research Funds
FX We thank Drs. Jean-Marc Fritschy and Werner Sieghart for generously
   sharing their GABA<INF>A</INF>R subunit-specific antisera that have made
   these studies possible. We also thank Christine Huang and Yliana Cetina
   for outstanding assistance with tissue processing and figure
   preparation. This work was supported by National Institutes of Health
   Grants NS075245 (CRH), AA14022 and AA13004 (GEH), AA007680 (RWO), and
   Veterans Affairs Medical Research Funds (CRH).
NR 72
TC 4
Z9 4
U1 0
U2 0
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0364-3190
EI 1573-6903
J9 NEUROCHEM RES
JI Neurochem. Res.
PD JUN
PY 2014
VL 39
IS 6
SI SI
BP 1104
EP 1117
DI 10.1007/s11064-013-1202-1
PG 14
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA AH6WJ
UT WOS:000336272500013
PM 24352815
ER

PT J
AU Kim, WH
   Singh, V
   Chung, MK
   Hinrichs, C
   Pachauri, D
   Okonkwo, OC
   Johnson, SC
AF Kim, Won Hwa
   Singh, Vikas
   Chung, Moo K.
   Hinrichs, Chris
   Pachauri, Deepti
   Okonkwo, Ozioma C.
   Johnson, Sterling C.
CA Alzheimer's Dis Neuroimaging Initi
TI Multi-resolutional shape features via non-Euclidean wavelets:
   Applications to statistical analysis of cortical thickness
SO NEUROIMAGE
LA English
DT Article
DE Non-Euclidean wavelet; Multi-resolution analysis; Graph wavelets; Shape
   analysis; Cortical thickness discrimination; Alzheimer's disease
ID ALZHEIMERS-DISEASE; SURFACE-AREA; GRAY-MATTER; HEAT KERNEL; CHILDREN;
   CT; ADOLESCENTS; MRI; REPRESENTATION; SCHIZOPHRENIA
AB Statistical analysis on arbitrary surface meshes such as the cortical surface is an important approach to understanding brain diseases such as Alzheimer's disease (AD). Surface analysis may be able to identify specific cortical patterns that relate to certain disease characteristics or exhibit differences between groups. Our goal in this paper is to make group analysis of signals on surfaces more sensitive. To do this, we derive multi-scale shape descriptors that characterize the signal around each mesh vertex, i.e., its local context, at varying levels of resolution. In order to define such a shape descriptor, we make use of recent results from harmonic analysis that extend traditional continuous wavelet theory from the Euclidean to a non-Euclidean setting (i.e., a graph, mesh or network). Using this descriptor, we conduct experiments on two different datasets, the Alzheimer's Disease NeuroImaging Initiative (ADNI) data and images acquired at the Wisconsin Alzheimer's Disease Research Center (W-ADRC), focusing on individuals labeled as having Alzheimer's disease (AD), mild cognitive impairment (MCI) and healthy controls. In particular, we contrast traditional univariate methods with our multi-resolution approach which show increased sensitivity and improved statistical power to detect a group-level effects. We also provide an open source implementation. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Kim, Won Hwa; Singh, Vikas; Hinrichs, Chris; Pachauri, Deepti] Univ Wisconsin, Dept Comp Sci, Madison, WI 53706 USA.
   [Singh, Vikas; Chung, Moo K.] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI 53705 USA.
   [Kim, Won Hwa; Singh, Vikas; Okonkwo, Ozioma C.; Johnson, Sterling C.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI 53705 USA.
   [Okonkwo, Ozioma C.; Johnson, Sterling C.] Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin Alzheimers Dis Res Ctr, Madison, WI 53792 USA.
RP Kim, WH (reprint author), Univ Wisconsin, Dept Comp Sci, 1210 W Dayton St, Madison, WI 53706 USA.
EM wonhwa@cs.wisc.edu; vsingh@biostat.wisc.edu
OI Kim, Won Hwa/0000-0001-5393-0883; Johnson, Sterling/0000-0002-8501-545X
FU NIH [R01AG040396, R01AG021155, P30 AG010129, K01 AG030514]; NSF [RI
   1116584]; NSF CAREER award [1252725]; UW ADRC [P50 AG033514]; Wisconsin
   Partnership Program; UW ICTR [1UL1RR025011]; CIBM pre-doctoral
   fellowship via NLM grant [5T15LM007359]; Alzheimer's Disease
   Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01
   AG024904]; National Institute on Aging; National Institute of Biomedical
   Imaging and Bioengineering; Canadian Institutes of Health Research
FX We provide a freely downloadable implementation of this framework at
   http://pages.cs.wisc.edu/-wonhwa/CTA_toolbox/. This research was
   supported by funding from NIH R01AG040396, NIH R01AG021155, NSF RI
   1116584, NSF CAREER award 1252725, UW ADRC (P50 AG033514), the Wisconsin
   Partnership Program, UW ICTR (1UL1RR025011)and Chris Hinrichs was
   supported by a CIBM pre-doctoral fellowship via NLM grant 5T15LM007359.
   We appreciate N. Maritza Dowling, Jennifer Oh, Vamsi Ithapu, Joon H. Lee
   and Gun W. Park for their help in processing the data and/or the
   preparation of this manuscript.; Data collection and sharing for this
   project were funded by the Alzheimer's Disease Neuroimaging Initiative
   (ADNI) (National Institutes of Health Grant U01 AG024904). ADNI is
   funded by the National Institute on Aging, the National Institute of
   Biomedical Imaging and Bioengineering, and through generous
   contributions from the following: Alzheimer's Association; Alzheimer's
   Drug Discovery Foundation; BioClinica, Inc.; Biogen Idec Inc.;
   Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals, Inc.;
   Eli Lilly and Company; F. Hoffmann-La Roche Ltd and its affiliated
   company Genentech, Inc.; GE Healthcare; Innogenetics, N.V.; IXICO Ltd.;
   Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson &
   Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck
   & Co., Inc.; Mesa Scale Diagnostics, LLC.; NeuroRx Research; Novartis
   Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier;
   Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes
   of Health Research is providing funds to support ADNI clinical sites in
   Canada. Private sector contributions are facilitated by the Foundation
   for the National Institutes of Health (www.fnih.org). The grantee
   organization is the Northern California Institute for Research and
   Education, and the study is coordinated by the Alzheimer's Disease
   Cooperative Study at the University of California, San Diego. ADNI data
   are disseininated by the Laboratory for Neuro Imaging at the University
   of California, Los Angeles. This research was also supported by NIH
   grants P30 AG010129 and K01 AG030514.
NR 52
TC 12
Z9 12
U1 0
U2 13
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
EI 1095-9572
J9 NEUROIMAGE
JI Neuroimage
PD JUN
PY 2014
VL 93
BP 107
EP 123
DI 10.1016/j.neuroimage.2014.02.028
PN 1
PG 17
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
   Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA AH7WW
UT WOS:000336347100010
PM 24614060
ER

PT J
AU Portelius, E
   Holtta, M
   Soininen, H
   Bjerke, M
   Zetterberg, H
   Westerlund, A
   Herukka, SK
   Blennow, K
   Mattsson, N
AF Portelius, Erik
   Holtta, Mikko
   Soininen, Hilkka
   Bjerke, Maria
   Zetterberg, Henrik
   Westerlund, Anni
   Herukka, Sanna-Kaisa
   Blennow, Kaj
   Mattsson, Niklas
TI Altered Cerebrospinal Fluid Levels of Amyloid beta and Amyloid
   Precursor-Like Protein 1 Peptides in Down's Syndrome
SO NEUROMOLECULAR MEDICINE
LA English
DT Article
DE Down's syndrome; Amyloid beta; Amyloid precursor-like protein 1; Mass
   spectrometry; Cerebrospinal fluid
ID ALZHEIMERS-DISEASE; BRAIN; BIOMARKER; CLEAVAGE; SYSTEM
AB Down's syndrome (DS) patients develop early Alzheimer's disease pathology with abundant cortical amyloid plaques, likely due to overproduction of the amyloid precursor protein (APP), which subsequently leads to amyloid beta (A beta) aggregation. This is reflected in cerebrospinal fluid (CSF) levels of the 42-amino acid long A beta peptide (A beta 1-42), which are increased in young DS patients and decreases with age. However, it is unclear whether DS also affects other aspects of A beta metabolism, including production of shorter C- and N-terminal truncated A beta peptides, and production of peptides from the amyloid precursor-like protein 1 (APLP1), which is related to APP, and cleaved by the same enzymatic processing machinery. APLP1-derived peptides may be surrogate markers for A beta 1-42 production in the brain. Here, we used hybrid immunoaffinity-mass spectrometry and enzyme-linked immunosorbent assays to monitor several A beta and APLP1 peptides in CSF from DS patients (n = 12) and healthy controls (n = 20). CSF levels of A beta 1-42 and three endogenous peptides derived from APLP1 (APL1 beta 25, APL1 beta 27 and APL1 beta 28) were decreased in DS compared with controls, while a specific A beta peptide, A beta 1-28, was increased in a majority of the DS individuals. This study indicates that DS causes previously unknown specific alterations of APP and APLP1 metabolism.
C1 [Portelius, Erik; Holtta, Mikko; Bjerke, Maria; Zetterberg, Henrik; Westerlund, Anni; Blennow, Kaj; Mattsson, Niklas] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, Gothenburg, Sweden.
   [Soininen, Hilkka; Herukka, Sanna-Kaisa] Kuopio Univ Hosp, SF-70210 Kuopio, Finland.
   [Soininen, Hilkka; Herukka, Sanna-Kaisa] Univ Eastern Finland, Inst Clin Med Neurol, Sch Med, Kuopio 70211, Finland.
   [Zetterberg, Henrik] UCL Inst Neurol, Dept Mol Neurosci, London WC1N 3BG, England.
   [Mattsson, Niklas] Univ Calif San Francisco, San Francisco VA Med Ctr, CIND, San Francisco, CA USA.
   [Mattsson, Niklas] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA.
RP Portelius, E (reprint author), Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, Gothenburg, Sweden.
EM erik.portelius@neuro.gu.se
FU Swedish Research Council [14002, K2010-63P-21562-01-4,
   K2011-61X-20401-05-6]; Stiftelsen Gamla Tjanarinnor; Magn. Bergvalls
   Stiftelse; Gun och Bertil Stohnes Stiftelse; Swedish Brain Fund;
   Alzheimer Foundation, Sweden; Dementia Association, Sweden; Wenner-gren
   foundation; Strategic for UEF-BRAIN; JPND Project BIOMARKAPD; Goteborgs
   Lakaresallskap; Svenska Lakaresallskapet; Klinisk Biokemi i Norden;
   Carl-Bertil Laurells fond
FX The study was supported by the Swedish Research Council (Project Nos.
   14002, K2010-63P-21562-01-4, K2011-61X-20401-05-6), Stiftelsen Gamla
   Tjanarinnor, Magn. Bergvalls Stiftelse, Gun och Bertil Stohnes
   Stiftelse, the Swedish Brain Fund, the Alzheimer Foundation, Sweden, the
   Dementia Association, Sweden, Wenner-gren foundation, Strategic for
   UEF-BRAIN and the JPND Project BIOMARKAPD, Goteborgs Lakaresallskap,
   Svenska Lakaresallskapet, Klinisk Biokemi i Norden, Carl-Bertil Laurells
   fond.
NR 26
TC 7
Z9 7
U1 1
U2 2
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1535-1084
EI 1559-1174
J9 NEUROMOL MED
JI Neuromol. Med.
PD JUN
PY 2014
VL 16
IS 2
BP 510
EP 516
DI 10.1007/s12017-014-8302-1
PG 7
WC Neurosciences
SC Neurosciences & Neurology
GA AH6EW
UT WOS:000336224500022
PM 24740518
ER

PT J
AU Kemmerly, T
   Vuong, C
   Kaunitz, JD
AF Kemmerly, Thomas
   Vuong, Carolyn
   Kaunitz, Jonathan D.
TI A Novel Phosphorus Repletion Strategy in a Patient With Duodenal
   Perforation
SO NUTRITION IN CLINICAL PRACTICE
LA English
DT Article
DE adult; nutrition; phosphates; duodenum; drug shortage; parenteral
   formulas/compounding; GI access; phosphorus;
   fluids-electrolytes/acid-base; enteral access; parenteral nutrition;
   enema; life cycle; minerals/trace elements
ID SEVERE HYPOPHOSPHATEMIA; ENEMA; HYPERPHOSPHATEMIA; NUTRITION
AB We describe a case in which a patient receiving parenteral nutrition (PN) developed hypophosphatemia. Due to lack of availability of parenteral phosphate supplements, we chose to restore phosphate using diluted hypertonic sodium phosphate enemas. Due to the recent shortages of parenteral minerals and vitamins, such an alternate means of repletion is of increasing importance. Diluted hypertonic sodium phosphate enemas are inexpensive, easy to administer, and effective since phosphate is readily absorbed across the rectal mucosa. We hope that through this type of repletion, life-threatening hypophosphatemia among patients receiving PN can be avoided.
C1 [Kemmerly, Thomas] Cedars Sinai Med Residency Program, Los Angeles, CA USA.
   [Vuong, Carolyn] WLAVA Med Ctr, Greater Los Angeles Vet Affairs Healthcare Syst, Dept Med, Los Angeles, CA USA.
   [Vuong, Carolyn] WLAVA Med Ctr, Greater Los Angeles Vet Affairs Healthcare Syst, Dept Pharm, Los Angeles, CA USA.
   [Kaunitz, Jonathan D.] UCLA Sch Med, Dept Med, Los Angeles, CA 90073 USA.
   [Kaunitz, Jonathan D.] UCLA Sch Med, Dept Surg, Los Angeles, CA 90073 USA.
   [Kaunitz, Jonathan D.] Brentwood Biomed Res Inst, Los Angeles, CA USA.
RP Kaunitz, JD (reprint author), UCLA Sch Med, West Los Angeles VAMC, Bldg 114,Room 217E, Los Angeles, CA 90073 USA.
EM jake@ucla.edu
FU NIDDK NIH HHS [R01 DK054221]
NR 17
TC 1
Z9 1
U1 0
U2 2
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0884-5336
EI 1941-2452
J9 NUTR CLIN PRACT
JI Nutr. Clin. Pract.
PD JUN
PY 2014
VL 29
IS 3
BP 402
EP 405
DI 10.1177/0884533614529997
PG 4
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA AH0FP
UT WOS:000335794900020
PM 24743045
ER

PT J
AU Conhaim, RL
   Watson, KE
   Dovi, WF
   Bates, ML
AF Conhaim, Robert L.
   Watson, Kal E.
   Dovi, William F.
   Bates, Melissa L.
TI INHALED THROMBOLYTICS REDUCE LUNG MICROCLOT AND LEUKOCYTE INFILTRATION
   AFTER ACUTE BLOOD LOSS
SO SHOCK
LA English
DT Article
DE Acute lung injury; neutrophils; thromboembolism; shock lung; pulmonary
   circulation; fibrinolysis
ID NEBULIZED ANTICOAGULANTS; INTERALVEOLAR PERFUSION; FIBRIN; RATS; INJURY;
   MICROVESSELS; COAGULOPATHY; INFLAMMATION; EDEMA
AB We showed previously that a 30% blood loss in rats, without resuscitation, caused significant accumulation of microthrombi and leukocytes within the pulmonary circulation by 24 h. We hypothesized that the microthrombi formed spontaneously as a consequence of hemorrhage-induced stasis within the low-pressure pulmonary circuit and that the leukocytes were attracted to them. This suggested that elimination of the microthrombi, using an inhaled thrombolytic agent, could prevent the neutrophil sequestration after blood loss. To test this hypothesis, we removed 30% of the calculated blood volume from isoflurane-anesthetized, male Sprague-Dawley rats (350-500 g) over 5 min and allowed them to recover. Six hours later, we reanesthetized the rats and nebulized tissue plasminogen activator (80 or 320 mu g/kg), lactated Ringer's solution (LRS), or ipratropium bromide (i-bromide) into their lungs. We used i-bromide as a control after we discovered that nebulized LRS had thrombolytic properties. At 24 h, we removed and fixed the lungs and prepared sections for immunohistochemistry using antibodies against fibrinogen (microthrombi) and CD16 (leukocytes). Digital images of each section were obtained using a confocal microscope. Pixel counts of the images showed significantly less accumulation of microthrombi and leukocytes in lungs nebulized with tissue plasminogen activator or LRS than in nonnebulized lungs or in lungs nebulized with i-bromide (P 0.05). Lactated Ringer's solution becomes positively charged when nebulized (unlike i-bromide), suggesting that it eliminated microthrombi by fibrin depolymerization. We confirmed this using an in vitro assay. Our results demonstrate that lyses of microthrombi that accumulate in the lung after acute blood loss prevent subsequent leukocyte sequestration.
C1 [Conhaim, Robert L.; Watson, Kal E.] Univ Wisconsin, Dept Surg, Sch Med & Publ Heath, Madison, WI USA.
   [Conhaim, Robert L.; Dovi, William F.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
   [Bates, Melissa L.] Univ Wisconsin, Dept Pediat, Sch Med & Publ Heath, Madison, WI USA.
RP Conhaim, RL (reprint author), H5-301-BX3236,600 Highland Ave, Madison, WI 53792 USA.
EM rconhaim@wisc.edu
FU Veterans Health Administration, Office of Research and Development,
   Department of Veterans Affairs, Biomedical Laboratory Research and
   Development Service
FX This study was supported by the Veterans Health Administration, Office
   of Research and Development, Department of Veterans Affairs, Biomedical
   Laboratory Research and Development Service (R. L. C., principal
   investigator).
NR 24
TC 1
Z9 1
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1073-2322
EI 1540-0514
J9 SHOCK
JI Shock
PD JUN
PY 2014
VL 41
IS 6
BP 528
EP 536
DI 10.1097/SHK.0000000000000149
PG 9
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
   & Cardiology
GA AH6CI
UT WOS:000336217900010
PM 24837203
ER

PT J
AU Paruch, JL
   Merkow, RP
   Bentrem, DJ
   Ko, CY
   Posner, MC
   Cohen, ME
   Bilimoria, KY
   Weber, SM
AF Paruch, Jennifer L.
   Merkow, Ryan P.
   Bentrem, David J.
   Ko, Clifford Y.
   Posner, Mitchell C.
   Cohen, Mark E.
   Bilimoria, Karl Y.
   Weber, Sharon M.
TI Impact of Hepatectomy Surgical Complexity on Outcomes and Hospital
   Quality Rankings
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Article
ID RISK-ADJUSTMENT; IMPROVEMENT PROGRAM; LIVER RESECTION; NSQIP; SURGERY;
   MODELS
AB There is substantial variation in the surgical complexity of hepatectomy. Currently, the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) risk adjusts for hospital quality comparisons using only the primary procedure code. Our objectives were to (1) assess the association between secondary procedures and complications; (2) assess model performance with inclusion of surgical complexity adjustment; and (3) examine whether secondary procedures affect hospital quality rankings.
   Using ACS NSQIP (2007-2012), patients undergoing hepatectomy were identified. Secondary procedure codes and total work relative value units (RVUs) were used to approximate procedural complexity. The effect of procedural complexity variables on outcomes and hospital quality rankings were examined using hierarchical models.
   Among 11,826 patients who underwent hepatectomy at 261 hospitals, 32.8 % underwent at least one secondary procedure. Serious morbidity occurred in 18.0 % of patients. Seven of nine secondary procedures were significantly associated with death or serious morbidity on multivariable analysis. Model performance improved when secondary procedure categories were included, and secondary procedure categories outperformed total RVUs. The C-statistic for death or serious morbidity was 0.689 in the standard NSQIP model, 0.703 when total RVU was included, and 0.718 when secondary procedure categories were included. Of the 26 hospitals that were poor performers for death or serious morbidity using the standard ACS NSQIP model, three became average performers when secondary procedure categories were included in the model.
   Secondary procedures are associated with an increased risk of postoperative complications. Inclusion of secondary procedure code categories in research and risk prediction models should be considered for hepatectomy.
C1 [Paruch, Jennifer L.; Merkow, Ryan P.; Ko, Clifford Y.; Cohen, Mark E.; Bilimoria, Karl Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL 60611 USA.
   [Paruch, Jennifer L.; Merkow, Ryan P.; Posner, Mitchell C.] Univ Chicago, Dept Surg, Pritzker Sch Med, Chicago, IL 60637 USA.
   [Merkow, Ryan P.; Bentrem, David J.; Bilimoria, Karl Y.] Northwestern Univ, Dept Surg, Surg Outcomes & Qual Improvement Ctr, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Merkow, Ryan P.; Bentrem, David J.; Bilimoria, Karl Y.] Northwestern Univ, Northwestern Inst Comparat Effectiveness Res Onco, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.
   [Bentrem, David J.] Jesse Brown VA Med Ctr, Dept Surg, Chicago, IL USA.
   [Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA.
   [Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
   [Weber, Sharon M.] Univ Wisconsin, Dept Surg, Sch Med & Publ Hlth, Madison, WI USA.
RP Paruch, JL (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL 60611 USA.
EM jlparuch@gmail.com
FU American Cancer Society; National Comprehensive Cancer Network
FX This work was supported in part by the American Cancer Society (Drs.
   Merkow and Bilimoria) and the National Comprehensive Cancer Network (Dr.
   Bilimoria).
NR 20
TC 8
Z9 8
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
EI 1534-4681
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD JUN
PY 2014
VL 21
IS 6
BP 1773
EP 1780
DI 10.1245/s10434-014-3500-5
PG 8
WC Oncology; Surgery
SC Oncology; Surgery
GA AG9GH
UT WOS:000335726900005
PM 24558060
ER

PT J
AU Baldwin, MR
   Reid, MC
   Westlake, AA
   Rowe, JW
   Granieri, EC
   Wunsch, H
   Dam, TT
   Rabinowitz, D
   Goldstein, NE
   Maurer, MS
   Lederer, DJ
AF Baldwin, Matthew R.
   Reid, M. Cary
   Westlake, Amanda A.
   Rowe, John W.
   Granieri, Evelyn C.
   Wunsch, Hannah
   Thuy-Tien Dam
   Rabinowitz, Daniel
   Goldstein, Nathan E.
   Maurer, Mathew S.
   Lederer, David J.
TI The feasibility of measuring frailty to predict disability and mortality
   in older medical intensive care unit survivors
SO JOURNAL OF CRITICAL CARE
LA English
DT Article
DE Aged; Critically Ill; Frailty; Disability; Mortality
ID PROLONGED MECHANICAL VENTILATION; CHRONIC CRITICAL ILLNESS; ACQUIRED
   WEAKNESS; FUNCTIONAL STATUS; RANDOMIZED-TRIAL; MUSCLE STRENGTH;
   SKELETAL-MUSCLE; CRITICALLY-ILL; ADULTS; OUTCOMES
AB Purpose: To determine whether frailty can be measured within 4 days prior to hospital discharge in older intensive care unit (ICU) survivors of respiratory failure and whether it is associated with post-discharge disability and mortality.
   Materials and Methods: We performed a single-center prospective cohort study of 22 medical ICU survivors age 65 years or older who had received noninvasive or invasive mechanical ventilation for at least 24 hours. Frailty was defined as a score of >= 3 using Fried's 5-point scale. We measured disability with the Katz Activities of Daily Living. We estimated unadjusted associations between Fried's frailty score and incident disability at 1-month and 6-month mortality using Cox proportional hazard models.
   Results: The mean (SD) age was 77 (9) years, mean Acute Physiology and Chronic Health Evaluation II score was 27 (9.7), mean frailty score was 3.4 (1.3), and 18 (82%) were frail. Nine subjects (41%) died within 6 months, and all were frail. Each 1-point increase in frailty score was associated with a 90% increased rate of incident disability at 1-month (rate ratio: 1.9, 95% CI 0.7-4.9) and a threefold increase in 6-month mortality (rate ratio: 3.0, 95% CI 1.4-6.3).
   Conclusions: Frailty can be measured in older ICU survivors near hospital discharge and is associated with 6-month mortality in unadjusted analysis. Larger studies to determine if frailty independently predicts outcomes are warranted. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Baldwin, Matthew R.; Westlake, Amanda A.; Lederer, David J.] Columbia Univ, Coll Phys & Surg, Div Pulm & Crit Care, New York, NY USA.
   [Reid, M. Cary] Weill Cornell Med Ctr, Div Geriatr, New York, NY USA.
   [Rowe, John W.] Columbia Univ, Mailman Sch Publ Hlth, Dept Hlth Policy, New York, NY USA.
   [Granieri, Evelyn C.] Columbia Univ, Coll Phys & Surg, Div Geriatr Med & Aging, New York, NY USA.
   [Wunsch, Hannah; Thuy-Tien Dam; Lederer, David J.] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA.
   [Wunsch, Hannah] Columbia Univ, Coll Phys & Surg, Dept Anesthesiol, New York, NY USA.
   [Rabinowitz, Daniel] Columbia Univ, Dept Stat, New York, NY 10027 USA.
   [Goldstein, Nathan E.] Mt Sinai Sch Med, Div Geriatr & Palliat Med, New York, NY USA.
   [Goldstein, Nathan E.] James J Peters VA Med Ctr, Clin Ctr, New York, NY USA.
   [Maurer, Mathew S.] Columbia Univ, Coll Phys & Surg, Div Cardiol, New York, NY USA.
RP Baldwin, MR (reprint author), 622 W 168th St,PH-8,Room 101, New York, NY 10032 USA.
EM mrb45@columbia.edu
OI Reid, Cary/0000-0001-8117-662X; Lederer, David/0000-0001-5258-0228
FU National Institute on Aging (NIA) [3P30AG022845-078]
FX The authors of this manuscript have no conflicts of interest to disclose
   as described by the Journal of Critical Care. This study was funded by a
   sub-contract pilot grant from grant 3P30AG022845-078 from the National
   Institute on Aging (NIA), and the NIA had no role in the study design,
   analysis, or manuscript approval.
NR 51
TC 11
Z9 11
U1 5
U2 13
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0883-9441
EI 1557-8615
J9 J CRIT CARE
JI J. Crit. Care
PD JUN
PY 2014
VL 29
IS 3
BP 401
EP 408
DI 10.1016/j.jcrc.2013.12.019
PG 8
WC Critical Care Medicine
SC General & Internal Medicine
GA AH0OA
UT WOS:000335818300016
PM 24559575
ER

PT J
AU Schilero, GJ
   Radulovic, M
   Wecht, JM
   Spungen, AM
   Bauman, WA
   Lesser, M
AF Schilero, Gregory J.
   Radulovic, Miroslav
   Wecht, Jill M.
   Spungen, Ann M.
   Bauman, William A.
   Lesser, Marvin
TI A Center's Experience: Pulmonary Function in Spinal Cord Injury
SO LUNG
LA English
DT Review
DE Spinal cord injury; Tetraplegia; Pulmonary function; Respiratory muscle
   function; Nonspecific airway hyperreactivity; Airway inflammation;
   Obstructive sleep apnea
ID GASTROESOPHAGEAL-REFLUX DISEASE; OBSTRUCTIVE SLEEP-APNEA; AIR-FLOW
   OBSTRUCTION; RIB CAGE MOTION; BRONCHIAL HYPERRESPONSIVENESS; INDUCED
   BRONCHOCONSTRICTION; RESPIRATORY MECHANICS; TETRAPLEGIC SUBJECTS;
   IPRATROPIUM BROMIDE; VITAL CAPACITY
AB Traumatic spinal cord injury (SCI) is associated with significant psychological and physical challenges. A multidisciplinary approach to management is essential to ensure recovery during the acute phase, and comprehensive rehabilitative strategies are necessary to foster independence and quality of life throughout the chronic phase of injury. Complications that beset these individuals are often a unique consequence of SCI, and knowledge of the effects of SCI upon organ systems is essential for appropriate management. According to the National SCI Statistical Center (NSCISC), as of 2010 there were an estimated 265,000 persons living with SCI in the United States, with approximately 12,000 incidence cases annually. Although life expectancy for newly injured individuals with SCI is markedly reduced, persons with chronic SCI are expected to live about as long as individuals without SCI; however, longevity varies inversely with level of injury. Since 2005, 56 % of persons with SCI are tetraplegic, and due to paralysis of respiratory muscles, these individuals may be especially prone to pulmonary complications, which remain a major cause of mortality among persons with chronic SCI. We at the VA Rehabilitation Research and Development Center of Excellence for the Medical Consequences of SCI at the James J. Peters VA Medical Center have devoted more than 25 years to the study of secondary medical conditions that complicate SCI. Herein, we review pulmonary research at the Center, both our past and future endeavors, which form an integral part of our multidisciplinary approach toward achieving a greater understanding of and improving care for veterans with SCI.
C1 [Schilero, Gregory J.; Radulovic, Miroslav; Wecht, Jill M.; Spungen, Ann M.; Bauman, William A.; Lesser, Marvin] James J Peters VA Med Ctr, Bronx, NY 10468 USA.
   [Schilero, Gregory J.; Radulovic, Miroslav; Wecht, Jill M.; Spungen, Ann M.; Bauman, William A.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
RP Schilero, GJ (reprint author), James J Peters VA Med Ctr, Bronx, NY 10468 USA.
EM greg.schilero@va.gov
NR 63
TC 2
Z9 2
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0341-2040
EI 1432-1750
J9 LUNG
JI Lung
PD JUN
PY 2014
VL 192
IS 3
BP 339
EP 346
DI 10.1007/s00408-014-9575-8
PG 8
WC Respiratory System
SC Respiratory System
GA AH3LU
UT WOS:000336025900001
PM 24723067
ER

PT J
AU Tang, HY
   Sayers, SL
   Weissinger, G
   Riegel, B
AF Tang, Hsin-Yi (Jean)
   Sayers, Steven L.
   Weissinger, Guy
   Riegel, Barbara
TI The Role of Depression in Medication Adherence Among Heart Failure
   Patients
SO CLINICAL NURSING RESEARCH
LA English
DT Article
DE heart failure; depression; major depressive disorders; medication
   adherence
ID SELF-REPORT; NONADHERENCE; DISEASE; ANXIETY; RECOMMENDATIONS;
   NONCOMPLIANCE; INTERVENTION; METAANALYSIS; ASSOCIATION; PREVALENCE
AB The purpose of the study was to explore the association between depression and medication adherence in heart failure (HF) patients. Studies have shown that people with depression are likely to be nonadherent to their prescribed medication treatment. But other studies suggest that nonadherence may be overestimated by people with depression. A total of 244 adults with Stage C HF completed the study. Self-reported medication adherence was obtained using the Basel Assessment of Adherence Scale (BAAS); objective data on medication adherence were collected using the electronic Medication Event Monitoring System (MEMS). Depression was measured via self-report with the Patient Health Questionnaire (PHQ-9). There was a significant difference between depressed and nondepressed participants in self-reported medication nonadherence (p = .008), but not in objectively measured medication nonadherence (p = .72). The depressed sample was 2.3 times more likely to self-report poor medication adherence than those who were nondepressed (p = .006).
C1 [Tang, Hsin-Yi (Jean)] Seattle Univ, Coll Nursing, Seattle, WA 98125 USA.
   [Sayers, Steven L.] Vet Affairs Med Ctr, Philadelphia, PA USA.
   [Weissinger, Guy] Univ Penn, Perelman Sch Med, Aaron T Beck Ctr Psychopathol Res, Philadelphia, PA 19104 USA.
   [Riegel, Barbara] Univ Penn, Sch Nursing, Biobehav Res Ctr, Philadelphia, PA 19104 USA.
RP Tang, HY (reprint author), Seattle Univ, Coll Nursing, 901 12th Ave POB 222000, Seattle, WA 98125 USA.
EM jeantang@u.washington.edu
FU National Heart, Lung & Blood Institute [RO1 HL084394-01A1]; Philadelphia
   Veterans Affairs Medical Center, VISN 4 Mental Illness Research,
   Education, and Clinical Center (MIREC); Hope Heart Institute, Seattle,
   Washington
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: This work was
   funded by (a) National Heart, Lung & Blood Institute (RO1
   HL084394-01A1), (b) Philadelphia Veterans Affairs Medical Center, VISN 4
   Mental Illness Research, Education, and Clinical Center (MIREC) [the
   opinions expressed herein do not represent the official policy of the
   Department of Veterans Affairs], and (c) Hope Heart Institute, Seattle,
   Washington.
NR 40
TC 5
Z9 5
U1 2
U2 8
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1054-7738
EI 1552-3799
J9 CLIN NURS RES
JI Clin. Nurs. Res.
PD JUN
PY 2014
VL 23
IS 3
BP 231
EP 244
DI 10.1177/1054773813481801
PG 14
WC Nursing
SC Nursing
GA AG7EF
UT WOS:000335580200001
PM 23548500
ER

PT J
AU Shores, MM
   Matsumoto, AM
AF Shores, Molly M.
   Matsumoto, Alvin M.
TI Testosterone, aging and survival: biomarker or deficiency
SO CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY
LA English
DT Review
DE aging; androgens; biomarker; mortality; testosterone
ID LOW SERUM TESTOSTERONE; ALL-CAUSE MORTALITY; CORONARY-HEART-DISEASE;
   PLACEBO-CONTROLLED TRIALS; ENDOGENOUS SEX-HORMONES; POPULATION-BASED
   COHORT; LIFE-STYLE FACTORS; QUALITY-OF-LIFE; OLDER MEN;
   CARDIOVASCULAR-DISEASE
AB Purpose of reviewThe purpose of this study is to review recent studies that examined the association of endogenous and exogenous testosterone and mortality in older men.Recent findingsOver the past several years, there has been a steep rise in testosterone prescriptions. The increased use of testosterone occurred in the context of several studies that reported an association between low serum testosterone and increased cardiovascular events and mortality. In contrast, recent studies have reported an association between testosterone treatment and adverse events. A testosterone treatment trial of mobility-impaired elderly men with prevalent cardiovascular disease was stopped due to increased cardiovascular events in the T-treated men and a meta-analysis reported increased cardiovascular events in T-treated men. In two recent large observational studies, testosterone treatment was associated with an increased risk for serious adverse cardiovascular events.SummaryLow testosterone is associated with mortality in multiple cohort studies; however, it is unclear if this is a causal association or due to low testosterone being a biomarker of poor health. Given recent reports of adverse outcomes associated with testosterone treatment, a conservative use of testosterone is warranted in men with cardiovascular disease who may be at greater risk for adverse outcomes.
C1 [Shores, Molly M.] VA Puget Sound Healthcare Syst, Seattle, WA 98108 USA.
   [Shores, Molly M.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
   [Matsumoto, Alvin M.] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA USA.
   [Matsumoto, Alvin M.] GRECC, Seattle, WA USA.
RP Shores, MM (reprint author), VA Puget Sound Healthcare Syst, 1660 S Columbian Way,S-116A, Seattle, WA 98108 USA.
EM molly.shores@va.gov
FU VA Research Service; VA Geriatric Research Education and Clinical Center
   (GRECC); 1R01 AG042934-01; AbbVie; GSK Pharmaceuticals; Advisory Board
   for Abbott; Advisory Board for Endo; Forendo Pharmaceuticals; UpToDate.
FX The research was supported by the VA Research Service, the VA Geriatric
   Research Education and Clinical Center (GRECC) and by 1R01 AG042934-01.;
   Disclosure summary: Dr Matsumoto has the following disclosures to make -
   Research support from AbbVie and GSK Pharmaceuticals; Advisory Board for
   Abbott, Endo, and Forendo Pharmaceuticals; and Editor for UpToDate.
NR 80
TC 4
Z9 4
U1 0
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1752-296X
EI 1752-2978
J9 CURR OPIN ENDOCRINOL
JI Curr. Opin. Endocrinol. Diabetes Obes.
PD JUN
PY 2014
VL 21
IS 3
BP 209
EP 216
DI 10.1097/MED.0000000000000057
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA AG5FS
UT WOS:000335445500009
PM 24722173
ER

PT J
AU Punnen, S
   Freedland, SJ
   Presti, JC
   Aronson, WJ
   Terris, MK
   Kane, CJ
   Amling, CL
   Carroll, PR
   Cooperberg, MR
AF Punnen, Sanoj
   Freedland, Stephen J.
   Presti, Joseph C., Jr.
   Aronson, William J.
   Terris, Martha K.
   Kane, Christopher J.
   Amling, Christopher L.
   Carroll, Peter R.
   Cooperberg, Matthew R.
TI Multi-institutional Validation of the CAPRA-S Score to Predict Disease
   Recurrence and Mortality After Radical Prostatectomy
SO EUROPEAN UROLOGY
LA English
DT Article
DE Nomogram; Outcomes; Prostate cancer; Radical prostatectomy
ID RANDOMIZED CLINICAL-TRIAL; UNIVERSITY-OF-CALIFORNIA; RISK-ASSESSMENT
   SCORE; BIOCHEMICAL RECURRENCE; ADJUVANT RADIOTHERAPY; EXTERNAL
   VALIDATION; CANCER RECURRENCE; SAN-FRANCISCO; MODELS; SURVIVAL
AB Background: The University of California, San Francisco, Cancer of the Prostate Risk Assessment Postsurgical (CAPRA-S) score uses pathologic data from radical prostatectomy (RP) to predict prostate cancer recurrence and mortality. However, this clinical tool has never been validated externally.
   Objective: To validate CAPRA-S in a large, multi-institutional, external database.
   Design, setting, and participants: The Shared Equal Access Regional Cancer Hospital (SEARCH) database consists of 2892 men who underwent RP from 2001 to 2011. With a median follow-up of 58 mo, 2670men(92%) had complete data to calculate a CAPRA-S score. Intervention: RP.
   Outcome measurements and statistical analysis: The main outcome was biochemical recurrence. Performance of CAPRA-S in detecting recurrence was assessed and compared with a validated postoperative nomogram by concordance index (c-index), calibration plots, and decision curve analysis. Prediction of cancer-specific mortality was assessed by Kaplan-Meier analysis and the c-index. Results and limitations: The mean age was 62 yr (standard deviation: 6.3), and 34.3% of men had recurrence. The 5-yr progression-free probability for those patients with a CAPRA-S score of 0-2, 3-5, and 6-10 (defining low, intermediate, and high risk) was 72%, 39%, and 17%, respectively. The CAPRA-S c-index was 0.73 in this validation set, compared with a c-index of 0.72 for the Stephenson nomogram. Although CAPRA-S was optimistic in predicting the likelihood of being free of recurrence at 5 yr, it outperformed the Stephenson nomogram on both calibration plots and decision curve analysis. The cindex for predicting cancer-specific mortality was 0.85, with the caveat that this number is based on only 61 events.
   Conclusions: In this external validation, the CAPRA-S score predicted recurrence and mortality after RP with a c-index > 0.70. The score is an effective prognostic tool that may aid in determining the need for adjuvant therapy. (C) 2013 European Association of Urology. Published by Elsevier B. V. All rights reserved.
C1 [Punnen, Sanoj; Carroll, Peter R.; Cooperberg, Matthew R.] Univ Calif San Francisco, Dept Urol, Ctr Comprehens Canc, San Francisco, CA 94143 USA.
   [Freedland, Stephen J.] Duke Univ, Dept Surg, Div Urol, Durham, NC USA.
   [Freedland, Stephen J.] Durham Vet Adm Med Ctr, Urol Sect, Durham, NC USA.
   [Presti, Joseph C., Jr.] Stanford Univ, Sch Med, Dept Urol, Stanford, CA 94305 USA.
   [Presti, Joseph C., Jr.] Vet Adm Med Ctr, Dept Surg, Urol Sect, Palo Alto, CA 94304 USA.
   [Aronson, William J.] Vet Adm Greater Los Angeles Healthcare Syst, Urol Sect, Dept Surg, Los Angeles, CA USA.
   [Aronson, William J.] Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA USA.
   [Terris, Martha K.] Vet Adm Med Ctr, Dept Surg, Urol Sect, Augusta, GA 30904 USA.
   [Terris, Martha K.] Med Coll Georgia, Dept Surg, Augusta, GA 30912 USA.
   [Kane, Christopher J.] Univ Calif San Diego, Dept Urol, San Diego, CA 92103 USA.
   [Amling, Christopher L.] Oregon Hlth & Sci Univ, Dept Urol, Portland, OR USA.
   [Cooperberg, Matthew R.] Vet Adm Med Ctr, Dept Surg, Urol Sect, San Francisco, CA 94121 USA.
RP Cooperberg, MR (reprint author), Univ Calif San Francisco, Dept Urol, 1600 Divisadero St,Box 1695, San Francisco, CA 94143 USA.
EM mcooperberg@urology.ucsf.edu
OI Terris, Martha/0000-0002-3843-7270
FU US Department of Veterans Affairs; US Department of Defense; Prostate
   Cancer Research Program; NIH [R01CA100938]; NIH Specialized Programs of
   Research Excellence [P50 CA92131-01A1]; Georgia Cancer Coalition;
   American Urological Association Foundation/Astellas Rising Star in
   Urology Award
FX Funding for the collection and management of the data was from the US
   Department of Veterans Affairs, the US Department of Defense, Prostate
   Cancer Research Program (C.J.K., S.J.F), NIH R01CA100938 (W.J.A), NIH
   Specialized Programs of Research Excellence Grant P50 CA92131-01A1
   (W.J.A), Georgia Cancer Coalition (M.K.T), and the American Urological
   Association Foundation/Astellas Rising Star in Urology Award (S.J.E).
   Views and opinions of and endorsements by the authors do not reflect
   thsoe of the US Army or the Department of Defense.
NR 26
TC 40
Z9 41
U1 1
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0302-2838
EI 1873-7560
J9 EUR UROL
JI Eur. Urol.
PD JUN
PY 2014
VL 65
IS 6
BP 1171
EP 1177
DI 10.1016/j.eururo.2013.03.058
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA AG4JV
UT WOS:000335386700044
PM 23587869
ER

PT J
AU Byers, AL
   Yaffe, K
AF Byers, Amy L.
   Yaffe, Kristine
TI Depression and dementias among military veterans
SO ALZHEIMERS & DEMENTIA
LA English
DT Article
DE Dementia; Alzheimer's disease; Cognitive impairment; Depression;
   Posttraumatic stress disorder; Traumatic brain injury; Older veterans
ID TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; MILD COGNITIVE
   IMPAIRMENT; LATE-LIFE DEPRESSION; WHITE-MATTER HYPERINTENSITIES;
   CARDIOVASCULAR RISK-FACTORS; ALZHEIMERS-DISEASE; HIPPOCAMPAL VOLUME;
   MAJOR DEPRESSION; GERIATRIC DEPRESSION
AB Depression is very common throughout the course of veterans' lives, and dementia is common in late life. Previous studies suggest an association between depression and dementia in military veterans. The most likely biologic mechanisms that may link depression and dementia among military veterans include vascular disease, changes in glucocorticoid steroids and hippocampal atrophy, deposition of beta-amyloid plaques, inflammatory changes, and alterations of nerve growth factors. In addition, military veterans often have depression comorbid with posttraumatic stress disorder or traumatic brain injury. Therefore, in military veterans, these hypothesized biologic pathways going from depression to dementia are more than likely influenced by trauma-related processes. Treatment strategies for depression, posttraumatic stress disorder, or traumatic brain injury could alter these pathways and as a result decrease the risk for dementia. Given the projected increase of dementia, as well as the projected increase in the older segment of the veteran population, in the future, it is critically important that we understand whether treatment for depression alone or combined with other regimens improves cognition. In this review, we summarize the principal mechanisms of this relationship and discuss treatment implications in military veterans. (C) 2014 The Alzheimer's Association. All rights reserved.
C1 [Byers, Amy L.; Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA.
   [Byers, Amy L.; Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA.
   [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
   [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
RP Byers, AL (reprint author), Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA.
EM Amy.Byers@ucsf.edu
FU United States Army Medical Research and Materiel Command
FX Publication of this article was supported by the United States Army
   Medical Research and Materiel Command.
NR 114
TC 5
Z9 6
U1 5
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1552-5260
EI 1552-5279
J9 ALZHEIMERS DEMENT
JI Alzheimers. Dement.
PD JUN
PY 2014
VL 10
IS 3
SU 1
BP S166
EP S173
DI 10.1016/j.jalz.2014.04.007
PG 8
WC Clinical Neurology
SC Neurosciences & Neurology
GA CP8GM
UT WOS:000360130700011
PM 24924668
ER

PT J
AU Durazzo, TC
   Mattsson, N
   Weiner, MW
AF Durazzo, Timothy C.
   Mattsson, Niklas
   Weiner, Michael W.
CA Alzheimer's Dis Neuroimaging
TI Smoking and increased Alzheimer's disease risk: A review of potential
   mechanisms
SO ALZHEIMERS & DEMENTIA
LA English
DT Article
DE Alzheimer's disease; Cigarette smoking; Tobacco; Risk; Amyloid; Tau;
   Military; Oxidative stress; US Armed Services
ID CHRONIC CIGARETTE-SMOKING; MILD COGNITIVE IMPAIRMENT; ALCOHOL-DEPENDENT
   INDIVIDUALS; POSITRON-EMISSION-TOMOGRAPHY; CEREBRAL AMYLOID ANGIOPATHY;
   NICOTINIC ACETYLCHOLINE-RECEPTOR; TRAUMATIC BRAIN-INJURY; PITTSBURGH
   COMPOUND-B; FREE-RADICAL DAMAGE; STRESS IN-VIVO
AB Background: Cigarette smoking has been linked with both increased and decreased risk for Alzheimer's disease (AD). This is relevant for the US military because the prevalence of smoking in the military is approximately 11% higher than in civilians.
   Methods: A systematic review of published studies on the association between smoking and increased risk for AD and preclinical and human literature on the relationships between smoking, nicotine exposure, and AD-related neuropathology was conducted. Original data from comparisons of smoking and never-smoking cognitively normal elders on in vivo amyloid imaging are also presented.
   Results: Overall, literature indicates that former/active smoking is related to a significantly increased risk for AD. Cigarette smoke/smoking is associated with AD neuropathology in preclinical models and humans. Smoking-related cerebral oxidative stress is a potential mechanism promoting AD pathology and increased risk for AD.
   Conclusions: A reduction in the incidence of smoking will likely reduce the future prevalence of AD. (C) 2014 The Alzheimer's Association. All rights reserved.
C1 [Durazzo, Timothy C.; Mattsson, Niklas; Weiner, Michael W.] San Francisco VA Med Ctr, CIND, San Francisco, CA 94121 USA.
   [Durazzo, Timothy C.; Mattsson, Niklas; Weiner, Michael W.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA.
   [Mattsson, Niklas] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Clin Neurochem Lab, Molndal, Sweden.
   [Weiner, Michael W.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
   [Weiner, Michael W.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
   [Weiner, Michael W.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
RP Durazzo, TC (reprint author), San Francisco VA Med Ctr, CIND, San Francisco, CA 94121 USA.
EM timothy.durazzo@ucsf.edu
FU National Institutes of Health [NIH DA24136, P30 AG010129, K01 AG030514,
   R01 AG010897, R01 AG012435]; ADNI; National Institute on Aging [U01
   AG024904]; National Institute of Biomedical Imaging and Bioengineering;
   Dana Foundation
FX T.C.D. was responsible for the concept and design of the review,
   completed all statistical analyses on the original data presented, and
   wrote the original and revised versions of the manuscript. N.M. and
   M.W.W. were involved in manuscript editing, data interpretation, and
   manuscript draft revisions. T.C.D. had full access to all the original
   data presented study and takes responsibility for the integrity of the
   data and the accuracy of the data analyses. This work was supported by
   the National Institutes of Health (NIH DA24136 to T.C.D.) and by the use
   of resources and facilities at the San Francisco Veterans Administration
   Medical Center. Florbetapir data collection and sharing for this project
   was funded by ADNI. ADNI is funded by the National Institute on Aging
   (U01 AG024904), the National Institute of Biomedical Imaging and
   Bioengineering, and through generous contributions from the following:
   Abbott; AstraZeneca AB; Bayer Schering Pharma AG; Bristol-Myers Squibb;
   Eisai Global Clinical Development; Elan Corporation; Genentech; GE
   Healthcare; GlaxoSmithKline; Innogenetics; Johnson and Johnson; Eli
   Lilly and Co.; Medpace, Inc.; Merck and Co., Inc.; Novartis AG; Pfizer
   Inc; F. Hoffman-La Roche; Schering-Plough; Synarc, Inc.; and Wyeth, as
   well as nonprofit partners such as the Alzheimer's Association and
   Alzheimer Drug Discovery Foundation, with participation from the U.S.
   Food and Drug Administration. Private sector contributions to ADNI are
   facilitated by the Foundation for the National Institutes of Health
   (www.fnih.org; http://www.fnih.org; http://www.fnih.org;
   http://www.fnih.org). The grantee organization is the Northern
   California Institute for Research and Education, and the study is
   coordinated by the Alzheimer's Disease Cooperative Study at the
   University of California, San Diego. ADNI data are disseminated by the
   Laboratory for Neuro Imaging at the University Southern California. This
   research was also supported by National Institutes of Health grants P30
   AG010129, K01 AG030514, R01 AG010897, and R01 AG012435, and The Dana
   Foundation and by resources by resources and the use of facilities at
   the San Francisco Veterans Administration Medical Center, San Francisco,
   CA. The aforementioned funding agencies had no role in the design and
   conduct of the study; collection, management, analysis, and
   interpretation of the data; and preparation, review, or approval of the
   manuscript. Original data used in preparation of this article were
   obtained from the ADNI database (www.loni.usc.edu/ADNI). As such, the
   investigators within the ADNI contributed to the design and
   implementation of ADNI and/or provided data but did not participate in
   analysis or writing of this report. A complete listing of ADNI
   investigators can be found at:
   http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Authorship
   _List. pdf
NR 260
TC 39
Z9 41
U1 5
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1552-5260
EI 1552-5279
J9 ALZHEIMERS DEMENT
JI Alzheimers. Dement.
PD JUN
PY 2014
VL 10
IS 3
SU 1
BP S122
EP S145
DI 10.1016/j.jalz.2014.04.009
PG 24
WC Clinical Neurology
SC Neurosciences & Neurology
GA CP8GM
UT WOS:000360130700008
PM 24924665
ER

PT J
AU Meziab, O
   Kirby, KA
   Williams, B
   Yaffe, K
   Byers, AL
   Barnes, DE
AF Meziab, Omar
   Kirby, Katharine A.
   Williams, Brie
   Yaffe, Kristine
   Byers, Amy L.
   Barnes, Deborah E.
TI Prisoner of war status, posttraumatic stress disorder, and dementia in
   older veterans
SO ALZHEIMERS & DEMENTIA
LA English
DT Article
DE Dementia; Risk factors; Veterans; Aged; POW; Posttraumatic stress
   disorder
ID FOLLOW-UP; PLASMA-CORTISOL; HUMAN-MEMORY; FAR-EAST; RISK; DISABILITY;
   DISEASE; HEALTH; MALNUTRITION; PREVALENCE
AB Background: It is not known whether prisoners of war (POWs) are more likely to develop dementia independently of the effects of posttraumatic stress disorder (PTSD).
   Methods: We performed a retrospective cohort study in 182,879 U.S. veterans age 55 years and older, and examined associations between POW status and PTSD at baseline (October 1, 2000-September 30, 2003), and incident dementia during follow-up (October 1, 2003-September 30, 2012).
   Results: A total of 484 veterans (0.3%) reported being POWs, of whom 150 (31.0%) also had PTSD. After adjusting for demographics, medical and psychiatric comorbidities, period of service, and the competing risk of death, the risk of dementia was increased in veterans who were POWs only (hazard ratio [HR], 1.61; 95% confidence interval [CI], 1.30-1.98) or had PTSD only (HR, 1.52; 95% CI, 1.41-1.64) and was greatest in veterans who were POWs and also had PTSD (HR, 2.24; 95% CI, 1.72-2.92).
   Conclusions: POW status and PTSD increase risk of dementia in an independent, additive manner in older veterans. (C) 2014 Published by Elsevier Inc. on behalf of The Alzheimer's Association.
C1 [Meziab, Omar] Univ Arizona, Sch Med, Tucson, AZ USA.
   [Kirby, Katharine A.; Williams, Brie] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA USA.
   [Kirby, Katharine A.; Williams, Brie; Yaffe, Kristine; Byers, Amy L.; Barnes, Deborah E.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
   [Yaffe, Kristine; Byers, Amy L.; Barnes, Deborah E.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
   [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
   [Yaffe, Kristine; Barnes, Deborah E.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
RP Barnes, DE (reprint author), San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
EM Deborah.barnes@ucsf.edu
FU Department of Defense/NCIRE (The Veterans Health Research Institute)
   [W81XWH-11-2-0189, 1610, 1614, W81XWH-12-1-0581]; National Institutes of
   Health [K24 AG031155]
FX This study was supported by the Department of Defense/NCIRE (The
   Veterans Health Research Institute) (Barnes: W81XWH-11-2-0189, project
   1610; Byers: W81XWH-11-2-0189, project 1614; Yaffe: W81XWH-12-1-0581)
   and the National Institutes of Health (Yaffe: K24 AG031155). The views
   expressed do not necessarily reflect those of the U.S. government.
NR 40
TC 10
Z9 10
U1 2
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1552-5260
EI 1552-5279
J9 ALZHEIMERS DEMENT
JI Alzheimers. Dement.
PD JUN
PY 2014
VL 10
IS 3
SU 1
BP S236
EP S241
DI 10.1016/j.jalz.2014.04.004
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA CP8GM
UT WOS:000360130700017
PM 24924674
ER

PT J
AU Tanner, CM
   Goldman, SM
   Ross, GW
   Grate, SJ
AF Tanner, Caroline M.
   Goldman, Samuel M.
   Ross, G. Webster
   Grate, Stephen J.
TI The disease intersection of susceptibility and exposure: Chemical
   exposures and neurodegenerative disease risk
SO ALZHEIMERS & DEMENTIA
LA English
DT Article
DE Neurodegeneration; Parkinson's disease; Alzheimer's disease; Motor
   neuron disease; Military; Risk factors; Pesticides; Traumatic brain
   injury; Solvents; Gene-environment interaction
ID AMYOTROPHIC-LATERAL-SCLEROSIS; MOTOR-NEURON-DISEASE;
   METHYLAMINO-L-ALANINE; GULF-WAR VETERANS; STRIATAL DOPAMINE TRANSPORTER;
   CUMULATIVE LEAD-EXPOSURE; PERIOD-COHORT ANALYSIS; PARKINSONS-DISEASE;
   ALZHEIMERS-DISEASE; POLYCHLORINATED-BIPHENYLS
AB Alzheimer's disease, Parkinson's disease, and motor neuron disease, the most common of the late-life neurodegenerative disorders, are in most cases thought to have complex etiologies. Common features among these disorders include insidious onset, pathological findings of protein aggregates and selected neuronal degeneration, and resulting characteristic clinical syndromes. The number of elders in the United States, including aging veterans, is increasing. Investigation of causes and preventive interventions for neurodegenerative disorders is increasingly relevant. Recent epidemiological and laboratory studies suggest that exposures years or decades before diagnosis can trigger the processes that ultimately result in a neurodegenerative disease. If this is correct, preventive measures may be needed in midlife or earlier. This article will focus on putative risk factors relevant to military service. Published by Elsevier Inc. on behalf of The Alzheimer's Association.
C1 [Tanner, Caroline M.; Goldman, Samuel M.] San Francisco VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, San Francisco, CA 94121 USA.
   [Tanner, Caroline M.; Goldman, Samuel M.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
   [Tanner, Caroline M.; Goldman, Samuel M.] Parkinsons Inst, Sunnyvale, CA USA.
   [Ross, G. Webster] Vet Affairs Pacific Isl Hlth Care Syst, Honolulu, HI USA.
   [Grate, Stephen J.] MSAMRMC, Telemed & Adv Technol Res Ctr, Ft Detrick, MD USA.
RP Tanner, CM (reprint author), San Francisco VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, San Francisco, CA 94121 USA.
EM caroline.tanner@ucsf.edu
FU United States Army Medical Research and Materiel Command
FX Publication of this article was supported by the United States Army
   Medical Research and Materiel Command.
NR 176
TC 14
Z9 14
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1552-5260
EI 1552-5279
J9 ALZHEIMERS DEMENT
JI Alzheimers. Dement.
PD JUN
PY 2014
VL 10
IS 3
SU 1
BP S213
EP S225
DI 10.1016/j.jalz.2014.04.014
PG 13
WC Clinical Neurology
SC Neurosciences & Neurology
GA CP8GM
UT WOS:000360130700015
PM 24924672
ER

PT J
AU Yaffe, K
   Hoang, TD
   Byers, AL
   Barnes, DE
   Friedl, KE
AF Yaffe, Kristine
   Hoang, Tina D.
   Byers, Amy L.
   Barnes, Deborah E.
   Friedl, Karl E.
TI Lifestyle and health-related risk factors and risk of cognitive aging
   among older veterans
SO ALZHEIMERS & DEMENTIA
LA English
DT Article
DE Veterans; Dementia; Cognitive aging; Lifestyle behaviors; Health-related
   risk factors
ID POSTTRAUMATIC-STRESS-DISORDER; OBSTRUCTIVE SLEEP-APNEA; CEREBRAL
   WHITE-MATTER; US ARMY SOLDIERS; ALZHEIMERS-DISEASE; PHYSICAL-ACTIVITY;
   METABOLIC SYNDROME; BLOOD-PRESSURE; SOCIAL NETWORK; MENTAL-HEALTH
AB Lifestyle and health-related factors are critical components of the risk for cognitive aging among veterans. Because dementia has a prolonged prodromal phase, understanding effects across the life course could help focus the timing and duration of prevention targets. This perspective may be especially relevant for veterans and health behaviors. Military service may promote development and maintenance of healthy lifestyle behaviors, but the period directly after active duty has ended could be an important transition stage and opportunity to address some important risk factors. Targeting multiple pathways in one intervention may maximize efficiency and benefits for veterans. A recent review of modifiable risk factors for Alzheimer's disease estimated that a 25% reduction of a combination of seven modifiable risk factors including diabetes, hypertension, obesity, depression, physical inactivity, smoking, and education/cognitive inactivity could prevent up to 3 million cases worldwide and 492,000 cases in the United States. Lifestyle interventions to address cardiovascular health in veterans may serve as useful models with both physical and cognitive activity components, dietary intervention, and vascular risk factor management. Although the evidence is accumulating for lifestyle and health-related risk factors as well as military risk factors, more studies are needed to characterize these factors in veterans and to examine the potential interactions between them. Published by Elsevier Inc. on behalf of The Alzheimer's Association.
C1 [Yaffe, Kristine; Byers, Amy L.; Barnes, Deborah E.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
   [Yaffe, Kristine; Friedl, Karl E.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
   [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA.
   [Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA.
   [Hoang, Tina D.] Northern Calif Inst Res & Educ, San Francisco, CA USA.
RP Yaffe, K (reprint author), Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
EM kristine.yaffe@ucsf.edu
FU United States Army Medical Research and Materiel Command
FX Publication of this article was supported by the United States Army
   Medical Research and Materiel Command.
NR 160
TC 6
Z9 6
U1 2
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1552-5260
EI 1552-5279
J9 ALZHEIMERS DEMENT
JI Alzheimers. Dement.
PD JUN
PY 2014
VL 10
IS 3
SU 1
BP S111
EP S121
DI 10.1016/j.jalz.2014.04.010
PG 11
WC Clinical Neurology
SC Neurosciences & Neurology
GA CP8GM
UT WOS:000360130700007
PM 24924664
ER

PT J
AU U, KP
   Subramanian, V
   Nicholas, AP
   Thompson, PR
   Ferretti, P
AF U, Kin Pong
   Subramanian, Venkataraman
   Nicholas, Antony P.
   Thompson, Paul R.
   Ferretti, Patrizia
TI Modulation of calcium-induced cell death in human neural stem cells by
   the novel peptidylarginine deiminase-AIF pathway
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
LA English
DT Article
DE Apoptosis inducing factor (ALF); Cell death; Citrullination-deimination;
   Human neural stem cell; Peptidylarginine deiminase (PAD,PADI); Vimentin
ID CHICK SPINAL-CORD; CITRULLINATED PROTEINS; MULTIPLE-SCLEROSIS;
   TRANSCRIPTIONAL REGULATION; RHEUMATOID-ARTHRITIS; NUCLEAR-LOCALIZATION;
   HUMAN KERATINOCYTES; CALPAIN-I; APOPTOSIS; MOUSE
AB PADs (peptidylarginine deiminases) are calcium-dependent enzymes that change protein-bound arginine to citrulline (citrullination/deimination) affecting protein conformation and function. PAD up-regulation following chick spinal cord injury has been linked to extensive tissue damage and loss of regenerative capability. Having found that human neural stem cells (hNSCs) expressed PAD2 and PAD3, we studied PAD function in these cells and investigated PAD3 as a potential target for neuroprotection by mimicking calcium-induced secondary injury responses. We show that PAD3, rather than PAD2 is a modulator of cell growth/death and that PAD activity is not associated with caspase-3-dependent cell death, but is required for AIF (apoptosis inducing factor)-mediated apoptosis. PAD inhibition prevents association of PAD3 with AIF and AIF cleavage required for its translocation to the nucleus. Finally, PAD inhibition also hinders calcium-induced cytoskeleton disassembly and association of PAD3 with vimentin, that we show to be associated also with AIF; together this suggests that PAD-dependent cytoskeleton disassembly may play a role in AIF translocation to the nucleus. This is the first study highlighting a role of PAD activity in balancing hNSC survival/death, identifying PAD3 as an important upstream regulator of calciuminduced apoptosis, which could be targeted to reduce neural loss, and shedding light on the mechanisms involved. (C) 2014 The Authors. Published by Elsevier B.V.
C1 [U, Kin Pong; Ferretti, Patrizia] UCL Inst Child Hlth, Dev Biol Unit, 30 Guilford St, London WC1N LEH, England.
   [Subramanian, Venkataraman; Thompson, Paul R.] Scripps Res Inst, Dept Chem, Scripps Florida, FL 33458 USA.
   [Nicholas, Antony P.] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35294 USA.
   [Nicholas, Antony P.] Birmingham VA Med Ctr, Birmingham, AL 35294 USA.
RP Ferretti, P (reprint author), UCL Inst Child Hlth, Dev Biol Unit, 30 Guilford St, London WC1N LEH, England.
EM p.ferretti@ucl.ac.uk
OI Ferretti, Patrizia/0000-0002-3590-6772
FU Child Research Appeal Trust [08DB04]; Biotechnology and Biological
   Sciences Research Council; National Institutes of Health [GM079357];
   Medical Research Council [G070089]; Wellcome Trust [GR082557]
FX This work was supported by grants from the Child Research Appeal Trust
   (grant 08DB04 to PF), the Biotechnology and Biological Sciences Research
   Council (PF) and the National Institutes of Health (grant GM079357 to
   PRT). The human embryonic and fetal material was provided by the Human
   Developmental Biology Resource (http://lidbr.org) jointly funded by the
   Medical Research Council (grant G070089) and The Wellcome Trust (grant
   GR082557). We are grateful to J. Ham, JP Brockes and JC Sowden for
   reading the manuscript. The authors declare no competing financial
   interests.
NR 68
TC 10
Z9 10
U1 3
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0167-4889
EI 0006-3002
J9 BBA-MOL CELL RES
JI Biochim. Biophys. Acta-Mol. Cell Res.
PD JUN
PY 2014
VL 1843
IS 6
BP 1162
EP 1171
DI 10.1016/j.bbamcr.2014.02.018
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA AG7VW
UT WOS:000335627900011
PM 24607566
ER

PT J
AU Johnson, SD
   De Costa, AMA
   Young, MRI
AF Johnson, Sara D.
   De Costa, Anna-Maria A.
   Young, M. Rita I.
TI Effect of the Premalignant and Tumor Microenvironment on Immune Cell
   Cytokine Production in Head and Neck Cancer
SO CANCERS
LA English
DT Article
DE head and neck cancer; immunosuppression; tumor microenvironment;
   cytokines
AB Head and neck squamous cell carcinoma (HNSCC) is marked by immunosuppression, a state in which the established tumor escapes immune attack. However, the impact of the premalignant and tumor microenvironments on immune reactivity has yet to be elucidated. The purpose of this study was to determine how soluble mediators from cells established from carcinogen-induced oral premalignant lesions and HNSCC modulate immune cell cytokine production. It was found that premalignant cells secrete significantly increased levels of G-CSF, RANTES, MCP-1, and PGE(2) compared to HNSCC cells. Splenocytes incubated with premalignant supernatant secreted significantly increased levels of Th1-,Th2-, and Th17-associated cytokines compared to splenocytes incubated with HNSCC supernatant. These studies demonstrate that whereas the premalignant microenvironment elicits proinflammatory cytokine production, the tumor microenvironment is significantly less immune stimulatory and may contribute to immunosuppression in established HNSCC.
C1 [Johnson, Sara D.] Med Univ South Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA.
   [De Costa, Anna-Maria A.; Young, M. Rita I.] Med Univ South Carolina, Dept Otolaryngol Head & Neck Surg, 135 Rutledge Ave, Charleston, SC 29425 USA.
   [Young, M. Rita I.] Med Univ South Carolina, Dept Med, Charleston, SC 29425 USA.
   [Young, M. Rita I.] Ralph H Johnson Vet Affairs Med Ctr, Med Res Serv 151, Charleston, SC 29401 USA.
RP Young, MRI (reprint author), Med Univ South Carolina, Dept Otolaryngol Head & Neck Surg, 135 Rutledge Ave, Charleston, SC 29425 USA.
EM johsad@musc.edu; clarkann@musc.edu; rita.young@va.gov
FU Research Service of the Department of Veterans Affairs; National
   Institutes of Health [RO1 CA128837, RO1 DE018268]
FX This work was supported by Research Service of the Department of
   Veterans Affairs and by grants RO1 CA128837 and RO1 DE018268 from the
   National Institutes of Health (MRIY).
NR 44
TC 11
Z9 11
U1 0
U2 0
PU MDPI AG
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2072-6694
J9 CANCERS
JI Cancers
PD JUN
PY 2014
VL 6
IS 2
BP 756
EP 770
DI 10.3390/cancers6020756
PG 15
WC Oncology
SC Oncology
GA V47KL
UT WOS:000209950600008
PM 24698959
ER

PT J
AU Lin, Y
   Sharma, S
   John, MS
AF Lin, Yuan
   Sharma, Sherven
   John, Maie St.
TI CCL21 Cancer Immunotherapy
SO CANCERS
LA English
DT Review
DE CCL21; cancer immunotherapy; dendritic cell; polymer; T cell
AB Cancer, a major health problem, affects 12 million people worldwide every year. With surgery and chemo-radiation the long term survival rate for the majority of cancer patients is dismal. Thus novel treatments are urgently needed. Immunotherapy, the harnessing of the immune system to destroy cancer cells is an attractive option with potential for long term anti-tumor benefit. Cytokines are biological response modifiers that stimulate anti-tumor immune responses. In this review, we discuss the anti-tumor efficacy of the chemotactic cytokine CCL21 and its pre-clinical and clinical application in cancer.
C1 [Lin, Yuan; John, Maie St.] UCLA, David Geffen Sch Med, Dept Head & Neck Surg, 10833 Conte Ave, Los Angeles, CA 90095 USA.
   [Lin, Yuan; Sharma, Sherven; John, Maie St.] UCLA, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, 10833 Conte Ave, Los Angeles, CA 90095 USA.
   [Lin, Yuan; John, Maie St.] UCLA, David Geffen Sch Med, UCLA Head & Neck Canc Program, 10833 Conte Ave, Los Angeles, CA 90095 USA.
   [Lin, Yuan; Sharma, Sherven; John, Maie St.] UCLA, David Geffen Sch Med, Clin & Translat Sci Inst, 10833 Conte Ave, Los Angeles, CA 90095 USA.
   [Lin, Yuan; Sharma, Sherven] UCLA, David Geffen Sch Med, Dept Med, Div Pulm & Crit Care Med, 37-131 CHS,10833 Conte Ave, Los Angeles, CA 90095 USA.
   [Sharma, Sherven] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
RP Lin, Y (reprint author), UCLA, David Geffen Sch Med, Dept Head & Neck Surg, 10833 Conte Ave, Los Angeles, CA 90095 USA.; Lin, Y (reprint author), UCLA, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, 10833 Conte Ave, Los Angeles, CA 90095 USA.; Lin, Y (reprint author), UCLA, David Geffen Sch Med, UCLA Head & Neck Canc Program, 10833 Conte Ave, Los Angeles, CA 90095 USA.; Lin, Y (reprint author), UCLA, David Geffen Sch Med, Clin & Translat Sci Inst, 10833 Conte Ave, Los Angeles, CA 90095 USA.; Lin, Y (reprint author), UCLA, David Geffen Sch Med, Dept Med, Div Pulm & Crit Care Med, 37-131 CHS,10833 Conte Ave, Los Angeles, CA 90095 USA.
EM yuanlin@mednet.ucla.edu
RI lin, yuan/E-6062-2011
FU American Academy of Otolaryngology-American Head & Neck Society Surgeon
   Scientist Career Development Award; Tobacco-Related Disease Research
   Program of the University of California; STOP Cancer Foundation; Jonsson
   Cancer Center; NIDCR K23; Department of Veterans Affairs Medical
   Research Funds; National Institutes of Health (NIH) Grants [RO1
   CA126944]; Tobacco Related Disease Program Award Program of University
   of California [15RT-0207, 20FT0082]
FX This project was supported by the American Academy of
   Otolaryngology-American Head & Neck Society Surgeon Scientist Career
   Development Award (MSJ), the Tobacco-Related Disease Research Program of
   the University of California (MSJ), the STOP Cancer Foundation (MSJ),
   The Jonsson Cancer Center, and NIDCR K23 (MSJ) and Department of
   Veterans Affairs Medical Research Funds (SS), National Institutes of
   Health (NIH) Grants (RO1 CA126944) and Tobacco Related Disease Program
   Award Program of University of California (15RT-0207 and 20FT0082). The
   content is solely the responsibility of the authors and does not
   necessarily represent the official views of the NIH. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
NR 57
TC 7
Z9 7
U1 0
U2 1
PU MDPI AG
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2072-6694
J9 CANCERS
JI Cancers
PD JUN
PY 2014
VL 6
IS 2
BP 1098
EP 1110
DI 10.3390/cancers6021098
PG 13
WC Oncology
SC Oncology
GA V47KL
UT WOS:000209950600024
PM 24810425
ER

PT J
AU Bauman, WA
   Swonger, KN
   Rivera, DR
   LaFountaine, MF
AF Bauman, William A.
   Swonger, Kirsten N.
   Rivera, Dwindally Rosado
   LaFountaine, Michael F.
TI HOMA beta-Cell Function Negatively Correlates to the Vasodilatory
   Response of Insulin in the Cutaneous Microvasculature
SO ENDOCRINE REVIEWS
LA English
DT Meeting Abstract
C1 [Bauman, William A.; Swonger, Kirsten N.; Rivera, Dwindally Rosado] James J Peters VA Med Ctr, Bronx, NY USA.
   [LaFountaine, Michael F.] Seton Hall Univ, S Orange, NJ 07079 USA.
NR 1
TC 0
Z9 0
U1 0
U2 0
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0163-769X
EI 1945-7189
J9 ENDOCR REV
JI Endocr. Rev.
PD JUN
PY 2014
VL 35
IS 3
SU S
MA SAT-1029
PG 2
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA V45GM
UT WOS:000209805107120
ER

PT J
AU Cunningham, GR
   Rosen, RC
   Wang, C
   Stephens, A
   Ellenberg, S
   Matsumoto, AM
   Bhasin, S
   Molitch, ME
   Farrar, JT
   Cella, D
   Gill, TM
   Barrett-Connor, EL
   Cauley, JA
   Cifelli, D
   Crandall, JP
   Ensrud, KE
   Fluharty, L
   Hadley, E
   Lewis, CE
   Pahor, M
   Resnick, SM
   Romashkan, S
   Swerdloff, RS
   Snyder, PJ
AF Cunningham, Glenn R.
   Rosen, Raymond C.
   Wang, Christina
   Stephens, Alisa
   Ellenberg, Susan
   Matsumoto, Alvin M.
   Bhasin, Shalender
   Molitch, Mark E.
   Farrar, John T.
   Cella, David
   Gill, Thomas M.
   Barrett-Connor, Elizabeth Louise
   Cauley, Jane A.
   Cifelli, Denise
   Crandall, Jill P.
   Ensrud, Kristine E.
   Fluharty, Laura
   Hadley, Evan
   Lewis, Cora E.
   Pahor, Marco
   Resnick, Susan M.
   Romashkan, Sergei
   Swerdloff, Ronald S.
   Snyder, Peter J.
TI Free Testosterone but Not Total Testosterone or Estradiol Is Associated
   with Sexual Function in Symptomatic Older Hypogonadal Men in the Sexual
   Function Trial of the Testosterone Trials
SO ENDOCRINE REVIEWS
LA English
DT Meeting Abstract
C1 [Cunningham, Glenn R.] Baylor Coll Med, Houston, TX 77030 USA.
   [Rosen, Raymond C.] New England Res Inst Inc, Watertown, MA USA.
   [Wang, Christina] Harbor UCLA Med Ctr, Torrance, CA 90509 USA.
   [Wang, Christina; Swerdloff, Ronald S.] Los Angeles Biomed Res Inst, Torrance, CA USA.
   [Stephens, Alisa; Ellenberg, Susan; Farrar, John T.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
   [Matsumoto, Alvin M.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
   [Bhasin, Shalender] Brigham & Womens Hosp, Boston, MA 02115 USA.
   [Molitch, Mark E.; Cella, David] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Gill, Thomas M.] Yale Sch Med, New Haven, CT USA.
   [Barrett-Connor, Elizabeth Louise] Univ CA San Diego, La Jolla, CA USA.
   [Cauley, Jane A.] Univ Pittsburgh, Pittsburgh, PA USA.
   [Cifelli, Denise; Fluharty, Laura] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Crandall, Jill P.] Albert Einstein Coll Med, Bronx, NY 10467 USA.
   [Ensrud, Kristine E.] Univ Minnesota, Minneapolis, MN USA.
   [Hadley, Evan; Romashkan, Sergei] NIA, Bethesda, MD 20892 USA.
   [Lewis, Cora E.] Univ Alabama Birmingham, Birmingham, AL USA.
   [Pahor, Marco] Univ Florida, Gainesville, FL USA.
   [Resnick, Susan M.] NIA, Baltimore, MD 21224 USA.
   [Swerdloff, Ronald S.] Harbor Univ Calif Med Ctr, Torrance, CA USA.
   [Snyder, Peter J.] Univ PA, Philadelphia, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0163-769X
EI 1945-7189
J9 ENDOCR REV
JI Endocr. Rev.
PD JUN
PY 2014
VL 35
IS 3
SU S
MA SUN-0084
PG 3
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA V45GM
UT WOS:000209805107199
ER

PT J
AU Grimes, MC
   Mathew, I
   Bandi, A
   Martin, E
   Codario, R
   Rao, RH
AF Grimes, Michael C.
   Mathew, Indu
   Bandi, Archana
   Martin, Emily
   Codario, Ronald
   Rao, R. Harsha
TI Impact of U-500 Insulin on Glycemic Control, Risk of Hypoglycemia, and
   Mortality in Patients with Extreme Insulin Resistance: The VA Pittsburgh
   Experience
SO ENDOCRINE REVIEWS
LA English
DT Meeting Abstract
C1 [Grimes, Michael C.; Mathew, Indu] VA Pittsburgh Hlth Syst, Pittsburgh, PA USA.
   [Bandi, Archana] VAPHS Oakland, Wexford, PA USA.
   [Martin, Emily] VA Pittsburgh Healthcare Syst, Munhall, PA USA.
   [Codario, Ronald] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA.
   [Rao, R. Harsha] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0163-769X
EI 1945-7189
J9 ENDOCR REV
JI Endocr. Rev.
PD JUN
PY 2014
VL 35
IS 3
SU S
MA OR54-6
PG 2
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA V45GM
UT WOS:000209805100135
ER

PT J
AU Hershman, JM
   Liwanpo, L
   Ro, C
   ul Haq, MS
AF Hershman, Jerome M.
   Liwanpo, Llanyee
   Ro, Cynthia
   ul Haq, Muhammd Salman
TI Sunitinib Does Not Inhibit Thyroid Peroxidase in Patients
SO ENDOCRINE REVIEWS
LA English
DT Meeting Abstract
C1 [Hershman, Jerome M.] VA Greater LA Healthcare Syst, Los Angeles, CA USA.
   [Liwanpo, Llanyee; Ro, Cynthia] VA Greater Los Angeles, Los Angeles, CA USA.
   [ul Haq, Muhammd Salman] Sansum Clin, Santa Barbara, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0163-769X
EI 1945-7189
J9 ENDOCR REV
JI Endocr. Rev.
PD JUN
PY 2014
VL 35
IS 3
SU S
MA MON-0507
PG 2
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA V45GM
UT WOS:000209805109004
ER

PT J
AU Jensen, T
   Wang, CCL
AF Jensen, Thomas
   Wang, Cecilia C. Low
TI Double Trouble: A Case of Primary Hyperparathyroidism and Humoral
   Hypercalcemia of Malignancy
SO ENDOCRINE REVIEWS
LA English
DT Meeting Abstract
C1 [Jensen, Thomas] Univ Colorado, Sch Med, Aurora, CO USA.
   [Wang, Cecilia C. Low] Denver VAMC, Denver, CO USA.
   [Wang, Cecilia C. Low] Univ Colorado Sh, Denver, CO USA.
NR 2
TC 0
Z9 0
U1 0
U2 0
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0163-769X
EI 1945-7189
J9 ENDOCR REV
JI Endocr. Rev.
PD JUN
PY 2014
VL 35
IS 3
SU S
MA SAT-0202
PG 2
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA V45GM
UT WOS:000209805105128
ER

PT J
AU Kocarnik, BM
   Kahn, SE
   Fujimoto, WY
   Hayashi, T
   McNeely, MJ
   Leonetti, D
   Boyko, EJ
AF Kocarnik, Beverly M.
   Kahn, Steven E.
   Fujimoto, Wilfred Y.
   Hayashi, Tomoshige
   McNeely, Marguerite J.
   Leonetti, Donna
   Boyko, Edward J.
TI Estradiol Levels in Men Are Not Correlated Cross-Sectionally with
   Intra-Abdominal Fat Area and Do Not Predict Change in This Fat Depot
   Longitudinally
SO ENDOCRINE REVIEWS
LA English
DT Meeting Abstract
C1 [Kocarnik, Beverly M.; Kahn, Steven E.; McNeely, Marguerite J.; Leonetti, Donna] Univ Washington, Seattle, WA 98195 USA.
   [Kahn, Steven E.; Boyko, Edward J.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
   [Fujimoto, Wilfred Y.] Univ Washington, Kailua Kona, HI USA.
   [Hayashi, Tomoshige] Osaka Univ, Osaka, Japan.
NR 2
TC 0
Z9 0
U1 0
U2 0
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0163-769X
EI 1945-7189
J9 ENDOCR REV
JI Endocr. Rev.
PD JUN
PY 2014
VL 35
IS 3
SU S
MA SAT-0905
PG 2
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA V45GM
UT WOS:000209805103097
ER

PT J
AU Liu, XH
   Collier, L
   Ma, RS
   Latif, R
   Davies, TF
   Bauman, WA
   Cardozo, CP
AF Liu, Xin-Hua
   Collier, Lauren
   Ma, Risheng
   Latif, Rauf
   Davies, Terry F.
   Bauman, William A.
   Cardozo, Christopher Pratt
TI Androgens Promote Differentiation of Induced Pluripotent Stem Cells to
   Mesenchymal Progenitor Cells through Embryoid Body Formation
SO ENDOCRINE REVIEWS
LA English
DT Meeting Abstract
C1 [Liu, Xin-Hua; Collier, Lauren; Bauman, William A.; Cardozo, Christopher Pratt] JJ Peter VA Med Ctr, Bronx, NY USA.
   [Ma, Risheng] Mt Sinai Sch Med, Bronx, NY USA.
   [Latif, Rauf; Davies, Terry F.] Mt Sinai Sch Med, New York, NY USA.
   [Bauman, William A.] James J Peters VA Med Ctr, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0163-769X
EI 1945-7189
J9 ENDOCR REV
JI Endocr. Rev.
PD JUN
PY 2014
VL 35
IS 3
SU S
MA MON-0262
PG 2
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA V45GM
UT WOS:000209805105285
ER

PT J
AU Lombardi, A
   Inabnet, WB
   Owen, R
   Tomer, Y
AF Lombardi, Angela
   Inabnet, William B.
   Owen, Randall
   Tomer, Yaron
TI A New Mechanism for Iodine Independent Amiodarone-Induced Thyroiditis
   with Translational Implications
SO ENDOCRINE REVIEWS
LA English
DT Meeting Abstract
C1 [Lombardi, Angela; Inabnet, William B.; Owen, Randall; Tomer, Yaron] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
   [Tomer, Yaron] James J Peters VA Med Ctr, New York, NY USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0163-769X
EI 1945-7189
J9 ENDOCR REV
JI Endocr. Rev.
PD JUN
PY 2014
VL 35
IS 3
SU S
MA OR12-3
PG 2
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA V45GM
UT WOS:000209805109054
ER

PT J
AU Malhotra, S
   Gupta, N
   Galiveeti, S
   Milekic, B
   Greenberg, PD
AF Malhotra, Sheetal
   Gupta, Namita
   Galiveeti, Sneha
   Milekic, Bojana
   Greenberg, Pietra Dale
TI Sleeve Gastrectomy Outcomes in Veterans with Type II Diabetes
SO ENDOCRINE REVIEWS
LA English
DT Meeting Abstract
C1 [Malhotra, Sheetal; Galiveeti, Sneha; Milekic, Bojana] JJ Peters VA Med Ctr, Bronx, NY USA.
   [Gupta, Namita] Univ Nebraska Med Ctr, Omaha, NE USA.
   [Greenberg, Pietra Dale] James J Peters VA Med Ctr, Bronx, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0163-769X
EI 1945-7189
J9 ENDOCR REV
JI Endocr. Rev.
PD JUN
PY 2014
VL 35
IS 3
SU S
MA OR40-4
PG 2
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA V45GM
UT WOS:000209805100127
ER

PT J
AU Mathew, I
   Grimes, MC
   Rao, RH
   Cunningham, CA
   Muder, R
   Perreiah, PL
AF Mathew, Indu
   Grimes, Michael C.
   Rao, R. Harsha
   Cunningham, Candace Ann
   Muder, Robert
   Perreiah, Peter L.
TI Eliminating Deaths from Mediastinitis after Cardiac Surgery Using
   Aggressive Glycemic Intervention to Maintain Blood Glucose 80-140mg/DI:
   The VA Pittsburgh Experience
SO ENDOCRINE REVIEWS
LA English
DT Meeting Abstract
C1 [Mathew, Indu; Grimes, Michael C.; Muder, Robert] VA Pittsburgh Hlth Syst, Pittsburgh, PA USA.
   [Rao, R. Harsha; Cunningham, Candace Ann; Perreiah, Peter L.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
NR 2
TC 0
Z9 0
U1 0
U2 0
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0163-769X
EI 1945-7189
J9 ENDOCR REV
JI Endocr. Rev.
PD JUN
PY 2014
VL 35
IS 3
SU S
MA MON-0956
PG 3
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA V45GM
UT WOS:000209805106240
ER

PT J
AU Muram, D
   Matsumoto, AM
   Zhang, X
   Cui, ZLL
AF Muram, David
   Matsumoto, Alvin M.
   Zhang, Xiang
   Cui, Zhanglin Lin
TI Application of the Endocrine Society Clinical Guidelines on Testosterone
   Therapy in Men with Androgen Deficiency Syndromes in Clinical Practice
SO ENDOCRINE REVIEWS
LA English
DT Meeting Abstract
C1 [Muram, David; Zhang, Xiang; Cui, Zhanglin Lin] Eli Lilly & Co, Indianapolis, IN 46285 USA.
   [Matsumoto, Alvin M.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0163-769X
EI 1945-7189
J9 ENDOCR REV
JI Endocr. Rev.
PD JUN
PY 2014
VL 35
IS 3
SU S
MA MON-0021
PG 2
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA V45GM
UT WOS:000209805104173
ER

PT J
AU Qin, WP
   Pan, JP
   Bauman, WA
   Cardozo, CP
AF Qin, Weiping
   Pan, Jianping
   Bauman, William A.
   Cardozo, Christopher Pratt
TI Molecular Crosstalk Between Calcineurin and mTORC1 Signaling Pathways
SO ENDOCRINE REVIEWS
LA English
DT Meeting Abstract
C1 [Qin, Weiping; Pan, Jianping; Bauman, William A.; Cardozo, Christopher Pratt] James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
NR 5
TC 0
Z9 0
U1 0
U2 0
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0163-769X
EI 1945-7189
J9 ENDOCR REV
JI Endocr. Rev.
PD JUN
PY 2014
VL 35
IS 3
SU S
MA MON-0351
PG 2
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA V45GM
UT WOS:000209805100258
ER

PT J
AU Shi, Y
   Kim, MS
   Shu, ZJ
   Salmon, A
   Kamat, A
AF Shi, Yun
   Kim, Margaret S.
   Shu, Zhen-Ju
   Salmon, Adam
   Kamat, Amrita
TI Positive Association Between Beta(2)-Adrenergic Receptor (beta(2)-AR)
   Signaling and Cide Family Proteins in Hepatic Steatosis
SO ENDOCRINE REVIEWS
LA English
DT Meeting Abstract
C1 [Shi, Yun; Kim, Margaret S.; Shu, Zhen-Ju] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
   [Salmon, Adam; Kamat, Amrita] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
NR 3
TC 0
Z9 0
U1 0
U2 0
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0163-769X
EI 1945-7189
J9 ENDOCR REV
JI Endocr. Rev.
PD JUN
PY 2014
VL 35
IS 3
SU S
MA OR15-2
PG 3
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA V45GM
UT WOS:000209805106048
ER

PT J
AU Shores, MM
   Fox, AE
   Moore, KP
   Matsumoto, AM
   Forsberg, CW
   Smith, NL
   Heckbert, SR
   Thompson, ML
   Walsh, TJ
AF Shores, Molly M.
   Fox, Alexandra E.
   Moore, Kathryn P.
   Matsumoto, Alvin M.
   Forsberg, Christopher W.
   Smith, Nicholas L.
   Heckbert, Susan R.
   Thompson, Mary Lou
   Walsh, Thomas J.
TI Characteristics of Treated and Untreated Middle-Aged and Older Men with
   Low Testosterone and Testosterone Use in a National Veterans Affairs
   (VA) Cohort
SO ENDOCRINE REVIEWS
LA English
DT Meeting Abstract
C1 [Shores, Molly M.] Univ Washington, VA Puget Sound, Seattle, WA 98195 USA.
   [Fox, Alexandra E.] Seattle VA Epidemiol Res & Informat Ctr ERIC, Seattle, WA USA.
   [Moore, Kathryn P.; Forsberg, Christopher W.] Seattle VA ERIC, Seattle, WA USA.
   [Matsumoto, Alvin M.] VA Puget Sound Hlth Care Syste, Seattle, WA USA.
   [Smith, Nicholas L.; Heckbert, Susan R.; Thompson, Mary Lou; Walsh, Thomas J.] Univ Washington, Seattle, WA 98195 USA.
   [Smith, Nicholas L.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0163-769X
EI 1945-7189
J9 ENDOCR REV
JI Endocr. Rev.
PD JUN
PY 2014
VL 35
IS 3
SU S
MA SUN-0077
PG 2
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA V45GM
UT WOS:000209805107192
ER

PT J
AU Teng, XC
   Jin, T
   Brent, GA
   Wu, AH
   Teng, WP
   Shan, ZY
AF Teng, Xiaochun
   Jin, Ting
   Brent, Gregory A.
   Wu, An-hua
   Teng, Weiping
   Shan, Zhongyan
TI A Girl with Resistance to Thyroid Hormone (P453T) and a Suspected
   Thyrotropin-Secreting Pituitary Microadenoma
SO ENDOCRINE REVIEWS
LA English
DT Meeting Abstract
C1 [Teng, Xiaochun; Jin, Ting; Shan, Zhongyan] Inst Endocrinol, Shenyang, Peoples R China.
   [Brent, Gregory A.] Univ Calif Los Angeles, David Geffen Sch Med, Vet Affairs Greater Los Angeles Healthcare Syst, Mol Endocrinol Lab,Dept Med, Tarzana, CA USA.
   [Brent, Gregory A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Tarzana, CA USA.
   [Wu, An-hua] Dept Neurosurg, Shenyang, Peoples R China.
   [Teng, Weiping] Endocrine Inst, Shenyang, Peoples R China.
NR 3
TC 0
Z9 0
U1 0
U2 0
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0163-769X
EI 1945-7189
J9 ENDOCR REV
JI Endocr. Rev.
PD JUN
PY 2014
VL 35
IS 3
SU S
MA MON-0488
PG 3
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA V45GM
UT WOS:000209805108315
ER

PT J
AU Walker, RJ
   Smalls, BL
   Hernandez-Tejada, MA
   Campbell, JA
   Egede, LE
AF Walker, Rebekah J.
   Smalls, Brittany L.
   Hernandez-Tejada, Melba A.
   Campbell, Jennifer A.
   Egede, Leonard E.
TI EFFECT OF DIABETES SELF-EFFICACY ON GLYCEMIC CONTROL, MEDICATION
   ADHERENCE, SELF-CARE BEHAVIORS, AND QUALITY OF LIFE IN A PREDOMINANTLY
   LOW-INCOME, MINORITY POPULATION
SO ETHNICITY & DISEASE
LA English
DT Article
DE Diabetes Self-efficacy; Glycemic Control; Medication Adherence;
   Self-care Behaviors; Quality of Life; Low-income Population; Type 2
   Diabetes
ID AFRICAN-AMERICAN; FOOD INSECURITY; SOCIOECONOMIC-STATUS; HEALTH
   LITERACY; MANAGEMENT; ADULTS; INTERVENTION; ASSOCIATION; PERCEPTIONS;
   STRATEGIES
AB Objective: This study examined the effect of self-efficacy on glycemic control, self-care behaviors, and quality of life in low-income, minority adults with diabetes.
   Methods: Data on 378 participants were examined. Multiple linear regression assessed associations between self-efficacy, hemoglobin A1c, medication adherence, diabetes knowledge, self-care behaviors and quality of life.
   Results: Self-efficacy had modest correlations with glycemic control (r = -2.250, P < .001), medication adherence (r = -.352, P < .001), diabetes knowledge (r = -.118, P < .039), diet (r = -.420, P < .001), exercise (r = -.220, P < .001), blood sugar testing (r = -.213, P < .001), foot care (r = .121, P < .032), and mental health related quality of life (r = .137, P < .017). In the regression model, self-efficacy was significantly associated with glycemic control (beta = -.104, 95% CI: - .157, - .051), medication adherence (beta = -.067, 95% CI: - .090, - .044), diet (beta = .150, 95% CI:.108,.191), exercise (beta = -.113, 95% CI:.065,.161), blood sugar testing (beta = .107, 95% CI:.049,.164) and mental health related quality of life (beta = .112, 95% CI:.051,.173).
   Conclusion: Higher self-efficacy was associated with improved glycemic control, medication adherence, self-care behavior and mental health related quality of life.
   Practice Implications: Emphasis on self-efficacy is relevant for educational interventions developed for low-income, minority populations.
C1 [Walker, Rebekah J.; Smalls, Brittany L.; Hernandez-Tejada, Melba A.; Campbell, Jennifer A.; Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, Charleston, SC 29425 USA.
   [Egede, Leonard E.] Med Univ S Carolina, Div Gen Internal Med & Geriatr, Dept Med, Charleston, SC 29425 USA.
   [Egede, Leonard E.] Ralph H Johnson VA Med Ctr, Hlth Equity & Rural Outreach Innovat Ctr, Charleston VA COIN, Charleston, SC USA.
RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280G,POB 250593, Charleston, SC 29425 USA.
EM egedel@musc.edu
FU National Institute for Diabetes, Digestive and Kidney Disease
   [T35DK007431]
FX Supported by Grant #T35DK007431 from the National Institute for
   Diabetes, Digestive and Kidney Disease.
NR 53
TC 9
Z9 10
U1 1
U2 9
PU INT SOC HYPERTENSION BLACKS-ISHIB
PI ATLANTA
PA 100 AUBURN AVE NE STE 401, ATLANTA, GA 30303-2527 USA
SN 1049-510X
EI 1945-0826
J9 ETHNIC DIS
JI Ethn. Dis.
PD SUM
PY 2014
VL 24
IS 3
BP 349
EP 355
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA CU7KT
UT WOS:000363717300013
PM 25065078
ER

PT J
AU Boehme, AK
   McGwin, G
   Andes, DR
   Lyon, GM
   Chiller, T
   Pappas, PG
   Baddley, JW
AF Boehme, Amelia K.
   McGwin, Gerald
   Andes, David R.
   Lyon, G. Marshall
   Chiller, Tom
   Pappas, Peter G.
   Baddley, John W.
TI RACE AND INVASIVE FUNGAL INFECTION IN SOLID ORGAN TRANSPLANT RECIPIENTS
SO ETHNICITY & DISEASE
LA English
DT Article
DE Invasive Fungal Infection; Solid Organ Transplant; Aspergillosis;
   Candidiasis; Cryptococcosis
ID SURVEILLANCE NETWORK TRANSNET; LIVER-TRANSPLANTATION; ETHNIC
   DISPARITIES; RISK-FACTORS; COCCIDIOIDOMYCOSIS; SURVIVAL; ACCESS
AB Health disparities in access to solid organ transplantation (SOT) and graft survival are well recognized, but there are limited data on the relationship of race to risk of invasive fungal infection (IFI) among SOT recipients. We conducted a case-control study using data from the Transplant-Associated Infection Surveillance Network (TRANSNET) to investigate race and IFI. Cases (n=1,214) and controls (n=16,550) were compared on demographic variables using chi-square, and the relationship between race and IFI was assesses with unconditional logistic regression. Compared to White transplant patients, Blacks had similar odds of developing IFI (OR=.97, 95% CI 0.82-1.15, P=.7125), while participants who identified as other ethnicity were less likely to develop IFI (OR=.56, 95% CI .41-.75, P<.001). Blacks, when compared to White patients, were at increased odds of developing cryptococcal infection (OR 2.19, 95%CI 1.35-3.54, P=.002). Despite pharmacogenetic differences, Black transplant recipients were not more likely overall to develop IFI compared to White transplant recipients.
C1 [Boehme, Amelia K.] Univ Alabama Birmingham, Sch Publ Hlth, Birmingham, AL 35294 USA.
   [Andes, David R.] Univ Wisconsin, Madison, WI 53706 USA.
   [Lyon, G. Marshall] Emory Univ, Sch Med, Atlanta, GA 30322 USA.
   [Chiller, Tom] Ctr Dis Control, Atlanta, GA 30333 USA.
   [Pappas, Peter G.; Baddley, John W.] Univ Alabama Birmingham, Sch Med, Birmingham, AL 35294 USA.
   [Baddley, John W.] Birmingham VA Med Ctr, Birmingham, AL 35233 USA.
RP Baddley, JW (reprint author), Univ Alabama Birmingham, Div Infect Dis, 1900 Univ Blvd,THT 229, Birmingham, AL 35294 USA.
EM jbaddley@uab.edu
FU CDC; Astellas; Pfizer; Merck; Schering Plough
FX TRANSNET was sponsored by the CDC, Astellas, Pfizer, Merck, and Schering
   Plough. We would like to thank the following TRANSNET Investigators:
   Barbara Alexander, MD, Duke University; Elias Anaissie, MD, University
   of Arkansas; Michael Boeckh, MD, Fred Hutchinson Cancer Research Center;
   Janice Brown, MD, Stanford University; Lisa Brumble, MD, Mayo
   Clinic-Jacksonville; Alison Freifeld, MD, University of Nebraska; Yoav
   Golan, MD, and Susan Hadley, MD, Tufts University; Loreen Herwaldt, MD,
   University of Iowa; James Ito, MD, City of Hope National Medical Center;
   Carol Kauffman, MD, University of Michigan; Katherine Knapp, MD, St.
   Jude Children's Hospital; Dimitrios Kontoyiannis, MD, MD Anderson Cancer
   Center; Kieren Marr, MD and Trish Perl, MD, Johns Hopkins Medical
   Institute; Vicki Morrison, MD, University of Minnesota; Genovefa
   Papanicolaou, MD, Memorial Sloan-Kettering Cancer Center; Tom Patterson,
   MD, University of Texas HSC-San Antonio; Mindy Schuster, MD, University
   of Pennsylvania; Randall Walker, MD, Mayo Clinic-Rochester; Tom Walsh,
   MD, Weill Cornell Medical College; John Wingard, MD, University of
   Florida.
NR 17
TC 1
Z9 1
U1 0
U2 0
PU INT SOC HYPERTENSION BLACKS-ISHIB
PI ATLANTA
PA 100 AUBURN AVE NE STE 401, ATLANTA, GA 30303-2527 USA
SN 1049-510X
EI 1945-0826
J9 ETHNIC DIS
JI Ethn. Dis.
PD SUM
PY 2014
VL 24
IS 3
BP 382
EP 385
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA CU7KT
UT WOS:000363717300018
PM 25065083
ER

PT J
AU Molina, Y
   Lehavot, K
   Beadnell, B
   Simoni, J
AF Molina, Yamile
   Lehavot, Keren
   Beadnell, Blair
   Simoni, Jane
TI Racial Disparities in Health Behaviors and Conditions Among Lesbian and
   Bisexual Women: The Role of Internalized Stigma
SO LGBT HEALTH
LA English
DT Article
DE bisexual; health disparities; lesbian/gay; physical health;
   race/ethnicity; women
ID FEMINIST IDENTITY DEVELOPMENT; ACTIVITY QUESTIONNAIRE IPAQ; BODY-FAT
   DISTRIBUTION; SEXUAL ORIENTATION; AFRICAN-AMERICAN; PHYSICAL-ACTIVITY;
   US ADULTS; GAY MEN; PSYCHOLOGICAL DISTRESS; VEGETABLE INTAKE
AB There are documented disparities in physical health behaviors and conditions, such as physical activity and obesity, with regard to both race/ethnicity and sexual orientation. However, physical health disparities for lesbian and bisexual (LB) women who are also racial minorities are relatively unexplored. Minority stressors, such as internalized stigma, may account for disparities in such multiply marginalized populations. We sought to (1) characterize inequalities among non-Hispanic white and African American LB women and (2) examine the roles of internalized sexism and homophobia in disparities. Data on health behaviors (diet, physical activity); physical health (hypertension, diabetes, overweight/obesity); internalized sexism; and internalized homophobia were collected via a web-based survey. Recruitment ads were sent electronically to over 200 listservs, online groups, and organizations serving the lesbian, gay, and bisexual community in all 50 U.S. states. The analytic sample consisted of 954 white and 75 African American LB women. African American participants were more likely than white participants to report low fruit/vegetable intake and physical activity, a higher body mass index, and a history of diabetes and hypertension. There were no racial differences in internalized homophobia, but African American women reported higher levels of internalized sexism. Internalized sexism partially mediated racial disparities in physical activity and diabetes, but not in the other outcomes. Findings suggest that African American LB women may be at greater risk than their white counterparts for poor health and that internalized sexism may be a mediator of racial differences for certain behaviors and conditions.
C1 [Molina, Yamile] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA.
   [Molina, Yamile] Univ Illinois, Epidemiol & Biostat Div, Chicago, IL USA.
   [Molina, Yamile] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
   [Lehavot, Keren] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
   [Beadnell, Blair] Univ Washington, Sch Social Work, Seattle, WA 98195 USA.
   [Simoni, Jane] Univ Washington, Dept Psychol, Seattle, WA 98195 USA.
   [Lehavot, Keren] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
RP Molina, Y (reprint author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N,M3-B232, Seattle, WA 98109 USA.
EM ymolina@fhcrc.org
OI Simoni, Jane/0000-0002-8711-1576
FU Centers for Disease Control Grant for Public Health Research
   Dissertation [R36 CD000996]; National Cancer Institute Supplement to
   Promote Diversity in Health-Related Research [P50CA148143];
   Biobehavioral Cancer Prevention and Control Training Program at the
   University of Washington [R25CA92408]
FX This research was supported by a Centers for Disease Control Grant for
   Public Health Research Dissertation (R36 CD000996) award to K.L.
   Manuscript preparation was supported by funding to Y.M. through a
   National Cancer Institute Supplement to Promote Diversity in
   Health-Related Research (P50CA148143) and a postdoctoral fellowship
   through the Biobehavioral Cancer Prevention and Control Training Program
   at the University of Washington (R25CA92408).
NR 89
TC 3
Z9 3
U1 3
U2 6
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2325-8292
EI 2325-8306
J9 LGBT HEALTH
JI LGBT Health
PD JUN
PY 2014
VL 1
IS 2
BP 131
EP 139
DI 10.1089/lgbt.2013.0007
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA CR9PV
UT WOS:000361689800012
PM 25364769
ER

PT J
AU Robbins, NM
   Swanson, RA
AF Robbins, Nathaniel M.
   Swanson, Raymond A.
TI Opposing Effects of Glucose on Stroke and Reperfusion Injury Acidosis,
   Oxidative Stress, and Energy Metabolism
SO STROKE
LA English
DT Article
DE acidosis; hemorrhage; hyperglycemia; hypoglycemia; reactive oxygen
   species; superoxides
C1 [Robbins, Nathaniel M.; Swanson, Raymond A.] Univ Calif San Francisco, Dept Neurol, 4150 Clement St, San Francisco, CA 94121 USA.
   [Swanson, Raymond A.] San Francisco VA Med Ctr, Neurol Serv, San Francisco, CA USA.
RP Swanson, RA (reprint author), Univ Calif San Francisco, Dept Neurol, 4150 Clement St, San Francisco, CA 94121 USA.; Swanson, RA (reprint author), Dept Vet Affairs Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA.
EM raymond.swanson@ucsf.edu
OI Swanson, Raymond/0000-0002-3664-5359
FU National Institutes of Health [NS041421, NS081149]; Department of
   Veterans Affairs
FX This review was supported by National Institutes of Health grants
   NS041421 and NS081149 to R.A. Swanson and by the Department of Veterans
   Affairs.
NR 48
TC 11
Z9 11
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0039-2499
EI 1524-4628
J9 STROKE
JI Stroke
PD JUN
PY 2014
VL 45
IS 6
BP 1881
EP 1886
DI 10.1161/STROKEAHA.114.004889
PG 6
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA V42VQ
UT WOS:000209641700001
PM 24743441
ER

PT J
AU Chen, Y
   Won, SJ
   Xu, Y
   Swanson, RA
AF Chen, Y.
   Won, S. J.
   Xu, Y.
   Swanson, R. A.
TI Targeting Microglial Activation in Stroke Therapy: Pharmacological Tools
   and Gender Effects
SO CURRENT MEDICINAL CHEMISTRY
LA English
DT Article
DE Brain; corticosteroid; female; HDAC; inflammation; ischemia;
   minocycline; PARP
ID FOCAL CEREBRAL-ISCHEMIA; HISTONE DEACETYLASE INHIBITORS;
   TUMOR-NECROSIS-FACTOR; GROUP BOX1-INHIBITING MECHANISM; BRAIN-INJURY;
   RAT-BRAIN; POLY(ADP-RIBOSE) POLYMERASE-1; GENE-EXPRESSION; FACTOR-ALPHA;
   CELL-DEATH
AB Ischemic stroke is caused by critical reductions in blood flow to brain or spinal cord. Microglia are the resident immune cells of the central nervous system, and they respond to stroke by assuming an activated phenotype that releases cytotoxic cytokines, reactive oxygen species, proteases, and other factors. This acute, innate immune response may be teleologically adapted to limit infection, but in stroke this response can exacerbate injury by further damaging or killing nearby neurons and other cell types, and by recruiting infiltration of circulating cytotoxic immune cells. The microglial response requires hours to days to fully develop, and this time interval presents a clinically accessible time window for initiating therapy. Because of redundancy in cytotoxic microglial responses, the most effective therapeutic approach may be to target the global gene expression changes involved in microglial activation. Several classes of drugs can do this, including histone deacetylase inhibitors, minocycline and other PARP inhibitors, corticosteroids, and inhibitors of TNF alpha and scavenger receptor signaling. Here we review the pre-clinical studies in which these drugs have been used to suppress microglial activation after stroke. We also review recent advances in the understanding of sex differences in the CNS inflammatory response, as these differences are likely to influence the efficacy of drugs targeting post-stroke brain inflammation.
C1 [Chen, Y.; Xu, Y.] Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp, Dept Neurol, Nanjing 210008, Jiangsu, Peoples R China.
   [Chen, Y.; Won, S. J.; Swanson, R. A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA.
   [Chen, Y.; Won, S. J.; Swanson, R. A.] San Francisco VA Med Ctr, Neurol Serv, San Francisco, CA 94121 USA.
RP Swanson, RA (reprint author), Univ Calif San Francisco, Dept Neurol, 4150 Clement St, San Francisco, CA 94121 USA.
EM raymond.swanson@ucsf.edu
OI Swanson, Raymond/0000-0002-3664-5359
FU Chinese Research Scholarship Council; U.S. National Institutes of Health
   [NS041421]; U.S. Department of Veterans Affairs
FX This work was supported by the Chinese Research Scholarship Council
   (Y.C.) the U.S. National Institutes of Health (grant # NS041421,
   R.A.S.), and the U.S. Department of Veterans Affairs.
NR 132
TC 20
Z9 20
U1 0
U2 15
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 0929-8673
EI 1875-533X
J9 CURR MED CHEM
JI Curr. Med. Chem.
PD JUN
PY 2014
VL 21
IS 19
BP 2146
EP 2155
PG 10
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology &
   Pharmacy
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA AG4MF
UT WOS:000335393300005
PM 24372213
ER

PT J
AU Fitten, LJ
   Ortiz, F
   Fairbanks, L
   Bartzokis, G
   Lu, P
   Klein, E
   Coppola, G
   Ringman, J
AF Fitten, L. Jaime
   Ortiz, Freddy
   Fairbanks, Lynn
   Bartzokis, George
   Lu, Po
   Klein, Eric
   Coppola, Giovanni
   Ringman, John
TI Younger age of dementia diagnosis in a Hispanic population in southern
   California
SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE diagnosis; Hispanic; onset; Alzheimer's disease; Latino; age; dementia;
   vascular dementia; APOE genotype; diagnosis
ID APOLIPOPROTEIN-E EPSILON-4; MINI-MENTAL-STATE; OLDER MEXICAN-AMERICANS;
   ALZHEIMERS-DISEASE; DIABETES-MELLITUS; AFRICAN-AMERICANS; CARIBBEAN
   HISPANICS; NORTHERN MANHATTAN; RISK; ONSET
AB Objective
   Prior studies of US Hispanics, largely performed on the East Coast, have found a younger age of dementia onset than in White non-Hispanics. We performed a cross-sectional study to examine clinical and sociodemographic variables associated with age of dementia diagnosis in older Hispanics and White, non-Hispanics in southern California.
   Methods
   Two hundred ninety (110 Hispanic and 180 White non-Hispanic) community dwelling, cognitively symptomatic subjects, aged 50 years and older, were assessed and diagnosed with probable Alzheimer's disease or probable vascular dementia. Apolipoprotein E (APOE) genotype was assessed in a subset of cases. Analysis of variance and multiple stepwise linear regression were used to assess main effects and interactions of ethnicity with dementia severity (indexed by mini mental state examination scores) and other sociodemographic and clinical variables on age of dementia diagnosis.
   Results
   Hispanics were younger by an average of 4 years at the time of diagnosis, regardless of dementia subtype, despite a similar prevalence of the APOE epsilon 4 genotype. The earlier age at diagnosis for Hispanics was not explained by gender, dementia severity, years of education, history of hypercholesterolemia, hypertension, or diabetes. Only ethnicity was significantly associated with age of onset.
   Conclusions
   These findings confirm that US Hispanics living in the southwestern USA tend to be younger at the time of dementia diagnosis than their White non-Hispanic counterparts. As this is not explained by the presence of the APOE epsilon 4 genotype, further studies should explore other cultural, medical, or genetic risk factors influencing the age of dementia onset in this population. Copyright (c) 2014 John Wiley & Sons, Ltd.
C1 [Fitten, L. Jaime; Ortiz, Freddy; Fairbanks, Lynn; Bartzokis, George; Lu, Po; Coppola, Giovanni; Ringman, John] Univ Calif Los Angeles, David Geffen Sch Med, Easton Ctr Alzheimer Dis Res, Los Angeles, CA 90095 USA.
   [Fitten, L. Jaime; Ortiz, Freddy] US Dept Vet Affairs, Greater Los Angeles Vet Affairs Healthcare Syst, Sepulveda Ambulatory Care Ctr, Los Angeles, CA USA.
   [Fitten, L. Jaime; Ortiz, Freddy] Univ Calif Los Angeles, Med Ctr, Dept Psychiat Olive View, Los Angeles, CA 90024 USA.
   [Fitten, L. Jaime; Fairbanks, Lynn; Bartzokis, George; Lu, Po; Klein, Eric; Coppola, Giovanni] Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.
   [Ortiz, Freddy; Lu, Po; Ringman, John] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.
   [Bartzokis, George] Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA.
   [Bartzokis, George] Greater Los Angeles VA Healthcare Syst, West Los Angeles, CA USA.
RP Fitten, LJ (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Easton Ctr Alzheimer Dis Res, Los Angeles, CA 90095 USA.
EM jfitten@ucla.edu
FU NIA-UCLA ADRC [P50 AG16570]; State of California Alzheimer's Disease
   Center at UCLA, the Easton Consortium for Alzheimer's Disease Drug
   Discovery and Biomarker Development; Olive View-UCLA Medical Center,
   Sylmar, CA, USA; VA Greater Los Angeles Healthcare System, Sepulveda,
   CA, USA
FX This study was supported by funding from the NIA-UCLA ADRC (P50
   AG16570); by the State of California Alzheimer's Disease Center at UCLA,
   the Easton Consortium for Alzheimer's Disease Drug Discovery and
   Biomarker Development; by the Olive View-UCLA Medical Center, Sylmar,
   CA, USA; and by the VA Greater Los Angeles Healthcare System, Sepulveda,
   CA, USA.
NR 37
TC 6
Z9 6
U1 3
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0885-6230
EI 1099-1166
J9 INT J GERIATR PSYCH
JI Int. J. Geriatr. Psychiatr.
PD JUN
PY 2014
VL 29
IS 6
BP 586
EP 593
DI 10.1002/gps.4040
PG 8
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA AG2ND
UT WOS:000335252300005
PM 24478258
ER

PT J
AU Raskind, MA
   Wang, LY
AF Raskind, Murray A.
   Wang, Lucy Y.
TI Antipsychotic drugs for psychosis and agitation in dementia: efficacy,
   safety, and a possible noradrenergic mechanism of action
SO INTERNATIONAL PSYCHOGERIATRICS
LA English
DT Editorial Material
ID PLACEBO-CONTROLLED-TRIAL; NURSING-HOME RESIDENTS; ALZHEIMERS-DISEASE;
   DOUBLE-BLIND; LOCUS-COERULEUS; BEHAVIORAL DISTURBANCES; SENILE DEMENTIA;
   CLINICAL-TRIAL; TYROSINE-HYDROXYLASE; COMPENSATORY CHANGES
AB The first patient described by Alzheimer in 1907 had both progressive cognitive deterioration and prominent comorbid signs and symptoms of psychosis and agitation (Alzheimer, 1907, 1987). In this editorial, we use "psychosis" to denote delusions and hallucinations and "agitation" to denote irritability, aggression, pressured motor activity, and active resistance to necessary care. Although advances have been made in the treatment of these non-cognitive symptoms, these psychosis and agitation symptoms continued to be burdensome and costly for dementia patients, caregivers, and society. Among the pharmacologic treatments available for psychosis and agitation, antipsychotic drugs are the drug class most consistently demonstrated effective for psychosis and agitation in dementia (Lyketsos et al., 2006; APA Work Group on Alzheimer's Disease and Other Dementias et al., 2007). These are widely prescribed for these behavioral problems, but their use remains controversial and their mechanism of action unclear.
C1 [Raskind, Murray A.] Univ Washington, Vet Affairs Northwest Network VISN 20, Mental Illness Res Educ & Clin Ctr, Mental Hlth Serv,VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA.
   Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
RP Raskind, MA (reprint author), Univ Washington, Vet Affairs Northwest Network VISN 20, Mental Illness Res Educ & Clin Ctr, Mental Hlth Serv,VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA.
EM murray.raskind@va.gov
NR 45
TC 1
Z9 1
U1 1
U2 15
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1041-6102
EI 1741-203X
J9 INT PSYCHOGERIATR
JI Int. Psychogeriatr.
PD JUN
PY 2014
VL 26
IS 6
BP 879
EP 883
AR PII S1041610214000477
DI 10.1017/S1041610214000477
PG 5
WC Psychology, Clinical; Geriatrics & Gerontology; Gerontology; Psychiatry;
   Psychology
SC Psychology; Geriatrics & Gerontology; Psychiatry
GA AG4RK
UT WOS:000335407700001
PM 24703502
ER

PT J
AU Vatsavayi, AVV
   Kofler, J
   DeMichele-Sweet, MAA
   Murray, PS
   Lopez, OL
   Sweet, RA
AF Vatsavayi, Anil Varma V.
   Kofler, Julia
   DeMichele-Sweet, Mary Ann A.
   Murray, Patrick S.
   Lopez, Oscar L.
   Sweet, Robert A.
TI TAR DNA-binding protein 43 pathology in Alzheimer's disease with
   psychosis
SO INTERNATIONAL PSYCHOGERIATRICS
LA English
DT Article
DE Alzheimer's disease; TDP-43; psychosis
ID FRONTOTEMPORAL LOBAR DEGENERATION; NEUROPATHOLOGIC ASSESSMENT; TDP-43
   IMMUNOREACTIVITY; HIPPOCAMPAL SCLEROSIS; RISK-FACTORS; DELUSIONS;
   SYMPTOMS; PHENOTYPE; DEMENTIA; BEHAVIOR
AB Background:
   TAR DNA-binding protein 43 (TDP-43) has been identified as a major disease protein in frontotemporal lobar degeneration. More recently, TDP-43 proteinopathy has also been observed in Alzheimer's disease (AD) with a characteristic distribution of TDP-43 predominantly in the mesial temporal lobe, and to a lesser degree in the neocortical areas. AD subjects with psychotic symptoms (AD+P) represent a subgroup characterized by greater impairment of frontal cortex-dependent cognitive functions and more severe frontal cortical neuropathology. The aim of this study is to determine whether there is an association between TDP-43 pathology and AD+P. We hypothesized that TDP-43 pathology would be more frequent in AD+P than in AD without psychosis.
   Methods:
   We studied the presence and distribution of TDP-43 pathology by immunohistochemistry in the dentate gyrus (DG) and prefrontal cortex (FC) of postmortem brain specimens from 68 subjects with a primary neuropathologic diagnosis of AD as determined by the Neuropathology Core of the University of Pittsburgh Alzheimer's Disease Research Center.
   Results:
   Forty-five (66%) subjects were classified as AD+P. Fourteen (20.6%) subjects had TDP-43 pathology in DG, eight (11.8%) had TDP-43 pathology in FC, and six (8.8%) had TDP-43 pathology in both regions. TDP-43 in DG was not significantly associated with AD+P. However, TDP-43 in FC demonstrated a trend toward reduced likelihood of psychosis (p = 0.068). TDP-43 pathology in DG, but not FC, was significantly associated with greater age at death and longer duration of illness.
   Conclusions:
   Our findings indicate that there was no association between concomitant TDP-43 pathology in DG or FC and AD+P.
C1 [Vatsavayi, Anil Varma V.; Murray, Patrick S.; Sweet, Robert A.] Univ Pittsburgh, Sch Med, Translat Neurosci Program, Pittsburgh, PA USA.
   [Vatsavayi, Anil Varma V.; DeMichele-Sweet, Mary Ann A.; Murray, Patrick S.; Lopez, Oscar L.; Sweet, Robert A.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA.
   [Vatsavayi, Anil Varma V.; Murray, Patrick S.; Sweet, Robert A.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr 4, Pittsburgh, PA USA.
   [Lopez, Oscar L.; Sweet, Robert A.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA.
   [Kofler, Julia] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA USA.
RP Sweet, RA (reprint author), Biomed Sci Tower,W1645 3811,OHara St, Pittsburgh, PA 15213 USA.
EM sweetra@upmc.edu
OI Murray, Patrick/0000-0002-6525-2888
FU National Institute of Aging [AG05133, AG027224]; VA Pittsburgh
   Healthcare System (VAPHS) [BX000452]
FX This work was supported in part by the National Institute of Aging
   grants AG05133 (OLL) and AG027224 (RAS), and the VA Pittsburgh
   Healthcare System (VAPHS) grant BX000452 (RAS). The content is solely
   the responsibility of the authors and does not necessarily represent the
   official views of the National Institute of Mental Health, the National
   Institutes of Health, the Department of Veterans Affairs, or the United
   States Government.
NR 40
TC 3
Z9 3
U1 2
U2 11
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1041-6102
EI 1741-203X
J9 INT PSYCHOGERIATR
JI Int. Psychogeriatr.
PD JUN
PY 2014
VL 26
IS 6
BP 987
EP 994
DI 10.1017/S1041610214000246
PG 8
WC Psychology, Clinical; Geriatrics & Gerontology; Gerontology; Psychiatry;
   Psychology
SC Psychology; Geriatrics & Gerontology; Psychiatry
GA AG4RK
UT WOS:000335407700013
PM 24588894
ER

PT J
AU Minzenberg, MJ
   Gomes, GC
   Yoon, JH
   Watrous, AJ
   Geng, J
   Firl, AJ
   Carter, CS
AF Minzenberg, Michael J.
   Gomes, Glenn C.
   Yoon, Jong H.
   Watrous, Andrew J.
   Geng, Joy
   Firl, Alana J.
   Carter, Cameron S.
TI Modafinil augments oscillatory power in middle frequencies during rule
   selection
SO PSYCHOPHYSIOLOGY
LA English
DT Article
DE Prefrontal cortex; Cognitive control; Oscillations; Theta; Modafinil;
   Rule selection
ID INDEPENDENT COMPONENT ANALYSIS; INTERNEURON DIVERSITY SERIES; PREFRONTAL
   CORTEX; LOCUS-COERULEUS; WORKING-MEMORY; THETA-OSCILLATIONS; COGNITIVE
   CONTROL; 1ST-EPISODE SCHIZOPHRENIA; PHASE SYNCHRONIZATION; NETWORK
   OSCILLATIONS
AB Control-related cognitive processes are associated with cortical oscillations and modulated by catecholamine neurotransmitters. It remains unclear how catecholamine systems modulate control-related oscillations. We tested modafinil effects on rule-related 4-30 Hz oscillations, with double-blind, placebo-controlled (within-subjects) testing of 22 healthy adults, using EEG during cognitive control task performance. EEG data underwent time-frequency decomposition with Morlet wavelets to determine power of 4-30 Hz oscillations. Modafinil enhanced oscillatory power associated with high-control rule selection in theta, alpha, and beta ranges, with a frontotemporal topography and minimal effects during rule maintenance. Augmentation of catecholamine signaling enhances middle-frequency cortical oscillatory power associated with rule selection, which may subserve diverse subcomponent processes in proactive cognitive control.
C1 [Minzenberg, Michael J.] Univ Calif San Francisco, Sch Med, Dept Psychiat, San Francisco, CA 94143 USA.
   [Minzenberg, Michael J.] San Francisco VA Med Ctr, San Francisco, CA USA.
   [Gomes, Glenn C.; Carter, Cameron S.] Univ Calif Davis, Sch Med, Dept Psychiat, Sacramento, CA 95817 USA.
   [Yoon, Jong H.] Stanford Univ, Sch Med, Dept Psychiat, Palo Alto, CA 94304 USA.
   [Yoon, Jong H.] Palo Alto Vet Affairs Med Ctr, Palo Alto, CA USA.
   [Watrous, Andrew J.; Geng, Joy; Carter, Cameron S.] Univ Calif Davis, Ctr Neurosci, Davis, CA 95616 USA.
   [Firl, Alana J.] Univ Calif Berkeley, Program Vis Neurosci, Berkeley, CA 94720 USA.
RP Minzenberg, MJ (reprint author), 116C San Francisco Vet Affairs Med Ctr, Outpatient Mental Hlth Serv, 4150 Clement St, San Francisco, CA 94121 USA.
EM Michael.minzenberg@ucsf.edu
FU Doris Duke Charitable Foundation; NARSAD (Brain and Behavior
   Foundation); National Center for Research Resources (NCRR), a component
   of the National Institutes of Health (NIH) [UL1 RR024146]; NIH Roadmap
   for Medical Research
FX This work was supported by a Clinical Scientist Development Award from
   the Doris Duke Charitable Foundation and a Young Investigator award from
   NARSAD (Brain and Behavior Foundation) to MJM. This publication was also
   made possible by Grant Number UL1 RR024146 from the National Center for
   Research Resources (NCRR), a component of the National Institutes of
   Health (NIH), and NIH Roadmap for Medical Research. Its contents are
   solely the responsibility of the authors and do not necessarily
   represent the official view of NCRR or NIH. The authors would like to
   acknowledge the assistance of Janeth Nunez del Prado, Jenny Yen, and
   Dennis Thompson in the conduct and analysis of the study.
NR 84
TC 4
Z9 4
U1 0
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0048-5772
EI 1469-8986
J9 PSYCHOPHYSIOLOGY
JI Psychophysiology
PD JUN
PY 2014
VL 51
IS 6
BP 510
EP 519
DI 10.1111/psyp.12201
PG 10
WC Psychology, Biological; Neurosciences; Physiology; Psychology;
   Psychology, Experimental
SC Psychology; Neurosciences & Neurology; Physiology
GA AG1SL
UT WOS:000335196300002
PM 24611660
ER

PT J
AU Kim, JY
   Kawabori, M
   Yenari, MA
AF Kim, J. Y.
   Kawabori, M.
   Yenari, M. A.
TI Innate Inflammatory Responses in Stroke: Mechanisms and Potential
   Therapeutic Targets
SO CURRENT MEDICINAL CHEMISTRY
LA English
DT Article
DE Brain ischemia; inflammation; neuroprotection; stroke
ID FOCAL CEREBRAL-ISCHEMIA; BLOOD-BRAIN-BARRIER; TUMOR-NECROSIS-FACTOR;
   NITRIC-OXIDE SYNTHASE; INTERCELLULAR-ADHESION MOLECULE-1;
   CENTRAL-NERVOUS-SYSTEM; MONOCYTE CHEMOATTRACTANT PROTEIN-1;
   INTERLEUKIN-1 RECEPTOR ANTAGONIST; NF-KAPPA-B; TRANSIENT FOREBRAIN
   ISCHEMIA
AB Stroke is a frequent cause of long-term disability and death worldwide. Ischemic stroke is more commonly encountered compared to hemorrhagic stroke, and leads to tissue death by ischemia due to occlusion of a cerebral artery. Inflammation is known to result as a result of ischemic injury, long thought to be involved in initiating the recovery and repair process. However, work over the past few decades indicates that aspects of this inflammatory response may in fact be detrimental to stroke outcome. Acutely, inflammation appears to have a detrimental effect, and anti-inflammatory treatments have been been studied as a potential therapeutic target. Chronically, reports suggest that post-ischemic inflammation is also essential for the tissue repairing and remodeling. The majority of the work in this area has centered around innate immune mechanisms, which will be the focus of this review. This review describes the different key players in neuroinflammation and their possible detrimental and protective effects in stroke. A better understanding of the roles of the different immune cells and their temporal profile of damage versus repair will help to clarify more effective modulation of inflammation post stroke.
C1 [Yenari, M. A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA.
   San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
RP Yenari, MA (reprint author), Univ Calif San Francisco, Dept Neurol, Calif 4150 Clement St, San Francisco, CA 94121 USA.
EM Yenari@alum.mit.edu
FU National Institutes of Health [NS40516]; Veteran's Merit Award; American
   Heart Association; Uehara Foundation; Veterans Affairs Medical Center,
   San Francisco, California
FX This work was supported by grants from the National Institutes of Health
   (NS40516, to MY), the Veteran's Merit Award (MY), the American Heart
   Association (to JYK), and the Uehara Foundation (2013 Research
   Fellowship, to MK). Grants to MY and JYK were administered by the
   Northern California Institute for Research and Education, and supported
   by resources of the Veterans Affairs Medical Center, San Francisco,
   California.
NR 351
TC 33
Z9 36
U1 2
U2 23
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 0929-8673
EI 1875-533X
J9 CURR MED CHEM
JI Curr. Med. Chem.
PD JUN
PY 2014
VL 21
IS 18
BP 2076
EP 2097
PG 22
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology &
   Pharmacy
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA AF6UM
UT WOS:000334850100006
PM 24372209
ER

PT J
AU Gin, JL
   Stein, JA
   Heslin, KC
   Dobalian, A
AF Gin, June L.
   Stein, Judith A.
   Heslin, Kevin C.
   Dobalian, Aram
TI Responding to risk: Awareness and action after the September 11, 2001
   terrorist attacks
SO SAFETY SCIENCE
LA English
DT Article
DE Emergency preparedness; Terrorism; Social psychology; Pre-disposing
   factors; Disaster planning; Cognitive awareness
ID INDIVIDUAL-RESPONSE; PREPAREDNESS; PERSPECTIVE; CANADA; HAZARD; STATES;
   MODEL
AB Adoption of preparedness measures among the US public remains low after the expansion of the all-hazards approach to personal preparedness campaigns following the terrorist attacks of September 11, 2001 (9/11). This study sought to understand factors influencing preparedness behavior, particularly how demographics might influence preparedness behavior and whether preparedness actions are related to preparedness attitudes and related behaviors that may prime individuals to take these actions. Using data from the 2008 General Social Survey (n = 1338), we tested a conceptual path model of preparedness that includes demographic variables and three latent variables as mediators of the effects of demographics on preparedness: Cognitive Preparedness; Peer Group Behavior Awareness, and Perceived Effectiveness. The model explains 65% of the variance in preparedness behavior. It suggests that the effects of demographic factors on preparedness actually reflect indirect relationships mediated by predisposing attitudes, behaviors and experiences, specifically, Cognitive Preparedness, Peer Group Behavior Awareness, and Perceived Effectiveness that predispose individuals toward taking preparedness actions. Because these social and cognitive factors reflect behaviors that, unlike fixed demographics, can be shaped by public education programs, efforts to increase public preparedness should focus on improving public awareness, social networks, and more persuasive messaging as keys to increasing preparedness behavior among the US public. (C) 2014 The Authors. Published by Elsevier Ltd. All rights reserved.
C1 [Gin, June L.; Stein, Judith A.; Heslin, Kevin C.; Dobalian, Aram] US Dept Vet Affairs, Vet Emergency Management Evaluat Ctr, North Hills, CA 91343 USA.
   [Heslin, Kevin C.; Dobalian, Aram] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA 90024 USA.
   [Dobalian, Aram] UCLA Sch Nursing, Los Angeles, CA USA.
RP Gin, JL (reprint author), US Dept Vet Affairs, Vet Emergency Management Evaluat Ctr, 16111 Plummer St,MS-152, North Hills, CA 91343 USA.
EM june.gin@va.gov; jastein@ucla.edu; kevin.heslin@va.gov;
   aram.dobalian@va.gov
FU US Department of Veterans Affairs, Veterans Health Administration,
   Office of Public Health
FX This material is based on work supported by the US Department of
   Veterans Affairs, Veterans Health Administration, Office of Public
   Health. The views expressed in this article are those of the authors and
   do not necessarily reflect the position or policy of the US Department
   of Veterans Affairs or the US government. The authors thank Michael N.
   Mitchell for statistical consulting assistance provided on the GSS data
   set.
NR 35
TC 1
Z9 2
U1 3
U2 33
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0925-7535
EI 1879-1042
J9 SAFETY SCI
JI Saf. Sci.
PD JUN
PY 2014
VL 65
BP 86
EP 92
DI 10.1016/j.ssci.2014.01.001
PG 7
WC Engineering, Industrial; Operations Research & Management Science
SC Engineering; Operations Research & Management Science
GA AD8JQ
UT WOS:000333512700011
ER

PT J
AU Rogers, T
   Milkman, KL
   Volpp, KG
AF Rogers, Todd
   Milkman, Katherine L.
   Volpp, Kevin G.
TI Commitment Devices Using Initiatives to Change Behavior
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
ID SMOKING-CESSATION
C1 [Rogers, Todd] Harvard Univ, Kennedy Sch, Boston, MA 02115 USA.
   [Milkman, Katherine L.; Volpp, Kevin G.] Univ Penn, Wharton Sch, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA.
   [Volpp, Kevin G.] Univ Penn, Philadelphia VA Med Ctr, Perelman Sch Med, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA.
RP Volpp, KG (reprint author), Univ Penn, Philadelphia VA Med Ctr, Perelman Sch Med, Ctr Hlth Incent & Behav Econ, 423 Guardian Dr,1120 Blockley Hall, Philadelphia, PA 19104 USA.
EM volpp70@exchange.upenn.edu
NR 7
TC 11
Z9 11
U1 2
U2 14
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD MAY 28
PY 2014
VL 311
IS 20
BP 2065
EP 2066
DI 10.1001/jama.2014.3485
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA AH8MQ
UT WOS:000336392400018
PM 24777472
ER

PT J
AU Cotton, PB
   Durkalski, V
   Romagnuolo, J
   Pauls, Q
   Fogel, E
   Tarnasky, P
   Aliperti, G
   Freeman, M
   Kozarek, R
   Jamidar, P
   Wilcox, M
   Serrano, J
   Brawman-Mintzer, O
   Elta, G
   Mauldin, P
   Thornhill, A
   Hawes, R
   Wood-Williams, A
   Orrell, K
   Drossman, D
   Robuck, P
AF Cotton, Peter B.
   Durkalski, Valerie
   Romagnuolo, Joseph
   Pauls, Qi
   Fogel, Evan
   Tarnasky, Paul
   Aliperti, Giuseppe
   Freeman, Martin
   Kozarek, Richard
   Jamidar, Priya
   Wilcox, Mel
   Serrano, Jose
   Brawman-Mintzer, Olga
   Elta, Grace
   Mauldin, Patrick
   Thornhill, Andre
   Hawes, Robert
   Wood-Williams, April
   Orrell, Kyle
   Drossman, Douglas
   Robuck, Patricia
TI Effect of Endoscopic Sphincterotomy for Suspected Sphincter of Oddi
   Dysfunction on Pain-Related Disability Following Cholecystectomy The
   EPISOD Randomized Clinical Trial
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; FUNCTIONAL GASTROINTESTINAL
   DISORDERS; FINDINGS TYPE-I; HEALTH-STATUS; RISK-FACTORS; DSM-IV; ERCP;
   GALLBLADDER; SYMPTOMS; DISEASE
AB IMPORTANCE Abdominal pain after cholecystectomy is common and may be attributed to sphincter of Oddi dysfunction. Management often involves endoscopic retrograde cholangiopancreatography (ERCP) with manometry and sphincterotomy.
   OBJECTIVE To determine whether endoscopic sphincterotomy reduces pain and whether sphincter manometric pressure is predictive of pain relief.
   DESIGN, SETTING, AND PATIENTS Multicenter, sham-controlled, randomized trial involving 214 patients with pain after cholecystectomy without significant abnormalities on imaging or laboratory studies, and no prior sphincter treatment or pancreatitis randomly assigned (August 6, 2008-March 23, 2012) to undergo sphincterotomy or sham therapy at 7 referral medical centers. One-year follow-up was blinded. The final follow-up visit was March 21, 2013.
   INTERVENTIONS After ERCP, patients were randomized 2: 1 to sphincterotomy (n = 141) or sham (n = 73) irrespective of manometry findings. Those randomized to sphincterotomy with elevated pancreatic sphincter pressures were randomized again (1: 1) to biliary or to both biliary and pancreatic sphincterotomies. Seventy-two were entered into an observational study with conventional ERCP managemeny.
   MAIN OUTCOMES AND MEASURES Success of treatment was defined as less than 6 days of disability due to pain in the prior 90 days both at months 9 and 12 after randomization, with no narcotic use and no further sphincter intervention.
   RESULTS Twenty-seven patients (37%; 95% CI, 25.9%-48.1%) in the sham treatment group vs 32 (23%; 95% CI, 15.8%-29.6%) in the sphincterotomy group experienced successful treatment (adjusted risk difference, -15.6%; 95% CI, -28.0% to -3.3%; P =.01). Of the patients with pancreatic sphincter hypertension, 14 (30%; 95% CI, 16.7%-42.9%) who underwent dual sphincterotomy and 10 (20%; 95% CI, 8.7%-30.5%) who underwent biliary sphincterotomy alone experienced successful treatment. Thirty-seven treated patients (26%; 95% CI, 19%-34%) and 25 patients (34%; 95% CI, 23%-45%) in the sham group underwent repeat ERCP interventions (P =.22). Manometry results were not associated with the outcome. No clinical subgroups appeared to benefit from sphincterotomy more than others. Pancreatitis occurred in 15 patients (11%) after primary sphincterotomies and in 11 patients (15%) in the sham group. Of the nonrandomized patients in the observational study group, 5 (24%; 95% CI, 6%-42%) who underwent biliary sphincterotomy, 12 (31%; 95% CI, 16%-45%) who underwent dual sphincterotomy, and 2 (17%; 95% CI, 0%-38%) who did not undergo sphincterotomy had successful treatment.
   CONCLUSIONS AND RELEVANCE In patients with abdominal pain after cholecystectomy undergoing ERCP with manometry, sphincterotomy vs sham did not reduce disability due to pain. These findings do not support ERCP and sphincterotomy for these patients.
C1 [Cotton, Peter B.; Durkalski, Valerie; Romagnuolo, Joseph; Pauls, Qi; Mauldin, Patrick; Thornhill, Andre; Hawes, Robert; Wood-Williams, April; Orrell, Kyle] Med Univ S Carolina, Charleston, SC 29425 USA.
   [Fogel, Evan] Indiana Univ, Indianapolis, IN 46204 USA.
   [Tarnasky, Paul] Dallas Med Ctr, Dallas, TX USA.
   [Aliperti, Giuseppe] Midwest Therapeut Endoscopy Consultants, St Louis, MO USA.
   [Freeman, Martin] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA.
   [Kozarek, Richard] Virginia Mason Med Ctr, Seattle, WA 98101 USA.
   [Jamidar, Priya] Yale Univ, New Haven, CT USA.
   [Wilcox, Mel] Univ Alabama Birmingham, Birmingham, AL USA.
   [Serrano, Jose; Robuck, Patricia] Natl Inst Diabet & Digest & Kidney Dis, Bethesda, MD USA.
   [Brawman-Mintzer, Olga] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
   [Elta, Grace] Univ Michigan, Ann Arbor, MI 48109 USA.
   [Hawes, Robert] Florida Hosp, Orlando, FL USA.
   [Drossman, Douglas] Univ N Carolina, Chapel Hill, NC USA.
   [Drossman, Douglas] Drossman Gastroenterol PLLC, Chapel Hill, NC USA.
RP Cotton, PB (reprint author), Med Univ S Carolina, Ctr Digest Dis, ART 7094,MSC 290,25 Courtenay Dr, Charleston, SC 29425 USA.
EM cottonp@musc.edu
FU National Institutes of Diabetes and Digestive and Kidney Diseases [U01
   DK074739]
FX This study was funded by grant U01 DK074739 from the National Institutes
   of Diabetes and Digestive and Kidney Diseases.
NR 40
TC 40
Z9 41
U1 9
U2 16
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD MAY 28
PY 2014
VL 311
IS 20
BP 2101
EP 2109
DI 10.1001/jama.2014.5220
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA AH8MQ
UT WOS:000336392400026
PM 24867013
ER

PT J
AU Zhao, X
   Chen, F
   Feng, ZJ
   Li, XS
   Zhou, XH
AF Zhao, Xing
   Chen, Fei
   Feng, Zijian
   Li, Xiaosong
   Zhou, Xiao-Hua
TI Characterizing the effect of temperature fluctuation on the incidence of
   malaria: an epidemiological study in south-west China using the varying
   coefficient distributed lag non-linear model
SO MALARIA JOURNAL
LA English
DT Article
ID DENGUE VIRUS TRANSMISSION; EAST-AFRICAN HIGHLANDS; METEOROLOGICAL
   FACTORS; YUNNAN PROVINCE; SPATIOTEMPORAL DISTRIBUTION;
   PLASMODIUM-FALCIPARUM; CLIMATE-CHANGE; AEDES-AEGYPTI; ASSOCIATION; RISK
AB Background: Malaria transmission is strongly determined by the environmental temperature and the environment is rarely constant. Therefore, mosquitoes and parasites are not only exposed to the mean temperature, but also to daily temperature variation. Recently, both theoretical and laboratory work has shown, in addition to mean temperatures, daily fluctuations in temperature can affect essential mosquito and parasite traits that determine malaria transmission intensity. However, so far there is no epidemiological evidence at the population level to this problem.
   Methods: Thirty counties in southwest China were selected, and corresponding weekly malaria cases and weekly meteorological variables were collected from 2004 to 2009. Particularly, maximum, mean and minimum temperatures were collected. The daily temperature fluctuation was measured by the diurnal temperature range (DTR), the difference between the maximum and minimum temperature. The distributed lag non-linear model (MDLNM) was used to study the correlation between weekly malaria incidences and weekly mean temperatures, and the correlation pattern was allowed to vary over different levels of daily temperature fluctuations.
   Results: The overall non-linear patterns for mean temperatures are distinct across different levels of DTR. When under cooler temperature conditions, the larger mean temperature effect on malaria incidences is found in the groups of higher DTR, suggesting that large daily temperature fluctuations act to speed up the malaria incidence in cooler environmental conditions. In contrast, high daily fluctuations under warmer conditions will lead to slow down the mean temperature effect. Furthermore, in the group of highest DTR, 24-25 degrees C or 21-23 degrees C are detected as the optimal temperature for the malaria transmission.
   Conclusion: The environment is rarely constant, and the result highlights the need to consider temperature fluctuations as well as mean temperatures, when trying to understand or predict malaria transmission. This work may be the first epidemiological study confirming that the effect of the mean temperature depends on temperature fluctuations, resulting in relevant evidence at the population level.
C1 [Zhao, Xing; Chen, Fei; Li, Xiaosong] Sichuan Univ, West China Sch Publ Hlth, Chengdu 610041, Peoples R China.
   [Zhao, Xing; Zhou, Xiao-Hua] Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98195 USA.
   [Feng, Zijian] Chinese Ctr Dis Control & Prevent, Off Dis Control & Emergency Response, Beijing 102206, Peoples R China.
   [Zhou, Xiao-Hua] VA Puget Sound Hlth Care Syst, HSR&D Ctr Excellence, Seattle, WA 98101 USA.
RP Li, XS (reprint author), Sichuan Univ, West China Sch Publ Hlth, 17 Sect 3,South Renmin Rd, Chengdu 610041, Peoples R China.
EM lixiaosong1101@126.com; azhou@u.washington.edu
FU Natural Science Foundation of China, China Scholarship Council
   [30571618]
FX The three reviewers' comments have greatly improved the content and
   readability of the manuscript. The Figure in the Additional file 1 was
   reproduced from a previous article written by same authors [35], and the
   Figure was included for the purpose of completeness. In addition, Table
   1, with some new data, was partly reproduced from that previous article.
   This study was supported by the Natural Science Foundation of China (No.
   30571618), China Scholarship Council (http://en.csc.edu.cn/).
NR 45
TC 5
Z9 5
U1 3
U2 14
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD MAY 27
PY 2014
VL 13
AR 192
DI 10.1186/1475-2875-13-192
PG 10
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA AL2JC
UT WOS:000338950900003
PM 24886630
ER

PT J
AU Kunchithapautham, K
   Atkinson, C
   Rohrer, B
AF Kunchithapautham, Kannan
   Atkinson, Carl
   Rohrer, Baerbel
TI Smoke Exposure Causes Endoplasmic Reticulum Stress and Lipid
   Accumulation in Retinal Pigment Epithelium through Oxidative Stress and
   Complement Activation
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID UNFOLDED PROTEIN RESPONSE; FACTOR-H POLYMORPHISM; MACULAR DEGENERATION;
   CIGARETTE-SMOKE; BRUCHS MEMBRANE; CHOROIDAL NEOVASCULARIZATION;
   REGULATORY PROTEINS; ALTERNATIVE PATHWAY; GEOGRAPHIC ATROPHY;
   APOLIPOPROTEIN-E
AB Age-related macular degeneration (AMD) is a complex disease caused by genetic and environmental factors, including genetic variants in complement components and smoking. Smoke exposure leads to oxidative stress, complement activation, endoplasmic reticulum (ER) stress, and lipid dysregulation, which have all been proposed to be associated with AMD pathogenesis. Here we examine the effects of smoke exposure on the retinal pigment epithelium (RPE). Mice were exposed to cigarette smoke or filtered air for 6 months. RPE cells grown as stable monolayers were exposed to 5% cigarette smoke extract (CSE). Effects of smoke were determined by biochemical, molecular, and histological measures. Effects of the alternative pathway (AP) of complement and complement C3a anaphylatoxin receptor signaling were analyzed using knock-out mice or specific inhibitors. ER stress markers were elevated after smoke exposure in RPE of intact mice, which was eliminated in AP-deficient mice. To examine this relationship further, RPE monolayers were exposed to CSE. Short term smoke exposure resulted in production and release of complement C3, the generation of C3a, oxidative stress, complement activation on the cell membrane, and ER stress. Long term exposure to CSE resulted in lipid accumulation, and secretion. All measures were reversed by blocking C3a complement receptor (C3aR), alternative complement pathway signaling, and antioxidant therapy. Taken together, our results provide clear evidence that smoke exposure results in oxidative stress and complement activation via the AP, resulting in ER stress-mediated lipid accumulation, and further suggesting that oxidative stress and complement act synergistically in the pathogenesis of AMD.
C1 [Kunchithapautham, Kannan; Rohrer, Baerbel] Med Univ S Carolina, Dept Ophthalmol, Charleston, SC 29425 USA.
   [Atkinson, Carl] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA.
   [Rohrer, Baerbel] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC 29401 USA.
RP Rohrer, B (reprint author), 167 Ashley Ave, Charleston, SC 29425 USA.
EM rohrer@musc.edu
FU National Institutes of Health [C06RR015455]
FX Animal studies were conducted in a facility constructed with support
   from the National Institutes of Health Grant C06RR015455.
NR 78
TC 26
Z9 26
U1 1
U2 6
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 23
PY 2014
VL 289
IS 21
BP 14534
EP 14546
DI 10.1074/jbc.M114.564674
PG 13
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AI9JE
UT WOS:000337248100012
PM 24711457
ER

PT J
AU Ma, QL
   Zuo, XH
   Yang, FS
   Ubeda, OJ
   Gant, DJ
   Alaverdyan, M
   Kiosea, NC
   Nazari, S
   Chen, PP
   Nothias, F
   Chan, P
   Teng, E
   Frautschy, SA
   Cole, GM
AF Ma, Qiu-Lan
   Zuo, Xiaohong
   Yang, Fusheng
   Ubeda, Oliver J.
   Gant, Dana J.
   Alaverdyan, Mher
   Kiosea, Nicolae C.
   Nazari, Sean
   Chen, Ping Ping
   Nothias, Fatiha
   Chan, Piu
   Teng, Edmond
   Frautschy, Sally A.
   Cole, Greg M.
TI Loss of MAP Function Leads to Hippocampal Synapse Loss and Deficits in
   the Morris Water Maze with Aging
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
DE Alzheimer's disease; knock-out; MAPs; Morris Water Maze; synaptic
   markers; tau
ID MICROTUBULE-ASSOCIATED PROTEIN; GLYCOGEN-SYNTHASE KINASE-3-BETA;
   ALPHA-LIPOIC ACID; ALZHEIMERS-DISEASE PATIENTS; MILD COGNITIVE
   IMPAIRMENT; N-TERMINAL KINASE; MOUSE MODEL; NEUROFIBRILLARY TANGLES;
   PHOSPHORYLATION SITES; NEURONAL CYTOSKELETON
AB Hyperphosphorylation and accumulation of tau aggregates are prominent features in tauopathies, including Alzheimer's disease, but the impact of loss of tau function on synaptic and cognitive deficits remains poorly understood. We report that old (19 - 20 months; OKO) but not middle-aged (8 - 9 months; MKO) tau knock-out mice develop Morris Water Maze(MWM) deficits and loss of hippocampal acetylated alpha-tubulin and excitatory synaptic proteins. Mild motor deficits and reduction in tyrosine hydroxylase (TH) in the substantia nigra were present by middle age, but did not affect MWM performance, whereas OKO mice showed MWM deficits paralleling hippocampal deficits. Deletion of tau, a microtubule-associated protein (MAP), resulted in increased levels of MAP1A, MAP1B, and MAP2 in MKO, followed by loss of MAP2 and MAP1B in OKO. Hippocampal synaptic deficits in OKO mice were partially corrected with dietary supplementation with docosahexaenoic acid (DHA) and both MWM and synaptic deficits were fully corrected by combining DHA with alpha-lipoic acid (ALA), which also prevented TH loss. DHA or DHA/ALA restored phosphorylated and total GSK3 beta and attenuated hyperactivation of the tau C-Jun N-terminal kinases (JNKs) while increasing MAP1B, dephosphorylated (active) MAP2, and acetylated alpha-tubulin, suggesting improved microtubule stability and maintenance of active compensatory MAPs. Our results implicate the loss of MAP function in age-associated hippocampal deficits and identify a safe dietary intervention, rescuing both MAP function and TH in OKO mice. Therefore, in addition to microtubule-stabilizing therapeutic drugs, preserving or restoring compensatory MAP function may be a useful new prevention strategy.
C1 [Ma, Qiu-Lan; Zuo, Xiaohong; Yang, Fusheng; Ubeda, Oliver J.; Gant, Dana J.; Alaverdyan, Mher; Kiosea, Nicolae C.; Nazari, Sean; Chen, Ping Ping; Teng, Edmond; Frautschy, Sally A.; Cole, Greg M.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90095 USA.
   [Ma, Qiu-Lan; Zuo, Xiaohong; Yang, Fusheng; Ubeda, Oliver J.; Gant, Dana J.; Alaverdyan, Mher; Kiosea, Nicolae C.; Nazari, Sean; Chen, Ping Ping; Teng, Edmond; Frautschy, Sally A.; Cole, Greg M.] Greater Los Angeles Vet Affairs Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA 90073 USA.
   [Nothias, Fatiha] Univ Paris 06, CNRS, INSERM U952, Unite Mixte Rech 7224, F-75005 Paris, France.
   [Chan, Piu] Capital Med Univ, Xuanwu Hosp, Beijing Inst Geriatr, Dept Neurobiol & Neurol, Beijing 10053, Peoples R China.
RP Cole, GM (reprint author), Vet Greater Los Angeles Healthcare, Mary S Easton Translat Ctr, 11301 Wilshire Blvd,Bldg 113,Rm 312, Los Angeles, CA 90073 USA.
EM frautsch@ucla.edu; gmcole@ucla.edu
RI Zuo, Xiaohong/H-6254-2016
FU National Institutes of Health [AT003008]; Alzheimer's Disease Research
   Center [P01AG16570, RC1AG035878, AG13471, U01 28583, R01AG021975];
   Alzheimer's Association [NIRG-07-59659]; UCLA Alzheimer's Disease
   Research Center Mary S. Easton Drug Discovery Program; UCLA Mary S.
   Easton Translational Center; Beijing High Standard Health Human Resource
   Cultural Program [e1e12]
FX This work was supported by the National Institutes of Health (Grant
   AT003008 to G. M. C.; Grant P01AG16570 from the Alzheimer's Disease
   Research Center to G. M. C.; Grant RC1AG035878 to G. M. C. and S. A. F.;
   Grant AG13471 to G. M. C.; Grant U01 28583 to S. A. F.; and Grant
   R01AG021975 to S. A. F.), the Alzheimer's Association (Grant
   NIRG-07-59659 to Q. L. M.), the UCLA Alzheimer's Disease Research Center
   Mary S. Easton Drug Discovery Program (G. M. C.), the UCLA Mary S.
   Easton Translational Center (G. M. C., S. A. F.), and David and Dr.
   Sharon Comden (S. A. F., G. M. C.). X.Z. was supported by the Beijing
   High Standard Health Human Resource Cultural Program (Grant e1e12 to P.
   P. C.). The polyclonal antibody to dephosphorylated, active MAP2 "MAP2
   972" was provided by Jesus Avila, PhD (Professor, Universidad Autonoma
   de Madrid, Spain).
NR 80
TC 28
Z9 29
U1 0
U2 9
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD MAY 21
PY 2014
VL 34
IS 21
BP 7124
EP 7136
DI 10.1523/JNEUROSCI.3439-13.2014
PG 13
WC Neurosciences
SC Neurosciences & Neurology
GA AI5HB
UT WOS:000336895200010
PM 24849348
ER

PT J
AU Volpp, KG
AF Volpp, Kevin G.
TI The Counseling African Americans to Control Hypertension Study and Ways
   to Enhance the Next Wave of Behavioral Interventions
SO CIRCULATION
LA English
DT Editorial Material
DE Editorials; hypertension; intervention studies; medication adherence
ID DEFAULT OPTIONS; CARE
C1 [Volpp, Kevin G.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
   [Volpp, Kevin G.] Univ Penn, Wharton Sch, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Volpp, Kevin G.] Univ Penn, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA.
RP Volpp, KG (reprint author), Univ Penn, Dept Med, 1120 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM volpp70@wharton.upenn.edu
NR 12
TC 1
Z9 1
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
EI 1524-4539
J9 CIRCULATION
JI Circulation
PD MAY 20
PY 2014
VL 129
IS 20
BP 2002
EP 2004
DI 10.1161/CIRCULATIONAHA.114.009409
PG 3
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA AI6KA
UT WOS:000336981400007
PM 24657990
ER

PT J
AU Alumkal, JJ
   Heiser, L
   Beer, TM
   Small, EJ
   Baertsch, R
   Stuart, J
   King, C
   Korkola, J
   Cetnar, J
   Graff, JN
   Thomas, G
   Ryan, CW
   Toschi, A
   Youngren, J
   Tucker, E
   Ellers, K
AF Alumkal, Joshi J.
   Heiser, Laura
   Beer, Tomasz M.
   Small, Eric Jay
   Baertsch, Robert
   Stuart, Josh
   King, Carly
   Korkola, James
   Cetnar, Jeremy
   Graff, Julie Nicole
   Thomas, George
   Ryan, Christopher W.
   Toschi, Alexandria
   Youngren, Jack
   Tucker, Erin
   Ellers, Kristi
CA AACR PCF Stand Up Canc West Coast
TI Identifying enzalutamide resistance mechanisms in men with
   castration-resistant prostate cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 30-JUN 03, 2014
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Oregon Hlth & Sci Univ, OHSU Knight Canc Inst, Portland, OR 97201 USA.
   Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
   Univ Calif San Francisco, San Francisco, CA 94143 USA.
   Univ Calif Santa Cruz, Santa Cruz, CA 95064 USA.
   Oregon Hlth & Sci Univ, Knight Canc Inst, Portland VA Med Ctr, Portland, OR 97201 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2014
VL 32
IS 15
SU S
MA TPS5104
PG 1
WC Oncology
SC Oncology
GA CN7KL
UT WOS:000358613202141
ER

PT J
AU Fisher, M
   Yim, YM
   Small, A
   Luthra, R
   Singer, J
   Schukman, J
   McAneny, BL
   Punekar, R
   Malin, J
AF Fisher, Maxine
   Yim, Yeun Mi
   Small, Art
   Luthra, Rakesh
   Singer, Joseph
   Schukman, Jay
   McAneny, Barbara L.
   Punekar, Rajeshjwari
   Malin, Jennifer
TI Comparative health care (HC) costs and quality of care in five cancer
   types by physician office (PO) and hospital outpatient (HOP) settings
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 30-JUN 03, 2014
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 HealthCore Inc, Wilmington, DE USA.
   Genentech Inc, San Francisco, CA 94080 USA.
   WellPoint Inc, Indianapolis, IN USA.
   New Mexico Oncol Hematol Consultants LTD, Albuquerque, NM USA.
   VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2014
VL 32
IS 15
SU S
MA 6528
PG 1
WC Oncology
SC Oncology
GA CN7KL
UT WOS:000358613203714
ER

PT J
AU Friedlander, TW
   Premasekharan, G
   Ngo, V
   Hang, E
   Graff, JN
   Ryan, CJ
   Paris, P
AF Friedlander, Terence W.
   Premasekharan, Gayatri
   Ngo, Vy
   Hang, Evelyn
   Graff, Julie Nicole
   Ryan, Charles J.
   Paris, Pamela
TI Molecular and genomic characterization of invasive circulating tumor
   cells (iCTCs) from men with metastatic castration-resistant prostate
   cancer (mCRPC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 30-JUN 03, 2014
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Calif San Francisco, San Francisco, CA 94143 USA.
   Univ Calif San Francisco, Med Ctr, San Francisco, CA USA.
   Oregon Hlth & Sci Univ, Knight Canc Inst, Portland VA Med Ctr, Portland, OR 97201 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2014
VL 32
IS 15
SU S
MA 11013
PG 1
WC Oncology
SC Oncology
GA CN7KL
UT WOS:000358613204746
ER

PT J
AU Matro, JM
   Yu, JQ
   Heinrich, MC
   Ramachandran, A
   Ku, N
   von Mehren, M
AF Matro, Jennifer Madeline
   Yu, Jian Qin
   Heinrich, Michael C.
   Ramachandran, Abhijit
   Ku, Nora
   von Mehren, Margaret
TI Correlation of PET/CT and CT RECIST response in GIST patients with
   PDGFRA D842V gene mutations treated with crenolanib.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 30-JUN 03, 2014
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
   OHSU Knight Canc Inst, Portland, OR USA.
   Portland VA Med Ctr, Portland, OR USA.
   AROG Pharmaceut LLC, Dallas, TX USA.
NR 0
TC 3
Z9 3
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2014
VL 32
IS 15
SU S
MA 10546
PG 1
WC Oncology
SC Oncology
GA CN7KL
UT WOS:000358613204679
ER

PT J
AU Moghanaki, D
   Cheuk, AV
   Fosmire, H
   Anscher, MS
   Hagan, MP
   Lutz, ST
   Dawson, GA
AF Moghanaki, Drew
   Cheuk, Alice V.
   Fosmire, Helen
   Anscher, Mitchell Steven
   Hagan, Michael Philip
   Lutz, Stephen T.
   Dawson, George A.
TI Availability of single-fraction palliative radiotherapy for cancer
   patients receiving end-of-life care within the Veterans Healthcare
   Administration.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 30-JUN 03, 2014
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Hunter Holmes McGuire Vet Affairs Med Ctr, Richmond, VA USA.
   James J Peters VA Med Ctr, New York, NY USA.
   Richard L Roudebush Vet Affairs Med Ctr, Indianapolis, IN 46202 USA.
   Virginia Commonwealth Univ, Med Ctr, Richmond, VA USA.
   US Dept Vet Affairs, Natl Radiat Oncol Program, Richmond, VA USA.
   Blanchard Valley Reg Hlth Ctr, Findlay, OH USA.
   VA New Jersey Healthcare Syst, E Orange, NJ USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2014
VL 32
IS 15
SU S
MA 9556
PG 1
WC Oncology
SC Oncology
GA CN7KL
UT WOS:000358613204440
ER

PT J
AU Nannini, M
   Astolfi, A
   Urbini, M
   Indio, V
   Santini, D
   Heinrich, MC
   Corless, CL
   Saponara, M
   Mandrioli, A
   Lolli, C
   Ercolani, G
   Biasco, G
   Pantaleo, MA
AF Nannini, Margherita
   Astolfi, Annalisa
   Urbini, Milena
   Indio, Valentina
   Santini, Donatella
   Heinrich, Michael C.
   Corless, Christopher L.
   Saponara, Maristella
   Mandrioli, Anna
   Lolli, Cristian
   Ercolani, Giorgio
   Biasco, Guido
   Pantaleo, Maria A.
TI Integrate whole genomic study of KIT/PDGFRA wild-type (WT) GIST.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 30-JUN 03, 2014
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Bologna, St Orsola Malpighi Hosp, Dept Specialized Expt & Diagnost Med, Bologna, Italy.
   Univ Bologna, Giorgio Prodi Canc Res Ctr, Bologna, Italy.
   Univ Bologna, S Orsola Malpighi Hosp, Pathol Unit, Bologna, Italy.
   OHSU Knight Canc Inst, Portland, OR USA.
   Portland VA Med Ctr, Portland, OR USA.
   Oregon Hlth & Sci Univ, Knight Diagnost Labs, Portland, OR 97201 USA.
   St Orsola Marcello Malpighi Hosp, Liver & Multiorgan Transplant Unit, Bologna, Italy.
   Univ Bologna, L&A Seragnoli Dept Hematol & Oncol Sci, Bologna, Italy.
RI Saponara, Maristella/J-9904-2016; Urbini, Milena/K-1351-2016; nannini,
   margherita/J-9866-2016
OI Saponara, Maristella/0000-0003-0715-171X; Urbini,
   Milena/0000-0002-3364-9098; 
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2014
VL 32
IS 15
SU S
MA 10513
PG 1
WC Oncology
SC Oncology
GA CN7KL
UT WOS:000358613204646
ER

PT J
AU Peled, N
   Abud-Hawa, M
   Liran, O
   Ilouze, M
   Gai-Mor, N
   Shlomi, D
   Ben-Nun, A
   Onn, A
   Bar, J
   Johnson, D
   Wells, J
   Millstone, S
   Bunn, PA
   Miller, YE
   Keith, RL
   Rikke, B
   Hirsch, FR
   Haick, H
AF Peled, Nir
   Abud-Hawa, Manal
   Liran, Ori
   Ilouze, Maya
   Gai-Mor, Naomi
   Shlomi, Dekel
   Ben-Nun, Alon
   Onn, Amir
   Bar, Jair
   Johnson, Douglas
   Wells, John
   Millstone, Stuart
   Bunn, Paul A.
   Miller, York E.
   Keith, Robert L.
   Rikke, Brad
   Hirsch, Fred R.
   Haick, Hossam
TI Breath analysis as a noninvasive biomarker for early detection of lung
   cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 30-JUN 03, 2014
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Rabin Med Ctr, Davidoff Canc Ctr, Thorac Canc Unit, Petach Tikwa, Israel.
   Technion Israel Inst Technol, Dept Chem Engn, IL-32000 Haifa, Israel.
   Technion Israel Inst Technol, Russell Berrie Nanotechnol Inst, Haifa, Israel.
   Chaim Sheba Med Ctr, Thorac Canc Res & Detect Ctr, Ramat Gan, Israel.
   Chaim Sheba Med Ctr, Inst Oncol, Thorac Oncol Unit, Ramat Gan, Israel.
   Chaim Sheba Med Ctr, Inst Oncol, Ramat Gan, Israel.
   Florida Radiat Oncol Grp, Jacksonville, FL USA.
   Univ Colorado, Ctr Canc, Aurora, CO USA.
   Univ Colorado, Ctr Canc, Denver, CO 80262 USA.
   Denver VA Med Ctr, Denver, CO USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2014
VL 32
IS 15
SU S
MA 7560
PG 1
WC Oncology
SC Oncology
GA CN7KL
UT WOS:000358613204018
ER

PT J
AU Wong, ML
   Wang, S
   Shi, Y
   Wozniak, CJ
   Walter, LC
AF Wong, Melisa L.
   Wang, Sunny
   Shi, Ying
   Wozniak, Curtis J.
   Walter, Louise C.
TI Impact of comorbidity and age on survival among older veterans with
   early stage non-small cell lung cancer (NSCLC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 50th Annual Meeting of the American-Society-of-Clinical-Oncology
CY MAY 30-JUN 03, 2014
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Calif San Francisco, San Francisco, CA 94143 USA.
   San Francisco VA Med Ctr, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2014
VL 32
IS 15
SU S
MA 7540
PG 1
WC Oncology
SC Oncology
GA CN7KL
UT WOS:000358613203976
ER

PT J
AU Riar, AK
   Narasimhan, M
   Rathinam, ML
   Vedpathak, D
   Mummidi, S
   Henderson, GI
   Mahimainathan, L
AF Riar, Amanjot Kaur
   Narasimhan, Madhusudhanan
   Rathinam, Mary Latha
   Vedpathak, Dhanashree
   Mummidi, Srinivas
   Henderson, George I.
   Mahimainathan, Lenin
TI Ethanol-Induced Transcriptional Activation of Programmed Cell Death 4
   (Pdcd4) Is Mediated by GSK-3 beta Signaling in Rat Cortical Neuroblasts
SO PLOS ONE
LA English
DT Article
ID FETAL ALCOHOL SYNDROME; TUMOR-SUPPRESSOR PDCD4; GLYCOGEN-SYNTHASE
   KINASE-3; BREAST-CANCER CELLS; NF-KAPPA-B; GENE-EXPRESSION;
   BETA-CATENIN; PRENATAL EXPOSURE; TRANSLATION INITIATION; PROTEIN
   TRANSLATION
AB Ingestion of ethanol (ETOH) during pregnancy induces grave abnormalities in developing fetal brain. We have previously reported that ETOH induces programmed cell death 4 (PDCD4), a critical regulator of cell growth, in cultured fetal cerebral cortical neurons (PCNs) and in the cerebral cortex in vivo and affect protein synthesis as observed in Fetal Alcohol Spectrum Disorder (FASD). However, the mechanism which activates PDCD4 in neuronal systems is unclear and understanding this regulation may provide a counteractive strategy to correct the protein synthesis associated developmental changes seen in FASD. The present study investigates the molecular mechanism by which ethanol regulates PDCD4 in cortical neuroblasts, the immediate precursor of neurons. ETOH treatment significantly increased PDCD4 protein and transcript expression in spontaneously immortalized rat brain neuroblasts. Since PDCD4 is regulated at both the post-translational and post-transcriptional level, we assessed ETOH's effect on PDCD4 protein and mRNA stability. Chase experiments demonstrated that ETOH does not significantly impact either PDCD4 protein or mRNA stabilization. PDCD4 promoter-reporter assays confirmed that PDCD4 is transcriptionally regulated by ETOH in neuroblasts. Given a critical role of glycogen synthase kinase 3 beta (GSK-3 beta) signaling in regulating protein synthesis and neurotoxic mechanisms, we investigated the involvement of GSK-3 beta and showed that multifunctional GSK-3 beta was significantly activated in response to ETOH in neuroblasts. In addition, we found that ETOH-induced activation of PDCD4 was inhibited by pharmacologic blockade of GSK-3 beta using inhibitors, lithium chloride (LiCl) and SB-216763 or siRNA mediated silencing of GSK-3 beta. These results suggest that ethanol transcriptionally upregulates PDCD4 by enhancing GSK-3 beta signaling in cortical neuroblasts. Further, we demonstrate that canonical Wnt-3a/GSK-3 beta signaling is involved in regulating PDCD4 protein expression. Altogether, we provide evidence that GSK-3 beta/PDCD4 network may represent a critical modulatory point to manage the protein synthetic anomalies and growth aberrations of neural cells seen in FASD.
C1 [Riar, Amanjot Kaur; Narasimhan, Madhusudhanan; Rathinam, Mary Latha; Vedpathak, Dhanashree; Henderson, George I.; Mahimainathan, Lenin] Texas Tech Univ, Hlth Sci Ctr, Dept Pharmacol & Neurosci, Lubbock, TX 79409 USA.
   [Narasimhan, Madhusudhanan; Henderson, George I.; Mahimainathan, Lenin] Texas Tech Univ, Hlth Sci Ctr, South Plains Alcohol & Addict Res Ctr, Lubbock, TX 79409 USA.
   [Mummidi, Srinivas] South Texas Vet Hlth Care Syst, Ctr Personalized Med, San Antonio, TX USA.
   [Mummidi, Srinivas] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
RP Mahimainathan, L (reprint author), Texas Tech Univ, Hlth Sci Ctr, Dept Pharmacol & Neurosci, Lubbock, TX 79409 USA.
EM lenin.mahimainathan@ttuhsc.edu
FU National Institutes of Health Research Project Grant Program [RO1
   AA010114]; Biomedical Laboratory Research and Development Service of the
   Veterans Affairs Office of Research and Development [1I01BX000975]; NIH
   [RO1AI043279]
FX This work was supported by RO1 AA010114 (National Institutes of Health
   Research Project Grant Program) to George I. Henderson. SM is supported
   by grants awarded by the Biomedical Laboratory Research and Development
   Service of the Veterans Affairs Office of Research and Development
   (1I01BX000975) and by RO1AI043279 (NIH). The funder had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
NR 78
TC 3
Z9 3
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 16
PY 2014
VL 9
IS 5
AR e98080
DI 10.1371/journal.pone.0098080
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AM1NZ
UT WOS:000339614800102
PM 24837604
ER

PT J
AU Chen, W
   McRoberts, JA
   Marvizon, JCG
AF Chen, W.
   McRoberts, J. A.
   Marvizon, J. C. G.
TI mu-OPIOID RECEPTOR INHIBITION OF SUBSTANCE P RELEASE FROM PRIMARY
   AFFERENTS DISAPPEARS IN NEUROPATHIC PAIN BUT NOT INFLAMMATORY PAIN
SO NEUROSCIENCE
LA English
DT Article
DE inflammation; internalization; opioid receptor; neurokinin 1 receptor;
   neuropathic pain; substance P
ID RAT SPINAL-CORD; ROOT GANGLION NEURONS; DORSAL-HORN NEURONS; SRC FAMILY
   KINASES; METHYL-D-ASPARTATE; G-PROTEIN; NEUROKININ-1 RECEPTOR; GABA(B)
   RECEPTORS; NMDA RECEPTORS; ANTINOCICEPTIVE EFFICACY
AB Opiate analgesia in the spinal cord is impaired during neuropathic pain. We hypothesized that this is caused by a decrease in mu-opioid receptor inhibition of neurotransmitter release from primary afferents. To investigate this possibility, we measured substance P release in the spinal dorsal horn as neurokinin 1 receptor (NK1R) internalization in rats with chronic constriction injury (CCI) of the sciatic nerve. Noxious stimulation of the paw with CCI produced inconsistent NK1R internalization, suggesting that transmission of nociceptive signals by the injured nerve was variably impaired after CCI. This idea was supported by the fact that CCI produced only small changes in the ability of exogenous substance P to induce NK1R internalization or in the release of substance P evoked centrally from site of nerve injury. In subsequent experiments, NK1R internalization was induced in spinal cord slices by stimulating the dorsal root ipsilateral to CCI. We observed a complete loss of the inhibition of substance P release by the mu-opioid receptor agonist [D-Ala(2), NMe-Phe(4), Gly-ol(5)]-enkephalin (DAMGO) in CCI rats but not in sham-operated rats. In contrast, DAMGO still inhibited substance P release after inflammation of the hind paw with complete Freund's adjuvant and in native rats. This loss of inhibition was not due to l-opioid receptor downregulation in primary afferents, because their colocalization with substance P was unchanged, both in dorsal root ganglion neurons and primary afferent fibers in the dorsal horn. In conclusion, nerve injury eliminates the inhibition of substance P release by l-opioid receptors, probably by hindering their signaling mechanisms. Published by Elsevier Ltd. on behalf of IBRO.
C1 [Chen, W.; McRoberts, J. A.; Marvizon, J. C. G.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
   [Chen, W.; McRoberts, J. A.; Marvizon, J. C. G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Digest Dis, Los Angeles, CA 90095 USA.
RP Marvizon, JCG (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Bldg 115,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM marvizon@ucla.edu
FU Rehabilitation Research & Development Service, Department of Veterans
   Affairs, USA [1I01RX000378]; National Institute of Drug Abuse, USA
   [R01-DA033059]
FX Supported by grants 1I01RX000378 from the Rehabilitation Research &
   Development Service, Department of Veterans Affairs, USA, to J.C.M. and
   R01-DA033059 from the National Institute of Drug Abuse, USA, to J.C.M
   and J.A.M. This study was done under the umbrella of the following UCLA
   institutes: Brain Research Institute, CURE: Digestive Diseases Research
   Center and the Oppenheimer Family Center for Neurobiology of Stress. We
   thank Wendy Walwyn for her valuable advice. The authors declare no
   competing financial interests.
NR 79
TC 7
Z9 10
U1 0
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4522
EI 1873-7544
J9 NEUROSCIENCE
JI Neuroscience
PD MAY 16
PY 2014
VL 267
BP 67
EP 82
DI 10.1016/j.neuroscience.2014.02.023
PG 16
WC Neurosciences
SC Neurosciences & Neurology
GA AF0KM
UT WOS:000334402700007
PM 24583035
ER

PT J
AU Afdhal, N
   Zeuzem, S
   Kwo, P
   Chojkier, M
   Gitlin, N
   Puoti, M
   Romero-Gomez, M
   Zarski, JP
   Agarwal, K
   Buggisch, P
   Foster, GR
   Brau, N
   Buti, M
   Jacobson, IM
   Subramanian, GM
   Ding, X
   Mo, HM
   Yang, JC
   Pang, PS
   Symonds, WT
   McHutchison, JG
   Muir, AJ
   Mangia, A
   Marcellin, P
AF Afdhal, Nezam
   Zeuzem, Stefan
   Kwo, Paul
   Chojkier, Mario
   Gitlin, Norman
   Puoti, Massimo
   Romero-Gomez, Manuel
   Zarski, Jean-Pierre
   Agarwal, Kosh
   Buggisch, Peter
   Foster, Graham R.
   Braeu, Norbert
   Buti, Maria
   Jacobson, Ira M.
   Subramanian, G. Mani
   Ding, Xiao
   Mo, Hongmei
   Yang, Jenny C.
   Pang, Phillip S.
   Symonds, William T.
   McHutchison, John G.
   Muir, Andrew J.
   Mangia, Alessandra
   Marcellin, Patrick
CA ION-1 Investigators
TI Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID CHRONIC HEPATITIS-C; VIRUS-INFECTION; THERAPY; COMBINATION; BOCEPREVIR;
   TELAPREVIR; RIBAVIRIN; CIRRHOSIS; TRIAL
AB BACKGROUND
   In phase 2 studies, treatment with the all-oral combination of the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor ledipasvir resulted in high rates of sustained virologic response among previously untreated patients with hepatitis C virus (HCV) genotype 1 infection.
   METHODS
   We conducted a phase 3, open-label study involving previously untreated patients with chronic HCV genotype 1 infection. Patients were randomly assigned in a 1:1:1:1 ratio to receive ledipasvir and sofosbuvir in a fixed-dose combination tablet once daily for 12 weeks, ledipasvir-sofosbuvir plus ribavirin for 12 weeks, ledipasvir-sofosbuvir for 24 weeks, or ledipasvir-sofosbuvir plus ribavirin for 24 weeks. The primary end point was a sustained virologic response at 12 weeks after the end of therapy.
   RESULTS
   Of the 865 patients who underwent randomization and were treated, 16% had cirrhosis, 12% were black, and 67% had HCV genotype 1a infection. The rates of sustained virologic response were 99% (95% confidence interval [CI], 96 to 100) in the group that received 12 weeks of ledipasvir-sofosbuvir; 97% (95% CI, 94 to 99) in the group that received 12 weeks of ledipasvir-sofosbuvir plus ribavirin; 98% (95% CI, 95 to 99) in the group that received 24 weeks of ledipasvir-sofosbuvir; and 99% (95% CI, 97 to 100) in the group that received 24 weeks of ledipasvir-sofosbuvir plus ribavirin. No patient in either 12-week group discontinued ledipasvir-sofosbuvir owing to an adverse event. The most common adverse events were fatigue, headache, insomnia, and nausea.
   CONCLUSIONS
   Once-daily ledipasvir-sofosbuvir with or without ribavirin for 12 or 24 weeks was highly effective in previously untreated patients with HCV genotype 1 infection.
C1 [Afdhal, Nezam] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
   [Zeuzem, Stefan] Goethe Univ Frankfurt, Med Ctr, D-60054 Frankfurt, Germany.
   [Buggisch, Peter] Asklepios Klin St Georg, Inst Interdisziplinare Med Studien, Hamburg, Germany.
   [Kwo, Paul] Indiana Univ Sch Med, Indianapolis, IN 46202 USA.
   [Chojkier, Mario] Univ Calif San Diego, Med Ctr, San Diego, CA 92103 USA.
   [Subramanian, G. Mani; Ding, Xiao; Mo, Hongmei; Yang, Jenny C.; Pang, Phillip S.; Symonds, William T.; McHutchison, John G.] Gilead Sci, Foster City, CA USA.
   [Gitlin, Norman] Atlanta Gastroenterol Associates, Atlanta, GA USA.
   [Puoti, Massimo] Azienda Osped Osped Niguarda Ca Granda, Milan, Italy.
   [Mangia, Alessandra] Casa Sollievo Sofferenza Hosp, San Giovanni Rotondo, Italy.
   [Romero-Gomez, Manuel] Hosp Univ Nuestra Senora de Valme, Seville, Spain.
   [Buti, Maria] Hosp Univ Vall dHebron, Barcelona, Spain.
   [Buti, Maria] Ciberhed, Inst Carlos 3, Barcelona, Spain.
   [Zarski, Jean-Pierre] CHU Grenoble, F-38043 Grenoble, France.
   [Marcellin, Patrick] Hop Beaujon, F-92110 Clichy, France.
   [Agarwal, Kosh] Kings Coll Hosp London, Inst Liver Studies, London SE5 8RX, England.
   [Foster, Graham R.] Queen Mary Univ London, London, England.
   [Braeu, Norbert] James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
   [Jacobson, Ira M.] Weill Cornell Med Coll, New York, NY USA.
   [Muir, Andrew J.] Duke Univ, Med Ctr, Durham, NC USA.
RP Afdhal, N (reprint author), Beth Israel Deaconess Med Ctr, 110 Francis St,Suite 4, Boston, MA 02215 USA.
EM nafdhal@bidmc.harvard.edu; patrick.marcellin@bjn.ap-hop-paris.fr
RI Romero Gomez, Manuel/L-8030-2014; IBIS, DIGESTIVAS/O-1913-2015
OI Davis, Mitchell/0000-0002-0526-5564; ANDREONE,
   PIETRO/0000-0002-4794-9809
FU Gilead Sciences
FX Supported by Gilead Sciences.
NR 21
TC 630
Z9 644
U1 7
U2 46
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAY 15
PY 2014
VL 370
IS 20
BP 1889
EP 1898
DI 10.1056/NEJMoa1402454
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA AH4UH
UT WOS:000336123600005
PM 24725239
ER

PT J
AU Lim, JK
   Tate, JP
   Fultz, SL
   Goulet, JL
   Conigliaro, J
   Bryant, KJ
   Gordon, AJ
   Gibert, C
   Rimland, D
   Goetz, MB
   Klein, MB
   Fiellin, DA
   Justice, AC
   Lo Re, V
AF Lim, Joseph K.
   Tate, Janet P.
   Fultz, Shawn L.
   Goulet, Joseph L.
   Conigliaro, Joseph
   Bryant, Kendall J.
   Gordon, Adam J.
   Gibert, Cynthia
   Rimland, David
   Goetz, Matthew Bidwell
   Klein, Marina B.
   Fiellin, David A.
   Justice, Amy C.
   Lo Re, Vincent, III
TI Relationship Between Alcohol Use Categories and Noninvasive Markers of
   Advanced Hepatic Fibrosis in HIV-Infected, Chronic Hepatitis C
   Virus-Infected, and Uninfected Patients
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE alcohol; liver fibrosis; HIV; hepatitis C; FIB-4
ID VETERANS AGING COHORT; PLATELET RATIO INDEX; PREDICTING LIVER FIBROSIS;
   SUBSTANCE USE DISORDERS; ASPARTATE-AMINOTRANSFERASE;
   PSYCHIATRIC-DIAGNOSIS; SAMPLING VARIABILITY; CIRRHOSIS; VALIDATION;
   TESTS
AB Background. It is unclear if the risk of liver disease associated with different levels of alcohol consumption is higher for patients infected with human immunodeficiency virus (HIV) or chronic hepatitis C virus (HCV). We evaluated associations between alcohol use categories and advanced hepatic fibrosis, by HIV and chronic HCV status.
   Methods. We performed a cross-sectional study among participants in the Veterans Aging Cohort Study who reported alcohol consumption at enrollment (701 HIV/HCV-coinfected; 1410 HIV-monoinfected; 296 HCV-monoinfected; 1158 HIV/HCV-uninfected). Alcohol use category was determined by the Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) questionnaire and alcohol-related diagnoses and was classified as nonhazardous drinking, hazardous/binge drinking, or alcohol-related diagnosis. Advanced hepatic fibrosis was defined by FIB-4 index >3.25.
   Results. Within each HIV/HCV group, the prevalence of advanced hepatic fibrosis increased as alcohol use category increased. For each alcohol use category, advanced hepatic fibrosis was more common among HIV-infected than uninfected (nonhazardous: 6.7% vs 1.4%; hazardous/binge: 9.5% vs 3.0%; alcohol-related diagnosis: 19.0% vs 8.6%; P < .01) and chronic HCV-infected than uninfected (nonhazardous: 13.6% vs 2.5%; hazardous/binge: 18.2% vs 3.1%; alcohol-related diagnosis: 22.1% vs 6.5%; P < .01) participants. Strong associations with advanced hepatic fibrosis (adjusted odds ratio [95% confidence interval]) were observed among HIV/HCV-coinfected patients with nonhazardous drinking (14.2 [5.91-34.0]), hazardous/binge drinking (18.9 [7.98-44.8]), and alcohol-related diagnoses (25.2 [10.6-59.7]) compared with uninfected nonhazardous drinkers.
   Conclusions. Advanced hepatic fibrosis was present at low levels of alcohol consumption, increased with higher alcohol use categories, and was more prevalent among HIV-infected and chronic HCV-infected patients than uninfected individuals. All alcohol use categories were strongly associated with advanced hepatic fibrosis in HIV/HCV-coinfected patients.
C1 [Lim, Joseph K.; Tate, Janet P.; Goulet, Joseph L.; Justice, Amy C.] Vet Affairs VA Connecticut Healthcare Syst, West Haven, CT USA.
   [Lim, Joseph K.; Tate, Janet P.; Goulet, Joseph L.; Fiellin, David A.; Justice, Amy C.] Yale Univ, Sch Med, New Haven, CT USA.
   [Fultz, Shawn L.] US FDA, Ctr Tobacco Prod, Washington, DC 20204 USA.
   Hofstra North Shore LIJ Sch Med, Lake Success, NY USA.
   [Conigliaro, Joseph] North Shore LIJ Hlth Syst, Lake Success, NY USA.
   [Bryant, Kendall J.] NIAAA, Bethesda, MD USA.
   [Gordon, Adam J.] Univ Pittsburgh, Pittsburgh, PA 15260 USA.
   [Gordon, Adam J.] Pittsburgh VA Med Ctr, Pittsburgh, PA USA.
   [Gibert, Cynthia] VA Med Ctr, Washington, DC USA.
   [Gibert, Cynthia] George Washington Univ, Med Ctr, Washington, DC 20037 USA.
   [Rimland, David] Atlanta VA Med Ctr, Atlanta, GA USA.
   [Rimland, David] Emory Univ, Sch Med, Atlanta, GA 30322 USA.
   [Goetz, Matthew Bidwell] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
   [Goetz, Matthew Bidwell] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
   [Klein, Marina B.] McGill Univ, Ctr Hlth, Chron Viral Illness Serv, Montreal, PQ, Canada.
   [Fiellin, David A.; Justice, Amy C.] Yale Univ, Sch Publ Hlth, Yale Ctr Interdisciplinary Res AIDS, New Haven, CT USA.
   [Lo Re, Vincent, III] Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA.
   [Lo Re, Vincent, III] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
RP Lo Re, V (reprint author), Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, 836 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM vincentl@mail.med.upenn.edu
RI Lo Re, Vincent/N-7817-2015
OI Goetz, Matthew/0000-0003-4542-992X; Fiellin, David/0000-0002-4006-010X;
   Goulet, Joseph/0000-0002-0842-804X
FU National Institute on Alcohol Abuse and Alcoholism [U01 AA13566, R21
   AA015894]; National Institute of Allergy and Infectious Diseases [K01
   AI070001]
FX This study was supported by the National Institute on Alcohol Abuse and
   Alcoholism (grant numbers U01 AA13566 to A. C. J. and R21 AA015894 to J.
   K. L and A. C. J.) and the National Institute of Allergy and Infectious
   Diseases (grant number K01 AI070001 to V. L. R.).
NR 60
TC 16
Z9 16
U1 1
U2 5
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD MAY 15
PY 2014
VL 58
IS 10
BP 1449
EP 1458
DI 10.1093/cid/ciu097
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AH3RZ
UT WOS:000336044200020
PM 24569533
ER

PT J
AU Harriff, MJ
   Cansler, ME
   Toren, KG
   Canfield, ET
   Kwak, S
   Gold, MC
   Lewinsohn, DM
AF Harriff, Melanie J.
   Cansler, Meghan E.
   Toren, Katelynne Gardner
   Canfield, Elizabeth T.
   Kwak, Stephen
   Gold, Marielle C.
   Lewinsohn, David M.
TI Human Lung Epithelial Cells Contain Mycobacterium tuberculosis in a Late
   Endosomal Vacuole and Are Efficiently Recognized by CD8(+) T Cells
SO PLOS ONE
LA English
DT Article
ID PHAGOSOME MATURATION; INTERFERON-GAMMA; ANTIGEN; INFECTION; PATHWAY;
   LYMPHOCYTES; ACTIVATION; FUSION; ARREST; IRON
AB Mycobacterium tuberculosis (Mtb) is transmitted via inhalation of aerosolized particles. While alveolar macrophages are thought to play a central role in the acquisition and control of this infection, Mtb also has ample opportunity to interact with the airway epithelium. In this regard, we have recently shown that the upper airways are enriched with a population of non-classical, MR1-restricted, Mtb-reactive CD8(+) T cells (MAIT cells). Additionally, we have demonstrated that Mtb-infected epithelial cells lining the upper airways are capable of stimulating IFN gamma production by MAIT cells. In this study, we demonstrate that airway epithelial cells efficiently stimulate IFN gamma release by MAIT cells as well as HLA-B45 and HLA-E restricted T cell clones. Characterization of the intracellular localization of Mtb in epithelial cells indicates that the vacuole occupied by Mtb in epithelial cells is distinct from DC in that it acquires Rab7 molecules and does not retain markers of early endosomes such as Rab5. The Mtb vacuole is also heterogeneous as there is a varying degree of association with Lamp1 and HLA-I. Although the Mtb vacuole shares markers associated with the late endosome, it does not acidify, and the bacteria are able to replicate within the cell. This work demonstrates that Mtb infected lung epithelial cells are surprisingly efficient at stimulating IFN gamma release by CD8(+) T cells.
C1 [Harriff, Melanie J.; Gold, Marielle C.; Lewinsohn, David M.] Portland VA Med Ctr, Portland, OR 97239 USA.
   [Harriff, Melanie J.; Canfield, Elizabeth T.; Kwak, Stephen; Gold, Marielle C.; Lewinsohn, David M.] Oregon Hlth & Sci Univ, Dept Pulm & Crit Care Med, Portland, OR 97201 USA.
   [Cansler, Meghan E.; Toren, Katelynne Gardner] Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97201 USA.
   [Gold, Marielle C.; Lewinsohn, David M.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA.
RP Harriff, MJ (reprint author), Portland VA Med Ctr, Portland, OR 97239 USA.
EM harriffm@ohsu.edu; lewinsod@ohsu.edu
RI ; Lewinsohn, David/I-4936-2013
OI Gold, Marielle/0000-0003-2505-3291; Lewinsohn, David/0000-0001-9906-9494
FU Department of Veterans Affairs, Veterans Health Administration, Office
   of Research and Development; Portland VA Medical Center; National
   Institutes of Health (NIH) [AI048090]
FX Funding was provided by the Department of Veterans Affairs, Veterans
   Health Administration, Office of Research and Development, with
   resources and the use of facilities at the Portland VA Medical Center
   (Merit Review, DM Lewinsohn; Career Development Award, MJH), and the
   National Institutes of Health (NIH) grant, AI048090 (DM Lewinsohn). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
NR 36
TC 20
Z9 20
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 14
PY 2014
VL 9
IS 5
AR e97515
DI 10.1371/journal.pone.0097515
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AI4TJ
UT WOS:000336857400104
PM 24828674
ER

PT J
AU Komers, R
   Xu, B
   Fu, Y
   McClelland, A
   Kantharidis, P
   Mittal, A
   Cohen, HT
   Cohen, DM
AF Komers, Radko
   Xu, Bei
   Fu, Yi
   McClelland, Aaron
   Kantharidis, Phillip
   Mittal, Amit
   Cohen, Herbert T.
   Cohen, David M.
TI Transcriptome-Based Analysis of Kidney Gene Expression Changes
   Associated with Diabetes in OVE26 Mice, in the Presence and Absence of
   Losartan Treatment
SO PLOS ONE
LA English
DT Article
ID ENDOPLASMIC-RETICULUM-STRESS; THIOREDOXIN-INTERACTING PROTEIN; TISSUE
   GROWTH-FACTOR; ANGIOTENSIN-RECEPTOR BLOCKADE; LOW-DENSITY-LIPOPROTEIN;
   HIPPEL-LINDAU-DISEASE; ER STRESS; ENDOTHELIAL DYSFUNCTION; METABOLIC
   SYNDROME; OXIDATIVE-STRESS
AB Diabetes is among the most common causes of end-stage renal disease, although its pathophysiology is incompletely understood. We performed next-generation sequencing-based transcriptome analysis of renal gene expression changes in the OVE26 murine model of diabetes (age 15 weeks), relative to non-diabetic control, in the presence and absence of short-term (seven-day) treatment with the angiotensin receptor blocker, losartan (n = 3-6 biological replicates per condition). We detected 1438 statistically significant changes in gene expression across conditions. Of the 638 genes dysregulated in diabetes relative to the non-diabetic state, >70% were down-regulation events. Unbiased functional annotation of genes up-and down-regulated by diabetes strongly associated (p<1x10(-8)) with terms for oxidative stress and for endoplasmic reticulum stress/protein folding. Most of the individual gene products up-or down-regulated with diabetes were unaffected by losartan treatment; however, of the gene products dysregulated in diabetes and influenced by losartan treatment, the vast majority of changes were in the direction of amelioration rather than exacerbation of the diabetic dysregulation. This group of losartan-protected genes associated strongly with annotation terms for endoplasmic reticulum stress, heat shock proteins, and chaperone function, but not oxidative stress; therefore, the losartan-unaffected genes suggest avenues for additional therapeutic opportunity in diabetes. Interestingly, the gene product most highly upregulated by diabetes (>52-fold), encoded by the cationic amino acid transporter Slc7a12, and the gene product most highly downregulated by diabetes (>99%) - encoded by the "pseudogene" Gm6300 - are adjacent in the murine genome, are members of the SLC7 gene family, and are likely paralogous. Therefore, diabetes activates a near-total genetic switch between these two paralogs. Other individual-level changes in gene expression are potentially relevant to diabetic pathophysiology, and novel pathways are suggested. Genes unaffected by diabetes alone but exhibiting increased renal expression with losartan produced a signature consistent with malignant potential.
C1 [Komers, Radko; Xu, Bei; Fu, Yi; Cohen, David M.] Oregon Hlth & Sci Univ, Dept Med, Div Nephrol & Hypertens, Portland, OR 97201 USA.
   [Komers, Radko; Xu, Bei; Fu, Yi; Cohen, David M.] Portland VA Med Ctr, Portland, OR USA.
   [Mittal, Amit; Cohen, Herbert T.] Boston Univ, Sch Med, Nephrol Sect, Boston, MA 02118 USA.
   [McClelland, Aaron; Kantharidis, Phillip] Baker IDI Heart & Diabet Inst, Diabet Div, JDRF Danielle Alberti Mem Ctr Diabet Complicat, Melbourne, Vic, Australia.
RP Cohen, DM (reprint author), Oregon Hlth & Sci Univ, Dept Med, Div Nephrol & Hypertens, Portland, OR 97201 USA.
EM cohend@ohsu.edu
FU National Institutes of Health; Department of Veterans Affairs; American
   Diabetes Association
FX This work was supported by grants from the National Institutes of
   Health, the Department of Veterans Affairs, and the American Diabetes
   Association (to DMC). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
NR 99
TC 0
Z9 0
U1 2
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 14
PY 2014
VL 9
IS 5
AR e96987
DI 10.1371/journal.pone.0096987
PG 21
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AI4TJ
UT WOS:000336857400050
PM 24827579
ER

PT J
AU Graham, DY
AF Graham, David Y.
TI History of Helicobacter pylori, duodenal ulcer, gastric ulcer and
   gastric cancer
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE Helicobacter pylori; Duodenal ulcer; Gastric ulcer; Gastric cancer;
   Medical history; Ulcer surgery; Epidemiology; Gastritis; Atrophic
   gastritis; Antiquity
ID PEPTIC-ULCER; CAMPYLOBACTER-PYLORI; HUMAN MIGRATIONS; STOMACH-CANCER;
   INFECTION; POPULATIONS; DISEASE; RISK; PATHOGENESIS; ERADICATION
AB Helicobacter pylori (H. pylori) infection underlies gastric ulcer disease, gastric cancer and duodenal ulcer disease. The disease expression reflects the pattern and extent of gastritis/gastric atrophy (i.e., duodenal ulcer with non-atrophic and gastric ulcer and gastric cancer with atrophic gastritis). Gastric and duodenal ulcers and gastric cancer have been known for thousands of years. Ulcers are generally non-fatal and until the 20th century were difficult to diagnose. However, the presence and pattern of gastritis in past civilizations can be deduced based on the diseases present. It has been suggested that gastric ulcer and duodenal ulcer both arose or became more frequent in Europe in the 19th century. Here, we show that gastric cancer and gastric ulcer were present throughout the 17th to 19th centuries consistent with atrophic gastritis being the predominant pattern, as it proved to be when it could be examined directly in the late 19th century. The environment before the 20th century favored acquisition of H. pylori infection and atrophic gastritis (e.g., poor sanitation and standards of living, seasonal diets poor in fresh fruits and vegetables, especially in winter, vitamin deficiencies, and frequent febrile infections in childhood). The latter part of the 19th century saw improvements in standards of living, sanitation, and diets with a corresponding decrease in rate of development of atrophic gastritis allowing duodenal ulcers to become more prominent. In the early 20th century physician's believed they could diagnose ulcers clinically and that the diagnosis required hospitalization for "surgical disease" or for "Sippy" diets. We show that while H. pylori remained common and virulent in Europe and the United States, environmental changes resulted in changes of the pattern of gastritis producing a change in the manifestations of H. pylori infections and subsequently to a rapid decline in transmission and a rapid decline in all H. pylori-related diseases. (C) 2014 Baishideng Publishing Group Co., Limited. All rights reserved.
C1 Baylor Coll Med, VA Med Ctr, Houston, TX 77030 USA.
RP Graham, DY (reprint author), Baylor Coll Med, VA Med Ctr, 2002 Holcombe Blvd,Rm 3A-318B 111D, Houston, TX 77030 USA.
EM dgraham@bcm.edu
FU Office of Research and Development Medical Research Service Department
   of Veterans Affairs, Public Health Service [DK062813, DK56338]; Texas
   Medical Center Digestive Diseases Center
FX Supported by In part by the Office of Research and Development Medical
   Research Service Department of Veterans Affairs, Public Health Service
   grants No. DK062813 and No. DK56338 which funds the Texas Medical Center
   Digestive Diseases Center
NR 90
TC 22
Z9 26
U1 3
U2 29
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA
SN 1007-9327
EI 2219-2840
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD MAY 14
PY 2014
VL 20
IS 18
BP 5191
EP 5204
DI 10.3748/wjg.v20.i18.5191
PG 14
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AH3TJ
UT WOS:000336048100003
PM 24833849
ER

PT J
AU Bradley, KA
   Kivlahan, DR
AF Bradley, Katharine A.
   Kivlahan, Daniel R.
TI Bringing Patient-Centered Care to Patients With Alcohol Use Disorders
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
ID SHARED DECISION-MAKING; HEALTH
C1 [Bradley, Katharine A.] Grp Hlth Res Inst, Seattle, WA 98101 USA.
   [Bradley, Katharine A.] Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA USA.
   [Bradley, Katharine A.] Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA.
   [Kivlahan, Daniel R.] Vet Hlth Adm, Washington, DC USA.
   [Bradley, Katharine A.] Univ Washington, Dept Med, Seattle, WA USA.
   [Bradley, Katharine A.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
   [Kivlahan, Daniel R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
RP Bradley, KA (reprint author), Grp Hlth Res Inst, Metropolitan Pk E,1730 Minor Ave,Ste 1600, Seattle, WA 98101 USA.
EM bradley.k@ghc.org
FU NIAAA NIH HHS [R01 AA018702, R01AA018702]
NR 16
TC 22
Z9 22
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD MAY 14
PY 2014
VL 311
IS 18
BP 1861
EP 1862
DI 10.1001/jama.2014.3629
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA AH0GT
UT WOS:000335798100017
PM 24825640
ER

PT J
AU Suri, P
   Boyko, EJ
   Goldberg, J
   Forsberg, CW
   Jarvik, JG
AF Suri, Pradeep
   Boyko, Edward J.
   Goldberg, Jack
   Forsberg, Christopher W.
   Jarvik, Jeffrey G.
TI Longitudinal associations between incident lumbar spine MRI findings and
   chronic low back pain or radicular symptoms: retrospective analysis of
   data from the longitudinal assessment of imaging and disability of the
   back (LAIDBACK)
SO BMC MUSCULOSKELETAL DISORDERS
LA English
DT Article
DE Sciatica; Annular; Tear; Fissure; Herniation; Bulge; Impingement;
   Endplate; Modic; Stenosis; Extrusion; Spondylolisthesis; Facet;
   Arthritis; Zygapophyseal; Disc
ID 7-YEAR FOLLOW-UP; RISK-FACTORS; ASYMPTOMATIC SUBJECTS; NATURAL-HISTORY;
   OSTEOARTHRITIS; PREVALENCE; COMORBIDITY; POPULATION; KNEE
AB Background: There are few longitudinal cohort studies examining associations between incident MRI findings and incident spine-related symptom outcomes. Prior studies do not discriminate between the two distinct outcomes of low back pain (LBP) and radicular symptoms. To address this gap in the literature, we conducted a secondary analysis of existing data from the Longitudinal Assessment of Imaging and Disability of the Back (LAIDBACK). The purpose of this study was to examine the association of incident lumbar MRI findings with two specific spine-related symptom outcomes: 1) incident chronic bothersome LBP, and 2) incident radicular symptoms such as pain, weakness, or sensation alterations in the lower extremity.
   Methods: The original LAIDBACK study followed 123 participants without current LBP or sciatica, administering standardized MRI assessments of the lumbar spine at baseline and at 3-year follow-up, and collecting information on participant-reported spine-related symptoms and signs every 4 months for 3 years. These analyses examined bivariable and multivariable associations between incident MRI findings and symptom outcomes (LBP and radicular symptoms) using logistic regression.
   Results: Three-year cumulative incidence of new MRI findings ranged between 2 and 8%, depending on the finding. Incident annular fissures were associated with incident chronic LBP, after adjustment for prior back pain and depression (adjusted odds ratio [OR] 6.6; 95% confidence interval [CI] 1.2-36.9). All participants with incident disc extrusions (OR 5.4) and nerve root impingement (OR 4.1) reported incident radicular symptoms, although associations were not statistically significant. No other incident MRI findings showed large magnitude associations with symptoms.
   Conclusions: Even when applying more specific definitions for spine-related symptom outcomes, few MRI findings showed large magnitude associations with symptom outcomes. Although incident annular fissures, disc extrusions, and nerve root impingement were associated with incident symptom outcomes, the 3-year incidence of these MRI findings was extremely low, and did not explain the vast majority of incident symptom cases.
C1 [Suri, Pradeep; Boyko, Edward J.; Goldberg, Jack; Forsberg, Christopher W.] VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA 98108 USA.
   [Suri, Pradeep] VA Puget Sound Hlth Care Syst, Div Rehabil Care Serv, Seattle, WA USA.
   [Suri, Pradeep] Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA.
   [Boyko, Edward J.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA.
   [Goldberg, Jack] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA.
   [Jarvik, Jeffrey G.] Univ Washington, Sch Med, Dept Radiol, Seattle, WA 98195 USA.
   [Jarvik, Jeffrey G.] Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98195 USA.
   [Jarvik, Jeffrey G.] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA.
RP Suri, P (reprint author), VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA 98108 USA.
EM pradeep.suriyaarachchi@va.gov
OI Boyko, Edward/0000-0002-3695-192X
FU Seattle VA Epidemiologic Research and Information Center (ERIC); VA
   Puget Sound; AHRQ [R01 HS019222-01]; NIH [1UH2AT007766-01]
FX The LAIDBACK study was funded by the Seattle VA Epidemiologic Research
   and Information Center (ERIC). VA Puget Sound provided support for Dr.
   Suri's participation in this research. VA Puget Sound provided support
   for Dr. Goldberg's participation in this research. VA Puget Sound
   provided support for Mr. Forsberg's participation in this research. Dr.
   Jarvik was funded in part by AHRQ (R01 HS019222-01) and NIH
   (1UH2AT007766-01). VA Puget Sound provided support for Dr. Boyko's
   participation in this research.
NR 34
TC 3
Z9 3
U1 4
U2 14
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2474
J9 BMC MUSCULOSKEL DIS
JI BMC Musculoskelet. Disord.
PD MAY 13
PY 2014
VL 15
AR 152
DI 10.1186/1471-2474-15-152
PG 10
WC Orthopedics; Rheumatology
SC Orthopedics; Rheumatology
GA AH2XV
UT WOS:000335986300001
PM 24886265
ER

PT J
AU Luoto, J
   Shekelle, PG
   Maglione, MA
   Johnsen, B
   Perry, T
AF Luoto, Jill
   Shekelle, Paul G.
   Maglione, Margaret A.
   Johnsen, Breanne
   Perry, Tanja
TI Reporting of context and implementation in studies of global health
   interventions: a pilot study
SO IMPLEMENTATION SCIENCE
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; TO-CHILD TRANSMISSION; SAFE STORAGE;
   SOUTH-AFRICA; SERVICES; CARE; HIV; CHLORINATION; PREVENTION; MORTALITY
AB Background: There is an increasing push for 'evidence-based' decision making in global health policy circles. However, at present there are no agreed upon standards or guidelines for how to evaluate evidence in global health. Recent evaluations of existing evidence frameworks that could serve such a purpose have identified details of program context and project implementation as missing components needed to inform policy. We performed a pilot study to assess the current state of reporting of context and implementation in studies of global health interventions.
   Methods: We identified three existing criteria sets for implementation reporting and selected from them 10 criteria potentially relevant to the needs of policy makers in global health contexts. We applied these 10 criteria to 15 articles included in the evidence base for three global health interventions chosen to represent a diverse set of advocated global health programs or interventions: household water chlorination, prevention of mother-to-child transmission of HIV, and lay community health workers to reduce child mortality. We used a good-fair-poor/none scale for the ratings.
   Results: The proportion of criteria for which reporting was poor/none ranged from 11% to 54% with an average of 30%. Eight articles had 'good' or 'fair' documentation for greater than 75% of criteria, while five articles had 'poor or none' documentation for 50% of criteria or more. Examples of good reporting were identified.
   Conclusions: Reporting of context and implementation information in studies of global health interventions is mostly fair or poor, and highly variable. The idiosyncratic variability in reporting indicates that global health investigators need more guidance about what aspects of context and implementation to measure and how to report them. This lack of context and implementation information is a major gap in the evidence needed by global health policy makers to reach decisions.
C1 [Luoto, Jill; Shekelle, Paul G.; Maglione, Margaret A.; Johnsen, Breanne; Perry, Tanja] RAND Corp, Santa Monica, CA 90407 USA.
   [Shekelle, Paul G.] W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA.
RP Luoto, J (reprint author), RAND Corp, 1776 Main St, Santa Monica, CA 90407 USA.
EM jluoto@rand.org
FU PHS HHS [HHSA290200710062I]
NR 30
TC 7
Z9 7
U1 3
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1748-5908
J9 IMPLEMENT SCI
JI Implement. Sci.
PD MAY 12
PY 2014
VL 9
AR 57
DI 10.1186/1748-5908-9-57
PG 9
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA AI3NW
UT WOS:000336769400001
PM 24886201
ER

PT J
AU Prabhu, SD
AF Prabhu, Sumanth D.
TI It Takes Two to Tango Monocyte and Macrophage Duality in the Infarcted
   Heart
SO CIRCULATION RESEARCH
LA English
DT Editorial Material
DE Editorials; macrophages; monocytes; myocardial infarction; nuclear
   receptor subfamily 4; group A; member 1; ventricular remodeling
ID ACUTE MYOCARDIAL-INFARCTION; SURVIVAL; PHENOTYPE; INJURY; REPAIR; CELLS;
   MICE
C1 Univ Alabama Birmingham, Div Cardiovasc Dis, Dept Med, Birmingham, AL 35294 USA.
   Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA.
RP Prabhu, SD (reprint author), Univ Alabama Birmingham, Div Cardiovasc Dis, 311 Tinsley Harrison Tower,1900 Univ Blvd, Birmingham, AL 35294 USA.
EM sprabhu@uab.edu
FU NHLBI NIH HHS [HL-78825, P01 HL078825, R01 HL099014, HL-99014]
NR 22
TC 4
Z9 4
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7330
EI 1524-4571
J9 CIRC RES
JI Circ.Res.
PD MAY 9
PY 2014
VL 114
IS 10
BP 1558
EP 1560
DI 10.1161/CIRCRESAHA.114.303933
PG 3
WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular
   Disease
SC Cardiovascular System & Cardiology; Hematology
GA AH2HF
UT WOS:000335941400015
PM 24812348
ER

PT J
AU Novgorodov, SA
   Riley, CL
   Yu, J
   Borg, KT
   Hannun, YA
   Proia, RL
   Kindy, MS
   Gudz, TI
AF Novgorodov, Sergei A.
   Riley, Christopher L.
   Yu, Jin
   Borg, Keith T.
   Hannun, Yusuf A.
   Proia, Richard L.
   Kindy, Mark S.
   Gudz, Tatyana I.
TI Essential Roles of Neutral Ceramidase and Sphingosine in Mitochondrial
   Dysfunction Due to Traumatic Brain Injury
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE Brain; Cell Death; Mitochondria; Respiratory Chain; Sphingolipid
ID CYTOCHROME-C-OXIDASE; SUBCELLULAR-LOCALIZATION; CHRONIC ACTIVATION;
   RESPIRATORY-CHAIN; MOLECULAR-CLONING; RAT-BRAIN; IN-VITRO; KINASE;
   SPHINGOSINE-1-PHOSPHATE; SPHINGOLIPIDS
AB Background: A cardinal feature of many neurological disorders is mitochondrial dysfunction. Results: Knocking down neutral ceramidase reduces mitochondrial sphingosine, preserves mitochondrial function, and improves brain function recovery after trauma. Conclusion: Activation of the sphingosine-generating pathway plays a significant role in promoting mitochondrial injury. Significance: This is the first direct evidence of endogenous sphingosine involvement in regulation of mitochondrial function.
   In addition to immediate brain damage, traumatic brain injury (TBI) initiates a cascade of pathophysiological events producing secondary injury. The biochemical and cellular mechanisms that comprise secondary injury are not entirely understood. Herein, we report a substantial deregulation of cerebral sphingolipid metabolism in a mouse model of TBI. Sphingolipid profile analysis demonstrated increases in sphingomyelin species and sphingosine concurrently with up-regulation of intermediates of de novo sphingolipid biosynthesis in the brain. Investigation of intracellular sites of sphingosine accumulation revealed an elevation of sphingosine in mitochondria due to the activation of neutral ceramidase (NCDase) and the reduced activity of sphingosine kinase 2 (SphK2). The lack of change in gene expression suggested that post-translational mechanisms are responsible for the shift in the activities of both enzymes. Immunoprecipitation studies revealed that SphK2 is complexed with NCDase and cytochrome oxidase (COX) subunit 1 in mitochondria and that brain injury hindered SphK2 association with the complex. Functional studies showed that sphingosine accumulation resulted in a decreased activity of COX, a rate-limiting enzyme of the mitochondrial electron transport chain. Knocking down NCDase reduced sphingosine accumulation in mitochondria and preserved COX activity after the brain injury. Also, NCDase knockdown improved brain function recovery and lessened brain contusion volume after trauma. These studies highlight a novel mechanism of secondary TBI involving a disturbance of sphingolipid-metabolizing enzymes in mitochondria and suggest a critical role for mitochondrial sphingosine in promoting brain injury after trauma.
C1 [Riley, Christopher L.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA.
   [Yu, Jin; Kindy, Mark S.; Gudz, Tatyana I.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA.
   [Novgorodov, Sergei A.; Kindy, Mark S.; Gudz, Tatyana I.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
   [Borg, Keith T.] Med Univ S Carolina, Dept Emergency Med, Charleston, SC 29425 USA.
   [Hannun, Yusuf A.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.
   [Proia, Richard L.] NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA.
RP Gudz, TI (reprint author), 114 Doughty St, Charleston, SC 29425 USA.
EM gudz@musc.edu
FU National Institutes of Health [P30 GM103339]; Veterans Affairs Merit
   Awards [I01RX000206, I01BX001104, I01RX000331]; American Diabetes
   Association [7-12-IN-28]
FX This work was supported, in whole or in part, by National Institutes of
   Health Grant P30 GM103339 (to S. A. N.). This work was also supported by
   Veterans Affairs Merit Awards I01RX000206 (to T. I. G.), I01BX001104 (to
   T. I. G.), and I01RX000331 (to M. S. K.). The Lipidomics Core Facility
   at Medical University of South Carolina is supported in part by National
   Institutes of Health Grant P30 GM103339.; Supported in part by American
   Diabetes Association Innovation Grant 7-12-IN-28.
NR 64
TC 10
Z9 11
U1 0
U2 7
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 9
PY 2014
VL 289
IS 19
BP 13142
EP 13154
DI 10.1074/jbc.M113.530311
PG 13
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AG6IR
UT WOS:000335522800016
PM 24659784
ER

PT J
AU Asch, DA
   Terwiesch, C
   Mahoney, KB
   Rosin, R
AF Asch, David A.
   Terwiesch, Christian
   Mahoney, Kevin B.
   Rosin, Roy
TI Insourcing Health Care Innovation
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Editorial Material
AB Rather than seek solutions to health care's problems in facile recommendations from management gurus with experience in unrelated industries, we'd do better to find a solution process to use from within. And the process for high-impact innovation can in fact be learned. Many health care professionals find it irritating when management gurus recommend solving health care's problems with approaches they would copy and paste from unrelated industries a former chief executive of a manufacturing company claims that the same simple lessons that enabled him to transform his own industry can improve value in health care, or a business-school professor offers an eight-point leadership plan that she's translated into health care as easily as if she'd translated it into French. Many people who work in health care value outside perspectives and are open to new approaches and yet bristle at facile ...
C1 [Asch, David A.] Univ Penn, Ctr Hlth Equ Res & Promot, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
   [Asch, David A.; Terwiesch, Christian; Mahoney, Kevin B.; Rosin, Roy] Univ Penn, Ctr Hlth Care Innovat, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Terwiesch, Christian] Univ Penn, Mack Inst Innovat Management, Wharton Sch, Philadelphia, PA 19104 USA.
RP Asch, DA (reprint author), Univ Penn, Ctr Hlth Equ Res & Promot, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
NR 1
TC 3
Z9 3
U1 0
U2 6
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAY 8
PY 2014
VL 370
IS 19
BP 1775
EP 1777
DI 10.1056/NEJMp1401135
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA AH3CD
UT WOS:000335997900003
PM 24806157
ER

PT J
AU Yu, MK
   Weiss, NS
   Ding, XB
   Katon, WJ
   Zhou, XH
   Young, BA
AF Yu, Margaret K.
   Weiss, Noel S.
   Ding, Xiaobo
   Katon, Wayne J.
   Zhou, Xiao-Hua
   Young, Bessie A.
TI Associations between Depressive Symptoms and Incident ESRD in a Diabetic
   Cohort
SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID CHRONIC KIDNEY-DISEASE; PROPORTIONAL HAZARDS MODEL; MAJOR DEPRESSION;
   SELF-CARE; COMORBID DEPRESSION; MEDICATION ADHERENCE; RISK-FACTORS;
   FOLLOW-UP; ALL-CAUSE; MORTALITY
AB Background and objectivesComorbid major depression is associated with adverse health outcomes in patients with diabetes, but little is known regarding its associations with long-term renal outcomes in this population. Furthermore, the impact of minor depression on renal outcomes is not known. This study evaluated associations between depressive symptoms and risk of incident ESRD in a diabetic cohort.Design, setting, participants, & measurementsIn this prospective, observational cohort study, 3886 ambulatory adults with diabetes were recruited from primary care clinics of a large health maintenance organization in the state of Washington. Demographics, laboratory data, depressive symptoms (based on the Patient Health Questionnaire-9), and patterns of diabetes self-care were collected. Participants were considered depressed if they had the required number of depressive symptoms (5 for major or 2-4 for minor depressive symptoms), including depressed mood or anhedonia, >50% of the time for 2 weeks and a Patient Health Questionnaire-9 score10 for major and 5 for minor depressive symptoms. Risk of incident ESRD was estimated using Cox proportional hazards regression, with predialysis death as a competing risk.ResultsDuring a median follow-up of 8.8 years, 87 patients (2.2%) developed ESRD. Major depressive symptoms were associated with a higher risk of incident ESRD (hazard ratio, 1.85; 95% confidence interval, 1.02 to 3.33) after adjusting for age, sex, race/ethnicity, marital status, education, smoking, body mass index, diabetes duration, hemoglobin A1c, baseline kidney function, microalbuminuria, hypertension, renin-angiotensin system blockers, and adherence to diabetes self-care. Minor depressive symptoms were not significantly associated with incident ESRD (hazard ratio, 1.08; 95% confidence interval, 0.52 to 2.25).ConclusionMajor depressive symptoms, but not minor depressive symptoms, were associated with a higher risk of incident ESRD over 10 years. Additional studies are needed to determine whether treatment for depression can improve renal outcomes in patients with diabetes.
C1 [Yu, Margaret K.; Young, Bessie A.] Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA.
   [Zhou, Xiao-Hua; Young, Bessie A.] Vet Affairs Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA USA.
   [Yu, Margaret K.; Young, Bessie A.] Univ Washington, Sch Med, Dept Med, Div Nephrol, Seattle, WA 98195 USA.
   [Yu, Margaret K.; Young, Bessie A.] Univ Washington, Sch Med, Kidney Res Inst, Seattle, WA USA.
   [Katon, Wayne J.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
   [Yu, Margaret K.; Weiss, Noel S.; Young, Bessie A.] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA.
   [Ding, Xiaobo; Zhou, Xiao-Hua] Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98195 USA.
   [Young, Bessie A.] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA.
   [Ding, Xiaobo] Chinese Acad Sci, Acad Math & Syst Sci, Beijing, Peoples R China.
RP Young, BA (reprint author), Vet Affairs Puget Sound Hlth Care Syst 152E, Epidemiol Res & Informat Ctr, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM youngb@u.washington.edu
FU National Institute of Mental Health Services [MH41739, MH01643];
   American Kidney Fund; Veterans Affairs Puget Sound Health Care System
FX We thank Dr. Michael Von Korff, Dr. Elizabeth Lin, Dr. Evette Ludman,
   and Malia Oliver for their roles in study design, data acquisition, and
   obtainment of funding for the Pathways Study, which was supported by
   National Institute of Mental Health Services Grants MH41739 and
   MH01643.; M.K.Y. was supported, in part, by the American Kidney Fund. In
   addition, this material is the result of work supported by resources
   from the Veterans Affairs Puget Sound Health Care System(M.K.Y. and
   B.A.Y.).
NR 48
TC 10
Z9 10
U1 2
U2 7
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1555-9041
EI 1555-905X
J9 CLIN J AM SOC NEPHRO
JI Clin. J. Am. Soc. Nephrol.
PD MAY 7
PY 2014
VL 9
IS 5
BP 920
EP 928
DI 10.2215/CJN.08670813
PG 9
WC Urology & Nephrology
SC Urology & Nephrology
GA AG6HI
UT WOS:000335519300015
PM 24677559
ER

PT J
AU Aljebreen, AM
   Almadi, MA
   Leung, FW
AF Aljebreen, Abdulrahman M.
   Almadi, Majid A.
   Leung, Felix W.
TI Sedated vs unsedated colonoscopy: A prospective study
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE Sedation; Colonoscopy; Unsedated; Screening; Endoscopy
ID RANDOMIZED CONTROLLED-TRIAL; SCREENING COLONOSCOPY; SELECTIVE SEDATION;
   VETERANS; OPTIONS; ROUTINE
AB AIM: To compare sedated to unsedated colonoscopy in terms of duration, pain and the patient's willingness to repeat the procedure.
   METHODS: Consecutive patients who underwent colonoscopies over a 2-year period were invited to participate. All patients who were to undergo our endoscopy unit were offered sedation with standard intravenous sedatives and analgesics, or an unsedated colonoscopy was attempted. Demographic details were recorded. The patient anxiety level prior to the procedure, time to reach the cecum, total discharge time, patient and endoscopist pain assessments, satisfaction after the examination and the patient's willingness to return for the same procedure in the future were recorded.
   RESULTS: Among the 403 observed patients, more males were observed in the unsedated group (66.2% vs 55.2%, P = 0.04). Additionally, the unsedated group patients were less anxious prior to the procedure (5.1 vs 6.0, P < 0.01). The colonoscopy completion rates were comparable between the 2 groups (85.9% vs 84.2%, P = 0.66). The time to reach the cecum was also comparable (12.2 min vs 11.8 min); however, the total discharge times were shorter in the unsedated group (20.7 min vs 83.0 min, P < 0.01). Moreover, the average patient pain score (3.4 vs 5.7, P < 0.01) was lower in the sedated group, while the satisfaction score (8.8 vs 7.8, P < 0.01) was significantly higher. There was no significant difference, however, between the groups in terms of willingness to repeat the procedure if another was required in the future (83.3% vs 77.3%, P = 0.17).
   CONCLUSION: Unsedated colonoscopy is feasible in willing patients. The option saves the endoscopy units up to one hour per patient and does not affect the patient willingness to return to the same physician again for additional colonoscopies if a repeated procedure is needed. (C) 2014 Baishideng Publishing Group Co., Limited. All rights reserved.
C1 [Aljebreen, Abdulrahman M.; Almadi, Majid A.] King Saud Univ, King Khalid Univ Hosp, Div Gastroenterol, Riyadh 11461, Saudi Arabia.
   [Almadi, Majid A.] McGill Univ, Ctr Hlth, Div Gastroenterol, Montreal, PQ H3G 1A4, Canada.
   [Leung, Felix W.] Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, Res Serv, Los Angeles, CA 91343 USA.
   [Leung, Felix W.] Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, Med Serv, Los Angeles, CA 91343 USA.
   [Leung, Felix W.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 91343 USA.
RP Aljebreen, AM (reprint author), King Saud Univ, King Khalid Univ Hosp, Div Gastroenterol, POB 2925, Riyadh 11461, Saudi Arabia.
EM amaljebreen@gmail.com
FU College of Medicine Research Center, Deanship of Scientific Research,
   King Saud University
FX Supported by Partially by College of Medicine Research Center, Deanship
   of Scientific Research, King Saud University
NR 23
TC 4
Z9 4
U1 0
U2 2
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA
SN 1007-9327
EI 2219-2840
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD MAY 7
PY 2014
VL 20
IS 17
BP 5113
EP 5118
DI 10.3748/wjg.v20.i17.5113
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AH1YC
UT WOS:000335916700035
PM 24803827
ER

PT J
AU Mudumbai, SC
   Wagner, T
   Mahajan, S
   King, R
   Heidenreich, PA
   Hlatky, M
   Wallace, AW
   Mariano, ER
AF Mudumbai, Seshadri C.
   Wagner, Todd
   Mahajan, Satish
   King, Robert
   Heidenreich, Paul A.
   Hlatky, Mark
   Wallace, Arthur W.
   Mariano, Edward R.
TI Effectiveness of preoperative beta-blockade on intra-operative heart
   rate in vascular surgery cases conducted under regional or local
   anesthesia
SO SPRINGERPLUS
LA English
DT Article
DE Perioperative medicine; Vascular surgery; beta-blockers; Heart rate;
   General anesthesia; Regional anesthesia; Monitored anesthesia care;
   Effectiveness
ID GENERAL-ANESTHESIA; EPIDURAL-ANESTHESIA; ANALGESIA; BLOCKERS; EFFICACY;
   TRIALS; CARE
AB Background: Preoperative beta-blockade has been posited to result in better outcomes for vascular surgery patients by attenuating acute hemodynamic changes associated with stress. However, the incremental effectiveness, if any, of beta-blocker usage in blunting heart rate responsiveness for vascular surgery patients who avoid general anesthesia remains unknown.
   Methods: We reviewed an existing database and identified 213 consecutive vascular surgery cases from 2005-2011 conducted without general anesthesia (i.e., under monitored anesthesia care or regional anesthesia) at a tertiary care Veterans Administration medical center and categorized patients based on presence or absence of preoperative beta-blocker prescription. For this series of patients, with the primary outcome of maximum heart rate during the interval between operating room entry to surgical incision, we examined the association of maximal heart rate and preoperative beta-blocker usage by performing crude and multivariate linear regression, adjusting for relevant patient factors.
   Results: Of 213 eligible cases, 137 were prescribed preoperative beta-blockers, and 76 were not. The two groups were comparable across baseline patient factors and intraoperative medication doses. The beta-blocker group experienced lower maximal heart rates during the period of evaluation compared to the non-beta-blocker group (85 +/- 22 bpm vs. 98 +/- 36 bpm, respectively; p = 0.002). Adjusted linear regression confirmed a statistically-significant association between lower maximal heart rate and the use of beta-blockers (Beta = -11.5; 95% CI [-3.7, -19.3] p = 0.004).
   Conclusions: The addition of preoperative beta-blockers, even when general anesthesia is avoided, may be beneficial in further attenuating stress-induced hemodynamic changes for vascular surgery patients.
C1 [Mudumbai, Seshadri C.; King, Robert; Mariano, Edward R.] Vet Affairs Palo Alto Hlth Care Syst, Anesthesiol & Perioperat Care Serv, Palo Alto, CA 94304 USA.
   [Mudumbai, Seshadri C.; Mariano, Edward R.] Stanford Univ, Sch Med, Dept Anesthesiol Perioperat & Pain Med, Stanford, CA 94305 USA.
   [Wagner, Todd] Vet Affairs Palo Alto Hlth Care Syst, Ctr Innovat Implementat, Palo Alto, CA 94304 USA.
   [Mahajan, Satish] Vet Affairs Palo Alto Hlth Care Syst, Dept Nursing, Palo Alto, CA 94304 USA.
   [Heidenreich, Paul A.] Vet Affairs Palo Alto Hlth Care Syst, Serv Cardiol, Palo Alto, CA 94304 USA.
   [Heidenreich, Paul A.] Stanford Univ, Sch Med, Dept Cardiol, Stanford, CA 94305 USA.
   [Hlatky, Mark] Dept Hlth Res & Policy, Stanford, CA USA.
   [Hlatky, Mark] Dept Med Cardiovasc Med, Stanford, CA USA.
   [Wallace, Arthur W.] San Francisco VA Med Ctr, Anesthesia Serv, San Francisco, CA USA.
   [Wallace, Arthur W.] Univ Calif San Francisco, Dept Anesthesiol & Perioperat Care, San Francisco, CA 94143 USA.
RP Mudumbai, SC (reprint author), Vet Affairs Palo Alto Hlth Care Syst, Anesthesiol & Perioperat Care Serv, 3801 Miranda Ave, Palo Alto, CA 94304 USA.
EM mudumbai@stanford.edu
OI Heidenreich, Paul/0000-0001-7730-8490; Mariano,
   Edward/0000-0003-2735-248X
NR 22
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 2193-1801
J9 SPRINGERPLUS
JI SpringerPlus
PD MAY 5
PY 2014
VL 3
AR 227
DI 10.1186/2193-1801-3-227
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CO3EI
UT WOS:000359039000002
PM 24855591
ER

PT J
AU Chiyomaru, T
   Fukuhara, S
   Saini, S
   Majid, S
   Deng, GR
   Shahryari, V
   Chang, I
   Tanaka, Y
   Enokida, H
   Nakagawa, M
   Dahiya, R
   Yamamura, S
AF Chiyomaru, Takeshi
   Fukuhara, Shinichiro
   Saini, Sharanjot
   Majid, Shahana
   Deng, Guoren
   Shahryari, Varahram
   Chang, Inik
   Tanaka, Yuichiro
   Enokida, Hideki
   Nakagawa, Masayuki
   Dahiya, Rajvir
   Yamamura, Soichiro
TI Long Non-coding RNA HOTAIR Is Targeted and Regulated by miR-141 in Human
   Cancer Cells
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE Cancer Biology; Cell Growth; Gene Regulation; Invasion; MicroRNA;
   Genistein; HOTAIR; Long Non-coding RNA; miR-141; Renal Carcinoma
ID EPITHELIAL-MESENCHYMAL TRANSITION; MAMMALIAN MESSENGER-RNAS;
   TRANSCRIPTIONAL ACTIVITY; MICRORNA TARGETS; MIR-200 FAMILY; CODING
   REGIONS; PROSTATE-CANCER; GENE-EXPRESSION; REPRESSORS ZEB1;
   ALPHA-AMANITIN
AB Background: Silencing of long non-coding RNA (lncRNA) by microRNA (miRNA) has only been recently observed. Results: miR-141 binds to HOTAIR and suppresses its oncogenic function in Ago2 (Argounaute2). Conclusion: miR-141 targets and silences HOTAIR in an Ago2-dependent manner in cancer cells. Significance: Our results suggest that regulation of lncRNA expression by miRNA plays essential roles in gene expression and cellular functions. HOTAIR is a long non-coding RNA that interacts with the polycomb repressive complex and suppresses its target genes. HOTAIR has also been demonstrated to promote malignancy. MicroRNA-141 (miR-141) has been reported to play a role in the epithelial to mesenchymal transition process, and the expression of miR-141 is inversely correlated with tumorigenicity and invasiveness in several human cancers. We found that HOTAIR expression is inversely correlated to miR-141 expression in renal carcinoma cells. HOTAIR promotes malignancy, including proliferation and invasion, whereas miR-141 suppresses malignancy in human cancer cells. miR-141 binds to HOTAIR in a sequence-specific manner and suppresses HOTAIR expression and functions, including proliferation and invasion. Both HOTAIR and miR-141 were associated with the immunoprecipitated Ago2 (Argonaute2) complex, and the Ago2 complex cleaved HOTAIR in the presence of miR-141. These results demonstrate that HOTAIR is suppressed by miR-141 in an Ago2-dependent manner.
C1 [Chiyomaru, Takeshi; Fukuhara, Shinichiro; Saini, Sharanjot; Majid, Shahana; Deng, Guoren; Shahryari, Varahram; Tanaka, Yuichiro; Dahiya, Rajvir; Yamamura, Soichiro] San Francisco VA Med Ctr, Dept Urol, San Francisco, CA 94121 USA.
   [Chiyomaru, Takeshi; Fukuhara, Shinichiro; Saini, Sharanjot; Majid, Shahana; Deng, Guoren; Shahryari, Varahram; Tanaka, Yuichiro; Dahiya, Rajvir; Yamamura, Soichiro] Univ Calif San Francisco, San Francisco, CA 94121 USA.
   [Chang, Inik] Yonsei Univ, Coll Dent, Dept Oral Biol, Seoul 120752, South Korea.
   [Enokida, Hideki; Nakagawa, Masayuki] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Urol, Kagoshima 8908520, Japan.
RP Yamamura, S (reprint author), Vet Affairs Med Ctr, Urol Res Ctr 112F, 4150 Clement St, San Francisco, CA 94121 USA.
EM yamamuras@urology.ucsf.edu
FU National Institutes of Health [RO1CA130860]; Veterans Affairs Program
   Project; Veterans Affairs Merit Review grants
FX This work was supported, in whole or in part, by National Institutes of
   Health Grant RO1CA130860. This study was also supported by Veterans
   Affairs Program Project and Veterans Affairs Merit Review grants.
NR 61
TC 54
Z9 60
U1 3
U2 31
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 2
PY 2014
VL 289
IS 18
BP 12550
EP 12565
DI 10.1074/jbc.M113.488593
PG 16
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AG7ER
UT WOS:000335581400029
PM 24616104
ER

PT J
AU Kamnaksh, A
   Budde, MD
   Kovesdi, E
   Long, JB
   Frank, JA
   Agoston, DV
AF Kamnaksh, Alaa
   Budde, Matthew D.
   Kovesdi, Erzsebet
   Long, Joseph B.
   Frank, Joseph A.
   Agoston, Denes V.
TI Diffusion Tensor Imaging Reveals Acute Subcortical Changes after Mild
   Blast-Induced Traumatic Brain Injury
SO SCIENTIFIC REPORTS
LA English
DT Article
ID LONG-TERM CONSEQUENCES; AXONAL INJURY; MILITARY; CONCUSSION; BIOMARKERS;
   VETERANS; COMBAT; MODEL; RATS; MRI
AB Mild blast-induced traumatic brain injury (mbTBI) poses special diagnostic challenges due to its overlapping symptomatology with other neuropsychiatric conditions and the lack of objective outcome measures. Diffusion tensor imaging (DTI) can potentially provide clinically relevant information toward a differential diagnosis. In this study, we aimed to determine if single and repeated (5 total; administered on consecutive days) mild blast overpressure exposure results in detectable structural changes in the brain, especially in the hippocampus. Fixed rat brains were analyzed by ex vivo DTI at 2 h and 42 days after blast (or sham) exposure(s). An anatomy-based region of interest analysis revealed significant interactions in axial and radial diffusivity in a number of subcortical structures at 2 h only. Differences between single-and multiple-injured rats were largely in the thalamus but not the hippocampus. Our findings demonstrate the value and the limitations of DTI in providing a better understanding of mbTBI pathobiology.
C1 [Kamnaksh, Alaa; Agoston, Denes V.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA.
   [Kamnaksh, Alaa] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA.
   [Budde, Matthew D.; Frank, Joseph A.] Natl Inst Biomed Imaging & Bioengn, NIH, Bethesda, MD 20892 USA.
   [Kovesdi, Erzsebet] US Dept Vet Affairs, Vet Affairs Cent Off, Washington, DC 20420 USA.
   [Long, Joseph B.] Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci, Blast Induced Neurotrauma Branch, Silver Spring, MD 20910 USA.
RP Agoston, DV (reprint author), Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.
EM denes.agoston@usuhs.edu
FU Center for Neuroscience and Regenerative Medicine [G1703F]
FX We thank the Neurotrauma Team at the Walter Reed Army Institute of
   Research for their technical help during the exposures, along with Eric
   Gold and Lindsay Janes for assistance with the MRI experiments. This
   work was supported by the Center for Neuroscience and Regenerative
   Medicine grant number G1703F.
NR 59
TC 7
Z9 8
U1 2
U2 12
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAY 2
PY 2014
VL 4
AR 4809
DI 10.1038/srep04809
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AG1ZZ
UT WOS:000335216000001
PM 24786839
ER

PT J
AU Wisneski, AD
   Matthews, PB
   Azadani, AN
   Mookhoek, A
   Chitsaz, S
   Guccione, JM
   Ge, L
   Tseng, EE
AF Wisneski, Andrew D.
   Matthews, Peter B.
   Azadani, Ali N.
   Mookhoek, Aart
   Chitsaz, Sam
   Guccione, Julius M.
   Ge, Liang
   Tseng, Elaine E.
TI Human Pulmonary Autograft Wall Stress at Systemic Pressures Prior to
   Remodeling After the Ross Procedure
SO JOURNAL OF HEART VALVE DISEASE
LA English
DT Article
ID AORTIC-VALVE DISEASE; FINITE-ELEMENT; ROOT; DEGENERATION; REPLACEMENT;
   ANEURYSM
AB Background and aim of the study: Remodeling of the pulmonary autograft upon exposure to systemic pressure can lead to progressive dilatation and aneurysmal pathology. Remodeling is driven by changes in autograft wall stress upon exposure to systemic pressure; however, the magnitude of these changes is unknown. Previously, a porcine autograft finite element model was developed to determine wall stress, but the porcine and human material properties differed significantly. Hence, the study aim was to understand human pulmonary autograft biomechanics that lead to remodeling by determining wall stress magnitudes immediately after the Ross procedure using finite element analysis (FEA).
   Methods: Human pulmonary root was scanned by high-resolution microcomputed tomography to construct a realistic three-dimensional geometric mesh. Stress-strain data from biaxial stretch testing was incorporated into an Ogden hyperelastic model to describe autograft mechanical properties for an adult Ross patient. Autograft dilatation and wall stress distribution during pulmonic and systemic pressures prior to remodeling were determined using explicit FEA in LS-DYNA.
   Results: Human pulmonary autograft demonstrated non-linear material properties, being highly compliant in the low-strain region, and stiffening at high strain. The majority of dilatation occurred with <20 mmHg pressurization. From pulmonary to systemic pressures, the increases in autograft diameter were up to 17%. Likewise, the maximal wall stress increased approximately 14.6-fold compared to diastolic pressures (from 13.0 to 190.1kPa), and six-fold compared to systolic pressures (from 48.6 to 289.6kPa).
   Conclusion: The first finite element model of the human pulmonary autograft was developed and used to demonstrate how autograft material properties prevent significant dilatation upon initial exposure to systemic pressure. Mild dilatation was noted in the sinuses and sinotubular junction. Autograft wall stress was increased greatly when subjected to systemic pressures, and may trigger biomechanical remodeling of the autograft. Sustained exposure to higher wall stresses, coupled with inadequate remodeling, may lead to future autograft dilatation.
C1 [Wisneski, Andrew D.; Matthews, Peter B.; Azadani, Ali N.; Chitsaz, Sam; Guccione, Julius M.; Ge, Liang; Tseng, Elaine E.] Univ Calif San Francisco, Dept Surg, San Francisco, CA USA.
   [Wisneski, Andrew D.; Matthews, Peter B.; Azadani, Ali N.; Chitsaz, Sam; Guccione, Julius M.; Ge, Liang; Tseng, Elaine E.] San Francisco VA Med Ctr, San Francisco, CA USA.
   [Mookhoek, Aart] Erasmus MC, Dept Surg, Rotterdam, Netherlands.
RP Tseng, EE (reprint author), UCSF Med Ctr, Div Cardiothorac Surg, 500 Parnassus Ave,Suite 405W,Box 0118, San Francisco, CA 94143 USA.
EM elaine.tseng@ucsfmedctr.org
FU American Heart Association
FX This study was funded by American Heart Association Grant-in-Aid,
   administered by the Northern California Institute for Research and
   Education, using the resources of the San Francisco Veterans Affairs
   Medical Center. The authors also thank the California Organ Transplant
   Donor Network for heart specimens.
NR 26
TC 1
Z9 1
U1 0
U2 1
PU I C R PUBLISHERS
PI NORTHWOOD
PA CRISPIN HOUSE, 12/A SOUTH APPROACH, MOOR PARK, NORTHWOOD HA6 2ET,
   ENGLAND
SN 0966-8519
J9 J HEART VALVE DIS
JI J. Heart Valve Dis.
PD MAY
PY 2014
VL 23
IS 3
BP 377
EP 384
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CB4BJ
UT WOS:000349572900019
PM 25296465
ER

PT J
AU Winans-Mitrik, RL
   Hula, WD
   Dickey, MW
   Schumacher, JG
   Swoyer, B
   Doyle, PJ
AF Winans-Mitrik, Ronda L.
   Hula, William D.
   Dickey, Michael W.
   Schumacher, James G.
   Swoyer, Brooke
   Doyle, Patrick J.
TI Description of an Intensive Residential Aphasia Treatment Program:
   Rationale, Clinical Processes, and Outcomes
SO AMERICAN JOURNAL OF SPEECH-LANGUAGE PATHOLOGY
LA English
DT Article
DE aphasia; outcomes; response to intervention; stroke; effectiveness
ID HEALTH-CARE UTILIZATION; RURAL REGION; THERAPY; ADULTS; REHABILITATION;
   EFFICACY; ACCESS; FORMS; MODEL
AB Purpose: The purpose of this article is to describe the rationale, clinical processes, and outcomes of an intensive comprehensive aphasia program (ICAP).
   Method: Seventy-three community-dwelling adults with aphasia completed a residentially based ICAP. Participants received 5 hr of daily 1:1 evidence-based cognitivelinguistically oriented aphasia therapy, supplemented with weekly socially oriented and therapeutic group activities over a 23-day treatment course. Standardized measures of aphasia severity and communicative functioning were obtained at baseline, program entry, program exit, and follow-up.
   Results were analyzed using a Bayesian latent growth curve model with 2 factors representing (a) the initial level and (b) change over time, respectively, for each outcome measure. Results: Model parameter estimates showed reliable improvement on all outcome measures between the initial and final assessments. Improvement during the treatment interval was greater than change observed across the baseline interval, and gains were maintained at follow-up on all measures.
   Conclusions: The rationale, clinical processes, and outcomes of a residentially based ICAP have been described. ICAPs differ with respect to treatments delivered, dosing parameters, and outcomes measured. Specifying the defining components of complex interventions, establishing their feasibility, and describing their outcomes are necessary to guide the development of controlled clinical trials.
C1 [Winans-Mitrik, Ronda L.; Hula, William D.; Dickey, Michael W.; Schumacher, James G.; Swoyer, Brooke; Doyle, Patrick J.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15261 USA.
   [Hula, William D.; Dickey, Michael W.; Doyle, Patrick J.] Univ Pittsburgh, Pittsburgh, PA 15260 USA.
RP Doyle, PJ (reprint author), VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15261 USA.
EM patrick.doyle@va.gov
NR 57
TC 7
Z9 7
U1 7
U2 18
PU AMER SPEECH-LANGUAGE-HEARING ASSOC
PI ROCKVILLE
PA 10801 ROCKVILLE PIKE, ROCKVILLE, MD 20852-3279 USA
SN 1058-0360
EI 1558-9110
J9 AM J SPEECH-LANG PAT
JI Am. J. Speech-Lang. Pathol.
PD MAY
PY 2014
VL 23
IS 2
BP 330
EP 342
DI 10.1044/2014_AJSLP-13-0102
PG 13
WC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation
SC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation
GA AU5ZP
UT WOS:000345682200019
PM 24687159
ER

PT J
AU Post, JB
   Morin, KG
   Handrakis, JP
   Rivera, DR
   Yen, C
   Sano, M
   Spungen, AM
AF Post, James B.
   Morin, Kel G.
   Handrakis, John P.
   Rivera, Dwindally Rosado
   Yen, Christina
   Sano, Mary
   Spungen, Ann M.
TI Cognition may be related to arterial pulsatility index in HD patients
SO CLINICAL NEPHROLOGY
LA English
DT Article
DE pulsatility; cognitive impairment; hemodialysis
ID HEMODIALYSIS-PATIENTS; RENAL-DISEASE; CAROTID-ARTERY; IMPAIRMENT;
   HYPERPARATHYROIDISM; MICROANGIOPATHY
AB Aims: Hemodialysis (HD) patients have a heavy burden of subclinical cerebrovascular disease and cognitive changes consistent with a vascular etiology. Pulsatility index is associated with microangiopathy of cerebral blood vessels and an increased risk of cerebral infarction. The proposed study was to determine common carotid artery pulsatility index (CCAPI) and its relation to cognition in well-dialyzed HD patients with no history of stroke or dementia and matched controls. Methods: Observational, cross-sectional study of CCAPI and cognition in 37 hemodialysis outpatients and 18 matched controls with normal kidney function. Non-parametric analyses were used to compare variables between groups. Multiple regression and ANOVA models were used to adjust for risk factor differences. Results: Controls had a lower CCAPI than the HD group (1.7 +/- 0.3 vs. 2.1 +/- 0.4 cm/s, p = 0.006). HD patients scored significantly lower on all cognitive domains. Attention correlated with CCAPI in HD patients, independent of hypertension, diabetes, hyperlipidemia, and years on HD (r(2) = -0.36, p = 0.01). CCAPI correlated with years on HD, independent of traditional cardiovascular risk factors. (r(2) = 0.26, p = 0.04). Conclusion: In well-dialyzed hemodialysis patients with no history of stroke or dementia, -CCAPI may correlate with cognitive function and represent a marker for underlying cerebral microvascular disease.
C1 [Post, James B.] James J Peters VA Med Ctr, Div Nephrol, Bronx, NY 10468 USA.
   [Post, James B.; Morin, Kel G.; Handrakis, John P.; Rivera, Dwindally Rosado; Yen, Christina; Spungen, Ann M.] James J Peters VA Med Ctr, VA RR&D Ctr Excellence Med Consequences SCI, Bronx, NY 10468 USA.
   [Handrakis, John P.] New York Inst Technol, Sch Hlth Professionals, Dept Phys Therapy, Old Westbury, NY 11568 USA.
   [Sano, Mary] James J Peters VA Med Ctr, VA RR&D, Bronx, NY 10468 USA.
   [Post, James B.] Mt Sinai Sch Med, Dept Med, New York, NY USA.
   [Sano, Mary] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA.
   [Spungen, Ann M.] Mt Sinai Sch Med, Dept Rehabilitat Med, New York, NY USA.
RP Post, JB (reprint author), James J Peters VA Med Ctr, 130 West Kingsbridge Rd, Bronx, NY 10468 USA.
EM James.Post@va.gov
FU VA RRD CDA 2 [B5050W]; VA RR&D Center of Excellence [B4162C]
FX This project was funded by the VA RR&D CDA 2 #B5050W and VA RR&D Center
   of Excellence #B4162C. We would like to thank the kidney dialysis unit
   nursing staff for assisting with patient scheduling and communication.
NR 30
TC 2
Z9 2
U1 1
U2 5
PU DUSTRI-VERLAG DR KARL FEISTLE
PI DEISENHOFEN-MUENCHEN
PA BAHNHOFSTRASSE 9 POSTFACH 49, D-82032 DEISENHOFEN-MUENCHEN, GERMANY
SN 0301-0430
J9 CLIN NEPHROL
JI Clin. Nephrol.
PD MAY
PY 2014
VL 81
IS 5
BP 313
EP 319
DI 10.5414/CN107998
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA AT2WQ
UT WOS:000344795400002
PM 24780553
ER

PT J
AU Feeney, MP
   Stover, B
   Keefe, DH
   Garinis, AC
   Day, JE
   Seixas, N
AF Feeney, M. Patrick
   Stover, Bert
   Keefe, Douglas H.
   Garinis, Angela C.
   Day, Jessica E.
   Seixas, Noah
TI Sources of Variability in Wideband Energy Reflectance Measurements in
   Adults
SO JOURNAL OF THE AMERICAN ACADEMY OF AUDIOLOGY
LA English
DT Article
DE Wideband acoustic immittance; energy or power reflectance; absorbance;
   middle ear; tympanometry
ID MIDDLE-EAR DISORDERS; NORMAL-HEARING; OTOACOUSTIC EMISSIONS;
   ACOUSTIC-IMPEDANCE; OTOSCLEROTIC EARS; TYMPANOMETRY; COEFFICIENT;
   CHILDREN; INFANTS
AB Background: Wideband acoustic immittance measurements of the middle ear, such as wideband energy reflectance (ER), can provide information about how the middle ear functions across the traditional audiometric frequency range. These measurements are being investigated as a new means of evaluating conductive hearing disorders, and studies have been reported on a number of middle-ear disorders. However, the normative database for wideband ER is still being developed, and more information is needed about sources of test variability.
   Purpose: The purpose of the present study was to evaluate sources of variability in wideband ER measurements at baseline and across annual tests for up to 5 yr in subjects with normal hearing.
   Study Sample: The main group consisted of 112 subjects (187 ears), 24 females and 88 males, with normal hearing and normal 0.226-kHz admittance tympanometry. An additional 24 adults with abnormal 0.226-kHz tympanometry provided baseline comparison data.
   Research Design: A longitudinal design was used in obtaining annual measurements of audiometry, tympanometry, and wideband ER at ambient pressure in adults.
   Data Collection and Analysis: Clinical audiometry and tympanometry data and 1/3-octave wideband ER measurements were obtained at baseline and annually for up to four additional tests. Descriptive statistics and t-tests were used to explore differences in 1/3-octave baseline ER measures in terms of subject age, test ear, sex, and clinical tympanometry. Longitudinal mixed-effects linear regression models at 1.0, 2.0, and 4.0 kHz were used to examine the different sources of variance affecting ER over time.
   Results: There were small but statistically significant mean differences in ER for baseline measurements as a function of ear, sex, and age. Compared with these results, data for 29 ears with abnormal 0.226-kHz tympanometry differed from mean normal data across a broad frequency range by as much as 20%. ER varied as a function of peak compensated static acoustic admittance (Y-tm) for measures at 1.0 kHz but was unrelated to Ytm at 2.0 and 4.0 kHz. ER also varied as a function of the test ear, with significantly higher ER on the left at 1.0 and 2.0 kHz, but was not significantly related to the test ear at 4.0 kHz. The standard deviation for test-retest variability was about 0.1 at each frequency, which is consistent with previous studies.
   Conclusions: Mean wideband ER at baseline showed small but significant differences related to sex, ear, and age. ER was significantly related to Y-tm at 1.0 kHz in the longitudinal data but not at 2.0 or 4.0 kHz and to the test ear at 1.0 and 2.0 kHz but not at 4.0 kHz. When evaluated at ambient pressure, ER for ears with negative middle-ear pressure was similar to that of ears with abnormally low Y-tm. Therefore it might be necessary to evaluate wideband acoustic immittance compensated for middle-ear pressure by using tympanometry to obtain an effective differential diagnosis of middle-ear disorders in adults.
C1 [Feeney, M. Patrick; Garinis, Angela C.] Portland VA Med Ctr, NCRAR, Portland, OR 97239 USA.
   [Feeney, M. Patrick] Oregon Hlth & Sci Univ, Dept Otolaryngol Head & Neck Surg, Portland, OR 97201 USA.
   [Feeney, M. Patrick] Univ Washington, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USA.
   [Stover, Bert] Univ Washington, Dept Environm & Occupat Hlth Sci, Seattle, WA 98195 USA.
   [Keefe, Douglas H.] Boys Town Natl Res Hosp, Omaha, NE 68131 USA.
   [Day, Jessica E.] Univ Washington, Dept Speech & Hearing Sci, Seattle, WA 98195 USA.
RP Feeney, MP (reprint author), Portland VA Med Ctr, NCRAR, VA RR&D Natl Ctr Rehabilitat Auditory Res, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM Patrick.Feeney@va.gov
FU National Institute for Occupational Health and Safety of the US Centers
   for Disease Control and Prevention [5 R01 0H003912]; VA RRD award
   [C9230C]
FX This research was funded by the National Institute for Occupational
   Health and Safety of the US Centers for Disease Control and Prevention,
   5 R01 0H003912. Support for the first author was also provided by VA
   RR&D award C9230C. The content of this article does not represent the
   views of the Department of Veterans Affairs or of the United States
   Government.
NR 30
TC 3
Z9 3
U1 2
U2 11
PU AMER ACAD AUDIOLOGY
PI RESTON
PA 11730 PLAZA DR, STE 300, RESTON, VA 20190 USA
SN 1050-0545
EI 2157-3107
J9 J AM ACAD AUDIOL
JI J. Am. Acad. Audiol.
PD MAY
PY 2014
VL 25
IS 5
SI SI
BP 449
EP 461
DI 10.3766/jaaa.25.5.4
PG 13
WC Audiology & Speech-Language Pathology; Otorhinolaryngology
SC Audiology & Speech-Language Pathology; Otorhinolaryngology
GA AQ7RX
UT WOS:000343018000004
PM 25257719
ER

PT J
AU Feeney, MP
   Sanford, CA
   Putterman, DB
AF Feeney, M. Patrick
   Sanford, Chris A.
   Putterman, Daniel B.
TI Effects of Ear-Canal Static Pressure on Pure-Tone Thresholds and
   Wideband Acoustic Immittance
SO JOURNAL OF THE AMERICAN ACADEMY OF AUDIOLOGY
LA English
DT Article
DE Wideband acoustic immittance; middle ear; conductive hearing loss;
   otitis media
ID CONDUCTIVE HEARING-LOSS; REFLECTION COEFFICIENT; OTOACOUSTIC EMISSIONS;
   HUMAN INFANTS; IMPEDANCE; ADULTS; IDENTIFICATION; PRESSURIZATION;
   TYMPANOMETRY; ADMITTANCE
AB Background: Wideband acoustic immittance (WAI) measures provide information about middle-ear function across the traditional audiometric frequency range from 0.25 to 8.0 kHz. Recent studies have found that WAI is effective in predicting the presence of conductive hearing loss (CHL). It is not known whether WAI can accurately estimate the degree of threshold shift caused by CHL.
   Purpose: The purpose of the present study was to evaluate the relationship between changes in puretone threshold and changes in wideband absorbance and acoustic conductance levels induced by positive and negative ear-canal static pressure.
   Study Sample: Twenty young adult subjects with normal hearing and a negative history of middle-ear disorders participated in the study.
   Data Collection and Analysis: Experimental pure-tone thresholds at 0.5 and 2.0 kHz were estimated by using a three-interval, three-alternative forced-choice adaptive psychometric procedure under three conditions: ambient ear-canal pressure, +200 daPa static pressure, and 200 daPa static pressure. Wideband absorbance and conductance were obtained in the same subjects by using a Welch Allyn prototype diagnostic middle ear analyzer. Changes in pure-tone threshold from the ambient pressure condition to the static pressure condition were evaluated by using a paired-samples t test and Pearson productmoment correlation.
   Results: Wideband middle-ear absorbance and conductance at ambient pressure in this study were consistent with published data in adults with normal hearing. The mean change in threshold at 0.5 and 2.0 kHz with +200 daPa or -200 daPa ear-canal static pressure was similar to the mean change in absorbance and conductance levels in the same conditions. However, there was one statistically significant difference between the shift in pure-tone threshold and the change in conductance level for the +200 daPa pressure condition for 2.0 kHz, with the change in threshold being 1.5 dB greater than the change in conductance level (t = 2.39, p = 0.03). In contrast to the good performance of WAI measures in predicting mean threshold shifts caused by ear-canal pressure, the shifts in WAI were not correlated with threshold shifts. Thus WAI was not well suited to predict individual threshold changes caused by ear-canal static pressure.
   Conclusions: For the conditions of this study, results suggest that mean change in absorbance or conductance level caused by ear-canal static pressure of +200 daPa or 200 daPa provides a good estimate of the change in pure-tone threshold in the same conditions. However, individual threshold change was not accurately predicted by the change in absorbance or conductance level.
C1 [Feeney, M. Patrick; Putterman, Daniel B.] Portland VA Med Ctr, NCRAR, Portland, OR 97239 USA.
   [Feeney, M. Patrick; Putterman, Daniel B.] Oregon Hlth & Sci Univ, Dept Otolaryngol Head & Neck Surg, Portland, OR 97201 USA.
   [Feeney, M. Patrick] Univ Washington, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USA.
   [Sanford, Chris A.] Idaho State Univ, Dept Commun Sci & Disorders, Pocatello, ID 83209 USA.
RP Feeney, MP (reprint author), Portland VA Med Ctr, NCRAR, 3710 SW US Vet Hosp Rd,P5-NCRAR, Portland, OR 97239 USA.
EM Patrick.Feeney@va.gov
FU VA RRD award [C9230C]
FX Support for the first and last authors was provided by VA RR&D award
   C9230C. The content of this article does not represent the views of the
   Department of Veterans Affairs or the United States Government.
NR 29
TC 0
Z9 0
U1 1
U2 5
PU AMER ACAD AUDIOLOGY
PI RESTON
PA 11730 PLAZA DR, STE 300, RESTON, VA 20190 USA
SN 1050-0545
EI 2157-3107
J9 J AM ACAD AUDIOL
JI J. Am. Acad. Audiol.
PD MAY
PY 2014
VL 25
IS 5
SI SI
BP 462
EP 470
DI 10.3766/jaaa.25.5.5
PG 9
WC Audiology & Speech-Language Pathology; Otorhinolaryngology
SC Audiology & Speech-Language Pathology; Otorhinolaryngology
GA AQ7RX
UT WOS:000343018000005
PM 25257720
ER

PT J
AU Shaaban, AM
   Rezvani, M
   Elsayes, KM
   Baskin, H
   Mourad, A
   Foster, BR
   Jarboe, EA
   Menias, CO
AF Shaaban, Akram M.
   Rezvani, Maryam
   Elsayes, Khaled M.
   Baskin, Henry, Jr.
   Mourad, Amr
   Foster, Bryan R.
   Jarboe, Elke A.
   Menias, Christine O.
TI Ovarian Malignant Germ Cell Tumors: Cellular Classification and Clinical
   and Imaging Features
SO RADIOGRAPHICS
LA English
DT Article
ID MATURE CYSTIC TERATOMA; ENDODERMAL SINUS TUMOR; PSEUDO-MEIGS-SYNDROME;
   STRUMA OVARII; PATHOLOGICAL CORRELATION; CARCINOID-TUMORS;
   IMMUNOHISTOCHEMICAL ANALYSIS; DIFFERENTIAL-DIAGNOSIS; PREOPERATIVE
   DIAGNOSIS; IMMATURE TERATOMAS
AB Ovarian malignant germ cell tumors (OMGCTs) are heterogeneous tumors that are derived from the primitive germ cells of the embryonic gonad. OMGCTs are rare, accounting for about 2.6% of all ovarian malignancies, and typically manifest in adolescence, usually with abdominal pain, a palpable mass, and elevated serum tumor marker levels, which may serve as an adjunct in the initial diagnosis, monitoring during therapy, and posttreatment surveillance. Dysgerminoma, the most common malignant germ cell tumor, usually manifests as a solid mass. Immature teratomas manifest as a solid mass with scattered foci of fat and calcifications. Yolk sac tumors usually manifest as a mixed solid and cystic mass. Capsular rupture or the bright dot sign, a result of increased vascularity and the formation of small vascular aneurysms, may be present. Embryonal carcinomas and polyembryomas rarely manifest in a pure form and are more commonly part of a mixed germ cell tumor. Some OMGCTs have characteristic features that allow a diagnosis to be confidently made, whereas others have nonspecific features, which make them difficult to diagnose. However, imaging features, the patient's age at presentation, and tumor markers may help establish a reasonable differential diagnosis. Malignant ovarian germ cell tumors spread in the same manner as epithelial ovarian neoplasms but are more likely to involve regional lymph nodes. Preoperative imaging may depict local extension, peritoneal disease, and distant metastases. Suspicious areas may be sampled during surgery. Because OMGCTs are almost always unilateral and are chemosensitive, fertility-sparing surgery is the standard of care. (C)RSNA, 2014.
C1 [Shaaban, Akram M.; Rezvani, Maryam] Univ Utah, Dept Diagnost Radiol, Salt Lake City, UT 84132 USA.
   [Baskin, Henry, Jr.] Univ Utah, Dept Radiol, Primary Childrens Med Ctr, Salt Lake City, UT 84132 USA.
   [Elsayes, Khaled M.] Univ Texas MD Anderson Canc Ctr, Dept Radiol, Houston, TX 77030 USA.
   [Mourad, Amr] VA Pittsburgh Healthcare Syst, Dept Diagnost Radiol, Pittsburgh, PA USA.
   [Foster, Bryan R.] Oregon Hlth & Sci Univ, Dept Diagnost Radiol, Portland, OR 97201 USA.
   [Jarboe, Elke A.] Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT 84132 USA.
   [Menias, Christine O.] Mayo Clin, Dept Radiol, Scottsdale, AZ USA.
RP Shaaban, AM (reprint author), Univ Utah, Dept Diagnost Radiol, 30 N 1900 E,Room 1A71, Salt Lake City, UT 84132 USA.
EM akram.shaaban@hsc.utah.edu
NR 84
TC 7
Z9 9
U1 3
U2 8
PU RADIOLOGICAL SOC NORTH AMERICA
PI OAK BROOK
PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA
SN 0271-5333
J9 RADIOGRAPHICS
JI Radiographics
PD MAY-JUN
PY 2014
VL 34
IS 3
BP 777
EP 801
DI 10.1148/rg.343130067
PG 25
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA AP2PH
UT WOS:000341915200018
PM 24819795
ER

PT J
AU Chen, LLK
   Baca, CB
   Choe, J
   Chen, JW
   Ayad, ME
   Cheng, EM
AF Chen, Leo L. K.
   Baca, Christine B.
   Choe, Jessica
   Chen, James W.
   Ayad, Miriam E.
   Cheng, Eric M.
TI Posttraumatic Epilepsy in Operation Enduring Freedom/Operation Iraqi
   Freedom Veterans
SO MILITARY MEDICINE
LA English
DT Article
ID TRAUMATIC BRAIN-INJURY; EMOTIONAL RISK-FACTORS; HEAD-INJURY;
   NONEPILEPTIC SEIZURES; CODES; ASCERTAINMENT; DIAGNOSIS; ACCURACY;
   DISORDER; VALIDITY
AB Penetrating traumatic brain injury (TBI) is a well-established risk factor for post-traumatic epilepsy (PTE). However, many veterans in Operation Enduring Freedom (OEF) and Operation Iraqi Freedom (OIF) who suffer from TBI do so from blast injury, and its consequences are not fully known. Two neurologists performed a chart review to describe patterns of injury and health care among all 16 OEF/OIF veterans at the VA Greater Los Angeles Healthcare System who were assigned an outpatient diagnosis of both epilepsy and TBI in 2008-2009. All Veterans were male, and the mean age was 30 years. Blast exposure was the most common mechanism of TBI (81%). Although all Veterans were assigned a diagnosis code of seizures, the diagnosis of PTE was clinically confirmed in only 3 veterans. On the other hand, the diagnosis of post-traumatic stress disorder was confirmed in 81% of the sample and a diagnosis of nonepileptic seizures was suspected in 44% of the sample. Researchers who study PTE among the OEF/OIF population using administrative data also should perform chart reviews to account for the prevalence of psychogenic nonepileptic seizures.
C1 [Chen, Leo L. K.] Kaiser Permanente Fdn Hosp, Dept Neurol, Sacramento, CA 95825 USA.
   [Chen, Leo L. K.] UC Davis Hlth Syst, Dept Neurol, Sacramento, CA 95817 USA.
   [Baca, Christine B.; Choe, Jessica] Univ Calif San Diego, Dept Neurol, San Diego, CA 92103 USA.
   [Baca, Christine B.; Choe, Jessica; Chen, James W.; Ayad, Miriam E.; Cheng, Eric M.] VA Greater Los Angeles Healthcare Syst, Dept Neurol, Los Angeles, CA 90073 USA.
   [Chen, James W.; Ayad, Miriam E.; Cheng, Eric M.] UCLA, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.
RP Chen, LLK (reprint author), Kaiser Permanente Fdn Hosp, Dept Neurol, 2025 Morse Ave, Sacramento, CA 95825 USA.
FU VA Epilepsy Center of Excellence at VA Los Angeles; NIH/NINDS
   [K23NS058571]
FX The study was supported by the VA Epilepsy Center of Excellence at VA
   Los Angeles. Dr. Cheng was supported by Career Development Award from
   NIH/NINDS (K23NS058571).
NR 28
TC 5
Z9 5
U1 1
U2 3
PU ASSOC MILITARY SURG US
PI BETHESDA
PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA
SN 0026-4075
EI 1930-613X
J9 MIL MED
JI Milit. Med.
PD MAY
PY 2014
VL 179
IS 5
BP 492
EP 496
DI 10.7205/MILMED-D-13-00413
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA AN7UL
UT WOS:000340806400007
PM 24806494
ER

PT J
AU Lo-Ciganic, W
   Donohue, JM
   Thorpe, CT
   Thorpe, JM
   Perera, S
   Marcum, ZA
   Gellad, WF
AF Lo-Ciganic, W.
   Donohue, J. M.
   Thorpe, C. T.
   Thorpe, J. M.
   Perera, S.
   Marcum, Z. A.
   Gellad, W. F.
TI EXAMINING A THRESHOLD OF ADHERENCE TO ORAL HYPOGLYCEMIC AGENTS RELEVANT
   TO CLINICAL OUTCOMES IN DIABETES: A TREE-STRUCTURED SURVIVAL MODEL
SO VALUE IN HEALTH
LA English
DT Meeting Abstract
C1 [Lo-Ciganic, W.; Donohue, J. M.; Perera, S.; Marcum, Z. A.; Gellad, W. F.] Univ Pittsburgh, Pittsburgh, PA USA.
   [Thorpe, C. T.; Thorpe, J. M.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
   [Gellad, W. F.] RAND, VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1098-3015
EI 1524-4733
J9 VALUE HEALTH
JI Value Health
PD MAY
PY 2014
VL 17
IS 3
MA PDB88
BP A253
EP A253
PG 1
WC Economics; Health Care Sciences & Services; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA AO1OG
UT WOS:000341082001519
ER

PT J
AU Cerulli, C
   Kothari, CL
   Dichter, M
   Marcus, S
   Wiley, J
   Rhodes, KV
AF Cerulli, Catherine
   Kothari, Catherine L.
   Dichter, Melissa
   Marcus, Steve
   Wiley, James
   Rhodes, Karin V.
TI Victim Participation in Intimate Partner Violence Prosecution:
   Implications for Safety
SO VIOLENCE AGAINST WOMEN
LA English
DT Article
DE intimate partner violence; prosecution; safety
ID DOMESTIC VIOLENCE; PROTECTION ORDERS; DECISION-MAKING; HEALTH-CARE;
   WOMEN; BARRIERS; ARREST; LEGAL; RISK; INTERVENTION
AB Are intimate partner violence (IPV) victims safer if they use the criminal justice system? Concerns about perpetrator retaliation, in the face of data that protection orders can reduce future harm, make it important to understand how victim utilization (calling 911, talking to the prosecutor, and proceeding with prosecution) affects subsequent safety. We hypothesized participation would improve victims' safety, measured by decreases in subsequent IPV-related 911 calls and/or emergency department visits. Findings support contact with the prosecutor's office was associated with reduction in police-reported IPV, regardless of the victim's wish to proceed. Policy implications support pro-prosecution strategies coupled with victim contact.
C1 [Cerulli, Catherine] Univ Rochester, Rochester, NY 14642 USA.
   [Kothari, Catherine L.] Western Michigan Univ, Kalamazoo, MI 49008 USA.
   [Dichter, Melissa; Marcus, Steve] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA.
   [Marcus, Steve] Univ Penn, Philadelphia, PA 19104 USA.
   [Rhodes, Karin V.] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA.
   [Wiley, James] Univ Calif San Francisco, San Francisco, CA 94143 USA.
RP Cerulli, C (reprint author), Univ Rochester, Sch Med & Dent, 300 Crittenden Blvd, Rochester, NY 14642 USA.
EM Catherine_Cerulli@urmc.rochester.edu
NR 56
TC 2
Z9 2
U1 6
U2 19
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1077-8012
EI 1552-8448
J9 VIOLENCE AGAINST WOM
JI Violence Against Women
PD MAY
PY 2014
VL 20
IS 5
BP 539
EP 560
DI 10.1177/1077801214535105
PG 22
WC Women's Studies
SC Women's Studies
GA AN8VC
UT WOS:000340882200005
PM 24894959
ER

PT J
AU Corbelli, J
   Borrero, S
   Bonnema, R
   McNamara, M
   Kraemer, K
   Rubio, D
   Karpov, I
   McNeil, M
AF Corbelli, Jennifer
   Borrero, Sonya
   Bonnema, Rachel
   McNamara, Megan
   Kraemer, Kevin
   Rubio, Doris
   Karpov, Irina
   McNeil, Melissa
TI Physician Adherence to US Preventive Services Task Force Mammography
   Guidelines
SO WOMENS HEALTH ISSUES
LA English
DT Article
ID PRIMARY-CARE PHYSICIANS; BREAST-CANCER RISK; HEART-FAILURE;
   RECOMMENDATIONS; METAANALYSIS; MALPRACTICE; MANAGEMENT; ATTITUDES;
   SUPPORT; SYSTEMS
AB Background: In 2009, the U.S. Preventive Services Task Force (USPSTF) guidelines for screening mammography changed significantly, and are now in direct conflict with screening guidelines of other major national organizations. The extent to which physicians in different primary care specialties adhere to current USPSTF guidelines is unknown.
   Methods: We conducted a cross-sectional web-based survey completed by 316 physicians in internal medicine, family medicine (FM), and gynecology (GYN) from February to April 2012. Survey items assessed respondents' breast cancer screening recommendations in women of different ages at average risk for breast cancer. We used descriptive statistics to generate response distribution for survey items, and logistic regression models to compare responses among specialties.
   Findings: The response rate was 55.0% (316/575). A majority of providers in internal medicine (65%), FM (64%), and GYN (92%) recommended breast cancer screening starting at age 40 versus 50. A majority of providers in internal medicine (77%), FM (74%), and GYN (98%) recommended annual versus biennial screening. Gynecologists were significantly more likely than both internists and family physicians to recommend initial mammography at age 40 (p <= .0001) and yearly mammography (p = .0003). There were no other differences by respondent demographic.
   Conclusions: Primary care providers, especially gynecologists, have not implemented USPSTF guidelines. The extent to which these findings may be driven by patient versus provider preferences should be explored. These findings suggest that patients are likely to receive conflicting breast cancer screening recommendations from different providers. Copyright (C) 2014 by the Jacobs Institute of Women's Health. Published by Elsevier Inc.
C1 [Corbelli, Jennifer; Borrero, Sonya; Kraemer, Kevin; Rubio, Doris; McNeil, Melissa] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA USA.
   [Borrero, Sonya] VA Pittsburgh Healthcare Syst, Ctr Res Hlth Equ & Promot, Pittsburgh, PA USA.
   [Borrero, Sonya; Kraemer, Kevin; Rubio, Doris; Karpov, Irina] Univ Pittsburgh, Ctr Res Hlth Care, Pittsburgh, PA USA.
   [Bonnema, Rachel] Univ Nebraska Med Ctr, Div Gen Internal Med, Omaha, NE USA.
   [McNamara, Megan] Case Western Reserve Univ, Sch Med, Div Gen Internal Med, Cleveland, OH USA.
   [McNamara, Megan] Louis Stokes VA Healthcare Syst, Cleveland, OH USA.
RP Corbelli, J (reprint author), 200 Lothrop St,MUH 9W-33, Pittsburgh, PA 15213 USA.
EM corbellija@upmc.edu
NR 48
TC 9
Z9 9
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1049-3867
EI 1878-4321
J9 WOMEN HEALTH ISS
JI Womens Health Iss.
PD MAY-JUN
PY 2014
VL 24
IS 3
BP E313
EP E319
DI 10.1016/j.whi.2014.03.003
PG 7
WC Public, Environmental & Occupational Health; Women's Studies
SC Public, Environmental & Occupational Health; Women's Studies
GA AO1ZQ
UT WOS:000341114600008
PM 24794545
ER

PT J
AU Craig, AD
   Dehlendorf, C
   Borrero, S
   Harper, CC
   Rocca, CH
AF Craig, Amaranta D.
   Dehlendorf, Christine
   Borrero, Sonya
   Harper, Cynthia C.
   Rocca, Corinne H.
TI Exploring Young Adults' Contraceptive Knowledge and Attitudes:
   Disparities by Race/Ethnicity and Age
SO WOMENS HEALTH ISSUES
LA English
DT Article
ID 2002 NATIONAL-SURVEY; LOW-INCOME WOMEN; UNITED-STATES; UNINTENDED
   PREGNANCY; FAMILY GROWTH; RISK; CHOICE; DISCONTINUATION; HEALTH; SAMPLE
AB Background: Half of pregnancies in the United States are unintended, with the highest proportions occurring among Blacks, Hispanics, and teenagers. Understanding differences in knowledge and attitudes about contraception by race/ethnicity and age can improve efforts to reduce disparities in unintended pregnancy.
   Methods: This analysis used data from the 897 female respondents in National Survey of Reproductive and Contraceptive Knowledge, a survey exploring young adults' knowledge and attitudes about contraception and pregnancy. Bivariate and multivariate logistic regression analyses were used to assess racial/ethnic and age group differences in knowledge and attitudes about contraceptives.
   Findings: Hispanics and teenagers (aged 18-19) had lower awareness of available contraceptive methods, and lower knowledge about individual methods compared with White women and young adults (age 20-29). For example, Hispanics (74%) and teenagers (77%) were less likely to have heard of the intrauterine device (IUD) than were White women (90%) and young adults (90%), and were less likely to know that a woman experiencing side effects could switch brands of oral contraceptive pills (72% of Hispanics vs. 86% of White women; 76% of teenagers vs. 90% of young adults). Hispanics born outside the United States had lower knowledge about contraceptives than U.S.-born Hispanics. For example, foreign-born Hispanics were less likely than U.S.-born Hispanics to have heard of the IUD (59% vs. 82%) or the vaginal ring (55% vs. 95%).
   Conclusions: Lower contraceptive knowledge among teenagers and Hispanics, particularly immigrants, suggests the importance of disseminating family planning information to these women as one means to address disparities in unintended pregnancy. Copyright (C) 2014 by the Jacobs Institute of Women's Health. Published by Elsevier Inc.
C1 [Craig, Amaranta D.; Dehlendorf, Christine] Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA.
   [Craig, Amaranta D.; Dehlendorf, Christine; Harper, Cynthia C.; Rocca, Corinne H.] Univ Calif San Francisco, Bixby Ctr Global Reprod Hlth, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA.
   [Borrero, Sonya] Univ Pittsburgh, Ctr Res Hlth Care, Pittsburgh, PA USA.
   [Borrero, Sonya] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
RP Craig, AD (reprint author), Univ Calif San Francisco, Dept Family & Community Med, 1001 Potrero Ave,Ward 22, San Francisco, CA 94143 USA.
EM amaranta.craig@ucsf.edu
FU NICHD NIH HHS [K23HD067197, 1R21HD068736-01A1, K23 HD067197, R21
   HD068736]; NIMHD NIH HHS [R25 MD006832, R25MD006832]
NR 40
TC 19
Z9 20
U1 4
U2 25
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1049-3867
EI 1878-4321
J9 WOMEN HEALTH ISS
JI Womens Health Iss.
PD MAY-JUN
PY 2014
VL 24
IS 3
BP E281
EP E289
DI 10.1016/j.whi.2014.02.003
PG 9
WC Public, Environmental & Occupational Health; Women's Studies
SC Public, Environmental & Occupational Health; Women's Studies
GA AO1ZQ
UT WOS:000341114600004
PM 24725755
ER

PT J
AU Graff, JN
   Puri, S
   Bifulco, CB
   Fox, BA
   Beer, TM
AF Graff, Julie N.
   Puri, Sachin
   Bifulco, Carlo B.
   Fox, Bernard A.
   Beer, Tomasz M.
TI Sustained Complete Response to CTLA-4 Blockade in a Patient with
   Metastatic, Castration-Resistant Prostate Cancer
SO CANCER IMMUNOLOGY RESEARCH
LA English
DT Article
ID DOSE-ESCALATION TRIAL; IMMUNOTHERAPY; IPILIMUMAB; ANTIGEN; MUTATIONS;
   HYDROLASE; MELANOMA
AB We present the case of a man with metastatic, castration-resistant prostate cancer, who had a complete prostate-specific antigen (PSA) response after 2(1/2) doses of ipilimumab. His treatment course was complicated by diarrhea and autoimmune hepatitis, both of which resolved within 4 months. Sera and biopsy specimens were accessed, and sera from pretreatment and day 113 were analyzed. Augmented antibody responses were detected against 11 potential tumor antigens, with responses ranging from 5- to 20-fold in day 113 sera compared with baseline. Genes that were targets of a strong antibody response (arbitrarily set at 10-fold or greater increase) were analyzed by real-time PCR for expression in the tumor biopsy cDNA. Of the top 5 genes, only 3-hydroxyisobutyryl-CoA hydrolase (HIBCH) could be identified in the amplified tumor biopsy cDNA. Using an antibody to HIBCH, immunohistochemical analysis documented strong expression of the protein. Together, these data suggest that an augmented antibody response to HIBCH, an antigen that was expressed by the patient's prostate cancer, could have contributed to the clinical response. After 16 months of PSA stability, he discontinued his androgen-suppression therapy. With the return of his testosterone, his PSA increased slightly, likely originating from his intact prostate. He has been disease free for the past 6 years without any additional therapy. (C) 2014 AACR.
C1 [Graff, Julie N.] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97239 USA.
   [Graff, Julie N.; Fox, Bernard A.; Beer, Tomasz M.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97239 USA.
   [Fox, Bernard A.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA.
   [Puri, Sachin; Bifulco, Carlo B.; Fox, Bernard A.] Providence Canc Ctr, Earle A Chiles Res Inst, Robert W Franz Canc Res Ctr, Portland, OR USA.
   [Bifulco, Carlo B.] Providence Hlth Syst, Dept Pathol, Portland, OR USA.
RP Graff, JN (reprint author), Oregon Hlth & Sci Univ, 3303 SW Bond Ave,CH14R, Portland, OR 97239 USA.
EM graffj@ohsu.edu
FU Bristol-Myers Squibb
FX C.B. Bifulco is a consultant/advisory board member for EMD/Serono. J.N.
   Graff, B.A. Fox, and T.M. Beer have received commercial research support
   from Bristol-Myers Squibb.
NR 21
TC 9
Z9 9
U1 0
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 2326-6066
EI 2326-6074
J9 CANCER IMMUNOL RES
JI Cancer Immunol. Res.
PD MAY
PY 2014
VL 2
IS 5
BP 399
EP 403
DI 10.1158/2326-6066.CIR-13-0193
PG 5
WC Oncology; Immunology
SC Oncology; Immunology
GA AM7GT
UT WOS:000340034200003
PM 24795352
ER

PT J
AU Spaccarelli, N
   Gharavi, M
   Saboury, B
   Cheng, G
   Rook, AH
   Alavi, A
AF Spaccarelli, Natalie
   Gharavi, Mohammad
   Saboury, Babak
   Cheng, Gang
   Rook, Alain H.
   Alavi, Abass
TI Role of F-18-fluorodeoxyglucose positron emission tomography imaging in
   the management of primary cutaneous lymphomas
SO HELLENIC JOURNAL OF NUCLEAR MEDICINE
LA English
DT Review
DE Lymphoma; Skin cancer; F-18-FDG-PET; Staging lymphoma; Lymphoma response
   to therapy; Recurrence
ID T-CELL LYMPHOMA; NON-HODGKINS-LYMPHOMA; MYCOSIS-FUNGOIDES; FDG-PET/CT;
   COMPUTED-TOMOGRAPHY; PROGNOSTIC VALUE; SEZARY-SYNDROME; F-18
   FLUORODEOXYGLUCOSE; INTERNATIONAL-SOCIETY; TREATMENT RESPONSE
AB Primary cutaneous lymphomas (PCLs) include both cutaneous T-cell and B-cell lymphomas and comprise the second most common type of extra-nodal non-Hodgkin's lymphomas. The treatment and prognosis of PCLs typically depend on the extent of disease. In evaluating extent of disease in oncological processes, computed tomography (CT) provides a purely anatomical assessment of disease. In comparison, [F-18]-fluorodeoxyglucose positron emission tomography (F-18-FDG PET) both visualizes and quantifies the biological processes occurring in the disease at the cellular level. This paper reviews the available literature addressing the clinical role of F-18-FDG PET both alone and in combination with CT in PCLs and draws several conclusions. While F-18-FDG PET seems superior to CT in its detection of nodal and cutaneous PCL lesions,F-18-FDG PET does not seem to adequately detect erythroderma, plaque, or patch cutaneous PCL lesions. In addition, several case series have demonstrated that physicians may be able to use the semi-quantitative measurement of F-18-FDG uptake provided by F-18-FDG PET to predict which lesions are most aggressive. Other case series have shown that the integrated F-18-FDG PET/CT may provide an objective measure of treatment response in patients with PCLs.
C1 [Spaccarelli, Natalie; Alavi, Abass] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Gharavi, Mohammad; Saboury, Babak; Alavi, Abass] Hosp Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA.
   [Cheng, Gang] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
   [Rook, Alain H.] Hosp Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA.
RP Alavi, A (reprint author), Hosp Univ Penn, 3400 Spruce St 4283, Philadelphia, PA 19104 USA.
EM abass.alavi@uphs.upenn.edu
NR 40
TC 4
Z9 4
U1 0
U2 1
PU HELLENIC SOC NUCLEAR MEDICINE
PI THESSALONIKI
PA 51 HERMU ST, THESSALONIKI, 546 23, GREECE
SN 1790-5427
J9 HELL J NUCL MED
JI Hell. J. Nucl. Med.
PD MAY-AUG
PY 2014
VL 17
IS 2
BP 78
EP 84
PG 7
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA AM7CZ
UT WOS:000340023600002
PM 24997076
ER

PT J
AU La Fountaine, MF
   Cirnigliaro, CM
   Kirshblum, SC
   Galea, M
   Spungen, AM
   Bauman, WA
AF La Fountaine, Michael F.
   Cirnigliaro, Christopher M.
   Kirshblum, Steven C.
   Galea, Marinella
   Spungen, Ann M.
   Bauman, William A.
TI The Role of Severe Physical Inactivity on High Density Lipoprotein
   Particle Size and Number: Perspectives from NMR Spectroscopy in Persons
   with Chronic Spinal Cord Injury
SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE
LA English
DT Meeting Abstract
CT 61st Annual Meeting of the American-College-of-Sports-Medicine
CY APR 01-04, 2014
CL Atlanta, GA
SP Amer Coll Sports Med
C1 [La Fountaine, Michael F.] Seton Hall Univ, S Orange, NJ 07079 USA.
   [Cirnigliaro, Christopher M.; Galea, Marinella; Spungen, Ann M.; Bauman, William A.] James J Peters VA Med Ctr, Bronx, NY USA.
   [Kirshblum, Steven C.] Kessler Inst Rehabil, W Orange, NJ USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0195-9131
EI 1530-0315
J9 MED SCI SPORT EXER
JI Med. Sci. Sports Exerc.
PD MAY
PY 2014
VL 46
IS 5
SU 1
MA 2372
BP 636
EP 636
PG 1
WC Sport Sciences
SC Sport Sciences
GA AL4PW
UT WOS:000339115904177
ER

PT J
AU Cirnigliaro, CM
   Dengel, DR
   Liu, J
   LaFountaine, MF
   Kirshblum, SC
   Galea, M
   Spungen, AM
   Bauman, WA
AF Cirnigliaro, Christopher M.
   Dengel, Donald R.
   Liu, Ji
   LaFountaine, Michael F.
   Kirshblum, Steven C.
   Galea, Marinella
   Spungen, Ann M.
   Bauman, William A.
TI Increased Visceral Fat in Persons with Spinal Cord Injury
SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE
LA English
DT Meeting Abstract
CT 61st Annual Meeting of the American-College-of-Sports-Medicine
CY APR 01-04, 2014
CL Atlanta, GA
SP Amer Coll Sports Med
C1 [Cirnigliaro, Christopher M.; LaFountaine, Michael F.; Galea, Marinella; Spungen, Ann M.; Bauman, William A.] James J Peters VA Med Ctr, Bronx, NY USA.
   [Dengel, Donald R.] Univ Minnesota, Minneapolis, MN USA.
   [Liu, Ji] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA.
   [Kirshblum, Steven C.] Kessler Inst Rehabil, W Orange, NJ USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0195-9131
EI 1530-0315
J9 MED SCI SPORT EXER
JI Med. Sci. Sports Exerc.
PD MAY
PY 2014
VL 46
IS 5
SU 1
MA 2940
BP 800
EP 800
PG 1
WC Sport Sciences
SC Sport Sciences
GA AL4PW
UT WOS:000339115905271
ER

PT J
AU La Fountaine, MF
   Toda, M
   Testa, A
   Bauman, WA
AF La Fountaine, Michael F.
   Toda, Michita
   Testa, Anthony
   Bauman, William A.
TI The Spontaneous Appearance Of Wandering Atrial Pacemaker And Frequent
   Atrial Ectopy Following Concussion
SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE
LA English
DT Meeting Abstract
CT 61st Annual Meeting of the American-College-of-Sports-Medicine
CY APR 01-04, 2014
CL Atlanta, GA
SP Amer Coll Sports Med
C1 [La Fountaine, Michael F.; Toda, Michita; Testa, Anthony] Seton Hall Univ, S Orange, NJ 07079 USA.
   [Bauman, William A.] James J Peters VA Med Ctr, Bronx, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0195-9131
EI 1530-0315
J9 MED SCI SPORT EXER
JI Med. Sci. Sports Exerc.
PD MAY
PY 2014
VL 46
IS 5
SU 1
MA 3202
BP 865
EP 865
PG 1
WC Sport Sciences
SC Sport Sciences
GA AL4PW
UT WOS:000339115905458
ER

PT J
AU Sittig, DF
   Ash, JS
   Singh, H
AF Sittig, Dean F.
   Ash, Joan S.
   Singh, Hardeep
TI The SAFER Guides: Empowering Organizations to Improve the Safety and
   Effectiveness of Electronic Health Records
SO AMERICAN JOURNAL OF MANAGED CARE
LA English
DT Article
ID PROVIDER ORDER ENTRY; PATIENT-SAFETY; FOLLOW-UP; INFORMATICS; SYSTEMS
AB Electronic health records (EHRs) have potential to improve quality and safety of healthcare. However, EHR users have experienced safety concerns from EHR design and usability features that are not optimally adapted for the complex work flow of real-world practice. Few strategies exist to address unintended consequences from implementation of EHRs and other health information technologies. We propose that organizations equipped with EHRs should consider the strategy of "proactive risk assessment" of their EHR-enabled healthcare system to identify and address EHR-related safety concerns. In this paper, we describe the conceptual underpinning of an EHR-related self-assessment strategy to provide institutions a foundation upon which they could build their safety efforts. With support from the Office of the National Coordinator for Health Information Technology (ONC), we used a rigorous, iterative process to develop a set of 9 self-assessment tools to optimize the safety and safe use of EHRs. These tools,referred to as the Safety Assurance Factors for EHR Resilience (SAFER) guides, could be used to self-assess safety and effectiveness of EHR implementations, identify specific areas of vulnerability, and create solutions and culture change to mitigate risks. A variety of audiences could conduct these assessments, including frontline clinicians or care teams in different practices, or clinical, quality, or administrative leaders within larger institutions. The guides use a multifaceted systems-based approach to assess risk and empower organizations to work with internal or external stakeholders (eg, EHR developers) on optimizing EHR functionality and using EHRs to drive improvements in the quality and safety of healthcare.
C1 [Sittig, Dean F.] Univ Texas Hlth Sci Ctr Houston, Houstons Sch Biomed Informat, Houston, TX 77030 USA.
   [Sittig, Dean F.] UT Mem Hermann Ctr Healthcare Qual & Safety, Houston, TX 77030 USA.
   [Ash, Joan S.] Oregon Hlth & Sci Univ, Sch Med, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA.
   [Singh, Hardeep] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston Vet Adm Hlth Serv Res, Houston, TX 77030 USA.
   [Singh, Hardeep] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dev Ctr Innovat Qual Effectiveness & Safety, Houston, TX 77030 USA.
   [Singh, Hardeep] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA.
RP Sittig, DF (reprint author), UT Mem Hermann Ctr Healthcare Qual & Safety, 6410 Fannin St,UTPB 1100-43, Houston, TX 77030 USA.
EM dean.f.sittig@uth.tmc.edu
FU Westat - Office of the National Coordinator for Health Information
   Technology (ONC) [HHSP-23320095655WC0095655, HH-SP23337003T]; Department
   of Veterans Affairs, Veterans Health Administration, Office of Research
   and Development; Center for Innovations in Quality, Effectiveness and
   Safety [CIN 13-413]
FX Source of Funding:. The SAFER project is supported through a subcontract
   from Westat (HHSP-23320095655WC0095655; Anticipating the Unintended
   Consequences of Health IT) funded by the Office of the National
   Coordinator for Health Information Technology (ONC) (HH-SP23337003T; to
   Drs Sittig, Ash, and Singh). Dr Singh was supported in part by the
   Department of Veterans Affairs, Veterans Health Administration, Office
   of Research and Development and the Center for Innovations in Quality,
   Effectiveness and Safety (CIN 13-413).
NR 32
TC 14
Z9 14
U1 2
U2 5
PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC
PI PLAINSBORO
PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA
SN 1088-0224
J9 AM J MANAG CARE
JI Am. J. Manag. Care
PD MAY
PY 2014
VL 20
IS 5
BP 418
EP 423
PG 6
WC Health Care Sciences & Services; Health Policy & Services; Medicine,
   General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AL5AV
UT WOS:000339146800012
PM 25181570
ER

PT J
AU Barnett, PG
   Chow, A
   Joyce, VR
   Bayoumi, AM
   Griffin, SC
   Sun, H
   Holodniy, M
   Brown, ST
   Cameron, DW
   Sculpher, M
   Youle, M
   Anis, AH
   Owens, DK
AF Barnett, Paul G.
   Chow, Adam
   Joyce, Vilija R.
   Bayoumi, Ahmed M.
   Griffin, Susan C.
   Sun, Huiying
   Holodniy, Mark
   Brown, Sheldon T.
   Cameron, D. William
   Sculpher, Mark
   Youle, Mike
   Anis, Aslam H.
   Owens, Douglas K.
TI Effect of Management Strategies and Clinical Status on Costs of Care for
   Advanced HIV
SO AMERICAN JOURNAL OF MANAGED CARE
LA English
DT Article
ID ACTIVE ANTIRETROVIRAL THERAPY; INFECTED PATIENTS; HEALTH-CARE; LIFETIME
   COST; UNITED-STATES; ERA; EXPENDITURES; MEDICAID; PATTERNS; MODELS
AB Objectives
   To determine the association between preexisting characteristics and current health and the cost of different types of advanced human immunodeficiency virus (HIV) care.
   Methods
   Treatment-experienced patients failing highly active antiretroviral treatment (ART) in the United States, Canada, and the United Kingdom were factorial randomized to an antiretroviral-free period and ART intensification. Cost was estimated by multiplying patient-reported utilization by a unit cost.
   Results
   A total of 367 participants were followed for a mean of 15.3 quarters (range 1-26). Medication accounted for most (61.8%) of the $26,832 annual cost. Cost averaged $4147 per quarter for ART, $1981 for inpatient care, $580 for outpatient care, and $346 for other medications. Cost for inpatient stays, outpatient visits, and other medications was 171% higher (P<.01) and cost of ART was 32% lower (P<.01) when cluster of differentiation 4 (CD4) count was <50 cells/mu L compared with periods when CD4 count was >200 cells/mu L. Some baseline characteristics, including low CD4 count, high viral load, and HIV from injection drug use with hepatitis C coinfection, had a sustained effect on cost.
   Conclusions
   The association between health status and cost depended on the type of care. Indicators of poor health were associated with higher inpatient and concomitant medication costs and lower cost for ART medication. Although ART has supplanted hospitalization as the most important cost in HIV care, some patients continue to incur high hospitalization costs in periods when they are using less ART. The cost of interventions to improve the use of ART might be offset by the reduction of other costs.
C1 [Barnett, Paul G.; Chow, Adam; Joyce, Vilija R.] VA HSR&D Hlth Econ Res Ctr, VA Palo Alto Healthcare Syst, VA Cooperative Studies Program, Menlo Pk, CA 94025 USA.
   [Bayoumi, Ahmed M.] St Michaels Hosp, Ctr Res Inner City Hlth, Keenan Res Ctr, Li Ka Shing Knowledge Inst, Toronto, ON, Canada.
   [Bayoumi, Ahmed M.] St Michaels Hosp, Div Gen Internal Med, Toronto, ON, Canada.
   [Bayoumi, Ahmed M.] Univ Toronto, Dept Med, Dept Hlth Policy, Dept Management & Evaluat, Toronto, ON, Canada.
   [Griffin, Susan C.; Sculpher, Mark] Univ York, Ctr Hlth Econ, York, N Yorkshire, England.
   [Holodniy, Mark; Owens, Douglas K.] VA Palo Alto Healthcare Syst, Palo Alto, CA USA.
   [Owens, Douglas K.] Stanford Univ, Ctr Primary Care & Outcomes Res, Ctr Hlth Policy, Stanford, CA USA.
   [Brown, Sheldon T.] James J Peters VA Med Ctr, Bronx, NY USA.
   [Cameron, D. William] Univ Ottawa, Ottawa Hosp, Div Infect Dis, Ottawa, ON, Canada.
   [Youle, Mike] Royal Free Hosp, London, England.
   [Sun, Huiying; Anis, Aslam H.] CIHR, Canadian HIV Trials Network, Vancouver, BC, Canada.
   [Anis, Aslam H.] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada.
RP Barnett, PG (reprint author), HERC, VA Palo Alto Hlth Care Syst, 795 Willow Rd 152, Menlo Pk, CA 94025 USA.
EM paul.barnett@va.gov
RI Joyce, Vilija/A-2578-2013
OI Joyce, Vilija/0000-0002-2484-4625
FU US Department of Veterans Affairs Cooperative Studies Program; United
   Kingdom Medical Research Council; Canadian Institutes for Health
   Research
FX Source of Funding: US Department of Veterans Affairs Cooperative Studies
   Program, the United Kingdom Medical Research Council, and the Canadian
   Institutes for Health Research.
NR 36
TC 2
Z9 2
U1 0
U2 2
PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC
PI PLAINSBORO
PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA
SN 1088-0224
J9 AM J MANAG CARE
JI Am. J. Manag. Care
PD MAY
PY 2014
VL 20
IS 5
BP E129
EP E137
PG 9
WC Health Care Sciences & Services; Health Policy & Services; Medicine,
   General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AL5AV
UT WOS:000339146800002
PM 25326927
ER

PT J
AU Cerimele, JM
   Halperin, AC
   Saxon, AJ
AF Cerimele, Joseph M.
   Halperin, Abigail C.
   Saxon, Andrew J.
TI Tobacco Use Treatment in Primary Care Patients with Psychiatric Illness
SO JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE
LA English
DT Article
DE Mental Disorders; Tobacco Use Cessation
ID SMOKING-CESSATION PHARMACOTHERAPIES; RANDOMIZED CLINICAL-TRIAL; SEVERE
   MENTAL-ILLNESS; BIPOLAR DISORDER; CIGARETTE-SMOKING; MAJOR DEPRESSION;
   ANXIETY DISORDERS; HEALTH-SERVICES; UNITED-STATES; QUIT DAY
AB The prevalence of smoking is higher in patients with psychiatric illness compared with the general population. Smoking causes chronic illnesses, which lead to premature mortality in those with psychiatric illness, is associated with greater burden of psychiatric symptoms, and contributes to the social isolation experienced by individuals with psychiatric disorders. Most patients with a psychiatric illness present initially to primary care rather than specialty care settings, and some patients receive care exclusively in the primary care setting. Therefore, family physicians and other primary care clinicians have an important role in the recognition and treatment of tobacco use disorders in patients with psychiatric illnesses. In this article we review common myths associated with smoking and psychiatric illness, techniques for implementing evidence-based tobacco use treatments, the evidence base for tobacco use treatment for patients with specific psychiatric diagnoses, and factors to consider when treating tobacco use disorders in patients with psychiatric illness.
C1 [Cerimele, Joseph M.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
   [Halperin, Abigail C.] Univ Washington, Sch Med, Dept Family Med, Seattle, WA 98195 USA.
   [Halperin, Abigail C.] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA.
   [Saxon, Andrew J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
RP Cerimele, JM (reprint author), Univ Washington, Sch Med, Dept Psychiat & Behav Sci, 1959 NE Pacific St,Box 356560, Seattle, WA 98195 USA.
EM cerimele@uw.edu
FU National Institute of Mental Health [T-32 MH020021-16]
FX JMC is supported by a grant from the National Institute of Mental Health
   (T-32 MH020021-16).
NR 72
TC 3
Z9 4
U1 4
U2 12
PU AMER BOARD FAMILY MEDICINE
PI LEXINGTON
PA 2228 YOUNG DR, LEXINGTON, KY 40505 USA
SN 1557-2625
EI 1558-7118
J9 J AM BOARD FAM MED
JI J. Am. Board Fam. Med.
PD MAY-JUN
PY 2014
VL 27
IS 3
BP 399
EP 410
DI 10.3122/jabfm.2014.03.130252
PG 12
WC Primary Health Care; Medicine, General & Internal
SC General & Internal Medicine
GA AL5IL
UT WOS:000339167000015
PM 24808119
ER

PT J
AU Wang, J
   Mathalon, DH
   Roach, BJ
   Reilly, J
   Keedy, SK
   Sweeney, JA
   Ford, JM
AF Wang, Jun
   Mathalon, Daniel H.
   Roach, Brian J.
   Reilly, James
   Keedy, Sarah K.
   Sweeney, John A.
   Ford, Judith M.
TI Action planning and predictive coding when speaking
SO NEUROIMAGE
LA English
DT Article
DE Corollary discharge; Efference copy; IFG; STG
ID HUMAN AUDITORY-CORTEX; COROLLARY DISCHARGE DYSFUNCTION; SPEECH
   PRODUCTION; NEUROMAGNETIC RESPONSES; OWN VOICE; SCHIZOPHRENIA; FEEDBACK;
   EEG; DYNAMICS; SOUNDS
AB Across the animal kingdom, sensations resulting from an animal's own actions are processed differently from sensations resulting from external sources, with self-generated sensations being suppressed. A forward model has been proposed to explain this process across sensorimotor domains. During vocalization, reduced processing of one's own speech is believed to result from a comparison of speech sounds to corollary discharges of intended speech production generated from efference copies of commands to speak. Until now, anatomical and functional evidence validating this model in humans has been indirect. Using EEG with anatomical MRI to facilitate source localization, we demonstrate that inferior frontal gyrus activity during the 300 ms before speaking was associated with suppressed processing of speech sounds in auditory cortex around 100 ms after speech onset (N1). These findings indicate that an efference copy from speech areas in prefrontal cortex is transmitted to auditory cortex, where it is used to suppress processing of anticipated speech sounds. About 100 ms after N1, a subsequent auditory cortical component (P2) was not suppressed during talking. The combined N1 and P2 effects suggest that although sensory processing is suppressed as reflected in N1, perceptual gaps may be filled as reflected in the lack of P2 suppression, explaining the discrepancy between sensory suppression and preserved sensory experiences. These findings, coupled with the coherence between relevant brain regions before and during speech, provide new mechanistic understanding of the complex interactions between action planning and sensory processing that provide for differentiated tagging and monitoring of one's own speech, processes disrupted in neuropsychiatric disorders. Published by Elsevier Inc.
C1 [Wang, Jun; Sweeney, John A.] Univ Texas Southwestern, Dept Psychiat, Dallas, TX 75390 USA.
   [Mathalon, Daniel H.; Roach, Brian J.; Ford, Judith M.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
   [Mathalon, Daniel H.; Ford, Judith M.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA.
   [Reilly, James] Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA.
   [Keedy, Sarah K.] Univ Chicago, Dept Psychiat & Behav Neurosci, Chicago, IL 60637 USA.
RP Ford, JM (reprint author), San Francisco VA Med Ctr, Psychiat Serv 116D, 4150 Clement St, San Francisco, CA 94121 USA.
EM Judith.ford@ucsf.edu
RI Keedy, Sarah/H-6557-2014
OI Keedy, Sarah/0000-0002-2139-9271; Roach, Brian/0000-0002-3264-1465
FU NIMH [MH077862, MH085485, MH058262]
FX This work was supported by grants from NIMH MH077862, MH085485, and
   MH058262. We thank Brett Clementz for comments on an early draft.
NR 62
TC 15
Z9 15
U1 6
U2 19
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
EI 1095-9572
J9 NEUROIMAGE
JI Neuroimage
PD MAY 1
PY 2014
VL 91
BP 91
EP 98
DI 10.1016/j.neuroimage.2014.01.003
PG 8
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
   Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA AL1VJ
UT WOS:000338914100011
PM 24423729
ER

PT J
AU Johnson, HM
   Thorpe, CT
   Bartels, CM
   Schumacher, JR
   Palta, M
   Pandhi, N
   Sheehy, AM
   Smith, MA
AF Johnson, Heather M.
   Thorpe, Carolyn T.
   Bartels, Christie M.
   Schumacher, Jessica R.
   Palta, Mari
   Pandhi, Nancy
   Sheehy, Ann M.
   Smith, Maureen A.
TI Antihypertensive Medication Initiation Among Young Adults with Regular
   Primary Care Use
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE hypertension; ambulatory care; disease management
ID BLOOD-PRESSURE; UNITED-STATES; CARDIOVASCULAR-DISEASE; HYPERTENSION
   TREATMENT; ADMINISTRATIVE DATA; DRUG-THERAPY; RISK-FACTORS; IMPACT;
   COMORBIDITIES; OPPORTUNITIES
AB BACKGROUND: Young adults with hypertension have the lowest prevalence of controlled blood pressure compared to middle-aged and older adults. Uncontrolled hypertension, even among young adults, increases future cardiovascular event risk. However, antihypertensive medication initiation is poorly understood among young adults and may be an important intervention point for this group.
   OBJECTIVE: The purpose of this study was to compare rates and predictors of antihypertensive medication initiation between young adults and middle-aged and older adults with incident hypertension and regular primary care contact.
   DESIGN: A retrospective analysis
   PARTICIPANTS: Adults >= 18 years old (n=10,022) with incident hypertension and no prior antihypertensive prescription, who received primary care at a large, Midwestern, academic practice from 2008-2011.
   MAIN MEASURES: The primary outcome was time from date of meeting hypertension criteria to antihypertensive medication initiation, or blood pressure normalization without medication. Kaplan-Meier analysis was used to estimate the probability of antihypertensive medication initiation over time. Cox proportional-hazard models (HR; 95 % CI) were fit to identify predictors of delays in medication initiation, with a subsequent subpopulation analysis for young adults (18-39 years old).
   KEY RESULTS: After a mean follow-up of 20 (+/- 13) months, 34 % of 18-39 year-olds with hypertension met the endpoint, compared to 44 % of 40-59 year-olds and 56 % of >= 60 year-olds. Adjusting for patient and provider factors, 18-39 year-olds had a 44 % slower rate of medication initiation (HR 0.56; 0.47-0.67) than >= 60 year-olds. Among young adults, males, patients with mild hypertension, and White patients had a slower rate of medication initiation. Young adults with Medicaid and more clinic visits had faster rates.
   CONCLUSIONS: Even with regular primary care contact and continued elevated blood pressure, young adults had slower rates of antihypertensive medication initiation than middle-aged and older adults. Interventions are needed to address multifactorial barriers contributing to poor hypertension control among young adults.
C1 [Johnson, Heather M.; Bartels, Christie M.; Sheehy, Ann M.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53792 USA.
   [Johnson, Heather M.; Bartels, Christie M.; Schumacher, Jessica R.; Pandhi, Nancy; Sheehy, Ann M.; Smith, Maureen A.] Univ Wisconsin, Sch Med & Publ Hlth, Hlth Innovat Program, Madison, WI 53792 USA.
   [Thorpe, Carolyn T.] Vet Affairs Pittsburgh Healthcare Syst, Hlth Serv Res & Dev, Pittsburgh, PA USA.
   [Thorpe, Carolyn T.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA.
   [Schumacher, Jessica R.; Palta, Mari; Smith, Maureen A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI 53792 USA.
   [Palta, Mari] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI 53792 USA.
   [Pandhi, Nancy; Smith, Maureen A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Family Med, Madison, WI 53792 USA.
   [Smith, Maureen A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, Madison, WI 53792 USA.
   [Johnson, Heather M.] Univ Wisconsin, Sch Med & Publ Hlth, Div Cardiovasc Med, Madison, WI 53792 USA.
RP Johnson, HM (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Div Cardiovasc Med, H4-512 CSC,MC 3248,600 Highland Ave, Madison, WI 53792 USA.
EM hm2@medicine.wisc.edu
OI Johnson, Heather/0000-0002-4916-3519
FU Clinical and Translational Science Award (CTSA) program [UL1RR025011];
   National Center for Advancing Translational Sciences (NCATS) of the
   National Institutes of Health [U54TR000021]; National Heart, Lung, and
   Blood Institute of the National Institutes of Health [K23HL112907];
   University of Wisconsin Centennial Scholars Program of the University of
   Wisconsin School of Medicine and Public Health; National Institute of
   Arthritis and Musculoskeletal and Skin Diseases of the National
   Institutes of Health [K23AR062381]; National Institute on Aging of the
   National Institutes of Health [K08AG029527]; University of Wisconsin
   Health Innovation Program; University of Wisconsin School of Medicine
   and Public Health from The Wisconsin Partnership Program
FX Research reported in this manuscript was supported by the Clinical and
   Translational Science Award (CTSA) program, previously through the
   National Center for Research Resources (NCRR) under award number
   UL1RR025011, and now by the National Center for Advancing Translational
   Sciences (NCATS) of the National Institutes of Health under award number
   U54TR000021. Heather Johnson is supported by the National Heart, Lung,
   and Blood Institute of the National Institutes of Health under award
   number K23HL112907, and also by the University of Wisconsin Centennial
   Scholars Program of the University of Wisconsin School of Medicine and
   Public Health. Christie Bartels is supported by the National Institute
   of Arthritis and Musculoskeletal and Skin Diseases of the National
   Institutes of Health under award number K23AR062381. Nancy Pandhi is
   supported by the National Institute on Aging of the National Institutes
   of Health under award number K08AG029527. The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the National Institutes of Health.; Additional funding
   for this project was provided by the University of Wisconsin Health
   Innovation Program and the University of Wisconsin School of Medicine
   and Public Health from The Wisconsin Partnership Program.
NR 42
TC 11
Z9 11
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD MAY
PY 2014
VL 29
IS 5
BP 723
EP 731
DI 10.1007/s11606-014-2790-4
PG 9
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AK1VL
UT WOS:000338205700012
PM 24493322
ER

PT J
AU Sen, AP
   Sewell, TB
   Riley, EB
   Stearman, B
   Bellamy, SL
   Hu, MF
   Tao, YY
   Zhu, JS
   Park, JD
   Loewenstein, G
   Asch, DA
   Volpp, KG
AF Sen, Aditi P.
   Sewell, Taylor B.
   Riley, E. Brooks
   Stearman, Beth
   Bellamy, Scarlett L.
   Hu, Michelle F.
   Tao, Yuanyuan
   Zhu, Jingsan
   Park, James D.
   Loewenstein, George
   Asch, David A.
   Volpp, Kevin G.
TI Financial Incentives for Home-Based Health Monitoring: A Randomized
   Controlled Trial
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE chronic disease; health information technology; health behavior; disease
   management; adherence
ID IMPROVE WARFARIN ADHERENCE; LONGITUDINAL DATA-ANALYSIS;
   DIABETIC-PATIENTS; HEART-FAILURE; BLOOD-GLUCOSE; WEIGHT-LOSS; LOTTERY;
   INSULIN; REWARD; REGRET
AB BACKGROUND: Home wireless device monitoring could play an important role in improving the health of patients with poorly controlled chronic diseases, but daily engagement rates among these patients may be low.
   OBJECTIVE: To test the effectiveness of two different magnitudes of financial incentives for improving adherence to remote-monitoring regimens among patients with poorly controlled diabetes.
   DESIGN: Randomized, controlled trial. (Clinicaltrials.govIdentifier: NCT01282957).
   PARTICIPANTS: Seventy-five patients with a hemoglobin A1c greater than or equal to 7.5 % recruited from a Primary Care Medical Home practice at the University of Pennsylvania Health System.
   INTERVENTIONS: Twelve weeks of daily home-monitoring of blood glucose, blood pressure, and weight (control group; n=28); a lottery incentive with expected daily value of $2.80 (n=26) for daily monitoring; and a lottery incentive with expected daily value of $1.40 (n=21) for daily monitoring.
   MAIN MEASURES: Daily use of three home-monitoring devices during the three-month intervention (primary outcome) and during the three-month follow-up period and change in A1c over the intervention period (secondary outcomes).
   KEY RESULTS: Incentive arm participants used devices on a higher proportion of days relative to control (81 % low incentive vs. 58 %, P=0.007; 77 % high incentive vs. 58 %, P=0.02) during the three-month intervention period. There was no difference in adherence between the two incentive arms (P=0.58). When incentives were removed, adherence in the high incentive arm declined while remaining relatively high in the low incentive arm. In month 6, the low incentive arm had an adherence rate of 62 % compared to 35 % in the high incentive arm (P=0.015) and 27 % in the control group (P=0.002).
   CONCLUSIONS: A daily lottery incentive worth $1.40 per day improved monitoring rates relative to control and had significantly better efficacy once incentives were removed than a higher incentive.
C1 [Sen, Aditi P.; Stearman, Beth; Tao, Yuanyuan; Zhu, Jingsan; Loewenstein, George; Asch, David A.; Volpp, Kevin G.] Penn CMU Roybal P30 Ctr Behav Econ & Hlth, Philadelphia, PA USA.
   [Sen, Aditi P.; Stearman, Beth; Tao, Yuanyuan; Zhu, Jingsan; Loewenstein, George; Asch, David A.; Volpp, Kevin G.] Leonard Davis Inst Ctr Hlth Incent & Behav Econ, Philadelphia, PA USA.
   [Sen, Aditi P.; Sewell, Taylor B.; Asch, David A.; Volpp, Kevin G.] Univ Penn, Wharton Sch, Dept Hlth Care Management, Philadelphia, PA 19104 USA.
   [Sewell, Taylor B.; Riley, E. Brooks; Hu, Michelle F.; Tao, Yuanyuan; Zhu, Jingsan; Park, James D.; Asch, David A.; Volpp, Kevin G.] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA.
   [Stearman, Beth] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
   [Bellamy, Scarlett L.] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
   [Park, James D.] Rutgers, Robert Wood Johnson Med Sch, Camden, NJ USA.
   [Loewenstein, George] Carnegie Mellon Univ, Dept Social & Decis Sci, Pittsburgh, PA 15213 USA.
   [Asch, David A.; Volpp, Kevin G.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
RP Sen, AP (reprint author), Univ Penn, Wharton Sch, Dept Hlth Care Management, 3461 Locust Walk, Philadelphia, PA 19104 USA.
EM Aditisen@wharton.upenn.edu
OI Asch, David/0000-0002-7970-286X
FU National Institute on Aging [RC2AG036592, P30AG034546]
FX This work was supported by grants RC2AG036592 and P30AG034546 from the
   National Institute on Aging.
NR 26
TC 12
Z9 12
U1 3
U2 17
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD MAY
PY 2014
VL 29
IS 5
BP 770
EP 777
DI 10.1007/s11606-014-2778-0
PG 8
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AK1VL
UT WOS:000338205700018
PM 24522623
ER

PT J
AU Yano, EM
AF Yano, Elizabeth M.
TI Teaching Commentary on "A Primary Care-Based Multidisciplinary
   Readmission Prevention Program": Essential Aspects of Comparability and
   Context in Practice-Based Program Evaluation
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Editorial Material
ID HEALTH-CARE; IMPLEMENTATION; SCIENCE
C1 [Yano, Elizabeth M.] VA Greater Los Angeles Healthcare Syst, VA HSR&D Ctr Study Healthcare Innovat Implementat, Sepulveda, CA 91343 USA.
   [Yano, Elizabeth M.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA.
RP Yano, EM (reprint author), VA Greater Los Angeles Healthcare Syst, VA HSR&D Ctr Study Healthcare Innovat Implementat, 16111 Plummer St,Mailcode 152, Sepulveda, CA 91343 USA.
EM Elizabeth.yano@va.gov
NR 22
TC 0
Z9 0
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD MAY
PY 2014
VL 29
IS 5
BP 805
EP 807
DI 10.1007/s11606-014-2820-2
PG 3
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AK1VL
UT WOS:000338205700026
PM 24627269
ER

PT J
AU Chiovaro, J
   Douglas, V
   Gaggar, A
   Dhaliwal, G
AF Chiovaro, Joseph
   Douglas, Vanja
   Gaggar, Anuj
   Dhaliwal, Gurpreet
TI Exhausting the Differential
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Editorial Material
DE cerebral aneurysms; motor weakness; dyspnea
ID PROBLEM REPRESENTATION; MYASTHENIA-GRAVIS; SIGN-OUT; STRATEGIES;
   RECOMMENDATIONS; QUALITY; CARE
C1 [Chiovaro, Joseph] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA.
   [Chiovaro, Joseph] Portland VA Med Ctr, Portland, OR USA.
   [Douglas, Vanja] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
   [Gaggar, Anuj; Dhaliwal, Gurpreet] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
   [Dhaliwal, Gurpreet] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Chiovaro, J (reprint author), P3 Med Portland VA Med Ctr, Dept Med, 3710 Southwest US Vet Hosp Rd, Portland, OR 97239 USA.
EM jchiovaro@gmail.com
NR 13
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD MAY
PY 2014
VL 29
IS 5
BP 808
EP 812
DI 10.1007/s11606-013-2730-8
PG 5
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AK1VL
UT WOS:000338205700027
PM 24395100
ER

PT J
AU Rhee, C
   Moradi, H
   Brunelli, S
   Jing, JN
   Nakata, T
   Nguyen, D
   Kovesdy, C
   Brent, G
   Kalantar-Zadeh, K
AF Rhee, Connie
   Moradi, Hamid
   Brunelli, Steven
   Jing, Jennie
   Nakata, Tracy
   Danh, Nguyen
   Kovesdy, Csaba
   Brent, Gregory
   Kalantar-Zadeh, Kamyar
TI ASSOCIATION BETWEEN ADIPONECTIN AND MORTALITY IN HEMODIALYSIS PATIENTS
   FROM THE MADRAD STUDY
SO NEPHROLOGY DIALYSIS TRANSPLANTATION
LA English
DT Meeting Abstract
CT 51st Congress of the
   European-Renal-Association(ERA)/European-Dialysis-and-Transplant-Associa
   tion (EDTA)
CY MAY 31-JUN 03, 2014
CL Amsterdam, NETHERLANDS
SP European Renal Assoc, European Dialysis & Transplant Assoc
C1 [Rhee, Connie; Moradi, Hamid; Jing, Jennie; Nakata, Tracy; Danh, Nguyen; Kalantar-Zadeh, Kamyar] Univ Calif Irvine, Orange, CA 92668 USA.
   [Brunelli, Steven] Brigham & Womens Hosp, Boston, MA 02115 USA.
   [Kovesdy, Csaba] Memphis VA Med Ctr, Memphis, TN USA.
   [Brent, Gregory] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0931-0509
EI 1460-2385
J9 NEPHROL DIAL TRANSPL
JI Nephrol. Dial. Transplant.
PD MAY
PY 2014
VL 29
SU 3
MA SP604
BP 274
EP 274
PG 1
WC Transplantation; Urology & Nephrology
SC Transplantation; Urology & Nephrology
GA AJ9FQ
UT WOS:000338013501083
ER

PT J
AU Vistamehr, A
   Kautz, SA
   Neptune, RR
AF Vistamehr, Arian
   Kautz, Steven A.
   Neptune, Richard R.
TI The influence of solid ankle-foot-orthoses on forward propulsion and
   dynamic balance in healthy adults during walking
SO CLINICAL BIOMECHANICS
LA English
DT Article
DE Gait; Orthotic; AFO; Angular momentum; Biomechanics
ID PLANE ANGULAR-MOMENTUM; HEMIPARETIC PATIENTS; MUSCLE CONTRIBUTIONS;
   HEMIPLEGIC PATIENTS; FRONTAL-PLANE; PUSH-OFF; GAIT; BODY; PROGRESSION;
   SUPPORT
AB Background: In post-stroke hemiparetic subjects, solid polypropylene ankle-foot-orthoses are commonly prescribed to assist in foot clearance during swing while bracing the ankle during stance. Mobility demands, such as changing walking speed and direction, are accomplished by accelerating or decelerating the body and maintaining dynamic balance. Previous studies have shown that the ankle plantarflexors are primary contributors to these essential biomechanical functions. Thus, with ankle-foot-orthoses limiting ankle motion and plantarflexor output during stance, execution of these walking subtasks may be compromised. This study examined the influence of a solid polypropylene ankle-foot-orthosis on forward propulsion and dynamic balance in healthy adults.
   Methods: Kinematic and kinetic data were recorded from 10 healthy adults walking with and without a unilateral ankle-foot-orthosis at steady-state slow (0.6 m/s) and moderate (1.2 m/s) speeds, and during accelerated (0-1.8 m/s at 0.06 m/s(2)) and decelerated (1.8-0 m/s at - 0.06 m/s(2)) walking. Propulsion was quantified by propulsive and braking impulses (i.e., time integral of the anterior-posterior ground reaction force) while dynamic balance was quantified by the peak-to-peak range of whole-body angular momentum.
   Findings: The propulsive impulses decreased in the leg with ankle-foot-orthosis compared to the contralateral leg and no ankle-foot-orthosis condition. Further, the ankle-foot-orthosis resulted in a greater range of angular momentum in both the frontal and sagittal planes, which were correlated with the reduced peak hip abduction and reduced ankle plantarflexor moments, respectively.
   Interpretation: Solid ankle-foot-orthoses limit the successful execution of important mobility subtasks in healthy adults and that the prescription of ankle-foot-orthosis should be carefully considered. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Vistamehr, Arian; Neptune, Richard R.] Univ Texas Austin, Dept Mech Engn, Austin, TX 78712 USA.
   [Kautz, Steven A.] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA.
   [Kautz, Steven A.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
RP Neptune, RR (reprint author), Univ Texas Austin, Dept Mech Engn, 204 E Dean Keeton St,Stop C2200, Austin, TX 78712 USA.
EM rneptune@mail.utexas.edu
OI Kautz, Steven/0000-0003-3151-8235
FU American Heart Association SouthWest Affiliate pre-doctoral fellowship
   [12PRE12030414]; Ralph H. Johnson VA Medical Center; Office of Research
   and Development, Rehabilitation Research and Development, U.S.
   Department of Veterans Affairs
FX The authors are grateful to the members of the Locomotion Energetics and
   Assessment Lab in the Center for Rehabilitation Research in Neurological
   Conditions at the Medical University of South Carolina for their help
   with subject recruitment and data collection. This work was supported by
   an American Heart Association SouthWest Affiliate pre-doctoral
   fellowship (12PRE12030414) and supported in part by the Ralph H. Johnson
   VA Medical Center and the Office of Research and Development,
   Rehabilitation Research and Development, U.S. Department of Veterans
   Affairs. The contents are solely the responsibility of the authors and
   do not necessarily represent the official views of the AHA or the VA.
NR 35
TC 4
Z9 5
U1 4
U2 29
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0268-0033
EI 1879-1271
J9 CLIN BIOMECH
JI Clin. Biomech.
PD MAY
PY 2014
VL 29
IS 5
BP 583
EP 589
DI 10.1016/j.clinbiomech.2014.02.007
PG 7
WC Engineering, Biomedical; Orthopedics; Sport Sciences
SC Engineering; Orthopedics; Sport Sciences
GA AJ7MN
UT WOS:000337880900017
PM 24698166
ER

PT J
AU Bowles, DW
   McDermott, JD
   Jimeno, A
AF Bowles, Daniel W.
   McDermott, Jessica D.
   Jimeno, Antonio
TI Novel treatments for head and neck squamous cell carcinoma: preclinical
   identification and clinical investigation
SO FUTURE ONCOLOGY
LA English
DT Review
DE c-MET; EGFR; head and neck squamous cell carcinoma; Hedgehog; human
   papillomavirus; immunotherapy; Notch; PI3K; tyrosine kinase inhibitors
ID GROWTH-FACTOR RECEPTOR; EPITHELIAL-MESENCHYMAL TRANSITION; REGULATORY
   T-CELLS; PHASE-II TRIAL; HUMAN-PAPILLOMAVIRUS INFECTION; CHEMOTHERAPY
   PLUS CETUXIMAB; ADVANCED SOLID TUMORS; HPV-ASSOCIATED HEAD;
   OROPHARYNGEAL CANCER; C-MET
AB Head and neck squamous cell carcinoma (HNSCC) is a common cancer worldwide. Classically, it is a disease related to tobacco and alcohol use; an increasing number of patients are being diagnosed with HNSCC caused by infection with the human papillomavirus. New deep-sequencing techniques have confirmed the importance of p53 and EGF receptor in HNSCC development, and have identified pathways of critical importance, such as PI3K/mTOR and NOTCH. Increasing knowledge of key molecular features has lead to new therapeutic avenues for HNSCC. Novel therapies under investigation in HNSCC include antibody and small molecule inhibitors of EGF receptor and its family members, PI3K inhibitors, antiangiogenic agents, immunotherapies and agents interacting with early developmental pathways such as Hedgehog.
C1 [Bowles, Daniel W.; McDermott, Jessica D.; Jimeno, Antonio] Univ Colorado, Div Med Oncol, Sch Med, Boulder, CO 80309 USA.
   [Bowles, Daniel W.] Eastern Colorado Hlth Care Syst, Denver Vet Affairs Med Ctr, Denver, CO USA.
RP Jimeno, A (reprint author), Univ Colorado, Div Med Oncol, Sch Med, Boulder, CO 80309 USA.
EM antonio.jimeno@ucdenver.edu
NR 161
TC 4
Z9 5
U1 1
U2 6
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1479-6694
EI 1744-8301
J9 FUTURE ONCOL
JI Future Oncol.
PD MAY
PY 2014
VL 10
IS 6
BP 1065
EP 1080
DI 10.2217/fon.14.18
PG 16
WC Oncology
SC Oncology
GA AJ8FO
UT WOS:000337938300020
PM 24941990
ER

PT J
AU Suhler, EB
   Lim, LL
   Beardsley, RM
   Giles, TR
   Pasadhilka, S
   Lee, ST
   Saint Sardos, AD
   Butler, NJ
   Smith, JR
   Rosenbaum, JT
AF Suhler, Eric B.
   Lim, Lyndell L.
   Beardsley, Robert M.
   Giles, Tracy R.
   Pasadhilka, Sirichai
   Lee, Shelly T.
   Saint Sardos, Alexandre de
   Butler, Nicholas J.
   Smith, Justine R.
   Rosenbaum, James T.
TI Rituximab Therapy for Refractory Orbital Inflammation Results of a Phase
   1/2, Dose-Ranging, Randomized Clinical Trial
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID RHEUMATOID-ARTHRITIS; EYE DISEASE; EFFICACY; MANAGEMENT;
   CYCLOPHOSPHAMIDE; VASCULITIS; RADIATION; SAFETY
AB IMPORTANCE Orbital inflammation is a potentially blinding and disfiguring disease process that is often treated with systemic corticosteroids and immunosuppression; better treatments are needed.
   OBJECTIVE To determine whether rituximab, a monoclonal antibody against the B-lymphocyte antigen CD20, is effective in the treatment of refractory orbital inflammation.
   DESIGN, SETTING, AND PARTICIPANTS A dose-ranging, randomized, double-masked phase 1/2 clinical trial was conducted at a tertiary referral ophthalmology clinic. Ten individuals with orbital inflammation refractory to systemic corticosteroids and at least 1 other immunosuppressive agent were enrolled from January 2007 to March 2010. INTERVENTIONS Rituximab infusions were administered on study days 1 and 15 at doses of either 500 mg or 1000 mg. Initial responders with recurrent inflammation after week 24 were permitted reinfusion with an additional cycle of 2 open-label 1000-mg rituximab infusions.
   MAIN OUTCOMES AND MEASURES The primary outcomes were reduction of inflammation measured with a validated orbital disease grading scale and corticosteroid dose reduction by at least 50%. The secondary outcomes were visual acuity, reduction in pain, and participantand physician-reported global health assessment.
   RESULTS Of 10 enrolled patients, 7 demonstrated improvement on the orbital disease grading scale at the 24-week end point with rituximab therapy. Of these 7 individuals, 4 were receiving corticosteroids at study inception and all achieved successful dose reduction. For the secondary outcome measures in the 10 participants, 7 patients and 8 patients improved in self-rated and physician global health scores, respectively, and 7 patients had reduction in pain by 25% or more at 24 weeks. Four patients who were positive responders at the week 24 end point experienced breakthrough inflammation after week 24 and received reinfusions between 24 and 48 weeks. Vision remained stable in all participants. Three of 10 patients had short-term objective or subjective worsening 2 to 8 weeks after receiving rituximab infusions, which was averted in subsequent patients with oral corticosteroids administered during the infusion and did not affect the eventual positive treatment outcome. No significant differences with regard to efficacy, toxicity, or likelihood of retreatment were noted between the dosing arms.
   CONCLUSIONS AND RELEVANCE Rituximab was safe and effective in 7 of 10 patients with noninfectious orbital disease, although 4 required reinfusion with rituximab to maintain control of orbital inflammation. Substantial toxicity was not noted. Rituximab should be considered in the treatment of refractory orbital inflammation.
C1 [Suhler, Eric B.] Portland VA Med Ctr, Portland, OR USA.
   [Suhler, Eric B.; Lim, Lyndell L.; Beardsley, Robert M.; Giles, Tracy R.; Pasadhilka, Sirichai; Lee, Shelly T.; Saint Sardos, Alexandre de; Butler, Nicholas J.; Smith, Justine R.; Rosenbaum, James T.] Oregon Hlth & Sci Univ, Dept Ophthalmol, Casey Eye Inst, Portland, OR 97239 USA.
   [Suhler, Eric B.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97239 USA.
   [Suhler, Eric B.; Lim, Lyndell L.] Univ Melbourne, Dept Ophthalmol, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Lim, Lyndell L.] Royal Victorian Eye & Ear Hosp, Dept Ophthalmol, Melbourne, Vic 3002, Australia.
   [Smith, Justine R.; Rosenbaum, James T.] Oregon Hlth & Sci Univ, Dept Cell Biol, Portland, OR 97201 USA.
   [Smith, Justine R.] Flinders Univ S Australia, Adelaide, SA 5001, Australia.
   [Rosenbaum, James T.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA.
   [Rosenbaum, James T.] Devers Eye Inst, Dept Ophthalmol, Portland, OR USA.
RP Suhler, EB (reprint author), Oregon Hlth & Sci Univ, Dept Ophthalmol, Casey Eye Inst, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA.
EM suhlere@ohsu.edu
OI Lim, Lyndell/0000-0003-2491-685X
FU Genentech, San Francisco, California; Department of Veterans' Affairs;
   Research to Prevent Blindness (unrestricted grant to Casey Eye
   Institute, Senior Scholar Award to Dr Rosenbaum); Rosenfeld Family
   Trust; William and Mary Bauman Foundation
FX Study expenses and drug were provided by Genentech, San Francisco,
   California. Additional research support was provided by the Department
   of Veterans' Affairs (Dr Suhler), Research to Prevent Blindness
   (unrestricted grant to Casey Eye Institute, Senior Scholar Award to Dr
   Rosenbaum), the Rosenfeld Family Trust (Dr Rosenbaum), and the William
   and Mary Bauman Foundation.
NR 32
TC 10
Z9 10
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD MAY
PY 2014
VL 132
IS 5
BP 572
EP 578
DI 10.1001/jamaophthalmol.2013.8179
PG 7
WC Ophthalmology
SC Ophthalmology
GA AJ7QW
UT WOS:000337892500009
PM 24652467
ER

PT J
AU Sanders, DS
   Read-Brown, S
   Tu, DC
   Lambert, WE
   Choi, D
   Almario, BM
   Yackel, TR
   Brown, AS
   Chiang, MF
AF Sanders, David S.
   Read-Brown, Sarah
   Tu, Daniel C.
   Lambert, William E.
   Choi, Dongseok
   Almario, Bella M.
   Yackel, Thomas R.
   Brown, Anna S.
   Chiang, Michael F.
TI Impact of an Electronic Health Record Operating Room Management System
   in Ophthalmology on Documentation Time, Surgical Volume, and Staffing
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID MEDICAL-RECORDS; INFORMATION-TECHNOLOGY; AMERICAN-ACADEMY; MEANINGFUL
   USE; PRIMARY-CARE; PHYSICIANS; EFFICIENCY; ADOPTION; COSTS; PAPER
AB IMPORTANCE Although electronic health record (EHR) systems have potential benefits, such as improved safety and quality of care, most ophthalmology practices in the United States have not adopted these systems. Concerns persist regarding potential negative impacts on clinical workflow. In particular, the impact of EHR operating room (OR) management systems on clinical efficiency in the ophthalmic surgery setting is unknown.
   OBJECTIVE To determine the impact of an EHR OR management system on intraoperative nursing documentation time, surgical volume, and staffing requirements.
   DESIGN. SETTING, AND PARTICIPANTS For documentation time and circulating nurses per procedure, a prospective cohort design was used between January 10, 2012, and January 10, 2013. For surgical volume and overall staffing requirements, a case series design was used between January 29, 2011, and January 28, 2013. This study involved ophthalmic OR nurses (n = 13) and surgeons (n = 25) at an academic medical center.
   EXPOSURES Electronic health record OR management system implementation.
   MAIN OUTCOMES AND MEASURES (1) Documentation time (percentage of operating time documenting [POTD], absolute documentation time in minutes), (2) surgical volume (procedures/time), and (3) staffing requirements (full-time equivalents, circulating nurses/procedure). Outcomes were measured during a baseline period when paper documentation was used and during the early (first 3 months) and late (4-12 months) periods after EHR implementation.
   RESULTS There was a worsening in total POTD in the early EHR period (83%) vs paper baseline (41%) (P <.001). This improved to baseline levels by the late EHR period (46%, P =.28), although POTD in the cataract group remained worse than at baseline (64%, P <.001). There was a worsening in absolute mean documentation time in the early EHR period (16.7 minutes) vs paper baseline (7.5 minutes) (P <.001). This improved in the late EHR period (9.2 minutes) but remained worse than in the paper baseline (P <.001). While cataract procedures required more circulating nurses in the early EHR (mean, 1.9 nurses/procedure) and late EHR (mean, 1.5 nurses/procedure) periods than in the paper baseline (mean, 1.0 nurses/procedure) (P <.001), overall staffing requirements and surgical volume were not significantly different between the periods.
   CONCLUSIONS AND RELEVANCE Electronic health record OR management system implementation was associated with worsening of intraoperative nursing documentation time especially in shorter procedures. However, it is possible to implement an EHR OR management system without serious negative impacts on surgical volume and staffing requirements.
C1 [Sanders, David S.; Read-Brown, Sarah; Tu, Daniel C.; Almario, Bella M.; Brown, Anna S.; Chiang, Michael F.] Oregon Hlth & Sci Univ, Casey Eye Inst, Dept Ophthalmol, Portland, OR 97239 USA.
   [Tu, Daniel C.] Portland VA Med Ctr, Operat Care Div, Portland, OR USA.
   [Lambert, William E.; Choi, Dongseok] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97239 USA.
   [Yackel, Thomas R.; Chiang, Michael F.] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97239 USA.
RP Chiang, MF (reprint author), Oregon Hlth & Sci Univ, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA.
EM chiangm@ohsu.edu
OI Read-Brown, Sarah/0000-0002-6526-2939
FU Research to Prevent Blindness (New York, New York); National Institutes
   of Health [EY10572]
FX This work was supported by unrestricted departmental funding from
   Research to Prevent Blindness (New York, New York) (Mr Sanders, Mss
   Read-Brown and Brown, and Drs Tu and Chiang). Dr Choi is supported by
   National Institutes of Health grant EY10572.
NR 33
TC 6
Z9 6
U1 5
U2 12
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD MAY
PY 2014
VL 132
IS 5
BP 586
EP 592
DI 10.1001/jamaophthalmol.2013.8196
PG 7
WC Ophthalmology
SC Ophthalmology
GA AJ7QW
UT WOS:000337892500011
PM 24676217
ER

PT J
AU Dingle, TC
   Clarridge, JE
AF Dingle, Tanis C.
   Clarridge, Jill E., III
TI Clinical Significance and Characterization of Haemophilus influenzae
   Type b Genogroup Isolates from Urine Samples in an Adult Male Population
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID HEMOPHILUS-INFLUENZAE; TRACT INFECTIONS; PARAINFLUENZAE; CHILDREN; MEN
AB The occurrence and significance of Haemophilus spp. isolated from the genitourinary tract are not well known. Herein, we describe the clinical significance and characteristics of Haemophilus influenzae type b genogroup strains isolated from genitourinary tract specimens from an adult male veteran patient population and, in particular, their associations with prostatitis and epididymitis.
C1 [Dingle, Tanis C.; Clarridge, Jill E., III] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA.
   [Clarridge, Jill E., III] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
RP Clarridge, JE (reprint author), Univ Washington, Dept Lab Med, Seattle, WA 98195 USA.
EM jill.clarridge@va.gov
NR 19
TC 2
Z9 2
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
EI 1098-660X
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD MAY
PY 2014
VL 52
IS 5
BP 1745
EP 1748
DI 10.1128/JCM.00506-14
PG 4
WC Microbiology
SC Microbiology
GA AJ7XV
UT WOS:000337915700069
PM 24599984
ER

PT J
AU Alzhanova, D
   Hammarlund, E
   Reed, J
   Meermeier, E
   Rawlings, S
   Ray, CA
   Edwards, DM
   Bimber, B
   Legasse, A
   Planer, S
   Sprague, J
   Axthelm, MK
   Pickup, DJ
   Lewinsohn, DM
   Gold, MC
   Wong, SW
   Sacha, JB
   Slifka, MK
   Fruh, K
AF Alzhanova, Dina
   Hammarlund, Erika
   Reed, Jason
   Meermeier, Erin
   Rawlings, Stephanie
   Ray, Caroline A.
   Edwards, David M.
   Bimber, Ben
   Legasse, Alfred
   Planer, Shannon
   Sprague, Jerald
   Axthelm, Michael K.
   Pickup, David J.
   Lewinsohn, David M.
   Gold, Marielle C.
   Wong, Scott W.
   Sacha, Jonah B.
   Slifka, Mark K.
   Frueh, Klaus
TI T Cell Inactivation by Poxviral B22 Family Proteins Increases Viral
   Virulence
SO PLOS PATHOGENS
LA English
DT Article
ID MONKEYPOX VIRUS; COWPOX VIRUS; CONGO BASIN; CLASS-I; IMMUNODEFICIENCY
   VIRUS; PROTECTIVE IMMUNITY; NONHUMAN PRIMATE; AFRICAN STRAINS;
   DOWN-REGULATION; WEST-AFRICAN
AB Infections with monkeypox, cowpox and weaponized variola virus remain a threat to the increasingly unvaccinated human population, but little is known about their mechanisms of virulence and immune evasion. We now demonstrate that B22 proteins, encoded by the largest genes of these viruses, render human T cells unresponsive to stimulation of the T cell receptor by MHC-dependent antigen presentation or by MHC-independent stimulation. In contrast, stimuli that bypass TCR-signaling are not inhibited. In a non-human primate model of monkeypox, virus lacking the B22R homologue (MPXV Delta 197) caused only mild disease with lower viremia and cutaneous pox lesions compared to wild type MPXV which caused high viremia, morbidity and mortality. Since MPXV Delta 197-infected animals displayed accelerated T cell responses and less T cell dysregulation than MPXV US2003, we conclude that B22 family proteins cause viral virulence by suppressing T cell control of viral dissemination.
C1 [Alzhanova, Dina; Reed, Jason; Rawlings, Stephanie; Edwards, David M.; Sprague, Jerald; Axthelm, Michael K.; Wong, Scott W.; Sacha, Jonah B.; Frueh, Klaus] Oregon Natl Primate Res Ctr, Vaccine & Gene Therapy Inst, Portland, OR 97239 USA.
   [Hammarlund, Erika; Slifka, Mark K.] Oregon Natl Primate Res Ctr, Div Neurosci, Portland, OR USA.
   [Meermeier, Erin; Lewinsohn, David M.; Gold, Marielle C.] Oregon Hlth & Sci Univ, Dept Pulm & Crit Care Med, Portland, OR 97201 USA.
   [Meermeier, Erin; Lewinsohn, David M.; Gold, Marielle C.] Portland VA Med Ctr, Portland, OR USA.
   [Ray, Caroline A.; Pickup, David J.] Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC USA.
   [Bimber, Ben; Legasse, Alfred; Planer, Shannon; Axthelm, Michael K.; Wong, Scott W.; Sacha, Jonah B.; Frueh, Klaus] Oregon Natl Primate Res Ctr, Div Pathobiol & Immunol, Portland, OR USA.
RP Alzhanova, D (reprint author), Oregon Natl Primate Res Ctr, Vaccine & Gene Therapy Inst, Portland, OR 97239 USA.
EM fruehk@ohsu.edu
RI Lewinsohn, David/I-4936-2013
OI Lewinsohn, David/0000-0001-9906-9494; Gold,
   Marielle/0000-0003-2505-3291; Meermeier, Erin/0000-0002-9709-7624
FU National Institute of Health [U19AI109948]; National Center for Research
   Resources [P51OD011092]; Office of Research Infrastructure Programs of
   the National Institutes of Health
FX This work was funded by grants U19AI109948 from the National Institute
   of Health and P51OD011092 from the National Center for Research
   Resources and the Office of Research Infrastructure Programs of the
   National Institutes of Health to KF and MKS and supported with resources
   and the use of facilities at the Portland VA Medical Center. The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
NR 60
TC 6
Z9 6
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7366
EI 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD MAY
PY 2014
VL 10
IS 5
AR e1004123
DI 10.1371/journal.ppat.1004123
PG 19
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA AJ5NX
UT WOS:000337732300034
PM 24832205
ER

PT J
AU Park, YD
   Shin, S
   Panepinto, J
   Ramos, J
   Qiu, J
   Frases, S
   Albuquerque, P
   Cordero, RJB
   Zhang, NN
   Himmelreich, U
   Beenhouwer, D
   Bennett, JE
   Casadevall, A
   Williamson, PR
AF Park, Yoon-Dong
   Shin, Soowan
   Panepinto, John
   Ramos, Jeanie
   Qiu, Jin
   Frases, Susana
   Albuquerque, Patricia
   Cordero, Radames J. B.
   Zhang, Nannan
   Himmelreich, Uwe
   Beenhouwer, David
   Bennett, John E.
   Casadevall, Arturo
   Williamson, Peter R.
TI A Role for LHC1 in Higher Order Structure and Complement Binding of the
   Cryptococcus neoformans Capsule
SO PLOS PATHOGENS
LA English
DT Article
ID POLYSACCHARIDE CAPSULE; MONOCLONAL-ANTIBODIES; FUSARIUM-OXYSPORUM;
   VIRULENCE FACTOR; LACCASE; CELL; ACTIVATION; COMPONENTS; INFECTION;
   STRAINS
AB Polysaccharide capsules are important virulence factors for many microbial pathogens including the opportunistic fungus Cryptococcus neoformans. In the present study, we demonstrate an unusual role for a secreted lactonohydrolase of C. neoformans, LHC1 in capsular higher order structure. Analysis of extracted capsular polysaccharide from wild-type and lhc1 (Delta) over bar strains by dynamic and static light scattering suggested a role for the LHC1 locus in altering the capsular polysaccharide, both reducing dimensions and altering its branching, density and solvation. These changes in the capsular structure resulted in LHC1-dependent alterations of antibody binding patterns, reductions in human and mouse complement binding and phagocytosis by the macrophage-like cell line J774, as well as increased virulence in mice. These findings identify a unique molecular mechanism for tertiary structural changes in a microbial capsule, facilitating immune evasion and virulence of a fungal pathogen.
C1 [Park, Yoon-Dong; Qiu, Jin; Zhang, Nannan; Bennett, John E.; Williamson, Peter R.] NIAID, Lab Clin Infect Dis, NIH, Bethesda, MD 20892 USA.
   [Shin, Soowan; Ramos, Jeanie; Williamson, Peter R.] Univ Illinois, Dept Med, Coll Med, Infect Dis Sect, Chicago, IL USA.
   [Panepinto, John] SUNY Buffalo, Dept Microbiol & Immunol, Buffalo, NY 14260 USA.
   [Frases, Susana; Albuquerque, Patricia; Cordero, Radames J. B.; Casadevall, Arturo] Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USA.
   [Frases, Susana; Albuquerque, Patricia; Cordero, Radames J. B.; Casadevall, Arturo] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Div Infect Dis, Bronx, NY 10467 USA.
   [Frases, Susana] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Lab Ultraestrutura Cellular Hertha Meyer, BR-21941 Rio De Janeiro, Brazil.
   [Himmelreich, Uwe] Katholieke Univ Leuven, Div Radiol, Dept Med Diagnost Sci, Biomed NMR Unit, Leuven, Belgium.
   [Beenhouwer, David] Vet Affairs Greater Los Angeles Healthcare Syst, Div Infect Dis, Los Angeles, CA USA.
   [Beenhouwer, David] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
RP Park, YD (reprint author), NIAID, Lab Clin Infect Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
EM williamsonpr@mail.nih.gov
RI Albuquerque, Patricia/H-1403-2011
OI Cordero, Radames JB/0000-0002-3026-7094
FU United States Public Health Service [NIH-AI45995, AI49371, AI007506,
   AI033142, AI47087, HL059842-3, A1033774, A1052733, AI033142.]; Flemish
   government [FWO G.0804.11]; KUL [PF10/017]; CAPES-Brazil; NIH, NIAID
FX This work was supported, in part, by United States Public Health Service
   Grants NIH-AI45995, AI49371, AI007506, AI033142, AI47087, HL059842-3,
   A1033774, A1052733, and AI033142. Flemish governmental funding FWO
   G.0804.11 and KUL funding PF10/017 and a CAPES-Brazil/Fulbright
   scholarship (PA). This research was also supported, in part, by the
   Intramural Research Program of the NIH, NIAID. The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
NR 60
TC 6
Z9 6
U1 1
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7366
EI 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD MAY
PY 2014
VL 10
IS 5
AR e1004037
DI 10.1371/journal.ppat.1004037
PG 13
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA AJ5NX
UT WOS:000337732300003
PM 24789368
ER

PT J
AU Turner, AP
   Sloan, AP
   Kivlahan, DR
   Haselkorn, JK
AF Turner, Aaron P.
   Sloan, Alicia P.
   Kivlahan, Daniel R.
   Haselkorn, Jodie K.
TI Telephone Counseling and Home Telehealth Monitoring to Improve
   Medication Adherence: Results of a Pilot Trial Among Individuals With
   Multiple Sclerosis
SO REHABILITATION PSYCHOLOGY
LA English
DT Article
DE multiple sclerosis; medication adherence; motivational interviewing;
   self-management; telehealth
ID DISEASE-MODIFYING THERAPIES; RANDOMIZED CONTROLLED-TRIAL; TRAUMATIC
   BRAIN-INJURY; QUALITY-OF-LIFE; INJECTION ANXIETY; CHRONIC ILLNESS;
   PRIMARY-CARE; SELF-INJECT; ALCOHOL-DEPENDENCE; DEPRESSION
AB Objective: To evaluate the impact upon medication adherence of brief telephone-based counseling using principles of motivational interviewing and telehealth home monitoring. Design: Randomized controlled pilot trial of 19 veterans with multiple sclerosis (MS) currently prescribed disease modifying therapy (DMT) who endorsed missing doses. Follow-up was conducted at 1, 3, and 6 months. Results: Participants in the intervention condition reported better adherence relative to controls at 6-month follow-up [M (SD) = 1.3 (2.1) vs. 8.2 (12.3) past month missed doses]. All participants in the intervention condition completed all 3 telephone counseling sessions and 90% or greater rated the program as highly successful. Conclusion: Brief telephone counseling represents a promising mechanism for improving medication adherence. The primary components, motivational interviewing and home telehealth monitoring, provided complementary mechanisms for initiating and sustaining behavior change over time. The intervention was well tolerated and provided an opportunity to extend access and reduce barriers to care by bringing it into the homes of participants.
C1 [Turner, Aaron P.; Sloan, Alicia P.; Kivlahan, Daniel R.; Haselkorn, Jodie K.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
   [Turner, Aaron P.; Sloan, Alicia P.; Haselkorn, Jodie K.] VA MS Ctr Excellence West, Seattle, WA USA.
   [Turner, Aaron P.; Kivlahan, Daniel R.] VA Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA USA.
   [Turner, Aaron P.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA.
   [Kivlahan, Daniel R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
   [Haselkorn, Jodie K.] Univ Washington, VA Puget Sound Hlth Care Syst, VA MS Ctr Excellence West, Dept Rehabil Med, Seattle, WA 98195 USA.
   [Haselkorn, Jodie K.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
RP Turner, AP (reprint author), VA Puget Sound Hlth Care Syst, Rehabil Care Serv, S-117-RCS,1660 S Columbian Way, Seattle, WA 98108 USA.
EM Aaron.Turner@med.va.gov
OI sloan, alicia/0000-0003-4891-3266; Turner, Aaron/0000-0001-6897-8003
NR 75
TC 4
Z9 4
U1 4
U2 11
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 0090-5550
EI 1939-1544
J9 REHABIL PSYCHOL
JI Rehabil. Psychol.
PD MAY
PY 2014
VL 59
IS 2
BP 136
EP 146
DI 10.1037/a0036322
PG 11
WC Psychology, Clinical; Rehabilitation
SC Psychology; Rehabilitation
GA AJ7SQ
UT WOS:000337897800003
PM 24708232
ER

PT J
AU Bambara, JK
   Turner, AP
   Williams, RM
   Haselkorn, JK
AF Bambara, Jennifer K.
   Turner, Aaron P.
   Williams, Rhonda M.
   Haselkorn, Jodie K.
TI Social Support and Depressive Symptoms Among Caregivers of Veterans With
   Multiple Sclerosis
SO REHABILITATION PSYCHOLOGY
LA English
DT Article
DE multiple sclerosis; caregiver; social support; depression; veterans
ID DISEASE-MODIFYING THERAPIES; QUALITY-OF-LIFE; FAMILY CAREGIVERS; HEALTH;
   IMPAIRMENT; ADHERENCE; VALIDATION; DISABILITY; ADJUSTMENT; VALIDITY
AB Purpose/Objective: The primary aim of this study was to examine the relationship between perceived social support and depressive symptoms among family caregivers of veterans with multiple sclerosis (MS). A secondary aim of this study was to examine the relationship between caregiver perceived social support and caregiver demographic variables, veteran health-related variables, and caregiver depressive symptoms. Research Method/Design: As part of a larger study, 42 family caregivers of veterans with MS completed questionnaires by telephone. Hierarchical regression was used to examine the relationship between caregiver depressive symptoms and perceived social support. Results: Greater MS disease severity and poorer overall veteran health were associated with higher levels of depressive symptoms among caregivers. Caregiver perceived social support was associated with depressive symptoms after controlling for veterans' MS disease severity and overall physical health. Conclusions/Implications: Psychosocial interventions aimed at enhancing social support among caregivers of veterans with MS in multiple life domains, such as work, finances, housing, social life, marriage, and family, may be important for family caregiver mood management, particularly as MS disease severity increases.
C1 [Bambara, Jennifer K.; Turner, Aaron P.; Williams, Rhonda M.; Haselkorn, Jodie K.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
   [Turner, Aaron P.; Haselkorn, Jodie K.] VA MS Ctr Excellence West, Seattle, WA USA.
   [Turner, Aaron P.; Williams, Rhonda M.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA.
   [Haselkorn, Jodie K.] Univ Washington, Dept Rehabil Med & Epidemiol, Seattle, WA 98195 USA.
RP Bambara, JK (reprint author), Vet Adm Puget Sound Hlth Care Syst, Seattle Div, Rehabil Care Serv, S-117-RCS,1660 S Columbian Way, Seattle, WA 98108 USA.
EM jennifer.bambara@va.gov
OI Turner, Aaron/0000-0001-6897-8003
NR 29
TC 1
Z9 1
U1 2
U2 10
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 0090-5550
EI 1939-1544
J9 REHABIL PSYCHOL
JI Rehabil. Psychol.
PD MAY
PY 2014
VL 59
IS 2
BP 230
EP 235
DI 10.1037/a0036312
PG 6
WC Psychology, Clinical; Rehabilitation
SC Psychology; Rehabilitation
GA AJ7SQ
UT WOS:000337897800014
PM 24730574
ER

PT J
AU Bachhuber, MA
   Southern, WN
   Cunningham, CO
AF Bachhuber, Marcus A.
   Southern, William N.
   Cunningham, Chinazo O.
TI Profiting and Providing Less Care Comprehensive Services at For-Profit,
   Nonprofit, and Public Opioid Treatment Programs in the United States
SO MEDICAL CARE
LA English
DT Article
DE drug abuse; mental health; social services; infectious disease; health
   care organization
ID SUBSTANCE-ABUSE TREATMENT; INJECTION-DRUG USERS; MAINTENANCE TREATMENT
   PROGRAMS; METHADONE-MAINTAINED PATIENTS; PSYCHIATRIC COMORBIDITY;
   HEPATITIS-C; PSYCHOSOCIAL SERVICES; HIV-INFECTION; MEDICAL-CARE;
   PREVENTION
AB Background:Opioid use disorders are frequently associated with medical and psychiatric comorbidities (eg, HIV infection and depression), as well as social problems (eg, lack of health insurance). Comprehensive services addressing these conditions improve outcomes.Objective:To compare the proportion of for-profit, nonprofit, and public opioid treatment programs offering comprehensive services, which are not mandated by government regulations.Design, Setting, and Participants:Cross-sectional analysis of opioid treatment programs offering outpatient care in the United States (n=1036).Main Outcome Measure:Self-reported offering of communicable disease (HIV, sexually transmitted infections, and viral hepatitis) testing, psychiatric services (screening, assessment and diagnostic evaluation, and pharmacotherapy), and social services support (assistance in applying for programs such as Medicaid). Mixed-effects logistic regression models were developed to adjust for several county-level factors.Results:Of opioid treatment programs, 58.0% were for profit, 33.5% were nonprofit, and 8.5% were public. Nonprofit programs were more likely than for-profit programs to offer testing for all communicable diseases [adjusted odds ratios (AOR), 1.7; 95% confidence interval (CI), 1.2, 2.5], all psychiatric services (AOR, 8.0; 95% CI, 4.9, 13.1), and social services support (AOR, 3.3; 95% CI, 2.3, 4.8). Public programs were also more likely than for-profit programs to offer communicable disease testing (AOR, 6.4; 95% CI, 3.5, 11.7), all psychiatric services (AOR, 25.8; 95% CI, 12.6, 52.5), and social services support (AOR, 2.4; 95% CI, 1.4, 4.3).Conclusions:For-profit programs were significantly less likely than nonprofit and public programs to offer comprehensive services. Interventions to increase the offering of comprehensive services are needed, particularly among for-profit programs.
C1 [Bachhuber, Marcus A.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
   [Bachhuber, Marcus A.] Robert Wood Johnson Fdn, Clin Scholars Program, Philadelphia, PA USA.
   [Bachhuber, Marcus A.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
   [Southern, William N.] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Div Hosp Med, Bronx, NY 10467 USA.
   [Cunningham, Chinazo O.] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Div Gen Internal Med, Bronx, NY 10467 USA.
RP Bachhuber, MA (reprint author), 1303-A Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM marcus.bachhuber@gmail.com
OI Bachhuber, Marcus/0000-0002-5610-8382
FU NIH [R34DA031066, R01DA032110, R25DA023021]; Center for AIDS Research at
   the Albert Einstein College of Medicine; Montefiore Medical Center [NIH
   AI-51519]
FX Supported by NIH R34DA031066, R01DA032110, R25DA023021, and the Center
   for AIDS Research at the Albert Einstein College of Medicine and
   Montefiore Medical Center (NIH AI-51519).
NR 52
TC 0
Z9 0
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7079
EI 1537-1948
J9 MED CARE
JI Med. Care
PD MAY
PY 2014
VL 52
IS 5
BP 428
EP 434
DI 10.1097/MLR.0000000000000121
PG 7
WC Health Care Sciences & Services; Health Policy & Services; Public,
   Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
GA AJ0BB
UT WOS:000337312800009
PM 24638120
ER

PT J
AU Gabrielian, S
   Yuan, AH
   Andersen, RM
   Rubenstein, LV
   Gelberg, L
AF Gabrielian, Sonya
   Yuan, Anita H.
   Andersen, Ronald M.
   Rubenstein, Lisa V.
   Gelberg, Lillian
TI VA Health Service Utilization for Homeless and Low-income Veterans A
   Spotlight on the VA Supportive Housing (VASH) Program in Greater Los
   Angeles
SO MEDICAL CARE
LA English
DT Article
DE veterans; homelessness; supportive housing
ID ANDERSEN BEHAVIORAL-MODEL; MENTAL-ILLNESS; MEDICAL-CARE; VULNERABLE
   POPULATIONS; EMERGENCY-DEPARTMENT; PUBLIC-HEALTH; ACCESS; WOMEN; 1ST;
   INDIVIDUALS
AB Background:The US Department of Housing and Urban Development (HUD)-VA Supportive Housing (VASH) programthe VA's Housing First effortis central to efforts to end Veteran homelessness. Yet, little is known about health care utilization patterns associated with achieving HUD-VASH housing.Objectives:We compare health service utilization at the VA Greater Los Angeles among: (1) formerly homeless Veterans housed through HUD-VASH (HUD-VASH Veterans); (2) currently homeless Veterans; (3) housed, low-income Veterans not in HUD-VASH; and (4) housed, not low-income Veterans.Research Design:We performed a secondary database analysis of Veterans (n=62,459) who received VA Greater Los Angeles care between October 1, 2010 and September 30, 2011. We described medical/surgical and mental health utilization [inpatient, outpatient, and emergency department (ED)]. We controlled for demographics, need, and primary care use in regression analyses of utilization data by housing and income status.Results:HUD-VASH Veterans had more inpatient, outpatient, and ED use than currently homeless Veterans. Adjusting for demographics and need, HUD-VASH Veterans and the low-income housed Veterans had similar likelihoods of medical/surgical inpatient and outpatient utilization, compared with the housed, not low-income group. Adjusting first for demographics and need (model 1), then also for primary care use (model 2), HUD-VASH Veterans had the greatest decrease in incident rates of specialty medical/surgical, mental health, and ED care from models 1 to 2, becoming similar to the currently homeless, compared with the housed, not low-income group.Conclusions:Our findings suggest that currently homeless Veterans underuse health care relative to housed Veterans. HUD-VASH may address this disparity by providing housing and linkages to primary care.
C1 [Gabrielian, Sonya] VA Greater Los Angeles, Dept Psychiat, Los Angeles, CA USA.
   [Gabrielian, Sonya] VA Greater Los Angeles, Mental Illness Res Educ & Clin Ctr, Los Angeles, CA USA.
   [Gabrielian, Sonya; Yuan, Anita H.; Andersen, Ronald M.; Rubenstein, Lisa V.; Gelberg, Lillian] VA Greater Los Angeles, Hlth Serv Res & Dev Ctr Excellence Study Healthca, Los Angeles, CA USA.
   [Gabrielian, Sonya] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.
   [Yuan, Anita H.] Univ Calif Los Angeles, Vet Emergency Management Evaluat Ctr, Los Angeles, CA USA.
   [Andersen, Ronald M.; Gelberg, Lillian] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA.
   [Rubenstein, Lisa V.] VA Greater Los Angeles, Dept Med, Los Angeles, CA USA.
   [Rubenstein, Lisa V.] RAND Corp, Santa Monica, CA USA.
   [Gelberg, Lillian] Univ Calif Los Angeles, Dept Family Med, Los Angeles, CA USA.
RP Gabrielian, S (reprint author), WLA, VA Greater Los Angeles, 11301 Wilshire Blvd,Bldg 210A, Los Angeles, CA 90073 USA.
EM sonya.gabrielian@va.gov
FU Locally Initiated Project Grant from the Health Services Research &
   Development Center of Excellence for the Study of Healthcare Provider
   Behavior at the VA Greater Los Angeles [LIP 65-029]; VA Office of
   Patient Care Services; Office of Academic Affiliations, Advanced
   Fellowship Program in Mental Illness Research and Treatment, Department
   of Veterans Affairs; Veterans Emergency Management Evaluation Center
   (VEMEC); Office of Academic Affiliations, Advanced Fellowship Program in
   Health Services Research, Department of Veterans Affairs [TPP 65-013];
   NIDA [DA 022445]; UCLA/Drew Project EXPORT, National Center on Minority
   Health and Health Disparities [P20MD000148/P20MD000182]; VAIL-PCC [XVA
   650-18]
FX Supported by a Locally Initiated Project Grant from the Health Services
   Research & Development Center of Excellence for the Study of Healthcare
   Provider Behavior at the VA Greater Los Angeles (LIP 65-029). In part,
   this work was undertaken through the Veterans Administration's PACT
   Demonstration Laboratory initiative, supporting and evaluating VA's
   transition to a patient-centered medical home. Funding for the PACT
   Demonstration Laboratory initiative is provided by the VA Office of
   Patient Care Services. S. G. was supported in part by the Office of
   Academic Affiliations, Advanced Fellowship Program in Mental Illness
   Research and Treatment, Department of Veterans Affairs. A.H.Y. was
   supported by the Veterans Emergency Management Evaluation Center (VEMEC)
   and the Office of Academic Affiliations, Advanced Fellowship Program in
   Health Services Research, Department of Veterans Affairs (TPP 65-013).
   L. G. and R. M. A. were supported in part by NIDA DA 022445. R. M. A.
   received additional support from the UCLA/Drew Project EXPORT, National
   Center on Minority Health and Health Disparities,
   P20MD000148/P20MD000182. L. R. was supported in part by VAIL-PCC (XVA
   650-18).
NR 48
TC 4
Z9 4
U1 3
U2 19
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7079
EI 1537-1948
J9 MED CARE
JI Med. Care
PD MAY
PY 2014
VL 52
IS 5
BP 454
EP 461
DI 10.1097/MLR.0000000000000112
PG 8
WC Health Care Sciences & Services; Health Policy & Services; Public,
   Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
GA AJ0BB
UT WOS:000337312800014
PM 24714583
ER

PT J
AU Fidler, R
   Hirsch, J
   Stechert, M
   Johnson, M
AF Fidler, Richard
   Hirsch, Jan
   Stechert, Martin
   Johnson, Meshell
TI Three modes of cardiac compressions in a single patient: A comparison of
   usual manual compressions, automated compressions, and open cardiac
   massage
SO RESUSCITATION
LA English
DT Letter
ID CARDIOPULMONARY-RESUSCITATION; ARREST
C1 [Fidler, Richard; Hirsch, Jan; Stechert, Martin] Univ Calif San Francisco, Dept Anesthesia, San Francisco VA Med Ctr, San Francisco, CA 94143 USA.
   [Johnson, Meshell] Univ Calif San Francisco, Dept Med, San Francisco VA Med Ctr, San Francisco, CA USA.
RP Fidler, R (reprint author), San Francisco VA Med Ctr, 4150 Clement St,Anesthesiol 129, San Francisco, CA 94121 USA.
EM richard.fidler@ucsf.edu
OI Fidler, Richard/0000-0003-4358-7887
NR 5
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0300-9572
J9 RESUSCITATION
JI Resuscitation
PD MAY
PY 2014
VL 85
IS 5
BP E75
EP E76
DI 10.1016/j.resuscitation.2014.01.010
PG 2
WC Critical Care Medicine; Emergency Medicine
SC General & Internal Medicine; Emergency Medicine
GA AJ0GX
UT WOS:000337329500005
PM 24447422
ER

PT J
AU Lai, YY
   Dilidaer, D
   Chen, B
   Xu, G
   Shi, JB
   Lee, RJ
   Cohen, NA
AF Lai, Yinyan
   Dilidaer, D.
   Chen, Bei
   Xu, Geng
   Shi, Jianbo
   Lee, Robert J.
   Cohen, Noam A.
TI In vitro studies of a distillate of rectified essential oils on
   sinonasal components of mucociliary clearance
SO AMERICAN JOURNAL OF RHINOLOGY & ALLERGY
LA English
DT Article
ID CILIARY BEAT FREQUENCY; UPPER RESPIRATORY-INFECTION; CHRONIC
   RHINOSINUSITIS; FLUID SECRETION; TRANSPORT; CILIOGENESIS; T2R38
AB Background: Herbal remedies predate written history and continue to be used frequently for many common ailments. The essential oil mixture standardized is a phytopharmaceutical with a distillate of a mixture of rectified essential oils of eucalyptus, sweet orange, myrtle, and lemon as active ingredients used to treat respiratory diseases such as bronchitis and rhinosinusitis. We evaluated the pharmacologic effects of a distillate of rectified essential oils standardized on primary human upper respiratory epithelial cultures specifically addressing electrolyte transport, cilia beat frequency (CBF), airway surface liquid (ASL) hydration, and mucus transport velocity.
   Methods: Well-differentiated primary human sinonasal epithelial cultures grown at an air-liquid interface were treated on the apical or basolateral surface with varying concentrations of a distillate of rectified essential oils standardized. Changes in CBF were determined using the Sissons-Ammons Video Analysis system while changes in chloride flux were determined using the fluorescent dye 6-methoxy-N-(3-sulfopropyl) quinolinium. ASL hydration was quantified using Texas red dextran and mucociliary transport velocity was measured using fluorescent microspheres and time lapse photography.
   Results: When applied to the basolateral surface, a distillate of rectified essential oils standardized activated chloride efflux and ciliary beat in a dose-dependent fashion, increasing ASL height and accelerating mucociliary transport velocity. The ancillary apical application of a distillate of rectified essential oils standardized had minimal effects on the CBF.
   Conclusion: Basolateral application of a distillate of rectified essential oils standardized stimulates both chloride efflux and cilia beat frequency resulting in a synergistic effect dramatically augmenting mucociliary transport velocity. These in vitro data support the clinical efficacy of this phytopharmaceutical in respiratory inflammatory disorders.
C1 [Lai, Yinyan; Dilidaer, D.; Chen, Bei; Lee, Robert J.] Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA.
   [Lai, Yinyan; Dilidaer, D.; Xu, Geng; Shi, Jianbo; Cohen, Noam A.] Sun Yat Sen Univ, Affiliated Hosp 1, Otorhinolaryngol Hosp, Guangzhou 510275, Guangdong, Peoples R China.
   [Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Surg Serv, Div Otolaryngol, Philadelphia, PA USA.
RP Cohen, NA (reprint author), Univ Penn, Med Ctr, Dept Otorhinolaryngol Head & Neck Surg, Div Rhinol, 5th Floor Ravdin Bldg,3400 Spruce St, Philadelphia, PA 19104 USA.
EM cohenn@uphs.upenn.edu
OI Cohen, Noam/0000-0002-9462-3932; Lee, Robert/0000-0001-5826-6686
FU G. Pohl Boskamp, Hohenlockstedt, Germany
FX Funded by G. Pohl Boskamp, Hohenlockstedt, Germany
NR 20
TC 4
Z9 6
U1 0
U2 9
PU OCEAN SIDE PUBLICATIONS INC
PI PROVIDENCE
PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA
SN 1945-8924
EI 1945-8932
J9 AM J RHINOL ALLERGY
JI Am. J. Rhinol. Allergy
PD MAY-JUN
PY 2014
VL 28
IS 3
BP 244
EP 248
DI 10.2500/ajra.2014.28.4036
PG 5
WC Otorhinolaryngology
SC Otorhinolaryngology
GA AI9QY
UT WOS:000337269100016
PM 24980236
ER

PT J
AU Luxton, DD
   Pruitt, LD
   O'Brien, K
   Stanfill, K
   Jenkins-Guarnieri, MA
   Johnson, K
   Wagner, A
   Thomas, E
   Gahm, GA
AF Luxton, David D.
   Pruitt, Larry D.
   O'Brien, Karen
   Stanfill, Katherine
   Jenkins-Guarnieri, Michael A.
   Johnson, Kristine
   Wagner, Amy
   Thomas, Elissa
   Gahm, Gregory A.
TI Design and methodology of a randomized clinical trial of home-based
   telemental health treatment for US military personnel and veterans with
   depression
SO CONTEMPORARY CLINICAL TRIALS
LA English
DT Article
DE Telemental health; Telehealth; Home-based; Depression; Military;
   Veterans
ID POSTTRAUMATIC-STRESS-DISORDER; BEHAVIORAL ACTIVATION; THERAPY; SCALE;
   NONINFERIORITY; OUTCOMES; PTSD
AB Home-based telemental health (TMH) treatments have the potential to address current and future health needs of military service members, veterans, and their families, especially for those who live in rural or underserved areas. The use of home-based TMH treatments to address the behavioral health care needs of U.S. military healthcare beneficiaries is not presently considered standard of care in the Military Health System. The feasibility, safety, and clinical efficacy of home-based TMH treatments must be established before broad dissemination of home-based treatment programs can be implemented. This paper describes the design, methodology, and protocol of a clinical trial that compares in-office to home-based Behavioral Activation for Depression (BATD) treatment delivered via web-based video technology for service members and veterans with depression. This grant funded three-year randomized clinical trial is being conducted at the National Center for Telehealth and Technology at Joint-base Lewis-McChord and at the Portland VA Medical Center. Best practice recommendations regarding the implementation of in-home telehealth in the military setting as well as the cultural and contextual factors of providing in-home care to active duty and veteran military populations are also discussed. Published by Elsevier Inc.
C1 [Luxton, David D.; Pruitt, Larry D.; O'Brien, Karen; Stanfill, Katherine; Jenkins-Guarnieri, Michael A.; Johnson, Kristine; Thomas, Elissa; Gahm, Gregory A.] Natl Ctr Telehealth & Technol, Tacoma, WA USA.
   [Luxton, David D.; Gahm, Gregory A.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
   [Wagner, Amy] Portland VA Med Ctr, Portland, OR USA.
RP Luxton, DD (reprint author), Def Ctr Excellence Psychol Hlth & Traumat Brain I, Natl Ctr Telehealth & Technol T2, 9933 West Hayes St, Tacoma, WA 98431 USA.
EM david.d.luxton.civ@mail.mil
OI Pruitt, Larry/0000-0001-6925-7830
FU U.S. Army Medical Research & Materiel Command (USAMRMC); Telemedicine &
   Advanced Technology Research Center (TATRC), at Fort Detrick, MD
   [W81XWH-11-2-0118]
FX This research grant was awarded and administered by the U.S. Army
   Medical Research & Materiel Command (USAMRMC) and the Telemedicine &
   Advanced Technology Research Center (TATRC), at Fort Detrick, MD (award
   # W81XWH-11-2-0118). The content of this information does not
   necessarily reflect the position or the policy of the Government, and no
   official endorsement should be inferred.
NR 39
TC 5
Z9 5
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1551-7144
EI 1559-2030
J9 CONTEMP CLIN TRIALS
JI Contemp. Clin. Trials
PD MAY
PY 2014
VL 38
IS 1
BP 134
EP 144
DI 10.1016/j.cct.2014.04.002
PG 11
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA AI8VA
UT WOS:000337203900015
PM 24747488
ER

PT J
AU Milian, MJ
   Fone, K
   Steckler, T
   Horan, WP
AF Milian, Mark J.
   Fone, Kevin
   Steckler, Thomas
   Horan, William P.
TI Negative symptoms of schizophrenia: Clinical characteristics,
   pathophysiological substrates, experimental models and prospects for
   improved treatment
SO EUROPEAN NEUROPSYCHOPHARMACOLOGY
LA English
DT Editorial Material
DE Prefrontal cortex; Striatum; Motivation; Social cognition; Social
   interaction; Oxytocin
ID TRANSCRANIAL MAGNETIC STIMULATION; CONDITIONED PLACE PREFERENCE;
   RANDOMIZED CONTROLLED-TRIALS; SOCIAL-INTERACTION DEFICITS; VENTRAL
   HIPPOCAMPAL LESION; COGNITIVE-BEHAVIOR THERAPY; AUTISM SPECTRUM
   DISORDERS; 1ST EPISODE PSYCHOSIS; DEVELOPMENTAL NEUROPSYCHIATRIC
   DISORDERS; NEURODEVELOPMENTAL RAT MODEL
AB Schizophrenia is a complex and multifactorial disorder generally diagnosed in young adults at the time of the first psychotic episode of delusions and hallucinations. These positive symptoms can be controlled in most patients by currently-available antipsychotics. Conversely, they are poorly effective against concomitant neurocognitive dysfunction, deficits in social cognition and negative symptoms (NS), which strongly contribute to poor functional outcome. The precise notion of NS has evolved over the past century, with recent studies - underpinned by novel rating methods - suggesting two major sub-domains: "decreased emotional expression", incorporating blunted affect and poverty of speech, and "avolition", which embraces amotivation, asociality and "anhedonia" (inability to anticipate pleasure). Recent studies implicate a dysfunction of frontocortico-temporal networks in the aetiology of NS, together with a disruption of cortico-striatal circuits, though other structures are also involved, like the insular and parietal cortices, amygdala and thalamus. At the cellular level, a disruption of GABAergicglutannatergic balance, dopaminergic signalling and, possibly, oxytocinergic and cannibinoidergic transmission may be involved. Several agents are currently under clinical investigation for the potentially improved control of NS, including oxytocin itself, N-Methyl-D-Aspartate receptor modulators and minocycline. Further, magnetic-electrical "stimulation" strategies to recruit cortical circuits and "cognitive-behavioural-psychosocial" therapies likewise hold promise. To acquire novel insights into the causes and treatment of NS, experimental study is crucial, and opportunities are emerging for improved genetic, pharmacological and developmental modelling, together with more refined readouts related to deficits in reward, sociality and "expression". The present article comprises an integrative overview of the above issues as a platform for this Special Issue of European Neuropsychopharmacology in which five clinical and five preclinical articles treat individual themes in greater detail. This Volume provides, then, a framework for progress in the understanding - and ultimately control - of the debilitating NS of schizophrenia. (c) 2014 Elsevier B.V. and ECNP.
C1 [Milian, Mark J.] Inst Rech Servier, F-78290 Paris, France.
   [Fone, Kevin] Univ Nottingham, Queens Med Ctr, Sch Med, Sch Biomed Sci, Nottingham NG7 2UH, England.
   [Steckler, Thomas] Janssen Res & Dev, B-2340 Beerse, Belgium.
   [Horan, William P.] Univ Calif Los Angeles, VA Greater Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
RP Milian, MJ (reprint author), Inst Rech Servier, 125 Chemin Ronde, F-78290 Paris, France.
EM mark.millan@fr.netgrs.com
NR 467
TC 10
Z9 12
U1 7
U2 30
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0924-977X
EI 1873-7862
J9 EUR NEUROPSYCHOPHARM
JI Eur. Neuropsychopharmacol.
PD MAY
PY 2014
VL 24
IS 5
SI SI
BP 645
EP 692
DI 10.1016/j.euroneuro.2014.03.008
PG 48
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA AI8YE
UT WOS:000337212100001
ER

PT J
AU Linnemann, AK
   Baan, M
   Davis, DB
AF Linnemann, Amelia K.
   Baan, Mieke
   Davis, Dawn Belt
TI Pancreatic beta-Cell Proliferation in Obesity
SO ADVANCES IN NUTRITION
LA English
DT Review
ID HEPATOCYTE GROWTH-FACTOR; HIGH-FAT DIET; GLUCAGON-LIKE PEPTIDE-1;
   DIABETES SUSCEPTIBILITY LOCI; SCALE ASSOCIATION ANALYSIS; INDUCED
   INSULIN-RESISTANCE; ACTIVATED-RECEPTOR-GAMMA; CYCLIN D2 EXPRESSION;
   GENE-EXPRESSION; GLUCOSE-INTOLERANCE
AB Because obesity rates have increased dramatically over the past 3 decades, type 2 diabetes has become increasingly prevalent as well. Type 2 diabetes is associated with decreased pancreatic beta-cell mass and function, resulting in inadequate insulin production. Conversely, in nondiabetic obesity, an expansion in beta-cell mass occurs to provide sufficient insulin and to prevent hyperglycemia. This expansion is at least in part due to beta-cell proliferation. This review focuses on the mechanisms regulating obesity-induced beta-cell proliferation in humans and mice. Many factors have potential roles in the regulation of obesity-driven beta-cell proliferation, including nutrients, insulin, incretins, hepatocyte growth factor, and recently identified liver-derived secreted factors. Much is still unknown about the regulation of beta-cell replication, especially in humans. The extracellular signals that activate proliferative pathways in obesity, the relative importance of each of these pathways, and the extent of cross-talk between these pathways are important areas of future study.
C1 [Linnemann, Amelia K.; Baan, Mieke; Davis, Dawn Belt] Univ Wisconsin, Dept Med, Div Endocrinol, Madison, WI 53706 USA.
   [Baan, Mieke] Univ Wisconsin, Sch Vet Med, Madison, WI USA.
   [Davis, Dawn Belt] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
RP Davis, DB (reprint author), Univ Wisconsin, Dept Med, Div Endocrinol, Madison, WI 53706 USA.
EM dbd@medicine.wisc.edu
FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
   [DK083442]; NIH Ruth L. Kirschstein National Research Service Award
   Institutional Training Grant from the National Center for Research
   Resources [T32 RR023916/OD010423]
FX D.B.D. is supported by National Institute of Diabetes and Digestive and
   Kidney Diseases (NIDDK) DK083442 M.B. is supported by the NIH Ruth L.
   Kirschstein National Research Service Award Institutional Training Grant
   T32 RR023916/OD010423 from the National Center for Research Resources.
   The William S. Middleton Memorial Veterans Hospital provided resources
   and use of facilities. The contents of this manuscript do not
   necessarily represent the views of the Department of Veterans Affairs or
   the U.S. Government
NR 95
TC 16
Z9 16
U1 0
U2 4
PU AMER SOC NUTRITION-ASN
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 2161-8313
EI 2156-5376
J9 ADV NUTR
JI Adv. Nutr.
PD MAY
PY 2014
VL 5
IS 3
BP 278
EP 288
DI 10.3945/an.113.005488
PG 11
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA AI5CV
UT WOS:000336883900007
PM 24829474
ER

PT J
AU Chacon-Heszele, MF
   Zuo, XF
   Hellman, NE
   McKenna, S
   Choi, SY
   Huang, LW
   Tobias, JW
   Park, KM
   Lipschutz, JH
AF Chacon-Heszele, Maria F.
   Zuo, Xiaofeng
   Hellman, Nathan E.
   McKenna, Sarah
   Choi, Soo Young
   Huang, Liwei
   Tobias, John W.
   Park, Kwon Moo
   Lipschutz, Joshua H.
TI Novel MAPK-dependent and -independent tubulogenes identified via
   microarray analysis of 3D-cultured Madin-Darby canine kidney cells
SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY
LA English
DT Article
DE mitogen-activated protein kinase; matrix metalloproteinase; development;
   kidney; tubulogenesis
ID HEPATOCYTE GROWTH-FACTOR; IN-VITRO; EPITHELIAL-CELLS; MDCK CELLS; LINE
   MDCK; ENDOPLASMIC-RETICULUM; EMBRYONIC KIDNEY; GAMMA-CATENIN;
   MORPHOGENESIS; EXPRESSION
AB Cystogenesis and tubulogenesis are basic building blocks for many epithelial organs, including the kidney. Most researchers have used two-dimensional (2D) cell culture to investigate signaling pathways downstream of hepatocyte growth factor (HGF). We hypothesize that three-dimensional (3D) collagen-grown Madin-Darby canine kidney (MDCK) cells, which form cysts and then tubulate in response to HGF, are a much more in vivo-like system for the identification of novel tubulogenes. With the use of a canine microarray containing over 20,000 genes, 2,417 genes were identified as potential tubulogenes that were differentially regulated, exclusively in 3D-grown MDCK cells. Among these, 840 were dependent on MAPK signaling. Importantly, this work shows that many putative tubulogenes, previously identified via microarray analysis of 2D cultures, including by us, do not change in 3D culture and vice versa. The use of a 3D-culture system allowed for the identification of novel MAPK dependent and -independent genes that regulate early renal tubulogenesis in vitro, e. g., matrix metalloproteinase 1 (MMP1). Knockdown of MMP1 led to defects in cystogenesis and tubulogenesis in 3D-grown MDCK cells, most likely due to problems establishing normal polarity. We suggest that data obtained from 2D cultures, even those using MDCK cells treated with HGF, should not be automatically extrapolated to factors important for cystogenesis and tubulogenesis. Instead, 3D culture, which more closely replicates the biological environment and is therefore a more accurate model for identifying tubulogenes, is preferred. Results from the present analysis will be used to build a more accurate model of the signaling pathways that control cystogenesis and tubulogenesis.
C1 [Chacon-Heszele, Maria F.; Zuo, Xiaofeng; Hellman, Nathan E.; McKenna, Sarah; Choi, Soo Young; Huang, Liwei; Lipschutz, Joshua H.] Univ Penn, Renal Electrolyte & Hypertens Div, Dept Med, Philadelphia, PA 19104 USA.
   [Tobias, John W.] Univ Penn, Genom Inst, Bioinformat Core, Philadelphia, PA 19104 USA.
   [Park, Kwon Moo] Kyungpook Natl Univ, Sch Med, Dept Anat, Taegu 702701, South Korea.
   [Lipschutz, Joshua H.] Philadelphia Vet Affairs Med Ctr, Dept Med, Philadelphia, PA USA.
RP Lipschutz, JH (reprint author), Univ Penn, Renal Electrolyte & Hypertens Div, Rm 405C,Clin Res Bldg, Philadelphia, PA 19104 USA.
EM jhlipsch@mail.med.upenn.edu
FU VA Merit Award [I01BX000820]; National Institute of Diabetes and
   Digestive and Kidney Diseases [DK069909, DK047757, DK093625]; NephHope
   Foundation; Satellite Healthcare (Norman S. Coplon Extramural Research
   Grant); University of Pennsylvania Translational Medicine Institute
   (Pilot Grant)
FX Support for this work was provided, in part, by grants from the VA Merit
   Award (I01BX000820 to J. H. Lipschutz), National Institute of Diabetes
   and Digestive and Kidney Diseases (DK069909 and DK047757 to J. H.
   Lipschutz and DK093625 to L. Huang), NephHope Foundation (fellowship to
   M. F. Chacon-Heszele), Satellite Healthcare (Norman S. Coplon Extramural
   Research Grant to J. H. Lipschutz), and University of Pennsylvania
   Translational Medicine Institute (Pilot Grant to J. H. Lipschutz).
NR 46
TC 4
Z9 4
U1 0
U2 2
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1931-857X
EI 1522-1466
J9 AM J PHYSIOL-RENAL
JI Am. J. Physiol.-Renal Physiol.
PD MAY
PY 2014
VL 306
IS 9
BP F1047
EP F1058
DI 10.1152/ajprenal.00589.2013
PG 12
WC Physiology; Urology & Nephrology
SC Physiology; Urology & Nephrology
GA AI4OO
UT WOS:000336844900011
PM 24573390
ER

PT J
AU Kemp, JJ
   Lickel, JJ
   Deacon, BJ
AF Kemp, Joshua J.
   Lickel, James J.
   Deacon, Brett J.
TI Effects of a chemical imbalance causal explanation on individuals'
   perceptions of their depressive symptoms
SO BEHAVIOUR RESEARCH AND THERAPY
LA English
DT Article
DE Depression; Chemical imbalance; Stigma; Prognosis; Etiology
ID MENTAL-DISORDER; MOOD-REGULATION; STIGMA; EXPECTANCIES
AB Although the chemical imbalance theory is the dominant causal explanation of depression in the United States, little is known about the effects of this explanation on depressed individuals. This experiment examined the impact of chemical imbalance test feedback on perceptions of stigma, prognosis, negative mood regulation expectancies, and treatment credibility and expectancy. Participants endorsing a past or current depressive episode received results of a bogus but credible biological test demonstrating their depressive symptoms to be caused, or not caused, by a chemical imbalance in the brain. Results showed that chemical imbalance test feedback failed to reduce self-blame, elicited worse prognostic pessimism and negative mood regulation expectancies, and led participants to view pharmacotherapy as more credible and effective than psychotherapy. The present findings add to a growing literature highlighting the unhelpful and potentially iatrogenic effects of attributing depressive symptoms to a chemical imbalance. Clinical and societal implications of these findings are discussed. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Kemp, Joshua J.; Deacon, Brett J.] Univ Wyoming, Dept Psychol, Laramie, WY 82071 USA.
   [Lickel, James J.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA.
RP Deacon, BJ (reprint author), Univ Wyoming, Dept Psychol, Dept 3415,1000 E Univ Ave, Laramie, WY 82071 USA.
EM bdeacon@uwyo.edu
NR 30
TC 10
Z9 10
U1 3
U2 23
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0005-7967
EI 1873-622X
J9 BEHAV RES THER
JI Behav. Res. Ther.
PD MAY
PY 2014
VL 56
BP 47
EP 52
DI 10.1016/j.brat.2014.02.009
PG 6
WC Psychology, Clinical
SC Psychology
GA AI6WJ
UT WOS:000337017400007
PM 24657311
ER

PT J
AU Valente, MAE
   Voors, AA
   Damman, K
   Van Veldhuisen, DJ
   Massie, BM
   O'Connor, CM
   Metra, M
   Ponikowski, P
   Teerlink, JR
   Cotter, G
   Davison, B
   Cleland, JGF
   Givertz, MM
   Bloomfield, DM
   Fiuzat, M
   Dittrich, HC
   Hillege, HL
AF Valente, Mattia A. E.
   Voors, Adriaan A.
   Damman, Kevin
   Van Veldhuisen, Dirk J.
   Massie, Barrie M.
   O'Connor, Christopher M.
   Metra, Marco
   Ponikowski, Piotr
   Teerlink, John R.
   Cotter, Gad
   Davison, Beth
   Cleland, John G. F.
   Givertz, Michael M.
   Bloomfield, Daniel M.
   Fiuzat, Mona
   Dittrich, Howard C.
   Hillege, Hans L.
TI Diuretic response in acute heart failure: clinical characteristics and
   prognostic significance
SO EUROPEAN HEART JOURNAL
LA English
DT Article
DE Diuretics; Heart failure; Diuretic resistance; Cardiorenal syndrome;
   Worsening renal function; Renal dysfunction; Prognosis; Mortality;
   Rehospitalization
ID WORSENING RENAL-FUNCTION; CARDIORENAL SYNDROME; CONTINUOUS-INFUSION;
   BOLUS INJECTION; DYSPNEA RELIEF; ROLOFYLLINE; FUROSEMIDE; MORTALITY;
   ULTRAFILTRATION; RESISTANCE
AB Aim Diminished diuretic response is common in patients with acute heart failure, although a clinically useful definition is lacking. Our aim was to investigate a practical, workable metric for diuretic response, examine associated patient characteristics and relationships with outcome.
   Methods and results We examined diuretic response (defined as Delta weight kg/40 mg furosemide) in 1745 hospitalized acute heart failure patients from the PROTECT trial. Day 4 response was used to allow maximum differentiation in responsiveness and tailoring of diuretic doses to clinical response, following sensitivity analyses. We investigated predictors of diuretic response and relationships with outcome. The median diuretic response was -0.38 (-0.80 to -0.13) kg/40 mg furosemide. Poor diuretic response was independently associated with low systolic blood pressure, high blood urea nitrogen, diabetes, and atherosclerotic disease (all P < 0.05). Worse diuretic response independently predicted 180-day mortality (HR: 1.42; 95% CI: 1.11-1.81, P = 0.005), 60-day death or renal or cardiovascular rehospitalization (HR: 1.34; 95% CI: 1.14-1.59, P < 0.001) and 60-day HF rehospitalization (HR: 1.57; 95% CI: 1.24-2.01, P < 0.001) in multivariable models. The proposed metric-weight loss indexed to diuretic dose-better captures a dose-response relationship. Model diagnostics showed diuretic response provided essentially the same or slightly better prognostic information compared with its individual components (weight loss and diuretic dose) in this population, while providing a less biased, more easily interpreted signal.
   Conclusions Worse diuretic response was associated with more advanced heart failure, renal impairment, diabetes, atherosclerotic disease and in-hospital worsening heart failure, and predicts mortality and heart failure rehospitalization in this post hoc, hypothesis-generating study.
C1 [Valente, Mattia A. E.; Voors, Adriaan A.; Damman, Kevin; Van Veldhuisen, Dirk J.; Hillege, Hans L.] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, NL-9713 AV Groningen, Netherlands.
   [Massie, Barrie M.; Teerlink, John R.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Massie, Barrie M.; Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA USA.
   [O'Connor, Christopher M.; Fiuzat, Mona] Duke Univ, Med Ctr, Durham, NC USA.
   [Metra, Marco] Univ Brescia, Brescia, Italy.
   [Ponikowski, Piotr] Med Univ, Clin Mil Hosp, Wroclaw, Poland.
   [Cotter, Gad; Davison, Beth] Momentum Res, Durham, NC USA.
   [Cleland, John G. F.] Univ Hull, Kingston Upon Hull, Yorks, England.
   [Givertz, Michael M.] Brigham & Womens Hosp, Boston, MA 02115 USA.
   [Bloomfield, Daniel M.] Merck Res Labs, Rahway, NJ USA.
   [Dittrich, Howard C.] Univ Iowa, Cardiovasc Res Ctr, Carver Coll Med, Iowa City, IA USA.
   [Hillege, Hans L.] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, NL-9713 GZ Groningen, Netherlands.
RP Voors, AA (reprint author), Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, NL-9713 AV Groningen, Netherlands.
EM a.a.voors@umcg.nl
RI Ponikowski, Piotr/O-6454-2015
OI Ponikowski, Piotr/0000-0002-3391-7064; Davison,
   Beth/0000-0003-2374-6449; Cleland, John/0000-0002-1471-7016; Metra,
   Marco/0000-0001-6691-8568
FU Merck; NovaCardia; Amgen; BG Medicine; Biocontrol; Johnson and Johnson;
   Novartis; Sorbent; Vifor; Abbott; Biogen Idec; Corthera; Cytokinetics;
   Johnson and Johnson/ Scios; Relypsa; Solvay
FX M.A.E.V, K. D., M. F., and H. L. H. have nothing to disclose. A. A. V.
   has received speaker and consultancy fees from Merck and NovaCardia.
   D.J.V.V. has received Board Membership fees from Amgen, BG Medicine,
   Biocontrol, Johnson and Johnson, Novartis, Sorbent, and Vifor. B. M. M.
   has received consulting fees from NovaCardia, sponsors of the study, and
   from Merck, that purchased the rights to rolofylline after the
   completion of the PROTECT pilot study. C.M.O.C. is a consultant to
   Merck. M. M. has received honoraria and reimbursements from NovaCardia,
   sponsors of the study, and from Merck, that purchased the rights to
   rolofylline after completion of the PROTECT pilot study. P. P. has
   received honoraria from Merck. J.R.T. has received research funds and
   consulting fees from Merck, the producer of rolofylline for the conduct
   of this study and has also received research funds and consulting fees
   from Abbott, Amgen, Biogen Idec, Corthera, Cytokinetics, Johnson and
   Johnson/ Scios, Novartis, Relypsa, and Solvay for research in related
   areas. G. C. and B. A. W. are employees of Momentum Research, Inc.,
   which was contracted to perform work on the project by Merck & Co.,
   Inc., J.G.F.C. was on the Steering Committee for the study, served on
   the Advisory Board for MSD, and received payments for both. M. M. G. has
   received institutional research support and served on a scientific
   Advisory Board for Merck. D. A. B. is an employee of Merck. H. C. D was
   an employee of NovaCardia and a consultant to Merck.
NR 49
TC 39
Z9 40
U1 1
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
EI 1522-9645
J9 EUR HEART J
JI Eur. Heart J.
PD MAY
PY 2014
VL 35
IS 19
BP 1284
EP +
DI 10.1093/eurheartj/ehu065
PG 11
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AI6QB
UT WOS:000336999400014
PM 24585267
ER

PT J
AU Lee, SJ
AF Lee, Sei J.
TI So Much Insulin, So Much Hypoglycemia
SO JAMA INTERNAL MEDICINE
LA English
DT Editorial Material
ID OLDER PATIENTS; RISK
C1 [Lee, Sei J.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94121 USA.
   [Lee, Sei J.] San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA USA.
RP Lee, SJ (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, Div Geriatr, 4150 Clement St,Bldg 1,Room 220F, San Francisco, CA 94121 USA.
EM sei.lee@ucsf.edu
FU NIA NIH HHS [K23 AG040779, P30 AG044281]
NR 11
TC 5
Z9 5
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD MAY
PY 2014
VL 174
IS 5
BP 686
EP 688
DI 10.1001/jamainternmed.2013.13307
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA AI4NS
UT WOS:000336842700008
PM 24614940
ER

PT J
AU Makam, AN
   Auerbach, AD
   Steinman, MA
AF Makam, Anil N.
   Auerbach, Andrew D.
   Steinman, Michael A.
TI Blood Culture Use in the Emergency Department in Patients Hospitalized
   for Community-Acquired Pneumonia
SO JAMA INTERNAL MEDICINE
LA English
DT Letter
C1 [Makam, Anil N.] Univ Texas SW Med Ctr Dallas, Div Gen Internal Med, Dallas, TX 75390 USA.
   [Auerbach, Andrew D.] Univ Calif San Francisco, Div Hosp Med, San Francisco, CA 94143 USA.
   [Steinman, Michael A.] San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA USA.
   [Steinman, Michael A.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
RP Makam, AN (reprint author), Univ Texas SW Med Ctr Dallas, Div Gen Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.
EM anil.makam@utsouthwestern.edu
OI Makam, Anil/0000-0001-7072-9946
FU NIA NIH HHS [K23 AG030999]; PHS HHS [T32HP19025-07-00]
NR 7
TC 7
Z9 7
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD MAY
PY 2014
VL 174
IS 5
BP 803
EP 806
DI 10.1001/jamainternmed.2013.13808
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA AI4NS
UT WOS:000336842700030
PM 24614986
ER

PT J
AU Blanco, CL
   Moreira, AG
   McGill-Vargas, LL
   Anzueto, DG
   Nathanielsz, P
   Musi, N
AF Blanco, Cynthia L.
   Moreira, Alvaro G.
   McGill-Vargas, Lisa L.
   Anzueto, Diana G.
   Nathanielsz, Peter
   Musi, Nicolas
TI Antenatal corticosteroids alter insulin signaling pathways in fetal
   baboon skeletal muscle
SO JOURNAL OF ENDOCRINOLOGY
LA English
DT Article
DE insulin; fetus; primate; muscle; glucocorticoid; corticosteroid; preterm
ID BRONCHOPULMONARY DYSPLASIA; GLUCOSE-HOMEOSTASIS; PRETERM INFANTS;
   KINASE-B; GROWTH; DEXAMETHASONE; FETUS; GLUCOCORTICOIDS; HYPERGLYCEMIA;
   RESISTANCE
AB We hypothesize that prenatal exposure to glucocorticoids (GCs) negatively alters the insulin signal transduction pathway and has differing effects on the fetus according to gestational age (GA) at exposure. Twenty-three fetal baboons were delivered from 23 healthy, nondiabetic mothers. Twelve preterm (0.67 GA) and 11 near-term (0.95 GA) baboons were killed immediately after delivery. Half of the pregnant baboons at each gestation received two doses of i.m. betamethasone 24 h apart (170 mg/kg) before delivery, while the other half received no intervention. Vastus lateralis muscle was obtained from postnatal animals tomeasure the protein content and gene expression of insulin receptor beta (IRb; INSR), IRb Tyr 1361 phosphorylation (pIRb), IR substrate 1 (IRS1), IRS1 tyrosine phosphorylation (pIRS1), p85 subunit of PI3-kinase, AKT (protein kinase B), phospho-AKT Ser473 (pAKT), AKT1, AKT2, and glucose transporters (GLUT1 and GLUT4). Skeletal muscle from preterm baboons exposed to GCs had markedly reduced protein content of AKTand AKT1 (respectively, 73 and 72% from 0.67 GA control, P! 0.001); IRb and pIRb were also decreased (respectively, 94 and 85%, P! 0.01) in themuscle of premature GCexposedfetusesbut not intermfetuses. GLUT1andGLUT4tendedto increasewithGCexposure in preterm animals (PZ0.09), while GLUT4 increased sixfold in term animals after exposure to GC (P! 0.05). In conclusion, exposure to a single course of antenatal GCs during fetal life alters the insulin signaling pathway in fetal muscle in a manner dependent on the stage of gestation.
C1 [Blanco, Cynthia L.; Moreira, Alvaro G.; McGill-Vargas, Lisa L.; Anzueto, Diana G.] Univ Texas Hlth Sci Ctr San Antonio, Div Neonatol, Dept Pediat, San Antonio, TX 78229 USA.
   [Musi, Nicolas] Univ Texas Hlth Sci Ctr San Antonio, Diabet Div, Dept Med, San Antonio, TX 78229 USA.
   [Musi, Nicolas] South Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78229 USA.
   [Musi, Nicolas] Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA.
   [Nathanielsz, Peter] Univ Texas Hlth Sci Ctr San Antonio, Dept Obstet, Ctr Pregnancy & Newborn Res, San Antonio, TX 78229 USA.
RP Blanco, CL (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Neonatol, Dept Pediat, San Antonio, TX 78229 USA.
EM blanco@uthscsa.edu
OI Nathanielsz, Peter/0000-0001-8410-6280
FU Robert Wood Johnson Foundation; UTHSCSA CTSA [UL1RR025767]; American
   Diabetes Association; National Institutes of Health [HL52636, AG030979]
FX This work was supported by grants from the Robert Wood Johnson
   Foundation (C L B), UTHSCSA CTSA (UL1RR025767; C L B), American Diabetes
   Association (C L B and N M), the National Institutes of Health (HL52636
   to BPD resource Center, AG030979 to N M), P51RR13986 for facility
   support at the Southwest Foundation for Biomedical Research, the San
   Antonio Nathan Shock Center (N M), the UTHSCSA Executive Research
   Committee (N M), and the South Texas Health Research Center (N M).
NR 40
TC 5
Z9 5
U1 0
U2 2
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT,
   ENGLAND
SN 0022-0795
EI 1479-6805
J9 J ENDOCRINOL
JI J. Endocrinol.
PD MAY
PY 2014
VL 221
IS 2
BP 253
EP 260
DI 10.1530/JOE-13-0504
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA AI7WC
UT WOS:000337110900012
PM 24756099
ER

PT J
AU Gong, JJ
   Munoz, AR
   Chan, D
   Ghosh, R
   Kumar, AP
AF Gong, Jingjing
   Munoz, Amanda R.
   Chan, Daniel
   Ghosh, Rita
   Kumar, Addanki P.
TI STAT3 down regulates LC3 to inhibit autophagy and pancreatic cancer cell
   growth
SO ONCOTARGET
LA English
DT Article
DE Pancreatic cancer; Nexrutine (R); STAT3; inflammation; autophagy; LC3
ID PROSTATE-CANCER; BINDING-PROTEIN; DEATH; NEXRUTINE; APOPTOSIS;
   ACTIVATION; RECEPTOR; AKT; ADENOCARCINOMA; GLIOBLASTOMA
AB The dismal 5-year survival (<5%) for pancreatic cancer (PanCA) underscores the need for developing effective therapeutic options. Recent studies from our laboratory have shown that Nexrutine (R) (Nx), a bark extract from Phellodendron amurense exhibits excellent anticancer activity in human pancreatic cancer cells through inhibition of inflammatory signaling via STAT3/NF kappa B/Cox-2. Given the apparent high oxidative stress and autophagic activity in pancreatic tumors, we investigated the potential of Nx to modulate autophagy, reactive oxygen species (ROS), and their crosstalk. Our results show that Nx inhibits autophagy and decreases ROS generation. Pharmacological inhibition of autophagy led to decreased ROS generation and proliferation with no significant effect on apoptosis. Further, using combination index analysis we also found that combination of late-stage autophagy inhibitor with Nx exhibited a moderate synergistic to additive effect. Additionally, genetic or pharmacological inactivation of STAT3 reduced LC3-II levels and expression indicating a possible role for STAT3 in transcriptional regulation of autophagy. Since both inflammatory and oxidative stress signaling activate STAT3, our data implicates that STAT3 plays a vital role in the regulation of autophagy through its contributions to the positive feedback loop between ROS and autophagy. Overall, our findings reveal an important role for STAT3/LC3/ROS in Nx-mediated anti-pancreatic cancer effects.
C1 [Gong, Jingjing; Munoz, Amanda R.; Ghosh, Rita; Kumar, Addanki P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Urol, San Antonio, TX 78229 USA.
   [Chan, Daniel] Univ Colorado, Div Med Oncol, Aurora, CO USA.
   [Ghosh, Rita; Kumar, Addanki P.] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA.
   [Kumar, Addanki P.] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
RP Kumar, AP (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Urol, San Antonio, TX 78229 USA.
EM kumara3@uthscsa.edu
FU NCCAM [AT005513-01A1, AT 007448-01]; Veterans Affairs-Merit Award [1 I01
   BX 000766-01]; NCI [1R01 CA149516]; TST predoctoral fellowship [8UL1
   TR000149]; Cancer Therapy and Research Center at University of Texas
   Health Science Center San Antonio through the National Cancer Institute
   [2P30 CA 054174-17]
FX This work was supported in part by funds from NCCAM AT005513-01A1, AT
   007448-01 and Veterans Affairs-Merit Award 1 I01 BX 000766-01(APK); NCI
   1R01 CA149516 (RG); TST predoctoral fellowship 8UL1 TR000149 (JJ). We
   acknowledge support provided by flow cytometry and optical imaging cores
   of Cancer Therapy and Research Center at University of Texas Health
   Science Center San Antonio through the National Cancer Institute support
   grant # 2P30 CA 054174-17 (APK).
NR 63
TC 20
Z9 22
U1 0
U2 6
PU IMPACT JOURNALS LLC
PI ALBANY
PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA
SN 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD MAY
PY 2014
VL 5
IS 9
BP 2529
EP 2541
PG 13
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA AI6FI
UT WOS:000336966600016
PM 24796733
ER

PT J
AU Perandones, C
   Giugni, JC
   Calvo, DS
   Raina, GB
   Lopez, LDJ
   Volpini, V
   Zabetian, CP
   Mata, IF
   Caputo, M
   Corach, D
   Radrizzani, M
   Micheli, FE
AF Perandones, C.
   Giugni, J. C.
   Calvo, D. S.
   Raina, G. B.
   De Jorge Lopez, L.
   Volpini, V.
   Zabetian, C. P.
   Mata, I. F.
   Caputo, M.
   Corach, D.
   Radrizzani, M.
   Micheli, F. E.
TI Mosaicism of alpha-synuclein gene rearrangements: Report of two
   unrelated cases of early-onset parkinsonism
SO PARKINSONISM & RELATED DISORDERS
LA English
DT Letter
DE Parkinson's disease; alpha-Synuclein; Mosaicism; Gene multiplication
ID DISEASE; MITOCHONDRIAL; DUPLICATION; DNA
C1 [Perandones, C.; Giugni, J. C.; Calvo, D. S.; Raina, G. B.; Micheli, F. E.] Univ Buenos Aires, Parkinsons Dis & Movement Disorders Program, Hosp Clin, RA-1053 Buenos Aires, DF, Argentina.
   [Perandones, C.] Natl Agcy Labs & Hlth Inst Argentina ANUS, Buenos Aires, DF, Argentina.
   [De Jorge Lopez, L.; Volpini, V.] Inst Invest Biomed Bellvitge, Barcelona, Spain.
   [Zabetian, C. P.; Mata, I. F.] Univ Washington, Seattle, WA 98195 USA.
   [Zabetian, C. P.; Mata, I. F.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
   [Caputo, M.; Corach, D.] Univ Buenos Aires, Sch Pharm & Biochem, Serv Huellas Digit Genet, RA-1053 Buenos Aires, DF, Argentina.
   [Radrizzani, M.] Natl Univ San Martin, CONICET, Lab Neuro & Mol Cytogenet, Buenos Aires, DF, Argentina.
RP Perandones, C (reprint author), Univ Buenos Aires, Parkinsons Dis & Movement Disorders Program, Hosp Clin, Ciudad Autonoma Buenos Aires C1120AAR, RA-1053 Buenos Aires, DF, Argentina.
EM claudia.perandones@gmail.com
OI Zabetian, Cyrus/0000-0002-7739-4306
FU NINDS NIH HHS [R01 NS065070]
NR 9
TC 5
Z9 5
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1353-8020
EI 1873-5126
J9 PARKINSONISM RELAT D
JI Parkinsonism Relat. Disord.
PD MAY
PY 2014
VL 20
IS 5
BP 558
EP 561
DI 10.1016/j.Parkreldis.2013.11.014
PG 4
WC Clinical Neurology
SC Neurosciences & Neurology
GA AI7LE
UT WOS:000337071300017
PM 24552873
ER

PT J
AU Findlay, VJ
   Wang, C
   Watson, DK
   Camp, ER
AF Findlay, V. J.
   Wang, C.
   Watson, D. K.
   Camp, E. R.
TI Epithelial-to-mesenchymal transition and the cancer stem cell phenotype:
   insights from cancer biology with therapeutic implications for
   colorectal cancer
SO CANCER GENE THERAPY
LA English
DT Review
ID EPIDERMAL-GROWTH-FACTOR; METASTATIC COLON-CANCER; TUMOR-INITIATING
   CELLS; ACUTE MYELOID-LEUKEMIA; E-CADHERIN EXPRESSION; BREAST-CANCER;
   RECTAL-CANCER; PANCREATIC-CANCER; DOWN-REGULATION; FACTOR RECEPTOR
AB Although mortality from colorectal cancer (CRC) is decreasing, CRC is still the second highest cause of cancer-related deaths in America. Chemotherapy and radiation therapy now have central roles in our strategies to fight cancer, although we continue to lack novel strategies overcoming therapeutic resistance. Molecular mechanisms of therapeutic resistance in CRC continue to be under intense investigation. In this review, we highlight the recent evidence linking epithelial-to-mesenchynnal transition (EMT) with aggressive tumor biology as well as with the cancer stem cells (CSCs) across multiple organ systems including colon cancer. Furthermore, in the era of neo-adjuvant treatment, the clinical implications are concerning that our treatments may have the potential to induce more aggressive cancer cells through EMT, perhaps even generating CSCs more capable of metastasis and further resistant to treatment. This concern and potential reality highlights the critical need for further understanding the impact of clinical therapy on the pathobiology of cancer and further supports the need to therapeutically target the CSC. Besides serving as potential biomarkers for aggressive tumor biology and therapeutic resistance, EMT and CSC molecular pathways may highlight novel therapeutic targets as strategies for improving the response to conventional anti-neoplastic agents translating into improved oncologic outcomes.
C1 [Findlay, V. J.; Watson, D. K.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA.
   [Wang, C.; Camp, E. R.] Med Univ S Carolina, Dept Surg, Div Surg Oncol, Charleston, SC 29425 USA.
   [Watson, D. K.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.
   [Watson, D. K.; Camp, E. R.] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA.
   [Camp, E. R.] Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA.
RP Camp, ER (reprint author), Med Univ S Carolina, Dept Surg, Div Surg Oncol, 25 Courtenay Dr,Room 7018, Charleston, SC 29425 USA.
EM campe@musc.edu
FU National Institutes of Health [5R 1K08CA142904]; Hollings Cancer Center
   Translational Research Award; American Cancer Society: Institutional
   Research Grant
FX This study was supported by National Institutes of Health, 5R
   1K08CA142904 (ERC), Hollings Cancer Center Translational Research Award
   and American Cancer Society: Institutional Research Grant.
NR 106
TC 43
Z9 45
U1 3
U2 21
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0929-1903
EI 1476-5500
J9 CANCER GENE THER
JI Cancer Gene Ther.
PD MAY
PY 2014
VL 21
IS 5
BP 181
EP 187
DI 10.1038/cgt.2014.15
PG 7
WC Biotechnology & Applied Microbiology; Oncology; Genetics & Heredity;
   Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Oncology; Genetics & Heredity;
   Research & Experimental Medicine
GA AI3QK
UT WOS:000336776800002
PM 24787239
ER

PT J
AU Laserna, E
   Sibila, O
   Fernandez, JF
   Maselli, DJ
   Mortensen, EM
   Anzueto, A
   Waterer, G
   Restrepo, MI
AF Laserna, Elena
   Sibila, Oriol
   Fernandez, Juan Felipe
   Maselli, Diego Jose
   Mortensen, Eric M.
   Anzueto, Antonio
   Waterer, Grant
   Restrepo, Marcos I.
TI Impact of Macrolide Therapy in Patients Hospitalized With Pseudomonas
   aeruginosa Community-Acquired Pneumonia
SO CHEST
LA English
DT Article
ID BACTEREMIC PNEUMOCOCCAL PNEUMONIA; RANDOMIZED CONTROLLED-TRIAL;
   CARE-ASSOCIATED PNEUMONIA; GRAM-NEGATIVE BACILLI; RISK-FACTORS;
   BETA-LACTAM; MORTALITY; OUTCOMES; AZITHROMYCIN; EXACERBATIONS
AB Background: Several studies have described a clinical benefit of macrolides due to their immunomodulatory properties in various respiratory diseases. We aimed to assess the effect of macrolide therapy on mortality in patients hospitalized for Pseudomonas aeruginosa community-acquired pneumonia (CAP).
   Methods: We performed a retrospective population-based study of > 150 hospitals in the US Veterans Health Administration. Patients were included if they had a diagnosis of CAP and P aeruginosa was identified as the causative pathogen. Patients with health-care-associated pneumonia and immunosuppression were excluded. Macrolide therapy was considered when administered within the first 48 h of admission. Univariate and multivariable analyses were performed using 30-day mortality as the dependent measure.
   Results: We included 402 patients with P aeruginosa CAP, of whom 171 (42.5%) received a macrolide during the first 48 h of admission. These patients were older and white. Macrolide use was not associated with lower 30-day mortality (hazard ratio, 1.14; 95% CI, 0.70-1.83; P=.5). In addition, patients treated with macrolides had no differences in ICU admission, use of mechanical ventilation, use of vasopressors, and length of stay (LOS) compared with patients not treated with macrolides. A subgroup analysis among patients with P aeruginosa CAP in the ICU showed no differences in baseline characteristics and outcomes.
   Conclusions: Macrolide therapy in the first 48 h of admission is not associated with decreased 30-day mortality, ICU admission, need for mechanical ventilation, and LOS in hospitalized patients with P aeruginosa CAP. Larger cohort studies should address the benefit of macrolides as immuno-modulators in patients with P aeruginosa CAP.
C1 [Laserna, Elena] Hosp Comarcal de Mollet, Mollet Del Valles, Spain.
   [Laserna, Elena; Sibila, Oriol; Fernandez, Juan Felipe; Maselli, Diego Jose; Anzueto, Antonio; Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
   [Sibila, Oriol] Hosp Santa Creu & Sant Pau, Serv Pneumol, Barcelona, Spain.
   [Sibila, Oriol] Inst Invest Biomed St Pau, Barcelona, Spain.
   [Fernandez, Juan Felipe; Maselli, Diego Jose; Anzueto, Antonio; Restrepo, Marcos I.] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
   [Mortensen, Eric M.] North Texas Vet Hlth Care Syst, Dallas, TX USA.
   [Mortensen, Eric M.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
   [Waterer, Grant] Univ Western Australia, Perth, WA 6009, Australia.
   [Waterer, Grant] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
RP Restrepo, MI (reprint author), South Texas Vet Hlth Care Syst, Audrey L Murphy Div, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA.
EM restrepom@uthscsa.edu
RI Restrepo, Marcos/H-4442-2014
OI Mortensen, Eric/0000-0002-3880-5563
FU Howard Hughes Medical Institute faculty [00378-001]; Department of
   Veterans Affairs Veterans Integrated Service Network 17 new faculty
   grant; Sociedad Espanola de Neumologia y Cirugia Toracica (SEPAR);
   Societat Catalana de Pneumologia (SOCAP); Fundacio Catalana de
   Pneumologia (FUCAP); Instituto de Salud Carlos III [BAE11/00102]
FX This research was supported by Howard Hughes Medical Institute faculty
   [Start-up Grant 00378-001] and a Department of Veterans Affairs Veterans
   Integrated Service Network 17 new faculty grant. Drs Laserna and Sibila
   are supported by Sociedad Espanola de Neumologia y Cirugia Toracica
   (SEPAR), Societat Catalana de Pneumologia (SOCAP), and Fundacio Catalana
   de Pneumologia (FUCAP). Dr Sibila is supported by Instituto de Salud
   Carlos III [BAE11/00102]. Dr Restrepo's time is partially protected by
   K23-HL096054 from the National Heart, Lung, and Blood Institute.
NR 33
TC 4
Z9 4
U1 1
U2 4
PU AMER COLL CHEST PHYSICIANS
PI NORTHBROOK
PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA
SN 0012-3692
J9 CHEST
JI Chest
PD MAY
PY 2014
VL 145
IS 5
BP 1114
EP 1120
DI 10.1378/chest.13-1607
PG 7
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA AI0IZ
UT WOS:000336532100029
PM 24458223
ER

PT J
AU Naik, AD
AF Naik, Aanand D.
TI Peering Inside the Black Box of Patient-Centered Care
SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES
LA English
DT Editorial Material
DE Ediorials; health care quality, access, and evaluation; decision support
   techniques; patient-centered care; patient participation; shared
   decision making
ID DECISION-MAKING; DIABETES-MELLITUS; ENDOSCOPY
C1 [Naik, Aanand D.] Michael E DeBakey VA Med Ctr, Ctr Innovat Qual Effectiveness & Safety IQuESt, Houston, TX USA.
   [Naik, Aanand D.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
RP Naik, AD (reprint author), Michael E DeBakey VA Med Ctr 152, Houston Ctr Innovat Qual Effectiveness & Safety, 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM anaik@bcm.edu
FU HSRD VA [I01 HX000486]
NR 18
TC 0
Z9 0
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-7705
EI 1941-7713
J9 CIRC-CARDIOVASC QUAL
JI Circ.-Cardiovasc. Qual. Outcomes
PD MAY
PY 2014
VL 7
IS 3
BP 347
EP 349
DI 10.1161/CIRCOUTCOMES.114.001038
PG 3
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AI3WQ
UT WOS:000336796300001
PM 24823950
ER

PT J
AU Kangovi, S
   Levy, K
   Barg, FK
   Carter, T
   Long, JA
   Grande, D
AF Kangovi, Shreya
   Levy, Kathryn
   Barg, Frances K.
   Carter, Tamala
   Long, Judith A.
   Grande, David
TI Perspectives of Older Adults of Low Socioeconomic Status on the
   Post-hospital Transition
SO JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED
LA English
DT Article
DE Low socioeconomic status; dually-eligible individuals; post-hospital
   transition; disparities
ID RANDOMIZED CONTROLLED-TRIAL; LOW-INCOME SENIORS; HEART-FAILURE; MEDICARE
   BENEFICIARIES; CARE; READMISSION; EXPERIENCES; MORTALITY; QUALITY;
   HEALTH
AB Background. Older adults of low socioeconomic status are at high risk for poor post-hospital outcomes. Design. A qualitative researcher, who was also an outreach worker from the West Philadelphia community, conducted in-depth interviews with 25 participants within 30 days of their hospital discharge. Participants. Eligible participants were: 1) residents of high-poverty ZIP codes; 2) dually eligible for Medicare and Medicaid; 3) had capacity or a caregiver who could be interviewed as a proxy; 4) general medicine or cardiology patients. Results. Participants were unable to access the care and accommodations needed to cope with post-hospital frailty. As a result, medical disability was amplified by socioeconomic disability. Participants were ashamed of the resulting loss of control and had difficulty asking for help, particularly from potential supports who were perceived as emotionally controlling or judgmental. Conclusion. Strategies that address socioeconomic stressors of hospitalization and provide empathic support may improve the post-hospital transition for these high-risk individuals.
C1 [Kangovi, Shreya; Long, Judith A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
   [Kangovi, Shreya] Univ Penn, Robert Wood Johnson Fdn Clin Scholars Program, Philadelphia, PA 19104 USA.
   [Kangovi, Shreya; Levy, Kathryn; Long, Judith A.; Grande, David] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Kangovi, Shreya; Long, Judith A.; Grande, David] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
   [Barg, Frances K.; Carter, Tamala] Univ Penn, Perelman Sch Med, Dept Family Med & Community Hlth, Philadelphia, PA 19104 USA.
   [Long, Judith A.] Philadelphia VA Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
RP Kangovi, S (reprint author), 1233 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM kangovi@upenn.edu
NR 46
TC 2
Z9 2
U1 0
U2 9
PU JOHNS HOPKINS UNIV PRESS
PI BALTIMORE
PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD
   21218-4363 USA
SN 1049-2089
EI 1548-6869
J9 J HEALTH CARE POOR U
JI J. Health Care Poor Underserved
PD MAY
PY 2014
VL 25
IS 2
BP 746
EP 756
PG 11
WC Health Policy & Services; Public, Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
GA AH7VJ
UT WOS:000336343100025
PM 24858883
ER

PT J
AU Lyerly, MJ
   Albright, KC
   Boehme, AK
   Shahripour, RB
   Houston, JT
   Rawal, PV
   Kapoor, N
   Alvi, M
   Sisson, A
   Alexandrov, AW
   Alexandrov, AV
AF Lyerly, Michael J.
   Albright, Karen C.
   Boehme, Amelia K.
   Shahripour, Reza Bavarsad
   Houston, James T.
   Rawal, Pawan V.
   Kapoor, Niren
   Alvi, Muhammad
   Sisson, April
   Alexandrov, Anne W.
   Alexandrov, Andrei V.
TI Safety of Protocol Violations in Acute Stroke tPA Administration
SO JOURNAL OF STROKE & CEREBROVASCULAR DISEASES
LA English
DT Article
DE Acute ischemic stroke; thrombolysis; patient safety; protocol violation;
   symptomatic intracerebral hemorrhage
ID ACUTE ISCHEMIC-STROKE; TISSUE-PLASMINOGEN ACTIVATOR; OFF-LABEL
   THROMBOLYSIS; INTRAVENOUS THROMBOLYSIS; HEMORRHAGIC COMPLICATIONS;
   ALTEPLASE; US
AB Background: Intravenous (IV) tissue plasminogen activator remains the only approved therapy for acute ischemic stroke (AIS) in the United States; however, less than 10% of patients receive treatment. This is partially because of the large number of contraindications, narrow treatment window, and physician reluctance to deviate from these criteria. Methods: We retrospectively analyzed consecutive patients who received IV thrombolysis at our stroke center for National Institute of Neurological Disorders and Stroke (NINDS) protocol violations and rates of symptomatic intracerebral hemorrhage (sICH). Other outcome variables included systemic hemorrhage, modified Rankin Scale at discharge, and discharge disposition. Results: A total of 212 patients were identified in our stroke registry between 2009 and 2011 and included in the analysis. Protocol violations occurred in 76 patients (36%). The most common violations were thrombolysis beyond 3 hours (26%), aggressive blood pressure management (15%), elevated prothrombin time (PT) or partial thromboplastin time (PTT) (6.6%), minor or resolving deficits (4.2%), unclear time of onset (3.9%), and stroke within 3 months (3%). There were no significant differences in any of the safety outcomes or discharge disposition between patients with or without protocol violations. Controlling for age, National Institutes of Health Stroke Scale on admission, and glucose on admission, there was no significant increase in sICH (odds ratio: 3.8; 95% confidence interval: .37-38.72) in the patients who had protocol violations. Conclusions: Despite more than one third of patients receiving thrombolysis with protocol violations, overall rates of hemorrhage remained low and did not differ from those who did not have violations. Our data support the need to expand access to thrombolysis in AIS patients.
C1 [Lyerly, Michael J.; Albright, Karen C.; Boehme, Amelia K.; Shahripour, Reza Bavarsad; Houston, James T.; Rawal, Pawan V.; Kapoor, Niren; Alvi, Muhammad; Sisson, April; Alexandrov, Anne W.; Alexandrov, Andrei V.] Univ Alabama Birmingham, Dept Neurol, Sch Med, Birmingham, AL 35294 USA.
   [Lyerly, Michael J.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
   [Albright, Karen C.; Boehme, Amelia K.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA.
   [Albright, Karen C.] Univ Alabama Birmingham, Hlth Serv, Birmingham, AL 35294 USA.
   [Albright, Karen C.] Univ Alabama Birmingham, Outcomes Res Ctr Outcome & Effectiveness Res & Ed, Birmingham, AL 35294 USA.
   [Albright, Karen C.] Univ Alabama Birmingham, Ctr Excellence Comparat Effectiveness Res Elimina, Minor Hlth & Hlth Dispar Res Ctr, Birmingham, AL 35294 USA.
   [Alexandrov, Anne W.] Univ Alabama Birmingham, Sch Nursing, Birmingham, AL 35294 USA.
RP Lyerly, MJ (reprint author), Univ Alabama Birmingham, Dept Neurol, Stroke Program, 1813 6th Ave S,RWUH M226, Birmingham, AL 35294 USA.
EM mjlyerly@uab.edu
OI Alexandrov, Andrei V/0000-0001-8871-1023; Boehme,
   Amelia/0000-0002-7109-6025; Lyerly, Michael/0000-0003-4236-1018
FU Agency for Healthcare Research and Quality [5 T32 HS013852-10]; National
   Institute on Minority Health and Health Disparities [3 P60
   MD000502-08S1]; National Institutes of Health; American Heart
   Association [13PRE13830003]
FX K.C.A. is supported by award numbers 5 T32 HS013852-10 from The Agency
   for Healthcare Research and Quality, 3 P60 MD000502-08S1 from The
   National Institute on Minority Health and Health Disparities, and
   National Institutes of Health. A.K.B. is supported by award
   13PRE13830003 from the American Heart Association. The content is solely
   the responsibility of the authors and does not necessarily represent the
   official views of the Agency for Healthcare Research and Quality,
   American Heart Association, or the National Institutes of Health.
NR 25
TC 9
Z9 9
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1052-3057
EI 1532-8511
J9 J STROKE CEREBROVASC
JI J. Stroke Cerebrovasc. Dis.
PD MAY-JUN
PY 2014
VL 23
IS 5
BP 855
EP 860
DI 10.1016/j.jstrokecerebrovasdis.2013.07.019
PG 6
WC Neurosciences; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA AH9SI
UT WOS:000336482000026
PM 23954609
ER

PT J
AU Montagnini, M
   Kaiser, RM
   Clark, PG
   Dodd, MA
   Goodwin, C
   Periyakoil, VS
   Ramsel, D
   Sanchez-Reilly, SE
   Semla, TP
   Smith, H
   Supiano, K
   Tsukuda, RA
   Zeiss, A
   OngChansanchai, LC
AF Montagnini, Marcos
   Kaiser, Robert M.
   Clark, Phillip G.
   Dodd, Melanie A.
   Goodwin, Carol
   Periyakoil, Vyjeyanthi S.
   Ramsel, Dee
   Sanchez-Reilly, Sandra E.
   Semla, Todd P.
   Smith, Heather
   Supiano, Katherine
   Tsukuda, Ruth Ann
   Zeiss, Antonette
   OngChansanchai, Li-Chia
CA Partnership Hlth Aging Workgrp Int
TI Position Statement on Interdisciplinary Team Training in Geriatrics: An
   Essential Component of Quality Health Care for Older Adults
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE interdisciplinary; team training; geriatrics education
ID RANDOMIZED CONTROLLED-TRIAL; ALL-INCLUSIVE CARE; INTERPROFESSIONAL
   EDUCATION; PROGRAM; MANAGEMENT; LESSONS; MODEL; PACE
AB Interdisciplinary team training (IDT) is an important component of ensuring quality geriatric care delivery, which can be complex and time intensive, requiring coordination of many medical, psychosocial, and therapeutic interventions and professionals. The Partnership for Health in Aging (PHA), a loose coalition of more than 30 organizations representing healthcare professionals who care for older adults supported by the American Geriatrics Society, identified IDT training in geriatrics as a priority area in addressing the geriatrics workforce shortage described in the 2008 Institute of Medicine report, Retooling for An Aging America: Building the Health Care Workforce. A PHA Workgroup on Interdisciplinary Team Training in Geriatrics was convened to review the literature focused on geriatrics IDT training and to develop a position statement that would inform and influence groups involved in the development and expansion of academic and continuing education programs in IDT training, including professional associations, credentialing and licensing bodies, accreditation organizations, and university administrators. There are significant challenges to expanding the development and implementation of geriatrics IDT training for health professionals, and such training will be successful only with substantial and sustained advocacy from the above professional groups.
C1 [Montagnini, Marcos] Univ Michigan, VA Ann Arbor Healthcare Syst, GRECC, Ann Arbor, MI 48109 USA.
   [Kaiser, Robert M.] George Washington Univ, Sch Med, DC Vet Affairs Med Ctr, Washington, DC USA.
   [Clark, Phillip G.] Univ Rhode Isl, Providence, RI 02908 USA.
   [Dodd, Melanie A.] Univ New Mexico, Coll Pharm, Albuquerque, NM 87131 USA.
   [Goodwin, Carol] Amer Geriatr Soc, New York, NY USA.
   [Periyakoil, Vyjeyanthi S.] Stanford Univ, Sch Med, Palo Alto Hlth Care Syst, Stanford, CA 94305 USA.
   [Ramsel, Dee] Med Coll Wisconsin, VHA Natl Ctr Org Dev, Milwaukee, WI 53226 USA.
   [Sanchez-Reilly, Sandra E.] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
   [Semla, Todd P.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Smith, Heather] Med Coll Wisconsin, Clement J Zablocki VAMC, Milwaukee, WI 53226 USA.
   [Supiano, Katherine] Univ Utah, Coll Nursing, Salt Lake City, UT 84112 USA.
   [Tsukuda, Ruth Ann] Portland VA Med Ctr, Portland, OR USA.
   [Zeiss, Antonette] Dept Vet Affairs, VA Cent Off, Washington, DC USA.
RP Montagnini, M (reprint author), VA Ann Arbor Healthcare Syst, GRECC, 2215 Fuller Rd 11-G, Ann Arbor, MI 48105 USA.
EM mmontag@umich.edu
OI Supiano, Katherine/0000-0001-7267-7705
FU MedEd Portal Interprofessional Educational Collaborative Collection
FX Dr. Dodd has received grant support from MedEd Portal Interprofessional
   Educational Collaborative Collection and a 10% salary release from
   Donald W. Reynolds Foundation Next Steps in Physician's Training in
   Geriatrics Grant.
NR 48
TC 10
Z9 10
U1 1
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2014
VL 62
IS 5
BP 961
EP 965
DI 10.1111/jgs.12822
PG 5
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA AH8JY
UT WOS:000336385300027
ER

PT J
AU Zhu, CW
   Sano, M
   Ferris, SH
   Whitehouse, PJ
   Patterson, MB
   Galasko, D
   Schneider, LS
   Aisen, PS
AF Zhu, Carolyn W.
   Sano, Mary
   Ferris, Steven H.
   Whitehouse, Peter J.
   Patterson, Marian B.
   Galasko, Douglas
   Schneider, Lon S.
   Aisen, Paul S.
TI ALZHEIMER'S DISEASE COOPERATIVE STUDY PREVENTION INSTRUMENT PROJECT
   ASSESSING RESOURCE USE AND VOLUNTEER AND PAID WORK IN HEALTHY ELDERS: A
   LONGITUDINAL STUDY
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Letter
ID DEMENTIA
C1 [Zhu, Carolyn W.] Mt Sinai Sch Med, Dept Geriatr & Palliat Med, New York, NY 10029 USA.
   [Sano, Mary] Mt Sinai Sch Med, Dept Psychiat, Alzheimer Dis Res Ctr, New York, NY USA.
   [Sano, Mary] James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
   [Ferris, Steven H.] NYU, Alzheimers Dis Ctr, Langone Med Ctr, New York, NY USA.
   [Whitehouse, Peter J.; Patterson, Marian B.] Case Western Reserve Univ, Dept Neurol, Cleveland, OH 44106 USA.
   [Galasko, Douglas; Aisen, Paul S.] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA.
   [Schneider, Lon S.] Univ So Calif, Keck Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90033 USA.
   [Schneider, Lon S.] Univ So Calif, Keck Sch Med, Dept Neurol, Los Angeles, CA 90033 USA.
RP Zhu, CW (reprint author), Mt Sinai Sch Med, Dept Geriatr & Palliat Med, New York, NY 10029 USA.
OI Ferris, Steven/0000-0001-8641-6223
FU NIA NIH HHS [P30 AG008051, P50 AG005131, P50 AG005138, P50 AG005142, U01
   AG010483, U01AG10483, U19 AG010483]
NR 7
TC 0
Z9 0
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2014
VL 62
IS 5
BP 985
EP 988
DI 10.1111/jgs.12816
PG 4
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA AH8JY
UT WOS:000336385300040
PM 24828933
ER

PT J
AU Groah, SL
   Ljungberg, I
   Lichy, A
   Oyster, M
   Boninger, ML
AF Groah, Suzanne L.
   Ljungberg, Inger
   Lichy, Alison
   Oyster, Michelle
   Boninger, Michael L.
TI Disparities in Wheelchair Procurement by Payer Among People With Spinal
   Cord Injury
SO PM&R
LA English
DT Article
ID ELECTRIC-POWERED WHEELCHAIRS; MANUAL WHEELCHAIRS; ANSI/RESNA STANDARDS;
   PROPULSION; PARTICIPATION; BIOMECHANICS; DURABILITY; POSITION; COST
AB Objective: To identify insurance provider-related disparities in the receipt of lightweight, customizable manual wheelchairs or power wheelchairs with programmable controls among community-dwelling people with spinal cord injury (SCI).
   Setting: Six Spinal Cord Injury Model System centers.
   Design: A multicenter cross-sectional study.
   Participants: A total of 359 individuals at least 16 years of age or older and 1 year after SCI who use a manual or power wheelchair as their. primary means of mobility. The subjects were stratified by payer, and payers were grouped according to reimbursement characteristics as follows: Medicaid/Department of Vocational Rehabilitation (DVR), private/prepaid, Medicare, Worker's Compensation (WC)/Veterans Affairs (VA), and self pay.
   Methods: Demographic, wheelchair, and payer data were collected by medical record review and face-to-face interview.
   Results: There were 125 participants in the Medicaid/DVR group, 120 in the private/ prepaid group, 55 in the Medicare group, 30 in the WC/VA group, and 29 in the self-pay group. For manual wheelchair users, the likelihood of having a lightweight, customizable wheelchair was 97.5% for private/prepaid, 96.3% for Medicaid/DVR, 94.1% for WC/VA, 87.5% for Medicare, and 82.6% for self pay. For power wheelchair users, those with WC/ VA (100%) were most likely to receive a customizable power wheelchair with programmable controls, followed by private/prepaid (95.1%), Medicaid/DVR (86.0 %), Medicare (83.9%), and self pay (50.0%).
   Conclusions: The only payer group for which all beneficiaries received wheelchairs that met standard of care were power wheelchairs provided by WC/VA. Fewer than 90% of people whose manual wheelchair was paid for by Medicare and self pay, and whose power wheelchair was paid for by Medicaid/DVR, Medicare, and self pay did not meet standard of care. Although these findings need to be correlated with long-term risks, such as overuse injuries, breakdowns, and participation, this study demonstrates that disparities in wheelchair procurement by insurance provider persist.
C1 [Groah, Suzanne L.] Natl Rehabil Hosp, Washington, DC 20010 USA.
   [Ljungberg, Inger; Lichy, Alison] MedStar Natl Rehabil Hosp, Washington, DC USA.
   [Oyster, Michelle; Boninger, Michael L.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA.
   [Oyster, Michelle; Boninger, Michael L.] VA Pittsburgh Healthcare Syst, Sch Med, Pittsburgh, PA USA.
   [Oyster, Michelle; Boninger, Michael L.] VA Pittsburgh Healthcare Syst, Ctr Excellence Wheelchairs & Associated Rehabil E, Pittsburgh, PA USA.
RP Groah, SL (reprint author), Natl Rehabil Hosp, 102 Irving St, Washington, DC 20010 USA.
EM suzanne.l.groah@medstar.net
OI Boninger, Michael/0000-0001-6966-919X
FU Department of Education/National Institute on Disability and
   Rehabilitation Research; National Institute on Disability and
   Rehabilitation Research
FX grant, Department of Education/National Institute on Disability and
   Rehabilitation Research; Grant, National Institute on Disability and
   Rehabilitation Research
NR 24
TC 3
Z9 3
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1934-1482
EI 1934-1563
J9 PM&R
JI PM&R
PD MAY
PY 2014
VL 6
IS 5
BP 412
EP 417
DI 10.1016/j.pmrj.2013.11.004
PG 6
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA AI0SR
UT WOS:000336560700007
PM 24211695
ER

PT J
AU Furman, MB
   Plastaras, CT
   Popescu, A
   Tekmyster, G
   Davidoff, S
   Kennedy, DJ
AF Furman, Michael B.
   Plastaras, Christopher T.
   Popescu, Adrian
   Tekmyster, Gene
   Davidoff, Scott
   Kennedy, David J.
TI Should Antiplatelet Medications Be Held Before Cervical Epidural
   Injections?
SO PM&R
LA English
DT Editorial Material
ID THERAPY; DISCONTINUATION; CLOPIDOGREL; RISK; PAIN
C1 [Furman, Michael B.] OSS Hlth, York, PA USA.
   [Plastaras, Christopher T.] Univ Penn, Dept Phys Med & Rehabil, Perelman Sch Med, Penn Spine Ctr, Philadelphia, PA 19104 USA.
   [Popescu, Adrian] Hosp Univ Penn, Philadelphia VA Med Ctr, Pain Med Div, Dept Phys Med & Rehabil, Philadelphia, PA 19104 USA.
   [Tekmyster, Gene] Orthopaed & Sports Med Ctr, Trumbull, CT USA.
   [Davidoff, Scott] Main Line Spine, King Of Prussia, PA USA.
   [Kennedy, David J.] Stanford Univ, Dept Orthopaed, Redwood City, CA 94063 USA.
RP Kennedy, DJ (reprint author), Stanford Univ, Dept Orthopaed, 450 Broadway St,MC 6342, Redwood City, CA 94063 USA.
EM djkenned@stanford.edu
NR 14
TC 1
Z9 1
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1934-1482
EI 1934-1563
J9 PM&R
JI PM&R
PD MAY
PY 2014
VL 6
IS 5
BP 442
EP 445
DI 10.1016/j.pmrj.2014.04.012
PG 4
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA AI0SR
UT WOS:000336560700011
PM 24863733
ER

PT J
AU Furman, MB
   Plastaras, CT
   Popescu, A
   Tekmyster, G
   Davidoff, S
   Kennedy, DJ
AF Furman, Michael B.
   Plastaras, Christopher T.
   Popescu, Adrian
   Tekmyster, Gene
   Davidoff, Scott
   Kennedy, David J.
TI Should Antiplatelet Medications Be Held Before Cervical Epidural
   Injections? Response
SO PM&R
LA English
DT Editorial Material
ID TRANSFORAMINAL INJECTIONS; PERIOPERATIVE MANAGEMENT; CLOPIDOGREL
   THERAPY; PRACTICE GUIDELINES; EUROPEAN-SOCIETY; CARDIOLOGY ESC;
   TASK-FORCE; STENT; IMPLANTATION; DURATION
C1 [Furman, Michael B.] OSS Hlth, York, PA USA.
   [Plastaras, Christopher T.] Univ Penn, Penn Spine Ctr, Perelman Sch Med, Dept Phys Med & Rehabil, Philadelphia, PA 19104 USA.
   [Popescu, Adrian] Hosp Univ Penn, Philadelphia VA Med Ctr, Pain Med Div, Dept Phys Med & Rehabil, Philadelphia, PA 19104 USA.
   [Tekmyster, Gene] Orthopaed & Sports Med Ctr, Trumbull, CT USA.
   [Davidoff, Scott] Main Line Spine, King Of Prussia, PA USA.
   [Kennedy, David J.] Stanford Univ, Dept Orthopaed, Redwood City, CA 94063 USA.
RP Kennedy, DJ (reprint author), Stanford Univ, Dept Orthopaed, 450 Broadway St,MC 6342, Redwood City, CA 94063 USA.
EM djkenned@stanford.edu
NR 19
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1934-1482
EI 1934-1563
J9 PM&R
JI PM&R
PD MAY
PY 2014
VL 6
IS 5
BP 445
EP 447
PG 3
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA AI0SR
UT WOS:000336560700012
ER

PT J
AU Furman, MB
   Plastaras, CT
   Popescu, A
   Tekmyster, G
   Davidoff, S
   Kennedy, DJ
AF Furman, Michael B.
   Plastaras, Christopher T.
   Popescu, Adrian
   Tekmyster, Gene
   Davidoff, Scott
   Kennedy, David J.
TI Should Antiplatelet Medications Be Held Before Cervical Epidural
   Injections?
SO PM&R
LA English
DT Editorial Material
ID ANGIOGRAPHY
C1 [Furman, Michael B.] OSS Hlth, York, PA USA.
   [Plastaras, Christopher T.] Univ Penn, Penn Spine Ctr, Perelman Sch Med, Dept Phys Med & Rehabil, Philadelphia, PA 19104 USA.
   [Popescu, Adrian] Hosp Univ Penn, Dept Phys Med & Rehabil, Pain Med Div, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA.
   [Tekmyster, Gene] Orthopaed & Sports Med Ctr, Trumbull, CT USA.
   [Davidoff, Scott] Main Line Spine, King Of Prussia, PA USA.
   [Kennedy, David J.] Stanford Univ, Dept Orthopaed, Redwood City, CA 94063 USA.
RP Kennedy, DJ (reprint author), Stanford Univ, Dept Orthopaed, 450 Broadway St,MC 6342, Redwood City, CA 94063 USA.
EM djkenned@stanford.edu
NR 5
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1934-1482
EI 1934-1563
J9 PM&R
JI PM&R
PD MAY
PY 2014
VL 6
IS 5
BP 447
EP 448
PG 2
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA AI0SR
UT WOS:000336560700013
ER

PT J
AU Furman, MB
   Plastaras, CT
   Popescu, A
   Tekmyster, G
   Davidoff, S
   Kennedy, DJ
AF Furman, Michael B.
   Plastaras, Christopher T.
   Popescu, Adrian
   Tekmyster, Gene
   Davidoff, Scott
   Kennedy, David J.
TI Should Antiplatelet Medications Be Held Before Cervical Epidural
   Injections?
SO PM&R
LA English
DT Editorial Material
ID LONG-TERM DURATION; HEMATOMA; THERAPY; MANAGEMENT; TRIAL; PAIN
C1 [Furman, Michael B.] OSS Hlth, York, PA USA.
   [Plastaras, Christopher T.] Univ Penn, Dept Phys Med & Rehabil, Perelman Sch Med, Penn Spine Ctr, Philadelphia, PA USA.
   [Popescu, Adrian] Hosp Univ Penn, Philadelphia VA Med Ctr, Pain Med Div, Dept Phys Med & Rehabil, Philadelphia, PA 19104 USA.
   [Tekmyster, Gene] Orthopaed & Sports Med Ctr, Trumbull, CT USA.
   [Davidoff, Scott] Main Line Spine, King Of Prussia, PA USA.
   [Kennedy, David J.] Stanford Univ, Dept Orthopaed, Redwood City, CA 94063 USA.
RP Kennedy, DJ (reprint author), Stanford Univ, Dept Orthopaed, 450 Broadway St,MC 6342, Redwood City, CA 94063 USA.
EM djkenned@stanford.edu
NR 13
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1934-1482
EI 1934-1563
J9 PM&R
JI PM&R
PD MAY
PY 2014
VL 6
IS 5
BP 448
EP 450
PG 3
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA AI0SR
UT WOS:000336560700014
ER

PT J
AU Samuelson, KW
   Koenig, CJ
   McCamish, N
   Choucroun, G
   Tarasovsky, G
   Bertenthal, D
   Seal, KH
AF Samuelson, Kristin W.
   Koenig, Christopher J.
   McCamish, Nicole
   Choucroun, Gerard
   Tarasovsky, Gary
   Bertenthal, Daniel
   Seal, Karen H.
TI Web-Based PTSD Training for Primary Care Providers: A Pilot Study
SO PSYCHOLOGICAL SERVICES
LA English
DT Article
DE posttraumatic stress disorder; primary care; veterans; Web-based
ID POSTTRAUMATIC-STRESS-DISORDER; NATIONAL COMORBIDITY SURVEY;
   MENTAL-HEALTH DIAGNOSES; AFGHANISTAN VETERANS; FUNCTIONAL IMPAIRMENT;
   SURVEY REPLICATION; ANXIETY DISORDERS; IRAQ; SERVICES; BARRIERS
AB Veterans with posttraumatic stress disorder (PTSD) symptoms frequently present to primary care providers (PCPs) and are reluctant to seek out or accept referrals to specialty mental health care. Most PCPs have not been trained to assess for and manage symptoms of PTSD. Web-based programs are increasingly used for medical education, but there are no published evaluations of online PTSD trainings for PCPs. We developed a 70-min Web-based training that focused on military-related PTSD for PCPs practicing in Veterans Affairs (VA) hospitals, but was applicable to PCPs treating veterans and other trauma-exposed patients outside VA settings. The training consisted of four modules: (1) Detection and Assessment; (2) Comorbid Conditions and Related Problems; (3) Pharmacological Interventions; and (4) Psychotherapeutic Interventions. Clinical vignettes dramatized key training concepts. Seventy-three PCPs completed the training and assessments pre- and posttraining and 30 days later. Paired t tests compared change in PTSD-related knowledge and comfort with PTSD-related skills, and qualitative methods were used to summarize participant feedback. After the training, mean knowledge score improved from 46% to 75% items correct, with sustained improvement at 30 days. Thirty days posttraining, PCPs reported significantly greater comfort regarding PTSD-related skills assessed; 47% reported using training content in their clinical practice. Qualitatively, PCPs appreciated the flexibility of asynchronous, self-paced online modules, but suggested more interactive content. Given the numerous barriers to specialty mental health treatment, coupled with a preference among veterans with PTSD for accessing treatment through primary care, improving PTSD competency among PCPs may help better serve veterans' mental health needs.
C1 [Samuelson, Kristin W.] Alliant Int Univ, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94133 USA.
   [Samuelson, Kristin W.] Alliant Int Univ, Dept Mental Hlth, San Francisco, CA 94133 USA.
   [Samuelson, Kristin W.] Alliant Int Univ, Calif Sch Profess Psychol, San Francisco, CA 94133 USA.
   [Koenig, Christopher J.; McCamish, Nicole; Choucroun, Gerard; Tarasovsky, Gary; Bertenthal, Daniel; Seal, Karen H.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA.
   [Koenig, Christopher J.; McCamish, Nicole; Choucroun, Gerard; Tarasovsky, Gary; Bertenthal, Daniel] San Francisco VA Med Ctr, Dept Mental Hlth, San Francisco, CA USA.
   [Seal, Karen H.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
   [Seal, Karen H.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
RP Samuelson, KW (reprint author), Alliant Int Univ, 1 Beach St,Suite 100, San Francisco, CA 94133 USA.
EM ksamuelson@alliant.edu
OI Koenig, Christopher J./0000-0003-0884-4120
NR 40
TC 0
Z9 0
U1 2
U2 8
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 1541-1559
EI 1939-148X
J9 PSYCHOL SERV
JI Psychol. Serv.
PD MAY
PY 2014
VL 11
IS 2
BP 153
EP 161
DI 10.1037/a0034855
PG 9
WC Psychology, Clinical
SC Psychology
GA AI3TC
UT WOS:000336784900004
PM 24364595
ER

PT J
AU Mendez, MF
   Fong, SS
   Shapira, JS
   Jimenez, EE
   Kaiser, NC
   Kremen, SA
   Tsai, PH
AF Mendez, Mario F.
   Fong, Sylvia S.
   Shapira, Jill S.
   Jimenez, Elvira E.
   Kaiser, Natalie C.
   Kremen, Sarah A.
   Tsai, Po-Heng
TI Observation of Social Behavior in Frontotemporal Dementia
SO AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS
LA English
DT Article
DE dementia; frontotemporal lobar degeneration; Alzheimer's disease; social
   behavior; autism
ID LOBAR DEGENERATION; DIAGNOSTIC-CRITERIA; ALZHEIMERS-DISEASE; MIND
   DEFICITS; RATING-SCALE; VARIANT; COGNITION; CONSENSUS
AB Background: The most characteristic manifestations of behavioral variant frontotemporal dementia (bvFTD) are abnormalities in social behavior. However, distinguishing bvFTD based on social behavior can be difficult in structured clinical settings.
   Methods: Using a Social Observation Inventory, 10 patients with bvFTD and 10 patients with Alzheimer's disease (AD) were compared to their caregiver interlocutors on 1-hour mealtime, in-home videotaped segments.
   Results: Compared to caregivers and patients with AD, patients with bvFTD were significantly disturbed in social behavior. In contrast, patients with AD were indistinguishable from their caregivers. The lack of you comments and decreased tact and manners distinguished 92.6% of the patients with bvFTD from patients with AD and caregivers. The Social Observation Inventory scores correlated with scores on frontal-executive tests and socioemotional scales.
   Conclusions: The systematic observation of social behavior during routine activities may be one of the best ways to distinguish patients with bvFTD from normal individuals and from patients with other dementias.
C1 [Mendez, Mario F.; Fong, Sylvia S.; Shapira, Jill S.; Jimenez, Elvira E.; Kaiser, Natalie C.; Kremen, Sarah A.; Tsai, Po-Heng] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.
   [Mendez, Mario F.; Fong, Sylvia S.; Shapira, Jill S.; Jimenez, Elvira E.; Kaiser, Natalie C.; Tsai, Po-Heng] VA Greater Los Angeles Healthcare Ctr, Los Angeles, CA 90073 USA.
RP Mendez, MF (reprint author), VA Greater Los Angeles Healthcare Ctr, Neurobehav Unit 691 116AF, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM mmendez@UCLA.edu
FU NIH [R01AG034499-03]
FX The authors disclosed receipt of the following financial support for the
   research, authorship and/or publication of this article: This work was
   supported by NIH grant #R01AG034499-03.
NR 37
TC 14
Z9 14
U1 2
U2 9
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1533-3175
EI 1938-2731
J9 AM J ALZHEIMERS DIS
JI Am. J. Alzheimers Dis. Other Dement.
PD MAY
PY 2014
VL 29
IS 3
BP 215
EP 221
DI 10.1177/1533317513517035
PG 7
WC Geriatrics & Gerontology; Clinical Neurology
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA AI0HL
UT WOS:000336527000005
PM 24370617
ER

PT J
AU Kasckow, J
   Golshan, S
   Zisook, S
AF Kasckow, John
   Golshan, Shahrokh
   Zisook, Sidney
TI Does Age Moderate the Relationship Between Depressive Symptoms and
   Suicidal Ideation in Middle-Aged and Older Patients with Schizophrenia
   and Subthreshold Depression?
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE Age; depression; moderation; schizophrenia; suicidal ideation
ID RATING-SCALE
AB Background: Suicidal deaths in middle-aged and older individuals with schizophrenia are a public health concern. Depression and schizophrenia are major risk factors for suicide. However, it is unknown whether age moderates the relationship between depression and suicidal ideation in patients with schizophrenia and subthreshold depression. Methods: Suicidal ideation was assessed with the InterSePT Scale for Suicidal Ideation and the Clinical Global Impression-Suicide Severity Scale in outpatients older than 39 years with schizophrenia and subthreshold depression (n = 213). Using linear regression, we examined whether depression (based on Calgary Depression Rating Scale scores), age, and "age by depressive symptoms" predicted suicidal ideation. Results: Depressive symptoms predicted suicidal ideation. Neither age nor "depressive symptoms by age" predicted suicidal ideation. Conclusions: In this population, age does not appear to moderate the relationship between depressive symptoms and suicidal behavior. Thus, assessing depressive symptoms as a risk factor is important at all ages in this population.
C1 [Kasckow, John] VA Pittsburgh Hlth Care Syst, MIRECC, Pittsburgh, PA 15240 USA.
   [Kasckow, John] Univ Pittsburgh, Med Ctr, Behav Hlth Serv, Pittsburgh, PA USA.
   [Kasckow, John] Univ Pittsburgh, Western Psychiat Inst & Clin, Med Ctr, Pittsburgh, PA 15213 USA.
   [Golshan, Shahrokh; Zisook, Sidney] VA San Diego Hlth Care Syst, San Diego, CA USA.
   [Golshan, Shahrokh; Zisook, Sidney] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA.
RP Kasckow, J (reprint author), VA Pittsburgh Hlth Care Syst, Behav Hlth, Univ Dr, Pittsburgh, PA 15240 USA.
EM kasckowjw@upmc.edu
FU VA HSRD [PPO 10-249-2]; VISN [4, 22 MIRECC]; University of California,
   San Diego Center for Community-Based Research in Older People with
   Psychoses; Cincinnati VAMC; University of Cincinnati College of
   Medicine; PamLab; Astra Zeneca;  [MH6398]
FX This work was supported by MH6398 (SZ and JK), VA HSRD PPO 10-249-2
   (JK), the VISN 4 and VISN 22 MIRECC, and the University of California,
   San Diego Center for Community-Based Research in Older People with
   Psychoses. The authors thank the Cincinnati VAMC and the University of
   Cincinnati College of Medicine for support. The contents of this article
   do not represent the views of the US government or the Department of
   Veterans Affairs of the US government. SZ has received research support
   from PamLab, and JK has received research support from Astra Zeneca.
NR 10
TC 2
Z9 2
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1064-7481
EI 1545-7214
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD MAY
PY 2014
VL 22
IS 5
BP 437
EP 441
DI 10.1016/j.jagp.2013.01.039
PG 5
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA AH4HE
UT WOS:000336087200003
PM 23567374
ER

PT J
AU McDaniel, SH
   Grus, CL
   Cubic, BA
   Hunter, CL
   Kearney, LK
   Schuman, CC
   Karel, MJ
   Kessler, RS
   Larkin, KT
   McCutcheon, S
   Miller, BF
   Nash, J
   Qualls, SH
   Connolly, KS
   Stancin, T
   Stanton, AL
   Sturm, LA
   Johnson, SB
AF McDaniel, Susan H.
   Grus, Catherine L.
   Cubic, Barbara A.
   Hunter, Christopher L.
   Kearney, Lisa K.
   Schuman, Catherine C.
   Karel, Michele J.
   Kessler, Rodger S.
   Larkin, Kevin T.
   McCutcheon, Stephen
   Miller, Benjamin F.
   Nash, Justin
   Qualls, Sara H.
   Connolly, Kathryn Sanders
   Stancin, Terry
   Stanton, Annette L.
   Sturm, Lynne A.
   Johnson, Suzanne Bennett
TI Competencies for Psychology Practice in Primary Care
SO AMERICAN PSYCHOLOGIST
LA English
DT Article
DE primary care; competence; education and training
ID CENTERED MEDICAL HOME; PROFESSIONAL PSYCHOLOGY; BEHAVIORAL HEALTH;
   POPULATION HEALTH; MODEL; EDUCATION; PROJECT; GEROPSYCHOLOGY;
   BENCHMARKS; SERVICES
AB This article reports on the outcome of a presidential initiative of 2012 American Psychological Association President Suzanne Bennett Johnson to delineate competencies for primary care (PC) psychology in six broad domains: science, systems, professionalism, relationships, application, and education. Essential knowledge, skills, and attitudes are described for each PC psychology competency. Two behavioral examples are provided to illustrate each competency. Clinical vignettes demonstrate the competencies in action. Delineation of these competencies is intended to inform education, practice, and research in PC psychology and efforts to further develop team-based competencies in PC.
C1 [McDaniel, Susan H.] Univ Rochester, Med Ctr, Inst Family, Dept Psychiat, Rochester, NY 14620 USA.
   [McDaniel, Susan H.] Univ Rochester, Med Ctr, Dept Family Med, Rochester, NY 14620 USA.
   [Grus, Catherine L.] Amer Psychol Assoc, Educ Directorate, Washington, DC 20036 USA.
   [Cubic, Barbara A.] Eastern Virginia Med Sch, Dept Family Med, Norfolk, VA USA.
   [Hunter, Christopher L.] Def Hlth Agcy, Patient Ctr Med Home Branch, Clin Support Div, Falls Church, VA USA.
   [Kearney, Lisa K.] Vet Hlth Adm, Off Mental Hlth Operat, Dept Vet Affairs, Cent Off, Washington, DC USA.
   [Kearney, Lisa K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA.
   [Schuman, Catherine C.] Harvard Univ, Sch Med, Dept Psychiat, Div Psychol, Cambridge, MA 02138 USA.
   [Karel, Michele J.] Dept Vet Affairs, Off Mental Hlth Serv, Cent Off, Washington, DC USA.
   [Kessler, Rodger S.] Vermont Coll Med, Dept Family Med, Burlington, VT USA.
   [Larkin, Kevin T.] W Virginia Univ, Dept Psychol, Morgantown, WV 26506 USA.
   [McCutcheon, Stephen] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
   [Miller, Benjamin F.] Univ Colorado Denver, Sch Med, Dept Family Med, Denver, CO USA.
   [Nash, Justin] Brown Univ, Dept Family Med, Pawtucket, RI USA.
   [Nash, Justin] Brown Univ, Mem Hosp Rhode Isl, Pawtucket, RI 02860 USA.
   [Qualls, Sara H.] Univ Colorado, Dept Psychol, Colorado Springs, CO 80933 USA.
   [Connolly, Kathryn Sanders] Vet Affairs Connecticut Healthcare Syst, Psychol Serv, West Haven, CT USA.
   [Connolly, Kathryn Sanders] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06520 USA.
   [Stancin, Terry] MetroHlth Med Ctr, Div Child & Adolescent Psychiat & Psychol, Cleveland, OH USA.
   [Stancin, Terry] Case Western Reserve Univ, Sch Med, Cleveland, OH 44106 USA.
   [Stanton, Annette L.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA.
   [Sturm, Lynne A.] Indiana Univ Sch Med, Dept Pediat, Indianapolis, IN 46202 USA.
   [Johnson, Suzanne Bennett] Florida State Univ, Coll Med, Dept Med Humanities & Social Sci, Tallahassee, FL 32306 USA.
RP McDaniel, SH (reprint author), Univ Rochester, Med Ctr, Dept Family Med, 777 S Clinton Ave, Rochester, NY 14620 USA.
EM susanh2_mcdaniel@urmc.rochester.edu
OI Miller, Benjamin/0000-0003-1647-0122
NR 71
TC 36
Z9 36
U1 2
U2 15
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0003-066X
EI 1935-990X
J9 AM PSYCHOL
JI Am. Psychol.
PD MAY-JUN
PY 2014
VL 69
IS 4
SI SI
BP 409
EP 429
DI 10.1037/a0036072
PG 21
WC Psychology, Multidisciplinary
SC Psychology
GA AH5ER
UT WOS:000336151800009
PM 24820690
ER

PT J
AU Williams, BA
   Schott, NJ
   Mangione, MP
   Ibinson, JW
AF Williams, Brian A.
   Schott, Nicholas J.
   Mangione, Michael P.
   Ibinson, James W.
TI Perineural Dexamethasone and Multimodal Perineural Analgesia: How Much
   Is Too Much?
SO ANESTHESIA AND ANALGESIA
LA English
DT Editorial Material
ID SCIATIC-NERVE BLOCK; ELIMINATING POSTOPERATIVE NAUSEA; OFF-PATENT
   ANTIEMETICS; OUTPATIENT SURGERY; LOCAL-ANESTHETICS; ROPIVACAINE;
   DURATION; RAT; DEXMEDETOMIDINE; METAANALYSIS
C1 [Williams, Brian A.; Ibinson, James W.] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15261 USA.
   [Schott, Nicholas J.] UPMC, Dept Anesthesiol, Pittsburgh, PA USA.
   [Mangione, Michael P.] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15261 USA.
RP Williams, BA (reprint author), Univ Pittsburgh, Sch Med, Dept Anesthesiol, Vet Affairs Pittsburgh Healthcare Syst, 200 Lothrop St,A-1305, Pittsburgh, PA 15261 USA.
EM Williamsba@anes.upmc.edu
NR 20
TC 11
Z9 11
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0003-2999
EI 1526-7598
J9 ANESTH ANALG
JI Anesth. Analg.
PD MAY
PY 2014
VL 118
IS 5
BP 912
EP 914
DI 10.1213/ANE.0000000000000203
PG 3
WC Anesthesiology
SC Anesthesiology
GA AG4NE
UT WOS:000335395900008
PM 24781562
ER

PT J
AU Kruse, JL
   Jeffrey, JK
   Davis, MC
   Dearlove, J
   IsHak, WW
   Brooks, JO
AF Kruse, Jennifer L.
   Jeffrey, Jessica K.
   Davis, Michael C.
   Dearlove, Joanna
   IsHak, Waguih William
   Brooks, John O., III
TI Anti-N-methyl-D-aspartate receptor encephalitis: A targeted review of
   clinical presentation, diagnosis, and approaches to psychopharmacologic
   management
SO ANNALS OF CLINICAL PSYCHIATRY
LA English
DT Review
DE N-methyl-D-aspartate receptor; limbic encephalitis; behavioral symptoms;
   benzodiazepines; antipsychotic agents
ID NMDAR ENCEPHALITIS; ANTIBODIES; ADOLESCENTS; DISEASES; CHILDREN
AB BACKGROUND: Anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis was formally described in 2007 and includes a range of psychiatric and neurologic symptoms. Most patients with anti-NMDAR encephalitis initially present to psychiatrists for diagnosis and treatment. However, there is limited literature summarizing treatment strategies for psychiatric symptoms. In an effort to improve identification and treatment, this review article provides an overview of anti-NMDAR encephalitis, with a focus on psychopharmacologic treatment strategies. Two case reports provide a clinical context for the literature review.
   METHODS: The authors conducted a PubMed search.
   RESULTS: Prominent psychiatric symptoms of anti-NMDAR encephalitis include psychosis, agitation, insomnia, and catatonia. Neuroleptics may be helpful for managing psychosis and agitation, but may exacerbate movement abnormalities. Diphenhydramine and benzodiazepines are helpful for agitation and insomnia. In addition, the anticholinergic affinity of diphenhydramine can improve dystonia or rigidity attributable to anti-NMDAR encephalitis, while benzodiazepines and electroconvulsive therapy have been used for catatonia associated with this condition.
   CONCLUSIONS: Psychiatrists play an important role in the diagnosis and treatment of anti-NMDAR encephalitis. Recognizing the typical clinical progression and closely monitoring for accompanying neurologic symptoms will facilitate diagnosis and timely treatment. Careful selection of psychopharmacological interventions may reduce suffering.
C1 [Kruse, Jennifer L.; Jeffrey, Jessica K.; Davis, Michael C.; Brooks, John O., III] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
   [Kruse, Jennifer L.] Mayo Clin, Dept Psychiat & Psychol, Rochester, MN USA.
   [Davis, Michael C.] VA Greater Los Angeles, Los Angeles, CA USA.
   [Dearlove, Joanna] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.
   [IsHak, Waguih William] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Dept Psychiat & Behav Neurosci,Cedars Sinai Med C, Los Angeles, CA 90095 USA.
RP Brooks, JO (reprint author), UCLA Semel Inst, 760 Westwood Plaza,B3-267, Los Angeles, CA 90024 USA.
EM john.brooks@ucla.edu
RI Davis, Michael/L-8920-2013
OI Davis, Michael/0000-0003-2293-5694
FU Pfizer
FX Dr. Brooks has received a research grant from Pfizer, and is a speaker
   for Sunovion. Drs. Kruse, Jeffrey, Davis, Dearlove, and IsHak report no
   financial relationships with any company whose products are mentioned in
   this article or with manufacturers of competing products.
NR 23
TC 15
Z9 16
U1 1
U2 5
PU QUADRANT HEALTHCOM INC
PI PARSIPPANY
PA 7 CENTURY DRIVE, STE 302, PARSIPPANY, NJ 07054-4603 USA
SN 1040-1237
EI 1547-3325
J9 ANN CLIN PSYCHIATRY
JI Ann. Clin. Psychiatry
PD MAY
PY 2014
VL 26
IS 2
BP 111
EP 119
PG 9
WC Psychiatry
SC Psychiatry
GA AH7WX
UT WOS:000336347200005
PM 24501734
ER

PT J
AU Uneyama, H
   Takeuchi, K
   Tache, YF
AF Uneyama, Hisayuki
   Takeuchi, Koji
   Tache, Yvette F.
TI Molecular Basis of Gastrointestinal Chemical Senses
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Editorial Material
DE Taste; gut nutrient-sensing; gastrointestinal diseases
ID GUT
C1 [Uneyama, Hisayuki] Ajinomoto Co Inc, Inst Innovat, Frontier Res Labs, Umami Wellness Res Grp, Kawasaki, Kanagawa 2108681, Japan.
   [Takeuchi, Koji] Kyoto Pharmaceut Univ, Dept Pharmacol & Expt Therapeut, Div Pathol Sci, Yamashina Ku, Kyoto 6078414, Japan.
   [Tache, Yvette F.] Univ Calif Los Angeles, CURE Digest Dis Res Ctr, Los Angeles, CA 90024 USA.
   [Tache, Yvette F.] Univ Calif Los Angeles, Ctr Neurobiol Stress, Vet Affairs Greater Los Angeles Healthcare Syst, Dept Med,Digest Dis Div, Los Angeles, CA 90024 USA.
   [Tache, Yvette F.] VA Greater Los Angeles Healght Care Syst, Los Angeles, CA USA.
RP Uneyama, H (reprint author), Ajinomoto Co Inc, Inst Innovat, Frontier Res Labs, Umami Wellness Res Grp, 1-1 Suzuki Cho, Kawasaki, Kanagawa 2108681, Japan.
EM hisayuki_uneyama@ajinomoto.com
NR 21
TC 0
Z9 0
U1 1
U2 2
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PD MAY
PY 2014
VL 20
IS 16
BP 2667
EP 2668
PG 2
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA AH5NB
UT WOS:000336175700001
PM 24828701
ER

PT J
AU Tache, Y
   Adelson, D
   Yang, H
AF Tache, Yvette
   Adelson, David
   Yang, Hong
TI TRH/TRH-R1 Receptor Signaling in the Brain Medulla as a Pathway of
   Vagally Mediated Gut Responses During the Cephalic Phase
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Article
DE Dorsal vagal complex; enteric nervous system; gastric secretion; TRH;
   sham feeding and vagus
ID THYROTROPIN-RELEASING-HORMONE; GASTRIC-ACID-SECRETION; DORSAL MOTOR
   NUCLEUS; RAPHE PALLIDUS NEURONS; CENTRAL-NERVOUS-SYSTEM; SUBSTANCE-P;
   NUTRITIONAL IMPLICATIONS; INTRACISTERNAL TRH; STABILIZED ANALOG;
   MYENTERIC NEURONS
AB Pavlov's seminal findings in the early twentieth century showed that the sight, smell or taste of food in dogs with chronic esophagostomy induces a vagal-dependent gastric acid secretion. These observations established the concept of the cephalic phase of digestion. Compelling experimental evidence in rats indicates that the three amino acid peptide thyrotropin-releasing hormone (TRH) expressed in the brainstem plays a key role in the vagal stimulation of gastric function. Neurons in the dorsal motor nucleus of the vagus (DMN) expressed TRH receptor subtype (TRH-R1) and received efferent input from TRH containing fibers arising from TRH synthesizing neurons in the raphe pallidus, raphe obscurus, and the parapyramidal regions. TRH microinjected into the DMN or intracisternally excites the firing of DMN neurons and stimulates efferent activity in the gastric branch of the vagus nerve and gastric myenteric cholinergic neurons. At the functional level, this results in a vagally-mediated and atropine-sensitive stimulation of gastric epithelial and endocrine cells secreting acid, pepsin, serotonin, histamine and ghrelin, and enteric neurons leading to increased gastric motility and emptying. Importantly, the blockade of TRH or TRH-R1 in the brainstem by pretreatment into the cisterna magna or the DMN with TRH antibody or TRH-R1 oligodeoxynucleotide antisense respectively abolishes the stimulation of gastric acid induced by sham-feeding. The gastric response to TRH injected into the DMN is potentiated by serotonin and the proTRH flanking peptide, Ps4 and suppressed by a number of brainstem peptides and cytokines activated during stress or immune response and inhibiting food intake and gastric acid secretion. These convergent data strongly support a physiological involvement of TRH signaling pathway in the brainstem to stimulate vagal activity and identified TRH-TRH-R1 system as a major effector in the dorsal vagal complex to drive the vagally mediated gut response triggered by the cephalic phase.
C1 Univ Calif Los Angeles, CURE Digest Dis Res Ctr David Geffen Sch, Los Angeles, CA 90073 USA.
   Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Ctr Neurobiol Stress,Dept Med,Digest Dis Div, Los Angeles, CA 90073 USA.
   VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
RP Tache, Y (reprint author), VA Greater Los Angeles Healthcare Syst, CURE DDRC, Bldg 115,Rm 117,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM ytache@mednet.ucla.edu
OI Adelson, David/0000-0002-4623-6030
FU NIHDDK [DK 33061]; Center (Animal Core) [DK 41301]
FX The authors' work was supported by the NIHDDK grant DK 33061, the Center
   grant DK 41301 (Animal Core), VA Merit Award and VA Research Career
   Scientist Award. We thank Eugenia Hu for helping in the preparation of
   to the manuscript.
NR 102
TC 7
Z9 7
U1 0
U2 4
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PD MAY
PY 2014
VL 20
IS 16
BP 2725
EP 2730
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA AH5NB
UT WOS:000336175700007
PM 23886382
ER

PT J
AU Akiba, Y
   Kaunitz, JD
AF Akiba, Yasutada
   Kaunitz, Jonathan D.
TI Duodenal Luminal Chemosensing; Acid, ATP, and Nutrients
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Article
DE Luminal nutrient; G-protein coupled receptors and gut hormone release
ID PROTEIN-COUPLED RECEPTOR; DIPEPTIDYL-PEPTIDASE-IV; GLUCAGON-LIKE
   PEPTIDE-2; BICARBONATE SECRETION; RAT DUODENUM; GASTROINTESTINAL-TRACT;
   TASTE RECEPTORS; HCO3-SECRETION; CARBONIC-ANHYDRASES; CALCIUM-ABSORPTION
AB Intestinal chemosensing of endogenous and exogenous luminal compounds, including acid, CO2, bile acids and nutrients is an emerging area of gastrointestinal research, since gut hormones, particularly including incretins and glucagon-like peptide-2 (GLP-2) are released in response to luminal nutrients. Identification of luminal chemosensors such as nutrient-ligand G-protein coupled receptors (GPCRs) in enteroendocrine cells has linked luminal compounds to the corresponding gut hormone release. Mucosal chemical sensors are necessary to exert physiological responses such as secretion, digestion, absorption, and motility. We have been studying the mechanisms by which luminal compounds are sensed via mucosal acid sensors and GPCRs, which trigger mucosal defense mechanisms. In addition to luminal acid/CO2 sensing in the duodenum, recent studies also show that compounds present post-prandially such as amino acids, bile acids and fatty acids, enhance duodenal mucosal defenses, with digestion following the initial gastric processing. These studies may form the basis for therapies in which luminal nutrients release gut hormones that affect the mucosal protection, appetite, satiety, and systemic metabolisms.
C1 Univ Calif Los Angeles, Sch Med, Dept Med, Vet Affairs Greater Los Angles Healthcare Syst, Los Angeles, CA 90073 USA.
   Brentwood Biomed Res Inst, Los Angeles, CA 90073 USA.
RP Akiba, Y (reprint author), West Los Angeles VA Med Ctr, Bldg 114,Suite 217,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM yakiba@mednet.ucla.edu
FU Ajinomoto Inc., Japan; AstraZeneca [IRUSESOM0424]; Department of
   Veterans Affairs Merit Review Award; NIH-NIDDK [R01 DK54221]
FX Supported by a research grant from Ajinomoto Inc., Japan (Y. Akiba),
   Investigator-Sponsored Study Program of AstraZeneca IRUSESOM0424 (Y.
   Akiba), Department of Veterans Affairs Merit Review Award (J. Kaunitz),
   and NIH-NIDDK R01 DK54221 (J. Kaunitz).
NR 65
TC 7
Z9 7
U1 2
U2 6
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PD MAY
PY 2014
VL 20
IS 16
BP 2760
EP 2765
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA AH5NB
UT WOS:000336175700013
PM 23886391
ER

PT J
AU Chen, WL
   Walwyn, W
   Ennes, HS
   Kim, H
   McRoberts, JA
   Marvizon, JCG
AF Chen, Wenling
   Walwyn, Wendy
   Ennes, Helena S.
   Kim, Hyeyoung
   McRoberts, James A.
   Marvizon, Juan Carlos G.
TI BDNF released during neuropathic pain potentiates NMDA receptors in
   primary afferent terminals
SO EUROPEAN JOURNAL OF NEUROSCIENCE
LA English
DT Article
DE microglia; mouse; neurokinin 1 receptor; rat; substance P; trkB receptor
ID RAT SPINAL-CORD; DORSAL-ROOT GANGLIA; SUBSTANCE-P RELEASE; PRIMARY
   SENSORY NEURONS; D-ASPARTATE RECEPTORS; SRC FAMILY KINASES; NEUROTROPHIC
   FACTOR; MEDIATED PHOSPHORYLATION; NEUROKININ-1 RECEPTOR;
   SYNAPTIC-TRANSMISSION
AB NMDA receptors in primary afferent terminals can contribute to hyperalgesia by increasing neurotransmitter release. In rats and mice, we found that the ability of intrathecal NMDA to induce neurokinin 1 receptor (NK1R) internalization (a measure of substanceP release) required a previous injection of BDNF. Selective knock-down of NMDA receptors in primary afferents decreased NMDA-induced NK1R internalization, confirming the presynaptic location of these receptors. The effect of BDNF was mediated by tropomyosin-related kinaseB (trkB) receptors and not p75 neurotrophin receptors (p75(NTR)), because it was not produced by proBDNF and was inhibited by the trkB antagonist ANA-12 but not by the p75(NTR) inhibitor TAT-Pep5. These effects are probably mediated through the truncated form of the trkB receptor as there is little expression of full-length trkB in dorsal root ganglion (DRG) neurons. Src family kinase inhibitors blocked the effect of BDNF, suggesting that trkB receptors promote the activation of these NMDA receptors by Src family kinase phosphorylation. Western blots of cultured DRG neurons revealed that BDNF increased Tyr(1472) phosphorylation of the NR2B subunit of the NMDA receptor, known to have a potentiating effect. Patch-clamp recordings showed that BDNF, but not proBDNF, increased NMDA receptor currents in cultured DRG neurons. NMDA-induced NK1R internalization was also enabled in a neuropathic pain model or by activating dorsal horn microglia with lipopolysaccharide. These effects were decreased by a BDNF scavenger, a trkB receptor antagonist and a Src family kinase inhibitor, indicating that BDNF released by microglia potentiates NMDA receptors in primary afferents during neuropathic pain.
C1 [Chen, Wenling; McRoberts, James A.; Marvizon, Juan Carlos G.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
   [Chen, Wenling; Ennes, Helena S.; Kim, Hyeyoung; McRoberts, James A.; Marvizon, Juan Carlos G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Digest Dis, Los Angeles, CA 90095 USA.
   [Walwyn, Wendy] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90095 USA.
RP Marvizon, JCG (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
EM marvizon@ucla.edu
FU National Institute of Drug Abuse [R01-DA033059]; Rehabilitation Research
   & Development Service, Department of Veterans Affairs [1I01RX000378];
   Division of Digestive Diseases at the David Geffen School of Medicine,
   UCLA; NIH [1S10RR028124]
FX Supported by grant R01-DA033059 to J.C.M and J.A.M. from the National
   Institute of Drug Abuse, grant 1I01RX000378 to J.C.M. from the
   Rehabilitation Research & Development Service, Department of Veterans
   Affairs and research funds from the Division of Digestive Diseases at
   the David Geffen School of Medicine, UCLA. Mutant mice were provided by
   the UCLA Behavioral Core by under the direction of Michael Fanselow and
   supported by NIH grant 1S10RR028124. This study was done under the
   umbrella of the following UCLA institutes: Brain Research Institute,
   Center for the Study of Opioid Receptors and Drugs of Abuse, CURE:
   Digestive Diseases Research Center and the Oppenheimer Family Center for
   Neurobiology of Stress. The authors declare no competing financial
   interests.
NR 83
TC 14
Z9 14
U1 1
U2 13
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0953-816X
EI 1460-9568
J9 EUR J NEUROSCI
JI Eur. J. Neurosci.
PD MAY
PY 2014
VL 39
IS 9
BP 1439
EP 1454
DI 10.1111/ejn.12516
PG 16
WC Neurosciences
SC Neurosciences & Neurology
GA AG1ZP
UT WOS:000335215000005
PM 24611998
ER

PT J
AU Sanfilippo, KM
   McTigue, KM
   Fidler, CJ
   Neaton, JD
   Chang, YF
   Fried, LF
   Liu, SM
   Kuller, LH
AF Sanfilippo, Kristen M.
   McTigue, Kathleen M.
   Fidler, Christian J.
   Neaton, James D.
   Chang, Yuefang
   Fried, Linda F.
   Liu, Simin
   Kuller, Lewis H.
TI Hypertension and Obesity and the Risk of Kidney Cancer in 2 Large
   Cohorts of US Men and Women
SO HYPERTENSION
LA English
DT Article
DE blood pressure; body weight; epidemiology; kidney neoplasms; obesity
ID RENAL-CELL CARCINOMA; HIPPEL-LINDAU GENE; BLOOD-PRESSURE;
   ANTIHYPERTENSIVE MEDICATION; POSTMENOPAUSAL WOMEN; LIPID-PEROXIDATION;
   CIGARETTE-SMOKING; UNITED-STATES; MECHANISMS; ASCERTAINMENT
AB Kidney cancer incidence is increasing globally. Reasons for this rise are unclear but could relate to obesity and hypertension. We analyzed longitudinal relationships between hypertension and obesity and kidney cancer incidence in 156 774 participants of the Women's Health Initiative clinical trials and observational studies over 10.8 years. In addition, we examined the effect of blood pressure (BP) on kidney cancer deaths for over 25 years among the 353 340 men screened for the Multiple Risk Factor Intervention Trial (MRFIT). In the Women's Health Initiative, systolic BP (SBP) was categorized in 6 groups from <120 to >160 mm Hg, and body mass index was categorized using standard criteria. In age-adjusted analyses, kidney cancer risk increased across SBP categories (P value for trend <0.0001) and body mass index categories (P value for trend <0.0001). In adjusted Cox proportional hazards models, both SBP levels and body mass index were predictors of kidney cancer. In the MRFIT sample, there were 906 deaths after an average of 25 years of follow-up attributed to kidney cancer among the 353 340 participants aged 35 to 57 years at screening. The risk of death from kidney cancer increased in a dose-response fashion with increasing SBP (hazard ratio, 1.87 for SBP>160 versus <120 mm Hg; 95% confidence interval, 1.38-2.53). Risk was increased among cigarette smokers. Further research is needed to determine the pathophysiologic basis of relationships between both higher BP and the risk of kidney cancer, and whether specific drug therapies for hypertension can reduce kidney cancer risk.
C1 [Sanfilippo, Kristen M.] Washington Univ, Dept Hematol, St Louis, MO USA.
   [Sanfilippo, Kristen M.] VA St Louis Healthcare Syst, Res Serv, St Louis, MO USA.
   [McTigue, Kathleen M.; Fried, Linda F.] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA.
   [Chang, Yuefang] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA.
   [McTigue, Kathleen M.; Fried, Linda F.; Kuller, Lewis H.] Univ Pittsburgh, Dept Epidemiol, Grad Sch Publ Hlth, Pittsburgh, PA 15260 USA.
   [Fidler, Christian J.] Abington Mem Hosp, Rosenfeld Canc Ctr, Abington, PA 19001 USA.
   [Neaton, James D.] Univ Minnesota, Sch Publ Hlth, Div Biostat, Minneapolis, MN 55455 USA.
   [Fried, Linda F.] VA Pittsburgh Healthcare Syst, Dept Peritoneal Dialysis, Pittsburgh, PA USA.
   [Liu, Simin] Brown Univ, Dept Epidemiol, Providence, RI 02912 USA.
RP McTigue, KM (reprint author), Univ Pittsburgh, Dept Med & Epidemiol, 230 McKee Pl Suite 600, Pittsburgh, PA 15213 USA.
EM kmm34@pitt.edu
RI Liu, Simin/I-3689-2014
OI Liu, Simin/0000-0003-2098-3844
FU Women's Health Initiative (WHI); National Heart, Lung, and Blood
   Institute (NHLBI); National Institutes of Health (NIH); US Department of
   Health and Human Services [HHSN268201100046C, HHSN268201100001C,
   HHSN268201100002C, HHSN268201100003C, HHSN268201100004C,
   HHSN271201100004C]; University of Pittsburgh Internal Medicine Residency
   program; NHLBI, NIH, Bethesda, MD; NIH/NHLBI [R01-HL-43232,
   R01-HL-68140]
FX The Women's Health Initiative (WHI) program is funded by the National
   Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health
   (NIH), US Department of Health and Human Services through contracts
   HHSN268201100046C, HHSN268201100001C, HHSN268201100002C,
   HHSN268201100003C, HHSN268201100004C, and HHSN271201100004C. Dr
   Sanfilippo's time on this project was supported by the University of
   Pittsburgh Internal Medicine Residency program. The Multiple Risk Factor
   Intervention Trial was contracted by the NHLBI, NIH, Bethesda, MD.
   Followup after the end of the trial was supported with NIH/NHLBI grants
   -R01-HL-43232 and R01-HL-68140.
NR 35
TC 9
Z9 10
U1 0
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0194-911X
EI 1524-4563
J9 HYPERTENSION
JI Hypertension
PD MAY
PY 2014
VL 63
IS 5
BP 934
EP 941
DI 10.1161/HYPERTENSIONAHA.113.02953
PG 8
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA AE9IG
UT WOS:000334320900021
PM 24637660
ER

PT J
AU Hanson, L
   VandeVusse, L
   Duster, M
   Warrack, S
   Safdar, N
AF Hanson, Lisa
   VandeVusse, Leona
   Duster, Megan
   Warrack, Simone
   Safdar, Nasia
TI Feasibility of Oral Prenatal Probiotics against Maternal Group B
   Streptococcus Vaginal and Rectal Colonization
SO JOGNN-JOURNAL OF OBSTETRIC GYNECOLOGIC AND NEONATAL NURSING
LA English
DT Article
DE pregnancy; probiotics; group B Streptococcus
ID PATIENT PREFERENCE; ANTIBIOTICS; INFECTIONS; WOMEN; RISK; LACTOBACILLI;
   PROPHYLAXIS; EXPOSURE; EFFICACY; OUTCOMES
AB ObjectiveTo examine the effect of an oral prenatal probiotic on group B Streptococcus (GBS) colonization and to demonstrate the feasibility of a larger randomized controlled trial.
   DesignThis pilot study was an open-label, two-group quasi-experiment.
   SettingAn urban central city nurse-midwifery and wellness center serving a diverse population.
   ParticipantsTen pregnant participants received the oral probiotic (Florajen3) taken once daily, and 10 participants served as controls.
   MethodsA questionnaire on dietary practices, vaginal cleansing, sexual history, and symptoms and GBS colony count samples were taken at 28-, 32-, and 36-weeks gestation.
   ResultsParticipants in the probiotic group reported no adverse events or minor side effects; one half reported improved gastrointestinal symptoms. Although two women in each group had positive qualitative prenatal GBS cultures at 36weeks, the probiotic group participants had lower quantitative GBS colony counts. The eight GBS negative averaged 90% probiotic adherence compared with two GBS positive women who averaged 68%. Yogurt ingestion was inversely related (p=.02) to GBS colonization.
   ConclusionsPrenatal probiotic therapy has the potential to reduce GBS colonization. The potential of the probiotic intervention appears to be linked to daily adherence. A controlled clinical trial with a larger, adequately powered sample is feasible and justified.
C1 [Hanson, Lisa; VandeVusse, Leona] Marquette Univ, Coll Nursing, Nurse Midwifery Program, Milwaukee, WI 53201 USA.
   [Hanson, Lisa] Aurora Sinai Midwifery & Wellness Ctr, Milwaukee, WI USA.
   [Duster, Megan] Univ Wisconsin, Sch Med & Publ Hlth, Infect Dis Res Lab, Div Infect Dis, Madison, WI USA.
   [Warrack, Simone] Univ Wisconsin, Sch Med & Publ Hlth, Infect Dis Res Lab, Madison, WI USA.
   [Safdar, Nasia] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med & Infect Dis, Madison, WI USA.
   [Safdar, Nasia] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
RP Hanson, L (reprint author), Marquette Univ, Coll Nursing, Clark Hall 341,POB 1881, Milwaukee, WI 53201 USA.
EM lisa.hanson@mu.edu
FU American Lifeline Inc.
FX Funded by an unrestricted research grant from American Lifeline Inc.
NR 37
TC 7
Z9 7
U1 2
U2 15
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0884-2175
EI 1552-6909
J9 JOGNN-J OBST GYN NEO
JI JOGNN
PD MAY
PY 2014
VL 43
IS 3
BP 294
EP 304
DI 10.1111/1552-6909.12308
PG 11
WC Nursing; Obstetrics & Gynecology
SC Nursing; Obstetrics & Gynecology
GA AH0SB
UT WOS:000335829500007
PM 24754328
ER

PT J
AU Stefan, M
   Zhang, WJ
   Concepcion, E
   Yi, ZZ
   Tomer, Y
AF Stefan, Mihaela
   Zhang, Weijia
   Concepcion, Erlinda
   Yi, Zhengzi
   Tomer, Yaron
TI DNA methylation profiles in type 1 diabetes twins point to strong
   epigenetic effects on etiology
SO JOURNAL OF AUTOIMMUNITY
LA English
DT Article
DE Type I diabetes; DNA methylation; Monozygotic twins; Transcriptional
   regulation
ID RHEUMATOID-ARTHRITIS; MELLITUS; PROMOTER
AB Type 1 diabetes (T1D) shows similar to 40% concordance rate in monozygotic twins (MZ) suggesting a role for environmental factors and/or epigenetic modifications in the etiology of the disease. The aim of our study was to dissect the contribution of epigenetic factors, particularly, DNA methylation (DNAm), to the incomplete penetrance of T1D. We performed DNAm profiling in lymphocyte cell lines from 3 monozygotic (MZ) twin pairs discordant for T1D and 6 MZ twin pairs concordant for the disease using HumanMethylation27 BeadChip. This assay assesses the methylation state of 27,578 CpG sites, mostly located within proximal promoter regions. We identified 88 CpG sites displaying significant methylation changes in all T1D-discordant MZ twin pairs. Functional annotation of the genes with distinct CpG methylation profiles in T1D samples showed differential DNAm of immune response and defense response pathways between affected and unaffected twins. Integration of DNAm data with GWAS data mapped several known T1D associated genes, HLA, INS, IL-2RB, CD226, which showed significant differences in DNAm between affected and unaffected of twins.
   Our findings suggest that abnormalities of DNA methylation patterns, known to regulate gene transcription, may be involved in the pathogenesis of TI D. Published by Elsevier Ltd.
C1 [Stefan, Mihaela; Concepcion, Erlinda; Tomer, Yaron] Mt Sinai Sch Med, Div Endocrinol, New York, NY 10029 USA.
   [Zhang, Weijia; Yi, Zhengzi] Mt Sinai Sch Med, Dept Med, Bioinformat Core, New York, NY 10029 USA.
   [Stefan, Mihaela; Tomer, Yaron] James J Peters Vet Adm Med Ctr, Bronx, NY 10468 USA.
RP Tomer, Y (reprint author), Mt Sinai Med Ctr, Div Endocrinol, Box 1055,One Gustave L Levy Pl, New York, NY 10029 USA.
EM Yaron.Tomer@mssm.edu
FU NIDDK [DK061659, DK067555 82, DK073681]; Department of Veterans
   Affairs,Veterans Health Administration, Office of Research and
   Development; VA Biomedical Laboratory Research and Development Merit
   Award [1I01BX002031]
FX We thank the National Disease Research Interchange (NDRI, Philadelphia,
   PA) for providing us with the DNA samples of the diabetes twins. This
   work was supported in part by grants DK061659, DK067555 82 DK073681 from
   NIDDK (to YT). In addition this material is based upon work supported in
   part by the Department of Veterans Affairs, Veterans Health
   Administration, Office of Research and Development, and by the VA
   Biomedical Laboratory Research and Development Merit Award 1I01BX002031
   (to YT).
NR 22
TC 38
Z9 42
U1 1
U2 21
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0896-8411
EI 1095-9157
J9 J AUTOIMMUN
JI J. Autoimmun.
PD MAY
PY 2014
VL 50
BP 33
EP 37
DI 10.1016/j.jaut.2013.10.001
PG 5
WC Immunology
SC Immunology
GA AH4RB
UT WOS:000336114600004
PM 24210274
ER

PT J
AU Todoran, TM
   Basile, JN
   Zile, MR
AF Todoran, Thomas M.
   Basile, Jan N.
   Zile, Michael R.
TI Renal Sympathetic Denervation for Blood Pressure Control: A Review of
   the Current Evidence and Ongoing Studies
SO JOURNAL OF CLINICAL HYPERTENSION
LA English
DT Editorial Material
ID DRUG-RESISTANT HYPERTENSION; AMERICAN-HEART-ASSOCIATION; GLOBAL
   SYMPLICITY REGISTRY; ARTERY DENERVATION; NERVOUS-SYSTEM; TRIAL;
   CATHETER; ULTRASOUND; RATIONALE; STATEMENT
AB Few randomized trials have compared visit-to-visit variability (VVV) of systolic blood pressure (SBP) across drug classes. The authors compared VVV of SBP among 24,004 participants randomized to chlorthalidone, amlodipine, or lisinopril in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). VVV of SBP was calculated across 5 to 7 visits occurring 6 to 28months following randomization. The standard deviation (SD) of SBP was 10.6 (SD=5.0), 10.5 (SD=4.9), and 12.2 (SD=5.8) for participants randomized to chlorthalidone, amlodipine, and lisinopril, respectively. After multivariable adjustment including mean SBP across visits and compared with participants randomized to chlorthalidone, participants randomized to amlodipine had a 0.36 (standard error [SE]: 0.07) lower SD of SBP and participants randomized to lisinopril had a 0.77 (SE=0.08) higher SD of SBP. Results were consistent using other VVV of SBP metrics. These data suggest chlorthalidone and amlodipine are associated with lower VVV of SBP than lisinopril.
C1 [Todoran, Thomas M.; Basile, Jan N.; Zile, Michael R.] Med Univ S Carolina, Div Cardiol, Charleston, SC 29425 USA.
   [Todoran, Thomas M.; Basile, Jan N.; Zile, Michael R.] Vet Affairs Med Ctr, Ralph H Johnson Dept, Charleston, SC 29403 USA.
RP Todoran, TM (reprint author), 25 Courtenay Dr MSC 592, Charleston, SC 29425 USA.
EM todoran@musc.edu
NR 33
TC 4
Z9 4
U1 1
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1524-6175
EI 1751-7176
J9 J CLIN HYPERTENS
JI J. Clin. Hypertens.
PD MAY
PY 2014
VL 16
IS 5
BP 331
EP 341
DI 10.1111/jch.12290
PG 11
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA AH0IL
UT WOS:000335802500004
PM 24655555
ER

PT J
AU Eng, JA
   Steinman, MA
AF Eng, Jessica A.
   Steinman, Michael A.
TI Changing Chronic Medications in Hospitalized Patients-Bridging the
   Inpatient-Outpatient Divide
SO JOURNAL OF HOSPITAL MEDICINE
LA English
DT Editorial Material
ID DECISION-MAKING; DISCHARGE
C1 Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA.
   [Eng, Jessica A.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
RP Eng, JA (reprint author), San Francisco VA Med Ctr, 4150 Clement St,181G, San Francisco, CA 94121 USA.
EM jessica.eng@ucsf.edu
FU NIA NIH HHS [P30 AG044281, K23 AG030999, 1K23-AG030999]
NR 6
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1553-5592
EI 1553-5606
J9 J HOSP MED
JI J. Hosp. Med.
PD MAY
PY 2014
VL 9
IS 5
BP 332
EP 333
DI 10.1002/jhm.2172
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA AG8JI
UT WOS:000335664200011
PM 24616285
ER

PT J
AU Han, XS
   Li, R
   Zhang, WB
   Yang, XH
   Wheeler, CG
   Friedman, GK
   Province, P
   Ding, Q
   You, ZY
   Fathallah-Shaykh, HM
   Gillespie, GY
   Zhao, XY
   King, PH
   Nabors, LB
AF Han, Xiaosi
   Li, Rong
   Zhang, Wenbin
   Yang, Xiuhua
   Wheeler, Crystal G.
   Friedman, Gregory K.
   Province, Paula
   Ding, Qiang
   You, Zhiying
   Fathallah-Shaykh, Hassan M.
   Gillespie, G. Yancey
   Zhao, Xinyang
   King, Peter H.
   Nabors, L. Burt
TI Expression of PRMT5 correlates with malignant grade in gliomas and plays
   a pivotal role in tumor growth in vitro
SO JOURNAL OF NEURO-ONCOLOGY
LA English
DT Article
DE Diffuse astrocytoma; Anaplastic astrocytoma; Glioblastoma; PRMT5; ERK1/2
ID PROTEIN ARGININE METHYLTRANSFERASE; CANCER CELLS; GERM-CELLS;
   METHYLATION; ACTIVATION; HISTONE; DIFFERENTIATION; GLIOBLASTOMA;
   DIMETHYLARGININE; TRANSCRIPTION
AB Protein arginine methyltransferase 5 (PRMT5) catalyzes the formation of omega-NG,N'G-symmetric dimethylarginine residues on histones as well as other proteins. These modifications play an important role in cell differentiation and tumor cell growth. However, the role of PRMT5 in human glioma cells has not been characterized. In this study, we assessed protein expression profiles of PRMT5 in control brain, WHO grade II astrocytomas, anaplastic astrocytomas, and glioblastoma multiforme (GBM) by immunohistochemistry. PRMT5 was low in glial cells in control brain tissues and low grade astrocytomas. Its expression increased in parallel with malignant progression, and was highly expressed in GBM. Knockdown of PRMT5 by small hairpin RNA caused alterations of p-ERK1/2 and significantly repressed the clonogenic potential and viability of glioma cells. These findings indicate that PRMT5 is a marker of malignant progression in glioma tumors and plays a pivotal role in tumor growth.
C1 [Han, Xiaosi; Zhang, Wenbin; Yang, Xiuhua; Wheeler, Crystal G.; Province, Paula; Fathallah-Shaykh, Hassan M.; King, Peter H.; Nabors, L. Burt] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35294 USA.
   [Han, Xiaosi; King, Peter H.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35295 USA.
   [Li, Rong] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
   [Friedman, Gregory K.] Univ Alabama Birmingham, Dept Pediat, Div Hematol Oncol, Birmingham, AL 35294 USA.
   [Ding, Qiang] Univ Alabama Birmingham, Div Pulm Med, Dept Med, Birmingham, AL 35294 USA.
   [You, Zhiying] Univ Alabama Birmingham, Dept Prevent Med, Birmingham, AL 35294 USA.
   [Gillespie, G. Yancey] Univ Alabama Birmingham, Dept Neurosurg, Birmingham, AL 35294 USA.
   [Zhao, Xinyang] Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA.
RP Han, XS (reprint author), Univ Alabama Birmingham, Dept Neurol, FOT 1020,1530 3rd Ave S, Birmingham, AL 35294 USA.
EM xhan@uab.edu
OI Friedman, Gregory/0000-0002-6653-7420; Zhao, Xinyang/0000-0001-6677-7072
FU NIH NCI [P30CA013148, P50CA097247, P20CA151129]; St. Baldrick's
   Foundation; VA Merit Review
FX NIH NCI Grants P30CA013148 (UAB Comprehensive Cancer Center Core Support
   Grant); P50CA097247, P20CA151129 (G. Y. Gillespie); St. Baldrick's
   Foundation (G. K. Friedman); VA Merit Review (P. H. King).
NR 42
TC 14
Z9 15
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-594X
EI 1573-7373
J9 J NEURO-ONCOL
JI J. Neuro-Oncol.
PD MAY
PY 2014
VL 118
IS 1
BP 61
EP 72
DI 10.1007/s11060-014-1419-0
PG 12
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA AH8HC
UT WOS:000336376700007
PM 24664369
ER

PT J
AU Kelley, AS
   Langa, KM
   Smith, AK
   Cagle, J
   Ornstein, K
   Silveira, MJ
   Nicholas, L
   Covinsky, KE
   Ritchie, CS
AF Kelley, Amy S.
   Langa, Kenneth M.
   Smith, Alexander K.
   Cagle, John
   Ornstein, Katherine
   Silveira, Maria J.
   Nicholas, Lauren
   Covinsky, Kenneth E.
   Ritchie, Christine S.
TI Leveraging the Health and Retirement Study To Advance Palliative Care
   Research
SO JOURNAL OF PALLIATIVE MEDICINE
LA English
DT Article
ID LAST 6 MONTHS; RESEARCH PRIORITIES; UNITED-STATES; SERIOUS ILLNESS;
   OLDER-ADULTS; LATER LIFE; NURSING-HOMES; DEMOGRAPHICS; DEMENTIA; MEMORY
AB Background: The critical need to expand and develop the palliative care evidence base was recently highlighted by the Journal of Palliative Medicine's series of articles describing the Research Priorities in Geriatric Palliative Care. The Health and Retirement Study (HRS) is uniquely positioned to address many priority areas of palliative care research. This nationally representative, ongoing, longitudinal study collects detailed survey data every 2 years, including demographics, health and functional characteristics, information on family and caregivers, and personal finances, and also conducts a proxy interview after each subject's death. The HRS can also be linked with Medicare claims data and many other data sources, e.g., U.S. Census, Dartmouth Atlas of Health Care. Setting: While the HRS offers innumerable research opportunities, these data are complex and limitations do exist. Therefore, we assembled an interdisciplinary group of investigators using the HRS for palliative care research to identify the key palliative care research gaps that may be amenable to study within the HRS and the strengths and weaknesses of the HRS for each of these topic areas. Conclusion: In this article we present the work of this group as a potential roadmap for investigators contemplating the use of HRS data for palliative care research.
C1 [Kelley, Amy S.; Ornstein, Katherine] Icahn Sch Med Mt Sinai, Brookdale Dept Geriatr & Palliat Med, New York, NY 10029 USA.
   [Kelley, Amy S.] James J Peters VA Med Ctr, Geriatr Res Educ Ctr, Bronx, NY USA.
   [Kelley, Amy S.] James J Peters VA Med Ctr, Clin Ctr, Bronx, NY USA.
   [Langa, Kenneth M.; Silveira, Maria J.] Vet Adm Ann Arbor, Ctr Clin Mangement Res, Ann Arbor, MI USA.
   [Langa, Kenneth M.; Silveira, Maria J.] Univ Michigan, Div Gen Med, Ann Arbor, MI 48109 USA.
   [Langa, Kenneth M.; Nicholas, Lauren] Univ Michigan, Inst Social Res, Ann Arbor, MI USA.
   [Langa, Kenneth M.] Univ Michigan, Inst Gerontol, Ann Arbor, MI 48109 USA.
   [Langa, Kenneth M.] Univ Michigan, Inst Healthcare Policy & Innovat, Ann Arbor, MI 48109 USA.
   [Smith, Alexander K.; Covinsky, Kenneth E.; Ritchie, Christine S.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA USA.
   [Cagle, John] Univ Maryland, Sch Social Work, Baltimore, MD 21201 USA.
RP Kelley, AS (reprint author), Icahn Sch Med Mt Sinai, Brookdale Dept Geriatr & Palliat Med, 1 Gustave L Levy Pl,Box 1070, New York, NY 10029 USA.
EM amy.kelley@mssm.edu
FU National Palliative Care Research Center; Advanced Illness and
   Multimorbidity Geriatric Academic Leadership Award [1K07AG31779];
   Improving Care for Older Adults with Serious Illness National Institute
   on Aging [1K23AG040774-01A1]; American Federation for Aging Research;
   National Institute on Aging [U01 AG009740]; Social Security
   Administration
FX Funded by the National Palliative Care Research Center; Advanced Illness
   and Multimorbidity Geriatric Academic Leadership Award (1K07AG31779);
   Improving Care for Older Adults with Serious Illness National Institute
   on Aging (1K23AG040774-01A1); and the American Federation for Aging
   Research.; The Health and Retirement Study is funded by the National
   Institute on Aging (U01 AG009740) and the Social Security
   Administration, and is performed at the Institute for Social Research,
   University of Michigan.
NR 40
TC 2
Z9 2
U1 2
U2 9
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1096-6218
EI 1557-7740
J9 J PALLIAT MED
JI J. Palliat. Med.
PD MAY 1
PY 2014
VL 17
IS 5
BP 506
EP 511
DI 10.1089/jpm.2013.0648
PG 6
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA AG7EV
UT WOS:000335581800005
PM 24694096
ER

PT J
AU Lackey, AE
   Moshiri, M
   Pandey, T
   Lall, C
   Lalwani, N
   Bhargava, P
AF Lackey, Amanda E.
   Moshiri, Mariam
   Pandey, Tarun
   Lall, Chandana
   Lalwani, Neeraj
   Bhargava, Puneet
TI Productivity, Part 1: Getting Things Done, Using E-Mail, Scanners,
   Reference Managers, Note-taking Applications, and Text Expanders
SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY
LA English
DT Article
DE Productivity; workflow; time management
AB In an era of declining reimbursements and tightening of the job market, today's radiologists are forced to "make do with less." With the rollout of the Patient Protection and Affordable Care Act, commonly called "Obamacare," radiologists will be expected not only to interpret studies but to also take on many additional roles, adding a new layer of complexity to already demanding daily duties. These changes make it more important than ever to develop a personal workflow management system incorporating some of the most potent productivity tools. In this article, the authors discuss current productivity techniques and related software with the most potential to help radiologists keep up with the ever increasing demands on their time at the work place and help us lead more balanced lives.
C1 [Lackey, Amanda E.; Pandey, Tarun] Univ Arkansas Med Sci, Dept Radiol, Little Rock, AR 72205 USA.
   [Moshiri, Mariam; Lalwani, Neeraj] Univ Washington, Sch Med, Dept Radiol, Seattle, WA 98195 USA.
   [Lall, Chandana] Univ Calif Irvine, Orange, CA 92668 USA.
   [Bhargava, Puneet] Univ Washington, Dept Radiol, Seattle, WA 98195 USA.
   [Bhargava, Puneet] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
RP Bhargava, P (reprint author), Univ Washington, Mail Box 358280,S-114 Radiol, Seattle, WA 98108 USA.
EM bhargp@uw.edu
RI Lalwani, Neeraj/A-3490-2011
OI Lalwani, Neeraj/0000-0001-5514-2805; Bhargava,
   Puneet/0000-0002-3849-9666
NR 24
TC 3
Z9 3
U1 4
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1546-1440
J9 J AM COLL RADIOL
JI J. Am. Coll. Radiol.
PD MAY
PY 2014
VL 11
IS 5
BP 481
EP 489
DI 10.1016/j.jacr.2013.11.020
PG 9
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA AH5TE
UT WOS:000336193200012
PM 24656443
ER

PT J
AU Coca, SG
   Garg, AX
   Thiessen-Philbrook, H
   Koyner, JL
   Patel, UD
   Krumholz, HM
   Shlipak, MG
   Parikh, CR
AF Coca, Steven G.
   Garg, Amit X.
   Thiessen-Philbrook, Heather
   Koyner, Jay L.
   Patel, Uptal D.
   Krumholz, Harlan M.
   Shlipak, Michael G.
   Parikh, Chirag R.
CA TRIBE-AKI Consortium
TI Urinary Biomarkers of AKI and Mortality 3 Years after Cardiac Surgery
SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID ACUTE KIDNEY INJURY; ACUTE-RENAL-FAILURE; PERITUBULAR CAPILLARIES; POOR
   OUTCOMES; DISEASE; RECLASSIFICATION; ASSOCIATION; PROTEINURIA; DAMAGE;
   RISK
AB The endothelin system has emerged as a novel target for the treatment of diabetic nephropathy. Endothelin-1 promotes mesangial cell proliferation and sclerosis. However, no direct pathogenic effect of endothelin-1 on podocytes has been shown in vivo and endothelin-1 signaling in podocytes has not been investigated. This study investigated endothelin effects in podocytes during experimental diabetic nephropathy. Stimulation of primary mouse podocytes with endothelin-1 elicited rapid calcium transients mediated by endothelin type A receptors (ETARs) and endothelin type B receptors (ETBRs). We then generated mice with a podocyte-specific double deletion of ETAR and ETBR (NPHS2-CrexEdnra(lox/lox)xEdnrb(lox/lox) [Pod-ETRKO]). In vitro, treatment with endothelin-1 increased total beta-catenin and phospho-NF-kappa B expression in wild-type glomeruli, but this effect was attenuated in Pod-ETRKO glomeruli. After streptozotocin injection to induce diabetes, wild-type mice developed mild diabetic nephropathy with microalbuminuria, mesangial matrix expansion, glomerular basement membrane thickening, and podocyte loss, whereas Pod-ETRKO mice presented less albuminuria and were completely protected from glomerulosclerosis and podocyte loss, even when uninephrectomized. Moreover, glomeruli from normal and diabetic Pod-ETRKO mice expressed substantially less total beta-catenin and phospho-NF-kappa B compared with glomeruli from counterpart wild-type mice. This evidence suggests that endothelin-1 drives development of glomerulosclerosis and podocyte loss through direct activation of endothelin receptors and NF-kappa B and beta-catenin pathways in podocytes. Notably, both the expression and function of the ETBR subtype were found to be important. Furthermore, these results indicate that activation of the endothelin-1 pathways selectively in podocytes mediates pathophysiologic crosstalk that influences mesangial architecture and sclerosis.
C1 [Coca, Steven G.; Parikh, Chirag R.] Yale Univ, Sch Med, Program Appl Translat Res, Sch Med,Vet Affairs Connecticut Healthcare Syst, New Haven, CT 06510 USA.
   [Garg, Amit X.; Thiessen-Philbrook, Heather] Univ Western Ontario, Dept Med, Div Nephrol, London, ON, Canada.
   [Koyner, Jay L.] Univ Chicago, Dept Med, Nephrol Sect, Chicago, IL 60637 USA.
   [Patel, Uptal D.] Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA.
   [Krumholz, Harlan M.] Yale Univ, Ctr Outcomes Res & Evaluat, Yale New Haven Hosp, Sect Cardiovasc Med,Dept Internal Med,Sch Med, New Haven, CT 06510 USA.
   [Shlipak, Michael G.] Univ Calif San Francisco, Div Gen Internal Med, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA.
RP Parikh, CR (reprint author), Yale Univ, Sch Med, Nephrol Sect, 60 Temple Street,Suite 6C, New Haven, CT 06510 USA.
EM chirag.parikh@yale.edu
FU National Institutes of Health (NIH) [R01HL085757]; NIH [K23DK080132,
   K24DK090203, U01DK082185]; Ontario Ministry of Health and Long-Term Care
FX The urine biomarker assays were donated by Abbott Diagnostics (IL-18 and
   NGAL) and Sekisui Diagnostics LLC (KIM-1 and L-FABP). This study was
   supported by the National Institutes of Health (NIH) (R01HL085757 to
   C.R.P.) to fund the TRIBE-AKI Consortium to study novel biomarkers of
   AKI in cardiac surgery. S.G.C. has been supported by an NIH Career
   Development Award (K23DK080132). C.R.P. is supported by the NIH
   (K24DK090203). S.G.C., A.X.G., and C.R.P. are also members of the
   NIH-sponsored Assess, Serial Evaluation, and Subsequent Sequelae in
   Acute Kidney Injury Consortium (U01DK082185). The granting agencies,
   Abbott Diagnostics, and Sekisui Diagnostics, Inc. did not participate in
   the design and conduct of the study, collection, management, analysis,
   and interpretation of the data, and preparation, review, or approval of
   the manuscript. The Institute for Clinical Evaluative Sciences receives
   funding from the Ontario Ministry of Health and Long-Term Care. The
   opinions, results, and conclusions reported in this article are those of
   the authors and are independent from the funding sources. The results
   presented in this article have not been published previously in whole or
   part, except in abstract form.
NR 27
TC 32
Z9 32
U1 2
U2 6
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1046-6673
EI 1533-3450
J9 J AM SOC NEPHROL
JI J. Am. Soc. Nephrol.
PD MAY
PY 2014
VL 25
IS 5
BP 1063
EP 1071
PG 9
WC Urology & Nephrology
SC Urology & Nephrology
GA AG7FM
UT WOS:000335583700024
PM 24357673
ER

PT J
AU Corbelli, J
   Borrero, S
   Bonnema, R
   McNamara, M
   Kraemer, K
   Rubio, D
   Karpov, I
   McNeil, M
AF Corbelli, Jennifer
   Borrero, Sonya
   Bonnema, Rachel
   McNamara, Megan
   Kraemer, Kevin
   Rubio, Doris
   Karpov, Irina
   McNeil, Melissa
TI Differences Among Primary Care Physicians' Adherence to 2009 ACOG
   Guidelines for Cervical Cancer Screening
SO JOURNAL OF WOMENS HEALTH
LA English
DT Article
ID BREAST-CANCER; HUMAN-PAPILLOMAVIRUS; WOMENS HEALTH; HEART-FAILURE;
   UNITED-STATES; ATTITUDES; RECOMMENDATIONS; PREFERENCES; MANAGEMENT;
   INTERVALS
AB Background: In 2009, the American Congress of Obstetrics and Gynecology (ACOG) guidelines for cervical cancer screening changed significantly, to recommend less frequent screening than prior guidelines. The extent to which physicians in different specialties implemented these guidelines in the years following publication is unknown. Methods: Cross-sectional survey completed by 316 physicians in internal medicine, family medicine, and gynecology. Survey items assessed respondents' cervical cancer screening practices in women of different ages and medical histories. We used descriptive statistics to generate response distribution for survey items, and logistic regression models to compare responses among specialties. Results: Our response rate was 55% (316/575). Thirty-four percent of respondents' screening practices were inconsistent with ACOG guidelines for women under age 21, and 49% were inconsistent with guidelines for women over age 30. Internists (50%) were less likely than family medicine (89%, p<0.001) and gynecology (80%, p=0.02) physicians to delay pap testing until age 21. Internists (41%) were less likely than both family medicine (60%, p=0.009) and gynecology (68%, p=0.03) physicians to follow guidelines for women over age 30 (p=0.003). Overall 22% percent of physicians followed guidelines for women ages 21-29 years, with no significant differences between specialties. Differences remained significant in multivariable models. Conclusions: Despite consensus among national organizations as to optimal regimens for cervical cancer screening, a significant proportion of providers, especially in internal medicine, do not adhere to ACOG's 2009 guidelines. The lack of comprehensive guideline implementation suggests that adherence to new 2012 guidelines, which advocate for less frequent screening, will likely be suboptimal and discrepant by specialty.
C1 [Corbelli, Jennifer; Borrero, Sonya; Kraemer, Kevin; Rubio, Doris; McNeil, Melissa] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA 15213 USA.
   [Borrero, Sonya] VA Pittsburgh Healthcare Syst, Ctr Res Hlth Equity & Promot, Pittsburgh, PA USA.
   [Borrero, Sonya; Kraemer, Kevin; Rubio, Doris; Karpov, Irina] Univ Pittsburgh, Ctr Res Hlth Care, Pittsburgh, PA 15213 USA.
   [Bonnema, Rachel] Univ Nebraska Med Ctr, Div Gen Internal Med, Omaha, NE USA.
   [McNamara, Megan] Case Western Reserve Univ, Sch Med, Div Gen Internal Med, Cleveland, OH USA.
   [McNamara, Megan] Louis Stokes Cleveland VA Med Ctr, Cleveland, OH USA.
RP Corbelli, J (reprint author), Univ Pittsburgh, Dept Gen Internal Med, Med Ctr, 200 Lothrop St,MUH 9W-33, Pittsburgh, PA 15213 USA.
EM corbellija@upmc.edu
FU Thomas H. Nimick Jr. Competitive Research Fund; Department of Medicine
   at University of Pittsburgh; U.S. Department of Veteran's Affairs
FX The Thomas H. Nimick Jr. Competitive Research Fund provided money for
   the purchase of iPads that were given as incentives to two randomly
   selected study participants. The Department of Medicine at University of
   Pittsburgh provided funding for data management. Dr. Corbelli's
   fellowship training is funded by the U.S. Department of Veteran's
   Affairs. These funding sources had no role in the study design or
   implementation, analysis of results, or manuscript preparation.
NR 33
TC 11
Z9 11
U1 1
U2 4
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-9996
EI 1931-843X
J9 J WOMENS HEALTH
JI J. Womens Health
PD MAY 1
PY 2014
VL 23
IS 5
BP 397
EP 403
DI 10.1089/jwh.2013.4475
PG 7
WC Public, Environmental & Occupational Health; Medicine, General &
   Internal; Obstetrics & Gynecology; Women's Studies
SC Public, Environmental & Occupational Health; General & Internal
   Medicine; Obstetrics & Gynecology; Women's Studies
GA AG9KY
UT WOS:000335739300006
PM 24380500
ER

PT J
AU Danielson, CK
   Walsh, K
   McCauley, J
   Ruggiero, KJ
   Brown, JL
   Sales, JM
   Rose, E
   Wingood, GM
   DiClemente, RJ
AF Danielson, Carla Kmett
   Walsh, Kate
   McCauley, Jenna
   Ruggiero, Kenneth J.
   Brown, Jennifer L.
   Sales, Jessica M.
   Rose, Eve
   Wingood, Gina M.
   DiClemente, Ralph J.
TI HIV-Related Sexual Risk Behavior Among African American Adolescent Girls
SO JOURNAL OF WOMENS HEALTH
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; SUBSTANCE USE; PREVENTION INTERVENTIONS;
   ABUSE; STRESS; IMPACT; WOMEN; DISPARITIES; PREDICTORS; PARTNERS
AB Background: Latent class analysis (LCA) is a useful statistical tool that can be used to enhance understanding of how various patterns of combined sexual behavior risk factors may confer differential levels of HIV infection risk and to identify subtypes among African American adolescent girls. Methods: Data for this analysis is derived from baseline assessments completed prior to randomization in an HIV prevention trial. Participants were African American girls (n=701) aged 14-20 years presenting to sexual health clinics. Girls completed an audio computer-assisted self-interview, which assessed a range of variables regarding sexual history and current and past sexual behavior. Results: Two latent classes were identified with the probability statistics for the two groups in this model being 0.89 and 0.88, respectively. In the final multivariate model, class 1 (the higher risk group; n=331) was distinguished by a higher likelihood of >5 lifetime sexual partners, having sex while high on alcohol/drugs, less frequent condom use, and history of sexually transmitted diseases (STDs), when compared with class 2 (the lower risk group; n=370). The derived model correctly classified 85.3% of participants into the two groups and accounted for 71% of the variance in the latent HIV-related sexual behavior risk variable. The higher risk class also had worse scores on all hypothesized correlates (e.g., self-esteem, history of sexual assault or physical abuse) relative to the lower risk class. Conclusions: Sexual health clinics represent a unique point of access for HIV-related sexual risk behavior intervention delivery by capitalizing on contact with adolescent girls when they present for services. Four empirically supported risk factors differentiated higher versus lower HIV risk. Replication of these findings is warranted and may offer an empirical basis for parsimonious screening recommendations for girls presenting for sexual healthcare services.
C1 [Danielson, Carla Kmett; McCauley, Jenna; Ruggiero, Kenneth J.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
   [Walsh, Kate] Columbia Univ, Dept Epidemiol, New York, NY USA.
   [Ruggiero, Kenneth J.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
   [Brown, Jennifer L.; Sales, Jessica M.; Rose, Eve; Wingood, Gina M.; DiClemente, Ralph J.] Texas Tech Univ, Dept Psychol, Lubbock, TX 79409 USA.
   [Sales, Jessica M.; Wingood, Gina M.; DiClemente, Ralph J.] Emory Univ, Rollins Sch Publ Hlth, Dept Behav Sci & Hlth Educ, Atlanta, GA 30322 USA.
   [Sales, Jessica M.; Wingood, Gina M.; DiClemente, Ralph J.] Emory Univ, Rollins Sch Publ Hlth, Ctr AIDS Res, Atlanta, GA 30322 USA.
   [Sales, Jessica M.; Wingood, Gina M.; DiClemente, Ralph J.] Emory Univ, Sch Med, Dept Pediat, Div Infect Dis Epidemiol & Immunol, Atlanta, GA USA.
RP Danielson, CK (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, Natl Crime Victims Res & Treatment Ctr, MSC 861,Suite 207, Charleston, SC 29425 USA.
EM danielso@musc.edu
FU National Institute of Mental Health (NIMH) [5R01MH070537]; National
   Institute on Drug Abuse (NIDA) [K23DA018686, R01DA031285]; National
   Institute on Alcohol Abuse and Alcoholism (NIAAA) [P50 AA010761]
FX The study was supported by grant award 5R01MH070537 from the National
   Institute of Mental Health (NIMH; PI: DiClemente). The preparation of
   this manuscript was supported by grant awards K23DA018686 and
   R01DA031285 from the National Institute on Drug Abuse (NIDA; PI:
   Danielson) and grant award P50 AA010761 from the National Institute on
   Alcohol Abuse and Alcoholism (NIAAA; Center PI: Becker). The views,
   policies, and opinions expressed in this article are those of the
   authors and do not necessarily reflect those of NIMH, NIDA, and NIAAA.
NR 40
TC 4
Z9 4
U1 3
U2 14
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-9996
EI 1931-843X
J9 J WOMENS HEALTH
JI J. Womens Health
PD MAY 1
PY 2014
VL 23
IS 5
BP 413
EP 419
DI 10.1089/jwh.2013.4599
PG 7
WC Public, Environmental & Occupational Health; Medicine, General &
   Internal; Obstetrics & Gynecology; Women's Studies
SC Public, Environmental & Occupational Health; General & Internal
   Medicine; Obstetrics & Gynecology; Women's Studies
GA AG9KY
UT WOS:000335739300008
PM 24749895
ER

PT J
AU Golob, AL
   Wipf, JE
AF Golob, Anna L.
   Wipf, Joyce E.
TI Low Back Pain
SO MEDICAL CLINICS OF NORTH AMERICA
LA English
DT Article
DE Acute low back pain; Chronic low back pain; Risk factors; Cause;
   Diagnosis; Imaging; Treatment; Sciatica
ID CLINICAL-PRACTICE GUIDELINE; RANDOMIZED CONTROLLED-TRIAL; PRIMARY-CARE;
   LUMBAR SPINE; AMERICAN-COLLEGE; INCEPTION COHORT; PREVALENCE; SOCIETY;
   EPIDEMIOLOGY; DISABILITY
AB Low back pain is one of the most frequent complaints for which patients are seen in primary care. Low back pain has a substantial economic impact, estimated at $100 billion per year including direct and indirect costs. The evaluation of low back pain involves a thorough history and physical examination. Imaging is only indicated when a more serious underlying cause or neurologic abnormality is suspected. Abnormalities detected on imaging do not strongly correlate with symptoms. Generally, a specific underlying cause for low back pain is not identified. Treatment consists of a multidisciplinary approach with goal to maintain function and minimize disability.
C1 [Golob, Anna L.; Wipf, Joyce E.] Univ Washington, Dept Med, Seattle, WA 98195 USA.
   [Golob, Anna L.; Wipf, Joyce E.] VA Puget Sound Healthcare Syst, Gen Med Serv, Seattle, WA 98108 USA.
RP Golob, AL (reprint author), VA Puget Sound Healthcare Syst, Gen Med Serv, S-123 PCC,1660 South Columbian Way, Seattle, WA 98108 USA.
EM zilanna@uw.edu
FU UpToDate chapter royalties
FX Financial Disclosures: None (A.L. Golob); UpToDate chapter royalties
   (J.E. Wipf).
NR 48
TC 6
Z9 10
U1 1
U2 11
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0025-7125
EI 1557-9859
J9 MED CLIN N AM
JI Med. Clin. N. Am.
PD MAY
PY 2014
VL 98
IS 3
BP 405
EP +
DI 10.1016/j.mcna.2014.01.003
PG 25
WC Medicine, General & Internal
SC General & Internal Medicine
GA AH5RK
UT WOS:000336188500003
PM 24758954
ER

PT J
AU Berger, D
AF Berger, Douglas
TI Leg Discomfort: Beyond the Joints
SO MEDICAL CLINICS OF NORTH AMERICA
LA English
DT Article
DE Leg pain; Paresthesia; Claudication; Neuropathy; Myalgia; Cramp
ID LUMBAR SPINAL STENOSIS; PERIPHERAL ARTERIAL-DISEASE; CLINICAL-PRACTICE
   GUIDELINES; DEEP-VEIN THROMBOSIS; MERALGIA-PARESTHETICA;
   LOWER-EXTREMITY; MUSCLE CRAMPS; MUSCULOSKELETAL PAIN;
   DIAGNOSTIC-CRITERIA; AMERICAN-COLLEGE
AB Although discussions of leg pain usually begin with the hip, knee, and ankle, patients often present with leg symptoms unrelated to articular or periarticular structures. Pain, paresthesias, cramping, heaviness, or numbness may arise from a variety of vascular, neurologic, and musculoskeletal causes beyond the joints. This article describes the presentation, diagnosis, and treatment of common causes of such symptoms, including peripheral arterial disease, chronic venous insufficiency, deep vein thrombosis, lumbosacral radiculopathy, lumbar spinal stenosis, peripheral neuropathy, statin myalgia, cramps, and restless legs syndrome.
C1 Univ Washington, VA Puget Sound, Dept Med, Gen Med Serv, Seattle, WA 98108 USA.
RP Berger, D (reprint author), Univ Washington, VA Puget Sound, Dept Med, Gen Med Serv, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM douglas.berger@va.gov
NR 91
TC 2
Z9 2
U1 0
U2 6
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0025-7125
EI 1557-9859
J9 MED CLIN N AM
JI Med. Clin. N. Am.
PD MAY
PY 2014
VL 98
IS 3
BP 429
EP +
DI 10.1016/j.mcna.2014.01.004
PG 17
WC Medicine, General & Internal
SC General & Internal Medicine
GA AH5RK
UT WOS:000336188500004
PM 24758955
ER

PT J
AU Overland, MK
AF Overland, Maryann Katherine
TI Dyspepsia
SO MEDICAL CLINICS OF NORTH AMERICA
LA English
DT Article
DE Functional dyspepsia; Helicobacter pylori test and treat; Peptic ulcer
   disease; Gastroesophageal reflux disease
ID PLACEBO-CONTROLLED TRIAL; GASTROESOPHAGEAL-REFLUX DISEASE; FUNCTIONAL
   GASTRODUODENAL DISORDERS; HELICOBACTER-PYLORI ERADICATION; RANDOMIZED
   CLINICAL-TRIAL; PROTON PUMP INHIBITOR; DOUBLE-BLIND; GASTRIC
   ACCOMMODATION; NONULCER DYSPEPSIA; SYMPTOMS
AB Dyspepsia is a common and complex condition consisting of chronic upper gastrointestinal symptoms. A rational approach to diagnosis and treatment of dyspepsia includes identifying those patients with alarm symptoms and referring them for prompt endoscopy. Those without alarm symptoms can be differentiated into patients who do and do not have symptoms consistent with gastroesophageal reflux disease. In the absence of predominant heartburn and regurgitation, patients should be tested and treated for Helicobacter pylori. Functional (nonulcer) dyspepsia is a multifactorial disorder with several possible pathophysiologic mechanisms, but no clear guidelines for therapy. There is some evidence of efficacy of proton pump inhibitors, antisecretory agents, antidepressants, and psychotherapy for functional dyspepsia.
C1 Univ Washington, VA Puget Sound Hlth Care Syst, Primary Care Clin, Div Gen Internal Med, Seattle, WA 98108 USA.
RP Overland, MK (reprint author), Univ Washington, VA Puget Sound Hlth Care Syst, Primary Care Clin, Div Gen Internal Med, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM Maryann.Overland@va.gov
NR 68
TC 5
Z9 6
U1 0
U2 5
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0025-7125
EI 1557-9859
J9 MED CLIN N AM
JI Med. Clin. N. Am.
PD MAY
PY 2014
VL 98
IS 3
BP 549
EP +
DI 10.1016/j.mcna.2014.01.007
PG 18
WC Medicine, General & Internal
SC General & Internal Medicine
GA AH5RK
UT WOS:000336188500009
PM 24758960
ER

PT J
AU Molnar, A
   McGee, S
AF Molnar, Alexandra
   McGee, Steven
TI Diagnosing and Treating Dizziness
SO MEDICAL CLINICS OF NORTH AMERICA
LA English
DT Article
DE Dizziness; Vertigo; Epley; Primary care
ID PAROXYSMAL POSITIONAL VERTIGO; HEAD IMPULSE TEST; MENIERES-DISEASE;
   DIZZY PATIENT; PERSISTENT DIZZINESS; EMERGENCY-DEPARTMENT;
   ELDERLY-PATIENTS; PRIMARY-CARE; POPULATION; COMMUNITY
AB Dizziness is a common presenting concern in primary care practice. The most useful diagnostic approach in distinguishing different types of dizziness is a thorough history and physical examination; additional tests are rarely necessary. Effective treatments exist for many causes of dizziness, and these treatments are often accomplished in the clinic or at home without the need for medication.
C1 [Molnar, Alexandra] Univ Washington, Harborview Med Ctr, Dept Med, Seattle, WA 98104 USA.
   [McGee, Steven] Univ Washington, Dept Med, Vet Affairs Puget Sound Healthcare Syst, Seattle Div, Seattle, WA 98108 USA.
RP Molnar, A (reprint author), Univ Washington, Harborview Med Ctr, Dept Med, Box 359895,325 9th Ave, Seattle, WA 98104 USA.
EM amolnar@uw.edu
OI Molnar, Alexandra/0000-0003-3258-6782
NR 35
TC 3
Z9 3
U1 3
U2 8
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0025-7125
EI 1557-9859
J9 MED CLIN N AM
JI Med. Clin. N. Am.
PD MAY
PY 2014
VL 98
IS 3
BP 583
EP +
DI 10.1016/j.mcna.2014.01.014
PG 15
WC Medicine, General & Internal
SC General & Internal Medicine
GA AH5RK
UT WOS:000336188500011
PM 24758962
ER

PT J
AU Evans, G
AF Evans, Ginger
TI Identifying and Treating the Causes of Neck Pain
SO MEDICAL CLINICS OF NORTH AMERICA
LA English
DT Article
DE Neck pain; Cervical spondylosis; Radiculopathy; Myelopathy; Chronic pain
ID 2000-2010 TASK-FORCE; CERVICAL SPONDYLOTIC MYELOPATHY;
   GENERAL-POPULATION; DISK DISEASE; DIAGNOSTIC-ACCURACY; DISORDERS;
   RADICULOPATHY; SPINE; BONE; ROOT
AB Chronic neck pain is a common and often disabling problem. It can describe pain in the neck region alone or include related disorders of radiculopathy or myelopathy. This review of the literature is aimed at the practicing primary care provider, who is diagnosing and managing non-traumatic neck pain in the clinic. It includes an anatomic review, definition of related disorders, differential diagnosis, and discussion of common diagnostic uncertainty for mechanical neck pain. Important history and physical examination techniques, the role of imaging, and the available literature on conservative and invasive treatment options are reviewed.
C1 Univ Washington, Dept Med, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
RP Evans, G (reprint author), Univ Washington, Dept Med, VA Puget Sound Hlth Care Syst, 1660 South Columbia Way,S-123-PCC, Seattle, WA 98108 USA.
EM gingere@u.washington.edu
NR 73
TC 2
Z9 2
U1 1
U2 8
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0025-7125
EI 1557-9859
J9 MED CLIN N AM
JI Med. Clin. N. Am.
PD MAY
PY 2014
VL 98
IS 3
BP 645
EP +
DI 10.1016/j.mcna.2014.01.015
PG 18
WC Medicine, General & Internal
SC General & Internal Medicine
GA AH5RK
UT WOS:000336188500015
PM 24758966
ER

PT J
AU Tanner, CM
   Meng, CC
   Ravina, B
   Lang, A
   Kurlan, R
   Marek, K
   Oakes, D
   Seibyl, J
   Flagg, E
   Gauger, L
   Guest, DD
   Goetz, CG
   Kieburtz, K
   DiEuliis, D
   Fahn, S
   Elliott, RA
   Shoulson, I
AF Tanner, Caroline M.
   Meng, Cheryl C.
   Ravina, Bernard
   Lang, Anthony
   Kurlan, Roger
   Marek, Kenneth
   Oakes, David
   Seibyl, John
   Flagg, Emily
   Gauger, Lisa
   Guest, Dolores D.
   Goetz, Christopher G.
   Kieburtz, Karl
   DiEuliis, Diane
   Fahn, Stanley
   Elliott, Robin A.
   Shoulson, Ira
TI A Practical Approach to Remote Longitudinal Follow-up of Parkinson's
   Disease: The FOUND Study
SO MOVEMENT DISORDERS
LA English
DT Article
DE Parkinson's disease; longitudinal; follow-up
ID RATING-SCALE; SYDNEY MULTICENTER; CLINICAL-TRIAL; PROGRESSION;
   RETENTION; DEMENTIA; RECRUITMENT; ASSESSMENTS; IMPAIRMENT; DISABILITY
AB The objective of this study was to examine a remote method for maintaining long-term contact with Parkinson's disease (PD) patients participating in clinical studies. Long-term follow-up of PD patients is needed to fill critical information gaps on progression, biomarkers, and treatment. Prospective in-person assessment can be costly and may be impossible for some patients. Remote assessment using mail and telephone contact may be a practical follow-up method. Patients enrolled in the multi-center Longitudinal and Biomarker Study in Parkinson's Disease (LABS-PD) in-person follow-up study in 2006 were invited to enroll in Follow-up of Persons With Neurologic Diseases (FOUND), which is overseen by a single center under a separate, central institutional review board protocol. FOUND uses mailed questionnaires and telephone interviews to assess PD status. FOUND follow-up continued when LABS-PD in-person visits ended in 2011. Retention and agreement between remote and in-person assessments were determined. In total, 422 of 499 (84.5%) of eligible patients volunteered, AND 96% of participants were retained. Of 60 patients who withdrew consent from LABS-PD, 51 were retained in FOUND. Of 341 patients who were active in LABS-PD, 340 were retained in FOUND (99.7%) when the in-person visits ceased. Exact agreement between remote and in-person assessments was 80% for diagnosis, disease features (eg, dyskinesias), and PD medication. Correlation between expert-rated and self-reported Unified Parkinson's Disease Rating Scale and Movement Disorder Society Unified Parkinson's Disease Rating Scale, which were examined at times separated by several months, was moderate or substantial for most items. Retention was excellent using remote follow-up of research participants with PD, providing a safety net when combined with in-person visits, and also is effective as a stand-alone assessment method, providing a useful alternative when in-person evaluation is not feasible. (c) 2014 International Parkinson and Movement Disorder Society
C1 [Tanner, Caroline M.; Meng, Cheryl C.; Guest, Dolores D.; Fahn, Stanley] Parkinsons Inst, Sunnyvale, CA USA.
   [Tanner, Caroline M.] Stanford Univ, Dept Hlth Res & Policy, Palo Alto, CA 94304 USA.
   [Ravina, Bernard] Biogen Idec Inc, Cambridge, MA USA.
   [Lang, Anthony] Univ Toronto, Toronto Western Hosp, Edmond J Safra Program Parkinsons Dis, Toronto, ON M5S 1A1, Canada.
   [Kurlan, Roger] Overlook Hosp, Atlantic Neurosci Inst, Summit, NJ USA.
   [Marek, Kenneth; Seibyl, John] Inst Neurodegenerat Disorders, New Haven, CT USA.
   [Oakes, David; Flagg, Emily; Kieburtz, Karl] Univ Rochester, Dept Neurol, Rochester, NY USA.
   [Gauger, Lisa] Duke Univ, Dept Neurol, Med Ctr, Durham, NC USA.
   [Goetz, Christopher G.] Rush Univ, Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA.
   [DiEuliis, Diane] US Dept HHS, Off Assistant Secretary Preparedness & Response, Washington, DC 20201 USA.
   Columbia Univ, Dept Neurol, New York, NY USA.
   [Elliott, Robin A.] Parkinsons Dis Fdn, New York, NY USA.
   [Shoulson, Ira] Georgetown Univ, Med Ctr, Dept Neurol, Washington, DC 20007 USA.
RP Tanner, CM (reprint author), San Francisco VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, 4150 Clement St 127P, San Francisco, CA 94121 USA.
EM ctannermd@aol.com
FU Parkinson's Disease Foundation; National Institutes of Health; H.
   Lundbeck A/S; James Sharron Clark; Cephalon, Inc.
FX This study was supported by the Parkinson's Disease Foundation; the
   National Institutes of Health; Cephalon, Inc.; H. Lundbeck A/S; and
   James & Sharron Clark.
NR 40
TC 5
Z9 5
U1 2
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0885-3185
EI 1531-8257
J9 MOVEMENT DISORD
JI Mov. Disord.
PD MAY
PY 2014
VL 29
IS 6
BP 743
EP 749
DI 10.1002/mds.25814
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA AG4BI
UT WOS:000335363300008
PM 24515275
ER

PT J
AU Cholerton, BA
   Zabetian, CP
   Wan, JY
   Montine, TJ
   Quinn, JF
   Mata, IF
   Chung, KA
   Peterson, A
   Espay, AJ
   Revilla, FJ
   Devoto, J
   Watson, GS
   Hu, SC
   Leverenz, JB
   Edwards, KL
AF Cholerton, Brenna A.
   Zabetian, Cyrus P.
   Wan, Jia Y.
   Montine, Thomas J.
   Quinn, Joseph F.
   Mata, Ignacio F.
   Chung, Kathryn A.
   Peterson, Amie
   Espay, Alberto J.
   Revilla, Fredy J.
   Devoto, Johnna
   Watson, G. Stennis
   Hu, Shu-Ching
   Leverenz, James B.
   Edwards, Karen L.
TI Evaluation of Mild Cognitive Impairment Subtypes in Parkinson's Disease
SO MOVEMENT DISORDERS
LA English
DT Article
DE Parkinson disease; cognition; mild cognitive impairment;
   neuropsychological assessment
ID MINI-MENTAL-STATE; DIAGNOSTIC-CRITERIA; NORMATIVE DATA; DEMENTIA; TASK;
   ALZHEIMERS; CIRCUITRY; INCIDENT; DECLINE; COHORT
AB Mild cognitive impairment in Parkinson's disease (PD-MCI) is common and increases the risk for dementia. Establishing distinct PD-MCI cognitive subtypes could be valuable for eventually predicting those most likely to convert to dementia. However, the study of PD-MCI subtypes has not yielded consistent results among cohorts. To determine whether there are distinct cognitive subtypes among participants diagnosed with PD-MCI in the Pacific Northwest Udall Center Clinical Consortium, we cognitively subtyped 95 patients with PD-MCI, using the Movement Disorders Society Task Force diagnostic guidelines. Psychometric test scores were then subjected to principle components factor analysis to determine whether similar cognitive subgroups could be identified using statistical methodology. Multiple-domain PD-MCI was diagnosed in 95% of the sample, and a range of cognitive impairments were noted. Factor analysis yielded seven factors and demonstrated overlap of phonemic verbal fluency on two factors, as well as the loading of verbal fluency on the same factor as a visuospatial measure; however, these factors did not partition the sample into distinct cognitive subtypes. Separation of cognitive subtypes based on the current PD-MCI criteria, or via statistical methods, may not provide sufficient information to describe distinct PD groups. Future efforts to validate the PD-MCI criteria and identify combinations of genetic or other risk factors for cognitive impairment are warranted. (c) 2014 International Parkinson and Movement Disorder Society
C1 [Cholerton, Brenna A.; Zabetian, Cyrus P.; Mata, Ignacio F.; Leverenz, James B.] Geriatr Res Educ & Clin Ctr, Seattle, WA USA.
   [Zabetian, Cyrus P.; Leverenz, James B.] Parkinsons Dis Res Educ & Clin Ctr, Seattle, WA USA.
   [Leverenz, James B.] Vet Affairs Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA USA.
   [Cholerton, Brenna A.; Watson, G. Stennis; Leverenz, James B.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
   [Zabetian, Cyrus P.; Hu, Shu-Ching; Leverenz, James B.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA.
   [Wan, Jia Y.; Edwards, Karen L.] Univ Washington, Dept Epidemiol, Sch Med, Seattle, WA 98195 USA.
   [Montine, Thomas J.] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA.
   [Quinn, Joseph F.; Chung, Kathryn A.; Peterson, Amie] Portland VA Med Ctr, Portland, OR USA.
   [Quinn, Joseph F.; Chung, Kathryn A.; Peterson, Amie] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA.
   [Espay, Alberto J.; Revilla, Fredy J.; Devoto, Johnna] Univ Cincinnati, Dept Neurol & Rehabil Med, Cincinnati, OH USA.
   [Revilla, Fredy J.] Cincinnati Veteran Affairs Med Ctr, Cincinnati, OH USA.
RP Cholerton, BA (reprint author), VA Puget Sound Hlth Care Syst, GRECC A-182,9600 Vet Dr SW, Tacoma, WA 98493 USA.
EM bchol@u.washington.edu
OI Espay, Alberto/0000-0002-3389-136X; Zabetian, Cyrus/0000-0002-7739-4306
FU Nancy and Buster Alvord Endowment; Department of Veterans Affairs; 
   [NS065070];  [NS062684]
FX This study was supported by NS062684 and NS065070, the Nancy and Buster
   Alvord Endowment, and the Department of Veterans Affairs. The funding
   sources did not provide scientific input for the study.
NR 48
TC 16
Z9 16
U1 1
U2 13
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0885-3185
EI 1531-8257
J9 MOVEMENT DISORD
JI Mov. Disord.
PD MAY
PY 2014
VL 29
IS 6
BP 756
EP 764
DI 10.1002/mds.25875
PG 9
WC Clinical Neurology
SC Neurosciences & Neurology
GA AG4BI
UT WOS:000335363300010
PM 24710804
ER

PT J
AU Meffert, SM
   Abdo, AO
   Abd Alla, OA
   Elmakki, YOM
   Omer, AA
   Yousif, S
   Metzler, TJ
   Marmar, CR
AF Meffert, Susan M.
   Abdo, Akram Osman
   Abd Alla, Omayma Ahmed
   Elmakki, Yasir Omer Mustafa
   Omer, Afrah Abdelrahim
   Yousif, Sahar
   Metzler, Thomas J.
   Marmar, Charles R.
TI A Pilot Randomized Controlled Trial of Interpersonal Psychotherapy for
   Sudanese Refugees in Cairo, Egypt
SO PSYCHOLOGICAL TRAUMA-THEORY RESEARCH PRACTICE AND POLICY
LA English
DT Article
DE refugee; Sudan; global mental health; PTSD; depression; violence
ID POSTTRAUMATIC-STRESS-DISORDER; WORLD-TRADE-CENTER; SOCIAL SUPPORT;
   VIETNAM VETERANS; TRAUMATIC STRESS; MENTAL-HEALTH; RURAL UGANDA;
   RISK-FACTORS; ATTACHMENT; DEPRESSION
AB Approximately one third of a population exposed to mass violence develops posttraumatic stress disorder (PTSD) and approximately half develops depression, yet little is known about how to effectively treat these populations. This study's objective was to examine the impact of interpersonal psychotherapy (IPT) on Sudanese refugees living in Cairo, Egypt, who had symptoms of PTSD. A randomized controlled trial (April-August 2008) with 22 Sudanese refugees in Cairo, Egypt, tested two hypotheses: (1) After IPT, participants will have fewer symptoms of depression and PTSD compared with waitlist controls. (2) After IPT, participants will have less interpersonal violence compared with waitlist controls. Participants were randomly assigned to either 6 sessions of IPT delivered by Sudanese community therapists without previous mental health training or a waitlist control group. Measures taken at baseline and trial conclusion included the Harvard Trauma Questionnaire, the Beck Depression Index-II, the Conflict Tactics Scale, and the State-Trait Anger Inventory, all translated and adapted for local use. The effect sizes of IPT treatment for PTSD symptoms, depression, state anger, trait anger, and Conflict Tactics Scale-Violence Toward Household were -2.52, -2.38, -1.21, -1.43, and -0.84, respectively. IPT predicted a significant decrease in symptoms of PTSD, state anger, and depression using a conservative intent-to-treat analysis. This study represents the first randomized controlled trial of IPT to address PTSD, depression, and interpersonal violence in a refugee population. The study's preliminary success has positive implications for development of effective and sustainable mental health interventions to support the recovery of traumatized populations.
C1 [Meffert, Susan M.; Marmar, Charles R.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
   [Abdo, Akram Osman; Abd Alla, Omayma Ahmed; Elmakki, Yasir Omer Mustafa; Omer, Afrah Abdelrahim; Yousif, Sahar] Maan Org, Cairo, Egypt.
   [Abd Alla, Omayma Ahmed] St Andrews United Church Cairo, Cairo, Egypt.
   [Metzler, Thomas J.] San Francisco Vet Adm Med Ctr, Mental Hlth Serv, San Francisco, CA USA.
RP Meffert, SM (reprint author), 50 Beale St,Suite 1200,Box 1224, San Francisco, CA 94105 USA.
EM SusanM@lppi.uscf.edu
NR 55
TC 5
Z9 5
U1 5
U2 21
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 1942-9681
EI 1942-969X
J9 PSYCHOL TRAUMA-US
JI Psychol. Trauma
PD MAY
PY 2014
VL 6
IS 3
BP 240
EP 249
DI 10.1037/a0023540
PG 10
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA AH4FC
UT WOS:000336081500007
ER

PT J
AU Davis, MM
   Freeman, M
   Kaye, J
   Vuckovic, N
   Buckley, DI
AF Davis, Melinda M.
   Freeman, Michele
   Kaye, Jeffrey
   Vuckovic, Nancy
   Buckley, David I.
TI A Systematic Review of Clinician and Staff Views on the Acceptability of
   Incorporating Remote Monitoring Technology into Primary Care
SO TELEMEDICINE AND E-HEALTH
LA English
DT Article
DE home health monitoring; e-health; telehealth
ID NORTHERN GERMANY; CHRONIC DISEASE; TELEHOMECARE; PILOT; PROGRAM;
   DEVICES; DESIGN; ISSUES; HEALTH; HOME
AB Objective:Remote monitoring technology (RMT) may enhance healthcare quality and reduce costs. RMT adoption depends on perceptions of the end-user (e.g., patients, caregivers, healthcare providers). We conducted a systematic review exploring the acceptability and feasibility of RMT use in routine adult patient care, from the perspectives of primary care clinicians, administrators, and clinic staff.Materials and Methods:We searched the databases of Medline, IEEE Xplore, and Compendex for original articles published from January 1996 through February 2013. We manually screened bibliographies of pertinent studies and consulted experts to identify English-language studies meeting our inclusion criteria.Results:Of 939 citations identified, 15 studies reported in 16 publications met inclusion criteria. Studies were heterogeneous by country, type of RMT used, patient and provider characteristics, and method of implementation and evaluation. Clinicians, staff, and administrators generally held positive views about RMTs. Concerns emerged regarding clinical relevance of RMT data, changing clinical roles and patterns of care (e.g., reduced quality of care from fewer patient visits, overtreatment), insufficient staffing or time to monitor and discuss RMT data, data incompatibility with a clinic's electronic health record (EHR), and unclear legal liability regarding response protocols.Conclusions:This small body of heterogeneous literature suggests that for RMTs to be adopted in primary care, researchers and developers must ensure clinical relevance, support adequate infrastructure, streamline data transmission into EHR systems, attend to changing care patterns and professional roles, and clarify response protocols. There is a critical need to engage end-users in the development and implementation of RMT.
C1 [Davis, Melinda M.; Buckley, David I.] Oregon Hlth & Sci Univ, Oregon Rural Practice Based Res Network, Portland, OR 97239 USA.
   [Davis, Melinda M.; Buckley, David I.] Oregon Hlth & Sci Univ, Dept Family Med, Portland, OR 97239 USA.
   [Kaye, Jeffrey] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA.
   [Buckley, David I.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97239 USA.
   [Buckley, David I.] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97239 USA.
   [Kaye, Jeffrey] Oregon Hlth & Sci Univ, Oregon Ctr Aging & Technol, Portland, OR 97239 USA.
   [Freeman, Michele] Portland VA Med Ctr, VA Evidence Based Synth Program, Portland, OR USA.
   [Kaye, Jeffrey] Portland VA Med Ctr, Dept Neurol, Portland, OR USA.
   [Vuckovic, Nancy] Intel Corp, Hillsboro, OR 97124 USA.
RP Davis, MM (reprint author), Oregon Hlth & Sci Univ, Dept Family Med, 3181 SW Sam Jackson Pk Rd,Mail Code L222, Portland, OR 97239 USA.
EM davismel@ohsu.edu; freemanm@ohsu.edu
OI Kaye, Jeffrey/0000-0002-9971-3478
FU Oregon Roybal Center for Translational Research on Aging at OHSU,
   Portland, OR [P30AG024978]; Clinical and Translational Science Award
   from the National Center for Research Resources, National Institutes of
   Health [1 UL1 RR024140 01]; National Institute on Aging, National
   Institutes of Health [P30AG024978, P30AG008017]
FX We thank Andrew Hamilton, Oregon Health & Science University (OHSU)
   senior reference and instruction librarian, for his assistance with the
   search strategy. Funding for this project is provided by the Oregon
   Roybal Center for Translational Research on Aging (grant P30AG024978) at
   OHSU, Portland, OR, and by a Clinical and Translational Science Award to
   OHSU (grant 1 UL1 RR024140 01 from the National Center for Research
   Resources, National Institutes of Health). J.K.'s time was supported by
   grants P30AG024978 and P30AG008017 from the National Institute on Aging,
   National Institutes of Health.
NR 28
TC 6
Z9 6
U1 0
U2 10
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1530-5627
EI 1556-3669
J9 TELEMED E-HEALTH
JI Telemed. e-Health
PD MAY 1
PY 2014
VL 20
IS 5
BP 428
EP 438
DI 10.1089/tmj.2013.0166
PG 11
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA AG4MG
UT WOS:000335393400006
PM 24731239
ER

PT J
AU Fazeli, PL
   Doyle, KL
   Scott, JC
   Iudicello, JE
   Casaletto, KB
   Weber, E
   Moore, DJ
   Morgan, EE
   Grant, I
   Woods, SP
AF Fazeli, Pariya L.
   Doyle, Katie L.
   Scott, J. Cobb
   Iudicello, Jennifer E.
   Casaletto, Kaitlin B.
   Weber, Erica
   Moore, David J.
   Morgan, Erin E.
   Grant, Igor
   Woods, Steven Paul
CA HIV Neurobehav Res Program HNRP
TI Shallow Encoding and Forgetting Are Associated with Dependence in
   Instrumental Activities of Daily Living Among Older Adults Living with
   HIV Infection
SO ARCHIVES OF CLINICAL NEUROPSYCHOLOGY
LA English
DT Article
DE Aging; Disability; Everyday functioning; Learning and memory
ID HUMAN-IMMUNODEFICIENCY-VIRUS; VERBAL MEMORY PERFORMANCE; NEUROCOGNITIVE
   DISORDERS; NEUROPSYCHOLOGICAL PERFORMANCE; COGNITIVE IMPAIRMENT;
   MEDICATION ADHERENCE; CORTICAL HYPOTHESIS; CONSTRUCT-VALIDITY; YOUNGER
   ADULTS; LEARNING TEST
AB Aging and HIV are both risk factors for memory deficits and declines in real-world functioning. However, we know little about the profile of memory deficits driving instrumental activities of daily living (IADL) declines across the lifespan in HIV. This study examined 145 younger (< 50 years) and 119 older (a parts per thousand yen50 years) adults with HIV who completed the California Verbal Learning Test-Second Edition (CVLT-II), the Wechsler Memory Scale-Third Edition Logical Memory subtest (WMS-III LM), and a modified Lawton and Brody ADL questionnaire. No memory predictors of IADL dependence emerged in the younger cohort. In the older group, IADL dependence was uniquely associated with worse performance on all primary CVLT-II variables, as well as elevated recency effects. Poorer immediate and delayed recall of the WMS-III LM was also associated with IADL dependence, although recognition was intact. Findings suggest older HIV-infected adults with shallow encoding and forgetting are at risk for IADL dependence.
C1 [Fazeli, Pariya L.; Doyle, Katie L.; Iudicello, Jennifer E.; Casaletto, Kaitlin B.; Weber, Erica; Moore, David J.; Morgan, Erin E.; Grant, Igor; Woods, Steven Paul] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA.
   [Doyle, Katie L.; Casaletto, Kaitlin B.; Weber, Erica] San Diego State Univ, Joint Doctoral Program Clin Psychol, San Diego, CA 92182 USA.
   [Doyle, Katie L.; Casaletto, Kaitlin B.; Weber, Erica] Univ Calif San Diego, San Diego, CA 92103 USA.
   [Scott, J. Cobb] Univ Penn, Dept Psychiat, Perelman Sch Med, Neuropsychiat Sect, Philadelphia, PA 19104 USA.
   [Scott, J. Cobb] Philadelphia VA Med Ctr, Philadelphia, PA USA.
   [Scott, J. Cobb] VISN 4 Mental Illness Res Educ & Clin Ctr MIRECC, Philadelphia, PA USA.
RP Woods, SP (reprint author), Univ Calif San Diego, Dept Psychiat 8231, 220 Dickinson St,Suite B, San Diego, CA 92103 USA.
EM spwoods@ucsd.edu
FU National Institutes of Health (NIH) [R01-MH073419, T32-DA031098,
   P30-MH062512, F31-DA034510, F31-DA035708, L30-DA032120, L30-DA034362];
   California HIV/AIDS Research Program (CHRP) [R25-MH081482, R01-MH099987,
   L30-AG045921, ID10-SD-057]
FX This research was supported by National Institutes of Health (NIH)
   grants R01-MH073419, T32-DA031098, P30-MH062512, F31-DA034510,
   F31-DA035708, L30-DA032120, and L30-DA034362. Dr. Fazeli is supported by
   R25-MH081482, R01-MH099987, L30-AG045921, and ID10-SD-057 from
   California HIV/AIDS Research Program (CHRP).
NR 64
TC 2
Z9 2
U1 0
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0887-6177
EI 1873-5843
J9 ARCH CLIN NEUROPSYCH
JI Arch. Clin. Neuropsychol.
PD MAY
PY 2014
VL 29
IS 3
BP 278
EP 288
DI 10.1093/arclin/acu009
PG 11
WC Psychology, Clinical; Psychology
SC Psychology
GA AG9WC
UT WOS:000335769700007
PM 24695591
ER

PT J
AU Pietrzak, RH
   Scott, JC
   Neumeister, A
   Lim, YY
   Ames, D
   Ellis, KA
   Harrington, K
   Lautenschlager, NT
   Szoeke, C
   Martins, RN
   Masters, CL
   Villemagne, VL
   Rowe, CC
   Maruff, P
AF Pietrzak, Robert H.
   Scott, J. Cobb
   Neumeister, Alexander
   Lim, Yen Ying
   Ames, David
   Ellis, Kathryn A.
   Harrington, Karra
   Lautenschlager, Nicola T.
   Szoeke, Cassandra
   Martins, Ralph N.
   Masters, Colin L.
   Villemagne, Victor L.
   Rowe, Christopher C.
   Maruff, Paul
CA Australian Imaging Biomarkers
TI Anxiety symptoms, cerebral amyloid burden and memory decline in healthy
   older adults without dementia: 3-year prospective cohort study
SO BRITISH JOURNAL OF PSYCHIATRY
LA English
DT Article
ID COGNITIVE IMPAIRMENT; DEPRESSION
AB Although beta-amyloid, anxiety and depression have been linked cross-sectionally to reduced memory function in healthy older adults without dementia, prospective data evaluating these associations are lacking. Using data from an observational cohort study of 178 healthy older adults without dementia followed for 3 years, we found that anxiety symptoms significantly moderated the relationship between beta-amyloid level and decline in verbal (Cohen's d=0.65) and episodic (Cohen's d=0.38) memory. Anxiety symptoms were additionally linked to greater decline in executive function, irrespective of beta-amyloid and other risk factors. These findings suggest that interventions to mitigate anxiety symptoms may help delay memory decline in otherwise healthy older adults with elevated beta-amyloid.
C1 [Pietrzak, Robert H.; Scott, J. Cobb] VA Connecticut Healthcare Syst, Clin Neurosci Div, US Dept Vet Affairs, Natl Ctr Posttraumat Stress Disorder, West Haven, CT USA.
   [Pietrzak, Robert H.; Scott, J. Cobb] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA.
   [Neumeister, Alexander] NYU, Sch Med, Dept Psychiat, New York, NY USA.
   [Neumeister, Alexander] NYU, Dept Radiol, Sch Med, New York, NY 10016 USA.
   [Lim, Yen Ying; Ellis, Kathryn A.; Harrington, Karra; Masters, Colin L.; Villemagne, Victor L.; Maruff, Paul] Florey Inst Neurosci & Mental Hlth, Parkville, Vic, Australia.
   [Ames, David; Ellis, Kathryn A.] Univ Melbourne, Kew & Natl Ageing Res Inst, Dept Psychiat, Acad Unit Psychiat Old Age,St Vincents Hlth, Parkville, Vic 3052, Australia.
   [Lautenschlager, Nicola T.] Univ Melbourne, Dept Psychiat, Acad Unit Psychiat Old Age, St Vincents Hlth, Kew, Vic, Australia.
   [Lautenschlager, Nicola T.] Univ Western Australia, Sch Psychiat & Clin Neurosci, Perth, WA 6009, Australia.
   [Lautenschlager, Nicola T.] Univ Western Australia, WA Ctr Hlth & Ageing, Perth, WA 6009, Australia.
   [Szoeke, Cassandra] Natl Ageing Res Inst, Parkville, Vic, Australia.
   [Szoeke, Cassandra] Univ Melbourne, Mental Hlth Res Inst, Parkville, Vic 3052, Australia.
   [Szoeke, Cassandra] CSIRO Preventat Hlth Flagship, Parkville, Vic, Australia.
   [Martins, Ralph N.] Edith Cowan Univ, Sch Exercise Biomed & Hlth Sci, Ctr Excellence Alzheimers Dis Res & Care, Perth, WA, Australia.
   [Villemagne, Victor L.; Rowe, Christopher C.] Austin Hlth, Dept Nucl Med, Heidelberg, Vic, Australia.
   [Villemagne, Victor L.; Rowe, Christopher C.] Austin Hlth, Ctr PET, Heidelberg, Vic, Australia.
   [Villemagne, Victor L.; Rowe, Christopher C.] Univ Melbourne, Austin Hlth, Dept Med, Heidelberg, Vic, Australia.
   [Maruff, Paul] Cog State Ltd, Melbourne, Vic, Australia.
RP Pietrzak, RH (reprint author), VA Connecticut Healthcare Syst, Natl Ctr PTSD, 950 Campbell Ave 161E, West Haven, CT 06516 USA.
EM robert.pietrzak@yale.edu
OI Maruff, Paul/0000-0002-6947-9537; Szoeke, Cassandra/0000-0002-3698-2590
NR 10
TC 9
Z9 9
U1 0
U2 3
PU ROYAL COLLEGE OF PSYCHIATRISTS
PI LONDON
PA BRITISH JOURNAL OF PSYCHIATRY 17 BELGRAVE SQUARE, LONDON SW1X 8PG,
   ENGLAND
SN 0007-1250
EI 1472-1465
J9 BRIT J PSYCHIAT
JI Br. J. Psychiatry
PD MAY
PY 2014
VL 204
IS 5
BP 400
EP 401
DI 10.1192/bjp.bp.113.134239
PG 2
WC Psychiatry
SC Psychiatry
GA AH3HY
UT WOS:000336015500015
PM 24526746
ER

PT J
AU Friedman, MJ
AF Friedman, Matthew J.
TI Suicide Risk Among Soldiers Early Findings From Army Study to Assess
   Risk and Resilience in Servicemembers (Army STARRS)
SO JAMA PSYCHIATRY
LA English
DT Editorial Material
ID US MILITARY PERSONNEL; MENTAL-HEALTH
C1 [Friedman, Matthew J.] US Dept Vet Affairs, Natl Ctr PTSD, Washington, DC USA.
   [Friedman, Matthew J.] Geisel Sch Med Dartmouth, Dept Psychiat, Hanover, NH USA.
   [Friedman, Matthew J.] Geisel Sch Med Dartmouth, Dept Pharmacol & Toxicol, Hanover, NH USA.
RP Friedman, MJ (reprint author), VA Med Ctr, US Natl Ctr PTSD, Geisel Sch Med Dartmouth, Dept Pharmacol & Psychiat, 215 N Main St, White River Jct, VT 05009 USA.
EM matthew.j.friedman@dartmouth.edu
NR 10
TC 8
Z9 8
U1 1
U2 6
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-622X
EI 2168-6238
J9 JAMA PSYCHIAT
JI JAMA Psychiatry
PD MAY
PY 2014
VL 71
IS 5
BP 487
EP 489
DI 10.1001/jamapsychiatry.2014.24
PG 3
WC Psychiatry
SC Psychiatry
GA AH2JP
UT WOS:000335947600003
PM 24590002
ER

PT J
AU Byers, AL
   Covinsky, KE
   Neylan, TC
   Yaffe, K
AF Byers, Amy L.
   Covinsky, Kenneth E.
   Neylan, Thomas C.
   Yaffe, Kristine
TI Chronicity of Posttraumatic Stress Disorder and Risk of Disability in
   Older Persons
SO JAMA PSYCHIATRY
LA English
DT Article
ID COMORBIDITY SURVEY REPLICATION; WORLD-HEALTH-ORGANIZATION;
   QUALITY-OF-LIFE; FUNCTIONAL IMPAIRMENT; PHYSICAL-DISABILITY;
   PRIMARY-CARE; GERIATRIC DEPRESSION; FUTURE-RESEARCH; SYMPTOMS; DECLINE
AB IMPORTANCE Little is known about the association between posttraumatic stress disorder (PTSD) and disability into later life. Most studies of late-life psychiatric disorders and function have focused on depression and generalized anxiety disorder.
   OBJECTIVES To determine the association between PTSD and disability among older adults and investigate if association differs by chronicity of PTSD.
   DESIGN, SETTING, AND PARTICIPANTS In total, 3287 participants 55 years and older (mean [SD] age, 66.0 [8.7] years, 60.1% women) involved in the Collaborative Psychiatric Epidemiology Surveys (2001-2003), including 3 aggregated, nationally representative studies (National Comorbidity Survey Replication, National Survey of American Life, and National Latino and Asian American Study). Analyses used weights and complex design-corrected statistical tests to infer generalizability to the US population.
   MAIN OUTCOMES AND MEASURES Disability defined by 5 domains (out of role, self-care, mobility, cognition, and social) using theWorld Health Organization Disability Assessment Schedule.
   RESULTS Of the 3.7% older adults who had a history of PTSD defined by DSM-IV criteria, 1.8% had persistent PTSD into later life (age of onset < 55 years as well as a recent diagnosis). Frequency of any disability was 79.7% for persistent PTSD, 69.6% for pre-late life (age of onset < 55 years and age at last diagnosis < 55 years), and 36.9% for no PTSD (P <.001). In logistic regression analyses, adjusting for demographics, smoking, individual medical conditions, depression, generalized anxiety disorder, and substance use disorders, respondents with persistent PTSD were 3 times more likely to have any disability than were respondents with no PTSD (odds ratio, 3.18; 95% CI, 1.32-7.64). Global disability results were nonsignificant for pre-late life relative to no PTSD (odds ratio, 1.99; 95% CI, 0.97-4.08).
   CONCLUSIONS AND RELEVANCE Disability in older Americans is strongly associated with PTSD, particularly PTSD that persists into later life. These findings suggest that monitoring and treatment of PTSD are important over the long term.
C1 [Byers, Amy L.; Neylan, Thomas C.; Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
   [Byers, Amy L.; Covinsky, Kenneth E.; Neylan, Thomas C.; Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
   [Covinsky, Kenneth E.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
   [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
   [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
RP Byers, AL (reprint author), San Francisco VA Med Ctr, Dept Psychiat, 4150 Clement St,Mail Code 116H, San Francisco, CA 94121 USA.
EM amy.byers@ucsf.edu
FU Department of Defense [W81XWH-11-2-0189]; National Institute of Mental
   Health [U01-MH60220, U01-MH57716, U01-MH062209, U01-MH62207]; National
   Institute of Drug Abuse [R01-DA12058-05]; Substance Abuse and Mental
   Health Services Administration; Robert Wood Johnson Foundation [044708];
   National Institutes of Health; University of Michigan, Ann Arbor
FX This study was supported by Department of Defense grant
   W81XWH-11-2-0189, which was administered by the Northern California
   Institute for Research and Education and with resources of the San
   Francisco Veterans Affairs Medical Center (Dr Byers), and in part by a
   K24 Midcareer Investigator Award (AG031155) from the National Institute
   on Aging (Dr Yaffe). The National Comorbidity Survey Replication was
   supported by the National Institute of Mental Health (U01-MH60220), with
   supplemental support from the National Institute of Drug Abuse
   (R01-DA12058-05), the Substance Abuse and Mental Health Services
   Administration, the Robert Wood Johnson Foundation (044708), and the
   JohnW. Alden Trust. The National Survey of American Life was supported
   by the National Institute of Mental Health (U01-MH57716), with
   supplemental support from the Office of Behavioral and Social Sciences
   Research at the National Institutes of Health and the University of
   Michigan, Ann Arbor. The National Latino and Asian American Study was
   supported by the National Institute of Mental Health (U01-MH062209 and
   U01-MH62207), with supplemental support from the Office of Behavioral
   and Social Sciences Research at the National Institutes of Health, the
   Substance Abuse and Mental Health Services Agency, and the Latino
   Research Program Project (P01-MH059876).
NR 40
TC 11
Z9 11
U1 3
U2 12
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-622X
EI 2168-6238
J9 JAMA PSYCHIAT
JI JAMA Psychiatry
PD MAY
PY 2014
VL 71
IS 5
BP 540
EP 546
DI 10.1001/jamapsychiatry.2014.5
PG 7
WC Psychiatry
SC Psychiatry
GA AH2JP
UT WOS:000335947600011
PM 24647756
ER

PT J
AU Yeghiazarians, Y
   Honbo, N
   Imhof, I
   Woods, B
   Aguilera, V
   Ye, JQ
   Boyle, AJ
   Karliner, JS
AF Yeghiazarians, Yerem
   Honbo, Norman
   Imhof, Isabella
   Woods, Brandon
   Aguilera, Vanessa
   Ye, Jianqin
   Boyle, Andrew J.
   Karliner, Joel S.
TI IL-15: A Novel Prosurvival Signaling Pathway in Cardiomyocytes
SO JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
LA English
DT Article
DE stem cell; IL-15; survival; cardiomyocyte
ID SPHINGOSINE 1-PHOSPHATE; ISCHEMIC-HEART; STEM-CELLS; FUNCTIONAL
   IMPROVEMENT; INTERLEUKIN-15; APOPTOSIS; HYPOXIA; ASSOCIATION;
   FIBROBLASTS; MYOCARDIUM
AB Cardiovascular disease is the leading cause of death in Western countries. A major limitation of current treatments is the inability to efficiently repair or replace dead myocardium. Recently, stem cell-based therapies have been explored as an avenue to circumvent current therapeutic limitations. Overall, these therapies seem to result in small improvements in the contractile function of the heart. The exact mechanism(s) of action that underlie these improvements remain unknown, and it is believed that paracrine effects play a significant role. Previously, we had reported that an extract derived from bone marrow cells, in the absence of any live cell, contained cardioprotective soluble factors. In this study, we identify IL-15 as a putative cardioprotectant within the bone marrow cells paracrine profile. Using an in vitro culture system, we assessed the ability of IL-15 to protect cardiomyocytes under hypoxic conditions. For the first time, we have identified IL-15 receptors on the surface of cardiomyocytes and delineated the signaling system by which hypoxic cardiomyocytes may be protected from cellular death and rescued from oxidative stress with IL-15 treatment.
C1 [Yeghiazarians, Yerem; Woods, Brandon; Aguilera, Vanessa; Ye, Jianqin; Boyle, Andrew J.; Karliner, Joel S.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
   [Yeghiazarians, Yerem; Boyle, Andrew J.] Univ Calif San Francisco, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, San Francisco, CA 94143 USA.
   [Yeghiazarians, Yerem; Karliner, Joel S.] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA.
   [Honbo, Norman; Imhof, Isabella; Karliner, Joel S.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA.
RP Yeghiazarians, Y (reprint author), Univ Calif San Francisco, Dept Med, 505 Parnassus Ave,Box 0103, San Francisco, CA 94143 USA.
EM yeghiaza@medicine.ucsf.edu
FU UCSF Translational Cardiac Stem Cell Program; Leone-Perkins Foundation;
   Torian Foundation; Vadasz Foundation; Foundation for Cardiac Research;
   Chatterjee Center for Cardiac Research;  [HL R01 090606]
FX Supported by the UCSF Translational Cardiac Stem Cell Program, the
   Leone-Perkins Foundation, the Torian Foundation and the Vadasz
   Foundation (all to Y.Y.), and by HL R01 090606, the Foundation for
   Cardiac Research, and the Chatterjee Center for Cardiac Research (all to
   J.S.K.).
NR 27
TC 3
Z9 4
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0160-2446
EI 1533-4023
J9 J CARDIOVASC PHARM
JI J. Cardiovasc. Pharmacol.
PD MAY
PY 2014
VL 63
IS 5
BP 406
EP 411
DI 10.1097/FJC.0000000000000061
PG 6
WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy
SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy
GA AH2KZ
UT WOS:000335951500003
PM 24805144
ER

PT J
AU Payne, VL
   Singh, H
   Meyer, AND
   Levy, L
   Harrison, D
   Graber, ML
AF Payne, Velma L.
   Singh, Hardeep
   Meyer, Ashley N. D.
   Levy, Lewis
   Harrison, David
   Graber, Mark L.
TI Patient-Initiated Second Opinions: Systematic Review of Characteristics
   and Impact on Diagnosis, Treatment, and Satisfaction
SO MAYO CLINIC PROCEEDINGS
LA English
DT Review
ID CANCER-PATIENTS; ALTERNATIVE MEDICINE; ANATOMIC PATHOLOGY; SURGICAL
   PATHOLOGY; ERRORS; NEURORADIOLOGY; 2ND-OPINION; CARE; INTERVENTIONS;
   CONSULTATION
AB The impact of second opinions on diagnosis in radiology and pathology is well documented; however, the value of patient-initiated second opinions for diagnosis and treatment in general medical practice is unknown. We conducted a systematic review of patient-initiated second opinions to assess their impact on clinical outcomes and patient satisfaction and to determine characteristics and motivating factors of patients who seek a second opinion. We searched PubMed, EMBASE, Cochrane, and Academic OneFile databases using Medical Subject Headings (MeSH) indexes and keyword searches. Search terms included referral and consultation, patient-initiated, patient preference, patient participation, second opinion, second review, and diagnosis. Multiple reviewers screened abstracts and articles to determine eligibility and extract data. We assessed risk of bias using the Cochrane Risk of Bias Tool and rated study quality using Cochrane's GRADE (Grades of Recommendation, Assessment, Development and Evaluation) approach. We screened 1342 abstracts and reviewed full text of 41 articles, identifying 7 articles that reported clinical agreement data and 10 that discussed patient characteristics, motivation, and satisfaction. We found that a second opinion typically confirms the original diagnosis or treatment regimen but that 90% of patients with poorly defined conditions remain undiagnosed. However, 10% to 62% of second opinions yield a major change in the diagnosis, treatment, or prognosis. A larger fraction of patients receive different advice on treatment than on diagnosis. Factors motivating a second opinion include diagnosis or treatment confirmation, dissatisfaction with a consultation, desire for more information, persistent symptoms, or treatment complications. Patients generally believed that second opinions were valuable. Second opinions can result in diagnostic and treatment differences. The literature on patient-initiated second opinions is limited, and the accuracy of the second opinion through follow-up is generally unknown. Standardized methods and outcome measures are needed to determine the value of second opinions, and the potential of second opinions to reduce diagnostic errors merits more rigorous evaluation. (C) 2014 Mayo Foundation for Medical Education and Research
C1 [Payne, Velma L.; Singh, Hardeep; Meyer, Ashley N. D.] Baylor Coll Med, Houston Vet Affairs Hlth Serv, Res & Dev Ctr Innovat Qual Effectiveness & Safety, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
   [Payne, Velma L.; Singh, Hardeep; Meyer, Ashley N. D.] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA.
   [Levy, Lewis; Harrison, David] Best Doctors Inc, Boston, MA USA.
   [Graber, Mark L.] RTI Int, Res Triangle Pk, NC USA.
RP Graber, ML (reprint author), 1 Breezy Hollow, St James, NY 11780 USA.
EM mgraber@rti.org
OI Graber, Mark/0000-0002-3600-0446; Meyer, Ashley/0000-0001-7993-8584
FU Department of Veterans Affairs, Veterans Health Administration, Office
   of Research and Development [CIN 13-413]; Center for Innovations in
   Quality, Effectiveness and Safety; VA Office of Academic Affiliations,
   Washington; Houston VA Center for Innovations in Quality, Effectiveness
   and Safety [CIN 13-413]
FX This work was supported in part by grant CIN 13-413 from the Department
   of Veterans Affairs, Veterans Health Administration, Office of Research
   and Development, and the Center for Innovations in Quality,
   Effectiveness and Safety. Dr Payne is supported by the VA Office of
   Academic Affiliations, Washington, DC. Drs Singh and Meyer are supported
   by the Houston VA Center for Innovations in Quality, Effectiveness and
   Safety (CIN 13-413).
NR 56
TC 7
Z9 7
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0025-6196
EI 1942-5546
J9 MAYO CLIN PROC
JI Mayo Clin. Proc.
PD MAY
PY 2014
VL 89
IS 5
BP 687
EP 696
DI 10.1016/j.mayocp.2014.02.015
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA AG6WU
UT WOS:000335560400016
PM 24797646
ER

PT J
AU Kostin, A
   Siegel, JM
   Alam, MN
AF Kostin, Andrey
   Siegel, Jerome M.
   Alam, Md. Noor
TI Lack of Hypocretin Attenuates Behavioral Changes Produced by
   Glutamatergic Activation of the Perifornical-Lateral Hypothalamic Area
SO SLEEP
LA English
DT Article
DE orexin; hypocretin; perifornical area; prepro-orexin knockout; sleep;
   dorsomedial hypothalamus; lateral hypothalamus; N-methyl-D-aspartate
ID OREXIN KNOCKOUT MICE; OREXIN/HYPOCRETIN NEURONS; SLEEP REGULATION; MOUSE
   MODELS; MCH NEURONS; NARCOLEPSY; WAKEFULNESS; RATS; DISCHARGE; WAKING
AB Study Objectives: The hypocretins (HCRTs) are two hypothalamic peptides predominantly localized to neurons in the perifornical, dorsomedial, and lateral hypothalamic area (PF-LHA). Evidence suggests that HCRT signaling is critical for the promotion and stabilization of active-arousal and its loss or malfunction leads to symptoms of narcolepsy. In the PF-LHA, HCRT neurons are intermingled with glutamate-expressing neurons and also co-express glutamate. Evidence suggests that HCRT-glutamate interactions within the PF-LHA may play a critical role in maintaining behavioral arousal. However, the relative contributions of the glutamate and HCRT in sleep-wake regulation are not known.
   Design: We determined whether a lack of HCRT signaling in the prepro-orexin-knockout (HCRT-KO) mouse attenuates/compromises the wake-promoting ability of glutamatergic activation of the PF-LHA region. We used reverse microdialysis to deliver N-methyl-D-aspartate (NMDA) into the HCRT zone of the PF-LHA in HCRT-KO and wild-type (WT) mice to evaluate the contributions of glutamatergic vs. HCRT signaling in sleep-wake regulation.
   Measurements and Results: As compared to respective controls, local perfusion of NMDA into the PF-LHA, dose-dependently increased active-waking with concomitant reductions in nonREM and REM sleep in spontaneously sleeping WT as well as HCRT-KO mice. However, compared to WT, the NMDA-induced behavioral changes in HCRT-KO mice were significantly attenuated, as evidenced by the higher dose of NMDA needed and lower magnitude of changes induced in sleep-wake parameters. Although not observed in WT mice, the number of cataplectic events increased significantly during NMDA-induced behavioral arousal in HCRT-KO mice.
   Conclusions: The findings of this study are consistent with a hypothesis that synergistic interactions between hypocretin and glutamatergic mechanisms within the perifornical, dorsomedial, and lateral hypothalamic area are critical for maintaining behavioral arousal, especially arousal involving elevated muscle tone.
C1 [Kostin, Andrey; Siegel, Jerome M.; Alam, Md. Noor] Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv 151A3, Sepulveda, CA 91343 USA.
   [Siegel, Jerome M.] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA USA.
   [Siegel, Jerome M.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA.
   [Alam, Md. Noor] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA.
RP Alam, MN (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv 151A3, 16111 Plummer St, Sepulveda, CA 91343 USA.
EM noor@ucla.edu
FU Medical Research Service, US Department of Veterans Affairs [MH064109]
FX This was not an industry supported study. This work was supported by the
   Medical Research Service, US Department of Veterans Affairs and
   MH064109. The authors have indicated no financial conflicts of interest.
NR 55
TC 7
Z9 7
U1 0
U2 2
PU AMER ACAD SLEEP MEDICINE
PI WESTCHESTER
PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA
SN 0161-8105
EI 1550-9109
J9 SLEEP
JI Sleep
PD MAY 1
PY 2014
VL 37
IS 5
BP 1011
EP 1020
DI 10.5665/sleep.3680
PG 10
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA AH3UZ
UT WOS:000336052600023
PM 24790280
ER

PT J
AU Schapira, MM
   Mackenzie, ER
   Lam, R
   Casarett, D
   Seluzicki, CM
   Barg, FK
   Mao, JJ
AF Schapira, Marilyn M.
   Mackenzie, Elizabeth R.
   Lam, Regina
   Casarett, David
   Seluzicki, Christina M.
   Barg, Frances K.
   Mao, Jun J.
TI Breast cancer survivors willingness to participate in an acupuncture
   clinical trial: a qualitative study
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article
DE Breast cancer survivors; Acupuncture; Clinical trials; Decision making
ID ALTERNATIVE MEDICINE USE; AFRICAN-AMERICANS; HOT FLASHES; COMPLEMENTARY;
   ATTITUDES; RECRUITMENT; CARE; MINORITIES; BARRIERS; ONCOLOGY
AB Purpose Acupuncture is a complementary and alternative medicine (CAM) modality that shows promise as a component of supportive breast cancer care. Lack of robust recruitment for clinical trial entry has limited the evidence base for acupuncture as a treatment modality among breast cancer survivors. The objective of this study is to identify key decision-making factors among breast cancer survivors considering entry into an acupuncture clinical trial for treatment of symptoms.
   Methods Semistructured interviews were conducted among African-American (n = 12) and Caucasian (n = 13) breast cancer survivors. Verbatim transcripts were made and analyzed by two or more independent coders using NVivo software. Major recurring themes were identified and a theoretical framework developed.
   Results Six themes emerged reflecting key attributes of the decision to enter a clinical trial: (1) symptom appraisal, (2) practical barriers (e. g., distance and travel), (3) beliefs about the interventions (e. g., fear of needles and dislike of medications), (4) comfort with elements of clinical trial design (e. g., randomization, the nature of the control intervention, and blinding), (5) trust, and (6) altruism. African-American and Caucasian women weighed similar attributes but differed in the information sources sought regarding clinical trial entry and in concerns regarding the use of a placebo in a clinical trial.
   Conclusions Our findings contribute to the development of a theoretical model of decision making for breast cancer survivors considering participation in a CAM clinical trial. Insights regarding the decision making process can inform interventions to support informed decision making and robust recruitment to CAM trials among cancer survivors.
C1 [Schapira, Marilyn M.] Univ Penn, Philadelphia VA Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA.
   [Schapira, Marilyn M.] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Schapira, Marilyn M.; Mao, Jun J.] Univ Penn, Abramson Canc Ctr, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Mackenzie, Elizabeth R.] Univ Penn, Div Appl Psychol Human Dev, Grad Sch Educ, Philadelphia, PA 19104 USA.
   [Lam, Regina; Seluzicki, Christina M.; Barg, Frances K.; Mao, Jun J.] Univ Penn, Dept Family Med & Community Hlth, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Casarett, David] Univ Penn, Dept Med, Div Geriatr, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Barg, Frances K.] Univ Penn, Dept Anthropol, Sch Arts & Sci, Philadelphia, PA 19104 USA.
RP Schapira, MM (reprint author), Univ Penn, Abramson Canc Ctr, Perelman Sch Med, 1122 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM mschap@upenn.edu
FU American Cancer Society [CCCDA-08-107]; National Institute of
   Health/National Center for Complementary and Alternative Medicine [R21
   AT004695, K23004112]
FX This research is funded in part from American Cancer Society
   CCCDA-08-107 award. Mao is a recipient of the National Institute of
   Health/National Center for Complementary and Alternative Medicine grants
   R21 AT004695 and K23004112. The funding agencies had no role in the
   design and conduct of the study.
NR 35
TC 3
Z9 4
U1 1
U2 24
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0941-4355
EI 1433-7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD MAY
PY 2014
VL 22
IS 5
BP 1207
EP 1215
DI 10.1007/s00520-013-2073-3
PG 9
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA AG9XY
UT WOS:000335774600008
PM 24362843
ER

PT J
AU Thames, AD
   Arbid, N
   Sayegh, P
AF Thames, April D.
   Arbid, Natalie
   Sayegh, Philip
TI Cannabis use and neurocognitive functioning in a non-clinical sample of
   users
SO ADDICTIVE BEHAVIORS
LA English
DT Article
DE Cannabis; Cognition; Premorbid IQ; Abstinence; Past use; Abuse
ID ADOLESCENT MARIJUANA USERS; ALCOHOL-USE; NEUROPSYCHOLOGICAL PERFORMANCE;
   EXECUTIVE FUNCTION; USE-DISORDERS; SUBSTANCE USE; YOUNG-ADULTS;
   DRUG-USE; BEHAVIOR; OUTCOMES
AB Objective: With the recent debates over marijuana legalization and increases in use, it is critical to examine its role in cognition. While many studies generally support the adverse acute effects of cannabis on neurocognition, the non-acute effects remain less clear. The current study used a cross-sectional design to examine relationships between recent and past cannabis use on neurocognitive functioning in a non-clinical adult sample.
   Method: One hundred and fifty-eight participants were recruited through fliers distributed around local college campuses and the community. All participants completed the Brief Drug Use History Form, the Structured Clinical Interview for DSM-IV Disorders, and neurocognitive assessment, and underwent urine toxicology screening. Participants consisted of recent users (n = 68), past users (n = 41), and non-users (n = 49).
   Results: Recent users demonstrated significantly (p < .05) worse performance than non-users across cognitive domains of attention/working memory (M = 42.4, SD = 16.1 vs. M = 50.5, SD = 10.2), information processing speed (M = 44.3, SD = 7.3 vs. M = 52.1, SD = 11.0), and executive functioning (M = 43.6, SD = 13.4 vs. M = 48.6, SD = 7.2). There were no statistically significant differences between recent users and past users on neurocognitive performance. Frequency of cannabis use in the last 4 weeks was negatively associated with global neurocognitive performance and all individual cognitive domains. Similarly, amount of daily cannabis use was negatively associated with global neurocognitive performance and individual cognitive domains.
   Conclusions: Our results support the widespread adverse effects of cannabis use on neurocognitive functioning. Although some of these adverse effects appear to attenuate with abstinence, past users' neurocognitive functioning was consistently lower than non-users. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Thames, April D.; Sayegh, Philip] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
   [Arbid, Natalie] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA 90024 USA.
RP Thames, AD (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, 740 Westwood Plaza C8-226, Los Angeles, CA 90095 USA.
EM athames@mednet.ucla.edu
RI Thames, April/K-1964-2014
OI Thames, April/0000-0001-8414-7189
FU National Academy of Neuropsychology; NIH/NIMH [K-23 MH095661]
FX Funding for this study was provided by the National Academy of
   Neuropsychology. Dr. Thames is currently supported by an NIH/NIMH Career
   Development Award (K-23 MH095661). NAN and NIH/NIMH had no further role
   in study design; in the collection, analysis and interpretation of data;
   in the writing of the report; or in the decision to submit the paper for
   publication.
NR 63
TC 20
Z9 20
U1 3
U2 46
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4603
EI 1873-6327
J9 ADDICT BEHAV
JI Addict. Behav.
PD MAY
PY 2014
VL 39
IS 5
BP 994
EP 999
DI 10.1016/j.addbeh.2014.01.019
PG 6
WC Psychology, Clinical; Substance Abuse
SC Psychology; Substance Abuse
GA AG7QH
UT WOS:000335612400026
PM 24556155
ER

PT J
AU Lu, LY
   Krumholz, HM
   Tu, JV
   Ross, JS
   Ko, DT
   Jackevicius, CA
AF Lu, Lingyun
   Krumholz, Harlan M.
   Tu, Jack V.
   Ross, Joseph S.
   Ko, Dennis T.
   Jackevicius, Cynthia A.
TI Impact of the ENHANCE Trial on the use of ezetimibe in the United States
   and Canada
SO AMERICAN HEART JOURNAL
LA English
DT Article
ID CARDIOVASCULAR-DISEASE; SIMVASTATIN; PREVENTION; THERAPY;
   RECOMMENDATIONS; DYSLIPIDEMIA; PUBLICATION; DIAGNOSIS; OUTCOMES; ONTARIO
AB Background We previously found that the use of ezetimibe increased rapidly with different patterns between the United States (US) and Canada prior to the landmark Ezetimibe and Simvastatin in Hypercholesterolemia Enhance Atherosclerosis Regression (ENHANCE) trial, which was reported in January 2008, and failed to show that the drug slowed the progression of atherosclerosis. What is not known is how practice in the 2 countries changed after the ENHANCE trial. We examined ezetimibe use trends in the US and Canada before and after the reporting of the ENHANCE trial.
   Methods We conducted a population-based, retrospective, time-series analysis using the data collected by IMS Health in the US and CompuScript in Canada from January 1, 2002, to December 31, 2009. The main outcome measure was monthly number of prescriptions for ezetimibe-containing products.
   Results The monthly number of ezetimibe prescriptions/100,000 population rose from 6 to 1,082 in the US from November 2002 to January 2008, then significantly declined to 572/100,000 population by December 2009 after the release of the ENHANCE trial, a decrease of 47.1% (P < .001). In contrast, in Canada, use continuously rose from 2 to 495/100,000 population from June 2003 to December 2009 (P = .2). United States expenditures totaled $2.24 billion in 2009.
   Conclusions Ezetimibe remains commonly used in both the US and Canada. Ezetimibe use has decreased in the US post-ENHANCE, whereas use has gradually but steadily increased in Canada. The diverging patterns of ezetimibe use in the US and Canada require further investigation, as they reveal that a common evidence base is eliciting very different utilization patterns in neighboring countries.
C1 [Lu, Lingyun; Jackevicius, Cynthia A.] Western Univ Hlth Sci, Coll Pharm, Dept Pharm Practice & Adm, Pomona, CA 91766 USA.
   [Lu, Lingyun; Jackevicius, Cynthia A.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
   [Krumholz, Harlan M.] Yale Univ, Dept Med, Sect Cardiovasc Med, New Haven, CT 06520 USA.
   [Krumholz, Harlan M.; Ross, Joseph S.] Yale Univ, Yale New Haven Hosp, Sch Med, Ctr Outcomes Res & Evaluat, New Haven, CT USA.
   [Krumholz, Harlan M.] Yale Univ, Dept Epidemiol & Publ Hlth, Sect Hlth Policy & Adm, New Haven, CT 06520 USA.
   [Krumholz, Harlan M.] Robert Wood Johnson Clin Scholars Program, New Haven, CT USA.
   [Tu, Jack V.; Ko, Dennis T.; Jackevicius, Cynthia A.] Inst Clin Evaluat Sci, Toronto, ON, Canada.
   [Tu, Jack V.; Ko, Dennis T.; Jackevicius, Cynthia A.] Univ Toronto, Fac Med, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada.
   [Tu, Jack V.; Ko, Dennis T.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Schulich Heart Ctr, Div Cardiol, Toronto, ON, Canada.
   [Ross, Joseph S.] Yale Univ, Dept Med, Gen Internal Med Sect, New Haven, CT 06520 USA.
   [Jackevicius, Cynthia A.] Univ Hlth Network, Toronto, ON, Canada.
RP Jackevicius, CA (reprint author), Western Univ Hlth Sci, Coll Pharm, 309 E Second St, Pomona, CA 91766 USA.
EM cjackevicius@westernu.edu
FU College of Pharmacy of Western University of Health Sciences, Pomona,
   CA; Canadian Institutes of Health Research; National Heart, Lung, and
   Blood Institute [U01-HL105270]; Heart and Stroke Foundation of Ontario,
   Toronto, Ontario; National Institute on Aging [K08 AG032886]; American
   Federation of Aging Research through the Paul B. Beeson Career
   Development Award Program; Heart and Stroke Foundation of Ontario;
   Ontario Ministry of Health and Long-Term Care, Toronto, Ontario
FX This study was funded in part by the College of Pharmacy of Western
   University of Health Sciences, Pomona, CA, and in part by a Canadian
   Institutes of Health Research team grant in cardiovascular outcomes
   research to the Canadian Cardiovascular Outcomes Research Team. Neither
   funding source had any role in the design and conduct of the study;
   collection, management, analysis, and interpretation of the data; and
   preparation, review, or approval of the manuscript. Dr Krumholz is chair
   of a cardiac scientific advisory board for UnitedHealth and supported by
   grant U01-HL105270 (Center for Cardiovascular Outcomes Research at Yale
   University) from the National Heart, Lung, and Blood Institute. Drs
   Krumholz and Ross receive support from Medtronic, Inc, to develop
   methods of clinical trial data sharing; from the Centers of Medicare and
   Medicaid Services to develop and maintain performance measures that are
   used for public reporting; and from the Food and Drug Administration to
   develop methods for postmarket surveillance of medical devices. Dr Tu is
   supported by a Canada Research Chair in Health Services Research and by
   a Career Investigator award of the Heart and Stroke Foundation of
   Ontario, Toronto, Ontario. Dr Ross is currently supported by the
   National Institute on Aging (K08 AG032886) and by the American
   Federation of Aging Research through the Paul B. Beeson Career
   Development Award Program. Dr Ko is supported by a Clinician Scientist
   (Phase II) Award from the Heart and Stroke Foundation of Ontario. The
   Institute for Clinical Evaluative Sciences is supported by an operating
   grant from the Ontario Ministry of Health and Long-Term Care, Toronto,
   Ontario.
NR 30
TC 10
Z9 10
U1 0
U2 4
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-8703
EI 1097-5330
J9 AM HEART J
JI Am. Heart J.
PD MAY
PY 2014
VL 167
IS 5
AR 683
DI 10.1016/j.ahj.2014.01.014
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AG5GP
UT WOS:000335447800008
PM 24766978
ER

PT J
AU Hernandez, J
   Tarbox, L
   Anstead, G
   Dyer, C
AF Hernandez, Judith
   Tarbox, Lauren
   Anstead, Gregory
   Dyer, Christopher
TI TENOFOVIR RELATED ACUTE INTERSTITIAL NEPHRITIS: A CASE SERIES
SO AMERICAN JOURNAL OF KIDNEY DISEASES
LA English
DT Meeting Abstract
CT Spring Clinical Meeting of the National-Kidney-Foundation (NKF)
CY APR 22-26, 2014
CL Las Vegas, NV
SP Natl Kidney Fdn
C1 Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
   South Texas Vet Hlth Care Syst, San Antonio, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-6386
EI 1523-6838
J9 AM J KIDNEY DIS
JI Am. J. Kidney Dis.
PD MAY
PY 2014
VL 63
IS 5
MA 147
BP A55
EP A55
PG 1
WC Urology & Nephrology
SC Urology & Nephrology
GA AG5JZ
UT WOS:000335456600149
ER

PT J
AU Nassar, T
   Tarbox, L
   Hernandez, J
   Dyer, C
AF Nassar, Tareq
   Tarbox, Lauren
   Hernandez, Judith
   Dyer, Christopher
TI PHYSICAL ACTIVITY AMONGST VETERANS WITH ESRD: PERCEPTIONS AND BARRIERS
SO AMERICAN JOURNAL OF KIDNEY DISEASES
LA English
DT Meeting Abstract
CT Spring Clinical Meeting of the National-Kidney-Foundation (NKF)
CY APR 22-26, 2014
CL Las Vegas, NV
SP Natl Kidney Fdn
C1 Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX USA.
   South Texas Vet Hlth Care Syst, San Antonio, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-6386
EI 1523-6838
J9 AM J KIDNEY DIS
JI Am. J. Kidney Dis.
PD MAY
PY 2014
VL 63
IS 5
MA 251
BP A81
EP A81
PG 1
WC Urology & Nephrology
SC Urology & Nephrology
GA AG5JZ
UT WOS:000335456600253
ER

PT J
AU Rohatgi, R
   Gentile, D
   Cancel-Santiago, R
   Gharitza, R
   Rindt, J
   Post, J
   He, JC
   Malina, J
   Langhoff, E
AF Rohatgi, Rajeev
   Gentile, Denise
   Cancel-Santiago, Rosemarie
   Gharitza, Retha
   Rindt, John
   Post, James
   He, John Cijiang
   Malina, Joanne
   Langhoff, Erik
TI TELENEPHROLOGY: A MODEL OF PATIENT CENTERED CARE
SO AMERICAN JOURNAL OF KIDNEY DISEASES
LA English
DT Meeting Abstract
CT Spring Clinical Meeting of the National-Kidney-Foundation (NKF)
CY APR 22-26, 2014
CL Las Vegas, NV
SP Natl Kidney Fdn
C1 James J Peters VAMC, Bronx, NY USA.
   Hudson Valley VAMC, Castle Point, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-6386
EI 1523-6838
J9 AM J KIDNEY DIS
JI Am. J. Kidney Dis.
PD MAY
PY 2014
VL 63
IS 5
MA 307
BP A95
EP A95
PG 1
WC Urology & Nephrology
SC Urology & Nephrology
GA AG5JZ
UT WOS:000335456600309
ER

PT J
AU Wong, RM
   Ianculescu, I
   Sharma, S
   Gage, DL
   Olevsky, OM
   Kotova, S
   Kostic, MN
   Grundfest, WS
   Hou, DM
   Cameron, RB
AF Wong, Raymond M.
   Ianculescu, Irina
   Sharma, Sherven
   Gage, Diana L.
   Olevsky, Olga M.
   Kotova, Svetlana
   Kostic, Marko N.
   Grundfest, Warren S.
   Hou, Dongmei
   Cameron, Robert B.
TI Immunotherapy for Malignant Pleural Mesothelioma Current Status and
   Future Prospects
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Review
DE mesothelioma; immunotherapy; immunosuppression; multimodality
ID T-REGULATORY CELLS; BETA GENE-TRANSFER; IMMUNE-RESPONSES; SURGICAL
   DEBULKING; ANTI-PD-1 ANTIBODY; ADVANCED MELANOMA; INTERFERON-BETA;
   TUMOR-CELLS; GM-CSF; THERAPY
AB Malignant pleural mesothelioma (MPM) is a rare malignancy of the pleura that is frequently resistant to conventional therapies. Immunotherapy is a promising investigational approach for MPM that has shown some evidence of clinical benefit in select patients. However, tumor-induced immunosuppression is likely a major impediment to achieving optimal clinical responses to immunotherapeutic intervention. MPM contains a variable degree of infiltrating T-regulatory cells and M2 macrophages, which are believed to facilitate tumor evasion from the host immune system. Additional immunosuppressive factors identified in other human tumor types, such as tumor-associated programmed death ligand-1 expression, may be relevant for investigation in MPM. Conventional cytoreductive therapies, such as radiation, chemotherapy, and surgery, may play a critical role in successful immunotherapeutic strategies by ablating intratumoral and/or systemic immunosuppressive factors, thus creating a host environment more amenable to immunotherapy. This article reviews the immunotherapeutic approachesbeing evaluated in patientswithMPM and discusses howimmunotherapymight be rationally combinedwith conventional tumor cytoreductive therapies for this disease.
C1 [Wong, Raymond M.; Ianculescu, Irina] Pacific Heart Lung & Blood Inst, Pacific Meso Ctr, Los Angeles, CA 90025 USA.
   [Sharma, Sherven] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Med Pulm & Crit Care, Los Angeles, CA USA.
   [Gage, Diana L.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Radiat Oncol, Los Angeles, CA USA.
   [Kotova, Svetlana; Cameron, Robert B.] Vet Affairs Greater Los Angeles Healthcare Syst, Div Thorac Surg, Los Angeles, CA USA.
   [Olevsky, Olga M.] Univ Calif Los Angeles, Dept Hematol & Oncol, Los Angeles, CA USA.
   [Kostic, Marko N.; Grundfest, Warren S.] Univ Calif Los Angeles, Dept Bioengn, Los Angeles, CA USA.
   [Hou, Dongmei; Cameron, Robert B.] Univ Calif Los Angeles, Div Thorac Surg, Los Angeles, CA USA.
   [Hou, Dongmei; Cameron, Robert B.] Univ Calif Los Angeles, Comprehens Mesothelioma Program, Los Angeles, CA USA.
RP Wong, RM (reprint author), Pacific Heart Lung & Blood Inst, Pacific Meso Ctr, 10780 Santa Monica Blvd 101, Los Angeles, CA 90025 USA.
EM rwong@phlbi.org
NR 48
TC 7
Z9 7
U1 0
U2 4
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1044-1549
EI 1535-4989
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD MAY
PY 2014
VL 50
IS 5
BP 870
EP 875
DI 10.1165/rcmb.2013-0472TR
PG 6
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA AG8DB
UT WOS:000335647900009
PM 24450537
ER

PT J
AU George, MS
   Raman, R
   Benedek, DM
   Pelic, CG
   Grammer, GG
   Stokes, KT
   Schmidt, M
   Spiegel, C
   DeAlmeida, N
   Beaver, KL
   Borckardt, JJ
   Sun, XY
   Jain, S
   Stein, MB
AF George, Mark S.
   Raman, Rema
   Benedek, David M.
   Pelic, Christopher G.
   Grammer, Geoffrey G.
   Stokes, Karen T.
   Schmidt, Matthew
   Spiegel, Chad
   DeAlmeida, Nancy
   Beaver, Kathryn L.
   Borckardt, Jeffrey J.
   Sun, Xiaoying
   Jain, Sonia
   Stein, Murray B.
TI A Two-site Pilot Randomized 3 Day Trial of High Dose Left Prefrontal
   Repetitive Transcranial Magnetic Stimulation (rTMS) for Suicidal
   Inpatients
SO BRAIN STIMULATION
LA English
DT Article
DE TMS; Transcranial; Suicide; Prefrontal; Magnetic
ID LEARNED HELPLESSNESS; RESISTANT DEPRESSION; BEHAVIORAL-CONTROL; MOTOR
   THRESHOLD; HEALTHY-ADULTS; PAIN; CORTEX; LITHIUM; PERCEPTION; PREVENTION
AB Background: Suicide attempts and completed suicides are common, yet there are no proven acute medication or device treatments for treating a suicidal crisis. Repeated daily left prefrontal repetitive transcranial magnetic stimulation (rTMS) for 4-6 weeks is a new FDA-approved treatment for acute depression. Some open-label rTMS studies have found rapid reductions in suicidality.
   Design: This study tests whether a high dose of rTMS to suicidal inpatients is feasible and safe, and also whether this higher dosing might rapidly improve suicidal thinking. This prospective, 2-site, randomized, active sham-controlled (1: 1 randomization) design incorporated 9 sessions of rTMS over 3 days as adjunctive to usual inpatient suicidality treatment. The setting was two inpatient military hospital wards (one VA, the other DOD).
   Patients: Research staff screened approximately 377 inpatients, yielding 41 adults admitted for suicidal crisis. Because of the funding source, all patients also had either post-traumatic stress disorder, mild traumatic brain injury, or both.
   TMS methods: Repetitive TMS (rTMS) was delivered to the left prefrontal cortex with a figure-eight solid core coil at 120% motor threshold, 10 Hertz (Hz), 5 second (s) train duration, 10 s intertrain interval for 30 minutes (6000 pulses) 3 times daily for 3 days (total 9 sessions; 54,000 stimuli). Sham rTMS used a similar coil that contained a metal insert blocking the magnetic field and utilized electrodes on the scalp, which delivered a matched somatosensory sensation.
   Main outcome measure: Primary outcomes were the daily change in severity of suicidal thinking as measured by the Beck Scale of Suicidal Ideation (SSI) administered at baseline and then daily, as well as subjective visual analog scale measures before and after each TMS session. Mixed model repeated measures (MMRM) analysis was performed on modified intent to treat (mITT) and completer populations.
   Results: This intense schedule of rTMS with suicidal inpatients was feasible and safe. Minimal side effects occurred, none differing by arm, and the 3-day retention rate was 88%. No one died of suicide within the 6 month followup. From the mITT analyses, SSI scores declined rapidly over the 3 days for both groups (sham change -15.3 points, active change -15.4 points), with a trend for more rapid decline on the first day with active rTMS (sham change -6.4 points, active -10.7 points, P = 0.12). This decline was more pronounced in the completers subgroup [sham change -5.9 (95% CI: -10.1, -1.7), active -13 points (95% CI: -18.7, -7.4); P = 0.054]. Subjective ratings of 'being bothered by thoughts of suicide' declined non- significantly more with active rTMS than with sham at the end of 9 sessions of treatment in the mITT analysis [sham change 31.9 (95% CI: 41.7, 22.0), active change 42.5 (95% CI: 53.8, 31.2); P = 0.17]. There was a significant decrease in the completers sample [sham change -24.9 (95% CI: -34.4, -15.3), active change -43.8 (95% CI: -57.2, -30.3); P = 0.028].
   Conclusions: Delivering high doses of left prefrontal rTMS over three days (54,000 stimuli) to suicidal inpatients is possible and safe, with few side effects and no worsening of suicidal thinking. The suggestions of a rapid anti-suicide effect (day 1 SSI data, Visual Analogue Scale data over the 3 days) need to be tested for replication in a larger sample. (C) 2014 Elsevier Inc. All rights reserved.
C1 [George, Mark S.; Pelic, Christopher G.; Schmidt, Matthew; Beaver, Kathryn L.; Borckardt, Jeffrey J.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
   [George, Mark S.; Pelic, Christopher G.; Schmidt, Matthew; Beaver, Kathryn L.; Borckardt, Jeffrey J.] Med Univ S Carolina, Dept Psychiat, Brain Stimulat Div, Charleston, SC 29425 USA.
   [Benedek, David M.; Grammer, Geoffrey G.; Spiegel, Chad; DeAlmeida, Nancy] Walter Reed Natl Mil Med Ctr, Bethesda, MD 20889 USA.
   [Raman, Rema; Stokes, Karen T.; Sun, Xiaoying; Jain, Sonia; Stein, Murray B.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA.
RP George, MS (reprint author), MUSC, IOP, 502 N,67 President St, Charleston, SC 29425 USA.
EM georgem@musc.edu
FU U.S. Army Medical Research and Materiel Command (USAMRMC); DOD INTRuST
   [W81XWH-08-2-0159]
FX Funded by U.S. Army Medical Research and Materiel Command (USAMRMC).;
   Funding mechanism: Contract # W81XWH-08-2-0159, DOD INTRuST.
NR 59
TC 16
Z9 18
U1 7
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1935-861X
EI 1876-4754
J9 BRAIN STIMUL
JI Brain Stimul.
PD MAY-JUN
PY 2014
VL 7
IS 3
BP 421
EP 431
DI 10.1016/j.brs.2014.03.006
PG 11
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA AG9KZ
UT WOS:000335739400012
PM 24731434
ER

PT J
AU Chahine, G
   Short, B
   Spicer, K
   Schmidt, M
   Burns, C
   Atoui, M
   George, MS
   Sackeim, HA
   Nahas, Z
AF Chahine, George
   Short, Baron
   Spicer, Ken
   Schmidt, Matthew
   Burns, Carol
   Atoui, Mia
   George, Mark S.
   Sackeim, Harold A.
   Nahas, Ziad
TI Regional Cerebral Blood Flow Changes Associated With Focal Electrically
   Administered Seizure Therapy (FEAST)
SO BRAIN STIMULATION
LA English
DT Article
DE ECT; Electroconvulsive therapy; FEAST; Focally electrically administered
   seizure therapy; SPECT; Depression; Brain stimulation
ID ELECTROCONVULSIVE-THERAPY; MAJOR DEPRESSION; ECT; STIMULATION;
   METABOLISM; RECEPTORS; DISORDER; SPECT; FORM
AB Introduction: Use of electroconvulsive therapy (ECT) is limited by cognitive disturbance. Focal electrically-administered seizure therapy (FEAST) is designed to initiate focal seizures in the prefrontal cortex. To date, no studies have documented the effects of FEAST on regional cerebral blood flow (rCBF).
   Methods: A 72 year old depressed man underwent three single photon emission computed tomography (SPECT) scans to capture the onset and resolution of seizures triggered with right unilateral FEAST. We used Bioimage Suite for within-subject statistical analyses of perfusion differences ictally and post-ictally compared with the baseline scan.
   Results: Early ictal increases in regional cerebral blood flow (rCBF) were limited to the right prefrontal cortex. Post-ictally, perfusion was reduced in bilateral frontal and occipital cortices and increased in left motor and precuneus cortex.
   Conclusion: FEAST appears to triggers focal onsets of seizure activity in the right prefrontal cortex with subsequent generalization. Future studies are needed on a larger sample. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Chahine, George; Atoui, Mia; Nahas, Ziad] Amer Univ Beirut, Dept Psychiat, Beirut 11072020, Lebanon.
   [Short, Baron; Schmidt, Matthew; Burns, Carol; George, Mark S.] Med Univ S Carolina, Dept Psychiat, Brain Stimulat Lab, Charleston, SC USA.
   [Spicer, Ken] Med Univ S Carolina, Dept Radiol, Charleston, SC USA.
   [Schmidt, Matthew; George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
   [Sackeim, Harold A.] Columbia Univ, Dept Psychiat, New York, NY USA.
   [Sackeim, Harold A.] Columbia Univ, Dept Radiol, New York, NY USA.
RP Nahas, Z (reprint author), Amer Univ Beirut, Dept Psychiat, POB 11-0236, Beirut 11072020, Lebanon.
EM zn17@aub.edu.lb
NR 23
TC 4
Z9 4
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1935-861X
EI 1876-4754
J9 BRAIN STIMUL
JI Brain Stimul.
PD MAY-JUN
PY 2014
VL 7
IS 3
BP 483
EP 485
DI 10.1016/j.brs.2014.02.011
PG 3
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA AG9KZ
UT WOS:000335739400020
PM 24795198
ER

PT J
AU Binney, ZO
   Quest, TE
   Feingold, PL
   Buchman, T
   Majesko, AA
AF Binney, Zachary O.
   Quest, Tammie E.
   Feingold, Paul L.
   Buchman, Timothy
   Majesko, Alyssa A.
TI Feasibility and Economic Impact of Dedicated Hospice Inpatient Units for
   Terminally Ill ICU Patients*
SO CRITICAL CARE MEDICINE
LA English
DT Article
DE critical care; hospice care; terminal care; healthcare costs; palliative
   care
ID INTENSIVE-CARE-UNIT; OF-LIFE CARE; PALLIATIVE CARE; CONTROLLED-TRIAL;
   FAMILY-MEMBERS; CRITICALLY-ILL; SUSTAINING TREATMENT; MEDICAL
   EXPENDITURE; CANCER-PATIENTS; END
AB Objectives:
   End-of-life care is frequently provided in the ICU because patients receiving life-sustaining treatments are often unsuitable for transfer to home or community hospices. In-hospital dedicated hospice inpatient units are a novel option. This study was designed to 1) demonstrate the feasibility of ICU to dedicated hospice inpatient unit transfer in critically ill terminal patients; 2) describe the clinical characteristics of those transferred and compare them to similar patients who were not transferred; and 3) assess the operational and economic impact of dedicated hospice inpatient units.
   Design:
   Retrospective chart review.
   Setting:
   ICUs and dedicated hospice inpatient units at two southeast urban university hospitals.
   Interventions:
   Charts of ICU and dedicated hospice inpatient unit deaths over a 6-month period were reviewed.
   Patients:
   Dedicated hospice inpatient unit transfers were identified from hospice administrator records. Missed opportunities were patients admitted to the hospital for more than 48 hours who either adopted a comfort care course or had a planned termination of life-sustaining therapy. Patients were excluded if they were declared brain dead, were organ donors, required high-frequency ventilation, or if there was insufficient information in the medical record to make a determination.
   Measurements and Main Results:
   We identified 167 transfers and 99 missed opportunities; 37% of appropriate patients were not transferred. Transfers were older (66.9 vs 60.4 yr; p < 0.05), less likely to use mechanical ventilation (71.9% vs 90.9%) and vasopressors (70.9% vs 95.0%; p < 0.05), and less likely to receive a palliative care consult (70.4% vs 43.4%; p < 0.05) than missed opportunities. Transfers saved 585 ICU bed days.
   Conclusions:
   Dedicated hospice inpatient units are a feasible way to provide care for terminal ICU patients, but barriers including lack of knowledge of the units and provider or family comfort with leaving the ICU remain. Dedicated hospice inpatient units are potentially significant sources of bed days and cost savings for hospitals and the healthcare system overall.
C1 [Binney, Zachary O.; Majesko, Alyssa A.] Emory Univ, Emory Palliat Care Ctr, Atlanta, GA 30322 USA.
   [Quest, Tammie E.] Emory Univ, Sch Med, US Dept Vet Affairs, Med Ctr, Atlanta, GA USA.
   [Quest, Tammie E.] Emory Univ, Sch Med, Dept Emergency Med, Atlanta, GA USA.
   [Feingold, Paul L.; Buchman, Timothy] Emory Univ, Sch Med, Dept Surg, Atlanta, GA 30322 USA.
   [Buchman, Timothy; Majesko, Alyssa A.] Emory Univ, Emory Ctr Crit Care Med, Atlanta, GA 30322 USA.
RP Binney, ZO (reprint author), Emory Univ, Emory Palliat Care Ctr, Atlanta, GA 30322 USA.
EM zbinney@emory.edu
OI Buchman, Timothy/0000-0001-7350-5921; Feingold, Paul/0000-0002-3194-4309
FU James S. McDonnell Foundation
FX Dr. Quest is employed by Gentiva Hospice. Dr. Buchman's institution
   received grant support from the James S. McDonnell Foundation. The
   remaining authors have disclosed that they do not have any potential
   conflicts of interest.
NR 41
TC 3
Z9 3
U1 2
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0090-3493
EI 1530-0293
J9 CRIT CARE MED
JI Crit. Care Med.
PD MAY
PY 2014
VL 42
IS 5
BP 1074
EP 1080
DI 10.1097/CCM.0000000000000120
PG 7
WC Critical Care Medicine
SC General & Internal Medicine
GA AG4IU
UT WOS:000335383900022
PM 24351372
ER

PT J
AU Valente, AJ
   Irimpen, AM
   Siebenlist, U
   Chandrasekar, B
AF Valente, Anthony J.
   Irimpen, Anand M.
   Siebenlist, Ulrich
   Chandrasekar, Bysani
TI OxLDL induces endothelial dysfunction and death via TRAF3IP2: Inhibition
   by HDL3 and AMPK activators
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Atherosclerosis; Oxidative stress; NADPH oxidases; Endothelial
   dysfunction; Free radicals
ID LOW-DENSITY-LIPOPROTEIN; PROTEIN-KINASE; AIRWAY INFLAMMATION; CELL
   APOPTOSIS; UP-REGULATION; OXIDIZED LDL; CIKS ACT1; OX-LDL; OXIDATION;
   RECEPTOR
AB Oxidized low-density lipoprotein (oxLDL) induces endothelial cell death through the activation of NF-kappa B and AP-1 pathways. TRAF3IP2 is a redox-sensitive cytoplasmic adapter protein and an upstream regulator of IKK/NF-kappa B and JNK/AP-1. Here we show that oxLDL-induced death in human primary coronary artery endothelial cells (ECs) was markedly attenuated by the knockdown of TRAF3IP2 or the lectin-like oxLDL receptor I (LOX-1). Further, oxLDL induced Nox2/superoxide-dependent TRAF3IP2 expression, IKK/p65 and JNK/c-Jun activation, and LOX-I upregulation, suggesting a reinforcing mechanism. Similarly, the lysolipids present in oxLDL (16:0-LPC and 18:0-LPC) and minimally modified LDL also upregulated TRAF3IP2 expression. Notably, whereas native HDL3 reversed oxLDL-induced TRAF3IP2 expression and cell death, 15-lipoxygenase-modified HDL3 potentiated its proapoptotic effects. The activators of the AMPK/Akt pathway, adiponectin, AICAR, and metformin, attenuated superoxide generation, TRAF3IP2 expression, and oxLDL/TRAF3IP2-mediated EC death. Further, both HDL3 and adiponectin reversed oxLDL/TRAF3IP2-dependent monocyte adhesion to endothelial cells in vitro. Importantly, TRAF3IP2 gene deletion and the AMPK activators reversed oxLDL-induced impaired vasorelaxation ex vivo. These results indicate that oxLDL-induced endothelial cell death and dysfunction are mediated via TRAF3IP2 and that native HDL3 and the AMPK activators inhibit this response. Targeting TRAF3IP2 could potentially inhibit progression of atherosclerotic vascular diseases. (c) 2014 Elsevier Inc. All rights reserved.
C1 [Valente, Anthony J.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
   [Valente, Anthony J.] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
   [Irimpen, Anand M.; Chandrasekar, Bysani] Southeast Louisiana Vet Hlth Care Syst, Res Serv, New Orleans, LA 70161 USA.
   [Irimpen, Anand M.; Chandrasekar, Bysani] Tulane Univ, Sch Med, Inst Heart & Vasc, New Orleans, LA 70112 USA.
   [Siebenlist, Ulrich] NIAID, NIH, Lab Mol Immunol, Bethesda, MD 20892 USA.
RP Chandrasekar, B (reprint author), Tulane Univ, Sch Med, Inst Heart & Vasc, 1430 Tulane Ave,SL-48, New Orleans, LA 70112 USA.
EM bchandra@tulane.edu
FU Department of Veterans Affairs Research Career Scientist award; VA
   Office of Research and Development Biomedical Laboratory Research and
   Development Service Award [1I01BX000246]; NIH/NHLBI [HL-86787]
FX B.C. is the recipient of a Department of Veterans Affairs Research
   Career Scientist award and is supported by VA Office of Research and
   Development Biomedical Laboratory Research and Development Service Award
   1I01BX000246 and NIH/NHLBI Grant HL-86787. U.S. is supported by the
   Intramural Research Program of the NIH/NIAID. The contents of this
   report do not represent the views of the Department of Veterans Affairs
   or the United States government.
NR 41
TC 18
Z9 21
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0891-5849
EI 1873-4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD MAY
PY 2014
VL 70
BP 117
EP 128
DI 10.1016/j.freeradbiomed.2014.02.014
PG 12
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA AG5VP
UT WOS:000335487100012
PM 24561578
ER

PT J
AU Jacobs, RL
   Harper, N
   He, WJ
   Andrews, CP
   Rather, CG
   Ramirez, DA
   Ahuja, SK
AF Jacobs, Robert L.
   Harper, Nathan
   He, Weijing
   Andrews, Charles P.
   Rather, Cynthia G.
   Ramirez, Daniel A.
   Ahuja, Sunil K.
TI Effect of confounding cofactors on responses to pollens during natural
   season versus pollen challenge chamber exposure
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Article
DE Allergy; pollen; challenge; confounding; season
ID ALLERGIC RHINOCONJUNCTIVITIS; VALIDATION; EFFICACY; UNIT
AB Background: The severity of allergic rhinoconjunctivitis (AR) symptomatology elicited after exposure to pollen in the absence versus the presence of confounding cofactors, such as in a pollen challenge chamber (PCC) and the natural pollinating season, respectively, might differ.
   Objective: We sought to determine the correlation of AR severity in the natural season versus out-of-season PCC exposures.
   Methods: Twenty-four Virginia live oak (VLO)-positive, 14 VLO-negative, 16 mountain cedar (MC) 2 positive, 8 MCnegative, and 26 ragweed-positive participants recorded AR symptoms (total symptom score [TSS]) during the VLO, MC, and ragweed pollinating seasons and during 2 consecutive PCC exposures of 3 hours each to these pollens separately.
   Results: The TSSs recorded before the natural season were higher than the pre-PCC values. This prepriming was greater among VLO 1 than MC 1 participants, and it blunted further increases in TSSs during the VLO natural season. Nonatopic participants were nonreactive in the PCC. There was wide variation in the level of AR symptomatology after exposure to VLO, MC, or ragweed pollen in the PCC. Prepriming formed the basis for higher AR responses observed in the natural season than in the PCC, resulting in the identification of distinct PCC/natural season endophenotypes and a partial correlation between the TSSs recorded in the natural season versus those recorded in the PCC (r = 5 0.34, 0.54, and 0.65 for VLO+, MC+, and ragweed-positive participants, respectively).
   Conclusions: Prepriming in the natural pollinating season might obscure the true correlation between AR severity in the natural season versus the PCC. By mitigating confounding cofactors, PCC exposures have utility for evaluation of novel AR therapeutics.
C1 [Jacobs, Robert L.; Andrews, Charles P.; Rather, Cynthia G.; Ramirez, Daniel A.] Biogen Res Chamber LLC, San Antonio, TX 78229 USA.
   [Harper, Nathan; He, Weijing; Ahuja, Sunil K.] South Texas Vet Hlth Care Syst, Vet Adm Ctr Personalized Med, San Antonio, TX USA.
   [Harper, Nathan; He, Weijing; Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
   [Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, San Antonio, TX 78229 USA.
   [Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA.
RP Jacobs, RL (reprint author), Biogen Res Chamber LLC, 8299 Fredericksburg Rd, San Antonio, TX 78229 USA.
EM robert.jacobs7025@sbcglobal.net
RI Osborne, Nicholas/N-4915-2015
OI Osborne, Nicholas/0000-0002-6700-2284; Jacobs,
   Robert/0000-0002-2831-9086
FU Doris Duke Distinguished Clinical Scientist Award; Burroughs Wellcome
   Clinical Scientist in Translational Research Award; Max and Minnie
   Tomerlin Voelcker Scholar Award; Center for Personalized Medicine at the
   South Texas Veterans Health Care System
FX the Doris Duke Distinguished Clinical Scientist Award, the Burroughs
   Wellcome Clinical Scientist in Translational Research Award, the Max and
   Minnie Tomerlin Voelcker Scholar Award, and the Center for Personalized
   Medicine at the South Texas Veterans Health Care System.
NR 20
TC 8
Z9 8
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD MAY
PY 2014
VL 133
IS 5
BP 1340
EP U558
DI 10.1016/j.jaci.2013.09.051
PG 14
WC Allergy; Immunology
SC Allergy; Immunology
GA AG5HS
UT WOS:000335450700015
PM 24331377
ER

PT J
AU Jackevicius, CA
   Fan, CS
   Warner, A
AF Jackevicius, Cynthia A.
   Fan, Cindy Shutieng
   Warner, Alberta
TI Clinical Outcomes of Erythropoietin Use in Heart Failure Patients With
   Anemia of Chronic Kidney Disease
SO JOURNAL OF CARDIAC FAILURE
LA English
DT Article
DE Cardiac; health policy; outcome research
ID PRESERVED EJECTION FRACTION; DARBEPOETIN-ALPHA; EPOETIN-ALPHA;
   SUBCUTANEOUS ERYTHROPOIETIN; STIMULATING AGENTS; HEMOGLOBIN LEVEL;
   INTRAVENOUS IRON; MORTALITY; MORBIDITY; TRIAL
AB Background: Anemia and chronic kidney disease are common disorders in heart failure (HF) patients and are associated with increased morbidity and mortality. This study assessed clinical outcomes associated with erythropoietin (EPO) treatment in this cardiorenal anemia syndrome (CRAS) population.
   Methods and Results: This was a retrospective cohort study of Veterans Affairs patients with CRAS from January 2003 to December 2006. The primary outcome was a composite of death, acute coronary syndrome (ACS), HF, and stroke. Multiple Cox regression modeling was used to evaluate the outcome in patients prescribed (n = 213) and not prescribed EPO (n = 1845). Adjusted incidence of mortality was statistically significantly higher in EPO than in non-EPO users (33.8% vs 19.7%; hazard ratio 1.40, 95% confidence interval 1.06-1.85; P = .02). The unadjusted composite of cardiovascular events/death was higher in the EPO group, but not statistically significant when adjusted for confounders (P = .12). Crude ACS events were documented in 18.8% and 10.8% patients (P = .001), and stroke events occurred in 22.5% and 18.3% patients (P = .14) in EPO and non-EPO groups, respectively.
   Conclusions: We found that in CRAS patients, EPO use was associated with increased risk of mortality and a trend toward increased cardiovascular events. Therefore, clinicians considering EPO use in CRAS patients should assess whether any potential benefits outweigh the risks of use.
C1 [Jackevicius, Cynthia A.; Fan, Cindy Shutieng] Western Univ Hlth Sci, Coll Pharm, Pomona, CA 91766 USA.
   [Jackevicius, Cynthia A.; Fan, Cindy Shutieng; Warner, Alberta] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
   [Jackevicius, Cynthia A.] Inst Clin Evaluat Sci, Toronto, ON, Canada.
   [Jackevicius, Cynthia A.] Univ Toronto, Fac Med, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada.
   [Jackevicius, Cynthia A.] Univ Hlth Network, Toronto, ON, Canada.
   [Warner, Alberta] Univ Calif Los Angeles, Dept Med, Div Cardiol, Los Angeles, CA 90024 USA.
RP Jackevicius, CA (reprint author), Western Univ Hlth Sci, Coll Pharm, 309 E 2nd St, Pomona, CA 91766 USA.
EM cjackevicius@westernu.edu
FU American College of Clinical Pharmacy Watson Anemia Investigator
   Development Research Award
FX American College of Clinical Pharmacy Watson Anemia Investigator
   Development Research Award.
NR 35
TC 4
Z9 5
U1 1
U2 7
PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
PI PHILADELPHIA
PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA
SN 1071-9164
EI 1532-8414
J9 J CARD FAIL
JI J. Card. Fail.
PD MAY
PY 2014
VL 20
IS 5
BP 327
EP 333
DI 10.1016/j.cardfai1.2014.02.001
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AG9AI
UT WOS:000335710500007
PM 24530942
ER

PT J
AU Goldsmith, EC
   Bradshaw, AD
   Zile, MR
   Spinale, FG
AF Goldsmith, Edie C.
   Bradshaw, Amy D.
   Zile, Michael R.
   Spinale, Francis G.
TI Myocardial fibroblast-matrix interactions and potential therapeutic
   targets
SO JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
LA English
DT Review
DE Extracellular matrix; Fibroblast; Myofibroblast; Integrin; Discoidin
   Domain Receptor; Transformation
ID RECEPTOR TYROSINE KINASE; DISCOIDIN DOMAIN RECEPTOR-1; PROCOLLAGEN
   C-PROTEINASE; VASCULAR SMOOTH-MUSCLE; MESENCHYMAL STEM-CELLS;
   GROWTH-FACTOR-BETA; EXTRACELLULAR-MATRIX; CARDIAC FIBROBLASTS;
   PRESSURE-OVERLOAD; ACTIVATION PROTEIN
AB The cardiac extracellular matrix (ECM) is a dynamic structure, adapting to physiological and pathological stresses placed on the myocardium. Deposition and organization of the matrix fall under the purview of cardiac fibroblasts. While often overlooked compared to myocytes, fibroblasts play a critical role in maintaining ECM homeostasis under normal conditions and in response to pathological stimuli assume an activated, myofibroblast phenotype associated with excessive collagen accumulation contributing to impaired cardiac function. Complete appreciation of fibroblast function is hampered by the lack of fibroblast-specific reagents and the heterogeneity of fibroblast precursors. This is further complicated by our ability to dissect-the role of myofibroblasts versus fibroblasts in myocardial in remodeling. This review highlights critical points in the regulation of collagen deposition by fibroblasts, the current panel of molecular tools used to identify fibroblasts and the role of fibroblast-matrix interactions in fibroblast function and differentiation into the myofibroblast phenotype. The clinical potential of exploiting differences between fibroblasts and myofibroblasts and using them to target specific fibroblast populations is also discussed. This article is part of a Special Issue entitled "Myocyte-Fibroblast Signalling in Myocardium." (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Goldsmith, Edie C.; Spinale, Francis G.] Univ S Carolina, Sch Med, Dept Cell Biol & Anat, Columbia, SC 29208 USA.
   [Bradshaw, Amy D.; Zile, Michael R.] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA.
   [Bradshaw, Amy D.; Zile, Michael R.] Med Univ S Carolina, Gazes Cardiac Res Inst, Charleston, SC 29425 USA.
   [Spinale, Francis G.] Univ S Carolina, Sch Med, Cardiovasc Translat Res Ctr, Columbia, SC USA.
   [Spinale, Francis G.] WJB Dorn Vet Affairs Med Ctr, Columbia, SC USA.
RP Goldsmith, EC (reprint author), Univ S Carolina, Sch Med, Dept Cell Biol & Anat, 6439 Garners Ferry Rd, Columbia, SC 29208 USA.
EM edie.goldsmith@uscmed.sc.edu
FU American Heart Association; National Institutes of Health grant
   [HL095608]; Veterans' Affairs Health Administration [1101BX001385-01A1];
   Research Service of the Department of Veterans Affairs
FX This work was supported by an American Heart Association Grant-In-Aid
   (ECG), by the National Institutes of Health grant HL095608 (FGS), and
   Merit Award 1101BX001385-01A1 to ADB from the Veterans' Affairs Health
   Administration. Drs. Francis Spinale and Michael Zile are supported by
   the Research Service of the Department of Veterans Affairs. The authors
   would like to thank Shaun Riffle for graphics assistance and Charity Fix
   and Lorain Junor for staining and microscopy.
NR 99
TC 21
Z9 21
U1 1
U2 9
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-2828
EI 1095-8584
J9 J MOL CELL CARDIOL
JI J. Mol. Cell. Cardiol.
PD MAY
PY 2014
VL 70
BP 92
EP 99
DI 10.1016/j.yjmcc2014.01.008
PG 8
WC Cardiac & Cardiovascular Systems; Cell Biology
SC Cardiovascular System & Cardiology; Cell Biology
GA AG9BY
UT WOS:000335714900012
PM 24472826
ER

PT J
AU Hausmann, LRM
   Parks, A
   Youk, AO
   Kwoh, CK
AF Hausmann, Leslie R. M.
   Parks, Acacia
   Youk, Ada O.
   Kwoh, C. Kent
TI Reduction of Bodily Pain in Response to an Online Positive Activities
   Intervention
SO JOURNAL OF PAIN
LA English
DT Article
DE Pain management; internet; intervention studies; mind-body therapies;
   happiness
ID HEALTH SURVEY QUESTIONNAIRE; OUTCOME MEASURE; SOCIAL SUPPORT;
   PSYCHOLOGY; DIRECTIONS; SF-36; CARE; PSYCHOTHERAPY; METAANALYSIS; PEOPLE
AB Inducing temporary positive states reduces pain and increases pain tolerance in laboratory studies. We tested whether completing positive activities in one's daily life produces long-term reductions in self-reported bodily pain in a randomized controlled trial of an online positive activities intervention. Participants recruited via the Web were randomly assigned to complete 0, 2, 4, or 6 positive activities administered online over a 6-week period. Follow-up assessments were collected at the end of 6 weeks and at 1, 3, and 6 months postintervention. We used linear mixed effects models to examine whether the intervention reduced pain over time among those who had a score <67 on the bodily pain subscale of the Short Form-36 at baseline (N = 417; pain scores range from 0 to 100; higher scores indicate less pain). Mean pain scores improved from baseline to 6 months in the 2-activity (55.7 to 67.4), 4-activity (54.2 to 71.0), and 6-activity (50.9 to 67.9) groups. Improvements were significantly greater (P < .05) in the 4-activity and 6-activity groups than in the 0-activity control group (54.1 to 62.2) in unadjusted and adjusted models. This study suggests that positive activities administered online can reduce bodily pain in adults with at least mild to moderate baseline pain.
   Perspective: This study demonstrates that teaching people simple positive activities can decrease reported levels of bodily pain; moreover, these activities can be administered over the internet, a potential avenue for broadly disseminating health interventions at relatively low costs and with high sustainability. Published by Elsevier Inc. on behalf of the American Pain Society
C1 [Hausmann, Leslie R. M.; Youk, Ada O.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA.
   [Hausmann, Leslie R. M.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
   [Youk, Ada O.] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA.
   [Parks, Acacia] Hiram Coll, Dept Psychol, Hiram, OH USA.
   [Kwoh, C. Kent] Univ Arizona, Div Rheumatol, Tucson, AZ USA.
   [Kwoh, C. Kent] Univ Arizona, Arthrit Ctr, Tucson, AZ USA.
RP Hausmann, LRM (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot CHERP, Bldg 30,Univ Dr 151C, Pittsburgh, PA 15240 USA.
EM leslie.hausmann@gmail.com
OI Youk, Ada/0000-0001-6912-9759
NR 35
TC 6
Z9 6
U1 1
U2 8
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 1526-5900
J9 J PAIN
JI J. Pain
PD MAY
PY 2014
VL 15
IS 5
BP 560
EP 567
DI 10.1016/j.jpain.2014.02.004
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA AG9AU
UT WOS:000335711700011
PM 24568751
ER

PT J
AU O'Donovan, A
AF O'Donovan, Aoife
TI Inflammation and Depression: Unraveling the Complex Interplay in
   Inflammatory Bowel Disease
SO JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
LA English
DT Editorial Material
C1 [O'Donovan, Aoife] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
RP O'Donovan, A (reprint author), San Francisco VA Med Ctr, Mental Hlth Serv, 4150 Clement St,Bldg 16, San Francisco, CA 94121 USA.
EM aoife.odonovan@ucsf.edu
NR 12
TC 5
Z9 5
U1 1
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0277-2116
EI 1536-4801
J9 J PEDIATR GASTR NUTR
JI J. Pediatr. Gastroenterol. Nutr.
PD MAY
PY 2014
VL 58
IS 5
BP 541
EP 542
DI 10.1097/MPG.0000000000000292
PG 2
WC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics
SC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics
GA AG8FG
UT WOS:000335653600007
PM 24385077
ER

PT J
AU Kirwan, JR
   Boers, M
   Hewlett, S
   Beaton, D
   Bingham, CO
   Choy, E
   Conaghan, PG
   D'Agostino, MA
   Dougados, M
   Furst, DE
   Guillemin, F
   Gossec, L
   van der Heijde, DM
   Kloppenburg, M
   Kvien, TK
   Landewe, RBM
   Mackie, SL
   Matteson, EL
   Mease, PJ
   Merkel, PA
   Ostergaard, M
   Saketkoo, LA
   Simon, L
   Singh, JA
   Strand, V
   Tugwell, P
AF Kirwan, John R.
   Boers, Maarten
   Hewlett, Sarah
   Beaton, Dorcas
   Bingham, Clifton O., III
   Choy, Ernest
   Conaghan, Philip G.
   D'Agostino, Maria-Antonietta
   Dougados, Maxime
   Furst, Daniel E.
   Guillemin, Francis
   Gossec, Laure
   van der Heijde, Desiree M.
   Kloppenburg, Margreet
   Kvien, Tore K.
   Landewe, Robert B. M.
   Mackie, Sarah L.
   Matteson, Eric L.
   Mease, Philip J.
   Merkel, Peter A.
   Ostergaard, Mikkel
   Saketkoo, Lesley Ann
   Simon, Lee
   Singh, Jasvinder A.
   Strand, Vibeke
   Tugwell, Peter
TI Updating the OMERACT Filter: Core Areas as a Basis for Defining Core
   Outcome Sets
SO JOURNAL OF RHEUMATOLOGY
LA English
DT Article
DE OUTCOME MEASURES IN RHEUMATOLOGY; CLINICAL TRIALS; OUTCOME AND PROCESS
   ASSESSMENT; CONSENSUS DEVELOPMENT CONFERENCE
ID RHEUMATOID-ARTHRITIS; PATIENT PERSPECTIVE; INTERNATIONAL PATIENT;
   FATIGUE; FLARE
AB Objective. The Outcome Measures in Rheumatology (OMERACT) Filter provides guidelines for the development and validation of outcome measures for use in clinical research. The "Truth" section of the OMERACT Filter presupposes an explicit framework for identifying the relevant core outcomes that are universal to all studies of the effects of intervention effects. There is no published outline for instrument choice or development that is aimed at measuring outcome, was derived from broad consensus over its underlying philosophy, or includes a structured and documented critique. Therefore, a new proposal for defining core areas of measurement ("Filter 2.0 Core Areas of Measurement") was presented at OMERACT 11 to explore areas of consensus and to consider whether already endorsed core outcome sets fit into this newly proposed framework.
   Methods. Discussion groups critically reviewed the extent to which case studies of current OMERACT Working Groups complied with or negated the proposed framework, whether these observations had a more general application, and what issues remained to be resolved.
   Results. Although there was broad acceptance of the framework in general, several important areas of construction, presentation, and clarity of the framework were questioned. The discussion groups and subsequent feedback highlighted 20 such issues.
   Conclusion. These issues will require resolution to reach consensus on accepting the proposed Filter 2.0 framework of Core Areas as the basis for the selection of Core Outcome Domains and hence appropriate Core Outcome Sets for clinical trials.
C1 [Kirwan, John R.] Univ Bristol, Bristol Royal Infirm, Acad Rheumatol Unit, Bristol, Avon, England.
   [Boers, Maarten] Vrije Univ Amsterdam, Med Ctr, Dept Epidemiol & Biostat, Amsterdam, Netherlands.
   [Boers, Maarten] Vrije Univ Amsterdam, Med Ctr, Dept Rheumatol, Amsterdam, Netherlands.
   [Hewlett, Sarah] Univ W England, Bristol Royal Infirm, Acad Rheumatol Unit, Bristol BS16 1QY, Avon, England.
   [Beaton, Dorcas] Univ Toronto, Inst Hlth Policy Management & Evaluat, Dept Occupat Sci & Occupat Therapy, Toronto, ON, Canada.
   [Bingham, Clifton O., III] Johns Hopkins Univ, Div Rheumatol, Baltimore, MD USA.
   [Choy, Ernest] Cardiff Univ, Sch Med, Rheumatol Sect, Cardiff CF10 3AX, S Glam, Wales.
   [Conaghan, Philip G.] Univ Leeds, Div Musculoskeletal Dis, Leeds, W Yorkshire, England.
   UK Natl Inst Hlth Res NIHR Leeds Musculoskeletal, Leeds, W Yorkshire, England.
   [D'Agostino, Maria-Antonietta] Versailles St Quentin Yvelines Univ, Dept Rheumatol, Ambroise Pare Hosp, AP HP, Boulogne, France.
   [Dougados, Maxime] Paris Descartes Univ, Fac Med, Cochin Hosp, AP HP, Paris, France.
   [Furst, Daniel E.] Univ Calif Los Angeles, Geffen Sch Med, Los Angeles, CA USA.
   [Guillemin, Francis] Univ Paris 05, Univ Lorraine, Nancy, France.
   Univ Paris 06, Paris, France.
   [Gossec, Laure] Hop La Pitie Salpetriere, AP HP, Dept Rheumatol, Paris, France.
   [van der Heijde, Desiree M.; Kloppenburg, Margreet] Leiden Univ, Med Ctr, Dept Rheumatol, Leiden, Netherlands.
   [Kloppenburg, Margreet] Leiden Univ, Med Ctr, Dept Clin Epidemiol, Leiden, Netherlands.
   [Kvien, Tore K.] Diakonhjemmet Hosp, Dept Rheumatol, Oslo, Norway.
   [Landewe, Robert B. M.] Univ Amsterdam, Acad Med Ctr, Dept Clin Immunol & Rheumatol, NL-1012 WX Amsterdam, Netherlands.
   [Landewe, Robert B. M.] Atrium Med Ctr Heerlen, Heerlen, Netherlands.
   [Mackie, Sarah L.] Univ Leeds, Div Rheumat & Musculoskeletal Dis, NIHR Leeds Musculoskeletal Biomed Res Unit, Leeds, W Yorkshire, England.
   [Matteson, Eric L.] Mayo Clin, Coll Med, Div Rheumatol, Rochester, MN USA.
   Univ Washington, Sch Med, Seattle Rheumatol Associates, Swedish Med Ctr,Rheumatol Res Div, Seattle, WA USA.
   [Merkel, Peter A.] Univ Penn, Div Rheumatol, Philadelphia, PA 19104 USA.
   [Ostergaard, Mikkel] Copenhagen Univ Hosp Glostrup, Dept Rheumatol, Copenhagen, Denmark.
   [Saketkoo, Lesley Ann] Louisiana State Univ, Rheumatol Sect, Hlth Sci Ctr, New Orleans, LA USA.
   [Simon, Lee] SDG LLC, Cambridge, MA USA.
   [Singh, Jasvinder A.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
   [Singh, Jasvinder A.] Univ Alabama Birmingham, Birmingham, AL USA.
   [Strand, Vibeke] Stanford Univ, Sch Med, Div Immunol Rheumatol, Palo Alto, CA 94304 USA.
   [Tugwell, Peter] Univ Ottawa, Dept Med, Ottawa, ON, Canada.
RP Kirwan, JR (reprint author), Univ Bristol, Bristol Royal Infirm, Acad Rheumatol Unit, Bristol, Avon, England.
EM john.kirwan@bristol.ac.uk
RI DOUGADOS, MAXIME/P-5287-2016
OI Tugwell, Peter/0000-0001-5062-0556; Kirwan, John/0000-0002-6617-3217
FU Novartis; American College of Rheumatology; European League Against
   Rheumatism;; Takeda pharmaceutical; Savient pharmaceutical; Ardea
   pharmaceutical; Regeneron pharmaceutical; Allergan pharmaceutical; URL
   pharmaceutical; Takeda; Savient
FX Dr. Matteson is supported in part by grants from Novartis, the American
   College of Rheumatology, and the European League Against Rheumatism; and
   was a consultant to Horizon Pharmaceuticals; Dr. Singh received research
   grants from Takeda and Savient, consultant fees from Savient, Takeda,
   Ardea, Regeneron, Allergan, URL pharmaceuticals and Novartis; is a
   member of the OMERACT executive, which receives arms-length funding from
   36 companies; and is a member of the American College of Rheumatology's
   Guidelines Subcommittee of the Quality of Care Committee and the
   Veterans Affairs Rheumatology Field Advisory Committee.
NR 15
TC 10
Z9 10
U1 0
U2 4
PU J RHEUMATOL PUBL CO
PI TORONTO
PA 365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA
SN 0315-162X
EI 1499-2752
J9 J RHEUMATOL
JI J. Rheumatol.
PD MAY
PY 2014
VL 41
IS 5
BP 994
EP 999
DI 10.3899/jrheum.131309
PG 6
WC Rheumatology
SC Rheumatology
GA AG6FN
UT WOS:000335514500028
PM 24634204
ER

PT J
AU Tugwell, P
   Boers, M
   D'Agostino, MA
   Beaton, D
   Boonen, A
   Bingham, CO
   Choy, E
   Conaghan, PG
   Dougados, M
   Duarte, C
   Furst, DE
   Guillemin, F
   Gossec, L
   Heiberg, T
   van der Heijde, DM
   Hewlett, S
   Kirwan, JR
   Kvien, TK
   Landewe, RB
   Mease, PJ
   Ostergaard, M
   Simon, L
   Singh, JA
   Strand, V
   Wells, G
AF Tugwell, Peter
   Boers, Maarten
   D'Agostino, Maria-Antonietta
   Beaton, Dorcas
   Boonen, Annelies
   Bingham, Clifton O., III
   Choy, Ernest
   Conaghan, Philip G.
   Dougados, Maxime
   Duarte, Catia
   Furst, Daniel E.
   Guillemin, Francis
   Gossec, Laure
   Heiberg, Turid
   van der Heijde, Desiree M.
   Hewlett, Sarah
   Kirwan, John R.
   Kvien, Tore K.
   Landewe, Robert B.
   Mease, Philip J.
   Ostergaard, Mikkel
   Simon, Lee
   Singh, Jasvinder A.
   Strand, Vibeke
   Wells, George
TI Updating the OMERACT Filter: Implications of Filter 2.0 to Select
   Outcome Instruments Through Assessment of "Truth": Content, Face, and
   Construct Validity
SO JOURNAL OF RHEUMATOLOGY
LA English
DT Article
DE OMERACT; RANDOMIZED CONTROLLED TRIALS; OUTCOME AND PROCESS ASSESSMENT;
   CONSTRUCT VALIDITY; CONTENT VALIDITY; FACE VALIDITY
AB Objective. The Outcome Measures in Rheumatology (OMERACT) Filter provides guidelines for the development and validation of outcome measures for use in clinical research. The "Truth" section of the OMERACT Filter requires that criteria be met to demonstrate that the outcome instrument meets the criteria for content, face, and construct validity.
   Methods. Discussion groups critically reviewed a variety of ways in which case studies of current OMERACT Working Groups complied with the Truth component of the Filter and what issues remained to be resolved.
   Results. The case studies showed that there is broad agreement on criteria for meeting the Truth criteria through demonstration of content, face, and construct validity; however, several issues were identified that the Filter Working Group will need to address.
   Conclusion. These issues will require resolution to reach consensus on how Truth will be assessed for the proposed Filter 2.0 framework, for instruments to be endorsed by OMERACT.
C1 [Tugwell, Peter] Univ Ottawa, Dept Med, Ottawa, ON K1N 6N5, Canada.
   [Boers, Maarten] Vrije Univ Amsterdam, Med Ctr, Dept Epidemiol & Biostat, Amsterdam, Netherlands.
   [Boers, Maarten] Vrije Univ Amsterdam, Med Ctr, Dept Rheumatol, Amsterdam, Netherlands.
   [D'Agostino, Maria-Antonietta] Versailles St Quentin Yvelines Univ, Dept Rheumatol, Ambroise Pare Hosp, AP HP, Boulogne, France.
   [Dougados, Maxime] Paris Descartes Univ, Cochin Hosp, AP HP, Fac Med, Paris, France.
   [Beaton, Dorcas] Univ Toronto, Inst Hlth Policy Management & Evaluat, Dept Occupat Sci & Occupat Therapy, Toronto, ON, Canada.
   [Boonen, Annelies] Maastricht Univ, Med Ctr, Dept Internal Med, Div Rheumatol, Maastricht, Netherlands.
   [Boonen, Annelies] Maastricht Univ, Caphri Res Inst, Maastricht, Netherlands.
   [Bingham, Clifton O., III] Johns Hopkins Univ, Div Rheumatol, Baltimore, MD USA.
   [Choy, Ernest] Cardiff Univ, Rheumatol Sect, Sch Med, Cardiff CF10 3AX, S Glam, Wales.
   Univ Leeds, Div Musculoskeletal Dis, Leeds LS2 9JT, W Yorkshire, England.
   UK Natl Inst Hlth Res NIHR Leeds Musculoskeletal, Leeds, W Yorkshire, England.
   [Duarte, Catia] Ctr Hosp & Univ Coimbra, Dept Rheumatol, Coimbra, Portugal.
   [Furst, Daniel E.] Univ Calif Los Angeles, Dept Rheumatol, Geffen Sch Med, Los Angeles, CA USA.
   Univ Lorraine, EA APEMAC 4360, Nancy, France.
   [Gossec, Laure] Univ Paris 06, Pitie Salpetriere Hosp, AP HP, Dept Rheumatol,GRC UMPC EEMOIS 08, Paris, France.
   [Heiberg, Turid] Oslo Univ Hosp, Oslo, Norway.
   [Heiberg, Turid] Lovisenberg Diaconal Univ Coll, Oslo, Norway.
   [van der Heijde, Desiree M.] Leiden Univ, Med Ctr, Dept Rheumatol, Leiden, Netherlands.
   [Hewlett, Sarah] Univ W England, Acad Rheumatol Unit, Bristol Royal Infirm, Bristol BS16 1QY, Avon, England.
   [Kvien, Tore K.] Diakonhjemmet Hosp, Dept Rheumatol, Oslo, Norway.
   [Landewe, Robert B.] Univ Amsterdam, Acad Med Ctr, Dept Clin Immunol & Rheumatol, Heerlen, Netherlands.
   [Landewe, Robert B.] Atrium Med Ctr Heerlen, Heerlen, Netherlands.
   [Mease, Philip J.] Seattle Rheumatol Associates, Seattle, WA USA.
   [Mease, Philip J.] Swedish Med Ctr, Rheumatol Res Div, Seattle, WA USA.
   [Mease, Philip J.] Univ Washington, Sch Med, Seattle, WA USA.
   Univ Penn, Div Rheumatol, Philadelphia, PA 19104 USA.
   [Ostergaard, Mikkel] Copenhagen Univ Hosp Glostrup, Dept Rheumatol, Copenhagen, Denmark.
   [Simon, Lee] SDG LLC, Cambridge, MA USA.
   [Singh, Jasvinder A.] Univ Alabama Birmingham, Div Immunol Rheumatol, Birmingham, AL USA.
   [Singh, Jasvinder A.] Birmingham VA Med Ctr, Birmingham, AL USA.
   [Strand, Vibeke] Stanford Univ, Sch Med, Div Immunol Rheumatol, Palo Alto, CA 94304 USA.
   [Wells, George] Univ Ottawa, Dept Epidemiol & Community Med, Cardiovasc Res Methods Ctr, Ottawa, ON, Canada.
RP Tugwell, P (reprint author), Univ Ottawa, Ctr Global Hlth, Inst Populat Hlth, 1 Stewart St,Room 312, Ottawa, ON K1N 6N5, Canada.
EM tugwell.bb@uottawa.ca
RI DOUGADOS, MAXIME/P-5287-2016
OI Duarte, Catia/0000-0001-9327-6935; Tugwell, Peter/0000-0001-5062-0556
FU AHRQ HHS [HS013852, HS013852-07]; None [HS013852-07, HS013852]
NR 4
TC 13
Z9 13
U1 0
U2 3
PU J RHEUMATOL PUBL CO
PI TORONTO
PA 365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA
SN 0315-162X
EI 1499-2752
J9 J RHEUMATOL
JI J. Rheumatol.
PD MAY
PY 2014
VL 41
IS 5
BP 1000
EP 1004
DI 10.3899/jrheum.131310
PG 5
WC Rheumatology
SC Rheumatology
GA AG6FN
UT WOS:000335514500029
PM 24692531
ER

PT J
AU Wells, G
   Beaton, DE
   Tugwell, P
   Boers, M
   Kirwan, JR
   Bingham, CO
   Boonen, A
   Brooks, P
   Conaghan, PG
   D'Agostino, MA
   Dougados, M
   Furst, DE
   Gossec, L
   Guillemin, F
   Helliwell, P
   Hewlett, S
   Kvien, TK
   Landewe, RB
   March, L
   Mease, PJ
   Ostergaard, M
   Simon, L
   Singh, JA
   Strand, V
   van der Heijde, DM
AF Wells, George
   Beaton, Dorcas E.
   Tugwell, Peter
   Boers, Maarten
   Kirwan, John R.
   Bingham, Clifton O., III
   Boonen, Annelies
   Brooks, Peter
   Conaghan, Philip G.
   D'Agostino, Maria-Antonietta
   Dougados, Maxime
   Furst, Daniel E.
   Gossec, Laure
   Guillemin, Francis
   Helliwell, Philip
   Hewlett, Sarah
   Kvien, Tore K.
   Landewe, Robert B.
   March, Lyn
   Mease, Philip J.
   Ostergaard, Mikkel
   Simon, Lee
   Singh, Jasvinder A.
   Strand, Vibeke
   van der Heijde, Desiree M.
TI Updating the OMERACT Filter: Discrimination and Feasibility
SO JOURNAL OF RHEUMATOLOGY
LA English
DT Article
DE OUTCOME MEASURES IN RHEUMATOLOGY; OUTCOME AND PROCESS ASSESSMENT;
   FEASIBILITY; DISCRIMINATION
ID CLINICALLY IMPORTANT DIFFERENCE; HEALTH-STATUS; QUALITY
AB The "Discrimination" part of the OMERACT Filter asks whether a measure discriminates between situations that are of interest. "Feasibility" in the OMERACT Filter encompasses the practical considerations of using an instrument, including its ease of use, time to complete, monetary costs, and interpretability of the question(s) included in the instrument. Both the Discrimination and Reliability parts of the filter have been helpful but were agreed on primarily by consensus of OMERACT participants rather than through explicit evidence-based guidelines. In Filter 2.0 we wanted to improve this definition and provide specific guidance and advice to participants.
C1 [Wells, George] Univ Ottawa, Cardiovasc Res Methods Ctr, Dept Epidemiol & Community Med, Ottawa, ON K1H 8M5, Canada.
   [Tugwell, Peter] Univ Ottawa, Dept Med, Ottawa, ON K1H 8M5, Canada.
   [Boers, Maarten] Vrije Univ Amsterdam, Med Ctr, Dept Epidemiol & Biostat, Amsterdam, Netherlands.
   [Boers, Maarten] Vrije Univ Amsterdam, Med Ctr, Dept Rheumatol, Amsterdam, Netherlands.
   [Kirwan, John R.] Univ Bristol, Bristol Royal Infirm, Acad Rheumatol Unit, Bristol, Avon, England.
   [Beaton, Dorcas E.] Univ Toronto, Inst Hlth Policy Management & Evaluat, Dept Occupat Sci & Occupat Therapy, Toronto, ON, Canada.
   [Bingham, Clifton O., III] Johns Hopkins Univ, Div Rheumatol, Baltimore, MD USA.
   [Boonen, Annelies] Maastricht Univ, Dept Internal Med, Div Rheumatol, Med Ctr, Maastricht, Netherlands.
   [Boonen, Annelies] Maastricht Univ, Caphri Res Inst, Maastricht, Netherlands.
   [Brooks, Peter] Univ Melbourne, Sch Populat Hlth, AHWI, Melbourne, Vic, Australia.
   [Conaghan, Philip G.] Univ Leeds, Div Musculoskeletal Dis, Leeds, W Yorkshire, England.
   UK Natl Inst Hlth Res NIHR, Leeds Musculoskeletal Biomed Res Unit, Leeds, W Yorkshire, England.
   [D'Agostino, Maria-Antonietta] Versailles St Quentin Yvelines Univ, Dept Rheumatol, Ambroise Pare Hosp, AP HP, Boulogne, France.
   [Dougados, Maxime] Paris Descartes Univ, Cochin Hosp, AP HP, Fac Med, Paris, France.
   Cardiff Univ, Sch Med, Rheumatol Sect, Cardiff CF10 3AX, S Glam, Wales.
   [Furst, Daniel E.] Univ Calif Los Angeles, Geffen Sch Med, Dept Rheumatol, Los Angeles, CA USA.
   [Gossec, Laure] Univ Paris 06, Pitie Salpetriere Hosp, AP HP, Dept Rheumatol,GRC UMPC EEMOIS 08, Paris, France.
   [Guillemin, Francis] Univ Paris 05, Univ Lorraine, Nancy, France.
   [Helliwell, Philip] Univ Leeds, Sect Musculoskeletal Dis, LIMM Chapel Allerton Hosp, Leeds, W Yorkshire, England.
   [Hewlett, Sarah] Univ W England, Acad Rheumatol Unit, Bristol Royal Infirm, Bristol BS16 1QY, Avon, England.
   [Kvien, Tore K.] Diakonhjemmet Hosp, Dept Rheumatol, Oslo, Norway.
   [Landewe, Robert B.] Univ Amsterdam, Acad Med Ctr, Dept Clin Immunol & Rheumatol, NL-1012 WX Amsterdam, Netherlands.
   [Landewe, Robert B.] Atrium Med Ctr Heerlen, Heerlen, Netherlands.
   Univ Sydney, Inst Bone & Joint Res, Sydney Med Sch, Sydney, NSW 2006, Australia.
   [March, Lyn] Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia.
   [March, Lyn] Royal North Shore, Dept Rheumatol, St Leonards, NSW, Australia.
   Univ Washington, Sch Med, Seattle Rheumatol Associates, Swedish Med Ctr,Rheumatol Res Div, Seattle, WA USA.
   [Ostergaard, Mikkel] Copenhagen Univ Hosp Glostrup, Dept Rheumatol, Glostrup, Denmark.
   [Simon, Lee] SDG LLC, Cambridge, MA USA.
   [Singh, Jasvinder A.] Univ Alabama Birmingham, Div Immunol Rheumatol, Birmingham, AL USA.
   [Singh, Jasvinder A.] Birmingham VA Med Ctr, Birmingham, AL USA.
   [Strand, Vibeke] Stanford Univ, Sch Med, Div Immunol Rheumatol, Palo Alto, CA 94304 USA.
   [van der Heijde, Desiree M.] Leiden Univ, Med Ctr, Dept Rheumatol, Leiden, Netherlands.
RP Wells, G (reprint author), Univ Ottawa, 40 Ruskin St, Ottawa, ON K1H 8M5, Canada.
EM gawells@ottawaheart.ca
RI DOUGADOS, MAXIME/P-5287-2016
OI Tugwell, Peter/0000-0001-5062-0556
FU AHRQ HHS [HS013852, HS013852-07]; None [HS013852, HS013852-07]
NR 17
TC 8
Z9 8
U1 0
U2 1
PU J RHEUMATOL PUBL CO
PI TORONTO
PA 365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA
SN 0315-162X
EI 1499-2752
J9 J RHEUMATOL
JI J. Rheumatol.
PD MAY
PY 2014
VL 41
IS 5
BP 1005
EP 1010
DI 10.3899/jrheum.131311
PG 6
WC Rheumatology
SC Rheumatology
GA AG6FN
UT WOS:000335514500030
PM 24692522
ER

PT J
AU D'Agostino, MA
   Boers, M
   Kirwan, J
   van der Heijde, D
   Ostergaard, M
   Schett, G
   Landewe, RB
   Maksymowych, WP
   Naredo, E
   Dougados, M
   Iagnocco, A
   Bingham, CO
   Brooks, PM
   Beaton, DE
   Gandjbakhch, F
   Gossec, L
   Guillemin, F
   Hewlett, SE
   Kloppenburg, M
   March, L
   Mease, PJ
   Moller, I
   Simon, LS
   Singh, JA
   Strand, V
   Wakefield, RJ
   Wells, GA
   Tugwell, P
   Conaghan, PG
AF D'Agostino, Maria-Antonietta
   Boers, Maarten
   Kirwan, John
   van der Heijde, Desiree
   Ostergaard, Mikkel
   Schett, Georg
   Landewe, Robert B.
   Maksymowych, Walter P.
   Naredo, Esperanza
   Dougados, Maxime
   Iagnocco, Annamaria
   Bingham, Clifton O., III
   Brooks, Peter M.
   Beaton, Dorcas E.
   Gandjbakhch, Frederique
   Gossec, Laure
   Guillemin, Francis
   Hewlett, Sarah E.
   Kloppenburg, Margreet
   March, Lyn
   Mease, Philip J.
   Moller, Ingrid
   Simon, Lee S.
   Singh, Jasvinder A.
   Strand, Vibeke
   Wakefield, Richard J.
   Wells, George A.
   Tugwell, Peter
   Conaghan, Philip G.
TI Updating the OMERACT Filter: Implications for Imaging and Soluble
   Biomarkers
SO JOURNAL OF RHEUMATOLOGY
LA English
DT Article
DE BIOMARKERS; IMAGING; OUTCOME AND PROCESS ASSESSMENT; OMERACT FILTER;
   VALIDATION FRAMEWORK
ID EARLY RHEUMATOID-ARTHRITIS; SPONDYLOARTHRITIS RESEARCH CONSORTIUM;
   SACROILIAC JOINT INFLAMMATION; POWER DOPPLER ULTRASONOGRAPHY; PAINFUL
   KNEE OSTEOARTHRITIS; RANDOMIZED CONTROLLED-TRIAL; ULTRASOUND TASK-FORCE;
   ACUTE-PHASE RESPONSE; DAMAGE END-POINTS; ANKYLOSING-SPONDYLITIS
AB Objective. The Outcome Measures in Rheumatology (OMERACT) Filter provides a framework for the validation of outcome measures for use in rheumatology clinical research. However, imaging and biochemical measures may face additional validation challenges because of their technical nature. The Imaging and Soluble Biomarker Session at OMERACT 11 aimed to provide a guide for the iterative development of an imaging or biochemical measurement instrument so it can be used in therapeutic assessment.
   Methods. A hierarchical structure was proposed, reflecting 3 dimensions needed for validating an imaging or biochemical measurement instrument: outcome domain(s), study setting, and performance of the instrument. Movement along the axes in any dimension reflects increasing validation. For a given test instrument, the 3-axis structure assesses the extent to which the instrument is a validated measure for the chosen domain, whether it assesses a patient-centered or disease-centered variable, and whether its technical performance is adequate in the context of its application. Some currently used imaging and soluble biomarkers for rheumatoid arthritis, spondy-loarthritis, and knee osteoarthritis were then evaluated using the original OMERACT Filter and the newly proposed structure. Breakout groups critically reviewed the extent to which the candidate biomarkers complied with the proposed stepwise approach, as a way of examining the utility of the proposed 3-dimensional structure.
   Results. Although there was a broad acceptance of the value of the proposed structure in general, some areas for improvement were suggested including clarification of criteria for achieving a certain level of validation and how to deal with extension of the structure to areas beyond clinical trials.
   Conclusion. General support was obtained for a proposed tri-axis structure to assess validation of imaging and soluble biomarkers; nevertheless, additional work is required to better evaluate its place within the OMERACT Filter 2.0.
C1 [D'Agostino, Maria-Antonietta] Versailles St Quentin Yvelines Univ, Dept Rheumatol, Ambroise Pare Hosp, AP HP, Boulogne, France.
   [Boers, Maarten] Vrije Univ Amsterdam, Med Ctr, Dept Epidemiol & Biostat, Amsterdam, Netherlands.
   [Boers, Maarten] Vrije Univ Amsterdam, Med Ctr, Dept Rheumatol, Amsterdam, Netherlands.
   [Kirwan, John] Univ Bristol, Acad Rheumatol Unit, Bristol Royal Infirm, Bristol, Avon, England.
   [van der Heijde, Desiree; Kloppenburg, Margreet] Leiden Univ, Med Ctr, Dept Rheumatol, Leiden, Netherlands.
   [Ostergaard, Mikkel] Copenhagen Univ Hosp Glostrup, Copenhagen Ctr Arthrit Res, Ctr Rheumatol & Spine Dis, Copenhagen, Denmark.
   [Schett, Georg] Univ Erlangen Nurnberg, Dept Internal Med 3, D-91054 Erlangen, Germany.
   [Schett, Georg] Univ Erlangen Nurnberg, Inst Clin Immunol, D-91054 Erlangen, Germany.
   [Landewe, Robert B.] Univ Amsterdam, Acad Med Ctr, Dept Clin Immunol & Rheumatol, NL-1105 AZ Amsterdam, Netherlands.
   [Landewe, Robert B.] Atrium Med Ctr, Amsterdam, Netherlands.
   [Maksymowych, Walter P.] Univ Alberta, Dept Med, Edmonton, AB, Canada.
   [Naredo, Esperanza] Hosp Gen Gregorio Maranon, Dept Rheumatol, Madrid, Spain.
   [Dougados, Maxime] Paris Descartes Univ, Fac Med, Cochin Hosp, AP HP, Paris, France.
   [Iagnocco, Annamaria] Univ Roma La Sapienza, Rheumatol Unit, I-00185 Rome, Italy.
   [Bingham, Clifton O., III] Johns Hopkins Univ, Div Rheumatol, Baltimore, MD USA.
   [Brooks, Peter M.] Univ Melbourne, Melbourne, Vic, Australia.
   St Michaels Hosp, Mobil Program Clin Res Unit, Toronto, ON M5B 1W8, Canada.
   Inst Work & Hlth, Toronto, ON, Canada.
   Univ Toronto, Dept Hlth Policy Management & Evaluat, Dept Rehabil Sci, Toronto, ON, Canada.
   Dept Occupat Sci & Occupat Therapy, Toronto, ON, Canada.
   [Gossec, Laure] Univ Paris 06, Pitie Salpetriere Hosp, AP HP, Dept Rheumatol,GRC UPMC EEMOIS 08, Paris, France.
   [Guillemin, Francis] Univ Paris 05, Univ Lorraine, EA APEMAC 4360, Nancy, France.
   [Guillemin, Francis] CHU Nancy, Inserm CIC EC, Nancy, France.
   [Hewlett, Sarah E.] Univ W England, Dept Nursing, Bristol BS16 1QY, Avon, England.
   [Mease, Philip J.] Swedish Med Ctr, Seattle, WA USA.
   [Mease, Philip J.] Univ Washington, Seattle, WA 98195 USA.
   [Moller, Ingrid] Inst Poal, Barcelona, Spain.
   [Simon, Lee S.] SDG LLC, Cambridge, MA USA.
   [Singh, Jasvinder A.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
   [Singh, Jasvinder A.] Univ Alabama Birmingham, Birmingham, AL USA.
   [Strand, Vibeke] Stanford Univ, Sch Med, Div Immunol Rheumatol, Palo Alto, CA 94304 USA.
   [Wakefield, Richard J.; Conaghan, Philip G.] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England.
   UK Natl Inst Hlth Res, Leeds Musculoskeletal Biomed Res Unit, Leeds, W Yorkshire, England.
   Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON, Canada.
   [Tugwell, Peter] Univ Ottawa, Dept Med, Ottawa, ON, Canada.
RP D'Agostino, MA (reprint author), Hop Ambroise Pare, AP HP, Dept Rheumatol, 9 Ave Charles de Gaulle, F-92100 Boulogne, France.
EM maria-antonietta.dagostino@apr.aphp.fr
RI DOUGADOS, MAXIME/P-5287-2016
OI Tugwell, Peter/0000-0001-5062-0556
FU AHRQ HHS [HS013852, HS013852-07]; None [HS013852, HS013852-07]
NR 79
TC 5
Z9 5
U1 0
U2 4
PU J RHEUMATOL PUBL CO
PI TORONTO
PA 365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA
SN 0315-162X
EI 1499-2752
J9 J RHEUMATOL
JI J. Rheumatol.
PD MAY
PY 2014
VL 41
IS 5
BP 1016
EP 1024
DI 10.3899/jrheum.131313
PG 9
WC Rheumatology
SC Rheumatology
GA AG6FN
UT WOS:000335514500032
PM 24584916
ER

PT J
AU Sartor, CE
   Kranzler, HR
   Gelernter, J
AF Sartor, Carolyn E.
   Kranzler, Henry R.
   Gelernter, Joel
TI Characteristics and Course of Dependence in Cocaine-Dependent
   Individuals Who Never Used Alcohol or Marijuana or Used Cocaine First
SO JOURNAL OF STUDIES ON ALCOHOL AND DRUGS
LA English
DT Article
ID DRUG-USE; SUBSTANCE USE; SEMISTRUCTURED ASSESSMENT; GATEWAY HYPOTHESIS;
   INITIATION; SEQUENCE; ADOLESCENTS; CANNABIS; ASSOCIATIONS; COMORBIDITY
AB Objective: Cocaine users typically try alcohol or marijuana before cocaine, but this ordering of substance use initiation is not universal. Characterizing cocaine-dependent users who deviate from the typical sequence may be informative for understanding the multiple pathways to cocaine dependence. Method: Data were drawn from cocaine-dependent participants (N=6,333; 41% female) in a multisite study of the genetics of substance dependence who completed in-person structured psychiatric interviews. Participants were categorized with respect to alcohol or marijuana use as (a) never used, (b) used cocaine first, or (c) first used at the same age as or after first cocaine use. The association of a range of demographic, psychiatric, and childhood risk factors with sequences of initiation and the association of those sequences with indicators of dependence course (e.g., severity) were investigated in a series of regression analyses. Results: Women and non-European Americans were overrepresented in the atypical sequence groups. The atypical sequence groups also differed from the typical sequence groups with respect to rates of other substance use disorders. Sequences of substance use initiation were largely unrelated to other psychiatric disorders or childhood risk factors. Individuals who never used marijuana had a lower severity of dependence. Conclusions: Although only a minority of dependent cocaine users deviate from the typical sequence of substance use initiation, several characteristics distinguish them from those who follow the typical sequence. Findings underscore the diversity in pathways to cocaine dependence.
C1 [Sartor, Carolyn E.; Gelernter, Joel] Yale Univ, Sch Med, Dept Psychiat, West Haven, CT 06516 USA.
   [Kranzler, Henry R.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Kranzler, Henry R.] Philadelphia Vet Affairs Med Ctr, Vet Integrated Serv Network 4, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA.
   [Gelernter, Joel] Yale Univ, Sch Med, Dept Genet, West Haven, CT 06516 USA.
   [Gelernter, Joel] Yale Univ, Sch Med, Dept Neurobiol, West Haven, CT 06516 USA.
RP Sartor, CE (reprint author), Yale Univ, Sch Med, Dept Psychiat, VA Connecticut Healthcare Syst, 950 Campbell Ave 151D, West Haven, CT 06516 USA.
EM carolyn.sartor@yale.edu
FU National Institutes of Health [AA017921, DA12849, DA12690, AA11330,
   AA13736]; Veterans Affairs (VA) Connecticut; Philadelphia VA Mental
   Illness Research, Education, and Clinical Centers (MIRECCs)
FX This work was supported by National Institutes of Health Grants
   AA017921, DA12849, DA12690, AA11330, and AA13736 and the Veterans
   Affairs (VA) Connecticut and Philadelphia VA Mental Illness Research,
   Education, and Clinical Centers (MIRECCs).
NR 20
TC 3
Z9 3
U1 2
U2 4
PU ALCOHOL RES DOCUMENTATION INC CENT ALCOHOL STUD RUTGERS UNIV
PI PISCATAWAY
PA C/O DEIRDRE ENGLISH, 607 ALLISON RD, PISCATAWAY, NJ 08854-8001 USA
SN 1937-1888
EI 1938-4114
J9 J STUD ALCOHOL DRUGS
JI J. Stud. Alcohol Drugs
PD MAY
PY 2014
VL 75
IS 3
BP 423
EP 427
PG 5
WC Substance Abuse; Psychology
SC Substance Abuse; Psychology
GA AG7WY
UT WOS:000335630700007
PM 24766754
ER

PT J
AU Rolland, Y
   Resnick, B
   Katz, PR
   Little, MO
   Ouslander, JG
   Bonner, A
   Geary, CR
   Schumacher, KL
   Thompson, S
   Martin, FC
   Wilbers, J
   Zuniga, F
   Ausserhofer, D
   Schwendimann, R
   Schussler, S
   Dassen, T
   Lohrmann, C
   Levy, C
   Whitfield, E
   Barreto, PD
   Etherton-Beer, C
   Dilles, T
   Azermai, M
   Bourgeois, J
   Orrell, M
   Grossberg, GT
   Kergoat, H
   Thomas, DR
   Visschedijk, J
   Taylor, SJC
   Handajani, YS
   Widjaja, NT
   Turana, Y
   Rantz, MJ
   Skubic, M
   Morley, JE
AF Rolland, Yves
   Resnick, Barbara
   Katz, Paul R.
   Little, Milta O.
   Ouslander, Joseph G.
   Bonner, Alice
   Geary, Carol R.
   Schumacher, Karen L.
   Thompson, Sarah
   Martin, Finbarr C.
   Wilbers, Joachim
   Zuniga, Franziska
   Ausserhofer, D.
   Schwendimann, R.
   Schuessler, S.
   Dassen, Theo
   Lohrmann, Christa
   Levy, Cari
   Whitfield, Emily
   Barreto, Philipe de Souto
   Etherton-Beer, Christopher
   Dilles, Tinne
   Azermai, Majda
   Bourgeois, Jolyce
   Orrell, Martin
   Grossberg, George T.
   Kergoat, Helene
   Thomas, David R.
   Visschedijk, Jan
   Taylor, Stephanie J. C.
   Handajani, Yvonne S.
   Widjaja, Nelly T.
   Turana, Yuda
   Rantz, Marilyn J.
   Skubic, Marjorie
   Morley, John E.
CA OPERA Study Team
TI Nursing Home Research: The First International Association of
   Gerontology and Geriatrics (IAGG) Research Conference
SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION
LA English
DT Article
DE Research in long-term care; nursing home research; physician practice;
   transitions; quality improvement; European nursing homes; medical foster
   home; culture change; Pharmanurse; psychotropic drugs; cognitive
   stimulus therapy; depression in the nursing home; pressure ulcers; fear
   of falling; exercise intervention; homecare; technological nursing home;
   eye care in the nursing home
ID POTENTIALLY AVOIDABLE HOSPITALIZATIONS; RANDOMIZED CONTROLLED-TRIAL;
   LONG-TERM-CARE; MEDICAL STAFF ORGANIZATION; QUALITY-OF-LIFE; MDS 3.0;
   EXERCISE INTERVENTION; RESIDENTIAL CARE; OLDER PERSONS; OPERA TRIAL
AB The International Association of Gerontology and Geriatrics held its first conference on nursing home research in St Louis, MO, in November 2013. This article provides a summary of the presentations. (C) 2014 - American Medical Directors Association, Inc. All rights reserved.
C1 [Rolland, Yves; Barreto, Philipe de Souto] Gerontopole, Toulouse, France.
   [Resnick, Barbara] Univ Maryland, Sch Nursing, Baltimore, MD 21201 USA.
   [Katz, Paul R.] Univ Toronto, Baycrest Hlth Ctr, Toronto, ON, Canada.
   [Little, Milta O.; Morley, John E.] St Louis Univ, Sch Med, Div Geriatr Med, St Louis, MO 63104 USA.
   [Ouslander, Joseph G.] Florida Atlantic Univ, Charles E Schmidt Coll Med, Geriatr Programs, Boca Raton, FL 33431 USA.
   [Bonner, Alice] Northeastern Univ, Sch Nursing, Bouve Coll Hlth Sci, Boston, MA 02115 USA.
   [Geary, Carol R.; Schumacher, Karen L.] Univ Nebraska Med Ctr, Coll Nursing, Omaha, NE 68198 USA.
   [Thompson, Sarah] Univ Colorado, Coll Nursing, Denver, CO 80202 USA.
   [Martin, Finbarr C.] Guys & St Thomas NHS Trust, London, England.
   [Martin, Finbarr C.] Kings Coll London, London, England.
   [Wilbers, Joachim] ProjectCare, Frankfurt, Germany.
   [Zuniga, Franziska; Ausserhofer, D.; Schwendimann, R.] Univ Basel, Inst Nursing Sci, Basel, Switzerland.
   [Schuessler, S.; Lohrmann, Christa] Med Univ Graz, Inst Nursing Sci, Graz, Austria.
   [Dassen, Theo] Charite, Inst Hlth Sci Educ & Nursing Sci, D-13353 Berlin, Germany.
   [Levy, Cari; Whitfield, Emily] Denver Vet Affairs Med Ctr, Denver, CO USA.
   [Levy, Cari] Univ Colorado, Sch Med, Aurora, CO USA.
   [Etherton-Beer, Christopher] Univ Western Australia, Western Australian Ctr Hlth & Ageing, Crawley, WA, Australia.
   [Etherton-Beer, Christopher] Royal Perth Hosp, Perth, WA 6001, Australia.
   [Dilles, Tinne] Univ Antwerp, Ctr Res & Innovat Care, B-2020 Antwerp, Belgium.
   [Dilles, Tinne] Thomas More Univ Coll, Lier, Belgium.
   [Azermai, Majda; Bourgeois, Jolyce; Orrell, Martin] Univ Ghent, Heymans Inst Pharmacol, Clin Pharmacol Res Unit, B-9000 Ghent, Belgium.
   [Orrell, Martin] UCL, London, England.
   [Grossberg, George T.] St Louis Univ, Div Geriatr Psychiat, Dept Neurol & Psychiat, St Louis, MO 63104 USA.
   [Kergoat, Helene] Univ Montreal, Ecole Optometrie, Montreal, PQ, Canada.
   [Kergoat, Helene] Inst Univ Geriatrie Montreal, Montreal, PQ, Canada.
   [Visschedijk, Jan] Leiden Univ, Med Ctr, Dept Publ Hlth & Primary Care, Leiden, Netherlands.
   [Taylor, Stephanie J. C.] Queen Mary Univ London, Barts & London Sch Med & Dent, Ctr Primary Care & Publ Hlth, Blizard Inst, London, England.
   [Handajani, Yvonne S.; Widjaja, Nelly T.] Atma Jaya Catholic Univ, Sch Med, Ctr Hlth Res, Dept Publ Hlth, Jakarta, Indonesia.
   [Turana, Yuda] Atma Jaya Catholic Univ, Sch Med, Ctr Hlth Res, Dept Neurol, Jakarta, Indonesia.
   [Rantz, Marilyn J.] Univ Missouri, Sinclair Sch Nursing, Aging Pl Project, Columbia, MO USA.
   [Skubic, Marjorie] Univ Missouri, Ctr Eldercare & Rehabil Technol, Columbia, MO USA.
RP Morley, JE (reprint author), St Louis Univ, Sch Med, Div Geriatr Med, 1402 S Grand Blvd,M238, St Louis, MO 63104 USA.
EM morley@slu.edu
RI Etherton-Beer, Christopher/B-2714-2014; Dilles, Tinne/F-3393-2013
OI Etherton-Beer, Christopher/0000-0001-5148-0188; Dilles,
   Tinne/0000-0003-2817-0944; Taylor, Stephanie/0000-0001-7454-6354;
   Lohrmann, Christa/0000-0002-0778-5854; Zuniga,
   Franziska/0000-0002-8844-4903
FU National Institute of Nursing Research of the National Institutes of
   Health [1F31NR013596-01A1]; Fondation Caroline-Durand; Canadian National
   Institute for the Blind; Societe Alzheimer du Canada; National Institute
   for Health Research Health Technology Assessment Programme UK [01/02/01]
FX The research for Methodology for Study of Care Transitions (CRG, KLS,
   ST) was supported by National Institute of Nursing Research of the
   National Institutes of Health under award number 1F31NR013596-01A1. The
   content is solely the responsibility of the authors and does not
   necessarily represent the official views of the National Institutes of
   Health.; Vision in Older Institutionalized Individuals (HK) was funded
   by Fondation Caroline-Durand, Canadian National Institute for the Blind,
   Societe Alzheimer du Canada.; The OPERA project (SJCT) was funded by the
   National Institute for Health Research Health Technology Assessment
   Programme UK (project no. 01/02/01). The sponsors of the study played no
   part in the preparation of this paper. The views and opinions expressed
   here are those of the authors and do not necessarily reflect those of
   the Health Technology Assessment Programme, the National Institute for
   Health Research, or the Department of Health.
NR 88
TC 15
Z9 15
U1 3
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1525-8610
EI 1538-9375
J9 J AM MED DIR ASSOC
JI J. Am. Med. Dir. Assoc.
PD MAY
PY 2014
VL 15
IS 5
BP 313
EP 325
DI 10.1016/j.jamda.2014.03.004
PG 13
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA AG5DF
UT WOS:000335438700004
PM 24767432
ER

PT J
AU Sayegh, AI
   Washington, MC
   Raboin, SJ
   Aglan, AH
   Reeve, JR
AF Sayegh, Ayman I.
   Washington, Martha C.
   Raboin, Shannon J.
   Aglan, Amnah H.
   Reeve, Joseph R., Jr.
TI CCK-58 prolongs the intermeal interval, whereas CCK-8 reduces this
   interval: Not all forms of cholecystokinin have equal bioactivity
SO PEPTIDES
LA English
DT Article
DE Cholecystokinin; Satiation; Satiety; Satiety ratio; Intermeal interval
ID PANCREATIC ACINAR-CELLS; DECREASES FOOD-INTAKE; FREE-FEEDING RATS; MEAL
   SIZE; BIOLOGICAL-ACTIVITY; ENZYME-SECRETION; SATIETY; PANCREOZYMIN;
   METABOLISM; RECEPTORS
AB It has been accepted for decades that "all forms of cholecystokinin (CCK) have equal bioactivity," despite accumulating evidence to the contrary. To challenge this concept, we compared two feeding responses, meal size (MS, 10% sucrose) and intermeal interval (IMI), in response to CCK-58, which is the major endocrine form of CCK, and CCK-8, which is the most abundantly utilized form. Doses (0, 0.1, 0.5, 0.75, 1, 3 and 5 nmol/kg) were administered intraperitoneally over a 210-min test to Sprague Dawley rats that had been food-deprived overnight. We found that (1) all doses of CCK-58, except the lowest dose, and all doses of CCK-8, except the lowest two doses, reduced food intake more than vehicle did; (2) at two doses, 0.75 and 3 nmol/kg, CCK-58 increased the IMI, while CCK-8 failed to alter this feeding response; and (3) CCK-58, at all but the lowest two doses, increased the satiety ratio (IMI between first and second meals (min) divided by first MS (ml)) relative to vehicle, while CCK-8 did not affect this value. These findings demonstrate that the only circulating form of CCK in rats, CCK-58, prolongs the IMI more than CCK-8, the peptide generally utilized in feeding studies. Taken together, these results add to a growing list of functions where CCK-8 and CCK-58 express qualitatively different bioactivities. In conclusion, the hypothesis that "all forms of cholecystokinin (CCK) have equal bioactivity" is not supported. Published by Elsevier Inc.
C1 [Sayegh, Ayman I.; Washington, Martha C.; Raboin, Shannon J.] Tuskegee Univ, Coll Vet Med, Dept Biomed Sci, Gastroenterol Lab, Tuskegee, AL 36088 USA.
   [Aglan, Amnah H.] Wayne State Univ, Sch Med, Detroit, MI USA.
   [Reeve, Joseph R., Jr.] Univ Calif Los Angeles, Vet Adm Greater Los Angeles Healthcare Syst, CURE Digest Dis Res Ctr, Los Angeles, CA USA.
   [Reeve, Joseph R., Jr.] Univ Calif Los Angeles, Sch Med, Div Digest Dis, Los Angeles, CA USA.
RP Sayegh, AI (reprint author), Tuskegee Univ, Coll Vet Med, Dept Biomed Sci, Gastroenterol Lab, Tuskegee, AL 36088 USA.
EM sayeghai@mytu.tuskegee.edu
FU NIH [15C1DK094972-01A1]; Birmingham Racing Commission;  [R01 DK083449]
FX This study was supported by NIH 15C1DK094972-01A1 and the Birmingham
   Racing Commission (AIS) and R01 DK083449 (JRR, Jr.).
NR 41
TC 4
Z9 4
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0196-9781
EI 1873-5169
J9 PEPTIDES
JI Peptides
PD MAY
PY 2014
VL 55
BP 120
EP 125
DI 10.1016/j.peptides.2014.02.014
PG 6
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism;
   Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism;
   Pharmacology & Pharmacy
GA AG6BR
UT WOS:000335503900017
PM 24607725
ER

PT J
AU Wang, LX
   Mogami, S
   Karasawa, H
   Yamada, C
   Yakabi, S
   Yakabi, K
   Hattori, T
   Tache, Y
AF Wang, Lixin
   Mogami, Sachiko
   Karasawa, Hiroshi
   Yamada, Chihiro
   Yakabi, Seiichi
   Yakabi, Koji
   Hattori, Tomohisa
   Tache, Yvette
TI Preventive effect of rikkunshito on gastric motor function inhibited by
   L-dopa in rats
SO PEPTIDES
LA English
DT Article
DE Gastric motility; Ghrelin; L-dopa; Parkinson's disease; Rats;
   Rikkunshito
ID TRADITIONAL JAPANESE MEDICINE; PARKINSONS-DISEASE; RESPONSE
   FLUCTUATIONS; GASTROINTESTINAL MOTILITY; GASTROESOPHAGEAL-REFLUX;
   HEALTHY-VOLUNTEERS; INDUCED ANOREXIA; HERBAL MEDICINE; PLASMA GHRELIN;
   ACYL GHRELIN
AB We previously reported that ghrelin prevented L-dopa (LD)-induced inhibition of gastric emptying (GE) of a non-nutrient solution in rats. Parkinson's disease treatment involves the combined administration of L-dopa with the enzyme L-amino acid decarboxylase inhibitor, carbidopa (CD) to reduce peripheral formation of dopamine. We investigated the effect LD/CD given orogastrically (og) on GE of a non-nutrient or nutrient meal and whether og pretreatment with rikkunshito, a kampo medicine clinically used to treat gastroparesis, influenced LD/CD effect on GE and postprandial antral and duodenal motility in conscious rats. LD/CD (2012 mg kg) decreased significantly GE to 26.3 +/- 6.0% compared to 61.2 +/- 3.2% in og vehicle monitored 20-min after a non-nutrient meal and to 41.9 +/- 5.8% compared to 72.9 +/- 5.2% in og vehicle monitored 60 min after a nutrient meal. Rikkunshito (0.5 or 1.0 g kg(-1)) reduced the LD/CD (20/2 mg kg-1) inhibition of GE of non-nutrient meal (36.9 +/- 7.4% and 46.6 +/- 4.8% respectively vs. 12.1 +/- 7.4% in og vehicle plus LD/CD) while having no effect alone (56.6 +/- 8.5%). The ghrelin antagonist, [D-Lys(3)]-GHRP-6 (1 mg kg(-1)) injected intraperitoneally partially reversed rikkunshito preventive effect on LD/CD-inhibited GE. Rikkunshito (1.0 g kg(-1)) blocked LD/CD (20/2 mg kg(-1))-induced delayed GE of a nutrient meal and the reduction of postprandial antral motility. In 6-hydroxydopamine-induced Parkinson's disease rat model, rikkunshito (1.0 gkg(-1), og) also prevented LD/CD-inhibited gastric emptying of a nutrient meal and enhanced fasting plasma levels of acylated ghrelin. These data indicate that oral rikkunshito alleviates the delayed GE induced by LD/CD in naive and PD rat model in part through ghrelin-related mechanisms. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Wang, Lixin; Karasawa, Hiroshi; Yakabi, Seiichi; Tache, Yvette] Univ Calif Los Angeles, CURE Digest Dis Ctr, Los Angeles, CA USA.
   [Wang, Lixin; Karasawa, Hiroshi; Yakabi, Seiichi; Tache, Yvette] Univ Calif Los Angeles, Dept Med, Div Digest Dis, Ctr Neurobiol Stress, Los Angeles, CA 90024 USA.
   [Wang, Lixin; Karasawa, Hiroshi; Yakabi, Seiichi; Tache, Yvette] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA.
   [Mogami, Sachiko; Yamada, Chihiro; Hattori, Tomohisa] Tsumura Res Labs, Ibaraki, Japan.
   [Yakabi, Koji] Saitama Med Univ, Saitama Med Ctr, Dept Gastroenterol & Hepatol, Saitama, Japan.
RP Wang, LX (reprint author), 11301 Wilshire Blvd,Bldg 115, Los Angeles, CA 90073 USA.
EM lixinw@ucla.edu
RI Xu, Meiqu/C-5311-2016
FU Tsumura & Co. (Animal core, YT, LW) [NIHDDK-41303]; Fox Foundation
   Target Validation grant; Veterans Administration Research Career
   Scientist Award
FX This work was supported by Tsumura & Co., NIHDDK-41303 (Animal core, YT,
   LW), Fox Foundation Target Validation grant (LW, YT), and Veterans
   Administration Research Career Scientist Award (YT). We are grateful to
   Mrs. Honghui Liang for excellent technical support and we thank Ms.
   Eugenia Hu for reviewing the manuscript.
NR 66
TC 9
Z9 9
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0196-9781
EI 1873-5169
J9 PEPTIDES
JI Peptides
PD MAY
PY 2014
VL 55
BP 136
EP 144
DI 10.1016/j.peptides.2004.02.011
PG 9
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism;
   Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism;
   Pharmacology & Pharmacy
GA AG6BR
UT WOS:000335503900020
PM 24631952
ER

PT J
AU Akil, O
   Hall-Glenn, F
   Chang, JL
   Li, A
   Chang, WH
   Lustig, LR
   Alliston, T
   Hsiao, EC
AF Akil, Omar
   Hall-Glenn, Faith
   Chang, Jolie
   Li, Alfred
   Chang, Wenhan
   Lustig, Lawrence R.
   Alliston, Tamara
   Hsiao, Edward C.
TI Disrupted Bone Remodeling Leads to Cochlear Overgrowth and Hearing Loss
   in a Mouse Model of Fibrous Dysplasia
SO PLOS ONE
LA English
DT Article
ID PROTEIN-COUPLED RECEPTOR; ENGINEERED G(S)-COUPLED RECEPTOR; MICE LACKING
   PROSAPOSIN; TEMPORAL BONE; OTIC CAPSULE; OSTEOBLAST EXPRESSION;
   G(I)-COUPLED RECEPTOR; INNER-EAR; OSTEOPROTEGERIN; OTOSCLEROSIS
AB Normal hearing requires exquisite cooperation between bony and sensorineural structures within the cochlea. For example, the inner ear secretes proteins such as osteoprotegrin (OPG) that can prevent cochlear bone remodeling. Accordingly, diseases that affect bone regulation can also result in hearing loss. Patients with fibrous dysplasia develop trabecular bone overgrowth resulting in hearing loss if the lesions affect the temporal bones. Unfortunately, the mechanisms responsible for this hearing loss, which could be sensorineural and/or conductive, remain unclear. In this study, we used a unique transgenic mouse model of increased G(s) G-protein coupled receptor (GPCR) signaling induced by expression of an engineered receptor, Rs1, in osteoblastic cells. These ColI(2.3)(+)/Rs1(+) mice showed dramatic bone lesions that histologically and radiologically resembled fibrous dysplasia. We found that ColI(2.3)(+)/Rs1(+) mice showed progressive and severe conductive hearing loss. Ossicular chain impingement increased with the size and number of dysplastic lesions. While sensorineural structures were unaffected, ColI(2.3)(+)/Rs1(+) cochleae had abnormally high osteoclast activity, together with elevated tartrate resistant acid phosphatase (TRAP) activity and receptor activator of nuclear factor kappa-B ligand (Rankl) mRNA expression. ColI(2.3)(+)/Rs1(+) cochleae also showed decreased expression of Sclerostin (Sost), an antagonist of the Wnt signaling pathway that normally increases bone formation. The osteocyte canalicular networks of ColI(2.3)(+)/Rs1(+) cochleae were disrupted and showed abnormal osteocyte morphology. The osteocytes in the ColI(2.3)(+)/Rs1(+) cochleae showed increased expression of matrix metalloproteinase 13 (MMP-13) and TRAP, both of which can support osteocyte-mediated peri-lacunar remodeling. Thus, while the ossicular chain impingement is sufficient to account for the progressive hearing loss in fibrous dysplasia, the deregulation of bone remodeling extends to the cochlea as well. Our findings suggest that factors regulating bone remodeling, including peri-lacunar remodeling by osteocytes, may be useful targets for treating the bony overgrowths and hearing changes of fibrous dysplasia and other bony pathologies.
C1 [Akil, Omar; Chang, Jolie; Lustig, Lawrence R.] Univ Calif San Francisco, Dept Otolaryngol Head & Neck Surg, San Francisco, CA 94117 USA.
   [Hall-Glenn, Faith; Alliston, Tamara] Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA USA.
   [Li, Alfred; Chang, Wenhan] San Francisco VA Med Ctr, Endocrine Unit, San Francisco, CA USA.
   [Li, Alfred; Chang, Wenhan] San Francisco VA Med Ctr, Bone Imaging Core, San Francisco, CA USA.
   [Hsiao, Edward C.] Univ Calif San Francisco, Dept Med, Div Endocrinol & Metab, San Francisco, CA USA.
   [Hsiao, Edward C.] Univ Calif San Francisco, Inst Human Genet, Dept Med, San Francisco, CA USA.
RP Lustig, LR (reprint author), Univ Calif San Francisco, Dept Otolaryngol Head & Neck Surg, San Francisco, CA 94117 USA.
EM llustig@ohns.ucsf.edu; tamara.alliston@ucsf.edu; Edward.Hsiao@ucsf.edu
OI Alliston, Tamara/0000-0001-9992-2897
FU Hearing Research Inc; NIH [R01 DE019284, K08 AR056299]
FX This work was supported by Hearing Research Inc (TA, LL), NIH R01
   DE019284 (TA), and NIH K08 AR056299 (ECH). The funders had no role in
   study design, data collection/analysis, decision to publish, or
   preparation of the manuscript.
NR 54
TC 4
Z9 4
U1 0
U2 19
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 1
PY 2014
VL 9
IS 5
AR e94989
DI 10.1371/journal.pone.0094989
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AG6EE
UT WOS:000335510600023
PM 24788917
ER

PT J
AU Stone, AEL
   Mitchell, A
   Brownell, J
   Miklin, DJ
   Golden-Mason, L
   Polyak, SJ
   Gale, MJ
   Rosen, HR
AF Stone, Amy E. L.
   Mitchell, Angela
   Brownell, Jessica
   Miklin, Daniel J.
   Golden-Mason, Lucy
   Polyak, Stephen J.
   Gale, Michael J., Jr.
   Rosen, Hugo R.
TI Hepatitis C Virus Core Protein Inhibits Interferon Production by a Human
   Plasmacytoid Dendritic Cell Line and Dysregulates Interferon Regulatory
   Factor-7 and Signal Transducer and Activator of Transcription (STAT) 1
   Protein Expression
SO PLOS ONE
LA English
DT Article
ID CHRONIC HCV INFECTION; IFN-ALPHA PRODUCTION; RIG-I; ANTIVIRAL RESPONSE;
   RECOGNITION; THERAPY; IRF-7; GC1QR; INDUCTION; LIGAND
AB Plasmacytoid Dendritic Cells (pDCs) represent a key immune cell population in the defense against viruses. pDCs detect viral pathogen associated molecular patterns (PAMPs) through pattern recognition receptors (PRR). PRR/PAMP interactions trigger signaling events that induce interferon (IFN) production to initiate local and systemic responses. pDCs produce Type I and Type III (IFNL) IFNs in response to HCV RNA. Extracellular HCV core protein (Core) is found in the circulation in chronic infection. This study defined how Core modulates PRR signaling in pDCs. Type I and III IFN expression and production following exposure to recombinant Core or beta-galactosiade was assessed in human GEN2.2 cells, a pDC cell line. Core suppressed type I and III IFN production in response to TLR agonists and the HCV PAMP agonist of RIG-I. Core suppression of IFN induction was linked with decreased IRF-7 protein levels and increased non-phosphorylated STAT1 protein. Circulating Core protein interferes with PRR signaling by pDCs to suppress IFN production. Strategies to define and target Core effects on pDCs may serve to enhance IFN production and antiviral actions against HCV.
C1 [Stone, Amy E. L.; Mitchell, Angela; Golden-Mason, Lucy; Rosen, Hugo R.] Univ Colorado, Integrated Dept Immunol, Denver, CO 80202 USA.
   [Stone, Amy E. L.; Mitchell, Angela; Golden-Mason, Lucy; Rosen, Hugo R.] Natl Jewish Hlth, Denver, CO USA.
   [Stone, Amy E. L.; Mitchell, Angela; Miklin, Daniel J.; Golden-Mason, Lucy; Rosen, Hugo R.] Univ Colorado, Dept Med, Hepatitis C Ctr, Div Gastroenterol & Hepatol, Denver, CO 80202 USA.
   [Brownell, Jessica; Polyak, Stephen J.] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA.
   [Polyak, Stephen J.] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA.
   [Gale, Michael J., Jr.] Univ Washington, Dept Immunol, Seattle, WA 98195 USA.
   [Rosen, Hugo R.] Denver Vet Affairs Med Ctr, Denver, CO USA.
RP Rosen, HR (reprint author), Univ Colorado, Integrated Dept Immunol, Denver, CO 80202 USA.
EM Hugo.Rosen@UCDENVER.edu
OI Gale, Michael/0000-0002-6332-7436
FU NIH [U19 AI 1066328]; VA Merit Review grant; NIH/NCATS Colorado CTSI
   [TL1 TR000155]
FX This work was supported by NIH U19 AI 1066328, a VA Merit Review grant
   and NIH/NCATS Colorado CTSI Grant Number TL1 TR000155. Contents are the
   authors' sole responsibility and do not necessarily represent official
   NIH views. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
NR 46
TC 9
Z9 9
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 1
PY 2014
VL 9
IS 5
AR e95627
DI 10.1371/journal.pone.0095627
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AG6EE
UT WOS:000335510600044
PM 24788809
ER

PT J
AU Keshavan, MS
   Vinogradov, S
   Rumsey, J
   Sherrill, J
   Wagner, A
AF Keshavan, Matcheri S.
   Vinogradov, Sophia
   Rumsey, Judith
   Sherrill, Joel
   Wagner, Ann
TI Cognitive Training in Mental Disorders: Update and Future Directions
SO AMERICAN JOURNAL OF PSYCHIATRY
LA English
DT Review
ID DIRECT-CURRENT STIMULATION; REMEDIATION THERAPY CRT; PRIMARY MOTOR
   CORTEX; ADULT OWL MONKEYS; WORKING-MEMORY; ENHANCEMENT THERAPY; CORTICAL
   PLASTICITY; BIAS MODIFICATION; CONTROLLED-TRIAL; HAND REPRESENTATION
AB Objective: This article reviews the conceptual basis, definitions, and evolution of cognitive training approaches for the treatment of mental disorders.
   Method: The authors review the current state of the knowledge on cognitive training in psychiatric illnesses, and its neural and behavioral targets, and summarize the factors that appear to relate to a successful response, including learner characteristics that influence clinical outcome. They also discuss methodological issues relevant to the development and testing of cognitive training approaches, with the goal of creating maximally efficient and effective approaches to training. Finally, they identify gaps in existing knowledge and outline key research directions for the future.
   Results: While much of the early research has been conducted in schizophrenia, cognitive training has more recently been applied to a widening range of neuropsychiatric illnesses, including-attention deficit hyperactivity disorder, mood disorders, and substance use disorders. Cognitive training harnesses the inherent neuroplastic capacities of the brain, targeting neural system function across psychiatric disorders, thus improving the cognitive processes that play a, role in emotion regulation, clinical symptoms, and adaptive community functioning.
   Conclusions: Cognitive training offers considerable promise, especially given the limited efficacy of pharmacological interventions in a-meliorating cognitive deficits. However, more research is needed to understand the mechanisms underlying cognitive training, predictors of response, generalization and real-world applicability, and approaches to dissemination in practice settings.
C1 [Keshavan, Matcheri S.] Beth Israel Deaconess Med Ctr, Dept Psychiat, Boston, MA 02215 USA.
   Harvard Univ, Sch Med, Boston, MA USA.
   Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
   San Francisco VA Med Ctr, San Francisco, CA USA.
   NIMH, Clin Neurosci Res Branch, Div Adult Translat Res & Treatment Dev, Bethesda, MD 20892 USA.
   NIMH, Treatment & Prevent Intervent Res Branch, Div Serv & Intervent Res, Bethesda, MD 20892 USA.
   NIMH, Neurobehav Mechanisms Mental Disorders Branch, Div Dev Translat Res, Bethesda, MD 20892 USA.
RP Keshavan, MS (reprint author), Beth Israel Deaconess Med Ctr, Dept Psychiat, Boston, MA 02215 USA.
EM mkeshava@bidmc.harvard.edu
FU Sunovion; AmGen; Brain Plasticity Institute; EnVivo; Genentech; Hoffman
   La Roche; NIH [MH092440, MH060902, MH082818, MH068725, MH081051,
   MH081807]; Stanley Medical Research Institute; NIMH
FX Dr. Keshavan has received grant funding from Sunovion. Dr. Vinogradov
   has received consulting fees from AmGen, Brain Plasticity Institute,
   EnVivo, Genentech, and Hoffman La Roche. The other authors report no
   financial relationships with commercial interests.; Dr. Keshavan has
   been supported by NIH grants MH092440 and MH060902. Dr. Vinogradov has
   been supported by NIH grants MH068725, MH082818, MH068725, MH081051, and
   MH081807 and the Stanley Medical Research Institute.; This research is
   based on a workshop sponsored by NIMH that was held on April 9 and 10,
   2012. The workshop participants were Matcheri Keshavan, Harvard
   University (co-chair); Ann Wagner, NIMH (co-chair); Yair Bar-Haim, Tel
   Aviv University; Cameron Carter, University of California Davis; David
   Chambers, NIMH; Bruce Cuthbert, NIMH; Daniel Dickstein, Bradley
   Hospital/Brown University; Amy Dorin, FEGS Health and Human Services
   System, New York; Shaun Eack, University of Pittsburgh; Amit Etkin,
   Stanford University; Adam Gazzaley, University of California San
   Francisco; Russ Glasgow, National Cancer Institute; Adam Haim, NIMH;
   Jeffrey Halperin, Queens College; Courtenay Harding, The Coalition of
   Behavioral Health Agencies, New York; Robert Heinssen, NIMH; Thomas
   Insel, NIMH; Wendy Kates, SUNY Upstate Medical Center; Ellen Leibenluft,
   NIMH; Susan McGurk, Boston University; Alice Medalia, Columbia
   University; Sarah Morris, NIMH; Alvaro Pascual-Leone, Harvard Medical
   School; Daniel Pine, NIMH; Judith Rumsey, NIMH; Christopher Sarampote,
   NIMH; Suzy Scherf, Pennsylvania State University; Joel Sherrill, NIMH;
   David Sommers, NIMH; Leanne Tamm, Cincinnati Children's Hospital Medical
   Center; Carol Tamminga, University of Texas Southwestern Medical Center;
   Sophia Vinogradov, University of California San Francisco; Bruce Wexler,
   Yale University; Til Wykes, University of London Institute of
   Psychiatry.
NR 99
TC 49
Z9 50
U1 9
U2 76
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 0002-953X
EI 1535-7228
J9 AM J PSYCHIAT
JI Am. J. Psychiat.
PD MAY
PY 2014
VL 171
IS 5
BP 510
EP 522
DI 10.1176/appi.ajp.2013.13081075
PG 13
WC Psychiatry
SC Psychiatry
GA AG0SI
UT WOS:000335125500010
PM 24700194
ER

PT J
AU Tregellas, JR
   Smucny, J
   Harris, JG
   Olincy, A
   Maharajh, K
   Kronberg, E
   Eichman, LC
   Lyons, E
   Freedman, R
AF Tregellas, Jason R.
   Smucny, Jason
   Harris, Josette G.
   Olincy, Ann
   Maharajh, Keeran
   Kronberg, Eugene
   Eichman, Lindsay C.
   Lyons, Emma
   Freedman, Robert
TI Intrinsic Hippocampal Activity as a Biomarker for Cognition and Symptoms
   in Schizophrenia
SO AMERICAN JOURNAL OF PSYCHIATRY
LA English
DT Article
ID INDEPENDENT COMPONENT ANALYSIS; TEMPORAL-LOBE ABNORMALITIES; FUNCTIONAL
   CONNECTIVITY; NEGATIVE SYMPTOMS; HEMODYNAMIC-RESPONSE; BRAIN STRUCTURE;
   BATTERY MCCB; FMRI DATA; MEMORY; MRI
AB Objective: Identification of biomarkers for cognitive dysfunction in schizophrenia is a priority for psychiatry research. Functional imaging studies suggest that intrinsic "resting state" hippocampal hyperactivity is a characteristic feature of schizophrenia. The relationships between this phenotype and symptoms of the illness, however, are largely unexplored. The authors examined resting hippocampal activity in schizophrenia patients and healthy comparison subjects and analyzed the relationship between intrinsic hippocampal activity and cognitive function in patients as measured by the MATRICS Consensus Cognitive Battery (MCCB).
   Method: Twenty-eight schizophrenia patients and 28 age-matched healthy comparison subjects underwent functional "resting state" 3-T MR scanning. Hippocampal activity was extracted by group independent component analysis. Correlation analyses were used to examine the relationship between hippocampal activity and MCCB composite and domain scores in patients, as well as between hippocampal activity and positive and negative symptoms.
   Results: Greater activity of the right hippocampus at rest was observed in patients relative to comparison subjects. In patients, a significant negative correlation was observed between right hippocampal activity and composite MCCB T-score. The correlation was driven by the MCCB domains of attention/vigilance, working memory, and visual learning. Hippocampal activity was positively correlated with negative symptoms. MCCB scores were inversely correlated with negative symptoms.
   Conclusions: These findings suggest that greater intrinsic hippocampal activity is a characteristic feature of schizophrenia that is broadly associated with cognitive dysfunction, and they support hippocampal activity as a candidate biomarker for therapeutic development.
C1 [Tregellas, Jason R.] Univ Colorado, Sch Med, Dept Psychiat, Aurora, CO 80045 USA.
   Univ Colorado, Sch Med, Neurosci Program, Aurora, CO USA.
   Denver VA Med Ctr, Res Serv, Denver, CO USA.
RP Tregellas, JR (reprint author), Univ Colorado, Sch Med, Dept Psychiat, Anschutz Med Campus, Aurora, CO 80045 USA.
EM jason.tregellas@ucdenver.edu
RI Tregellas, Jason/J-3637-2015
OI Smucny, Jason/0000-0001-5656-7987
FU NIMH Conte Center Grant [MH-086383]; VA Biomedical Laboratory and
   Clinical Science Research and Development Service; Brain and Behavior
   Research Foundation; Blowitz-Ridgeway Foundation
FX Supported by NIMH Conte Center Grant MH-086383; the VA Biomedical
   Laboratory and Clinical Science Research and Development Service; the
   Brain and Behavior Research Foundation; and the Blowitz-Ridgeway
   Foundation.
NR 57
TC 33
Z9 33
U1 4
U2 22
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 0002-953X
EI 1535-7228
J9 AM J PSYCHIAT
JI Am. J. Psychiat.
PD MAY
PY 2014
VL 171
IS 5
BP 549
EP 556
DI 10.1176/appi.ajp.2013.13070981
PG 8
WC Psychiatry
SC Psychiatry
GA AG0SI
UT WOS:000335125500013
PM 24435071
ER

PT J
AU Ge, L
   Morrel, WG
   Ward, A
   Mishra, R
   Zhang, ZH
   Guccione, JM
   Grossi, EA
   Ratcliffe, MB
AF Ge, Liang
   Morrel, William G.
   Ward, Alison
   Mishra, Rakesh
   Zhang, Zhihong
   Guccione, Julius M.
   Grossi, Eugene A.
   Ratcliffe, Mark B.
TI Measurement of Mitral Leaflet and Annular Geometry and Stress After
   Repair of Posterior Leaflet Prolapse: Virtual Repair Using a
   Patient-Specific Finite Element Simulation
SO ANNALS OF THORACIC SURGERY
LA English
DT Article
ID VALVE REPAIR; LEFT-VENTRICLE; REGURGITATION; ANNULOPLASTY; DISEASE;
   DURABILITY; SOCIETY; MODEL; SHAPE
AB Background. Recurrent mitral regurgitation after mitral valve (MV) repair for degenerative disease occurs at a rate of 2.6% per year and reoperation rate progressively reaches 20% at 19.5 years. We believe that MV repair durability is related to initial postoperative leaflet and annular geometry with subsequent leaflet remodeling due to stress. We tested the hypothesis that MV leaflet and annular stress is increased after MV repair.
   Methods. Magnetic resonance imaging was performed before and intraoperative three-dimensional (3D) transesophageal echocardiography was performed before and after repair of posterior leaflet prolapse in a single patient. The repair consisted of triangular resection and annuloplasty band placement. Images of the heart were manually co-registered. The left ventricle and MV were contoured, surfaced, and a 3D finite element (FE) model was created. Elements of the posterior leaflet region were removed to model leaflet resection and virtual sutures were used to repair the leaflet defect and attach the annuloplasty ring.
   Results. The principal findings of the current study are the following: (1) FE simulation of MV repair is able to accurately predict changes in MV geometry including changes in annular dimensions and leaflet coaptation; (2) average posterior leaflet stress is increased; and (3) average anterior leaflet and annular stress are reduced after triangular resection and mitral annuloplasty.
   Conclusions. We successfully conducted virtual mitral valve prolapse repair using FE modeling methods. Future studies will examine the effects of leaflet resection type as well as annuloplasty ring size and shape. (C) 2014 by The Society of Thoracic Surgeons
C1 Univ Calif San Francisco, Dept Surg, Dept Bioengn, Dept Med, San Francisco, CA 94143 USA.
   Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA.
   Vet Affairs Med Ctr, San Francisco, CA USA.
   New York Sch Med, Dept Cardiothorac Surg, New York, NY USA.
RP Ratcliffe, MB (reprint author), San Francisco VA Med Ctr, Div Surg Serv 112, 4150 Clement St, San Francisco, CA 94121 USA.
EM mark.ratcliffe@va.gov
OI GROSSI, eugene/0000-0002-2066-7035
FU NIH [R01-HL-084431, 077921, 86400]
FX This study was supported by NIH grants R01-HL-084431, 077921 and 86400.
NR 25
TC 7
Z9 7
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
EI 1552-6259
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD MAY
PY 2014
VL 97
IS 5
BP 1496
EP 1503
DI 10.1016/j.athoracsur.2013.12.036
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA AG5HX
UT WOS:000335451200014
PM 24630767
ER

PT J
AU Roussos, P
AF Roussos, Panos
TI The Effect of Dopamine D1 Receptor on Cognitive Performance
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 69th Annual Scientific Convention and Meeting of the
   Society-of-Biological-Psychiatry
CY 2014
CL New York, NY
SP Soc Biol Psychiat
C1 [Roussos, Panos] James J Peters VAMC, Mt Sinai Sch Med, New York, NY USA.
RI Roussos, Panos/J-7090-2013
OI Roussos, Panos/0000-0002-4640-6239
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2014
VL 75
IS 9
SU S
MA 9
BP 4S
EP 4S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA AE6KS
UT WOS:000334101800011
ER

PT J
AU Siever, L
AF Siever, Larry
TI Dihydrexidine and Working Memory in the Schizophrenia Spectrum
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 69th Annual Scientific Convention and Meeting of the
   Society-of-Biological-Psychiatry
CY 2014
CL New York, NY
SP Soc Biol Psychiat
DE Dihydrexidine; working memory; D1 agonist; schizophrenia spectrum;
   schizotpal personality disorder
C1 [Siever, Larry] James J Peters VAMC, Mt Sinai Sch Med, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2014
VL 75
IS 9
SU S
MA 11
BP 4S
EP 5S
PG 2
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA AE6KS
UT WOS:000334101800013
ER

PT J
AU Walsh-Messinger, J
   Ramirez, PM
   Wong, P
   Antonius, D
   Aujero, N
   McMahon, K
   Opler, LA
   Malaspina, D
AF Walsh-Messinger, Julie
   Ramirez, Paul Michael
   Wong, Philip
   Antonius, Daniel
   Aujero, Nicole
   McMahon, Kevin
   Opler, Lewis A.
   Malaspina, Dolores
TI Impairment of Emotional Modulation of Attention and Memory in
   Schizophrenia
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 69th Annual Scientific Convention and Meeting of the
   Society-of-Biological-Psychiatry
CY 2014
CL New York, NY
SP Soc Biol Psychiat
DE Schizophrenia; Emotion Processing; Amygdala; Negative Symptoms
C1 [Walsh-Messinger, Julie] Icahn Sch Med Mt Sinai, New York, NY USA.
   [Walsh-Messinger, Julie] James J Peters VA Med Ctr, VISN Mental Illness Res Educ & Clin Ctr MIRECC 3, Bronx, NY USA.
   [Ramirez, Paul Michael; Wong, Philip] Long Isl Univ, Brooklyn, NY USA.
   [Antonius, Daniel] SUNY Buffalo, Buffalo, NY 14260 USA.
   [Antonius, Daniel] Erie Cty Med Ctr & Labs, Forens Mental Hlth Serv, Buffalo, NY USA.
   [Antonius, Daniel; Aujero, Nicole; McMahon, Kevin] NYU, Sch Med, InSPIRES, New York, NY USA.
   [Opler, Lewis A.] Columbia Univ, New York, NY USA.
   [Malaspina, Dolores] NYU, Sch Med, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2014
VL 75
IS 9
SU S
MA 185
BP 58S
EP 58S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA AE6KS
UT WOS:000334101800179
ER

PT J
AU Lener, MS
   Wong, E
   Tang, CY
   Byne, W
   Goldstein, KE
   Blair, NJ
   Haznedar, MM
   New, AS
   Chemerinski, E
   Chu, KW
   Rimsky, LS
   Siever, LJ
   Koenigsberg, HW
   Hazlett, EA
AF Lener, Marc S.
   Wong, Edmund
   Tang, Cheuk Y.
   Byne, William
   Goldstein, Kim E.
   Blair, Nicholas J.
   Haznedar, M. Mehmet
   New, Antonia S.
   Chemerinski, Eran
   Chu, King-Wai
   Rimsky, Liza S.
   Siever, Larry J.
   Koenigsberg, Harold W.
   Hazlett, Erin A.
TI White Matter Abnormalities in Schizophrenia and Schizotypal Personality
   Disorder
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 69th Annual Scientific Convention and Meeting of the
   Society-of-Biological-Psychiatry
CY 2014
CL New York, NY
SP Soc Biol Psychiat
DE DTI; Schizophrenia; Schizotypal; White Matter; Structural
C1 [Lener, Marc S.; Byne, William; Goldstein, Kim E.; Blair, Nicholas J.; Haznedar, M. Mehmet; New, Antonia S.; Rimsky, Liza S.; Siever, Larry J.; Koenigsberg, Harold W.; Hazlett, Erin A.] Icahn Sch Med Mt Sinai, New York, NY USA.
   [Wong, Edmund; Tang, Cheuk Y.] Icahn Sch Med Mt Sinai, Dept Radiol, Translat & Mol Imaging Inst, New York, NY USA.
   [Byne, William; Blair, Nicholas J.; New, Antonia S.; Chemerinski, Eran; Chu, King-Wai; Siever, Larry J.; Hazlett, Erin A.] Mental Illness Res Educ & Clin Ctr MIRECC VISN 3, James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
   [Byne, William; Haznedar, M. Mehmet; New, Antonia S.; Chemerinski, Eran; Siever, Larry J.; Koenigsberg, Harold W.] James J Peters Vet Affairs Med Ctr, Outpatient Psychiat Dept, Bronx, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2014
VL 75
IS 9
SU S
MA 337
BP 107S
EP 108S
PG 2
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA AE6KS
UT WOS:000334101800331
ER

PT J
AU Sher, L
   Grunebaum, MF
   Sullivan, GM
   Burke, AK
   Cooper, TB
   Mann, JJ
   Oquendo, MA
AF Sher, Leo
   Grunebaum, Michael F.
   Sullivan, Gregory M.
   Burke, Ainsley K.
   Cooper, Thomas B.
   Mann, J. John
   Oquendo, Maria A.
TI The Association of Testosterone Levels and Suicide Attempts in Women
   with Bipolar Disorder: A Prospective Study
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 69th Annual Scientific Convention and Meeting of the
   Society-of-Biological-Psychiatry
CY 2014
CL New York, NY
SP Soc Biol Psychiat
DE Testosterone; Bipolar; Suicide; Female; Prospective study
C1 [Sher, Leo] James J Peters VA Med Ctr, New York, NY USA.
   [Sher, Leo] Icahn Sch Med Mt Sinai, New York, NY USA.
   [Sher, Leo; Grunebaum, Michael F.; Sullivan, Gregory M.; Burke, Ainsley K.; Cooper, Thomas B.; Mann, J. John; Oquendo, Maria A.] New York State Psychiat Inst & Hosp, New York, NY 10032 USA.
   [Sher, Leo; Grunebaum, Michael F.; Sullivan, Gregory M.; Burke, Ainsley K.; Cooper, Thomas B.; Mann, J. John; Oquendo, Maria A.] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2014
VL 75
IS 9
SU S
MA 352
BP 112S
EP 113S
PG 2
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA AE6KS
UT WOS:000334101800346
ER

PT J
AU Loewy, R
   Fulford, D
   Pearson, R
   Hua, J
   Schlosser, D
   Stuart, BK
   Wolkowitz, O
   Epel, E
   Mathalon, D
   Vinogradov, S
AF Loewy, Rachel
   Fulford, Daniel
   Pearson, Rahel
   Hua, Jessica
   Schlosser, Danielle
   Stuart, Barbara K.
   Wolkowitz, Owen
   Epel, Elissa
   Mathalon, Daniel
   Vinogradov, Sophia
TI Childhood Trauma, Cortisol Response to Psychosocial Stressors and Risk
   for Psychosis
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 69th Annual Scientific Convention and Meeting of the
   Society-of-Biological-Psychiatry
CY 2014
CL New York, NY
SP Soc Biol Psychiat
DE Schizophrenia; Psychosis; Risk; Trauma; Stress
C1 [Loewy, Rachel; Fulford, Daniel; Hua, Jessica; Schlosser, Danielle; Stuart, Barbara K.; Wolkowitz, Owen; Epel, Elissa; Mathalon, Daniel; Vinogradov, Sophia] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Pearson, Rahel] Univ Texas Austin, Austin, TX 78712 USA.
   [Mathalon, Daniel; Vinogradov, Sophia] San Francisco VA Med Ctr, San Francisco, CA USA.
NR 0
TC 1
Z9 1
U1 1
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2014
VL 75
IS 9
SU S
MA 364
BP 116S
EP 116S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA AE6KS
UT WOS:000334101800358
ER

PT J
AU Perez-Rodriguez, MD
AF Perez-Rodriguez, Maria De Las Mercedes
TI Neuropeptides and BDNF and Emotion Dysregulation in Borderline
   Personality Disorder
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 69th Annual Scientific Convention and Meeting of the
   Society-of-Biological-Psychiatry
CY 2014
CL New York, NY
SP Soc Biol Psychiat
DE BDNF; amygdala; habituation; borderline personality disorder; emotion
   processing
C1 [Perez-Rodriguez, Maria De Las Mercedes] Icahn Sch Med Mt Sinai, New York, NY USA.
   [Perez-Rodriguez, Maria De Las Mercedes] James J Peters VAMC, MIRECC, Bronx, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2014
VL 75
IS 9
SU S
MA 537
BP 147S
EP 147S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA AE6KS
UT WOS:000334101801038
ER

PT J
AU Kling, MA
   Appleby, DH
   Zhu, HJ
   Motsinger-Reif, AA
   Matson, W
   Arnold, SE
   Kaddurah-Daouk, R
AF Kling, Mitchel A.
   Appleby, Dina H.
   Zhu, Hongjie
   Motsinger-Reif, Alison A.
   Matson, Wayne
   Arnold, Steven E.
   Kaddurah-Daouk, Rima
CA Pharmacometabolomics Res Network
TI Perturbations in Metabolic Pathways in Alzheimer-type Dementia and Mild
   Cognitive Impairment: Translational Implications
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 69th Annual Scientific Convention and Meeting of the
   Society-of-Biological-Psychiatry
CY 2014
CL New York, NY
SP Soc Biol Psychiat
DE Metabolomics; Alzheimer; networks; pathways; biomarkers
C1 [Kling, Mitchel A.; Appleby, Dina H.; Arnold, Steven E.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Kling, Mitchel A.] Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA.
   [Zhu, Hongjie; Kaddurah-Daouk, Rima] Duke Univ, Sch Med, Dept Psychiat & Behav Sci, Durham, NC USA.
   [Motsinger-Reif, Alison A.] N Carolina State Univ, Dept Stat, Raleigh, NC 27695 USA.
   [Matson, Wayne] Bedford VA Med Ctr, Dept Syst Biochem, Bedford, MA USA.
   [Arnold, Steven E.] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2014
VL 75
IS 9
SU S
MA 599
BP 168S
EP 168S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA AE6KS
UT WOS:000334101801100
ER

PT J
AU Yao, JK
AF Yao, Jeffrey K.
TI Metabolic Perturbations of Monoamine Pathways in Schizophrenia
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 69th Annual Scientific Convention and Meeting of the
   Society-of-Biological-Psychiatry
CY 2014
CL New York, NY
SP Soc Biol Psychiat
DE Monoamine Pathways; Schizophrenia; First-episode psychosis;
   Neuroleptic-naive; Targeted metabolomics
C1 [Yao, Jeffrey K.] VA Pittsburgh Healthcare Syst, Med Res Serv, Pittsburgh, PA USA.
   [Yao, Jeffrey K.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2014
VL 75
IS 9
SU S
MA 600
BP 168S
EP 168S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA AE6KS
UT WOS:000334101801101
ER

PT J
AU Rimsky, L
   Reddan, M
   Brosch, T
   Koenigsberg, H
   Schiller, D
AF Rimsky, Liza
   Reddan, Marianne
   Brosch, Tobias
   Koenigsberg, Harold
   Schiller, Daniela
TI The Fundamental Attribution Error in Borderline Personality Disorder
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 69th Annual Scientific Convention and Meeting of the
   Society-of-Biological-Psychiatry
CY 2014
CL New York, NY
SP Soc Biol Psychiat
DE fundamental attribution error; borderline personality disorder;
   affective neuroscience; social decision-making
C1 [Rimsky, Liza; Koenigsberg, Harold; Schiller, Daniela] Icahn Sch Med Mt Sinai, New York, NY USA.
   [Rimsky, Liza; Koenigsberg, Harold] James J Peters Bronx VA Med Ctr, Bronx, NY USA.
   [Reddan, Marianne] Univ Colorado Boulder, Boulder, CO USA.
   [Brosch, Tobias] Univ Geneva, Geneva, Switzerland.
NR 0
TC 0
Z9 0
U1 2
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2014
VL 75
IS 9
SU S
MA 698
BP 199S
EP 200S
PG 2
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA AE6KS
UT WOS:000334101801198
ER

PT J
AU Soehner, AM
   Saletin, J
   Kaplan, KA
   Talbot, LS
   Hairston, IS
   Eidelman, P
   Gruber, J
   Walker, MP
   Harvey, AG
AF Soehner, Adriane M.
   Saletin, Jared
   Kaplan, Katherine A.
   Talbot, Lisa S.
   Hairston, Ilana S.
   Eidelman, Polina
   Gruber, June
   Walker, Matthew P.
   Harvey, Allison G.
TI You'll Feel Better in the Morning: Slow Wave Activity and Overnight Mood
   Regulation in Bipolar Disorder
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 69th Annual Scientific Convention and Meeting of the
   Society-of-Biological-Psychiatry
CY 2014
CL New York, NY
SP Soc Biol Psychiat
DE Sleep; Mood
C1 [Soehner, Adriane M.; Saletin, Jared; Walker, Matthew P.; Harvey, Allison G.] Univ Calif Berkeley, Berkeley, CA 94720 USA.
   [Kaplan, Katherine A.] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA.
   [Talbot, Lisa S.] San Francisco VA Med Ctr, San Francisco, CA USA.
   [Hairston, Ilana S.] Univ Michigan, Ann Arbor, MI 48109 USA.
   [Eidelman, Polina] San Francisco Bay Area Ctr Cognit Therapy, Oakland, CA USA.
   [Gruber, June] Yale Univ, New Haven, CT USA.
NR 0
TC 0
Z9 0
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2014
VL 75
IS 9
SU S
MA 697
BP 199S
EP 199S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA AE6KS
UT WOS:000334101801197
ER

PT J
AU Fryer, SL
   Brandel, M
   Ford, JM
   Turner, JA
   Van Erp, TG
   Voyvodic, J
   Belger, A
   Bustillo, J
   O'Leary, D
   Mueller, B
   Calhoun, VD
   Wible, C
   Potkin, SG
   Mathalon, DH
AF Fryer, Susanna L.
   Brandel, Michael
   Ford, Judith M.
   Turner, Jessica A.
   Van Erp, Theodorus G.
   Voyvodic, James
   Belger, Aysenil
   Bustillo, Juan
   O'Leary, Daniel
   Mueller, Bryon
   Calhoun, Vince D.
   Wible, Cindy
   Potkin, Steven G.
   Mathalon, Daniel H.
CA FBIRN
TI Amplitude of Low Frequency Fluctuation Reductions in Schizophrenia
   Relate to Neurocognitive Performance: An Fbirn Study
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 69th Annual Scientific Convention and Meeting of the
   Society-of-Biological-Psychiatry
CY 2014
CL New York, NY
SP Soc Biol Psychiat
DE attention; executive functioning; psychosis; resting-state fMRI;
   cognitive biomarker
C1 [Fryer, Susanna L.; Brandel, Michael; Ford, Judith M.; Mathalon, Daniel H.] UCSF Sch Med, San Francisco, CA USA.
   [Fryer, Susanna L.; Brandel, Michael; Ford, Judith M.; Mathalon, Daniel H.] San Francisco VA Med Ctr, San Francisco, CA USA.
   [Turner, Jessica A.; Calhoun, Vince D.] Mind Res Network, Albuquerque, NM USA.
   [Van Erp, Theodorus G.; Potkin, Steven G.] Univ Calif Irvine, Irvine, CA USA.
   [Voyvodic, James] Duke Univ, Raleigh, NC USA.
   [Belger, Aysenil] Univ N Carolina, Chapel Hill, NC USA.
   [Bustillo, Juan] Univ New Mexico, Albuquerque, NM 87131 USA.
   [O'Leary, Daniel] Univ Iowa, Iowa City, IA USA.
   [Mueller, Bryon] Univ Minnesota, Minneapolis, MN USA.
   [Wible, Cindy] Harvard Univ, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2014
VL 75
IS 9
SU S
MA 715
BP 205S
EP 205S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA AE6KS
UT WOS:000334101801215
ER

PT J
AU Jahshan, C
   Wynn, JK
   Lee, J
   Horan, WP
   Mathis, KI
   Green, MF
AF Jahshan, Carol
   Wynn, Jonathan K.
   Lee, Junghee
   Horan, William P.
   Mathis, Kristopher I.
   Green, Michael F.
TI The Neurophysiology of Biological Motion Perception in Schizophrenia
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 69th Annual Scientific Convention and Meeting of the
   Society-of-Biological-Psychiatry
CY 2014
CL New York, NY
SP Soc Biol Psychiat
DE biological motion; motion perception; EEG; mu suppression; schizophrenia
C1 [Jahshan, Carol; Wynn, Jonathan K.; Lee, Junghee; Horan, William P.; Green, Michael F.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA.
   [Jahshan, Carol; Wynn, Jonathan K.; Lee, Junghee; Horan, William P.; Mathis, Kristopher I.; Green, Michael F.] VA Greater Los Angeles Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Los Angeles, CA USA.
RI Wynn, Jonathan/H-3749-2014
OI Wynn, Jonathan/0000-0002-1763-8540
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2014
VL 75
IS 9
SU S
MA 714
BP 205S
EP 205S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA AE6KS
UT WOS:000334101801214
ER

PT J
AU Light, GA
   Rissling, AJ
   Miyakoshi, M
   Sugar, CA
   Braff, DL
   Makeig, S
AF Light, Gregory A.
   Rissling, Anthony J.
   Miyakoshi, Makoto
   Sugar, Catherine A.
   Braff, David L.
   Makeig, Scott
TI Deconstructing the Neural Substrates and Functional Correlates of
   Sensory Processing Impairments in Schizophrenia
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 69th Annual Scientific Convention and Meeting of the
   Society-of-Biological-Psychiatry
CY 2014
CL New York, NY
SP Soc Biol Psychiat
DE schizophrenia; cognition; biomarker; EEG; function
C1 [Light, Gregory A.; Rissling, Anthony J.; Braff, David L.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA.
   [Light, Gregory A.; Braff, David L.] VA San Diego Healthcare Syst, Mental Illness Res Educ & Clin Ctr MIRECC VISN 22, San Diego, CA USA.
   [Miyakoshi, Makoto; Makeig, Scott] Univ Calif San Diego, Inst Neural Computat, Swartz Ctr Computat Neurosci, La Jolla, CA 92093 USA.
   [Sugar, Catherine A.] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA USA.
   [Sugar, Catherine A.] Univ Calif Los Angeles, Dept Biostat, Los Angeles, CA USA.
   [Sugar, Catherine A.] Greater Los Angeles VA Healthcare Syst, Mental Illness Res Educ & Clin Ctr MIRECC VISN 22, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2014
VL 75
IS 9
SU S
MA 716
BP 205S
EP 206S
PG 2
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA AE6KS
UT WOS:000334101801216
ER

PT J
AU Koenigsberg, HW
   Denny, B
   Fan, J
   Liu, X
   Rimsky, L
   McMaster, A
   New, AS
   Siever, LJ
AF Koenigsberg, Harold W.
   Denny, Bryan
   Fan, Jin
   Liu, Xun
   Rimsky, Liza
   McMaster, Antonia
   New, Antonia S.
   Siever, Larry J.
TI Affective Instability in Personality Disorder Patients is Inversely
   Correlated with Anterior Cingulate Activity during Habituation to
   Negative Stimuli
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 69th Annual Scientific Convention and Meeting of the
   Society-of-Biological-Psychiatry
CY 2014
CL New York, NY
SP Soc Biol Psychiat
DE Affective Instability; Borderline Personality Disorder; Avoidant
   Personality Disorder; Emotion Regulation; Habituation
C1 [Koenigsberg, Harold W.; Denny, Bryan; Fan, Jin; Liu, Xun; Rimsky, Liza; McMaster, Antonia; New, Antonia S.; Siever, Larry J.] Icahn Sch Med Mt Sinai, New York, NY USA.
   [Koenigsberg, Harold W.] James J Peters VA Med Ctr, Mental Hlth Patinet Care Ctr, Bronx, NY USA.
   [Fan, Jin] Queens Coll, Queens, NY USA.
   [Liu, Xun] Chinese Acad Sci, Inst Psychol, Beijing, Peoples R China.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2014
VL 75
IS 9
SU S
MA 828
BP 242S
EP 242S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA AE6KS
UT WOS:000334101801328
ER

PT J
AU Mathalon, DH
   Perkins, D
   Walker, E
   Addington, J
   Bearden, C
   Cadenhead, K
   Cornblatt, B
   McGlashan, T
   Seidman, L
   Tsuang, M
   Woods, S
   Cannon, TD
AF Mathalon, Daniel H.
   Perkins, Diana
   Walker, Elaine
   Addington, Jean
   Bearden, Carrie
   Cadenhead, Kristin
   Cornblatt, Barbara
   McGlashan, Thomas
   Seidman, Larry
   Tsuang, Ming
   Woods, Scott
   Cannon, Tyrone D.
CA NAPLS Consortium
TI Impaired Synaptic Plasticity, Synaptic Over-pruning, Inflammation, and
   Stress: A Pathogenic Model of the Transition to Psychosis in Clinical
   High Risk Youth
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 69th Annual Scientific Convention and Meeting of the
   Society-of-Biological-Psychiatry
CY 2014
CL New York, NY
SP Soc Biol Psychiat
DE Prodrome; Psychosis; Gray Matter; Mismatch Negativity; Inflamamtion
C1 [Mathalon, Daniel H.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Mathalon, Daniel H.] San Francisco VA Med Ctr, San Francisco, CA USA.
   [Perkins, Diana] Univ N Carolina, Raleigh Durham, NC USA.
   [Walker, Elaine] Emory Univ, Atlanta, GA 30322 USA.
   [Addington, Jean] Univ Calgary, Calgary, AB, Canada.
   [Bearden, Carrie] Univ Calif Los Angeles, Los Angeles, CA USA.
   [Cadenhead, Kristin; Tsuang, Ming] Univ Calif San Diego, San Diego, CA 92103 USA.
   [Cornblatt, Barbara] Hillside Hosp, New York, NY USA.
   [McGlashan, Thomas; Woods, Scott] Yale Univ, New Haven, CT USA.
   [Seidman, Larry] Harvard Univ, Boston, MA 02115 USA.
   [Cannon, Tyrone D.] Yale Univ, New Haven, CT USA.
NR 0
TC 0
Z9 0
U1 2
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2014
VL 75
IS 9
SU S
MA 1009
BP 277S
EP 278S
PG 2
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA AE6KS
UT WOS:000334101802010
ER

PT J
AU Davis, MC
   Green, MF
   Lee, J
   Horan, WP
   Wynn, JK
   Marder, SR
AF Davis, Michael C.
   Green, Michael F.
   Lee, Junghee
   Horan, William P.
   Wynn, Jonathan K.
   Marder, Stephen R.
TI Can Oxytocin Enhance Learning During Social Cognitive Skills Training in
   Schizophrenia?
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 69th Annual Scientific Convention and Meeting of the
   Society-of-Biological-Psychiatry
CY 2014
CL New York, NY
SP Soc Biol Psychiat
DE oxytocin; schizophrenia; social cognition; social cognitive skills
   training; empathy
C1 [Davis, Michael C.; Green, Michael F.; Lee, Junghee; Horan, William P.; Wynn, Jonathan K.; Marder, Stephen R.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA.
   [Davis, Michael C.; Green, Michael F.; Lee, Junghee; Horan, William P.; Wynn, Jonathan K.; Marder, Stephen R.] VA Greater Los Angeles, VISN Mental Illness Res Educ & Clin Ctr 22, Los Angeles, CA USA.
RI Wynn, Jonathan/H-3749-2014
OI Wynn, Jonathan/0000-0002-1763-8540
NR 0
TC 0
Z9 0
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2014
VL 75
IS 9
SU S
MA 1163
BP 326S
EP 326S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA AE6KS
UT WOS:000334101802156
ER

PT J
AU Perez-Rodriguez, MM
   Rothstein, E
   Rimsky, L
   Hoque, N
   Lichtman, T
   McMaster, A
   Chowdhury, S
   Mascitelli, K
   Bevilacqua, L
   Ungar, A
   Ripoll, L
   Goldman, D
   Hodgkinson, C
   Goodman, M
   New, AS
   Siever, LJ
AF Perez-Rodriguez, M. Mercedes
   Rothstein, Ethan
   Rimsky, Liza
   Hoque, Nabila
   Lichtman, Tamar
   McMaster, Antonia
   Chowdhury, Salwa
   Mascitelli, Katie
   Bevilacqua, Laura
   Ungar, Allison
   Ripoll, Luis
   Goldman, David
   Hodgkinson, Colin
   Goodman, Marianne
   New, Antonia S.
   Siever, Larry J.
TI Arginine Vasopressin Receptor Gene Variants Associated with Aggression,
   Borderline and Schizotypal Personality Disorder
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 69th Annual Scientific Convention and Meeting of the
   Society-of-Biological-Psychiatry
CY 2014
CL New York, NY
SP Soc Biol Psychiat
DE Vasopressin; Borderline personality disorder; Schizotypal personality
   disorder; SNP; Aggression
C1 [Perez-Rodriguez, M. Mercedes; Rothstein, Ethan; Rimsky, Liza; Hoque, Nabila; Lichtman, Tamar; McMaster, Antonia; Chowdhury, Salwa; Mascitelli, Katie; Ungar, Allison; Ripoll, Luis; Goodman, Marianne; New, Antonia S.; Siever, Larry J.] Icahn Sch Med Mt Sinai, New York, NY USA.
   [Perez-Rodriguez, M. Mercedes; Rothstein, Ethan; Rimsky, Liza; Hoque, Nabila; Lichtman, Tamar; McMaster, Antonia; Chowdhury, Salwa; Mascitelli, Katie; Goodman, Marianne; New, Antonia S.; Siever, Larry J.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
   [Bevilacqua, Laura; Goldman, David; Hodgkinson, Colin] NIAAA, Neurogenet Lab, NIH, Bethesda, MD USA.
RI Perez Rodriguez, Maria/B-9410-2013
OI Perez Rodriguez, Maria/0000-0001-5137-1993
NR 0
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2014
VL 75
IS 9
SU S
MA 1239
BP 349S
EP 349S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA AE6KS
UT WOS:000334101802232
ER

PT J
AU Kling, MA
   Goodenowe, DB
   Appleby, DH
   Xie, SX
   Arnold, SE
   Bennett, DA
AF Kling, Mitchel A.
   Goodenowe, Dayan B.
   Appleby, Dina H.
   Xie, Sharon X.
   Arnold, Steven E.
   Bennett, David A.
TI Mixed-effects Model Analysis of Serum Phospholipids in Alzheimer-type
   Dementia
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 69th Annual Scientific Convention and Meeting of the
   Society-of-Biological-Psychiatry
CY 2014
CL New York, NY
SP Soc Biol Psychiat
DE Lipidomics; Plasmalogens; Alzheimer's Disease; Biomarkers; Mass
   spectrometry
C1 [Kling, Mitchel A.; Appleby, Dina H.; Arnold, Steven E.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Kling, Mitchel A.] Philadelphia VA Med Ctr, Behav Hlth Serv, Philadelphia, PA USA.
   [Goodenowe, Dayan B.] Phenomenome Discoveries Inc, Off CEO, Saskatoon, SK, Canada.
   [Xie, Sharon X.] Univ Penn, Ctr Clin Epidemiol & Biostat, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Arnold, Steven E.] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Bennett, David A.] Rush Med Coll, Dept Neurol Sci, Chicago, IL 60612 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2014
VL 75
IS 9
SU S
MA 1253
BP 354S
EP 354S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA AE6KS
UT WOS:000334101802246
ER

PT J
AU Walsh-Messinger, J
   Ramirez, PM
   Wong, P
   McMahon, K
   Malone, T
   Opler, LA
   Malaspina, D
AF Walsh-Messinger, Julie
   Ramirez, Paul Michael
   Wong, Philip
   McMahon, Kevin
   Malone, Tara
   Opler, Lewis A.
   Malaspina, Dolores
TI Associations between Olfactory Hedonics and Smell Identification Vary by
   Sex in Schizophrenia Cases and Healthy Controls
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 69th Annual Scientific Convention and Meeting of the
   Society-of-Biological-Psychiatry
CY 2014
CL New York, NY
SP Soc Biol Psychiat
DE Olfaction; Schizophrenia; Sex Differences
C1 [Walsh-Messinger, Julie] Icahn Sch Med Mt Sinai, New York, NY USA.
   [Walsh-Messinger, Julie] James J Peters VA Med Ctr, MIRECC, Bronx, NY USA.
   [Ramirez, Paul Michael; Wong, Philip] Long Isl Univ, Brooklyn, NY USA.
   [McMahon, Kevin; Malone, Tara] NYU, Sch Med, InSPIRES, New York, NY USA.
   [Opler, Lewis A.] Columbia Univ, New York, NY USA.
   [Malaspina, Dolores] NYU, Sch Med, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2014
VL 75
IS 9
SU S
MA 1382
BP 395S
EP 396S
PG 2
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA AE6KS
UT WOS:000334101802375
ER

PT J
AU Lim, M
   Elkind, J
   Xiong, GX
   Rodin, J
   Galante, R
   Zhu, JX
   Zhang, L
   Lian, J
   Kuzma, N
   Pack, A
   Cohen, A
AF Lim, Miranda
   Elkind, Jaclynn
   Xiong, Guoxing
   Rodin, Julianna
   Galante, Ray
   Zhu, Jingxu
   Zhang, Lin
   Lian, Jie
   Kuzma, Nicholas
   Pack, Allan
   Cohen, Akiva
TI Mild TBI causes sleep disturbances which are mitigated by dietary
   therapy
SO BRAIN INJURY
LA English
DT Meeting Abstract
C1 [Lim, Miranda] Portland VA Med Ctr, Portland, OR USA.
   [Elkind, Jaclynn; Xiong, Guoxing; Cohen, Akiva] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
   [Rodin, Julianna; Galante, Ray; Zhu, Jingxu; Zhang, Lin; Lian, Jie; Kuzma, Nicholas; Pack, Allan] Univ Penn, Philadelphia, PA 19104 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0269-9052
EI 1362-301X
J9 BRAIN INJURY
JI Brain Inj.
PD MAY
PY 2014
VL 28
IS 5-6
MA 0005
BP 517
EP 518
PG 2
WC Neurosciences; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA AF9EA
UT WOS:000335017000003
ER

PT J
AU Pape, T
   Rosenow, J
   Steiner, M
   Parrish, T
   Guernon, A
   Harton, B
   McNamee, S
   Patil, V
   Walker, M
   Froelich, K
   Burress, C
   Odle, C
   Wang, X
   Herrold, A
   Zhao, WH
   Reda, D
   Coneely, M
   Nemeth, A
AF Pape, Theresa
   Rosenow, Joshua
   Steiner, Monica
   Parrish, Todd
   Guernon, Ann
   Harton, Brett
   McNamee, Shane
   Patil, Vijaya
   Walker, Matthew
   Froelich, Kathleen
   Burress, Catherine
   Odle, Cheryl
   Wang, Xue
   Herrold, Amy
   Zhao, Weihan
   Reda, Domenic
   Coneely, Mark
   Nemeth, Alexander
TI Therapeutic effect of familiar auditory sensory training for acute
   severe traumatic brain injury from a placebo-controlled trial
SO BRAIN INJURY
LA English
DT Meeting Abstract
C1 [Pape, Theresa; Steiner, Monica; Harton, Brett; Patil, Vijaya; Odle, Cheryl; Herrold, Amy; Reda, Domenic] US Dept Vet Affairs, Hines, VA USA.
   [Pape, Theresa; Steiner, Monica; Harton, Brett; Patil, Vijaya; Odle, Cheryl; Herrold, Amy; Reda, Domenic] US Dept Vet Affairs, Hines, IL USA.
   [Rosenow, Joshua; Parrish, Todd; Wang, Xue] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Guernon, Ann] Marianjoy Rehabil Hosp, Wheaton, IL USA.
   [McNamee, Shane] US Dept Vet Affairs, Hunter Holmes McGuire VAMC, Richmond, VA USA.
   [Walker, Matthew] Northshore Univ Hlth Syst, Evanston, IL USA.
   [Froelich, Kathleen; Burress, Catherine] Rehabil Inst Chicago, Chicago, IL 60611 USA.
   [Zhao, Weihan] Univ IL Chicago, Chicago, IL USA.
   [Coneely, Mark] Captain James A Lovell VAMC, N Chicago, IL USA.
   [Nemeth, Alexander] NW Mem Hosp, Chicago, IL 60611 USA.
   Loyola Univ Chicago, Stritch Sch Med, Maywood, IL USA.
NR 0
TC 0
Z9 0
U1 1
U2 4
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0269-9052
EI 1362-301X
J9 BRAIN INJURY
JI Brain Inj.
PD MAY
PY 2014
VL 28
IS 5-6
MA 0144
BP 566
EP 566
PG 1
WC Neurosciences; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA AF9EA
UT WOS:000335017000126
ER

PT J
AU Krych, D
   Biester, R
   Parrott, D
   Schmidt, MJ
   Murphy, MP
AF Krych, David
   Biester, Rosette
   Parrott, Devan
   Schmidt, M. J.
   Murphy, Mary Pat
TI Individuals with TBI and their significant others' perceptions of
   information given about the nature and possible consequences of brain
   injury: Analysis of a national survey
SO BRAIN INJURY
LA English
DT Meeting Abstract
C1 [Krych, David; Schmidt, M. J.; Murphy, Mary Pat] ReMed Recovery Care Ctr, Paoli, PA USA.
   [Biester, Rosette] Philadelphia VA Med Ctr, Philadelphia, PA USA.
   [Parrott, Devan] Rehabil Hosp Indiana, Indianapolis, IN USA.
   [Biester, Rosette] Univ Penn, Philadelphia, PA 19104 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0269-9052
EI 1362-301X
J9 BRAIN INJURY
JI Brain Inj.
PD MAY
PY 2014
VL 28
IS 5-6
MA 0219
BP 592
EP 592
PG 1
WC Neurosciences; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA AF9EA
UT WOS:000335017000189
ER

PT J
AU Jaramillo, C
   Eapen, B
   Robinson, J
   Amuan, M
   McGeary, C
   McGeary, D
   Pugh, MJ
AF Jaramillo, Carlos
   Eapen, Blessen
   Robinson, Jedediah
   Amuan, Megan
   McGeary, Cindy
   McGeary, Don
   Pugh, Mary Jo
TI Traumatic brain injury and common comorbidities associated with
   prevalence and persistence post-deployment headaches among US veterans
   of Afghanistan and Iraq wars
SO BRAIN INJURY
LA English
DT Meeting Abstract
C1 [Jaramillo, Carlos; Eapen, Blessen; Amuan, Megan; Pugh, Mary Jo] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
   [Robinson, Jedediah] Univ Texas Hlth Sci Ctr San Antonio, Dept Rehabil Medicien, San Antonio, TX 78229 USA.
   [McGeary, Cindy; McGeary, Don] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA.
   [Amuan, Megan] Edith Nourse Rogers Mem VA Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0269-9052
EI 1362-301X
J9 BRAIN INJURY
JI Brain Inj.
PD MAY
PY 2014
VL 28
IS 5-6
MA 0498
BP 700
EP 700
PG 1
WC Neurosciences; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA AF9EA
UT WOS:000335017000446
ER

PT J
AU Jaramillo, C
   Eapen, B
   Tate, D
   York, G
   Amuan, M
   Wang, CP
   Pugh, MJ
AF Jaramillo, Carlos
   Eapen, Blessen
   Tate, David
   York, Gerry
   Amuan, Megan
   Wang, Chen-Pin
   Pugh, Mary Jo
TI Post-deployment symptom clusters and associations with traumatic brain
   injury in US veterans of the Afghanistan and Iraq wars
SO BRAIN INJURY
LA English
DT Meeting Abstract
C1 [Jaramillo, Carlos; Eapen, Blessen; Wang, Chen-Pin; Pugh, Mary Jo] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
   [Tate, David; York, Gerry] Def & Vet Brain Injury Ctr, San Antonio, TX USA.
   [Amuan, Megan] Edith Nourse Rogers Mem VA Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA.
RI Tate, David/I-3963-2013
NR 0
TC 0
Z9 0
U1 0
U2 0
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0269-9052
EI 1362-301X
J9 BRAIN INJURY
JI Brain Inj.
PD MAY
PY 2014
VL 28
IS 5-6
MA 0500
BP 701
EP 701
PG 1
WC Neurosciences; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA AF9EA
UT WOS:000335017000448
ER

PT J
AU Pape, T
   Rosenow, J
   Patil, V
   Steiner, M
   Harton, B
   Wang, X
   Parrish, T
   Bhaumik, D
   Conneely, M
   Nemeth, A
   Guernon, A
   Zhao, WH
   Herrold, A
   Kletzel, S
AF Pape, Theresa
   Rosenow, Joshua
   Patil, Vijaya
   Steiner, Monica
   Harton, Brett
   Wang, Xue
   Parrish, Todd
   Bhaumik, Dulal
   Conneely, Mark
   Nemeth, Alexander
   Guernon, Ann
   Zhao, Weihan
   Herrold, Amy
   Kletzel, Sandra
TI TMS related changes in functional connectivity of default mode network
   and associated neurobehavioural gains for subjects in vegetative state
   after traumatic brain injury
SO BRAIN INJURY
LA English
DT Meeting Abstract
C1 [Pape, Theresa; Patil, Vijaya; Steiner, Monica; Harton, Brett; Herrold, Amy; Kletzel, Sandra] US Dept Vet Affairs, Hines, IL USA.
   [Rosenow, Joshua; Wang, Xue; Parrish, Todd; Nemeth, Alexander] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Bhaumik, Dulal; Zhao, Weihan] Univ Illinois, Chicago, IL USA.
   [Conneely, Mark] Fed Hlth Care Ctr, N Chicago, IL USA.
   [Guernon, Ann] Marianjoy Rehabiitat Hosp, Wheaton, IL USA.
NR 0
TC 0
Z9 0
U1 3
U2 9
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0269-9052
EI 1362-301X
J9 BRAIN INJURY
JI Brain Inj.
PD MAY
PY 2014
VL 28
IS 5-6
MA 0517
BP 708
EP 708
PG 1
WC Neurosciences; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA AF9EA
UT WOS:000335017000463
ER

PT J
AU Pugh, MJ
   Orman, J
   Jaramillo, C
   Salinsky, M
   McNamee, S
   Eapen, B
   Towne, A
   Grafman, J
AF Pugh, Mary Jo
   Orman, Jean
   Jaramillo, Carlos
   Salinsky, Martin
   McNamee, Shane
   Eapen, Blessen
   Towne, Alan
   Grafman, Jordan
TI The prevalence of epilepsy and association with traumatic brain injury
   in veterans of the Afghanistan and Iraq wars
SO BRAIN INJURY
LA English
DT Meeting Abstract
C1 [Pugh, Mary Jo; Jaramillo, Carlos; Eapen, Blessen] South Texas Vet Healthcare Syst, San Antonio, TX USA.
   [Orman, Jean] US Army, Inst Surg Res, San Antonio, TX USA.
   [Salinsky, Martin] Portland VA Med Ctr, Portland, OR USA.
   [McNamee, Shane; Towne, Alan] Hunter Holmes McGuire VA Med Ctr, Richmond, VA USA.
   [Grafman, Jordan] Rehabil Inst Chicago, Chicago, IL 60611 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0269-9052
EI 1362-301X
J9 BRAIN INJURY
JI Brain Inj.
PD MAY
PY 2014
VL 28
IS 5-6
MA 0781
BP 807
EP 807
PG 1
WC Neurosciences; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA AF9EA
UT WOS:000335017000706
ER

PT J
AU Smart, O
   Kuzma, N
   Lim, MM
AF Smart, Otis
   Kuzma, Nicholas
   Lim, Miranda M.
TI EEG cross-frequency coupling in mild traumatic brain injury
SO BRAIN INJURY
LA English
DT Meeting Abstract
C1 [Smart, Otis] Emory Univ, Atlanta, GA 30322 USA.
   [Kuzma, Nicholas] Portland State Univ, Portland, OR 97207 USA.
   [Lim, Miranda M.] Portland VA Med Ctr, Portland, OR USA.
   [Lim, Miranda M.] Oregon Hlth & Sci Univ, Div Sleep Med, Portland, OR 97201 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0269-9052
EI 1362-301X
J9 BRAIN INJURY
JI Brain Inj.
PD MAY
PY 2014
VL 28
IS 5-6
MA 0783
BP 808
EP 808
PG 1
WC Neurosciences; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA AF9EA
UT WOS:000335017000708
ER

PT J
AU Carlson, K
   O'Neil, M
   McAndrew, L
   Storzbach, D
   Cifu, D
   Sayer, N
AF Carlson, Kathleen
   O'Neil, Maya
   McAndrew, Lisa
   Storzbach, Daniel
   Cifu, David
   Sayer, Nina
TI Risk of hospitalization due to motor vehicle crashes among Iraq and
   Afghanistan war veterans diagnosed with traumatic brain injury
SO BRAIN INJURY
LA English
DT Meeting Abstract
C1 [Carlson, Kathleen; O'Neil, Maya; Storzbach, Daniel] Portland VA Med Ctr, Portland, OR USA.
   [McAndrew, Lisa] VA New Jersey Hlth Care Syst, E Orange, NJ USA.
   [Cifu, David] Hunter Holmes McGuire VA Med Ctr, Richmond, VA USA.
   [Sayer, Nina] Minneapolis VA Hlth Care Syst, Minneapolis, MN USA.
RI Sayer, Nina/E-3249-2016
NR 0
TC 0
Z9 0
U1 0
U2 2
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0269-9052
EI 1362-301X
J9 BRAIN INJURY
JI Brain Inj.
PD MAY
PY 2014
VL 28
IS 5-6
MA 0836
BP 830
EP 830
PG 1
WC Neurosciences; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA AF9EA
UT WOS:000335017000758
ER

PT J
AU Norman, R
   Jaramillo, C
   Eapen, B
   Amuan, M
   Pugh, MJ
AF Norman, Rocio
   Jaramillo, Carlos
   Eapen, Blessen
   Amuan, Megan
   Pugh, Mary Jo
TI Stuttering (fluency disorders) and traumatic brain injury in US veterans
   of Iraq and Afghanistan
SO BRAIN INJURY
LA English
DT Meeting Abstract
C1 [Norman, Rocio; Jaramillo, Carlos; Eapen, Blessen; Pugh, Mary Jo] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
   [Amuan, Megan] Edith Nourse Rogers Mem Vet Adm Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA 01730 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0269-9052
EI 1362-301X
J9 BRAIN INJURY
JI Brain Inj.
PD MAY
PY 2014
VL 28
IS 5-6
MA 0862
BP 840
EP 840
PG 1
WC Neurosciences; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA AF9EA
UT WOS:000335017000782
ER

PT J
AU Rodriguez, N
   Loya, F
   Binder, D
   Buchanan, B
   Novakovic-Agopian, T
   Murphy, M
   Bruhns, M
   Chen, A
AF Rodriguez, Nicholas
   Loya, Fred
   Binder, Deborah
   Buchanan, Bruce
   Novakovic-Agopian, Tatjana
   Murphy, Michelle
   Bruhns, Maya
   Chen, Anthony
TI 'Working your way up' from simple to complex situations in game-assisted
   training of attention regulation for individuals with brain injury
SO BRAIN INJURY
LA English
DT Meeting Abstract
C1 [Rodriguez, Nicholas; Loya, Fred; Binder, Deborah; Bruhns, Maya] VA Northern Calif Hlth Care Syst, Martinez, CA USA.
   [Buchanan, Bruce] Univ Calif Berkeley, Berkeley, CA 94720 USA.
   [Novakovic-Agopian, Tatjana; Murphy, Michelle] San Francisco VA Med Ctr, San Francisco, CA USA.
   [Chen, Anthony] Univ Calif San Francisco, San Francisco, CA 94143 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0269-9052
EI 1362-301X
J9 BRAIN INJURY
JI Brain Inj.
PD MAY
PY 2014
VL 28
IS 5-6
MA 0883
BP 848
EP 848
PG 1
WC Neurosciences; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA AF9EA
UT WOS:000335017000801
ER

PT J
AU Nachega, JB
   Parienti, JJ
   Uthman, OA
   Gross, R
   Dowdy, DW
   Sax, PE
   Gallant, JE
   Mugavero, MJ
   Mills, EJ
   Giordano, TP
AF Nachega, Jean B.
   Parienti, Jean-Jacques
   Uthman, Olalekan A.
   Gross, Robert
   Dowdy, David W.
   Sax, Paul E.
   Gallant, Joel E.
   Mugavero, Michael J.
   Mills, Edward J.
   Giordano, Thomas P.
TI Lower Pill Burden and Once-Daily Antiretroviral Treatment Regimens for
   HIV Infection: A Meta-Analysis of Randomized Controlled Trials
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE randomized controlled trials; ART; fixed-dose combination; once-daily;
   twice-daily
ID TWICE-DAILY LOPINAVIR/RITONAVIR; FIXED-DOSE COMBINATION;
   QUALITY-OF-LIFE; VIROLOGICALLY SUPPRESSED PATIENTS;
   REVERSE-TRANSCRIPTASE INHIBITORS; NON-INFERIORITY TRIAL; HIV-1-INFECTED
   PATIENTS; MEDICATION ADHERENCE; VIRAL SUPPRESSION; TREATMENT-NAIVE
AB Background. Contemporary antiretroviral treatment regimens are simpler than in the past, with lower pill burden and once-daily dosing frequency common. We performed a meta-analysis of randomized controlled trials (RCTs) to investigate the impact of pill burden and once-daily vs twice-daily dosing on ART adherence and virological outcomes.
   Methods. A literature search of 4 electronic databases through 31 March 2013 was used. RCTs comparing once-daily vs twice-daily ART regimens that also reported on adherence and virological suppression were included. Study design, study population characteristics, intervention, outcome measures, and study quality were extracted. Study quality was rated using the Cochrane risk-of-bias tool.
   Results. Nineteen studies met our inclusion criteria (N = 6312 adult patients). Higher pill burden was associated with both lower adherence rates (P = .004) and worse virological suppression (P < .0001) in both once-daily and twice-daily subgroups, although the association with adherence in the once-daily subgroup was not statistically significant. The average adherence was modestly higher in once-daily regimens than twice-daily regimens (weighted mean difference = 2.55%; 95% confidence interval [CI], 1.23 to 3.87; P = .0002). Patients on once-daily regimens did not achieve virological suppression more frequently than patients on twice-daily regimens (relative risk [RR] = 1.01; 95% CI, 0.99 to 1.03; P = .50). Both adherence and viral load suppression decreased over time, but adherence decreased less with once-daily dosing than with twice-daily dosing.
   Conclusions. Lower pill burden was associated with both better adherence and virological suppression. Adherence, but not virological suppression, was slightly better with once- vs twice-daily regimens.
C1 [Nachega, Jean B.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15261 USA.
   [Nachega, Jean B.; Dowdy, David W.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
   [Nachega, Jean B.; Dowdy, David W.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA.
   [Nachega, Jean B.] Univ Stellenbosch, Dept Med, Cape Town, South Africa.
   [Nachega, Jean B.] Univ Stellenbosch, Fac Med & Hlth Sci, Ctr Infect Dis, Cape Town, South Africa.
   [Parienti, Jean-Jacques] Cote de Nacre Univ, Cote de Nacre Teaching Hosp, Dept Biostat & Clin Res, Caen, France.
   [Parienti, Jean-Jacques] Univ Caen Basse Normandie, Fac Med, EA Risque Microbien 4655, Caen, France.
   [Uthman, Olalekan A.] Univ Warwick, Warwick Med Sch, Warwick Ctr Appl Hlth Res & Delivery WCARHD, Div Hlth Sci, Coventry CV4 7AL, W Midlands, England.
   [Uthman, Olalekan A.] Univ Liverpool Liverpool Sch Trop Med, Int Hlth Grp, Liverpool, Merseyside, England.
   [Uthman, Olalekan A.] Univ Stellenbosch, Fac Hlth Sci, Ctr Evidence Based Hlth Care, Cape Town, South Africa.
   [Gross, Robert] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Gross, Robert] Univ Penn, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
   [Sax, Paul E.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
   [Gallant, Joel E.] Southwest CARE Ctr, Santa Fe, NM USA.
   [Mugavero, Michael J.] Univ Alabama Birmingham, Birmingham, AL USA.
   [Mills, Edward J.] Univ Ottawa, Fac Hlth Sci, Ottawa, ON K1N 6N5, Canada.
   [Giordano, Thomas P.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
   [Giordano, Thomas P.] Michael E DeBakey VA Med Ctr, Ctr Innovat Qual Effectiveness & Safety, Houston, TX USA.
RP Nachega, JB (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Infect Dis Epidemiol Program, 130 DeSoto St,503 Parran Hall, Pittsburgh, PA 15261 USA.
EM jbn16@pitt.edu
OI Uthman, Olalekan/0000-0002-8567-3081
FU US National Institutes for Allergy and Infectious Disease-National
   Institutes of Health (NIAID-NIH), AIDS Clinical Trial Group (ACTG),
   Stellenbosch University (SU)-Clinical Trial Unit (CTU) Award
   [2UM1AI069521-08]; US NIH-Fogarty International Center (FIC)/Health
   Resources and Services Administration (HRSA)/US President Emergency Plan
   for AIDS Relief (PEPFAR) Grant Award [T84HA21652-01-00]; European
   Developing Countries Clinical Trial Partnership (EDCTP) Senior
   Fellowship Award [TA-08-40200-021]; Wellcome Trust Southern Africa
   Consortium for Research Excellence (SACORE) [WT087537MA]; National
   Institutes of Mental Health NIMH-NIH [R34 MH083592-01A1]; Penn Center
   for AIDS Research (CFAR), an NIH [P30 AI 045008]; Department of Veteran
   Affairs Health Services Research and Development Center [CIN 13-413];
   Agence Nationale de Recherche contre le SIDA (ANRS)/Institut National de
   la Sante et de la Recherche Medicale (INSERM) ATIP Avenir Post-Doc
   program [2012-YY1137]; NIH; NIAID-NIH [UM1AI069412]
FX The US National Institutes for Allergy and Infectious Disease-National
   Institutes of Health (NIAID-NIH), AIDS Clinical Trial Group (ACTG),
   Stellenbosch University (SU)-Clinical Trial Unit (CTU) Award:
   2UM1AI069521-08 (J. B. N.); the US NIH-Fogarty International Center
   (FIC)/Health Resources and Services Administration (HRSA)/US President
   Emergency Plan for AIDS Relief (PEPFAR) Grant Award, T84HA21652-01-00
   for Medical Education Partnership Initiative (MEPI) (J. B. N.); the
   European Developing Countries Clinical Trial Partnership (EDCTP) Senior
   Fellowship Award: TA-08-40200-021 (J. B. N.); the Wellcome Trust
   Southern Africa Consortium for Research Excellence (SACORE): WT087537MA
   (J. B. N.); the National Institutes of Mental Health NIMH-NIH R34
   MH083592-01A1 (E. J. M.). FAS Marie Curie International Post Doc:
   2012-0064 (O. A. U.); the Penn Center for AIDS Research (CFAR), an
   NIH-funded program (P30 AI 045008) (R. G.). The Department of Veteran
   Affairs Health Services Research and Development Center Grant Award CIN
   13-413 (T. P. G.). Agence Nationale de Recherche contre le SIDA
   (ANRS)/Institut National de la Sante et de la Recherche Medicale
   (INSERM) ATIP Avenir Post-Doc program: 2012-YY1137 (J. J. P.); NIH
   Grant; NIAID-NIH Grant Award: UM1AI069412 (P. S.).
NR 88
TC 75
Z9 77
U1 1
U2 7
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD MAY 1
PY 2014
VL 58
IS 9
BP 1297
EP 1307
DI 10.1093/cid/ciu046
PG 11
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AF9AJ
UT WOS:000335006900016
PM 24457345
ER

PT J
AU Smith, A
   Doutrich, D
   Goudreau, K
   Guido, G
   Eddy, L
AF Smith, Alexandra
   Doutrich, Dawn
   Goudreau, Kelly
   Guido, Ginny
   Eddy, Linda
TI Exemplar Describing the Clinical Nurse Specialist's Three Spheres of
   Influence in the Development of a Programmatic Intervention for Chronic
   Persistent Pain
SO CLINICAL NURSE SPECIALIST
LA English
DT Meeting Abstract
C1 [Smith, Alexandra] Portland VA Med Ctr, Bend, OR USA.
   [Doutrich, Dawn; Guido, Ginny; Eddy, Linda] Washington State Univ, Vancouver, WA USA.
   [Goudreau, Kelly] Southern Oregon Rehabil Ctr & Clin, White City, OR USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0887-6274
EI 1538-9782
J9 CLIN NURSE SPEC
JI Clin. Nurse Spec.
PD MAY-JUN
PY 2014
VL 28
IS 3
BP 174
EP 175
PG 2
WC Nursing
SC Nursing
GA AF7XW
UT WOS:000334929800016
ER

PT J
AU Archer, M
AF Archer, Molly
TI Implantable Cardioverter Defibrillators ( ICD): Effects of Enhanced
   Education on Self-efficacy and Device Acceptance
SO CLINICAL NURSE SPECIALIST
LA English
DT Meeting Abstract
C1 [Archer, Molly] Portland VA Med Ctr, Scappoose, OR USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0887-6274
EI 1538-9782
J9 CLIN NURSE SPEC
JI Clin. Nurse Spec.
PD MAY-JUN
PY 2014
VL 28
IS 3
BP 176
EP 177
PG 2
WC Nursing
SC Nursing
GA AF7XW
UT WOS:000334929800021
ER

PT J
AU Slane, JD
   Klump, KL
   McGue, M
   Iacono, G
AF Slane, Jennifer D.
   Klump, Kelly L.
   McGue, Matthew
   Iacono, G.
TI Genetic and Environmental Factors Underlying Comorbid Bulimic Behaviours
   and Alcohol Use Disorders: A Moderating Role for the Dysregulated
   Personality Cluster?
SO EUROPEAN EATING DISORDERS REVIEW
LA English
DT Article
DE bulimia nervosa; alcohol use disorders; personality
ID SUBSTANCE USE DISORDERS; POPULATION-BASED TWIN; EATING-DISORDERS;
   PSYCHIATRIC-DISORDERS; NERVOSA; WOMEN; DEPENDENCE; ABUSE; HERITABILITY;
   SAMPLE
AB Women with bulimia nervosa (BN) frequently have co-occurring alcohol use disorders (AUDs). Studies of shared genetic transmission of these disorders have been mixed. Personality heterogeneity among individuals with BN may explain discrepant findings. Cluster analysis has characterized women with BN in groups on the basis of personality profiles. One group, the Dysregulated cluster, characterized largely by behavioural disinhibition and emotional dysregulation may be more closely linked etiologically to AUDs. This study examined whether genetic associations between BN and AUDs are the strongest among the Dysregulated cluster. Symptoms of BN and AUDs were assessed in female twins at ages 17 and 25years from the Minnesota Twin Family Study. Personality clusters were defined using the Multidimensional Personality Questionnaire. Twin moderation models suggested small-to-moderate common genetic transmission between BN and AUDs. However, shared genetic effects did not differ by personality cluster. Findings suggest that personality clusters are unlikely to account for inconsistent findings regarding their shared aetiology. Copyright (c) 2014 John Wiley & Sons, Ltd and Eating Disorders Association.
C1 [Slane, Jennifer D.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res 4, Educ & Clin Ctr, Pittsburgh, PA 15240 USA.
   [Slane, Jennifer D.] Univ Pittsburgh, Med Ctr, Dept Psychiat, Pittsburgh, PA USA.
   [Klump, Kelly L.] Michigan State Univ, Dept Psychol, E Lansing, MI 48824 USA.
   [McGue, Matthew; Iacono, G.] Univ Minnesota, Dept Psychol, Minneapolis, MN 55455 USA.
RP Slane, JD (reprint author), VA Pittsburgh Healthcare Syst, Univ Dr, Pittsburgh, PA 15240 USA.
EM slane@msu.edu
FU NIAAA NIH HHS [R01 AA009367]
NR 52
TC 3
Z9 3
U1 2
U2 23
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1072-4133
EI 1099-0968
J9 EUR EAT DISORD REV
JI Eur. Eat. Disord. Rev.
PD MAY
PY 2014
VL 22
IS 3
BP 159
EP 169
DI 10.1002/erv.2284
PG 11
WC Psychology, Clinical
SC Psychology
GA AE7IT
UT WOS:000334171700059
PM 24616026
ER

PT J
AU Lee, LC
   Genet, M
   Dang, AB
   Ge, L
   Guccione, JM
   Ratcliffe, MB
AF Lee, Lik Chuan
   Genet, Martin
   Dang, Alan B.
   Ge, Liang
   Guccione, Julius M.
   Ratcliffe, Mark B.
TI Applications of Computational Modeling in Cardiac Surgery
SO JOURNAL OF CARDIAC SURGERY
LA English
DT Article
ID FINITE-ELEMENT MODEL; ISCHEMIC MITRAL REGURGITATION; LEFT-VENTRICULAR
   MECHANICS; CHRONIC HEART-FAILURE; IN-VIVO; WALL STRESS; SUPPORT DEVICE;
   BORDER ZONE; OVINE MODEL; ANNULOPLASTY
AB Although computational modeling is common in many areas of science and engineering, only recently have advances in experimental techniques and medical imaging allowed this tool to be applied in cardiac surgery. Despite its infancy in cardiac surgery, computational modeling has been useful in calculating the effects of clinical devices and surgical procedures. In this review, we present several examples that demonstrate the capabilities of computational cardiac modeling in cardiac surgery. Specifically, we demonstrate its ability to simulate surgery, predict myofiber stress and pump function, and quantify changes to regional myocardial material properties. In addition, issues that would need to be resolved in order for computational modeling to play a greater role in cardiac surgery are discussed. doi: 10.1111/jocs.12332 (J Card Surg 2014;29:293-302)
C1 [Lee, Lik Chuan; Genet, Martin; Ge, Liang; Guccione, Julius M.; Ratcliffe, Mark B.] Univ Calif San Francisco, Dept Surg, San Francisco, CA USA.
   [Lee, Lik Chuan; Genet, Martin; Dang, Alan B.; Ge, Liang; Guccione, Julius M.; Ratcliffe, Mark B.] Univ Calif San Francisco, Dept Bioengn, San Francisco, CA 94143 USA.
   [Lee, Lik Chuan; Genet, Martin; Dang, Alan B.; Ge, Liang; Guccione, Julius M.; Ratcliffe, Mark B.] Vet Affairs Med Ctr, San Francisco, CA 94121 USA.
   [Dang, Alan B.] Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA USA.
RP Ratcliffe, MB (reprint author), San Francisco VA Med Ctr, Div Surg Serv 112, 4150 Clement St, San Francisco, CA 94121 USA.
EM mark.ratcliffe@va.gov
RI Genet, Martin/H-4247-2015
OI Genet, Martin/0000-0003-2204-201X
FU NIH [R01-HL-084431, R01-HL-077921, R01-HL-118627, R01-HL-63348]
FX Grant sponsor: NIH; Grant numbers: R01-HL-084431; R01-HL-077921;
   R01-HL-118627; R01-HL-63348
NR 48
TC 9
Z9 9
U1 1
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0886-0440
EI 1540-8191
J9 J CARDIAC SURG
JI J. Card. Surg.
PD MAY
PY 2014
VL 29
IS 3
BP 293
EP 302
DI 10.1111/jocs.12332
PG 10
WC Cardiac & Cardiovascular Systems; Surgery
SC Cardiovascular System & Cardiology; Surgery
GA AG1IQ
UT WOS:000335168900001
PM 24708036
ER

PT J
AU Brennan, CW
   Olds, DM
   Dolansky, M
   Estrada, CA
   Patrician, PA
AF Brennan, Caitlin W.
   Olds, Danielle M.
   Dolansky, Mary
   Estrada, Carlos A.
   Patrician, Patricia A.
TI Learning by doing: observing an interprofessional process as an
   interprofessional team
SO JOURNAL OF INTERPROFESSIONAL CARE
LA English
DT Article
DE Interprofessional collaboration; interprofessional education;
   interprofessional evaluation; teams
ID EDUCATION; PROGRAM; QUALITY
AB New competencies exist for interprofessional education, which are centered on the goal of improving quality of care and patient safety through improved interprofessional collaboration. Interprofessional education and effective interprofessional collaboration are cornerstones of the Veterans Affairs Quality Scholars fellowship program. The purpose of this project was to evaluate an innovative interprofessional education strategy in which teams of physicians and nurses were "learning by doing'' as they observed and analyzed the functioning of an interprofessional process, specifically, inpatient discharge. Fellows completed voluntary, anonymous surveys seeking their perspectives about the project. Fellows' feedback revealed several themes, with both positive and negative characteristics related to team functioning, interprofessional understanding, microsystem knowledge, pooled knowledge and assignment challenges. The strength of this strategy is exemplified by the fact that fellows not only learned from each other's separate professional observations, but also observed the emergence of a shared interprofessional perspective through working together.
C1 [Brennan, Caitlin W.] NIH, Ctr Clin, Dept Nursing Res & Practice Dev, Bethesda, MD 20892 USA.
   [Olds, Danielle M.] Univ Kansas, Med Ctr, NDNQI, Kansas City, KS 66103 USA.
   [Dolansky, Mary] Case Western Reserve Univ, Frances Payne Bolton Sch Nursing, Cleveland, OH 44106 USA.
   [Estrada, Carlos A.] Univ Alabama Birmingham, Birmingham VA Med Ctr, Birmingham, AL USA.
   [Patrician, Patricia A.] Univ Alabama Birmingham, Birmingham, AL USA.
RP Brennan, CW (reprint author), NIH, Ctr Clin, Dept Nursing, 10 Ctr Dr,Room 2B08, Bethesda, MD 20892 USA.
EM caitlin.brennan@nih.gov
FU Intramural NIH HHS [Z99 CL999999]
NR 6
TC 5
Z9 5
U1 0
U2 7
PU INFORMA HEALTHCARE
PI NEW YORK
PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA
SN 1356-1820
EI 1469-9567
J9 J INTERPROF CARE
JI J. Interprofessional Care
PD MAY
PY 2014
VL 28
IS 3
BP 249
EP 251
DI 10.3109/13561820.2013.838750
PG 3
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA AG2DI
UT WOS:000335225800012
PM 24070019
ER

PT J
AU Delgado, C
   Ward, P
   Chertow, GM
   Storer, L
   Dalrymple, L
   Block, T
   Kaysen, GA
   Kornak, J
   Grimes, B
   Kutner, NG
   Johansen, KL
AF Delgado, Cynthia
   Ward, Patricia
   Chertow, Glenn M.
   Storer, Lindsey
   Dalrymple, Lorien
   Block, Torin
   Kaysen, George A.
   Kornak, John
   Grimes, Barbara
   Kutner, Nancy G.
   Johansen, Kirsten L.
TI Calibration of the Brief Food Frequency Questionnaire Among Patients on
   Dialysis
SO JOURNAL OF RENAL NUTRITION
LA English
DT Article
ID NATIONAL-CANCER-INSTITUTE; DIETARY ASSESSMENT; HEMODIALYSIS-PATIENTS;
   HISTORY QUESTIONNAIRE; NUTRITIONAL EPIDEMIOLOGY; RECORDS; VALIDITY;
   RECALL; HEMO; ASSOCIATION
AB Objective: Estimating dietary intake is challenging in patients with chronic diseases. The aim of this study was to calibrate the Block Brief 2000 food frequency questionnaire (BFFQ) using 3-day food diary records among patients on dialysis.
   Methods: Data from 3-day food diary records from 146 patients new to dialysis were reviewed and entered into National Cancer Institute self-administered 24-hour dietary recall (ASA24), a web-based dietary interview system. The information was then re-entered omitting foods reported in the diaries that were not in the BFFQ to generate a "BFFQ-restricted'' set of intakes. We modeled each major dietary component (i.e., energy [total calories], protein, carbohydrate, fat) separately using linear regression. The main independent variables were BFFQ-restricted food diary estimates computed as the average of the 3 days of diaries, restricted to items included in the BFFQ, with the unrestricted 3-day food diary averages as dependent variables.
   Results: The BFFQ-restricted diary energy estimate of 1,325 +/- 545 kcal was 87% of the energy intake in the full food diary (1,510.3 +/- 510.4, P < .0001). The BFFQ-restricted diary carbohydrate intake was 83% of the full food diary (156.7 +/- 78.7 g vs. 190.4 +/- 72.7, P < .0001). The BFFQ-restricted fat intake was 90% of the full-diary-reported fat intake (50.1 +/- 24.1 g vs. 56.4 +/- 21.6 g, P < . 0001). Daily protein intake assessments were not statistically different by BFFQ-restricted diary and full diary assessment (63.1 +/- 28.5 vs. 64.1 +/- 21.4 g, P = .60). The associations between BFFQ-restricted diary intake and unrestricted intake were linear. Three-day diary-reported intake could be estimated from BFFQ-restricted intake with r(2) ranging from 0.36 to 0.56 (P < .0001 for energy [total calories], protein, carbohydrate, and fat). Final equations did not include adjustments for age, sex, or race because the patterns of associations were not significantly different.
   Conclusion: Energy and macronutrient estimates by BFFQ are lower than estimates from 3-day food diaries, but simple calibration equations can be used to approximate total intake from BFFQ responses. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.
C1 [Delgado, Cynthia; Storer, Lindsey; Johansen, Kirsten L.] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA.
   [Delgado, Cynthia; Storer, Lindsey; Johansen, Kirsten L.] San Francisco VA Med Ctr, San Francisco, CA USA.
   [Ward, Patricia] Emory Univ, Dept Rehabil Med, Atlanta, GA 30322 USA.
   [Chertow, Glenn M.] Stanford Univ, Sch Med, Div Nephrol, Palo Alto, CA 94304 USA.
   [Chertow, Glenn M.; Kaysen, George A.; Kornak, John; Grimes, Barbara; Johansen, Kirsten L.] US Renal Data Syst Nutr Special Studies, San Francisco, CA USA.
   [Dalrymple, Lorien; Kaysen, George A.] Univ Calif Davis, Div Nephrol, Davis, CA 95616 USA.
   [Block, Torin] NutritionQuest, Berkeley, CA USA.
   [Kornak, John; Grimes, Barbara] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
RP Delgado, C (reprint author), San Francisco Dept Vet Affairs, 4150 Clement St,Box 111J, San Francisco, CA 94121 USA.
EM cynthia.delgado@ucsf.edu
FU USRDS Nutrition Special Studies Center [N01-DK-7-0005]
FX This project is sponsored by the USRDS Nutrition Special Studies Center
   (N01-DK-7-0005). The interpretation and reporting of the data presented
   here are the responsibility of the authors and in no way should be seen
   as an official policy or interpretation of the US government.
NR 29
TC 1
Z9 1
U1 1
U2 8
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 1051-2276
EI 1532-8503
J9 J RENAL NUTR
JI J. Renal Nutr.
PD MAY
PY 2014
VL 24
IS 3
BP 151
EP U30
DI 10.1053/j.jrn.2013.12.004
PG 7
WC Nutrition & Dietetics; Urology & Nephrology
SC Nutrition & Dietetics; Urology & Nephrology
GA AG3JZ
UT WOS:000335313500004
PM 24613023
ER

PT J
AU Stephenson, K
   Meston, C
AF Stephenson, Kyle
   Meston, Cindy
TI WHY IS IMPAIRED SEXUAL FUNCTION DISTRESSING TO WOMEN? THE PRIMACY OF
   PLEASURE IN FEMALE SEXUAL DYSFUNCTION
SO JOURNAL OF SEXUAL MEDICINE
LA English
DT Meeting Abstract
C1 [Stephenson, Kyle] VA Puget Sound Healthcare Syst, Seattle, WA USA.
   [Meston, Cindy] Univ Texas Austin, Austin, TX 78712 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1743-6095
EI 1743-6109
J9 J SEX MED
JI J. Sex. Med.
PD MAY
PY 2014
VL 11
SU 4
MA 2
BP 225
EP 225
PG 1
WC Urology & Nephrology
SC Urology & Nephrology
GA AG0FM
UT WOS:000335091300036
ER

PT J
AU Sattui, SE
   Singh, JA
   Gaffo, AL
AF Sattui, Sebastian E.
   Singh, Jasvinder A.
   Gaffo, Angelo L.
TI Comorbidities in Patients with Crystal Diseases and Hyperuricemia
SO RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
LA English
DT Article
DE Crystal arthropathies; Comorbidities; Gout; Hyperuricemia;
   Cardiovascular disease; Metabolic syndrome; Renal disease; Calcium
   pyrophosphate arthropathy
ID SERUM URIC-ACID; CHRONIC-KIDNEY-DISEASE; PERIPHERAL ARTERIAL-DISEASE;
   INDUCED METABOLIC SYNDROME; DIHYDRATE DEPOSITION DISEASE;
   CARDIOMETABOLIC RISK-FACTORS; NUTRITION EXAMINATION SURVEY;
   XANTHINE-OXIDASE INHIBITION; MULTIPLE-SCLEROSIS PATIENTS;
   CALCIUM-PHOSPHATE CRYSTALS
AB Crystal arthropathies are among the most common causes of painful inflammatory arthritis. Gout, the most common example, has been associated with cardiovascular and renal disease. In recent years, evidence for these associations and those involving other comorbidities, such as the metabolic syndrome, have emerged, and the importance of asymptomatic hyperuricemia has been established. In this review, an update on evidence, both experimental and clinical, is presented, and associations between hyperuricemia, gout, and several comorbidities are described.. Causality regarding calcium pyrophosphate arthropathy and associated comorbidities is also reviewed.
C1 [Sattui, Sebastian E.] Univ Alabama Birmingham, Sch Med, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA.
   [Singh, Jasvinder A.] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit C SMART, Med Serv, Birmingham, AL 35233 USA.
   [Singh, Jasvinder A.] Univ Alabama, Sch Med, Dept Med, Div Clin Immunol & Rheumatol, Rochester, MN 55905 USA.
   [Singh, Jasvinder A.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA.
   [Gaffo, Angelo L.] Vet Affairs Med Ctr, Rheumatol Sect, Birmingham, AL 35233 USA.
   [Gaffo, Angelo L.] Univ Alabama Birmingham, Sch Med, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA.
RP Gaffo, AL (reprint author), Univ Alabama Birmingham, Sch Med, Dept Med, 1720 2nd Ave Suth,FOT 1203, Birmingham, AL 35294 USA.
EM agaffo@uab.edu
FU Savient; Takeda; Regeneron; Allergan; Agency for Health Quality and
   Research Center for Education and Research on Therapeutics (CERTs);
   National Institute of Arthritis, Musculoskeletal and Skin Diseases
   (NIAMS); National-Institute of Aging (NIA); National Cancer Institute
   (NCI); Birmingham VA Medical Center
FX S.E. Sattui and A.L. Gaffo have no conflict of interest. J.A. Singh has
   received research grants from Takeda and Savient and consultant fees
   from Savient, Takeda, Allergan, and Regeneron. J.A. Singh is supported
   by grants from the Agency for Health Quality and Research Center for
   Education and Research on Therapeutics (CERTs), National Institute of
   Arthritis, Musculoskeletal and Skin Diseases (NIAMS), National-Institute
   of Aging (NIA), and National Cancer Institute (NCI) and the resources
   and use of facilities at the Birmingham VA Medical Center, AL.
NR 214
TC 12
Z9 13
U1 0
U2 12
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0889-857X
EI 1558-3163
J9 RHEUM DIS CLIN N AM
JI Rheum. Dis. Clin. North Am.
PD MAY
PY 2014
VL 40
IS 2
BP 251
EP +
DI 10.1016/j.rdc.2014.01.005
PG 29
WC Rheumatology
SC Rheumatology
GA AG4WO
UT WOS:000335421300008
PM 24703346
ER

PT J
AU Lawson, EH
   Hall, BL
   Louie, R
   Zingmond, DS
   Ko, CY
AF Lawson, Elise H.
   Hall, Bruce Lee
   Louie, Rachel
   Zingmond, David S.
   Ko, Clifford Y.
TI Identification of modifiable factors for reducing readmission after
   colectomy: A national analysis
SO SURGERY
LA English
DT Article
ID LENGTH-OF-STAY; COLORECTAL SURGERY; HOSPITAL READMISSIONS;
   QUALITY-IMPROVEMENT; CLAIMS DATA; MORTALITY; REGISTRY
AB Background. Rates of hospital readmission are currently used for public reporting and pay for performance. Colectomy procedures account for a large number of readmissions among operative procedures. Our objective was to compare the importance of 3 groups of clinical variables (demographics, preoperative risk factors, and postoperative complications) in predicting readmission after colectomy procedures.
   Methods. Patient records (2005-2008) from the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) were linked to Medicare inpatient claims. Patient demographics (n = 2), preoperative risk factors (n = 23), and 30-day postoperative complications (n = 17) were identified from ACS-NSQIP, whereas 30-day postoperative readmissions and costs were determined from Medicare. Multivariable logistic regression models were used to examine risk-adjusted predictors of colectomy readmission.
   Results. Among 12,981 colectomy patients, the 30-day postoperative readmission rate was 13.5%. Readmitted patients had slightly greater rates of comorbidities and indicators of clinical severity and substantially greater rates of complications than non-readmitted patients. After risk adjustment, patients with a complication were 3.3 times as likely to be readmitted as patients without a complication. Among individual complications, progressive renal failure and organ-space surgical site infection had the highest risk-adjusted relative risks of readmission (4.6 and 4.0, respectively). Demographic, preoperative risk factor, and postoperative complication variables increased the dbility to discriminate readmissions (reflected by the c-statistic) by 5.3%, 23.3%, and 35.4%, respectively.
   Conclusion. Postoperative complications after colectomy are more predictive of readmiSsion than traditional risk factors. Focusing quality improvement efforts on preventing and managing postoperative complications may be the most important step toward reducing readmission rates.
C1 [Lawson, Elise H.; Ko, Clifford Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA.
   [Lawson, Elise H.; Hall, Bruce Lee; Ko, Clifford Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL USA.
   [Lawson, Elise H.; Ko, Clifford Y.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
   [Hall, Bruce Lee] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA.
   [Hall, Bruce Lee] Barnes Jewish Hosp, St Louis, MO 63110 USA.
   [Hall, Bruce Lee] Washington Univ, Ctr Hlth Policy, St Louis, MO USA.
   [Hall, Bruce Lee] Washington Univ, Olin Business Sch, St Louis, MO USA.
   [Hall, Bruce Lee] John Cochran Vet Affairs Med Ctr, Dept Surg, St Louis, MO USA.
   [Louie, Rachel; Zingmond, David S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
RP Lawson, EH (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, 10833 Le Conte Ave 72-215 CHS, Los Angeles, CA 90095 USA.
EM elawson@mednet.ucla.edu
FU Centers for Medicare & Medicaid Services (CMS); American College of
   Surgeons through the Robert Wood Johnson Foundation Clinical Scholars
   Program; VA Health Services Research and Development program [RWJ
   65-020]
FX E.H.L. and C.Y.K. are Former RWJF Clinical Scholars. This study was
   partially funded by a contract from the Centers for Medicare & Medicaid
   Services (CMS). EHL's time was supported by the VA Health Services
   Research and Development program (RWJ 65-020) and the American College
   of Surgeons through the Robert Wood Johnson Foundation Clinical Scholars
   Program. For the remaining authors, none were declared.
NR 18
TC 17
Z9 17
U1 1
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0039-6060
J9 SURGERY
JI Surgery
PD MAY
PY 2014
VL 155
IS 5
BP 754
EP 766
DI 10.1016/j.surg.2013.12.016
PG 13
WC Surgery
SC Surgery
GA AG3BP
UT WOS:000335291100005
PM 24787101
ER

PT J
AU Scales, CD
   Saigal, CS
   Hanley, JM
   Dick, AW
   Setodji, CM
   Litwin, MS
AF Scales, Charles D., Jr.
   Saigal, Christopher S.
   Hanley, Janet M.
   Dick, Andrew W.
   Setodji, Claude M.
   Litwin, Mark S.
CA NIDDK Urologic Dis Amer Project
TI The impact of unplanned postprocedure visits in the management of
   patients with urinary stones
SO SURGERY
LA English
DT Article
ID UNITED-STATES; URETERAL CALCULI; KIDNEY-STONES; READMISSIONS; SURGERY;
   VOLUME; UROLITHIASIS; PREVALENCE; CYSTECTOMY; HOSPITALS
AB Background. Unplanned follow-up care is the focus of intense health policy interest, as evidenced by recent financial penalties imposed under the Affordable Care Act. To date, however, unplanned postoperative care remains poorly characterized, particularly for patients with kidney stones. Our objective was to describe the frequency, variation, and financial impact of unplanned, high-acuity, follow-up visits in the treatment of patients with urinary stone disease.
   Methods. We identified privately insured patients undergoing percutaneous nephrostolithotomy,,ureteroscopy, or shock-wave lithotripsy for stone disease. The primary outcome was occurrence of an emergency department visit or hospital admission within 30 days of the procedure. Multivariable models estimated the odds of an unplanned visit and the incremental cost of those visits, controlling for important covariates.
   Results. We identified 93,523 initial procedures to fragment or remove stones. Overall, 1 in 7 patients had an unplanned postprocedural visit. Unplanned visits were least common after shock-wave lithotripsy (12%) and occurred with similar frequency after ureteroscopy and percutaneous nephrostolithotomy (15%). Procedures at high-volume facilities were substantially less likely to result in an unplanned visit (odds ratio 0.80, 95% confidence interval [95% CI] 0.74-0.87, P <.001). When an unplanned visit occurred, adjusted incremental expenditures per episode were greater after shockwave lithotripsy ($32,156 [95% CI $30,453-33,859]) than after ureteroscopy ($23,436 [95% CI $22,281-24,590]).
   Conclusion. Patients not infrequently experience an unplanned, high-acuity visit after low-risk procedures to remove urinary stones, and the cost of these encounters is substantial. Interventions are indicated to identify and reduce preventable unplanned visits.
C1 [Scales, Charles D., Jr.] Univ Calif Los Angeles, David Geffen Sch Med, Robert Wood Johnson Fdn, Clin Scholars Program, Los Angeles, CA 90095 USA.
   [Scales, Charles D., Jr.] Univ Calif Los Angeles, David Geffen Sch Med, US Dept Vet Affairs, Los Angeles, CA 90095 USA.
   [Scales, Charles D., Jr.; Saigal, Christopher S.; Litwin, Mark S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA.
   [Scales, Charles D., Jr.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
   [Hanley, Janet M.; Dick, Andrew W.; Setodji, Claude M.; Litwin, Mark S.] RAND Corp, Santa Monica, CA USA.
   [Litwin, Mark S.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA 90095 USA.
RP Scales, CD (reprint author), Duke Univ, Div Urol Surg, DUMC 3707, Durham, NC 27710 USA.
EM chuck.scales@duke.edu
FU Robert Wood Johnson Foundation Clinical Scholars program; US Department
   of Veterans Affairs; National Institute of Diabetes and Digestive and
   Kidney Diseases [HHSN276201200016C]; National Library of Medicine
FX Drs. Scales was supported by the Robert Wood Johnson Foundation Clinical
   Scholars program and the US Department of Veterans Affairs. The Urologic
   Diseases in America Project is supported by grant HHSN276201200016C from
   the National Institute of Diabetes and Digestive and Kidney Diseases and
   the National Library of Medicine.
NR 24
TC 13
Z9 13
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0039-6060
J9 SURGERY
JI Surgery
PD MAY
PY 2014
VL 155
IS 5
BP 769
EP 775
DI 10.1016/j.surg.2013.12.013
PG 7
WC Surgery
SC Surgery
GA AG3BP
UT WOS:000335291100007
PM 24787103
ER

PT J
AU Egede, LE
   Gebregziabher, M
   Echols, C
   Lynch, CP
AF Egede, Leonard E.
   Gebregziabher, Mulugeta
   Echols, Carrae
   Lynch, Cheryl P.
TI Longitudinal Effects of Medication Nonadherence on Glycemic Control
SO ANNALS OF PHARMACOTHERAPY
LA English
DT Article
DE databases; type 2 diabetes; epidemiology; outcomes research/analysis
ID OF-VETERANS-AFFAIRS; DIABETES-MELLITUS; CLAIMS DATA; ADHERENCE;
   OUTCOMES; CARE; HOSPITALIZATION; INTERVENTIONS; MANAGEMENT; PROGRAM
AB Background: Medication nonadherence is known to worsen glycemic control. Few studies have examined this relationship over several years. Objective: The aim of this study was to examine the longitudinal effect of medication nonadherence on glycennic control among a large cohort of veterans. Methods: Analysis was performed on a cohort of II 272 veterans with type 2 diabetes followed from April 1994 to May 2006. The primary outcome measures were mean glycosylated hemoglobin A 1 c (A 1 C) and proportion in poor control (A 1 C > 8%) over time. The main predictor was medication nonadherence based on medication possession ratio (MPR). Other covariates included sociodemographics and ICD-9 coded medical and psychiatric comorbidities. Generalized linear mixed models (GLMMs) were used to assess the relationship between MPR and A 1 C after adjusting for covariates. Results: Mean follow-up was 5.4 years. In the linear mixed model, after adjusting for baseline A 1 C and other confounding variables, mean A 1 C decreased by 0.24 (P < 0.001) for each 10% increase in MPR (95% Cl = -0.27, -0.21). In the fully adjusted GLMM, each percentage increase in MPR was associated with a 48% lower likelihood of having poor glycemic control (odds ratio = 0.52; 95% Cl = 0.4, 0.6). In both continuous and dichotomized A 1 C analyses, average A 1 C showed a decreasing trend over the study period (P < 0.001). Conclusions: In patients with type 2 diabetes, glycemic control worsens over time in the presence of medication nonadherence. Future studies need to take into account the complexity of patient-and system-level factors affecting long-term medication adherence to improve diabetes-related outcomes.
C1 [Egede, Leonard E.; Lynch, Cheryl P.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
   [Egede, Leonard E.; Gebregziabher, Mulugeta; Lynch, Cheryl P.] Med Univ S Carolina, Charleston, SC 29425 USA.
   [Echols, Carrae] US Dept Labor, Washington, DC 20210 USA.
RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280H,POB 250593, Charleston, SC 29425 USA.
EM egedel@musc.edu
OI Gebregziabher, Mulugeta/0000-0002-4826-481X
FU Center for Disease Prevention and Health Interventions for Diverse
   Populations [REA 08-261]; Veterans Health Affairs Health Services
   Research and Development
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This study
   was supported by Grant No. REA 08-261, Center for Disease Prevention and
   Health Interventions for Diverse Populations funded by Veterans Health
   Affairs Health Services Research and Development (PI: Leonard E. Egede).
NR 30
TC 11
Z9 13
U1 0
U2 4
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1060-0280
EI 1542-6270
J9 ANN PHARMACOTHER
JI Ann. Pharmacother.
PD MAY
PY 2014
VL 48
IS 5
BP 562
EP 570
DI 10.1177/1060028014526362
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA AF1NF
UT WOS:000334479900001
PM 24586059
ER

PT J
AU Mehta, SJ
   Asch, DA
AF Mehta, Shivan J.
   Asch, David A.
TI How to Help Gastroenterology Patients Help Themselves: Leveraging
   Insights From Behavioral Economics
SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Editorial Material
ID VETERANS
C1 [Mehta, Shivan J.] Univ Penn, Perelman Sch Med, Div Gastroenterol, Philadelphia, PA 19104 USA.
   [Mehta, Shivan J.; Asch, David A.] Penn Med Ctr Hlth Care Innovat, Philadelphia, PA USA.
   [Mehta, Shivan J.; Asch, David A.] Univ Penn, Leonard Davis Inst Hlth Econ, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA.
   [Asch, David A.] Philadelphia VA Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA.
RP Mehta, SJ (reprint author), Univ Penn, Perelman Sch Med, 1133 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM shivan.mehta@uphs.upenn
OI Asch, David/0000-0002-7970-286X
NR 11
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1542-3565
EI 1542-7714
J9 CLIN GASTROENTEROL H
JI Clin. Gastroenterol. Hepatol.
PD MAY
PY 2014
VL 12
IS 5
BP 711
EP 714
DI 10.1016/j.cgh.2014.02.022
PG 4
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AF1ZL
UT WOS:000334512300006
PM 24746170
ER

PT J
AU Hodgson, N
   Gitlin, LN
   Winter, L
   Hauck, WW
AF Hodgson, Nancy
   Gitlin, Laura N.
   Winter, Laraine
   Hauck, Walter W.
TI Caregiver's Perceptions of the Relationship of Pain to Behavioral and
   Psychiatric Symptoms in Older Community-residing Adults With Dementia
SO CLINICAL JOURNAL OF PAIN
LA English
DT Article
DE family caregiver; pain; behavioral and psychiatric symptoms; dementia
ID MENTAL-STATE-EXAMINATION; NURSING-HOME RESIDENTS; ALZHEIMERS-DISEASE;
   PSYCHOLOGICAL SYMPTOMS; NONPHARMACOLOGICAL INTERVENTION;
   NEUROPSYCHIATRIC SYMPTOMS; COGNITIVE IMPAIRMENT; SELF-REPORT; PEOPLE;
   INDIVIDUALS
AB Objectives:
   Pain is underrecognized and undermanaged in older adults with dementia. Because dementia patients have a diminished capacity to communicate discomfort, untreated pain may be expressed in the form of behavioral and psychiatric symptoms. The goal of the present study was to examine the relationship between pain and behavioral and psychiatric symptoms of dementia in community-residing older adults from the perspective of the family caregiver.
   Materials and Methods:
   Dyads composed of 272 dementia patients, and their family caregivers were assessed to determine dementia patient's mental status; family caregiver's assessment of care recipient's pain, functional dependence, and number of behavioral symptoms; analgesic use; and demographic information.
   Results:
   Hierarchical multiple regression analysis controlling for age, marital status, race, functional disability, and analgesic use showed that pain explained a small but significant percent of variance in the number of behavioral symptoms (3%, P < 0.001). Pain had a stronger influence on the number of behavioral and psychiatric symptoms of dementia among those with severe cognitive impairment (F-1,F-69=11.75, P < 0.001) compared with those with low to moderate cognitive impairment (F-1,F-199=4.543, P=0.034.).
   Discussion:
   The findings indicate that pain is a risk factor for behavioral symptoms in individuals with dementia and suggest that pain is a more significant predictor of behavior for individuals with severe dementia, compared with those with mild/moderate stage dementia. These results reinforce the importance of proper pain assessment and its management as part of dementia care planning.
C1 [Hodgson, Nancy; Gitlin, Laura N.] Johns Hopkins Univ, Sch Nursing, Baltimore, MD 21205 USA.
   [Winter, Laraine] Philadelphia VA Med Ctr, Philadelphia, PA USA.
   [Hauck, Walter W.] Sycamore Consulting LLC, Woodstock, GA USA.
RP Hodgson, N (reprint author), Johns Hopkins Univ, Sch Nursing, 525N Wolfe St, Baltimore, MD 21205 USA.
EM nhodgso1@jhu.edu
FU National Institute on Aging; National Institute on Nursing Research [RO1
   AG22254]
FX Supported in part by funds from the National Institute on Aging and the
   National Institute on Nursing Research (RO1 AG22254). The authors
   declare no conflict of interest.
NR 46
TC 5
Z9 5
U1 6
U2 14
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0749-8047
EI 1536-5409
J9 CLIN J PAIN
JI Clin. J. Pain
PD MAY
PY 2014
VL 30
IS 5
BP 421
EP 427
DI 10.1097/AJP.0000000000000018
PG 7
WC Anesthesiology; Clinical Neurology
SC Anesthesiology; Neurosciences & Neurology
GA AF3FV
UT WOS:000334597800006
PM 24281271
ER

PT J
AU Cuijpers, P
   Turner, EH
   Koole, SL
   van Dijke, A
   Smit, F
AF Cuijpers, Pim
   Turner, Erick H.
   Koole, Sander L.
   van Dijke, Annemiek
   Smit, Filip
TI WHAT IS THE THRESHOLD FOR A CLINICALLY RELEVANT EFFECT? THE CASE OF
   MAJOR DEPRESSIVE DISORDERS
SO DEPRESSION AND ANXIETY
LA English
DT Review
DE depression; effect size; clinical relevance; minimal important
   difference
ID IMPORTANT DIFFERENCE; HEALTH-STATUS; METAANALYSIS; PSYCHOTHERAPY;
   EFFICACY; SIZE
AB BackgroundRandomized trials can show whether a treatment effect is statistically significant and can describe the size of the effect. There are, however, no validated methods available for establishing the clinical relevance of these outcomes. Recently, it was proposed that a standardized mean difference (SMD) of 0.50 be used as cutoff for clinical relevance in the treatment of depression.
   MethodsWe explore what the effect size means and why the size of an effect has little bearing on its clinical relevance. We will also examine how the minimally important difference, as seen from the patient perspective, may be helpful in deciding where the cutoff for clinical relevance should be placed for a given condition.
   ResultsEffect sizes in itself cannot give an indication of the clinical relevance of an intervention because the outcome itself determines the clinical relevance and not only the size of the effects. The minimal important difference (MID) could be used as a starting point for pinpointing the cutoff for clinical relevance. A first, rough attempt to implement this approach for depression resulted in a tentative clinical relevance cutoff of SMD = 0.24. Using this cutoff, psychotherapy, pharmacotherapy, and combined treatment have effect sizes above this cutoff.
   DiscussionStatistical outcomes cannot be equated with clinical relevance. The MID may be used for pinpointing the cutoff for clinical relevance, but more work in this area is needed.
C1 [Cuijpers, Pim; Koole, Sander L.; Smit, Filip] Vrije Univ Amsterdam, Dept Clin Psychol, NL-1081 BT Amsterdam, Netherlands.
   [Cuijpers, Pim; Koole, Sander L.; Smit, Filip] Vrije Univ Amsterdam, VU Univ Med Ctr Amsterdam, EMGO Inst Hlth & Care Res, NL-1081 BT Amsterdam, Netherlands.
   [Cuijpers, Pim] Leuphana Univ, Lunebrug, Germany.
   [Turner, Erick H.] Portland VA Med Ctr, Behav Hlth & Neurosci Div, Portland, OR USA.
   [Turner, Erick H.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA.
   [Turner, Erick H.] Oregon Hlth & Sci Univ, Dept Pharmacol, Portland, OR 97201 USA.
   [van Dijke, Annemiek] Delta Psychiat Ctr, Poortugaal, Netherlands.
   [Smit, Filip] Netherlands Inst Mental Hlth & Addict, Trimbos Inst, Utrecht, Netherlands.
   [Smit, Filip] Vrije Univ Amsterdam Med Ctr, Dept Epidemiol & Biostat, Amsterdam, Netherlands.
RP Cuijpers, P (reprint author), Vrije Univ Amsterdam, Dept Clin Psychol, Boechorststr 1, NL-1081 BT Amsterdam, Netherlands.
EM p.cuijpers@vu.nl
OI Cuijpers, Pim/0000-0001-5497-2743
NR 21
TC 16
Z9 16
U1 1
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1091-4269
EI 1520-6394
J9 DEPRESS ANXIETY
JI Depress. Anxiety
PD MAY
PY 2014
VL 31
IS 5
BP 374
EP 378
DI 10.1002/da.22249
PG 5
WC Psychology, Clinical; Psychiatry; Psychology
SC Psychology; Psychiatry
GA AF6CX
UT WOS:000334803100002
PM 24677535
ER

PT J
AU Lopes-Virella, MF
   Baker, NL
   Hunt, KJ
   Cleary, PA
   Klein, R
   Virella, G
AF Lopes-Virella, Maria F.
   Baker, Nathaniel L.
   Hunt, Kelly J.
   Cleary, Patricia A.
   Klein, Richard
   Virella, Gabriel
CA DCCT EDIC Res Grp
TI Baseline Markers of Inflammation Are Associated With Progression to
   Macroalbuminuria in Type 1 Diabetic Subjects. Diabetes Care 2013; 36:
   2317-2323 RESPONSE
SO DIABETES CARE
LA English
DT Letter
ID ENDOTHELIAL DYSFUNCTION; IMMUNE-COMPLEXES; COMPLICATIONS; NEPHROPATHY
C1 [Lopes-Virella, Maria F.] Med Univ S Carolina, Dept Med & Lab Serv, Charleston, SC 29425 USA.
   [Lopes-Virella, Maria F.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
   [Baker, Nathaniel L.; Hunt, Kelly J.] Med Univ S Carolina, Dept Publ Hlth Serv, Charleston, SC 29425 USA.
   [Cleary, Patricia A.] George Washington Univ, Ctr Biostat, Washington, DC USA.
   [Klein, Richard] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
   [Virella, Gabriel] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA.
RP Lopes-Virella, MF (reprint author), Med Univ S Carolina, Dept Med & Lab Serv, Charleston, SC 29425 USA.
EM virellam@musc.edu
FU NIDDK NIH HHS [R01 DK081352]
NR 8
TC 0
Z9 0
U1 0
U2 0
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
EI 1935-5548
J9 DIABETES CARE
JI Diabetes Care
PD MAY
PY 2014
VL 37
IS 5
BP E108
EP E109
DI 10.2337/dc13-2976
PG 2
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA AF6QQ
UT WOS:000334840100014
PM 24496801
ER

PT J
AU Price, M
   Ruggiero, KJ
   Ferguson, PL
   Patel, SK
   Treiber, F
   Couillard, D
   Fahkry, SM
AF Price, Matthew
   Ruggiero, Kenneth J.
   Ferguson, Pamela L.
   Patel, Sachin K.
   Treiber, Frank
   Couillard, Deborah
   Fahkry, Samir M.
TI A feasibility pilot study on the use of text messages to track PTSD
   symptoms after a traumatic injury
SO GENERAL HOSPITAL PSYCHIATRY
LA English
DT Article
DE PTSD; Traumatic stress; Text messages; Technology
ID POSTTRAUMATIC-STRESS-DISORDER; INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW;
   RANDOMIZED CONTROLLED-TRIAL; MENTAL-HEALTH INTERVENTION; PHYSICAL
   INJURY; DSM-IV; CARE; DEPRESSION; EXPERIENCES; PREVENTION
AB Objective: Monitoring posttraumatic stress disorder (PTSD) symptoms after a traumatic injury is beneficial for patients and providers. Text messages can be used to automatically monitor symptoms and impose minimal burden to patients and providers. The present study piloted such a strategy with traumatic injury patients.
   Method: An automated daily text message was piloted to evaluate PTSD symptoms after discharge from the hospital. Twenty-nine patients who experienced a traumatic injury received 15 daily texts and were then followed up at 1-month and 3-months after discharge.
   Results: 82.8% of the sample responded at least once and the average response rate per participant was 63.1%. Response rates were correlated with PTSD symptoms at baseline but not at any other time. Patient satisfaction with this approach was high.
   Conclusion: Text messages are a viable method to monitor PTSD symptoms after a traumatic injury. Such an approach should be evaluated on a larger scale as part of a more comprehensive early intervention for traumatic stress. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Price, Matthew] Univ Vermont, Dept Psychol, Burlington, VT 05405 USA.
   [Ruggiero, Kenneth J.; Treiber, Frank] Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA.
   [Ruggiero, Kenneth J.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
   [Ferguson, Pamela L.; Couillard, Deborah; Fahkry, Samir M.] Med Univ S Carolina, Dept Surg, Charleston, SC 29425 USA.
   [Patel, Sachin K.; Treiber, Frank] Med Univ S Carolina, Coll Nursing, Technol Applicat Ctr Hlth Lifestyles, Charleston, SC 29425 USA.
RP Price, M (reprint author), Univ Vermont, Dept Psychol, John Dewey Hall,Room 248 2 Colchester Ave, Burlington, VT 05405 USA.
EM Matthew.Price@uvm.edu
FU NCATS NIH HHS [UL1 TR000062]; NHLBI NIH HHS [R01 HL114957]; NIDDK NIH
   HHS [R01 DK098777]; NIMH NIH HHS [R01 MH081056, R34 MH096907, T32
   MH018869]
NR 38
TC 8
Z9 8
U1 6
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0163-8343
EI 1873-7714
J9 GEN HOSP PSYCHIAT
JI Gen. Hosp. Psych.
PD MAY-JUN
PY 2014
VL 36
IS 3
BP 249
EP 254
DI 10.1016/j.genhosppsych.2014.02.004
PG 6
WC Psychiatry
SC Psychiatry
GA AF2AS
UT WOS:000334515600003
PM 24636721
ER

PT J
AU Zhang, Z
   Palmer, JN
   Morales, KH
   Howland, TJ
   Doghramji, LJ
   Adappa, ND
   Chiu, AG
   Cohen, NA
   Lautenbach, E
AF Zhang, Zi
   Palmer, James N.
   Morales, Knashawn H.
   Howland, Timothy J.
   Doghramji, Laurel J.
   Adappa, Nithin D.
   Chiu, Alexander G.
   Cohen, Noam A.
   Lautenbach, Ebbing
TI Culture-inappropriate antibiotic therapy decreases quality of life
   improvement after sinus surgery
SO INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY
LA English
DT Article
DE endoscopic sinus surgery; SNOT-22; culture; chronic rhinosinusitis;
   antibiotic therapy; 22-item Sinonasal Outcome Test; quality of life
ID CHRONIC RHINOSINUSITIS; COMPUTED-TOMOGRAPHY; CONTROLLED-TRIAL;
   DOUBLE-BLIND; ALLERGY; ASTHMA; OUTCOMES; IMPACT; ACID; POLYPOSIS
AB Background
   Despite their widespread use, antibiotics have not been shown to improve chronic rhinosinusitis (CRS) outcomes. We aimed to determine whether culture-inappropriate postoperative antibiotic therapy was associated with less quality-of-life (QOL) improvement following functional endoscopic sinus surgery (FESS).
   Methods
   This retrospective cohort study recruited 376 adult CRS patients undergoing FESS between October 1, 2007 to December 31, 2011. Patient demographics, comorbidities and medications were collected at baseline. Trimethoprim-sulfamethoxazole and clindamycin were administered for 2 weeks postoperatively. The antibiotic appropriateness was determined based on bacterial resistance profile of organisms identified during intraoperative culture. The QOL outcome was defined as change of 22-item Sinonasal Outcome Test scores from preoperative visit to 1-month, 3-month, and 6-month post-FESS. Clinically significant difference was defined as at least 0.5 standard deviations (SD) of baseline QOL score in the reference group. Mixed-effects regression models were performed.
   Results
   Seven percent of patients (n = 27) had culture-inappropriate antibiotic therapy, and additional 5% (n = 19) had culture-specific antibiotic adjustment. Compared to patients with culture-appropriate antibiotics, patients with culture-inappropriate antibiotics had significantly less improvement of QOL from baseline to postoperative 1-month and 3-month follow-up where the difference became clinically significant; patients with antibiotic adjustment had more QOL improvement from baseline to 1-month follow-up, but their QOL worsened at 3-month follow-up, and these changes were not clinically significant. However, all effects washed out at 6-month follow-up with no significant differences.
   Conclusion
   Culture-inappropriate postoperative antibiotic therapy decreased short-term QOL improvement to a clinically meaningful level after FESS. Culture guided selection of antibiotics may improve short-term FESS outcome.
C1 [Zhang, Zi; Morales, Knashawn H.; Lautenbach, Ebbing] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
   [Palmer, James N.; Howland, Timothy J.; Doghramji, Laurel J.; Adappa, Nithin D.; Cohen, Noam A.] Univ Penn, Perelman Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA.
   [Chiu, Alexander G.] Univ Arizona, Dept Surg, Tucson, AZ USA.
   [Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
   [Lautenbach, Ebbing] Univ Penn, Dept Med, Perelman Sch Med, Div Infect Dis, Philadelphia, PA 19104 USA.
RP Zhang, Z (reprint author), 8th Floor,Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM zizhang@mail.med.upenn.edu
RI Chiu, Alexander/J-1230-2014
OI Chiu, Alexander/0000-0002-7592-6575; Cohen, Noam/0000-0002-9462-3932
FU National Institutes of Health, National Institute of Allergy and
   Infectious Diseases (NIAID) [K24 AI080942/AI/NIAID NIH HHS/United
   States]
FX Funding sources for the study: National Institutes of Health, National
   Institute of Allergy and Infectious Diseases (NIAID) (K24
   AI080942/AI/NIAID NIH HHS/United States to E.L.).
NR 41
TC 4
Z9 4
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2042-6976
EI 2042-6984
J9 INT FORUM ALLERGY RH
JI Int. Forum Allergy Rhinol.
PD MAY
PY 2014
VL 4
IS 5
BP 403
EP 410
DI 10.1002/alr.21277
PG 8
WC Otorhinolaryngology
SC Otorhinolaryngology
GA AF7LF
UT WOS:000334895900011
PM 24415647
ER

PT J
AU Alley, DE
   Shardell, MD
   Peters, KW
   McLean, RR
   Dam, TTL
   Kenny, AM
   Fragala, MS
   Harris, TB
   Kiel, DP
   Guralnik, JM
   Ferrucci, L
   Kritchevsky, SB
   Studenski, SA
   Vassileva, MT
   Cawthon, PM
AF Alley, Dawn E.
   Shardell, Michelle D.
   Peters, Katherine W.
   McLean, Robert R.
   Dam, Thuy-Tien L.
   Kenny, Anne M.
   Fragala, Maren S.
   Harris, Tamara B.
   Kiel, Douglas P.
   Guralnik, Jack M.
   Ferrucci, Luigi
   Kritchevsky, Stephen B.
   Studenski, Stephanie A.
   Vassileva, Maria T.
   Cawthon, Peggy M.
TI Grip Strength Cutpoints for the Identification of Clinically Relevant
   Weakness
SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL
   SCIENCES
LA English
DT Article
DE Muscle; Sarcopenia; Grip strength; Physical function; Gait speed
ID BONE-MINERAL DENSITY; OLDER-ADULTS; MUSCLE STRENGTH; PHYSICAL
   PERFORMANCE; BODY-COMPOSITION; WOMENS HEALTH; WHITE WOMEN; MOBILITY;
   INCHIANTI; RISK
AB Weakness is common and contributes to disability, but no consensus exists regarding a strength cutpoint to identify persons at high risk. This analysis, conducted as part of the Foundation for the National Institutes of Health Sarcopenia Project, sought to identify cutpoints that distinguish weakness associated with mobility impairment, defined as gait speed less than 0.8 m/s.
   In pooled cross-sectional data (9,897 men and 10,950 women), Classification and Regression Tree analysis was used to derive cutpoints for grip strength associated with mobility impairment.
   In men, a grip strength of 2632 kg was classified as intermediate and less than 26 kg as weak; 11% of men were intermediate and 5% were weak. Compared with men with normal strength, odds ratios for mobility impairment were 3.63 (95% CI: 3.014.38) and 7.62 (95% CI 6.139.49), respectively. In women, a grip strength of 1620 kg was classified as intermediate and less than 16 kg as weak; 25% of women were intermediate and 18% were weak. Compared with women with normal strength, odds ratios for mobility impairment were 2.44 (95% CI 2.202.71) and 4.42 (95% CI 3.944.97), respectively. Weakness based on these cutpoints was associated with mobility impairment across subgroups based on age, body mass index, height, and disease status. Notably, in women, grip strength divided by body mass index provided better fit relative to grip strength alone, but fit was not sufficiently improved to merit different measures by gender and use of a more complex measure.
   Cutpoints for weakness derived from this large, diverse sample of older adults may be useful to identify populations who may benefit from interventions to improve muscle strength and function.
C1 [Alley, Dawn E.; Shardell, Michelle D.; Guralnik, Jack M.] Univ Maryland, Dept Epidemiol & Publ Hlth, Sch Med, Baltimore, MD 21201 USA.
   [Peters, Katherine W.; Cawthon, Peggy M.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA.
   [McLean, Robert R.; Kiel, Douglas P.] Beth Israel Deaconess Med Ctr, Div Gerontol, Boston, MA 02215 USA.
   [McLean, Robert R.; Kiel, Douglas P.] Harvard Univ, Sch Med, Boston, MA USA.
   [McLean, Robert R.; Kiel, Douglas P.] Hebrew Senior Life Inst Aging Res, Inst Aging Res, Boston, MA USA.
   [Dam, Thuy-Tien L.] Columbia Univ, Dept Med, New York, NY USA.
   [Kenny, Anne M.; Fragala, Maren S.] Univ Connecticut, Ctr Hlth, Ctr Aging, Farmington, CT USA.
   [Fragala, Maren S.] Univ Cent Florida, Orlando, FL 32816 USA.
   [Harris, Tamara B.] NIA, Bethesda, MD 20892 USA.
   [Ferrucci, Luigi] NIA, Baltimore, MD 21224 USA.
   [Kritchevsky, Stephen B.] Wake Forest Univ, Sticht Ctr Aging, Winston Salem, NC 27109 USA.
   [Kritchevsky, Stephen B.] Wake Forest Univ, Dept Internal Med, Winston Salem, NC 27109 USA.
   [Studenski, Stephanie A.] Univ Pittsburgh, Dept Internal Med, Pittsburgh, PA 15260 USA.
   [Studenski, Stephanie A.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
   [Vassileva, Maria T.] Fdn NIH Biomarkers Consortium, Bethesda, MD USA.
RP Alley, DE (reprint author), Univ Maryland, Sch Med, 660 W Redwood St 221B, Baltimore, MD 21201 USA.
EM dalley@epi.umaryland.edu
OI Kiel, Douglas/0000-0001-8474-0310
FU National Institute on Aging [1U13AG041583, P30 AG024827]; Food and Drug
   Administration; Foundation for the NIH; Abbott Nutrition; Amgen; Eli
   Lilly; Merck; Novartis; Dairy Research Institute; NIH, National
   Institute on Aging
FX Funding support for the conference and the work of the consortium was
   provided by the National Institute on Aging (1U13AG041583 and P30
   AG024827), the Food and Drug Administration, and through grants from the
   Foundation for the NIH, made possible by funding from Abbott Nutrition,
   Amgen, Eli Lilly, Merck, Novartis, and The Dairy Research Institute.
   This research was supported in part by the Intramural Research Program
   of the NIH, National Institute on Aging. Additional acknowledgements for
   each contributing cohort and members of the FNIH Sarcopenia Project can
   be found in an online supplement.
NR 34
TC 69
Z9 71
U1 3
U2 11
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1079-5006
EI 1758-535X
J9 J GERONTOL A-BIOL
JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci.
PD MAY
PY 2014
VL 69
IS 5
BP 559
EP 566
DI 10.1093/gerona/glu011
PG 8
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA AF5EY
UT WOS:000334738000008
PM 24737558
ER

PT J
AU Cawthon, PM
   Peters, KW
   Shardell, MD
   McLean, RR
   Dam, TTL
   Kenny, AM
   Fragala, MS
   Harris, TB
   Kiel, DP
   Guralnik, JM
   Ferrucci, L
   Kritchevsky, SB
   Vassileva, MT
   Studenski, SA
   Alley, DE
AF Cawthon, Peggy M.
   Peters, Katherine W.
   Shardell, Michelle D.
   McLean, Robert R.
   Dam, Thuy-Tien L.
   Kenny, Anne M.
   Fragala, Maren S.
   Harris, Tamara B.
   Kiel, Douglas P.
   Guralnik, Jack M.
   Ferrucci, Luigi
   Kritchevsky, Stephen B.
   Vassileva, Maria T.
   Studenski, Stephanie A.
   Alley, Dawn E.
TI Cutpoints for Low Appendicular Lean Mass That Identify Older Adults With
   Clinically Significant Weakness
SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL
   SCIENCES
LA English
DT Article
DE Muscle; Sarcopenia; Cutpoints
ID BONE-MINERAL DENSITY; ALTERNATIVE DEFINITIONS; PHYSICAL FUNCTION; MUSCLE
   STRENGTH; WHITE WOMEN; MEN; SARCOPENIA; HEALTH; RISK; PERFORMANCE
AB Low lean mass is potentially clinically important in older persons, but criteria have not been empirically validated. As part of the FNIH (Foundation for the National Institutes of Health) Sarcopenia Project, this analysis sought to identify cutpoints in lean mass by dual-energy x-ray absorptiometry that discriminate the presence or absence of weakness (defined in a previous report in the series as grip strength < 26kg in men and < 16kg in women).
   In pooled cross-sectional data stratified by sex (7,582 men and 3,688 women), classification and regression tree (CART) analysis was used to derive cutpoints for appendicular lean body mass (ALM) that best discriminated the presence or absence of weakness. Mixed-effects logistic regression was used to quantify the strength of the association between lean mass category and weakness.
   In primary analyses, CART models identified cutpoints for low lean mass (ALM < 19.75kg in men and < 15.02kg in women). Sensitivity analyses using ALM divided by body mass index (BMI: ALM(BMI)) identified a secondary definition (ALM(BMI) < 0.789 in men and ALM(BMI) < 0.512 in women). As expected, after accounting for study and age, low lean mass (compared with higher lean mass) was associated with weakness by both the primary (men, odds ratio [OR]: 6.9 [95% CI: 5.4, 8.9]; women, OR: 3.6 [95% CI: 2.9, 4.3]) and secondary definitions (men, OR: 4.3 [95% CI: 3.4, 5.5]; women, OR: 2.2 [95% CI: 1.8, 2.8]).
   ALM cutpoints derived from a large, diverse sample of older adults identified lean mass thresholds below which older adults had a higher likelihood of weakness.
C1 [Cawthon, Peggy M.; Peters, Katherine W.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA 94107 USA.
   [Shardell, Michelle D.; Guralnik, Jack M.; Alley, Dawn E.] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, College Pk, MD 20742 USA.
   [McLean, Robert R.; Kiel, Douglas P.] Beth Israel Deaconess Med Ctr, Div Gerontol, Boston, MA 02215 USA.
   [McLean, Robert R.; Kiel, Douglas P.] Harvard Univ, Sch Med, Boston, MA USA.
   [Dam, Thuy-Tien L.] Columbia Univ, Dept Med, New York, NY USA.
   [Kenny, Anne M.; Fragala, Maren S.] Univ Connecticut, Ctr Hlth, Ctr Aging, Farmington, CT USA.
   [Fragala, Maren S.] Univ Cent Florida, Orlando, FL 32816 USA.
   [Harris, Tamara B.; Ferrucci, Luigi] NIA, Bethesda, MD 20892 USA.
   [Kiel, Douglas P.] Hebrew Senior Life Inst Aging Res, Inst Aging Res, Boston, MA USA.
   [Kritchevsky, Stephen B.] Wake Forest Univ, Sticht Ctr Aging, Winston Salem, NC 27109 USA.
   [Kritchevsky, Stephen B.] Wake Forest Univ, Dept Internal Med, Winston Salem, NC 27109 USA.
   [Vassileva, Maria T.] Fdn NIH Biomarkers Consortium, Bethesda, MD USA.
   [Studenski, Stephanie A.] Univ Pittsburgh, Dept Internal Med, Pittsburgh, PA 15260 USA.
   [Studenski, Stephanie A.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Cawthon, PM (reprint author), Calif Pacific Med Ctr, Res Inst, 185 Berry St,Suite 5700, San Francisco, CA 94107 USA.
EM pcawthon@sfcc-cpmc.net
OI Kiel, Douglas/0000-0001-8474-0310
FU National Institute on Aging [1U13AG041583, P30 AG024827]; Food and Drug
   Administration; Foundation of the NIH; Abbott Nutrition; Amgen; Eli
   Lilly; Merck; Novartis; Dairy Research Institute
FX Support for the conference and the consortium was provided by the
   National Institute on Aging (1U13AG041583 and P30 AG024827), the Food
   and Drug Administration, and through a grant from the Foundation of the
   NIH, supported by funds from Abbott Nutrition, Amgen, Eli Lilly, Merck,
   Novartis, and The Dairy Research Institute.
NR 27
TC 53
Z9 53
U1 0
U2 13
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1079-5006
EI 1758-535X
J9 J GERONTOL A-BIOL
JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci.
PD MAY
PY 2014
VL 69
IS 5
BP 567
EP 575
DI 10.1093/gerona/glu023
PG 9
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA AF5EY
UT WOS:000334738000009
PM 24737559
ER

PT J
AU McLean, RR
   Shardell, MD
   Alley, DE
   Cawthon, PM
   Fragala, MS
   Harris, TB
   Kenny, AM
   Peters, KW
   Ferrucci, L
   Guralnik, JM
   Kritchevsky, SB
   Kiel, DP
   Vassileva, MT
   Xue, QL
   Perera, S
   Studenski, SA
   Dam, TTL
AF McLean, Robert R.
   Shardell, Michelle D.
   Alley, Dawn E.
   Cawthon, Peggy M.
   Fragala, Maren S.
   Harris, Tamara B.
   Kenny, Anne M.
   Peters, Katherine W.
   Ferrucci, Luigi
   Guralnik, Jack M.
   Kritchevsky, Stephen B.
   Kiel, Douglas P.
   Vassileva, Maria T.
   Xue, Qian-Li
   Perera, Subashan
   Studenski, Stephanie A.
   Dam, Thuy-Tien L.
TI Criteria for Clinically Relevant Weakness and Low Lean Mass and Their
   Longitudinal Association With Incident Mobility Impairment and
   Mortality: The Foundation for the National Institutes of Health (FNIH)
   Sarcopenia Project
SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL
   SCIENCES
LA English
DT Article
DE Muscle; Sarcopenia; Mobility; Impairment
ID LOWER-EXTREMITY FUNCTION; OSTEOPOROTIC FRACTURES; BODY-COMPOSITION;
   MUSCLE STRENGTH; OLDER PERSONS; WHITE WOMEN; MEN; EPIDEMIOLOGY; RISK;
   PERFORMANCE
AB This analysis sought to determine the associations of the Foundation for the National Institutes of Health Sarcopenia Project criteria for weakness and low lean mass with likelihood for mobility impairment (gait speed 0.8 m/s) and mortality. Providing validity for these criteria is essential for research and clinical evaluation.
   Among 4,411 men and 1,869 women pooled from 6 cohort studies, 3-year likelihood for incident mobility impairment and mortality over 10 years were determined for individuals with weakness, low lean mass, and for those having both. Weakness was defined as low grip strength (< 26kg men and < 16kg women) and low grip strength-to-body mass index (BMI; kg/m(2)) ratio (< 1.00 men and < 0.56 women). Low lean mass (dual-energy x-ray absorptiometry) was categorized as low appendicular lean mass (ALM; < 19.75kg men and < 15.02kg women) and low ALM-to-BMI ratio (< 0.789 men and < 0.512 women).
   Low grip strength (men: odds ratio [OR] 2.31, 95% confidence interval [CI] 1.343.99; women: OR 1.99, 95% CI 1.233.21), low grip strength-to-BMI ratio (men: OR 3.28, 95% CI 1.925.59; women: OR 2.54, 95% CI 1.105.83) and low ALM-to-BMI ratio (men: OR 1.58, 95% CI 1.122.25; women: OR 1.81, 95% CI 1.142.87), but not low ALM, were associated with increased likelihood for incident mobility impairment. Weakness increased likelihood of mobility impairment regardless of low lean mass. Mortality risk patterns were inconsistent.
   These findings support our cut-points for low grip strength and low ALM-to-BMI ratio as candidate criteria for clinically relevant weakness and low lean mass. Further validation in other populations and for alternate relevant outcomes is needed.
C1 [McLean, Robert R.; Kiel, Douglas P.] Hebrew SeniorLife Inst Aging Res, Boston, MA 02131 USA.
   [McLean, Robert R.; Kiel, Douglas P.] Harvard Univ, Beth Israel Deaconess Med Ctr, Dept Med, Sch Med, Boston, MA 02215 USA.
   [Shardell, Michelle D.; Alley, Dawn E.; Guralnik, Jack M.] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Baltimore, MD 21201 USA.
   [Cawthon, Peggy M.; Peters, Katherine W.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA.
   [Fragala, Maren S.; Kenny, Anne M.] Univ Connecticut, Ctr Hlth, Ctr Aging, Farmington, CT USA.
   [Fragala, Maren S.] Univ Cent Florida, Orlando, FL 32816 USA.
   [Harris, Tamara B.; Ferrucci, Luigi] NIA, Intramural Res Program, NIH, Bethesda, MD 20892 USA.
   [Kritchevsky, Stephen B.] Wake Forest Univ, Sch Med, Sticht Ctr Aging, Winston Salem, NC 27109 USA.
   [Kritchevsky, Stephen B.] Wake Forest Univ, Sch Med, Dept Internal Med, Winston Salem, NC 27109 USA.
   [Vassileva, Maria T.] Fdn Natl Inst Hlth, Biomarkers Consortium, Bethesda, MD USA.
   [Xue, Qian-Li] Johns Hopkins Univ, Sch Med, Dept Med, Div Geriatr Med & Gerontol, Baltimore, MD 21205 USA.
   [Xue, Qian-Li] Johns Hopkins Univ, Ctr Aging & Hlth, Baltimore, MD USA.
   [Perera, Subashan; Studenski, Stephanie A.] Univ Pittsburgh, Dept Internal Med, Sch Med, Pittsburgh, PA 15260 USA.
   [Studenski, Stephanie A.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
   [Dam, Thuy-Tien L.] Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY USA.
RP McLean, RR (reprint author), Hebrew SeniorLife Inst Aging Res, 1200 Ctr St, Boston, MA 02131 USA.
EM rmclean@hsl.harvard.edu
OI Kiel, Douglas/0000-0001-8474-0310
FU National Institute on Aging [1U13AG041583, P30 AG024827]; Food and Drug
   Administration; Foundation for the National Institutes of Health; Abbott
   Nutrition; Amgen; Eli Lilly; Merck; Novartis; Dairy Research Institute
FX Funding support for the conference and the work of the consortium was
   provided by the National Institute on Aging (1U13AG041583 and P30
   AG024827), the Food and Drug Administration and through grants from the
   Foundation for the National Institutes of Health, made possible by
   funding from Abbott Nutrition, Amgen, Eli Lilly, Merck, Novartis, and
   The Dairy Research Institute.
NR 33
TC 84
Z9 85
U1 4
U2 14
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1079-5006
EI 1758-535X
J9 J GERONTOL A-BIOL
JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci.
PD MAY
PY 2014
VL 69
IS 5
BP 576
EP 583
DI 10.1093/gerona/glu012
PG 8
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA AF5EY
UT WOS:000334738000010
PM 24737560
ER

PT J
AU Al Hazzouri, AZ
   Vittinghoff, E
   Byers, A
   Covinsky, K
   Blazer, D
   Diem, S
   Ensrud, KE
   Yaffe, K
AF Al Hazzouri, Adina Zeki
   Vittinghoff, Eric
   Byers, Amy
   Covinsky, Ken
   Blazer, Dan
   Diem, Susan
   Ensrud, Kristine E.
   Yaffe, Kristine
TI Long-term Cumulative Depressive Symptom Burden and Risk of Cognitive
   Decline and Dementia Among Very Old Women
SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL
   SCIENCES
LA English
DT Article
DE Depression; Cognition; Alzheimers
ID MINI-MENTAL-STATE; PRIMARY-CARE PATIENTS; BETA-AMYLOID LEVEL;
   ALZHEIMERS-DISEASE; VASCULAR-DISEASE; LATE-LIFE; IMPAIRMENT; COMMUNITY;
   TRAJECTORIES; ADULTS
AB Depressive symptoms and cognitive outcomes are strongly interrelated. Despite that rates of depressive symptoms fluctuate during late life, little is known about the impact of long-term cumulative depressive symptom burden on cognitive decline and dementia in older adults. This study examines the association of nearly 20 years of cumulative depressive symptoms with cognitive outcomes in a cohort of older women.
   We assessed depressive symptoms in 7,240 women using the Geriatric Depression scale (GDS) at serial visits. We used a Poisson model with random slopes to estimate GDS trajectories for each participant from baseline to death or end of follow-up, and then characterized depressive symptom burden by quartile of the area under the curve. We assessed cognitive outcomes using repeated measures of the Mini-Mental State Examination (MMSE) and Trails B score over 20 years, Year-20 neuropsychological test battery, and adjudicated dementia and mild cognitive impairment (MCI).
   Adjusting for potential confounders, compared with women in the lowest quartile of cumulative depressive symptoms burden, women in the highest quartile had 21% more MMSE errors over time (95% CI 17%, 26%), 20% worse Trails B score over time (95% CI 17%, 23%), worse scores on most of the Year-20 cognitive tests, and a twofold greater likelihood of developing dementia or MCI (95% CI 1.48, 3.11).
   Long-term cumulative depressive symptom burden was associated with cognitive decline and risk of dementia or MCI. Older adults with a history of depression should be closely monitored for recurrent episodes or unresolved depressive symptoms as well as any cognitive deficits.
C1 [Al Hazzouri, Adina Zeki; Vittinghoff, Eric; Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94107 USA.
   [Byers, Amy; Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94107 USA.
   [Byers, Amy; Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA.
   [Covinsky, Ken] Univ Calif San Francisco, Div Geriatr, Dept Med, San Francisco, CA 94107 USA.
   [Blazer, Dan] Duke Univ, Dept Psychiat & Behav Sci, Durham, NC USA.
   [Diem, Susan] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA.
   [Ensrud, Kristine E.] Univ Minnesota, Sch Publ Hlth, Minneapolis, MN USA.
   [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94107 USA.
RP Al Hazzouri, AZ (reprint author), Univ Calif San Francisco, Sch Med, Dept Epidemiol & Biostat, 185 Berry St,Lobby 5,Suite 5700, San Francisco, CA 94107 USA.
EM Adina.zekialhazzouri@ucsf.edu
FU National Institute of Mental Health [R01 MH086498]; National Institute
   on Aging [K24 AG031155, 2 R01 AG027574-22A1, R01 AG005407,
   R01AG027576-22, 2 R01 AG005394-22A1, AG05407, AG05394, AR35582, AR35583,
   AR35584, AG026720, R01 AG18037, R01 AG028144-01A1]; Alzheimer's
   Association [IIRG-08-88872]; American Heart Association/American Stroke
   Association/American Brain Foundation; National Institute of Arthritis
   and Musculoskeletal and Skin Diseases
FX This work was supported by the National Institute of Mental Health (R01
   MH086498); National Institute on Aging (K24 AG031155); and Alzheimer's
   Association (IIRG-08-88872). Dr. Z.A.H. is supported by the American
   Heart Association/American Stroke Association/American Brain Foundation
   Lawrence M. Brass, M. D. Stroke Research Postdoctoral Fellowship. The
   Study of Osteoporotic Fractures was supported by the National Institute
   of Arthritis and Musculoskeletal and Skin Diseases and the National
   Institute on Aging (Public Health Service grants: 2 R01 AG027574-22A1,
   R01 AG005407, R01AG027576-22, 2 R01 AG005394-22A1, AG05407, AG05394,
   AR35582, AR35583, AR35584, AG026720, R01 AG18037, and R01
   AG028144-01A1).
NR 40
TC 10
Z9 11
U1 3
U2 10
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1079-5006
EI 1758-535X
J9 J GERONTOL A-BIOL
JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci.
PD MAY
PY 2014
VL 69
IS 5
BP 595
EP 601
DI 10.1093/gerona/glt139
PG 7
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA AF5EY
UT WOS:000334738000013
ER

PT J
AU Gustafson, CE
   Higbee, D
   Yeckes, AR
   Wilson, CC
   De Zoeten, EF
   Jedlicka, P
   Janoff, EN
AF Gustafson, C. E.
   Higbee, D.
   Yeckes, A. R.
   Wilson, C. C.
   De Zoeten, E. F.
   Jedlicka, P.
   Janoff, E. N.
TI Limited expression of APRIL and its receptors prior to intestinal IgA
   plasma cell development during human infancy
SO MUCOSAL IMMUNOLOGY
LA English
DT Article
ID INDUCED CYTIDINE DEAMINASE; B-CELLS; LAMINA PROPRIA; IMMUNE-RESPONSES;
   LYMPHOID-TISSUE; IN-VITRO; GUT; TACI; MICROBIOTA; INDUCTION
AB The absence of immunoglobulin A (IgA) in the intestinal tract renders young infants highly susceptible to enteric infections. However, mediators of initial IgA induction in this population are undefined. We determined the temporal acquisition of plasma cells by isotype and expression of T cell-independent (TI) and -dependent (TD) IgA class switch factors in the human intestinal tract during early infancy. We found that IgA plasma cells were largely absent in the infant intestine until after 1 month of age, approaching adult densities later in infancy than both IgM and IgG. The restricted development of IgA plasma cells in the first month was accompanied by reduced expression of the TI factor a proliferation-inducing ligand (APRIL) and its receptors TACI (transmembrane activator and calcium-modulator and cyclophilin ligand interactor) and B cell maturation antigen (BCMA) within isolated lymphoid follicles (ILFs). Moreover, both APRIL and BCMA expression strongly correlated with increasing IgA plasma cell densities over time. Conversely, TD mediators (CD40 ligand (CD40L) and CD40) were expressed within ILFs before 1 month and were not associated with IgA plasma cell generation. In addition, preterm infants had lower densities of IgA plasma cells and reduced APRIL expression compared with full-term infants. Thus, blunted TI responses may contribute to the delayed induction of intestinal IgA during early human infancy.
C1 [Gustafson, C. E.; Higbee, D.; Wilson, C. C.; Janoff, E. N.] Univ Colorado, Div Infect Dis, Mucosal & Vaccine Res Program Colorado MAVRC, Aurora, CO 80045 USA.
   [Gustafson, C. E.; Wilson, C. C.; Janoff, E. N.] Univ Colorado, Natl Jewish Hlth, Integrated Dept Immunol, Aurora, CO USA.
   [Gustafson, C. E.; Higbee, D.; Janoff, E. N.] Denver Vet Affairs Med Ctr, Dept Med, Denver, CO USA.
   [Yeckes, A. R.; De Zoeten, E. F.] Univ Colorado, Dept Pediat, Aurora, CO USA.
   [Jedlicka, P.] Univ Colorado, Sch Med, Dept Pathol, Aurora, CO USA.
RP Janoff, EN (reprint author), Univ Colorado, Div Infect Dis, Mucosal & Vaccine Res Program Colorado MAVRC, Anschutz Med Campus, Aurora, CO 80045 USA.
EM edward.janoff@ucdenver.edu
OI de Zoeten, Edwin/0000-0002-0946-9759
FU National Institutes of Health [R01HD059527, R21AI083615]; NIH/NCATS
   Colorado CTSI [TL1 TR000155]; Veterans Affairs Research Service
FX We thank Stephanie Santorico PhD and Daniel Frank PhD for critical
   review of statistical analyses; Qi Wei, Dia Hani Barakat, Sara Williams,
   Matt Maulis, and Alison McMahon for their excellent technical support;
   and Eric Lee and Martin McCarter for support in specimen collection.
   This work has been supported by the National Institutes of Health
   (R01HD059527, R21AI083615), the NIH/NCATS Colorado CTSI Grant Number TL1
   TR000155, and the Veterans Affairs Research Service. Contents are the
   authors' sole responsibility and do not necessarily represent official
   NIH views. This work was presented in part at the International Congress
   of Mucosal Immunology (ICMI 2013, Vancouver BC, Canada, 17-20 July
   2013).
NR 38
TC 10
Z9 10
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1933-0219
EI 1935-3456
J9 MUCOSAL IMMUNOL
JI Mucosal Immunol.
PD MAY
PY 2014
VL 7
IS 3
BP 467
EP 477
DI 10.1038/mi.2013.64
PG 11
WC Immunology
SC Immunology
GA AF7VT
UT WOS:000334923700003
PM 24045575
ER

PT J
AU Cameron, MH
   Fitzpatrick, M
   Overs, S
   Murchison, C
   Manning, J
   Whitham, R
AF Cameron, Michelle H.
   Fitzpatrick, Mary
   Overs, Shannon
   Murchison, Charles
   Manning, Jane
   Whitham, Ruth
TI Dalfampridine improves walking speed, walking endurance, and community
   participation in veterans with multiple sclerosis: a longitudinal cohort
   study
SO MULTIPLE SCLEROSIS JOURNAL
LA English
DT Article
DE cohort studies; dalfampridine; Multiple sclerosis; cost
   effectiveness/economic; walking
ID 6-MINUTE WALK; FUNCTIONAL COMPOSITE; EXERCISE CAPACITY; TRIAL;
   FAMPRIDINE; MSWS-12; MS
AB Background:
   In short-term trials, dalfampridine extended release (ER) improves walking in people with multiple sclerosis (MS). The tolerability and effects of dalfampridine-ER in clinical practice have not been reported.
   Objectives:
   The objective of this paper is to determine the clinical tolerability and effects of dalfampridine on walking and community participation.
   Methods:
   All patients at the Portland VA Medical Center prescribed dalfampridine-ER over one year completed the Timed 25-Foot Walk (T25FW), Multiple Sclerosis Walking Scale-12 (MSWS-12), Two-Minute Timed Walk (2MTW), and Community Integration Questionnaire (CIQ) at baseline and follow-up clinic visits. Ongoing use and measures over one year were analyzed.
   Results:
   A total of 39 patients (mean age 56.5 years, mean disease duration 19.5 years, 82% male, 38% relapsing-remitting MS, 62% progressive MS) were prescribed dalfampridine-ER. Twenty-four (62%) continued to take dalfampridine-ER. At initial follow-up, all measures improved significantly from baseline (T25FW: -2.7 s, p = 0.004; 2MTW: 41 feet (ft), p = 0.002; MSWS12: -11, p < 0.001; CIQ: 1.2, p = 0.003). At one year, walking endurance and self-perceived walking were still significantly improved (2MTW: 33 ft, p = 0.03; MSWS-12: 5.9, p = 0.007).
   Conclusions:
   Dalfampridine-ER was associated with short-term improvements in walking speed and community participation, and sustained improvements in walking endurance and self-perceived impact of MS on walking for one year. Our study supports the utility of this medication in late MS.
C1 [Cameron, Michelle H.; Overs, Shannon; Murchison, Charles; Whitham, Ruth] Oregon Hlth & Sci Univ, Portland, OR 97219 USA.
   [Cameron, Michelle H.; Overs, Shannon; Murchison, Charles; Manning, Jane; Whitham, Ruth] Portland VA Med Ctr, Portland, OR 97219 USA.
RP Cameron, MH (reprint author), Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd,L226, Portland, OR 97219 USA.
EM cameromi@ohsu.edu
FU Acorda Therapeutics
FX Michelle Cameron has received research funding, honoraria and fees for
   consulting from Acorda Therapeutics. Mary Fitzpatrick is currently
   employed by Biogen Idec. Shannon Overs, Charles Murchison, Jane Manning
   and Ruth Whitham report no conflicts of interest.
NR 15
TC 2
Z9 2
U1 0
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1352-4585
EI 1477-0970
J9 MULT SCLER J
JI Mult. Scler. J.
PD MAY
PY 2014
VL 20
IS 6
BP 733
EP 738
DI 10.1177/1352458513507356
PG 6
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA AF7AN
UT WOS:000334865900012
PM 24099749
ER

PT J
AU Pearlson, GD
   Ford, JM
AF Pearlson, Godfrey D.
   Ford, Judith M.
TI Distinguishing Between Schizophrenia and Other Psychotic Disorders
SO SCHIZOPHRENIA BULLETIN
LA English
DT Article
DE schizophrenia; bipolar; validity; classification
ID COGNITIVE NEUROPSYCHIATRY; BIPOLAR DISORDER
AB The Diagnostic and Statistical Manual of Mental Disorders (DSM) has provided diagnostic reliability across observers while neglecting biological validity. The current theme issue explores the boundaries between schizophrenia and bipolar disorder, using neuro-cognition, systems neuroscience, and genetics as points of departure to begin consideration of a biologically based reclassification of these illnesses.
C1 [Pearlson, Godfrey D.] Yale Univ, Dept Psychiat, New Haven, CT 06520 USA.
   [Pearlson, Godfrey D.] Yale Univ, Dept Neurobiol, New Haven, CT USA.
   [Pearlson, Godfrey D.] IOL, ONRC, Hartford, CT 06106 USA.
   [Ford, Judith M.] San Francisco VA Med Ctr, San Francisco, CA USA.
   [Ford, Judith M.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
RP Pearlson, GD (reprint author), IOL, ONRC, Whitehall Bldg 207,200 Washington St, Hartford, CT 06106 USA.
EM godfrey.pearlson@yale.edu
FU National Institute of Mental Health [5 R37 MH43775, R01 MH07794,
   MH058262]
FX National Institute of Mental Health grants (5 R37 MH43775, MERIT) and
   (R01 MH077945 to G. D. P.); National Institute of Mental Health
   (MH058262 and Veterans Administration to J.M.F.).
NR 19
TC 5
Z9 5
U1 1
U2 8
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
EI 1745-1701
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAY
PY 2014
VL 40
IS 3
BP 501
EP 503
DI 10.1093/schbul/sbu055
PG 3
WC Psychiatry
SC Psychiatry
GA AF5JW
UT WOS:000334750800007
PM 24687045
ER

PT J
AU Post, RM
   Leverich, GS
   Kupka, R
   Keck, P
   McElroy, S
   Altshuler, L
   Frye, MA
   Luckenbaugh, DA
   Rowe, M
   Grunze, H
   Suppes, T
   Nolen, WA
AF Post, R. M.
   Leverich, G. S.
   Kupka, R.
   Keck, P., Jr.
   McElroy, S.
   Altshuler, L.
   Frye, M. A.
   Luckenbaugh, D. A.
   Rowe, M.
   Grunze, H.
   Suppes, T.
   Nolen, W. A.
TI Increased parental history of bipolar disorder in the United States:
   association with early age of onset
SO ACTA PSYCHIATRICA SCANDINAVICA
LA English
DT Article
DE assortative mating; bipolar disorder; childhood onset bipolar disorder;
   genetics
ID ASTERISK-D-CHILD; MATERNAL DEPRESSION; MENTAL-DISORDERS; OUTPATIENTS;
   RISK; RATINGS
AB Objective
   Early-onset bipolar (BP) disorder and other poor prognosis characteristics are more prevalent in patients from the United States than from the Netherlands and Germany (abbreviated as Europe). We explored the impact of parental loading for affective illness on onset and other characteristics of BP disorder.
   Method
   Parental history for unipolar (UP) and bipolar (BP) depression and course of illness characteristics were obtained from self-report in adults (average age 42) with BP disorder. Illness characteristics were examined by chi(2) and multinomial logistic regression in relationship to the degree of parental loading: i) both parents negative; ii) one UP disorder; iii) one with BP disorder; and iv) both affected.
   Results
   After controlling for many poor prognosis factors, compared with those from Europe, patients from the United States had more iii) one parent with BP disorder and iv) both parents affected. An early age of onset of BP disorder was independently associated with this increased parental loading for affective disorder.
   Conclusion
   Parental history of BP disorder and both parents with a mood disorder were more common in the United States than Europe and were associated with an early onset of bipolar disorder and other poor prognosis characteristics. These findings deserve replication and exploration of the potential mechanisms involved and their therapeutic implications.
C1 [Post, R. M.; Leverich, G. S.; Rowe, M.] Bipolar Collaborat Network, Bethesda, MD 20814 USA.
   [Post, R. M.] George Washington Univ, Dept Psychiat & Behav Sci, Washington, DC USA.
   [Kupka, R.] Vrije Univ Amsterdam, Dept Psychiat, Med Ctr, Amsterdam, Netherlands.
   [Keck, P., Jr.] Univ Cincinnati, Coll Med, Dept Psychiat & Behav Neurosci, Cincinnati, OH USA.
   [Keck, P., Jr.; McElroy, S.] Lindner Ctr HOPE, Mason, OH USA.
   [McElroy, S.] Univ Cincinnati, Coll Med, Biol Psychiat Program, Cincinnati, OH USA.
   [Altshuler, L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
   [Altshuler, L.] VA Greater Los Angeles Healthcare Syst, Dept Psychiat, West Los Angeles Healthcare Ctr, Los Angeles, CA USA.
   [Frye, M. A.] Mayo Clin, Dept Psychiat, Rochester, MI USA.
   [Luckenbaugh, D. A.] NIMH, NIH, Bethesda, MD 20892 USA.
   [Grunze, H.] Newcastle Univ, Inst Neurosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
   [Suppes, T.] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA.
   [Suppes, T.] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA.
   [Nolen, W. A.] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands.
RP Post, RM (reprint author), Bipolar Collaborat Network, 5415 W Cedar Lane 201B, Bethesda, MD 20814 USA.
EM robert.post@speakeasy.net
OI Grunze, Heinz/0000-0003-4712-8979
FU AstraZeneca; Alkermes; Cephalon; GlaxoSmithKline; Eli Lilly; Marriott
   Foundation; National Institute of Mental Health; National Institute of
   Drug Abuse; Orexigen; Pfizer Inc.; Shire; Abbott; Bristol-Myers Squibb;
   Forest; Jazz; Takeda; Johnson & Johnson Pharmaceutical Research
   Development; Sepracor; Takeda Pharmaceuticals North America, Inc.; H.
   Lundbeck A/S; Sunovion Pharmaceuticals Inc.; Pfizer; Astra-Zeneca; Bial;
   Janssen-Cilag; Sanofi-Aventis; Servier; United BioSource Corporation;
   Netherlands Organization for Health Research and Development; European
   Union; Stanley Medical Research Institute; Wyeth
FX Dr. Kupka has received research grants from AstraZeneca and honoraria
   from Eli Lilly, Janssen-Cilag, Bristol-Myers Squibb, and AstraZeneca.;
   Dr. Keck is employed by the University of Cincinnati College of Medicine
   and University of Cincinnati Physicians. Dr. Keck is a principal or
   coinvestigator on research studies sponsored by Alkermes, AstraZeneca,
   Cephalon, GlaxoSmithKline, Eli Lilly, Marriott Foundation, the National
   Institute of Mental Health, the National Institute of Drug Abuse,
   Orexigen, Pfizer Inc., and Shire, and has been reimbursed for consulting
   to, in the past 2 years, Bristol-Myers-Squibb, Teva, Otsuka, Forest,
   Merck, Sunovion, Alkermes, and Shire. Dr. Keck is also inventor on US
   Patent No. 6,387,956: Shapira NA, Goldsmith TD, Keck PE Jr (University
   of Cincinnati), Methods of Treating Obsessive-Compulsive Spectrum
   Disorder Comprises the Step of Administering an Effective Amount of
   Tramadol to an Individual; filed March 25, 1999; approved May 14, 2002.;
   Dr. McElroy is a consultant to or member of the scientific advisory
   boards of Eli Lilly and Schering-Plough and is a principal or
   coinvestigator on research studies sponsored by Abbott, AstraZeneca,
   Bristol-Myers Squibb, Cephalon, Eli Lilly, Forest, GlaxoSmithKline,
   Jazz, the Marriott Foundation, the National Institute of Mental Health,
   Orexigen, Shire, and Takeda. Dr. McElroy is also inventor on US Patent
   No. 6,323,236, Use of Sulfamate Derivatives for Treating Impulse Control
   Disorders, and, along with the patent's assignee, the University of
   Cincinnati, has received payments from Johnson & Johnson Pharmaceutical
   Research & Development, which has exclusive rights under the patent.;
   Dr. Altshuler has received past funding from Sepracor (advisory board
   honoraria, January 2010), and Eli Lilly (consultant, September 2010) and
   past and potential future funding from Takeda Pharmaceuticals North
   America, Inc., and H. Lundbeck A/S (advisory board honoraria, October
   2012) and Sunovion Pharmaceuticals Inc. (advisory board honoraria,
   January 2013).; Dr. Frye has received grant support from Pfizer (drug
   supply: varenicline), has been a consultant to Cephalon, Dainippon
   Sumitomo, Ortho McNeil/Janssen, Johnson & Johnson, Schering-Plough, and
   Pfizer, and has participated in supported CME activities for
   AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Otsuka,
   Pfizer, and Schering-Plough.; Dr. Grunze has received grant/research
   support, consulting fees, and honoraria within the last 3 years from
   Astra-Zeneca, Bial, Bristol-Myers Squibb, Eli Lilly, Lundbeck,
   Janssen-Cilag, Sanofi-Aventis, Servier, United BioSource Corporation.;
   Dr. Nolen has received grants from The Netherlands Organization for
   Health Research and Development, the European Union, The Stanley Medical
   Research Institute, AstraZeneca, Eli Lilly, GlaxoSmithKline, and Wyeth;
   has received honoraria or speaker's fees from AstraZeneca, Eli Lilly,
   Pfizer, Servier, and Wyeth; and has served on the advisory boards of
   AstraZeneca, Cyberonics, Pfizer, and Servier.
NR 25
TC 19
Z9 19
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0001-690X
EI 1600-0447
J9 ACTA PSYCHIAT SCAND
JI Acta Psychiatr. Scand.
PD MAY
PY 2014
VL 129
IS 5
SI SI
BP 375
EP 382
DI 10.1111/acps.12208
PG 8
WC Psychiatry
SC Psychiatry
GA AE8AP
UT WOS:000334221600006
PM 24138298
ER

PT J
AU Kirchmer, MN
   Franco, A
   Albasanz-Puig, A
   Murray, J
   Yagi, M
   Gao, L
   Dong, ZM
   Wijelath, ES
AF Kirchmer, Mayumi Namekata
   Franco, Anais
   Albasanz-Puig, Adaia
   Murray, Jacqueline
   Yagi, Mayumi
   Gao, Lu
   Dong, Zhao Ming
   Wijelath, Errol S.
TI Modulation of vascular smooth muscle cell phenotype by STAT-1 and STAT-3
SO ATHEROSCLEROSIS
LA English
DT Article
DE STAT-1; STAT-3; Smooth muscle cell; Phenotype; Oncostatin-M
ID COLONY-STIMULATING FACTOR; C-FOS PROMOTER; ONCOSTATIN-M;
   GENE-EXPRESSION; ACTIVATION; ATHEROSCLEROSIS; DIFFERENTIATION;
   INFLAMMATION; MYOCARDIN; PROLIFERATION
AB Objective: Smooth muscle cell (SMC) de-differentiation is a key step that leads to pathological narrowing of blood vessels. De-differentiation involves a reduction in the expression of the SMC contractile genes that are the hallmark of quiescent SMCs. While there is considerable evidence linking inflammation to vascular diseases, very little is known about the mechanisms by which inflammatory signals lead to SMC de-differentiation. Given that the Signal Transducers and Activators of Transcription (STAT) transcriptional factors are the key signaling molecules activated by many inflammatory cytokines and growth factors, the aim of the present study was to determine if STAT transcriptional factors play a role SMC dedifferentiation.
   Methods and results: Using shRNA targeted to STAT-1 and STAT-3, we show by real time RT-PCR and Western immunoblots that STAT-1 significantly reduces SMC contractile gene expression. In contrast, STAT-3 promotes expression of SMC contractile genes. Over-expression studies of STAT-1 and STAT-3 confirmed our observation that STAT-1 down-regulates whereas STAT-3 promotes SMC contractile gene expression. Bioinformatics analysis shows that promoters of all SMC contractile genes contain STAT binding sites. Finally, using ChIP analysis, we show that both STAT-1 and STAT-3 associate with the calponin gene.
   Conclusion: These data indicate that the balance of STAT-1 and STAT-3 influences the differentiation status of SMCs. Increased levels of STAT-1 promote SMC de-differentiation, whereas high levels of STAT-3 drive SMC into a more mature phenotype. Thus, inhibition of STAT-1 may represent a novel target for therapeutic intervention in the control of vascular diseases such as atherosclerosis and restenosis. Published by Elsevier Ireland Ltd.
C1 [Wijelath, Errol S.] VA Puget Sound Hlth Care Syst, Dept Surg, Div Vasc Surg, Seattle, WA USA.
   Univ Washington, Sch Med, Seattle, WA USA.
RP Wijelath, ES (reprint author), Dept Vet Affairs Med Ctr, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM errolw@u.washington.edu
FU U.S. Department of Veterans Affairs, Office of Research and Development,
   Biomedical Laboratory Research Program
FX This work was funded by a grant from the U.S. Department of Veterans
   Affairs, Office of Research and Development, Biomedical Laboratory
   Research Program.
NR 35
TC 8
Z9 9
U1 0
U2 5
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAY
PY 2014
VL 234
IS 1
BP 169
EP 175
DI 10.1016/j.atherosclerosis.2014.02.029
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA AE9ON
UT WOS:000334337300028
PM 24657387
ER

PT J
AU Lovejoy, TI
   Heckman, TG
AF Lovejoy, Travis I.
   Heckman, Timothy G.
CA Project SAFER Intervention Team
TI Telephone-Administered Motivational Interviewing and Behavioral Skills
   Training to Reduce Risky Sexual Behavior in HIV-Positive Late Middle-Age
   and Older Adults
SO COGNITIVE AND BEHAVIORAL PRACTICE
LA English
DT Article
DE HIV/AIDS; older adults; risky sexual behavior; motivational;
   interviewing; behavioral skills training
ID OUTCOMES; TRIAL
AB By 2014, 50% of all persons living with HIV/AIDS in the U.S. will be 50 years of age or older. An estimated 13% to 30% of HIV-positive older adults continue to engage in risky sexual behaviors that risk HIV transmission. Project SAFER, a large pilot randomized controlled trial, evaluated telephone-administered motivational interviewing and behavioral skills training to reduce sexual risk behavior in HIV-positive, urban-dwelling late middle-age and older adults. The intervention consists of 4 weekly integrated motivational interviewing and behavioral skills training sessions delivered by a mental health clinician over the telephone. This paper highlights study procedures and intervention outcomes. The primary focus, however, is a detailed description of the 4-session intervention with sample counselor-client dialogue that is thematically emblematic of topics addressed in the intervention. We conclude with lessons learned conducting telephone-administered motivational interviewing and behavioral skills training with HIV-positive late middle-age and older adults.
C1 [Lovejoy, Travis I.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
   [Lovejoy, Travis I.] Portland VA Med Ctr, Portland, OR 97239 USA.
   [Heckman, Timothy G.] Univ Georgia, Athens, GA 30602 USA.
   [Project SAFER Intervention Team] Ohio Univ, Athens, OH 45701 USA.
RP Lovejoy, TI (reprint author), Portland VA Med Ctr, Mental Hlth & Clin Neurosci Div, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM travis.lovejoy@va.gov
NR 24
TC 4
Z9 4
U1 1
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1077-7229
EI 1878-187X
J9 COGN BEHAV PRACT
JI Cogn. Behav. Pract.
PD MAY
PY 2014
VL 21
IS 2
BP 224
EP 236
PG 13
WC Psychology, Clinical
SC Psychology
GA AE7AZ
UT WOS:000334150400012
ER

PT J
AU Shamsi, MM
   Hassan, ZH
   Gharakhanlou, R
   Quinn, LS
   Azadmanesh, K
   Baghersad, L
   Isanejad, A
   Mahdavi, M
AF Shamsi, M. Molanouri
   Hassan, Z. H.
   Gharakhanlou, R.
   Quinn, L. S.
   Azadmanesh, K.
   Baghersad, L.
   Isanejad, A.
   Mahdavi, M.
TI Expression of interleukin-15 and inflammatory cytokines in skeletal
   muscles of STZ-induced diabetic rats: effect of resistance exercise
   training
SO ENDOCRINE
LA English
DT Article
DE Interleukin-15; Inflammatory cytokines; Resistance training; Type-1
   diabetes
ID RECEPTOR-ALPHA EXPRESSION; OXIDATIVE STRESS; GLUCOSE-UPTAKE;
   MESSENGER-RNA; GROWTH-FACTOR; IN-VITRO; HYPERTROPHY; ATROPHY; DAMAGE;
   RESPONSES
AB Skeletal muscle atrophy is associated with type-1 diabetes. Skeletal muscle is the source of pro- and anti-inflammatory cytokines that can mediate muscle hypertrophy and atrophy, while resistance exercise can modulate both muscle mass and muscle cytokine expression. This study determined the effects of a 5-week resistance exercise training regimen on the expression of muscle cytokines in healthy and streptozotocin-induced diabetic rats, with special emphasis on interleukin-15 (IL-15), a muscle-derived cytokine proposed to be involved in muscle hypertrophy or responses to stress. Induction of diabetes reduced muscle weight in both the fast flexor hallucis longus (FHL) and slow soleus muscles, while resistance training preserved FHL muscle weight in diabetic rats. IL-15 protein content was increased by training in both FHL and soleus muscles, as well as serum, in normal and diabetic rats. With regard to proinflammatory cytokines, muscle IL-6 levels were increased in diabetic rats, while training decreased muscle IL-6 levels in diabetic rats; training had no effect on FHL muscle IL-6 levels in healthy rats. Also, tumor necrosis factor-alpha (TNF-alpha) and IL-1 beta levels were increased by diabetes, but not changed by training. In conclusion, we found that in diabetic rats, resistance training increased muscle and serum IL-15 levels, decreased muscle IL-6 levels, and preserved FHL muscle mass.
C1 [Shamsi, M. Molanouri; Gharakhanlou, R.; Baghersad, L.] Tarbiat Modares Univ, Fac Humanities, Phys Educ & Sport Sci Dept, Tehran 1411713116, Iran.
   [Hassan, Z. H.] Tarbiat Modares Univ, Sch Med Sci, Dept Immunol, Tehran 1411513116, Iran.
   [Quinn, L. S.] Univ Washington, Geriatr Res Educ & Clin Ctr, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
   [Quinn, L. S.] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98108 USA.
   [Azadmanesh, K.; Mahdavi, M.] Pasteur Inst Iran, Dept Virol, Tehran, Iran.
   [Isanejad, A.] Shahed Univ, Fac Humanities, Phys Educ & Sport Sci Dept, Tehran, Iran.
RP Shamsi, MM (reprint author), Tarbiat Modares Univ, Fac Humanities, Phys Educ & Sport Sci Dept, Tehran 1411713116, Iran.
EM Mahdieh_molanouri@yahoo.com; Hassan_zm@modares.ac.ir;
   ghara_re@modares.ac.ir; quinnL@uw.edu; azadmanesh@pasteur.ac.ir;
   l.baghersad@gmail.com; sa61es@yahoo.com; mahdavivac@gmail.com
FU Research Center of Tarbiat Modares University (TMU), Tehran, Iran
FX This work was supported by the Research Center of Tarbiat Modares
   University (TMU), Tehran, Iran. We wish to thank Professor Yaghob
   Fathoallahy and Dr Alireza Mani for their kind help and sincere
   cooperation.
NR 59
TC 15
Z9 15
U1 0
U2 11
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1355-008X
EI 1559-0100
J9 ENDOCRINE
JI Endocrine
PD MAY
PY 2014
VL 46
IS 1
BP 60
EP 69
DI 10.1007/s12020-013-0038-4
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA AE7LP
UT WOS:000334179700010
ER

PT J
AU Werth, VP
AF Werth, V. P.
TI Introduction of approach
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT 3rd International Conference on Cutaneous Lupus Erythematosus
CY MAY 06-08, 2013
CL Edinburgh, SCOTLAND
C1 [Werth, V. P.] Philadelphia Vet Affairs Med Ctr, Dept Dermatol, Philadelphia, PA USA.
   [Werth, V. P.] Univ Penn, Philadelphia, PA 19104 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
EI 1523-1747
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2014
VL 134
IS 5
BP 1484
EP 1484
PG 1
WC Dermatology
SC Dermatology
GA AF2VJ
UT WOS:000334570300048
ER

PT J
AU Szepietowski, JC
   Werth, V
   Furukawa, F
   Samotij, D
   Reich, A
AF Szepietowski, J. C.
   Werth, V.
   Furukawa, F.
   Samotij, D.
   Reich, A.
TI Current practice variations in cutaneous lupus therapy and thoughts
   about international guidelines
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT 3rd International Conference on Cutaneous Lupus Erythematosus
CY MAY 06-08, 2013
CL Edinburgh, SCOTLAND
C1 [Szepietowski, J. C.; Samotij, D.; Reich, A.] Wroclaw Med Univ, Dept Dermatol Venereol & Allergol, Wroclaw, Poland.
   [Werth, V.] Philadelphia Vet Affairs Med Ctr, Dept Dermatol, Philadelphia, PA USA.
   [Werth, V.] Univ Penn, Philadelphia, PA 19104 USA.
   [Furukawa, F.] Wakayama Med Univ, Dept Dermatol, Wakayama, Japan.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
EI 1523-1747
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2014
VL 134
IS 5
BP 1485
EP 1485
PG 1
WC Dermatology
SC Dermatology
GA AF2VJ
UT WOS:000334570300058
ER

PT J
AU Verma, SM
   Werth, VP
AF Verma, S. M.
   Werth, V. P.
TI Quality of Life in Lupus and Dermatomyositis
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT 3rd International Conference on Cutaneous Lupus Erythematosus
CY MAY 06-08, 2013
CL Edinburgh, SCOTLAND
C1 [Verma, S. M.] Vet Affairs Med Ctr, Dept Dermatol, Philadelphia, PA USA.
   [Verma, S. M.] Univ Penn, Philadelphia, PA 19104 USA.
NR 0
TC 0
Z9 0
U1 2
U2 3
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
EI 1523-1747
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2014
VL 134
IS 5
BP 1485
EP 1485
PG 1
WC Dermatology
SC Dermatology
GA AF2VJ
UT WOS:000334570300054
ER

PT J
AU Werth, VP
AF Werth, V. P.
TI New clinical treatments in CLE
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT 3rd International Conference on Cutaneous Lupus Erythematosus
CY MAY 06-08, 2013
CL Edinburgh, SCOTLAND
C1 [Werth, V. P.] Philadelphia Vet Affairs Med Ctr, Dept Dermatol, Philadelphia, PA USA.
   [Werth, V. P.] Univ Penn, Philadelphia, PA 19104 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
EI 1523-1747
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2014
VL 134
IS 5
BP 1486
EP 1486
PG 1
WC Dermatology
SC Dermatology
GA AF2VJ
UT WOS:000334570300064
ER

PT J
AU Chun, AC
AF Chun, Ang Chia
TI Lung diseases in dermatomyositis
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT 3rd International Conference on Cutaneous Lupus Erythematosus
CY MAY 06-08, 2013
CL Edinburgh, SCOTLAND
C1 [Chun, Ang Chia] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
   [Chun, Ang Chia] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA.
   [Chun, Ang Chia] Changi Gen Hosp, Dept Dermatol, Singapore, Singapore.
RI hui, li/L-5008-2013
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
EI 1523-1747
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2014
VL 134
IS 5
BP 1488
EP 1488
PG 1
WC Dermatology
SC Dermatology
GA AF2VJ
UT WOS:000334570300075
ER

PT J
AU Ang, CC
   Anyanwu, C
   Werth, VP
AF Ang, C. C.
   Anyanwu, C.
   Werth, V. P.
TI Dermatomyositis patients with mechanic's hands have a higher risk of
   both early and established interstitial lung disease
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT 3rd International Conference on Cutaneous Lupus Erythematosus
CY MAY 06-08, 2013
CL Edinburgh, SCOTLAND
C1 Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA.
   Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
EI 1523-1747
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2014
VL 134
IS 5
BP 1489
EP 1489
PG 1
WC Dermatology
SC Dermatology
GA AF2VJ
UT WOS:000334570300079
ER

PT J
AU Anyanwu, C
   Propert, K
   Werth, VP
AF Anyanwu, C.
   Propert, K.
   Werth, V. P.
TI Determination of cutaneous dermatomyositis severity using the cutaneous
   dermatomyositis disease area and severity index
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT 3rd International Conference on Cutaneous Lupus Erythematosus
CY MAY 06-08, 2013
CL Edinburgh, SCOTLAND
C1 [Anyanwu, C.; Werth, V. P.] Univ Penn, Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
   [Anyanwu, C.; Werth, V. P.] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA.
   [Propert, K.] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
EI 1523-1747
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2014
VL 134
IS 5
BP 1489
EP 1489
PG 1
WC Dermatology
SC Dermatology
GA AF2VJ
UT WOS:000334570300081
ER

PT J
AU Boyers, LN
   Karimkhani, C
   Crane, L
   Asdigian, N
   Hollonds, A
   Dellavalle, R
AF Boyers, L. N.
   Karimkhani, C.
   Crane, L.
   Asdigian, N.
   Hollonds, A.
   Dellavalle, R.
TI Buying indoor UV tanning with university debit cards
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the Society-for-Investigative-Dermatology (SID)
CY MAY 07-10, 2014
CL Albuquerque, NM
SP Soc Invest Dermatol
C1 [Boyers, L. N.] Georgetown Univ, Sch Med, Washington, DC USA.
   [Dellavalle, R.] Univ Colorado, Sch Med, Denver, CO USA.
   [Dellavalle, R.] Dept Vet Affairs Denver, Denver, CO USA.
   [Karimkhani, C.] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA.
   [Crane, L.; Asdigian, N.; Hollonds, A.] Colorado Sch Publ Hlth, Dept Community & Behav Hlth, Denver, CO USA.
   [Dellavalle, R.] US Dept Vet Affairs, Denver, CO USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
EI 1523-1747
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2014
VL 134
SU 1
MA 290
BP S50
EP S50
PG 1
WC Dermatology
SC Dermatology
GA AF2RT
UT WOS:000334560400289
ER

PT J
AU Katiyar, SK
   Singh, T
   Vaid, M
AF Katiyar, S. K.
   Singh, T.
   Vaid, M.
TI Dietary proanthocyanidins inhibit UV-induced immune suppression by
   decreasing the functional activation of suppressor T cells in mice
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the Society-for-Investigative-Dermatology (SID)
CY MAY 07-10, 2014
CL Albuquerque, NM
SP Soc Invest Dermatol
C1 [Katiyar, S. K.; Singh, T.; Vaid, M.] Univ Alabama Birmingham, Birmingham, AL USA.
   [Katiyar, S. K.] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
EI 1523-1747
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2014
VL 134
SU 1
MA 651
BP S114
EP S114
PG 1
WC Dermatology
SC Dermatology
GA AF2RT
UT WOS:000334560400649
ER

PT J
AU Landow, S
   Oh, DH
   Weinstock, MA
AF Landow, S.
   Oh, D. H.
   Weinstock, M. A.
TI Teledermatology programs in the veterans health administration
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the Society-for-Investigative-Dermatology (SID)
CY MAY 07-10, 2014
CL Albuquerque, NM
SP Soc Invest Dermatol
C1 [Landow, S.; Weinstock, M. A.] Brown Univ, Providence, RI 02912 USA.
   [Oh, D. H.] UCSF, San Francisco, CA USA.
   [Landow, S.; Weinstock, M. A.] Providence VA Med Ctr, Dermatoepidemiol Unit, Providence, RI USA.
   [Oh, D. H.] San Francisco VA Med Ctr, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
EI 1523-1747
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2014
VL 134
SU 1
MA 324
BP S56
EP S56
PG 1
WC Dermatology
SC Dermatology
GA AF2RT
UT WOS:000334560400323
ER

PT J
AU Luo, Y
   Liu, S
   Kutty, LK
   Arcaroli, JJ
   Robinson, SE
   Robinson, WA
   Norris, DA
   Messersmith, WA
   Fujita, M
AF Luo, Y.
   Liu, S.
   Kutty, L. K.
   Arcaroli, J. J.
   Robinson, S. E.
   Robinson, W. A.
   Norris, D. A.
   Messersmith, W. A.
   Fujita, M.
TI Methods of generating single cell suspensions from tumor tissues
   influence the frequency of tumor-initiating cells
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the Society-for-Investigative-Dermatology (SID)
CY MAY 07-10, 2014
CL Albuquerque, NM
SP Soc Invest Dermatol
C1 [Luo, Y.; Liu, S.; Kutty, L. K.; Arcaroli, J. J.; Robinson, S. E.; Robinson, W. A.; Norris, D. A.; Messersmith, W. A.; Fujita, M.] Univ Colorado Denver, Aurora, CO USA.
   [Norris, D. A.; Fujita, M.] Denver Vet Affairs Med Ctr, Denver, CO USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
EI 1523-1747
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2014
VL 134
SU 1
MA 728
BP S127
EP S127
PG 1
WC Dermatology
SC Dermatology
GA AF2RT
UT WOS:000334560400726
ER

PT J
AU Luo, Y
   Liu, S
   Lee, J
   Robinson, SE
   Robinson, WA
   Norris, DA
   Dinarello, CA
   Fujita, M
AF Luo, Y.
   Liu, S.
   Lee, J.
   Robinson, S. E.
   Robinson, W. A.
   Norris, D. A.
   Dinarello, C. A.
   Fujita, M.
TI IL-37, an inhibitor of innate inflammation and adaptive immunity, is
   elevated in the blood of melanoma patients and is related with poor
   prognosis
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the Society-for-Investigative-Dermatology (SID)
CY MAY 07-10, 2014
CL Albuquerque, NM
SP Soc Invest Dermatol
C1 [Luo, Y.; Liu, S.; Lee, J.; Robinson, S. E.; Robinson, W. A.; Norris, D. A.; Dinarello, C. A.; Fujita, M.] Univ Colorado Denver, Aurora, CO USA.
   [Norris, D. A.; Fujita, M.] Denver Vet Affairs Med Ctr, Denver, CO USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
EI 1523-1747
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2014
VL 134
SU 1
MA 577
BP S100
EP S100
PG 1
WC Dermatology
SC Dermatology
GA AF2RT
UT WOS:000334560400576
ER

PT J
AU Okhovat, J
   Zhu, W
   Agak, GW
   Qin, M
   Park, AJ
   Garban, HJ
   Kim, J
AF Okhovat, J.
   Zhu, W.
   Agak, G. W.
   Qin, M.
   Park, A. J.
   Garban, H. J.
   Kim, J.
TI Differential inflammatory response of Propionibacterium acnes strains on
   sebocytes and keratinocytes
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the Society-for-Investigative-Dermatology (SID)
CY MAY 07-10, 2014
CL Albuquerque, NM
SP Soc Invest Dermatol
C1 [Okhovat, J.; Zhu, W.; Agak, G. W.; Qin, M.; Park, A. J.; Garban, H. J.; Kim, J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Dermatol, Los Angeles, CA 90095 USA.
   [Kim, J.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
EI 1523-1747
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2014
VL 134
SU 1
MA 642
BP S112
EP S112
PG 1
WC Dermatology
SC Dermatology
GA AF2RT
UT WOS:000334560400640
ER

PT J
AU Okon, LG
   Feng, R
   Werth, V
AF Okon, L. G.
   Feng, R.
   Werth, V.
TI Novel topical cream delivers safe and effective alternative to
   traditional psoriasis phototherapy
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the Society-for-Investigative-Dermatology (SID)
CY MAY 07-10, 2014
CL Albuquerque, NM
SP Soc Invest Dermatol
C1 [Werth, V.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
   [Okon, L. G.; Feng, R.; Werth, V.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
EI 1523-1747
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2014
VL 134
SU 1
BP S97
EP S97
PG 1
WC Dermatology
SC Dermatology
GA AF2RT
UT WOS:000334560400558
ER

PT J
AU Park, AJ
   Oin, M
   Garban, HJ
   Kim, J
AF Park, A. J.
   Oin, M.
   Garban, H. J.
   Kim, J.
TI Interleukin-37 is a potent inhibitor of inflammatory responses induced
   by Propionibacterium acnes and ultraviolet B radiation in human
   keratinocytes
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the Society-for-Investigative-Dermatology (SID)
CY MAY 07-10, 2014
CL Albuquerque, NM
SP Soc Invest Dermatol
C1 [Park, A. J.; Oin, M.; Garban, H. J.; Kim, J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Dermatol, Los Angeles, CA 90095 USA.
   [Kim, J.] Greater Los Angeles Vet Affairs Healthcare Syst, Dept Dermatol, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
EI 1523-1747
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2014
VL 134
SU 1
MA 640
BP S112
EP S112
PG 1
WC Dermatology
SC Dermatology
GA AF2RT
UT WOS:000334560400638
ER

PT J
AU Park, AJ
   Qin, M
   Hisaw, LD
   Pirouz, A
   Agak, GW
   Marinelli, L
   Garban, HJ
   Kim, J
AF Park, A. J.
   Qin, M.
   Hisaw, L. D.
   Pirouz, A.
   Agak, G. W.
   Marinelli, L.
   Garban, H. J.
   Kim, J.
TI G2A attenuates Propionibacterium acnes induction of inflammatory
   cytokines via regulation of MAPK signaling and is regulated by
   13-cis-retinoic acid
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the Society-for-Investigative-Dermatology (SID)
CY MAY 07-10, 2014
CL Albuquerque, NM
SP Soc Invest Dermatol
C1 [Park, A. J.; Qin, M.; Hisaw, L. D.; Pirouz, A.; Agak, G. W.; Marinelli, L.; Garban, H. J.; Kim, J.] Univ Calif Los Angeles, David Geffen Sch Med, Div Dermatol, Dept Med, Los Angeles, CA 90095 USA.
   [Kim, J.] VA Greater Los Angeles Healthcare Syst, Dept Dermatol, Los Angeles, CA USA.
   [Marinelli, L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
EI 1523-1747
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2014
VL 134
SU 1
MA 627
BP S109
EP S109
PG 1
WC Dermatology
SC Dermatology
GA AF2RT
UT WOS:000334560400625
ER

PT J
AU Prasad, R
   Vaid, M
   Singh, T
   Katiyar, SK
AF Prasad, R.
   Vaid, M.
   Singh, T.
   Katiyar, S. K.
TI High-fat diet stimulates the growth of UV radiation-induced skin tumors
   by enhancing DNA hypermethylation and silencing of tumor suppressor
   genes in mouse skin and tumors
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the Society-for-Investigative-Dermatology (SID)
CY MAY 07-10, 2014
CL Albuquerque, NM
SP Soc Invest Dermatol
C1 [Prasad, R.; Vaid, M.; Singh, T.; Katiyar, S. K.] Univ Alabama Birmingham, Birmingham, AL USA.
   [Katiyar, S. K.] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
EI 1523-1747
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2014
VL 134
SU 1
MA 652
BP S114
EP S114
PG 1
WC Dermatology
SC Dermatology
GA AF2RT
UT WOS:000334560400650
ER

PT J
AU Qin, M
   Park, AJ
   Agak, GW
   Garban, HJ
   Kim, J
AF Qin, M.
   Park, A. J.
   Agak, G. W.
   Garban, H. J.
   Kim, J.
TI Human keratinocytes display distinct NOD-like receptor expression
   signatures when exposed to Propionibacterium acnes and ultraviolet B
   radiation
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the Society-for-Investigative-Dermatology (SID)
CY MAY 07-10, 2014
CL Albuquerque, NM
SP Soc Invest Dermatol
C1 [Qin, M.; Park, A. J.; Agak, G. W.; Garban, H. J.; Kim, J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Dermatol, Los Angeles, CA 90095 USA.
   [Kim, J.] VA Greater Los Angeles Healthcare Syst, Dept Dermatol, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
EI 1523-1747
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2014
VL 134
SU 1
MA 644
BP S112
EP S112
PG 1
WC Dermatology
SC Dermatology
GA AF2RT
UT WOS:000334560400642
ER

PT J
AU Sharma, M
   Werth, V
AF Sharma, M.
   Werth, V.
TI Role of UVB-induced neutrophils in collagenase induction, and collagen
   fragmentation
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the Society-for-Investigative-Dermatology (SID)
CY MAY 07-10, 2014
CL Albuquerque, NM
SP Soc Invest Dermatol
C1 [Sharma, M.; Werth, V.] Univ Penn, Philadelphia, PA 19104 USA.
   [Sharma, M.; Werth, V.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
EI 1523-1747
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2014
VL 134
SU 1
MA 681
BP S119
EP S119
PG 1
WC Dermatology
SC Dermatology
GA AF2RT
UT WOS:000334560400679
ER

PT J
AU Yu, KK
   Crew, AB
   Messingham, K
   Fairley, JA
   Woodley, DT
AF Yu, K. K.
   Crew, A. B.
   Messingham, K.
   Fairley, J. A.
   Woodley, D. T.
TI Successful biologic therapy for bullous pemphigoid
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the Society-for-Investigative-Dermatology (SID)
CY MAY 07-10, 2014
CL Albuquerque, NM
SP Soc Invest Dermatol
C1 [Yu, K. K.; Crew, A. B.; Woodley, D. T.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA.
   [Messingham, K.; Fairley, J. A.] Univ Iowa, Carver Coll Med, Iowa City, IA USA.
   [Fairley, J. A.] Iowa City VA Med Ctr, Iowa City, IA USA.
   [Woodley, D. T.] Los Angeles VA Med Ctr, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
EI 1523-1747
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2014
VL 134
SU 1
MA 154
BP S26
EP S26
PG 1
WC Dermatology
SC Dermatology
GA AF2RT
UT WOS:000334560400155
ER

PT J
AU Zhai, Z
   Liu, W
   Kaur, M
   Luo, Y
   Norris, DA
   Dinarello, CA
   Spritz, RA
   Fujita, M
AF Zhai, Z.
   Liu, W.
   Kaur, M.
   Luo, Y.
   Norris, D. A.
   Dinarello, C. A.
   Spritz, R. A.
   Fujita, M.
TI NLRP1 is involved in melanoma tumorigenesis and temozolomide
   chemoresistance
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the Society-for-Investigative-Dermatology (SID)
CY MAY 07-10, 2014
CL Albuquerque, NM
SP Soc Invest Dermatol
C1 [Zhai, Z.; Liu, W.; Kaur, M.; Luo, Y.; Norris, D. A.; Dinarello, C. A.; Spritz, R. A.; Fujita, M.] Univ Colorado Denver SOM, Aurora, CO USA.
   [Norris, D. A.; Fujita, M.] Denver Vet Affairs Med Ctr, Denver, CO USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
EI 1523-1747
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2014
VL 134
SU 1
MA 727
BP S127
EP S127
PG 1
WC Dermatology
SC Dermatology
GA AF2RT
UT WOS:000334560400725
ER

PT J
AU Peterson, CL
   Riley, ZA
   Krepkovich, ET
   Murray, WM
   Perreault, EJ
AF Peterson, Carrie L.
   Riley, Zachary A.
   Krepkovich, Eileen T.
   Murray, Wendy M.
   Perreault, Eric J.
TI WITHDRAWAL REFLEXES IN THE UPPER LIMB ADAPT TO ARM POSTURE AND STIMULUS
   LOCATION
SO MUSCLE & NERVE
LA English
DT Article
DE endpoint force; fingertip stimulation; humans; motor control;
   nociceptive; spinal reflexes
ID II MUSCLE AFFERENTS; FUNCTIONAL-ORGANIZATION; CUTANEOUS AFFERENTS; UPPER
   EXTREMITY; ELECTRICAL-STIMULATION; FINGERTIP STIMULATION; MODULAR
   ORGANIZATION; NOCICEPTIVE REFLEXES; RECEPTIVE-FIELDS; FOOT-SOLE
AB Introduction: Withdrawal reflexes in the leg adapt in a context-appropriate manner to remove the limb from noxious stimuli, but the extent to which withdrawal reflexes adapt in the arm remains unknown. Methods: We examined the adaptability of withdrawal reflexes in response to nociceptive stimuli applied in different arm postures and to different digits. Reflexes were elicited at rest, and kinetic and electromyographic responses were recorded under isometric conditions, thereby allowing motorneuron pool excitability to be controlled. Results: Endpoint force changed from a posterior-lateral direction in a flexed posture to predominantly a posterior direction in a more extended posture [change in force angle (mean +/- standard deviation) 35.6 +/- 5.0 degrees], and the force direction changed similarly with digit I stimulation compared with digit V (change=22.9 +/- 2.9 degrees). Conclusions: The withdrawal reflex in the human upper limb adapts in a functionally relevant manner when elicited at rest. Muscle Nerve49: 716-723, 2014
C1 [Peterson, Carrie L.; Murray, Wendy M.; Perreault, Eric J.] Rehabil Inst Chicago, Sensory Motor Performance Program, Chicago, IL 60611 USA.
   [Peterson, Carrie L.; Murray, Wendy M.; Perreault, Eric J.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA.
   [Riley, Zachary A.] Indiana Univ Purdue Univ, Dept Kinesiol, Indianapolis, IN 46202 USA.
   [Krepkovich, Eileen T.] Barron Associates Inc, Charlottesville, VA USA.
   [Murray, Wendy M.; Perreault, Eric J.] Northwestern Univ, Dept Biomed Engn, Evanston, IL 60208 USA.
   [Murray, Wendy M.; Perreault, Eric J.] Northwestern Univ, Dept Phys Med & Rehabil, Evanston, IL USA.
RP Peterson, CL (reprint author), Rehabil Inst Chicago, Sensory Motor Performance Program, 345 East Super St, Chicago, IL 60611 USA.
EM cpeterson@ric.org
RI Murray, Wendy/B-7629-2009; Perreault, Eric/B-7632-2009; Murray,
   Wendy/D-1520-2009; Peterson, Carrie/C-6007-2016
OI Murray, Wendy/0000-0002-7547-621X; Peterson, Carrie/0000-0002-7169-2089
FU Nielsen Foundation [84054]
FX This work was funded by the Nielsen Foundation (84054).
NR 38
TC 0
Z9 0
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0148-639X
EI 1097-4598
J9 MUSCLE NERVE
JI Muscle Nerve
PD MAY
PY 2014
VL 49
IS 5
BP 716
EP 723
DI 10.1002/mus.23987
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA AF0TK
UT WOS:000334426800014
PM 23929755
ER

PT J
AU Siddesha, JM
   Valente, AJ
   Yoshida, T
   Sakamuri, SSVP
   Delafontaine, P
   Iba, H
   Noda, M
   Chandrasekar, B
AF Siddesha, Jalahalli M.
   Valente, Anthony J.
   Yoshida, Tadashi
   Sakamuri, Siva S. V. P.
   Delafontaine, Patrice
   Iba, Hideo
   Noda, Makoto
   Chandrasekar, Bysani
TI Docosahexaenoic acid reverses angiotensin II-induced RECK suppression
   and cardiac fibroblast migration
SO CELLULAR SIGNALLING
LA English
DT Article
DE Fibrosis; RECK; MicroRNA; omega-3 lipids; PTEN; SPRY1
ID POLYUNSATURATED FATTY-ACIDS; MYOCARDIAL-INFARCTION; CELL INVASION;
   METALLOPROTEINASE INHIBITORS; TARGETED DELETION; PRESSURE-OVERLOAD;
   HEART-FAILURE; EXPRESSION; MATRIX; MICRORNA-21
AB The omega-3 polyunsaturated fatty acids (omega-3 fatty adds) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have been reported to inhibit or delay the progression of cardiovascular diseases, including myocardial fibrosis. Recently we reported that angiotensin II (Ang II) promotes cardiac fibroblast (CF) migration by suppressing the MMP regulator reversion-inducing-cysteine-rich protein with Kazal motifs (RECK), through a mechanism dependent on AT1, ERK, and Sp1. Here we investigated the role of miR-21 in Ang II-mediated RECK suppression, and determined whether the to 3 fatty adds reverse these effects. Ang II induced miR-21 expression in primary mouse cardiac fibroblasts (CFs) via ERK-dependent AP-1 and STAT3 activation, and while a miR-21 inhibitor reversed Ang II-induced RECK suppression, a miR-21 mimic inhibited both RECK expression and Ang II-induced CF migration. Moreover, Ang II suppressed the pro-apoptotic PTEN, and the ERK negative regulator Sprouty homologue 1 (SPRY1), but induced the metalloendopeptidase MMP2, all in a manner that was miR-21-dependent. Further, forced expression of PTEN inhibited Akt phosphorylation, Spl activation, and MMP2 induction. Notably, while both EPA and DHA reversed Ang II-mediated RECK suppression, DHA appeared to be more effective, and reversed Ang II-induced miR-21 expression, RECK suppression, MMP2 induction, and CF migration. These results indicate that Ang II-induced CF migration is differentially regulated by miR-21-mediated MMP induction and RECK suppression, and that DHA has the potential to upregulate RECK, and therefore may exert potential beneficial effects in cardiac fibrosis. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Siddesha, Jalahalli M.; Chandrasekar, Bysani] Southeast Louisiana Vet Hlth Care Syst, Res Serv, New Orleans, LA 70161 USA.
   [Siddesha, Jalahalli M.; Yoshida, Tadashi; Sakamuri, Siva S. V. P.; Delafontaine, Patrice; Chandrasekar, Bysani] Tulane Univ, Sch Med, Inst Heart & Vasc, New Orleans, LA 70112 USA.
   [Valente, Anthony J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
   [Valente, Anthony J.] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
   [Iba, Hideo] Univ Tokyo, Dept Microbiol & Immunol, Tokyo 1088639, Japan.
   [Noda, Makoto] Kyoto Univ, Dept Mol Oncol, Grad Sch Med, Sakyo Ku, Kyoto 6068501, Japan.
RP Chandrasekar, B (reprint author), Tulane Univ, Sch Med, Inst Heart & Vasc, 1430 Tulane Ave,SL-48, New Orleans, LA 70112 USA.
EM bchandra@tulane.edu
OI Delafontaine, Patrice/0000-0003-3744-3617; Yoshida,
   Tadashi/0000-0002-4544-1497
FU Development Biomedical Laboratory Research and Development Service Award
   [1101BX000246]; NIH/NHLBI [HL-86787];  [HL-70241];  [HL-80682]
FX BC is a recipient of the Department of Veterans Affairs Research Career
   Scientist award, and is supported by the VA Office of Research and
   Development Biomedical Laboratory Research and Development Service Award
   1101BX000246 and the NIH/NHLBI grant HL-86787. PD is supported by
   HL-70241 and HL-80682. The contents of this report do not represent the
   views of the Department of Veterans Affairs or the United States
   Government.
NR 40
TC 9
Z9 9
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0898-6568
EI 1873-3913
J9 CELL SIGNAL
JI Cell. Signal.
PD MAY
PY 2014
VL 26
IS 5
BP 933
EP 941
DI 10.1016/j.cellsig2014.01.005
PG 9
WC Cell Biology
SC Cell Biology
GA AE4IT
UT WOS:000333946800011
PM 24447911
ER

PT J
AU Safdar, N
   Anderson, DJ
   Braun, BI
   Carling, P
   Cohen, S
   Donskey, C
   Drees, M
   Harris, A
   Henderson, DK
   Huang, SS
   Juthani-Mehta, M
   Lautenbach, E
   Linkin, DR
   Meddings, J
   Miller, LG
   Milstone, A
   Morgan, D
   Sengupta, S
   Varman, M
   Yokoe, D
   Zerr, DM
AF Safdar, Nasia
   Anderson, Deverick J.
   Braun, Barbara I.
   Carling, Philip
   Cohen, Stuart
   Donskey, Curtis
   Drees, Marci
   Harris, Anthony
   Henderson, David K.
   Huang, Susan S.
   Juthani-Mehta, Manisha
   Lautenbach, Ebbing
   Linkin, Darren R.
   Meddings, Jennifer
   Miller, Loren G.
   Milstone, Aaron
   Morgan, Daniel
   Sengupta, Sharmila
   Varman, Meera
   Yokoe, Deborah
   Zerr, Danielle M.
CA Soc Healthcare Epidemiology Amer
TI The Evolving Landscape of Healthcare-Associated Infections: Recent
   Advances in Prevention and a Road Map for Research
SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
LA English
DT Article
ID SURGICAL-SITE INFECTIONS; VENTILATOR-ASSOCIATED PNEUMONIA; RANDOMIZED
   CONTROLLED-TRIAL; CARBAPENEMASE-PRODUCING ENTEROBACTERIACEAE;
   CATHETER-RELATED INFECTIONS; GENTAMICIN-COLLAGEN SPONGE;
   URINARY-TRACT-INFECTIONS; BLOOD-STREAM INFECTION; CRITICALLY-ILL ADULTS;
   INTENSIVE-CARE
AB This white paper identifies knowledge gaps and new challenges in healthcare epidemiology research, assesses the progress made toward addressing research priorities, provides the Society for Healthcare Epidemiology of America (SHEA) Research Committee's recommendations for high-priority research topics, and proposes a road map for making progress toward these goals. It updates the 2010 SHEA Research Committee document, "Charting the Course for the Future of Science in Healthcare Epidemiology: Results of a Survey of the Membership of SHEA," which called for a national approach to healthcare-associated infections (HAIs) and a prioritized research agenda. This paper highlights recent studies that have advanced our understanding of HAIs, the establishment of the SHEA Research Network as a collaborative infrastructure to address research questions, prevention initiatives at state and national levels, changes in reporting and payment requirements, and new patterns in antimicrobial resistance.
C1 [Safdar, Nasia] Univ Wisconsin, Div Infect Dis, William S Middleton Mem Vet Hosp, Madison, WI USA.
   [Anderson, Deverick J.] Duke Univ, Med Ctr, Dept Infect Dis, Durham, NC USA.
   [Braun, Barbara I.] Joint Commiss, Oak Brook Terrace, IL USA.
   [Carling, Philip] Boston Univ, Sch Med, Boston, MA 02118 USA.
   [Cohen, Stuart] Univ Calif Davis, Div Infect Dis, Sch Med Hosp Epidemiol & Infect Prevent, Sacramento, CA 95817 USA.
   [Donskey, Curtis] Louis Stokes Cleveland Vet Affairs Med Ctr, Cleveland, OH USA.
   [Drees, Marci] Christiana Care Hlth Syst, Newark, DE USA.
   [Harris, Anthony] Univ Maryland, Sch Med, EPH Genom Epidemiol & Clin Outcomes, Baltimore, MD 21201 USA.
   [Henderson, David K.] NIH, Ctr Clin, Bethesda, MD 20892 USA.
   [Huang, Susan S.] Univ Calif Irvine, Sch Med, Irvine, CA 92717 USA.
   [Juthani-Mehta, Manisha] Yale Univ, Sch Med, Infect Dis Sect, New Haven, CT USA.
   [Lautenbach, Ebbing] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
   [Linkin, Darren R.] Univ Penn, Philadelphia, PA 19104 USA.
   [Meddings, Jennifer] Univ Michigan, Ann Arbor, MI 48109 USA.
   [Miller, Loren G.] Harbor UCLA Med Ctr, Div Infect Dis, Torrance, CA 90509 USA.
   [Milstone, Aaron] Johns Hopkins Univ, Baltimore, MD USA.
   [Morgan, Daniel] Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
   [Morgan, Daniel] Vet Affairs Maryland Healthcare Syst, Baltimore, MD USA.
   [Sengupta, Sharmila] BLK Super Specialty Hosp, Dept Microbiol, Delhi, India.
   [Varman, Meera] Creighton Univ, Med Ctr, Omaha, NE USA.
   [Yokoe, Deborah] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
   [Yokoe, Deborah] Harvard Univ, Sch Med, Boston, MA USA.
   [Zerr, Danielle M.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA.
   [Zerr, Danielle M.] Seattle Childrens Res Inst, Seattle, WA USA.
RP Safdar, N (reprint author), 600 Highland Ave,H4-574, Madison, WI 53792 USA.
EM ns2@medicine.wisc.edu
FU US Department of Veterans Affairs (VA); National Institutes of Health
   (NIH) [AG40669]; Centers for Disease Control and Prevention (CDC), Duke
   University/Duke Infection Control Outreach Network [U54CK000164];
   NIH/National Institute of Allergy and Infectious Diseases (NIAID) Duke
   University [K23AI095357]; CDC/Duke University [U54CK000172-01]; The
   Joint Commission: Agency for Healthcare Research and Quality (AHRQ)
   [1R13HS022174-0112]; CDC National Institute for Occupational Safety and
   Health National Personal Protective Technology Laboratory; AHRQ; CDC;
   state of Pennsylvania; Doris Duke Charitable Foundation; University of
   Pennsylvania; Pennsylvania Department of Health; VA National Center for
   Patient Safety; NIH/National Institute of Nursing Research; CDC [1U54
   CK000172-01]; NIH/NIAID; NIH/National Cancer Institute
FX Potential conflicts of interest. N.S. reports research grants and/or
   contracts from the US Department of Veterans Affairs (VA) and the
   National Institutes of Health (NIH; AG40669). D.J.A. reports a financial
   relationship with UpToDate Online, a company involved in treatment of
   subjects, and having received research grants or contracts from the
   Centers for Disease Control and Prevention (CDC), Duke University/Duke
   Infection Control Outreach Network (U54CK000164), NIH/National Institute
   of Allergy and Infectious Diseases (NIAID) Duke University
   (K23AI095357), and CDC/Duke University (U54CK000172-01). B.I.B. reports
   having received research grants or contracts from The Joint Commission:
   Agency for Healthcare Research and Quality (AHRQ; 1R13HS022174-0112) and
   the CDC National Institute for Occupational Safety and Health National
   Personal Protective Technology Laboratory. P.C. reports being an advisor
   or consultant for Ecolab and holding patents, copyrights, or licenses
   from Steris. S.C. reports having received research grants or contracts
   from Viropharma, Merck, and Cubist for clinical trials in C. difficile
   infection. A.H. reports financial involvement with companies involved in
   the treatment of subjects and having served in an advisory or consultant
   role for Premier, Cubist, and UpToDate. S.S.H. reports leading a
   clinical trial in which participating hospitals receive contributed
   product from Sage. E.L. reports having received research grants or
   contracts from AHRQ, the CDC, and the state of Pennsylvania. D.R.L.
   reports having received research grants/contracts from Doris Duke
   Charitable Foundation, the University of Pennsylvania, and the
   Pennsylvania Department of Health. J.M. reports having received research
   grants or contracts from AHRQ, VA National Center for Patient Safety,
   and the NIH/National Institute of Nursing Research. L.G.M. reports
   having received research grant or contracts from Merck Harbor-UCLA and
   Cerexa and honoraria from Durata. A.M. reports a financial relationship
   with Sage Products, a company involved in the treatment of subjects, and
   past research support and research grants or contracts from the NIH.
   D.M. reports serving in an advisory or consultant role for Welch-Allyn.
   D.Y. reports having received research grants or contracts from the CDC
   (1U54 CK000172-01). D.M.Z. reports having received research grants or
   contracts from the NIH/NIAID and the NIH/National Cancer Institute. All
   other authors report no conflicts of interest relevant to this article.
NR 77
TC 7
Z9 7
U1 1
U2 11
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0899-823X
EI 1559-6834
J9 INFECT CONT HOSP EP
JI Infect. Control Hosp. Epidemiol.
PD MAY 1
PY 2014
VL 35
IS 5
BP 480
EP 493
DI 10.1086/675821
PG 14
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA AE4EI
UT WOS:000333933900004
PM 24709716
ER

PT J
AU Balbale, SN
   Johnson, S
   Burns, SP
   Kralovic, SM
   Goldstein, B
   Gerding, DN
   Evans, CT
AF Balbale, Salva N.
   Johnson, Stuart
   Burns, Stephen P.
   Kralovic, Stephen M.
   Goldstein, Barry
   Gerding, Dale N.
   Evans, Charlesnika T.
TI Community-Associated Clostridium difficile Infection among Veterans with
   Spinal Cord Injury and Disorder
SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
LA English
DT Article
ID EPIDEMIOLOGY
AB The impact of community-associated Clostridium difficile infection (CA-CDI) on patients with spinal cord injuries and disorders (SCI/Ds) is not fully understood. We examined CA-CDI cases among veterans with SCI/D, comparing them with community-onset, healthcare facility-associated (CO-HCFA) cases. Generally, patients with CA-CDI had less comorbidity, less severe CDI, and lower likelihood of antibiotic exposure.
C1 [Balbale, Salva N.; Evans, Charlesnika T.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Ctr Innovat Complex Chron Healthcare, Hines, IL 60141 USA.
   [Balbale, Salva N.; Evans, Charlesnika T.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Spinal Cord Injury Qual Enhancement Res Initiat, Hines, IL 60141 USA.
   [Johnson, Stuart; Gerding, Dale N.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res Serv, Hines, IL 60141 USA.
   [Johnson, Stuart; Gerding, Dale N.] Loyola Univ, Med Ctr, Dept Med, Maywood, IL 60153 USA.
   [Burns, Stephen P.; Goldstein, Barry] Vet Affairs Puget Sound Hlth Care Syst, Spinal Cord Injury Qual Enhancement Res Initiat, Seattle, WA USA.
   [Burns, Stephen P.; Goldstein, Barry] Univ Washington, Seattle, WA 98195 USA.
   [Kralovic, Stephen M.] Cincinnati Vet Affairs Med Ctr, Cincinnati, OH USA.
   [Kralovic, Stephen M.] Univ Cincinnati, Coll Med, Cincinnati, OH USA.
   [Evans, Charlesnika T.] Northwestern Univ, Dept Prevent Med, Chicago, IL 60611 USA.
   [Evans, Charlesnika T.] Northwestern Univ, Ctr Healthcare Studies, Feinberg Sch Med, Chicago, IL 60611 USA.
RP Balbale, SN (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, 5000 South 5th Ave 151H,Room D304, Hines, IL 60141 USA.
EM salva.balbale@va.gov
FU Veterans Affairs Health Services Research and Development Service
   [IIR-10-148]
FX Veterans Affairs Health Services Research and Development Service
   (IIR-10-148).
NR 10
TC 1
Z9 1
U1 0
U2 2
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0899-823X
EI 1559-6834
J9 INFECT CONT HOSP EP
JI Infect. Control Hosp. Epidemiol.
PD MAY 1
PY 2014
VL 35
IS 5
BP 577
EP 580
DI 10.1086/675830
PG 4
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA AE4EI
UT WOS:000333933900017
PM 24709729
ER

PT J
AU Reisinger, HS
   Perencevich, EN
   Morgan, DJ
   Forrest, GN
   Shardell, M
   Schweizer, ML
   Graham, MM
   Franciscus, CL
   Vander Weg, MW
AF Reisinger, Heather Schacht
   Perencevich, Eli N.
   Morgan, Daniel J.
   Forrest, Graeme N.
   Shardell, Michelle
   Schweizer, Marin L.
   Graham, Margaret M.
   Franciscus, Carrie L.
   Vander Weg, Mark W.
TI Improving Hand Hygiene Compliance with Point-of-Use Reminder Signs
   Designed Using Theoretically Grounded Messages
SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
LA English
DT Editorial Material
ID BEHAVIOR
C1 [Reisinger, Heather Schacht; Perencevich, Eli N.; Schweizer, Marin L.; Graham, Margaret M.; Franciscus, Carrie L.; Vander Weg, Mark W.] Iowa City Vet Affairs VA Hlth Care Syst, Ctr Comprehens Access & Delivery Res & Evaluat CA, Iowa City, IA USA.
   [Reisinger, Heather Schacht; Perencevich, Eli N.; Schweizer, Marin L.; Vander Weg, Mark W.] Univ Iowa, Carver Coll Med, Iowa City, IA USA.
   [Morgan, Daniel J.] Maryland VA Hlth Care Syst, Baltimore, MD USA.
   [Morgan, Daniel J.; Shardell, Michelle] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Baltimore, MD 21201 USA.
   [Forrest, Graeme N.] Portland VA Med Ctr, Portland, OR USA.
RP Reisinger, HS (reprint author), 601 Highway 6 West, Iowa City, IA 52246 USA.
EM heather.reisinger@va.gov
NR 9
TC 1
Z9 2
U1 0
U2 3
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0899-823X
EI 1559-6834
J9 INFECT CONT HOSP EP
JI Infect. Control Hosp. Epidemiol.
PD MAY 1
PY 2014
VL 35
IS 5
BP 593
EP 594
DI 10.1086/675827
PG 2
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA AE4EI
UT WOS:000333933900022
PM 24709734
ER

PT J
AU Yaghoobi, M
   Yuan, Y
   Hunt, RH
AF Yaghoobi, M.
   Yuan, Y.
   Hunt, R. H.
TI Commentary: tenofovir is superior to entecavir in HBeAg-positive chronic
   hepatitis B patients - authors' reply
SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS
LA English
DT Editorial Material
C1 [Yaghoobi, M.] Med Univ S Carolina, Div Gastroenterol & Hepatol, Charleston, SC 29425 USA.
   [Yaghoobi, M.] Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA.
   [Yuan, Y.; Hunt, R. H.] McMaster Univ, Hlth Sci Ctr, Dept Med, Div Gastroenterol, Hamilton, ON, Canada.
RP Yaghoobi, M (reprint author), Med Univ S Carolina, Div Gastroenterol & Hepatol, Charleston, SC 29425 USA.
EM huntr@mcmaster.ca
NR 3
TC 1
Z9 1
U1 2
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0269-2813
EI 1365-2036
J9 ALIMENT PHARM THER
JI Aliment. Pharmacol. Ther.
PD MAY
PY 2014
VL 39
IS 9
BP 993
EP 993
DI 10.1111/apt.12708
PG 1
WC Gastroenterology & Hepatology; Pharmacology & Pharmacy
SC Gastroenterology & Hepatology; Pharmacology & Pharmacy
GA AD8ZA
UT WOS:000333553000012
PM 24689345
ER

PT J
AU Taylor, DJ
   Zimmerman, MR
   Gardner, CE
   Williams, JM
   Grieser, EA
   Tatum, JI
   Bramoweth, AD
   Francetich, JM
   Ruggero, C
AF Taylor, Daniel J.
   Zimmerman, Marian R.
   Gardner, Christie E.
   Williams, Jacob M.
   Grieser, Emily A.
   Tatum, Jolyn I.
   Bramoweth, Adam D.
   Francetich, Jade M.
   Ruggero, Camilo
TI A Pilot Randomized Controlled Trial of the Effects of
   Cognitive-Behavioral Therapy for Insomnia on Sleep and Daytime
   Functioning in College Students
SO BEHAVIOR THERAPY
LA English
DT Article
DE cognitive; behavioral; therapy; insomnia; college
ID QUALITY-OF-LIFE; GENERAL MEDICAL-PRACTICE; MOTOR-VEHICLE ACCIDENTS;
   OLDER-ADULTS; YOUNG-ADULTS; CLINICAL EFFECTIVENESS; DYSFUNCTIONAL
   BELIEFS; PERSISTENT INSOMNIA; BREAST-CANCER; MENTAL-HEALTH
AB The purpose of this study was to pilot test if cognitive behavioral therapy for insomnia (CBT-I) is an effective intervention for insomnia and daytime functioning in college students. College students' developmental stage and lifestyle are significantly different than the general adult population, yet there have been no studies of CBT-I in this age group.
   Thirty-four college students (ages 18-27; M = 19.71, SD = 2.10) were randomly assigned to and completed either six sessions of CBT-I or a 6-week wait list control (WLC). All participants completed 1-week sleep diaries and actigraphy, as well as sleep and daytime functioning questionnaires at baseline and posttreatment. The treatment group repeated all measures at 3-month follow-up.
   Students who received CBT-I showed greater baseline to posttreatment improvements in sleep efficiency, sleep onset latency, number of awakenings, time awake after sleep onset, sleep quality, insomnia severity, dysfunctional beliefs about sleep, general fatigue, and global sleep quality than the WLC group. These improvements were durable at 3-month follow-up. Ninety-four percent of participants in the CBT-I condition completed at least 4 sessions of treatment. Significantly more participants in the CBT-I group than the WLC group responded (68.8% vs 7.7%, respectively) and remitted (68.8% vs 15.4%, respectively). CBT-I is an effective treatment for insomnia in college students. This study found that treatment responses were similar to results from studies in the general population. The treatment appeared to be well tolerated based on very low attrition rates.
C1 [Taylor, Daniel J.; Zimmerman, Marian R.] Univ N Texas, Denton, TX 76203 USA.
   [Gardner, Christie E.] Texas Tech Univ, Lubbock, TX 79409 USA.
   [Williams, Jacob M.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX USA.
   [Grieser, Emily A.] Wilford Hall Ambulatory Surg Ctr, San Antonio, TX USA.
   [Tatum, Jolyn I.] Wright Patterson Med Ctr, Dayton, OH USA.
   [Bramoweth, Adam D.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
   [Taylor, Daniel J.; Francetich, Jade M.; Ruggero, Camilo] Univ N Texas, Dept Psychol, Denton, TX 76203 USA.
RP Taylor, DJ (reprint author), Univ N Texas, Dept Psychol, 1155 Union Circle 311280, Denton, TX 76203 USA.
EM djtaylor@unt.edu
NR 89
TC 6
Z9 6
U1 10
U2 42
PU ASSOC ADV BEHAVIOR THERAPY
PI NEW YORK
PA 305 7TH AVE #16A, NEW YORK, NY 10001-6008 USA
SN 0005-7894
EI 1878-1888
J9 BEHAV THER
JI Behav. Therapy
PD MAY
PY 2014
VL 45
IS 3
BP 376
EP 389
PG 14
WC Psychology, Clinical
SC Psychology
GA AE2GW
UT WOS:000333792300007
PM 24680232
ER

PT J
AU Peralta, CA
   Scherzer, R
   Grunfeld, C
   Abraham, A
   Tien, PC
   Devarajan, P
   Bennett, M
   Butch, AW
   Anastos, K
   Cohen, MH
   Nowicki, M
   Sharma, A
   Young, MA
   Sarnak, MJ
   Parikh, CR
   Shlipak, MG
AF Peralta, C. A.
   Scherzer, R.
   Grunfeld, C.
   Abraham, A.
   Tien, P. C.
   Devarajan, P.
   Bennett, M.
   Butch, A. W.
   Anastos, K.
   Cohen, M. H.
   Nowicki, M.
   Sharma, A.
   Young, M. A.
   Sarnak, M. J.
   Parikh, C. R.
   Shlipak, M. G.
TI Urinary biomarkers of kidney injury are associated with all-cause
   mortality in the Women's Interagency HIV Study (WIHS)
SO HIV MEDICINE
LA English
DT Article
DE kidney injury molecule-1; neutrophil gelatinase-associated lipocalin;
   interleukin-18; HIV; urinary biomarkers; liver fatty acid binding
   protein
ID ACID-BINDING PROTEIN; IMMUNODEFICIENCY-VIRUS-INFECTION;
   GELATINASE-ASSOCIATED LIPOCALIN; CYSTATIN-C; ANTIRETROVIRAL THERAPY;
   CARDIOVASCULAR EVENTS; FUNCTION DECLINE; CARDIAC-SURGERY; DISEASE;
   OUTCOMES
AB Objectives
   Chronic kidney disease (CKD) is common in HIV-infected individuals, and is associated with mortality in both the HIV-infected and general populations. Urinary markers of tubular injury have been associated with future kidney disease risk, but associations with mortality are unknown.
   Methods
   We evaluated the associations of urinary interleukin-18 (IL-18), liver fatty acid binding protein (L-FABP), kidney injury molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL) and the albumin-to-creatinine ratio (ACR) with 10-year, all-cause death in 908 HIV-infected women. Serum cystatin C was used to estimate the glomerular filtration rate (eGFRcys).
   Results
   There were 201 deaths during 9269 person-years of follow-up. After demographic adjustment, compared with the lowest tertile, the highest tertiles of IL-18 [hazard ratio (HR) 2.54; 95% confidence interval (CI) 1.75-3.68], KIM-1 (HR 2.04; 95% CI 1.44-2.89), NGAL (HR 1.50; 95% CI 1.05-2.14) and ACR (HR 1.63; 95% CI 1.13-2.36) were associated with higher mortality. After multivariable adjustment including adjustment for eGFRcys, only the highest tertiles of IL-18 (HR 1.88; 95% CI 1.29-2.74) and ACR (HR 1.46; 95% CI 1.01-2.12) remained independently associated with mortality. Findings for KIM-1 were borderline (HR 1.41; 95% CI 0.99-2.02). We found a J-shaped association between L-FABP and mortality. Compared with persons in the lowest tertile, the HR for the middle tertile of L-FABP was 0.67 (95% CI 0.46-0.98) after adjustment. Associations were stronger when IL-18, ACR and L-FABP were simultaneously included in models.
   Conclusions
   Among HIV-infected women, some urinary markers of tubular injury are associated with mortality risk, independently of eGFRcys and ACR. These markers represent potential tools with which to identify early kidney injury in persons with HIV infection.
C1 [Peralta, C. A.; Scherzer, R.; Grunfeld, C.; Tien, P. C.; Shlipak, M. G.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA 94121 USA.
   [Peralta, C. A.; Scherzer, R.; Grunfeld, C.; Tien, P. C.; Shlipak, M. G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
   [Abraham, A.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
   [Devarajan, P.; Bennett, M.] Cincinnati Childrens Hosp Med Ctr, Div Nephrol & Hypertens, Cincinnati, OH 45229 USA.
   [Butch, A. W.] Univ Calif Los Angeles, Clin Immunol Res Lab, Los Angeles, CA USA.
   [Anastos, K.] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA.
   [Anastos, K.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA.
   [Cohen, M. H.] John H Stroger Jr Hosp, Dept Med, Chicago, IL USA.
   [Cohen, M. H.] Rush Univ, Med Ctr, Dept Med, Chicago, IL 60612 USA.
   [Nowicki, M.] Univ So Calif, Los Angeles, CA USA.
   [Sharma, A.] Suny Downstate Med Ctr, Dept Med, Div Infect Dis, Brooklyn, NY 11203 USA.
   [Young, M. A.] Georgetown Univ, Med Ctr, Washington, DC 20007 USA.
   [Sarnak, M. J.] Tufts Med Ctr, Div Nephrol, Boston, MA USA.
   [Parikh, C. R.] Yale Univ, Dept Med, Sect Nephrol, New Haven, CT 06520 USA.
   [Parikh, C. R.] Yale Univ, Program Appl Translat Res, New Haven, CT USA.
RP Peralta, CA (reprint author), San Francisco VA Med Ctr, 4150 Clement St,Box 111A1, San Francisco, CA 94121 USA.
EM carmenalicia.peralta@ucsf.edu
FU National Institutes of Health [NIDDK 23]; Robert Wood Johnson Foundation
   Harold Amos Program; National Institute of Allergy and Infectious
   Diseases [UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989,
   UO1-AI-34993, UO1-AI-42590]; Eunice Kennedy Shriver National Institute
   of Child Health and Human Development [UO1-HD-32632]; National Cancer
   Institute, the National Institute on Drug Abuse; National Institute on
   Deafness and Other Communication Disorders; National Center for Research
   Resources (UCSF-CTSI Grant) [UL1 RR024131];  [1R01AG034853-01A2]
FX CAP has received funding from the National Institutes of Health (NIDDK
   23) and the Robert Wood Johnson Foundation Harold Amos Program. CRP is a
   co-inventor on an IL-18 patent issued to the University of Colorado. PD
   is a co-inventor on patents related to the use of NGAL as a marker of
   acute and chronic kidney injury. The WIHS Kidney Aging Study is funded
   by grant 1R01AG034853-01A2 (awarded to P. I. Shlipak), which was
   administered by the Northern California Institute for Research and
   Education, and with resources of the Veterans Affairs Medical Center,
   San Francisco, CA. Data in this manuscript were collected by the Women's
   Interagency HIV Study (WIHS) Collaborative Study Group with centres
   (principal investigators) at New York City/Bronx Consortium (Kathryn
   Anastos); Brooklyn, NY (Howard Minkoff); Washington DC Metropolitan
   Consortium (Mary Young); The Connie Wofsy Study Consortium of Northern
   California (Ruth Greenblatt); Los Angeles County/Southern California
   Consortium (Alexandra Levine); Chicago Consortium (Mardge Cohen); Data
   Coordinating Center (Stephen Gange). The WIHS is funded by the National
   Institute of Allergy and Infectious Diseases (UO1-AI-35004,
   UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993 and UO1-AI-42590)
   and by the Eunice Kennedy Shriver National Institute of Child Health and
   Human Development (UO1-HD-32632). The study is co-funded by the National
   Cancer Institute, the National Institute on Drug Abuse, and the National
   Institute on Deafness and Other Communication Disorders. Funding is also
   provided by the National Center for Research Resources (UCSF-CTSI Grant
   Number UL1 RR024131). The contents of this publication are solely the
   responsibility of the authors and do not necessarily represent the
   official views of the National Institutes of Health.
NR 36
TC 15
Z9 15
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1464-2662
EI 1468-1293
J9 HIV MED
JI HIV Med.
PD MAY
PY 2014
VL 15
IS 5
BP 291
EP 300
DI 10.1111/hiv.12113
PG 10
WC Infectious Diseases
SC Infectious Diseases
GA AE0TP
UT WOS:000333679400005
PM 24313986
ER

PT J
AU Benmansour, S
   Privratsky, AA
   Adeniji, OS
   Frazer, A
AF Benmansour, Saloua
   Privratsky, Anthony A.
   Adeniji, Opeyemi S.
   Frazer, Alan
TI Signaling mechanisms involved in the acute effects of estradiol on 5-HT
   clearance
SO INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
LA English
DT Article
DE ER agonist; estradiol; serotonin transporter; SSRI; signaling pathways
ID GROWTH-FACTOR-I; ACTIVATED PROTEIN-KINASE; METABOTROPIC GLUTAMATE
   RECEPTORS; MEMBRANE ESTROGEN-RECEPTORS; NEUROTROPHIC FACTOR BDNF;
   LONG-TERM POTENTIATION; MAP KINASE; ANTIDEPRESSANT TREATMENT; SEROTONIN
   TRANSPORTERS; MOLECULAR-MECHANISMS
AB Estradiol was found previously to have an antidepressant-like effect and to block the ability of selective serotonin reuptake inhibitors (SSRIs) to have an antidepressant-like effect. The antidepressant-like effect of estradiol was due to estrogen receptor beta (ER beta) and/or GPR30 activation, whereas estradiol's blockade of the effect of an SSRI was mediated by ER alpha. This study focuses on investigating signaling pathways as well as interacting receptors associated with these two effects of estradiol. In vivo chronoamperometry was used to measure serotonin transporter (SERT) function. The effect of local application of estradiol or selective agonists for ER alpha (PPT) or ER beta (DPN) into the CA(3) region of the hippocampus of ovariectomized (OVX) rats on 5-hydroxytryptamine (5-HT) clearance as well as on the ability of fluvoxamine to slow 5-HT clearance was examined after selective blockade of signaling pathways or that of interacting receptors. Estradiol- or DPN-induced slowing of 5-HT clearance mediated by ER beta was blocked after inhibition of MAPK/ERK1/2 but not of PI3K/Akt signaling pathways. This effect also involved interactions with TrkB, and IGF-1 receptors. Estradiol's or PPT's inhibition of the fluvoxamine-induced slowing of 5-HT clearance mediated by ER alpha, was blocked after inhibition of either MAPK/ERK1/2 or PI3K/Akt signaling pathways. This effect involved interactions with the IGF-1 receptor and with the metabotropic glutamate receptor 1, but not with TrkB. This study illustrates some of the signaling pathways required for the effects of estradiol on SERT function, and particularly shows that ER subtypes elicit different as well as common signaling pathways for their actions.
C1 [Benmansour, Saloua; Privratsky, Anthony A.; Adeniji, Opeyemi S.; Frazer, Alan] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA.
   [Frazer, Alan] South Texas Vet Hlth Care Syst, San Antonio, TX 78284 USA.
RP Benmansour, S (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, MC 7764,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM benmansour@uthscsa.edu
FU NARSAD; Department of Veterans Affairs; National Institute of Mental
   Health [MH090386]
FX This research was supported by funds from NARSAD to SB, the Department
   of Veterans Affairs and the National Institute of Mental Health
   (MH090386) to AF.
NR 78
TC 9
Z9 10
U1 0
U2 6
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1461-1457
EI 1469-5111
J9 INT J NEUROPSYCHOPH
JI Int. J. Neuropsychopharmacol.
PD MAY
PY 2014
VL 17
IS 5
BP 765
EP 777
DI 10.1017/S146114571300165X
PG 13
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA AD9CM
UT WOS:000333562300008
PM 24423185
ER

PT J
AU Bedard-Gilligan, M
   Cronce, JM
   Lehavot, K
   Blayney, JA
   Kaysen, D
AF Bedard-Gilligan, Michele
   Cronce, Jessica M.
   Lehavot, Keren
   Blayney, Jessica A.
   Kaysen, Debra
TI The Relationship Between Assault and Physical Health Complaints in a
   Sample of Female Drinkers Roles of Avoidant Coping and Alcohol Use
SO JOURNAL OF INTERPERSONAL VIOLENCE
LA English
DT Article
DE trauma exposure; physical health; PTSD; coping; college students;
   alcohol
ID POSTTRAUMATIC-STRESS-DISORDER; SUBSTANCE USE BEHAVIORS; SEXUAL ASSAULT;
   COLLEGE-STUDENTS; RISK-FACTORS; SYMPTOM SEVERITY; DRINKING MOTIVES;
   PERCEIVED HEALTH; TRAUMA EXPOSURE; IMMUNE-SYSTEM
AB Trauma exposure and PTSD are associated with poorer physical health. Psychological and behavioral mechanisms may help account for this relationship. In this study, we tested avoidant coping and alcohol use as mediators of the relationship between trauma exposure, PTSD, and self-reported physical health complaints in female drinkers. In 827 college women, we compared three groups: women with no trauma history, women with a sexual assault but no PTSD, and women with a sexual assault and PTSD, on avoidant coping, alcohol use, and physical health complaints. We found that PTSD was positively associated with alcohol use and that PTSD and trauma exposure were associated with increased avoidant coping. We also found that avoidant coping mediated the relationship between trauma, PTSD, and physical health complaints. Alcohol use did not predict physical health but was associated with PTSD. These results suggest that in female college students, coping may be more critical in the PTSD/physical health relationship than alcohol and have implications for targeting coping in young trauma-exposed women to improve physical health.
C1 [Bedard-Gilligan, Michele; Cronce, Jessica M.; Kaysen, Debra] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
   [Lehavot, Keren; Blayney, Jessica A.] Univ Washington, Seattle, WA 98195 USA.
   [Kaysen, Debra] Univ Washington, Dept Psychol, Seattle, WA 98195 USA.
   [Kaysen, Debra] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA.
   [Lehavot, Keren] VA Puget Sound Hlth Care Syst, MIRECC, Seattle, WA USA.
RP Bedard-Gilligan, M (reprint author), Univ Washington, Dept Psychiat & Behav Sci, Box 354944, Seattle, WA 98195 USA.
EM mab29@u.washington.edu
FU NIAAA NIH HHS [F32 AA018609, F32 AA18609, R21 AA016211]
NR 60
TC 4
Z9 4
U1 0
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0886-2605
EI 1552-6518
J9 J INTERPERS VIOLENCE
JI J. Interpers. Violence
PD MAY
PY 2014
VL 29
IS 8
BP 1359
EP 1379
DI 10.1177/0886260513507139
PG 21
WC Criminology & Penology; Family Studies; Psychology, Applied
SC Criminology & Penology; Family Studies; Psychology
GA AD6PD
UT WOS:000333382400001
PM 24288191
ER

PT J
AU Ahmad, S
   Varagic, J
   Groban, L
   Dell'Italia, LJ
   Nagata, S
   Kon, ND
   Ferrario, CM
AF Ahmad, Sarfaraz
   Varagic, Jasmina
   Groban, Leanne
   Dell'Italia, Louis J.
   Nagata, Sayaka
   Kon, Neal D.
   Ferrario, Carlos M.
TI Angiotensin-(1-12): A Chymase-Mediated Cellular Angiotensin II Substrate
SO CURRENT HYPERTENSION REPORTS
LA English
DT Article
DE Angiotensin-(1-12); Angiotensin II; Angiotensin-(1-7); Cardiac chymase;
   Angiotensin-converting enzyme; Metabolism; Renin-angiotensin system;
   Angiotensinogen
ID PLASMA-PROTEIN SUBSTRATE; CONVERTING ENZYME; BLOOD-PRESSURE; DOG HEART;
   PROANGIOTENSIN-12 PA12; INDEPENDENT MECHANISMS; CARDIOVASCULAR ACTIONS;
   DIASTOLIC DYSFUNCTION; MITRAL REGURGITATION; RECEPTOR BLOCKERS
AB The classical view of biochemical pathways for the formation of biologically active angiotensins continues to undergo significant revision as new data uncovers the existence of important species differences between humans and rodents. The discovery of two novel substrates that, cleaved from angiotensinogen, can lead to direct tissue angiotensin II formation has the potential of radically altering our understanding of how tissues source angiotensin II production and explain the relative lack of efficacy that characterizes the use of angiotensin converting enzyme inhibitors in cardiovascular disease. This review addresses the discovery of angiotensin-(1-12) as an endogenous substrate for the production of biologically active angiotensin peptides by a non-renin dependent mechanism and the revealing role of cardiac chymase as the angiotensin II convertase in the human heart. This new information provides a renewed argument for exploring the role of chymase inhibitors in the correction of cardiac arrhythmias and left ventricular systolic and diastolic dysfunction.
C1 [Ahmad, Sarfaraz; Varagic, Jasmina; Nagata, Sayaka; Ferrario, Carlos M.] Wake Forest Sch Med, Div Surg Sci, Winston Salem, NC 27157 USA.
   [Varagic, Jasmina; Groban, Leanne] Wake Forest Sch Med, Hypertens & Vasc Res Ctr, Winston Salem, NC 27157 USA.
   [Varagic, Jasmina; Ferrario, Carlos M.] Wake Forest Sch Med, Dept Physiol Pharmacol, Winston Salem, NC 27157 USA.
   [Groban, Leanne] Wake Forest Sch Med, Dept Anesthesiol, Winston Salem, NC 27157 USA.
   [Kon, Neal D.] Wake Forest Sch Med, Winston Salem, NC 27157 USA.
   [Ferrario, Carlos M.] Wake Forest Sch Med, Dept Internal Med Nephrol, Winston Salem, NC 27157 USA.
   [Dell'Italia, Louis J.] Univ Alabama Birmingham, Med Ctr, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA.
   [Dell'Italia, Louis J.] Birmingham VA Med Ctr, Birmingham, AL USA.
RP Ferrario, CM (reprint author), Wake Forest Sch Med, Dept Internal Med Nephrol, Med Ctr Blvd, Winston Salem, NC 27157 USA.
EM cferrari@wakehealth.edu
FU National Heart, Lung and Blood Institute [HL-051952]; National Institute
   on Aging of the NIH [AG042758, AG033727]
FX Leanne Groban and Carlos M. Ferrario have declared that this work was
   supported by grants HL-051952 from the National Heart, Lung and Blood
   Institute and AG042758 (LG) and AG033727 (LG) from the National
   Institute on Aging of the NIH.
NR 92
TC 9
Z9 9
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1522-6417
EI 1534-3111
J9 CURR HYPERTENS REP
JI Curr. Hypertens. Rep.
PD MAY
PY 2014
VL 16
IS 5
AR 429
DI 10.1007/s11906-014-0429-9
PG 8
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA AD0XO
UT WOS:000332957900004
PM 24633843
ER

PT J
AU Yarmush, L
AF Yarmush, L.
TI VALIDATING A VETERANS AFFAIRS PERIOPERATIVE SURGICAL HOME: OPTIMIZING
   PATIENTS WITH CORONARY ARTERY DISEASE IN THE PREOPERATIVE CLINIC
SO ANESTHESIA AND ANALGESIA
LA English
DT Meeting Abstract
C1 [Yarmush, L.] Houston VAMC, Anesthesiol, Houston, TX USA.
NR 3
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-2999
J9 ANESTH ANALG
JI Anesth. Analg.
PD MAY
PY 2014
VL 118
SU 1
MA S-127
BP S127
EP S127
PG 1
WC Anesthesiology
SC Anesthesiology
GA V45PD
UT WOS:000209827600113
ER

PT J
AU Waubant, E
   Maghzi, AH
   Revirajan, N
   Spain, R
   Julian, L
   Mowry, EM
   Marcus, J
   Liu, S
   Jin, CS
   Green, A
   McCulloch, CE
   Pelletier, D
AF Waubant, Emmanuelle
   Maghzi, Amir-Hadi
   Revirajan, Nisha
   Spain, Rebecca
   Julian, Laura
   Mowry, Ellen M.
   Marcus, Jacqueline
   Liu, Shuang
   Jin, Chengshi
   Green, Ari
   McCulloch, Charles E.
   Pelletier, Daniel
TI A randomized controlled phase II trial of riluzole in early multiple
   sclerosis
SO ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY
LA English
DT Article
AB Objectives: We evaluated the effect of riluzole versus placebo added to weekly IM interferon beta-1a in early multiple sclerosis (MS). Methods: This is a randomized (1: 1), double-blind, placebo-controlled trial of riluzole 50 mg twice daily in subjects with MS onset less than 1 year prior. Trial participation was up to 3 years. The primary endpoint was change in percent brain volume change. Secondary endpoints included changes in normalized gray and normal-appearing white matter volumes, retinal nerve fiber layer thickness (RNFL), MS Functional Composite and Symbol Digit Modalities Test scores. Mixed model regression analysis was used to compare the changes over time between groups. Results: Forty-three subjects were randomized to study drug (22 riluzole, 21 placebo). Baseline characteristics were overall similar between groups except for older age (P = 0.042), higher normalized cerebrospinal fluid volume (P = 0.050), lower normalized gray matter volume (P = 0.14), and thinner RNFL (P = 0.043) in the riluzole group. In the primary analysis, percent brain volume change in the placebo group decreased at a rate of 0.49% per year whereas the riluzole group decreased by 0.86% per year (0.37% more per year; 95% CI - 0.78, 0.024; P = 0.065). Although age did not influence the rate of brain volume decline, the difference between groups was attenuated after adjustment for baseline normalized gray matter and lesion volume (0.26% more per year in riluzole group; 95% CI - 0.057, 0.014; P = 0.22). Analyses of secondary outcomes showed no differences between groups. Interpretation: This trial provides class 1 evidence that riluzole treatment does not meaningfully reduce brain atrophy progression in early MS.
C1 [Waubant, Emmanuelle; Maghzi, Amir-Hadi; Revirajan, Nisha; Julian, Laura; Marcus, Jacqueline; Green, Ari] Univ Calif San Francisco, Dept Neurol, MS Ctr, San Francisco, CA USA.
   [Waubant, Emmanuelle] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA.
   [Spain, Rebecca] Portland VA Med Ctr, Portland, OR USA.
   [Spain, Rebecca] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
   [Mowry, Ellen M.] Hopkins MS Ctr, Dept Neurol, Baltimore, MD USA.
   [Liu, Shuang; Pelletier, Daniel] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA.
   [Jin, Chengshi; McCulloch, Charles E.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
   [Green, Ari] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA USA.
RP Waubant, E (reprint author), Neurosci Bldg,675 Nelson Rising Lane,Room 215B, San Francisco, CA 94158 USA.
EM Emmanuelle.waubant@ucsf.edu
NR 29
TC 11
Z9 11
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2328-9503
J9 ANN CLIN TRANSL NEUR
JI Ann. Clin. Transl. Neurol.
PD MAY
PY 2014
VL 1
IS 5
BP 340
EP 347
DI 10.1002/acn3.60
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA V45KH
UT WOS:000209815000004
PM 25356404
ER

PT J
AU Cunningham, M
   Wirth, J
   Eudaly, J
   Gilkeson, G
AF Cunningham, Melissa
   Wirth, Jena
   Eudaly, Jackie
   Gilkeson, Gary
TI Decreased inflammatory dendritic cells in lupus prone ER alpha KO mice
   correlate with increased survival
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
C1 [Cunningham, Melissa; Wirth, Jena; Eudaly, Jackie; Gilkeson, Gary] Med Univ SC, Med Rheumatol & Immunol, Charleston, SC USA.
   [Gilkeson, Gary] Ralph H Johnson VA Hosp, Med Rheumatol & Immunol, Charleston, SC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2014
VL 192
SU 1
MA BA4P.214
PG 1
WC Immunology
SC Immunology
GA V44RB
UT WOS:000209765002195
ER

PT J
AU Hamilton, J
   Li, J
   Wu, Q
   Yang, P
   Luo, B
   Bradley, J
   Taylor, J
   Randall, T
   Mountz, J
   Hsu, HC
AF Hamilton, Jennie
   Li, Jun
   Wu, Qi
   Yang, PingAr
   Luo, Bao
   Bradley, John
   Taylor, Justin
   Randall, Troy
   Mountz, John
   Hsu, Hui-Chen
TI Autoreactive B cell tetramer analysis reveals a type I
   interferon-mediated marginal zone precursor B cell defect in autoimmune
   BXD2 mice
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
C1 [Hamilton, Jennie; Li, Jun; Wu, Qi; Yang, PingAr; Luo, Bao; Bradley, John; Randall, Troy; Mountz, John; Hsu, Hui-Chen] Univ Alabama Birmingham, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA.
   [Taylor, Justin] Univ Minnesota, Sch Med, Ctr Immunol, Dept Microbiol, Minneapolis, MN 55455 USA.
   [Mountz, John] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2014
VL 192
SU 1
MA BA12P.102
PG 1
WC Immunology
SC Immunology
GA V44RB
UT WOS:000209765002136
ER

PT J
AU Kaplan, D
   Tanoue, S
AF Kaplan, David
   Tanoue, Shiroh
TI Monocyte-derived dendritic cells from cirrhotic patients retain similar
   capacity for maturation/activation and antigen presentation as those
   from healthy subjects
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
C1 [Kaplan, David] Philadelphia VA Med Ctr, Gastroenterol, Philadelphia, PA USA.
   [Kaplan, David; Tanoue, Shiroh] Univ Penn, Div Gastroenterol, Philadelphia, PA 19104 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2014
VL 192
SU 1
MA HUM7P.290
PG 2
WC Immunology
SC Immunology
GA V44RB
UT WOS:000209765000208
ER

PT J
AU Li, H
   Wu, Q
   Li, J
   Yang, PA
   Luo, B
   Edberg, J
   Hsu, HC
   Mountz, J
AF Li, Hao
   Wu, Qi
   Li, Jun
   Yang, PingAr
   Luo, Bao
   Edberg, Jeffrey
   Hsu, Hui-Chen
   Mountz, John
TI Anti-scavenger receptor immune complexes disrupted marginal zone
   macrophage integrity via bruton's tyrosine kinase
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
C1 [Li, Hao; Mountz, John] Univ Alabama Birmingham, Microbiol, Birmingham, AL USA.
   [Li, Hao; Wu, Qi; Li, Jun; Yang, PingAr; Luo, Bao; Edberg, Jeffrey; Hsu, Hui-Chen; Mountz, John] Univ Alabama Birmingham, Div Clin Immunol & Rheumatol, Birmingham, AL USA.
   [Mountz, John] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2014
VL 192
SU 1
MA BA4P.213
PG 1
WC Immunology
SC Immunology
GA V44RB
UT WOS:000209765002198
ER

PT J
AU Li, H
   Hsu, HC
   Wu, Q
   Yang, PA
   Li, J
   Luo, B
   Fu, YX
   Zhou, Y
   Mountz, J
AF Li, Hao
   Hsu, Hui-Chen
   Wu, Qi
   Yang, PingAr
   Li, Jun
   Luo, Bao
   Fu, Yang-Xin
   Zhou, Yong
   Mountz, John
TI Lymphotoxin-expressing marginal zone B cells support marginal zone
   integrity by maintaining the megakaryoblastic leukemia-1 expression
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
C1 [Li, Hao; Mountz, John] Univ Alabama Birmingham, Microbiol, Birmingham, AL USA.
   [Li, Hao; Hsu, Hui-Chen; Wu, Qi; Yang, PingAr; Li, Jun; Luo, Bao; Mountz, John] Univ Alabama Birmingham, Div Clin Immunol & Rheumatol, Birmingham, AL USA.
   [Fu, Yang-Xin] Univ Chicago, Pathol, Chicago, IL 60637 USA.
   [Zhou, Yong] Univ Alabama Birmingham, Div Pulm, Birmingham, AL USA.
   [Mountz, John] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2014
VL 192
SU 1
MA BA4P.221
PG 1
WC Immunology
SC Immunology
GA V44RB
UT WOS:000209765002200
ER

PT J
AU Li, J
   Hsu, HC
   Yang, PA
   Wu, Q
   Luo, B
   Mobley, J
   Bridges, S
   Mountz, J
AF Li, Jun
   Hsu, Hui-Chen
   Yang, PingAr
   Wu, Qi
   Luo, Bao
   Mobley, James
   Bridges, S.
   Mountz, John
TI Identification of a novel epigenetic code, histone H1 fucosylation, and
   its roles in macrophage plasticity in rheumatoid arthritis
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
C1 [Li, Jun; Hsu, Hui-Chen; Yang, PingAr; Wu, Qi; Luo, Bao; Mobley, James; Bridges, S.; Mountz, John] UAB, Med, Birmingham, AL USA.
   [Hsu, Hui-Chen; Mountz, John] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2014
VL 192
SU 1
MA IRM7P.491
PG 2
WC Immunology
SC Immunology
GA V44RB
UT WOS:000209765000111
ER

PT J
AU Qin, M
   Park, A
   Agak, G
   Garban, H
   Kim, J
AF Qin, Min
   Park, Andrew
   Agak, George
   Garban, Hermes
   Kim, Jenny
TI Dual role of Interleukin-37 in the regulation of inflammation triggered
   by Propionibacterium acnes in human monocytes
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
C1 [Qin, Min; Park, Andrew; Agak, George; Garban, Hermes; Kim, Jenny] Univ Calif Los Angeles, David Geffen Sch Med, Med, Los Angeles, CA 90095 USA.
   [Kim, Jenny] Greater Los Angeles Vet Affairs Healthcare Syst, Dermatol, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2014
VL 192
SU 1
MA INM8P.450
PG 1
WC Immunology
SC Immunology
GA V44RB
UT WOS:000209765004131
ER

PT J
AU Richard, ML
   Sato, S
   Suzuki, E
   Williams, S
   Nowling, T
   Zhaug, X
AF Richard, Mara Lennard
   Sato, Shuzo
   Suzuki, Eiji
   Williams, Sarah
   Nowling, Tamara
   Zhaug, Xian
TI Identification of Fli-1 as a novel regulator of the inflammatory
   chemokine CCL5/RANTES
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
C1 [Richard, Mara Lennard; Sato, Shuzo; Suzuki, Eiji; Nowling, Tamara; Zhaug, Xian] Med Univ South Carolina, Med, Charleston, SC USA.
   [Richard, Mara Lennard; Sato, Shuzo; Suzuki, Eiji; Nowling, Tamara; Zhaug, Xian] Med Univ South Carolina, Div Rheumatol & Immunol, Charleston, SC USA.
   [Williams, Sarah; Nowling, Tamara] Ralph H Johnson Vet Affairs Med Ctr, Med Res Serv, Charleston, SC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2014
VL 192
SU 1
MA CCR5P.253
PG 1
WC Immunology
SC Immunology
GA V44RB
UT WOS:000209765003187
ER

PT J
AU Weathington, N
   Snavely, C
   Zhao, J
   Chen, B
   Zhao, YT
   Mallampalli, R
AF Weathington, Nathaniel
   Snavely, Courtney
   Zhao, Jing
   Chen, Bill
   Zhao, Yutong
   Mallampalli, Rama
TI Interleukin 22 receptor abundance and signaling is regulated by the
   ubiquitin proteasome and glycogen synthase kinase 3 beta.
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
C1 [Weathington, Nathaniel; Snavely, Courtney; Zhao, Jing; Chen, Bill; Zhao, Yutong; Mallampalli, Rama] Univ Pittsburgh, Pulm & Crit Care Med, Pittsburgh, PA USA.
   [Zhao, Yutong; Mallampalli, Rama] Univ Pittsburgh, Cell Biol, Pittsburgh, PA USA.
   [Mallampalli, Rama] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2014
VL 192
SU 1
MA INM2P.422
PG 2
WC Immunology
SC Immunology
GA V44RB
UT WOS:000209765006126
ER

PT J
AU Berenji, G
   Silverman, D
AF Berenji, Gholam
   Silverman, Daniel
TI Perception of sensory/perceptual deficits and cerebellar hypometabolism
   in recently deployed veterans with post traumatic stress disorder (PTSD)
SO JOURNAL OF NUCLEAR MEDICINE
LA English
DT Meeting Abstract
CT Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging
   (SNMMI)
CY JUN 07-11, 2014
CL St Louis, MO
SP Soc Nucl Med & Mol Imaging
C1 [Silverman, Daniel] Univ Calif Los Angeles, Mol & Med Pharmacol, Los Angeles, CA USA.
   [Berenji, Gholam] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SOC NUCLEAR MEDICINE INC
PI RESTON
PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA
SN 0161-5505
EI 1535-5667
J9 J NUCL MED
JI J. Nucl. Med.
PD MAY
PY 2014
VL 55
SU 1
MA 1878
PG 1
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA CR6FA
UT WOS:000361438104039
ER

PT J
AU Berenji, G
   Silverman, D
AF Berenji, Gholam
   Silverman, Daniel
TI Perception of sensory/perceptual deficits and cerebellar hypometabolism
   in recently deployed veterans with post traumatic stress disorder (PTSD)
SO JOURNAL OF NUCLEAR MEDICINE
LA English
DT Meeting Abstract
CT Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging
   (SNMMI)
CY JUN 07-11, 2014
CL St Louis, MO
SP Soc Nucl Med & Mol Imaging
C1 [Silverman, Daniel] Univ Calif Los Angeles, Mol & Med Pharmacol, Los Angeles, CA USA.
   [Berenji, Gholam] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SOC NUCLEAR MEDICINE INC
PI RESTON
PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA
SN 0161-5505
EI 1535-5667
J9 J NUCL MED
JI J. Nucl. Med.
PD MAY
PY 2014
VL 55
SU 1
MA 1878
PG 1
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA CR6FA
UT WOS:000361438103049
ER

PT J
AU Ozok, AA
   Wu, HJ
   Garrido, M
   Pronovost, PJ
   Gurses, AP
AF Ozok, A. Ant
   Wu, Huijuan
   Garrido, Melissa
   Pronovost, Peter J.
   Gurses, Ayse P.
TI Usability and perceived usefulness of personal health records for
   preventive health care: A case study focusing on patients' and primary
   care providers' perspectives
SO APPLIED ERGONOMICS
LA English
DT Article
DE Personal health records; Usefulness; Usability
ID INFORMATION-TECHNOLOGY; SCREENING COMPLIANCE; ACTIVATION MEASURE;
   COLORECTAL-CANCER; SELF-MANAGEMENT; USER ACCEPTANCE; UNITED-STATES;
   ADOPTION; SYSTEMS; DEFINITION
AB Personal Health Records (PHR) are electronic applications for individuals to access, manage and share their health information in a secure environment. The goal of this study was to evaluate the usefulness and usability of a Web-based PHR technology aimed at improving preventive care, from both the patients' and primary care providers' perspectives. We conducted a multi-method descriptive study that included direct observations, concurrent think-aloud, surveys, interviews and focus groups in a suburban primary care clinic. Patients found the tailored health recommendations useful and the PHR easy to understand and use. They also reported asking useful health-related questions to their physicians because of using the system. Generally, care providers were interested in using the system due to its useful content and impact on patient activation. Future successful systems should be better integrated with hospital records; put more emphasis on system security; and offer more tailored health information based on comprehensive health databases. (C) 2013 Elsevier Ltd and The Ergonomics Society. All rights reserved.
C1 [Ozok, A. Ant; Wu, Huijuan] Univ Maryland Baltimore Cty, Dept Informat Syst, Baltimore, MD 21250 USA.
   [Garrido, Melissa] James J Peters VA Med Ctr, GRECC, Bronx, NY USA.
   [Pronovost, Peter J.; Gurses, Ayse P.] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Armstrong Inst Patient Safety & Qual, Baltimore, MD 21202 USA.
RP Ozok, AA (reprint author), Univ Maryland Baltimore Cty, Dept Informat Syst, 1000 Hilltop Circle, Baltimore, MD 21250 USA.
EM ozok@umbc.edu; huijuan.wu@umbc.edu; melissa.garrido@mssm.edu;
   ppronovo@jhmi.edu; agurses1@jhmi.edu
FU Medical Industry Leadership Institute of the University of Minnesota;
   Agency for Healthcare Research and Quality [HS018762]; Dept. of Veterans
   Affairs, Veterans Health Administration, Health Services Research and
   Development Service [CDA 11-201/CDP 12-255]
FX This study was funded by the Medical Industry Leadership Institute of
   the University of Minnesota. Dr. Ayse P. Gurses was supported in part by
   the Agency for Healthcare Research and Quality K01 grant #HS018762. We
   would like to thank Dr. David Moen and the participating primary care
   clinic care providers for their support of the study. Supported by Dept.
   of Veterans Affairs, Veterans Health Administration, Health Services
   Research and Development Service (CDA 11-201/CDP 12-255). The views
   expressed in this article are those of the authors and do not
   necessarily reflect the position or policy of the Department of Veterans
   Affairs or the United States government.
NR 79
TC 16
Z9 16
U1 2
U2 26
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0003-6870
EI 1872-9126
J9 APPL ERGON
JI Appl. Ergon.
PD MAY
PY 2014
VL 45
IS 3
BP 613
EP 628
DI 10.1016/j.apergo.2013.9.005
PG 16
WC Engineering, Industrial; Ergonomics; Psychology, Applied
SC Engineering; Psychology
GA AB0RZ
UT WOS:000331501100034
ER

PT J
AU Koppel, BS
   Brust, JCM
   Fife, T
   Bronstein, J
   Youssof, S
   Gronseth, G
   Gloss, D
AF Koppel, Barbara S.
   Brust, John C. M.
   Fife, Terry
   Bronstein, Jeff
   Youssof, Sarah
   Gronseth, Gary
   Gloss, David
TI Systematic review: Efficacy and safety of medical marijuana in selected
   neurologic disorders Report of the Guideline Development Subcommittee of
   the American Academy of Neurology
SO NEUROLOGY
LA English
DT Article
ID PLACEBO-CONTROLLED TRIAL; CANNABIS-BASED MEDICINE; RANDOMIZED
   CONTROLLED-TRIAL; MULTIPLE-SCLEROSIS CAMS; LONG-TERM USE; DOUBLE-BLIND;
   DELTA(9)-TETRAHYDROCANNABINOL THC; HUNTINGTONS-DISEASE; OUTCOME
   MEASURES; CROSSOVER TRIAL
AB Objective:To determine the efficacy of medical marijuana in several neurologic conditions.Methods:We performed a systematic review of medical marijuana (1948-November 2013) to address treatment of symptoms of multiple sclerosis (MS), epilepsy, and movement disorders. We graded the studies according to the American Academy of Neurology classification scheme for therapeutic articles.Results:Thirty-four studies met inclusion criteria; 8 were rated as Class I.Conclusions:The following were studied in patients with MS: (1) Spasticity: oral cannabis extract (OCE) is effective, and nabiximols and tetrahydrocannabinol (THC) are probably effective, for reducing patient-centered measures; it is possible both OCE and THC are effective for reducing both patient-centered and objective measures at 1 year. (2) Central pain or painful spasms (including spasticity-related pain, excluding neuropathic pain): OCE is effective; THC and nabiximols are probably effective. (3) Urinary dysfunction: nabiximols is probably effective for reducing bladder voids/day; THC and OCE are probably ineffective for reducing bladder complaints. (4) Tremor: THC and OCE are probably ineffective; nabiximols is possibly ineffective. (5) Other neurologic conditions: THC is probably ineffective for treating levodopa-induced dyskinesias in patients with Parkinson disease. Oral cannabinoids are of unknown efficacy in non-chorea-related symptoms of Huntington disease, Tourette syndrome, cervical dystonia, and epilepsy. The risks and benefits of medical marijuana should be weighed carefully. Risk of serious adverse psychopathologic effects was nearly 1%. Comparative effectiveness of medical marijuana vs other therapies is unknown for these indications.
C1 [Koppel, Barbara S.] New York Med Coll, Dept Neurol, New York, NY USA.
   [Brust, John C. M.] Columbia Univ Coll Phys & Surg, New York Neurol Inst, Dept Neurol, New York, NY 10032 USA.
   [Fife, Terry] Univ Arizona, Coll Med, Phoenix, AZ USA.
   [Bronstein, Jeff] Univ Calif Los Angeles, VA Greater Angeles Healthcare Syst, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90024 USA.
   [Youssof, Sarah] Univ New Mexico, Hlth Sci Ctr, Dept Neurol, Albuquerque, NM 87131 USA.
   [Gronseth, Gary] Univ Kansas, Sch Med, Dept Neurol, Kansas City, MO USA.
   [Gronseth, Gary] Geisinger Hlth Syst, Dept Neurol, Danville, PA USA.
RP Koppel, BS (reprint author), Amer Acad Neurol, Minneapolis, MN USA.
EM guidelines@aan.com
FU American Academy of Neurology
FX This systematic review was developed with financial support from the
   American Academy of Neurology. None of the authors received
   reimbursement, honoraria, or stipends for their participation in the
   development of this systematic review.
NR 40
TC 114
Z9 115
U1 34
U2 151
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD APR 29
PY 2014
VL 82
IS 17
BP 1556
EP 1563
DI 10.1212/WNL.0000000000000363
PG 8
WC Clinical Neurology
SC Neurosciences & Neurology
GA AH9WH
UT WOS:000336495300018
PM 24778283
ER

PT J
AU Fancy, RM
   Wang, LY
   Napier, T
   Lin, JB
   Jing, G
   Lucius, AL
   McDonald, JM
   Zhou, T
   Song, YH
AF Fancy, Romone M.
   Wang, Lingyun
   Napier, Tiara
   Lin, Jiabei
   Jing, Gu
   Lucius, Aaron L.
   McDonald, Jay M.
   Zhou, Tong
   Song, Yuhua
TI Characterization of Calmodulin-Fas Death Domain Interaction: An
   Integrated Experimental and Computational Study
SO BIOCHEMISTRY
LA English
DT Article
ID CIRCULAR-DICHROISM SPECTRA; AUTOIMMUNE-LYMPHOPROLIFERATIVE-SYNDROME;
   PROTEIN SECONDARY STRUCTURE; CHOLANGIOCARCINOMA CELLS; MEDIATED
   APOPTOSIS; SIGNALING COMPLEX; BINDING; GENE; CONFORMATION; MUTATIONS
AB The Fas death receptor-activated death-inducing signaling complex (DISC) regulates apoptosis in many normal and cancer cells. Qualitative biochemical experiments demonstrate that calmodulin (CaM) binds to the death domain of Fas. The interaction between CaM and Fas regulates Fas-mediated DISC formation. A quantitative understanding of the interaction between CaM and Fas is important for the optimal design of antagonists for CaM or Fas to regulate the CaM-Fas interaction, thus modulating Fas-mediated DISC formation and apoptosis. The V254N mutation of the Fas death domain (Fas DD) is analogous to an identified mutant allele of Fas in lpr-cg mice that have a deficiency in Fas-mediated apoptosis. In this study, the interactions of CaM with the Fas DD wild type (Fas DD WT) and with the Fas DD V254N mutant were characterized using isothermal titration calorimetry (ITC), circular dichroism spectroscopy (CD), and molecular dynamics (MD) simulations. ITC results reveal an endothermic binding characteristic and an entropy-driven interaction of CaM with Fas DD WT or with Fas DD V254N. The Fas DD V254N mutation decreased the association constant (K-a) for CaM-Fas DD binding from (1.79 +/- 0.20) X 10(6) to (0.88 +/- 0.14) x 10(6) M-1 and slightly increased a standard state Gibbs free energy (Delta G degrees) for CaM-Fas DD binding from -8.87 +/- 0.07 to -8.43 +/- 0.10 kcal/mol. CD secondary structure analysis and MD simulation results did not show significant secondary structural changes of the Fas DD caused by the V254N mutation. The conformational and dynamical motion analyses, the analyses of hydrogen bond formation within the CaM binding region, the contact numbers of each residue, and the electrostatic potential for the CaM binding region based on MD simulations demonstrated changes caused by the Fas DD V254N mutation. These changes caused by the Fas DD V254N mutation could affect the van der Waals interactions and electrostatic interactions between CaM and Fas DD, thereby affecting CaM-Fas DD interactions. Results from this study characterize CaM Fas DD interactions in a quantitative way, providing structural and thermodynamic evidence of the role of the Fas DD V254N mutation in the CaM-Fas DD interaction. Furthermore, the results could help to identify novel strategies for regulating CaM-Fas DD interactions and Fas DD conformation and thus to modulate Fas-mediated DISC formation and thus Fas-mediated apoptosis.
C1 [Fancy, Romone M.; Wang, Lingyun; Napier, Tiara; Song, Yuhua] Univ Alabama Birmingham, Dept Biomed Engn, Birmingham, AL 35294 USA.
   [Lin, Jiabei; Lucius, Aaron L.] Univ Alabama Birmingham, Dept Chem, Birmingham, AL 35294 USA.
   [Jing, Gu] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
   [McDonald, Jay M.; Zhou, Tong] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
   [McDonald, Jay M.] Univ Alabama Birmingham, Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA.
RP Song, YH (reprint author), Univ Alabama Birmingham, Dept Biomed Engn, 803 Shelby Interdisciplinary Biomed Res Bldg,1825, Birmingham, AL 35294 USA.
EM yhsong@uab.edu
OI Lucius, Aaron/0000-0001-8636-5411
FU National Institutes of Health K25 Award [5K25CA140791]; Veterans
   Administration Merit Award
FX This work was supported in part by a National Institutes of Health K25
   Award (5K25CA140791) to Y.S. and a Veterans Administration Merit Award
   to J.M.M.
NR 47
TC 3
Z9 3
U1 1
U2 9
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD APR 29
PY 2014
VL 53
IS 16
BP 2680
EP 2688
DI 10.1021/bi500228h
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AG3DY
UT WOS:000335297200013
PM 24702583
ER

PT J
AU Zavadzkas, JA
   Stroud, RE
   Bouges, S
   Mukherjee, R
   Jones, JR
   Patel, RK
   McDermott, PJ
   Spinale, FG
AF Zavadzkas, Juozas A.
   Stroud, Robert E.
   Bouges, Shenikqua
   Mukherjee, Rupak
   Jones, Jeffrey R.
   Patel, Risha K.
   McDermott, Paul J.
   Spinale, Francis G.
TI Targeted Overexpression of Tissue Inhibitor of Matrix
   Metalloproteinase-4 Modifies Post-Myocardial Infarction Remodeling in
   Mice
SO CIRCULATION RESEARCH
LA English
DT Article
DE extracellular matrix; myocardial infarction; tissue inhibitor of
   metalloproteinases; ventricular function
ID MYOCARDIAL-INFARCTION; PRESSURE-OVERLOAD; TIMPS; INDUCTION; FIBROSIS;
   SURVIVAL; DELETION; CANCER
AB Rationale: Myocardial infarction (MI) causes an imbalance between matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases (TIMPs) and is associated with adverse left ventricular (LV) remodeling. A uniform reduction in TIMP-4 post-MI has been observed.
   Objective: To examine post-MI remodeling with cardiac-restricted overexpression of TIMP-4, either through a transgenic or viral delivery approach.
   Methods and Results: MI was induced in mice and then randomized to targeted injection of an adenoviral construct (10 L; 8x10(9) plaque forming units/mL) encoding green fluorescent protein (GFP) and the full-length human TIMP-4 (Ad-GFP-TIMP4) or GFP. A transgenic construct with cardiac-restricted overexpression TIMP-4 (hTIMP-4exp) was used in a parallel set of studies. LV end-diastolic volume, an index of LV remodeling, increased by >60% from baseline at 5 days post-MI and by >100% at 21 days post-MI in the Ad-GFP only group. However, LV dilation was reduced by approximate to 50% in both the Ad-GFP-TIMP4 and hTIMP-4exp groups at these post-MI time points. LV ejection fraction was improved with either Ad-GFP-TIMP-4 or hTIMP-4exp. Fibrillar collagen expression and content were increased within the MI region with both TIMP-4 interventions, suggestive of matrix stabilization.
   Conclusions: This study is the first to demonstrate that selective myocardial targeting for TIMP-4 induction through either a viral or transgenic approach favorably altered the course of adverse LV remodeling post-MI. Thus, localized induction of endogenous matrix metalloproteinase inhibitors, such as TIMP-4, holds promise as a means to interrupt the progression of post-MI remodeling.
C1 [Zavadzkas, Juozas A.; Stroud, Robert E.; Bouges, Shenikqua; Mukherjee, Rupak; Jones, Jeffrey R.; Patel, Risha K.] Med Univ S Carolina, Dept Surg, Charleston, SC USA.
   [McDermott, Paul J.] Med Univ S Carolina, Dept Med, Charleston, SC USA.
   [Zavadzkas, Juozas A.; Stroud, Robert E.; Bouges, Shenikqua; Mukherjee, Rupak; Jones, Jeffrey R.; Patel, Risha K.; McDermott, Paul J.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
   [Spinale, Francis G.] Univ S Carolina, Sch Med, Dept Cell Biol & Anat & Surg, Columbia, SC 29209 USA.
   [Spinale, Francis G.] WJB Dorn VA Med Ctr, Columbia, SC USA.
RP Spinale, FG (reprint author), Univ S Carolina, Sch Med, CBA, Cardiovasc Translat Res Ctr, 6439 Garners Ferry Rd, Columbia, SC 29209 USA.
EM cvctrc@uscmed.sc.edu
FU National Institutes of Health [HL059165, HL057952, HL095608, HL078825];
   Veterans' Affairs Health Administration
FX This study was supported by National Institutes of Health grants
   HL059165, HL057952, HL095608, and HL078825 and Merit Awards from the
   Veterans' Affairs Health Administration.
NR 29
TC 12
Z9 14
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7330
EI 1524-4571
J9 CIRC RES
JI Circ.Res.
PD APR 25
PY 2014
VL 114
IS 9
BP 1435
EP 1445
DI 10.1161/CIRCRESAHA.114.303634
PG 11
WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular
   Disease
SC Cardiovascular System & Cardiology; Hematology
GA AG7KD
UT WOS:000335596000011
PM 24637197
ER

PT J
AU Sigel, K
   Wisnivesky, J
   Shahrir, S
   Brown, ST
   Justice, A
   Kim, J
   Rodriguez-Barradas, MC
   Akgun, KM
   Rimland, D
   Hoo, GWS
   Crothers, K
AF Sigel, Keith
   Wisnivesky, Juan
   Shahrir, Shahida
   Brown, Sheldon T.
   Justice, Amy
   Kim, Joon
   Rodriguez-Barradas, Maria C.
   Akguen, Kathleen M.
   Rimland, David
   Hoo, Guy W. Soo
   Crothers, Kristina
TI Findings in asymptomatic HIV-infected patients undergoing chest computed
   tomography testing: implications for lung cancer screening
SO AIDS
LA English
DT Article
DE lung cancer; non-AIDS malignancies; HIV; lung nodules; lung cancer
   screening
ID HUMAN-IMMUNODEFICIENCY-VIRUS; UNITED-STATES; PULMONARY-EMPHYSEMA;
   COST-EFFECTIVENESS; RISK; POPULATION; SMOKING; STRATEGIES; MORTALITY;
   DIAGNOSIS
AB Background:
   HIV-infected persons have a two-fold to five-fold increased unadjusted risk of lung cancer. In the National Lung Screening Trial (NLST), computed tomography (CT) screening was associated with a reduction in lung cancer mortality among high-risk smokers. These results may not generalize to HIV-infected persons, particularly if they are more likely to have false-positive chest CT findings.
   Methods:
   We utilized data including standardized chest CT scans from 160 HIV infected and 139 uninfected Veterans enrolled between 2009 and 2012 in the multicenter Examinations of HIV Associated Lung Emphysema (EXHALE) Study. Abnormal CT findings were abstracted from clinical interpretations of the scans and classified as positive by NLST criteria vs. other findings. Clinical evaluations and diagnoses that ensued were abstracted from the medical record.
   Results:
   There was no significant difference by HIV in the proportion of CT scans classified as positive by NLST criteria (29% of HIV infected and 24% of HIV uninfected, P = 0.3). However, HIV-infected participants with CD4(+) cell counts less than 200 cells/mu l had significantly higher odds of positive scans, a finding that persisted in multivariable analysis. Evaluations triggered by abnormal CT scans were also similar in HIV-infected and uninfected participants (all P > 0.05).
   Conclusion:
   HIV status was not associated with an increased risk of abnormal findings on CT or increased rates of follow-up testing in clinically stable outpatients with CD4(+) cell count more than 200. These data reflect favorably on the balance of benefits and harms associated with lung cancer screening for HIV-infected smokers with less severe immunodeficiency.
C1 [Sigel, Keith; Wisnivesky, Juan; Brown, Sheldon T.] Icahn Sch Med Mt Sinai, New York, NY USA.
   [Shahrir, Shahida; Crothers, Kristina] Univ Washington, Sch Med, Seattle, WA USA.
   [Brown, Sheldon T.; Kim, Joon] James J Peters VA Med Ctr, Bronx, NY USA.
   [Justice, Amy; Akguen, Kathleen M.] VA Connecticut Healthcare Syst, West Haven, CT USA.
   [Justice, Amy; Akguen, Kathleen M.] Yale Univ, Sch Med, New Haven, CT USA.
   [Rodriguez-Barradas, Maria C.] Michael E DeBakey VA Med Ctr, Houston, TX USA.
   [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Houston, TX 77030 USA.
   [Rimland, David] Atlanta VA Med Ctr, Atlanta, GA USA.
   [Rimland, David] Emory Univ, Sch Med, Atlanta, GA USA.
   [Hoo, Guy W. Soo] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
   [Hoo, Guy W. Soo] Univ Calif Los Angeles, Geffen Sch Med, Los Angeles, CA USA.
RP Sigel, K (reprint author), One Gustave Levy Pl, New York, NY 10029 USA.
EM Keith.Sigel@mssm.edu
OI Sigel, Keith/0000-0002-4051-4861
FU National Heart, Lung, and Blood Institute [R01HL090342]; National Cancer
   Institute [R01CA173754]; National Center for Research Resources
   [KL2TR000069]; Department of Veterans Affairs; National Institute on
   Alcohol and Alcohol Abuse [3U01AA13566]
FX This study was supported by the National Heart, Lung, and Blood
   Institute (R01HL090342 to K. C.), the National Cancer Institute
   (R01CA173754 to K. C. and J.W.), the National Center for Research
   Resources (KL2TR000069 to K. S.), Department of Veterans Affairs (VISN 1
   Career Development Award to K. A.), and the National Institute on
   Alcohol and Alcohol Abuse (3U01AA13566). The funder provided funding for
   the study and salary support for investigators. The funder did not play
   any role in the data collection, analysis, interpretation or article
   preparation.
NR 35
TC 13
Z9 13
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD APR 24
PY 2014
VL 28
IS 7
BP 1007
EP 1014
DI 10.1097/QAD.0000000000000189
PG 8
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA AG3WP
UT WOS:000335350900009
PM 24401647
ER

PT J
AU Medeiros, K
   O'Connor, MJ
   Baicu, CF
   Fitzgibbons, TP
   Shaw, P
   Tighe, DA
   Zile, MR
   Aurigemma, GP
AF Medeiros, Keith
   O'Connor, Mark J.
   Baicu, Catalin F.
   Fitzgibbons, Timothy P.
   Shaw, Peter
   Tighe, Dennis A.
   Zile, Michael R.
   Aurigemma, Gerard P.
TI Systolic and Diastolic Mechanics in Stress Cardiomyopathy
SO CIRCULATION
LA English
DT Article
DE cardiomyopathies; diastole; echocardiography; heart failure; myocardial
   infarction
ID TAKO-TSUBO CARDIOMYOPATHY; HEART-FAILURE; MYOCARDIAL-INFARCTION;
   TAKOTSUBO CARDIOMYOPATHY; 2-DIMENSIONAL STRAIN; LEFT-VENTRICLE;
   UNITED-STATES; ECHOCARDIOGRAPHY; RECOMMENDATIONS; QUANTIFICATION
AB Background Stress cardiomyopathy (SCM) is a peculiar form of reversible left ventricular dysfunction seen predominantly in women and occurs in response to emotional or physical stress. Because dysfunction in SCM is reversible and that of acute myocardial infarction (MI) is not, we hypothesized that these fundamental mechanistic differences between SCM and MI would be associated with different systolic and diastolic properties.
   Methods and Results We examined 3 groups, all women: patients with SCM (n=24; mean age, 6312 years), those with left anterior (LAD) ST-segment-elevation MI (n=36; mean age, 63 +/- 10 years), and referent control subjects (n=30; mean age, 62 +/- 8 years). All underwent angiography, ventriculography, and pressure measurements within 48 hours of presentation. Left ventricular volumes, diastolic pressures, and diastolic stiffness were higher in SCM and LAD MI patients than in control subjects but no different from each other. Similarly, left ventricular diastolic pressures and diastolic stiffness were elevated in the SCM and LAD MI groups compared with the control group. Left ventricular ejection fraction in SCM and LAD MI were 40.8 +/- 12.3% and 49.6 +/- 5.6%, respectively, versus 70.4 +/- 9.4% in control subjects (P<0.001), and stroke work less than half the value of control subjects. Indexes of contractility and ventricular-arterial coupling were similarly abnormal in SCM and LAD MI.
   Conclusions SCM and LAD MI show severe diastolic dysfunction. At similar left ventricular volumes, their diastolic pressures are more than twice as high as in control subjects, and systolic dysfunction is equally reduced in SCM and LAD MI. Despite a completely different pathophysiology in terms of systolic and diastolic function, SCM is indistinguishable from acute LAD-territory MI.
C1 [Medeiros, Keith; O'Connor, Mark J.; Fitzgibbons, Timothy P.; Shaw, Peter; Tighe, Dennis A.; Aurigemma, Gerard P.] Univ Massachusetts, Sch Med, Dept Med, Div Cardiovasc Med, Worcester, MA 01655 USA.
   [Baicu, Catalin F.; Zile, Michael R.] Med Univ S Carolina, Dept Med, Div Cardiol, Charleston, SC 29425 USA.
   [Baicu, Catalin F.; Zile, Michael R.] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA.
RP Aurigemma, GP (reprint author), Univ Massachusetts, Sch Med, Dept Med, Div Cardiovasc Med, 55 Lake Ave N,Room S3-860, Worcester, MA 01655 USA.
EM gerard.aurigemma@umassmed.edu
OI Fitzgibbons, Timothy/0000-0003-0229-034X
NR 26
TC 22
Z9 22
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
EI 1524-4539
J9 CIRCULATION
JI Circulation
PD APR 22
PY 2014
VL 129
IS 16
BP 1659
EP 1667
DI 10.1161/CIRCULATIONAHA.113.002781
PG 9
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA AF3XQ
UT WOS:000334646400016
PM 24503950
ER

PT J
AU Figlewicz, DP
   Hill, SR
   Jay, JL
   West, CH
   Zavosh, AS
   Sipols, AJ
AF Figlewicz, D. P.
   Hill, S. R.
   Jay, J. L.
   West, C. H.
   Zavosh, A. S.
   Sipols, A. J.
TI Effect of recurrent yohimbine on immediate and post-hoc behaviors,
   stress hormones, and energy homeostatic parameters
SO PHYSIOLOGY & BEHAVIOR
LA English
DT Article
DE Rats; Glucocorticoids; cFos; Stress
ID NORADRENERGIC MECHANISMS; METABOLIC SYNDROME; FOOD SEEKING; DRUG
   SEEKING; DISORDER; RATS; ANXIETY; REINSTATEMENT; INCUBATION; INJECTIONS
AB Evidence from experimental models has suggested that acute activation of brain stress and anxiety pathways imparts subsequent behaviors that are mediated or modulated by limbic circuitry. There have been limited investigations of prior or chronic activation of these pathways on subsequent limbic-mediated behaviors. In this study, we tested whether recurrent administration of the anxiogenic compound yohimbine (YOH) could have post-injection effects on brain activation, stress hormones, and performance in sucrose self-administration and startle response paradigms. Rats received six injections across two weeks of either 2 mg/kg YOH or saline. Behavioral evaluation confirmed the continued efficacy of the YOH regimen, and increased adrenal corticosterone (CORT) was observed. Several days following YOH or SAL administration, cFos, COAT and adrenocorticotropin hormone (ACTH), and behavioral performance were measured. cFos was elevated post-YOH in the hippocampus; ventral tegmental area/zona inserta; and central and medial nuclei of the amygdala. This activation is consistent with a sustained effect of YOH to activate fear and anxiety circuitries in the CNS. CORT but not ACTH was elevated in the YOH-rats following startle testing. Self-administration and startle tests suggested an increase of non-specific activity in the post-YOH rats; there was no increase in sucrose self-administration or startle response per se. Our findings suggest that recurrent YOH administration may prove a useful and reliable model for simulating recurrent stress/anxiety, and that enhancements to the paradigm such as higher or more frequent dosing of YOH could yield stronger or more extensive behavioral effects. Published by Elsevier Inc.
C1 [Figlewicz, D. P.; West, C. H.] VA Puget Sound Hlth Care Syst 151, Seattle, WA 98108 USA.
   [Figlewicz, D. P.; Jay, J. L.; Zavosh, A. S.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
   [Sipols, A. J.] Univ Latvia, Fac Med, Inst Expt & Clin Med, LV-1586 Riga, Latvia.
RP Figlewicz, DP (reprint author), VA Puget Sound Hlth Care Syst, 1660 So Columbian Way, Seattle, WA 98108 USA.
EM latte@u.washington.edu
FU NIH [DK40963]; University of Washington Training [NIH T32DK007120];
   University of Washington Diabetes Endocrinology Research Center
   [P30DK017047]; University of Latvia [Y5-AZ17-ZF-N-003]
FX Dianne Figlewicz Lattemann is a Senior Research Career Scientist,
   Biomedical Laboratory Research Program, Department of Veterans Affairs
   Puget Sound Health Care System, Seattle, Washington; and the research in
   this paper has been supported by NIH grant DK40963. Susan Hill was
   supported by the University of Washington Training Grant NIH
   T32DK007120, and by the University of Washington Diabetes Endocrinology
   Research Center Grant NIH P30DK017047. Alfred J. Sipols was supported by
   the University of Latvia grant Y5-AZ17-ZF-N-003. The authors thank the
   laboratory of Dr. Dennis Rasmussen (VAPSHCS) for assistance with the
   startle response measurements. We thank Ms. Amalie Alver and Ms. Lydia
   Wang for their excellent technical assistance.
NR 33
TC 2
Z9 2
U1 2
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0031-9384
J9 PHYSIOL BEHAV
JI Physiol. Behav.
PD APR 22
PY 2014
VL 129
BP 186
EP 193
DI 10.1016/j.physbeh.2014.02.019
PG 8
WC Psychology, Biological; Behavioral Sciences
SC Psychology; Behavioral Sciences
GA AH4SC
UT WOS:000336117300026
PM 24565792
ER

PT J
AU Gleason, JE
   Galaleldeen, A
   Peterson, RL
   Taylor, AB
   Holloway, SP
   Waninger-Saroni, J
   Cormack, BP
   Cabelli, DE
   Hart, PJ
   Culotta, VC
AF Gleason, Julie E.
   Galaleldeen, Ahmad
   Peterson, Ryan L.
   Taylor, Alexander B.
   Holloway, Stephen P.
   Waninger-Saroni, Jessica
   Cormack, Brendan P.
   Cabelli, Diane E.
   Hart, P. John
   Culotta, Valeria Cizewski
TI Candida albicans SOD5 represents the prototype of an unprecedented class
   of Cu-only superoxide dismutases required for pathogen defense
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID COPPER CHAPERONE CCS; MYCOBACTERIUM-TUBERCULOSIS; ANGSTROM RESOLUTION;
   ACTIVE-SITE; ZINC; VIRULENCE; MECHANISM; BINDING; OXYGEN; ERYTHROCUPREIN
AB The human fungal pathogens Candida albicans and Histoplasma capsulatum have been reported to protect against the oxidative burst of host innate immune cells using a family of extracellular proteins with similarity to Cu/Zn superoxide dismutase 1 (SOD1). We report here that these molecules are widespread throughout fungi and deviate from canonical SOD1 at the primary, tertiary, and quaternary levels. The structure of C. albicans SOD5 reveals that although the beta-barrel of Cu/Zn SODs is largely preserved, SOD5 is a monomeric copper protein that lacks a zinc-binding site and is missing the electrostatic loop element proposed to promote catalysis through superoxide guidance. Without an electrostatic loop, the copper site of SOD5 is not recessed and is readily accessible to bulk solvent. Despite these structural deviations, SOD5 has the capacity to disproportionate superoxide with kinetics that approach diffusion limits, similar to those of canonical SOD1. In cultures of C. albicans, SOD5 is secreted in a disulfide-oxidized form and apo-pools of secreted SOD5 can readily capture extracellular copper for rapid induction of enzyme activity. We suggest that the unusual attributes of SOD5-like fungal proteins, including the absence of zinc and an open active site that readily captures extracellular copper, make these SODs well suited to meet challenges in zinc and copper availability at the host-pathogen interface.
C1 [Gleason, Julie E.; Peterson, Ryan L.; Culotta, Valeria Cizewski] Johns Hopkins Univ, Dept Biochem & Mol Biol, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA.
   [Galaleldeen, Ahmad; Waninger-Saroni, Jessica] St Marys Univ, Dept Biol Sci, San Antonio, TX 78228 USA.
   [Taylor, Alexander B.; Holloway, Stephen P.; Hart, P. John] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA.
   [Cormack, Brendan P.] Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA.
   [Cabelli, Diane E.] Brookhaven Natl Labs, Dept Chem, Upton, NY 11973 USA.
   [Hart, P. John] South Texas Vet Hlth Care Syst, Dept Vet Affairs, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA.
RP Hart, PJ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA.
EM pjhart@biochem.uthscsa.edu; vculotta@jhsph.edu
FU National Institutes of Health [R21 AI097715, R37 GM50016, R01AI046223];
   Veterans Administration [VA 1I01BX000506]; Robert A. Welch Foundation
   [AQ-1399]; St. Mary's University; Biaggini Research Program; US
   Department of Energy Office of Science, Division of Chemical Sciences,
   Geosciences, and Biosciences [DE-AC02-98CH10886]; Office of the Vice
   President for Research at the University of Texas Health Science Center;
    [T32 CA009110]
FX We thank D. Kornitzer for kind gifts of yeast strains, and B. Demeler
   and V. Schirf for assistance in analytical ultracentrifugation
   experiments. This work was funded by National Institutes of Health
   Grants R21 AI097715 (to V. C. C.), R37 GM50016 (to V. C. C.), and
   R01AI046223 (to B. P. C.) and by Veterans Administration Grant VA
   1I01BX000506 and Robert A. Welch Foundation Grant AQ-1399 (to P.J.H.).
   J.E.G. and R. L. P. were supported by Grant T32 CA009110, and A. G. and
   J.W.-S. were supported by a St. Mary's University grant and the Biaggini
   Research Program. The work at Brookhaven National Laboratory was carried
   out at the Accelerator Center for Energy Research, supported by the US
   Department of Energy Office of Science, Division of Chemical Sciences,
   Geosciences, and Biosciences under Contract DE-AC02-98CH10886. The
   Center for Analytical Ultracentrifugation of Macromolecular Assemblies
   is supported by the Office of the Vice President for Research at the
   University of Texas Health Science Center.
NR 48
TC 22
Z9 23
U1 3
U2 24
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 22
PY 2014
VL 111
IS 16
BP 5866
EP 5871
DI 10.1073/pnas.1400137111
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AF4OV
UT WOS:000334694000041
PM 24711423
ER

PT J
AU Anacker, AMJ
   Ahern, TH
   Hostetler, CM
   Dufour, BD
   Smith, ML
   Cocking, DL
   Li, J
   Young, LJ
   Loftis, JM
   Ryabinin, AE
AF Anacker, Allison M. J.
   Ahern, Todd H.
   Hostetler, Caroline M.
   Dufour, Brett D.
   Smith, Monique L.
   Cocking, Davelle L.
   Li, Ju
   Young, Larry J.
   Loftis, Jennifer M.
   Ryabinin, Andrey E.
TI Drinking alcohol has sex-dependent effects on pair bond formation in
   prairie voles
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE anxiety; ethanol; substance use; oxytocin; vasopressin
ID CORTICOTROPIN-RELEASING-FACTOR; MICROTUS-OCHROGASTER; SOCIAL ATTACHMENT;
   PARTNER PREFERENCE; PHARMACOLOGICAL PARALLELS; MONOGAMOUS RODENT;
   NEUROPEPTIDE-Y; ADULT MALE; VASOPRESSIN; BEHAVIOR
AB Alcohol use and abuse profoundly influences a variety of behaviors, including social interactions. In some cases, it erodes social relationships; in others, it facilitates sociality. Here, we show that voluntary alcohol consumption can inhibit male partner preference (PP) formation (a laboratory proxy for pair bonding) in socially monogamous prairie voles (Microtus ochrogaster). Conversely, female PP is not inhibited, and may be facilitated by alcohol. Behavior and neurochemical analysis suggests that the effects of alcohol on social bonding are mediated by neural mechanisms regulating pair bond formation and not alcohol's effects on mating, locomotor, or aggressive behaviors. Several neuropeptide systems involved in the regulation of social behavior (especially neuropeptide Y and corticotropin-releasing factor) are modulated by alcohol drinking during cohabitation. These findings provide the first evidence to our knowledge that alcohol has a direct impact on the neural systems involved in social bonding in a sex-specific manner, providing an opportunity to explore the mechanisms by which alcohol affects social relationships.
C1 [Anacker, Allison M. J.; Hostetler, Caroline M.; Dufour, Brett D.; Smith, Monique L.; Cocking, Davelle L.; Li, Ju; Ryabinin, Andrey E.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA.
   [Loftis, Jennifer M.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97239 USA.
   [Anacker, Allison M. J.] Smith Coll, Neurosci Program, Northampton, MA 01063 USA.
   [Ahern, Todd H.] Quinnipiac Univ, Ctr Behav Neurosci, Dept Psychol, Hamden, CT 06518 USA.
   [Young, Larry J.] Emory Univ, Yerkes Natl Primate Res Ctr, Ctr Translat Social Neurosci, Dept Psychiat & Behav Sci, Atlanta, GA 30322 USA.
   [Loftis, Jennifer M.] Portland VA Med Ctr, Res & Dev Serv, Portland, OR 97239 USA.
RP Ryabinin, AE (reprint author), Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA.
EM ryabinin@ohsu.edu
RI Dufour, Brett/G-8172-2014
OI Dufour, Brett/0000-0001-9370-6149; Smith, Monique/0000-0002-2656-0677
FU National Science Foundation [IBN-9876754]; Office of Research
   Infrastructure Programs/Office of Director [P51OD11132];  [AA019793]; 
   [AA020126];  [MH64692]
FX We thank Heather Buxton and Alexandra MacColl Garfinkel for assistance
   in scoring animal behavior videos. This material is the result of work
   supported with resources and use of facilities at the Portland Veterans
   Affairs Medical Center. J.M.L. is a Research Scientist (Research and
   Development Service, Department of Veterans Affairs Medical Center).
   StopWatch Plus was provided by the Center for Behavioral Neuroscience, a
   Science and Technology Center Program of the National Science
   Foundation, under Agreement IBN-9876754. This work was funded by Grant
   AA019793 (to A. E. R.), Grant AA020126 (to A.M.J.A.), and Grant MH64692
   (to L.J.Y.), as well as by Office of Research Infrastructure
   Programs/Office of Director Grant P51OD11132 (to Stewart W. Caughman).
NR 73
TC 8
Z9 8
U1 4
U2 29
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 22
PY 2014
VL 111
IS 16
BP 6052
EP 6057
DI 10.1073/pnas.1320879111
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AF4OV
UT WOS:000334694000072
PM 24711424
ER

PT J
AU Bhattacharya, A
   Wei, R
   Hamilton, RT
   Chaudhuri, AR
AF Bhattacharya, Arunabh
   Wei, Rochelle
   Hamilton, Ryan T.
   Chaudhuri, Asish R.
TI Neuronal cells but not muscle cells are resistant to oxidative stress
   mediated protein misfolding and cell death: Role of molecular chaperones
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Protein misfolding; Heat shock proteins; Oxidative stress; Skeletal
   muscle; Neuron; Cell viability
ID AMYOTROPHIC-LATERAL-SCLEROSIS; HEAT-SHOCK PROTEINS; SKELETAL-MUSCLE;
   MUTANT SOD1; MOUSE MODEL; ATROPHY; OVEREXPRESSION; ASSOCIATION;
   ARIMOCLOMOL; DISEASE
AB Our recent study in a mouse model of familial-Amyotrophic Lateral Sclerosis (f-ALS) revealed that muscle proteins are equally sensitive to misfolding as spinal cord proteins despite the presence of low mutant CuZn-superoxide dismutase, which is considered to be the key toxic element for initiation and progression of f-ALS. More importantly, we observed differential level of heat shock proteins (Hsp's) between skeletal muscle and spinal cord tissues prior to the onset and during disease progression; spinal cord maintains significantly higher level of Hsp's compared to skeletal muscle. In this study, we report two important observations; (i) muscle cells (but not neuronal cells) are extremely vulnerable to protein misfolding and cell death during challenge with oxidative stress and (ii) muscle cells fail to mount Hsp's during challenge unlike neuronal cells. These two findings can possibly explain why muscle atrophy precedes the death of motor neurons in f-ALS mice. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Bhattacharya, Arunabh; Wei, Rochelle; Hamilton, Ryan T.; Chaudhuri, Asish R.] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA.
   [Chaudhuri, Asish R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA.
   [Bhattacharya, Arunabh] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
   [Chaudhuri, Asish R.] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
RP Chaudhuri, AR (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, Texas Res Pk Campus,15355 Lambda Dr, San Antonio, TX 78245 USA.
EM chaudhuria@uthscsa.edu
FU VA merit grant; AFAR Research Grant; National Institutes of Health
   [K01AG038555]
FX This study was supported by VA merit grant to Asish Chaudhuri and
   partially supported by AFAR Research Grant and National Institutes of
   Health (K01AG038555) grant to Arunabh Bhattachaiya. We like to thank Dr.
   Peter Hornsby and Anuja Mishra for providing and assisting in growing
   the NPC's.
NR 17
TC 2
Z9 2
U1 0
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD APR 18
PY 2014
VL 446
IS 4
BP 1250
EP 1254
DI 10.1016/j.bbrc.2014.03.097
PG 5
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA AG4CW
UT WOS:000335367900071
PM 24685484
ER

PT J
AU Clark, KB
AF Clark, Kevin B.
TI Basis for a neuronal version of Grover's quantum algorithm
SO FRONTIERS IN MOLECULAR NEUROSCIENCE
LA English
DT Article
DE biotechnology; calcium-induced calcium reactions (CICRs); cellular
   decision making; classical and quantum computation; inositol
   1,4,5-trisphosphate receptors (IP(3)Rs); intracellular calcium; neuronal
   plasticity; quantum molecular networks and memory
ID INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; CA2+ RELEASE CHANNELS;
   ENDOPLASMIC-RETICULUM; SYNAPTIC PLASTICITY; CALCIUM WAVES; IP3
   RECEPTORS; TRISPHOSPHATE RECEPTORS; LANDAUERS PRINCIPLE; FACTORING
   ALGORITHM; MATHEMATICAL-THEORY
AB Grover's quantum (search) algorithm exploits principles of quantum information theory and computation to surpass the strong Church-Turing limit governing classical computers. The algorithm initializes a search field into superposed N (eigen)states to later execute nonclassical "subroutines" involving unitary phase shifts of measured states and to produce root-rate or quadratic gain in the algorithmic time (O(N-1/2)) needed to find some "target" solution m. Akin to this fast technological search algorithm, single eukaryotic cells, such as differentiated neurons, perform natural quadratic speed-up in the search for appropriate store-operated Ca2+ response regulation of, among other processes, protein and lipid biosynthesis, cell energetics, stress responses, cell fate and death, synaptic plasticity, and immunoprotection. Such speed-up in cellular decision making results from spatiotemporal dynamics of networked intracellular Ca2+-induced Ca2+ release and the search (or signaling) velocity of Ca2+ wave propagation. As chemical processes, such as the duration of Ca2+ mobilization, become rate-limiting over interstore distances, Ca2+ waves quadratically decrease interstore-travel time from slow saltatory to fast continuous gradients proportional to the square-root of the classical Ca2+ diffusion coefficient, D-1/2, matching the computing efficiency of Grover's quantum algorithm. In this Hypothesis and Theory article, I elaborate on these traits using a fire-diffuse-fire model of store-operated cytosolic Ca2+ signaling valid for glutamatergic neurons. Salient model features corresponding to Grover's quantum algorithm are parameterized to meet requirements for the Oracle Hadamard transform and Grover's iteration. A neuronal version of Grover's quantum algorithm figures to benefit signal coincidence detection and integration, bidirectional synaptic plasticity, and other vital cell functions by rapidly selecting, ordering, and/or counting optional response regulation choices.
C1 [Clark, Kevin B.] Vet Affairs Greater Los Angeles Healthcare Syst, Res & Dev Serv, Los Angeles, CA USA.
   [Clark, Kevin B.] Complex Biol Syst Alliance, N Andover, MA USA.
RP Clark, KB (reprint author), 4229 SE Harney St, Portland, OR 97206 USA.
EM kbclarkphd@yahoo.com
NR 177
TC 1
Z9 1
U1 0
U2 7
PU FRONTIERS RESEARCH FOUNDATION
PI LAUSANNE
PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND
SN 1662-5099
J9 FRONT MOL NEUROSCI
JI Front. Molec. Neurosci.
PD APR 17
PY 2014
VL 7
AR 29
DI 10.3389/fnmol.2014.00029
PG 20
WC Neurosciences
SC Neurosciences & Neurology
GA AZ0YX
UT WOS:000347968800001
PM 24860419
ER

PT J
AU Goto, Y
   Panea, C
   Nakato, G
   Cebula, A
   Lee, C
   Diez, MG
   Laufer, TM
   Ignatowicz, L
   Ivanov, II
AF Goto, Yoshiyuki
   Panea, Casandra
   Nakato, Gaku
   Cebula, Anna
   Lee, Carolyn
   Diez, Marta Galan
   Laufer, Terri M.
   Ignatowicz, Leszek
   Ivanov, Ivaylo I.
TI Segmented Filamentous Bacteria Antigens Presented by Intestinal
   Dendritic Cells Drive Mucosal Th17 Cell Differentiation
SO IMMUNITY
LA English
DT Article
ID REGULATORY T-CELLS; CLASS-II MOLECULES; COMMENSAL BACTERIA;
   EPITHELIAL-CELLS; LAMINA PROPRIA; DEFICIENT MICE; IMMUNE-SYSTEM; CHAIN
   GENE; HOMEOSTASIS; MICROBIOTA
AB How commensal microbiota contributes to immune cell homeostasis at barrier surfaces is poorly understood. Lamina propria (LP) T helper 17 (Th17) cells participate in mucosal protection and are induced by commensal segmented filamentous bacteria (SFB). Here we show that MHCII-dependent antigen presentation of SFB antigens by intestinal dendritic cells (DCs) is crucial for Th17 cell induction. Expression of MHCII on CD11c(+) cells was necessary and sufficient for SFB-induced Th17 cell differentiation. Most SFB-induced Th17 cells recognized SFB in an MHCII-dependent manner. SFB primed and induced Th17 cells locally in the LP and Th17 cell induction occurred normally in mice lacking secondary lymphoid organs. The importance of other innate cells was unveiled by the finding that MHCII deficiency in group 3 innate lymphoid cells (ILCs) resulted in an increase in SFB-independent Th17 cell differentiation. Our results outline the complex role of DCs and ILCs in the regulation of intestinal Th17 cell homeostasis.
C1 [Goto, Yoshiyuki; Panea, Casandra; Nakato, Gaku; Lee, Carolyn; Diez, Marta Galan; Ivanov, Ivaylo I.] Columbia Univ, Med Ctr, Dept Microbiol & Immunol, New York, NY 10032 USA.
   [Cebula, Anna; Ignatowicz, Leszek] Georgia Regents Univ, Ctr Biotechnol & Genom Med, Augusta, GA 30912 USA.
   [Laufer, Terri M.] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA.
   [Laufer, Terri M.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
RP Ivanov, II (reprint author), Columbia Univ, Med Ctr, Dept Microbiol & Immunol, New York, NY 10032 USA.
EM ii2137@columbia.edu
FU National Institute of Health [1R01DK098378]; Crohn's and Colitis
   Foundation of America SRA [259540]; Toyobo Biofoundation; Pew Charitable
   Trust
FX We thank members of the I. I. I. laboratory for their help in all
   aspects of the project. We thank Yoshinori Umesaki at the Yakult Central
   Institute for providing feces from SFB-monocolonized mice. We thank
   Kenya Honda and Seiko Narushima for developing and sharing the SFB
   sorting protocol. We thank Steve Reiner and Boris Reizis for reading the
   manuscript and for invaluable scientific discussions. We thank Siu-Hong
   Ho at the Columbia Center for Translational Immunology Flow Cytometry
   Core and Amir Figueroa at the Department of Microbiology and Immunology
   Flow Cytometry Core for help with sorting. This work was supported by
   the National Institute of Health 1R01DK098378 to I. I. I. and by the
   Crohn's and Colitis Foundation of America SRA#259540 to I. I. I. G.N.
   was supported by a long-term research grant from Toyobo Biofoundation.
   I. I. I. is a Pew Scholar in the Biomedical Sciences, supported by the
   Pew Charitable Trust.
NR 49
TC 121
Z9 126
U1 3
U2 24
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1074-7613
EI 1097-4180
J9 IMMUNITY
JI Immunity
PD APR 17
PY 2014
VL 40
IS 4
BP 594
EP 607
DI 10.1016/j.immuni.2014.03.005
PG 14
WC Immunology
SC Immunology
GA AF6UF
UT WOS:000334849400016
PM 24684957
ER

PT J
AU Vogler, MA
   Smeaton, LM
   Wright, RL
   Cardoso, SW
   Sanchez, J
   Infante, R
   Moran, LE
   Godfrey, C
   Demeter, LM
   Johnson, VA
AF Vogler, Mary A.
   Smeaton, Laura M.
   Wright, Rodney L.
   Cardoso, Sandra W.
   Sanchez, Jorge
   Infante, Rosa
   Moran, Laura E.
   Godfrey, Catherine
   Demeter, Lisa M.
   Johnson, Victoria A.
TI Combination Antiretroviral Treatment for Women Previously Treated Only
   in Pregnancy: Week 24 Results of AIDS Clinical Trials Group Protocol
   A5227
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE antiretroviral therapy; postpartum women; efavirenz; adherence; pMTCT
ID STRUCTURED TREATMENT INTERRUPTIONS; SINGLE-DOSE NEVIRAPINE;
   DRUG-RESISTANT HIV-1; VERTICAL TRANSMISSION; RECEIVING NEVIRAPINE;
   HIV-1-INFECTED WOMEN; THERAPY; ZIDOVUDINE; MUTATIONS; ADHERENCE
AB Background: Women with HIV and prior exposure to combination antiretroviral therapy (cART) solely for prevention of mother-to-child transmission (pMTCT) need to know whether they can later be treated successfully with a commonly used regimen of efavirenz (EFV) and coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF).
   Methods: Nonpregnant women with plasma HIV-1 RNA of >= 500 copies per milliliter, previously cART exposed for pMTCT only, were eligible if they were off ART for >= 24 weeks before entry, were without evidence of drug resistance on standard genotyping, and were ready to start EFV plus FTC/TDF. The primary endpoint was virologic response (defined as plasma HIV RNA < 400 copies/mL) at 24 weeks.
   Results: Fifty-four women were enrolled between October 2007 and December 2009; 52 of 54 completed 24 weeks of follow-up. Median baseline CD4+ T-cell count was 265/mm(3) and baseline plasma HIV-1 RNA was 4.6 log(10) copies per milliliter. Median prior cART duration was 14 weeks, and median time elapsed from the last pMTCT dose to entry was 22 months. Virologic response at 24 weeks was observed in 42 of 52 women or 81% (exact 95% confidence interval: 68% to 90%). There were no differences in response by country, by number, or class of prior pMTCT exposures. Although confirmed virologic failure occurred in 8 women, no virologic failures were observed in women reporting perfect early adherence.
   Conclusions: In this first prospective clinical trial studying combination antiretroviral retreatment in women with a history of pregnancy-limited cART, the observed virologic response to TDF/FTC and EFV at 24 weeks was 81%. Virologic failures occurred and correlated with self-reported nonadherence.
C1 [Vogler, Mary A.] Cornell Univ, Weill Cornell Med Coll, New York Presbyterian Hosp, New York, NY 10021 USA.
   [Smeaton, Laura M.] Harvard Univ, Sch Publ Hlth, Ctr Biostat & AIDS Res, Boston, MA 02115 USA.
   [Wright, Rodney L.] Albert Einstein Coll Med, Dept Obstet & Gynecol, Bronx, NY 10467 USA.
   [Cardoso, Sandra W.] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, STD AIDS Clin Res Lab, Rio De Janeiro, Brazil.
   [Sanchez, Jorge; Infante, Rosa] Asociac Civil IMPACTA Salud & Educ, Lima, Peru.
   [Moran, Laura E.] Social & Sci Syst Inc, Silver Spring, MD USA.
   [Godfrey, Catherine] NIAID, HIV Res Branch, Div Aids, NIH, Bethesda, MD 20892 USA.
   [Demeter, Lisa M.] Univ Rochester, Sch Med & Dent, Rochester, NY USA.
   [Johnson, Victoria A.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
   [Johnson, Victoria A.] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA.
RP Vogler, MA (reprint author), Cornell Univ, Weill Cornell Med Coll, New York Presbyterian Hosp, New York, NY 10021 USA.
EM mav9046@med.cornell.edu
FU National Institute of Allergy and Infectious Diseases [U01AI068636];
   National Institute of Mental Health, National Institute of Dental and
   Craniofacial Research; Statistical and Data Management Center of the
   AIDS Clinical Trials Group under the National Institute of Allergy and
   Infectious Diseases [1 U01AI068634]; University of Alabama at Birmingham
   ACTG CTU grant [U01 AI069918]; Instituto de Pesquisa Clinica Evandro
   Chagas CRS Fiocruz Therapeutic and Prevention HIV AIDS CTU grant [12101,
   1 U01 AI069476-01]; IMPACTA Peru CTU grant [1U01AI069438-01]; Weill
   Cornell Medical College ACTG CTU grant [5U01AI069419]; University of
   Rochester CTU grant [1U01 AI069511]
FX Supported by Award no. U01AI068636 from the National Institute of
   Allergy and Infectious Diseases and supported by National Institute of
   Mental Health, National Institute of Dental and Craniofacial Research.
   The content is solely the responsibility of the authors and does not
   necessarily represent the official views of the National Institute of
   Allergy and Infectious Diseases or the National Institutes of Health.
   Supported by the Statistical and Data Management Center of the AIDS
   Clinical Trials Group under the National Institute of Allergy and
   Infectious Diseases grant no. 1 U01AI068634. UAB Virology Specialty
   Laboratory 54 support VSL UM1 AI068636 and UAB CFAR P30; AI27767 for
   laboratory support and core research facilities within UAB Center for
   AIDS Research/University of Alabama at Birmingham School of Medicine and
   Birmingham Veterans Affairs Medical Center, Birmingham Alabama;
   University of Alabama at Birmingham ACTG CTU grant no. U01 AI069918;
   Instituto de Pesquisa Clinica Evandro Chagas CRS (12101) Fiocruz
   Therapeutic and Prevention HIV AIDS CTU grant no. 1 U01 AI069476-01;
   IMPACTA Peru CTU grant no. 1U01AI069438-01; Weill Cornell Medical
   College ACTG CTU grant no. 5U01AI069419; University of Rochester CTU
   grant no. 1U01 AI069511; Bristol Myers Squibb Company, Gilead Sciences,
   Inc, and Merck & Co, Inc, provided study drugs.
NR 31
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD APR 15
PY 2014
VL 65
IS 5
BP 542
EP 550
PG 9
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA AJ4XX
UT WOS:000337684400009
PM 24759064
ER

PT J
AU Campo, M
   Oursler, KK
   Huang, L
   Goetz, MB
   Rimland, D
   Hoo, GS
   Brown, ST
   Rodriguez-Barradas, MC
   Au, D
   Akgun, KM
   Shahrir, S
   Crothers, K
AF Campo, Monica
   Oursler, Krisann K.
   Huang, Laurence
   Goetz, Matthew Bidwell
   Rimland, David
   Hoo, Guy Soo
   Brown, Sheldon T.
   Rodriguez-Barradas, Maria C.
   Au, David
   Akguen, Kathleen M.
   Shahrir, Shahida
   Crothers, Kristina
TI Association of Chronic Cough and Pulmonary Function With 6-Minute Walk
   Test Performance in HIV Infection
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE 6-MWT; HIV; airflow limitation; performance; pulmonary function tests;
   FEV1
ID HUMAN-IMMUNODEFICIENCY-VIRUS; VETERANS AGING COHORT; PEAK OXYGEN-UPTAKE;
   ANTIRETROVIRAL THERAPY; RESPIRATORY SYMPTOMS; REFERENCE EQUATIONS;
   DIFFUSING-CAPACITY; DISTANCE; ADULTS; LUNG
AB Objective: Chronic lung disease has been associated with greater impairment in self-reported physical function in HIV-infected patients. We sought to study this association using objective measures of physical function and pulmonary function.
   Design: Baseline data from the Examinations of HIV Associated Lung Emphysema study, a multicenter observational cohort of HIV-infected and uninfected veterans.
   Methods: We assessed the association between clinical, laboratory, and pulmonary function measures with 6-minute walk test (6-MWT). Multivariable linear regression models were generated to identify factors associated with 6-MWT performance.
   Results: Three hundred forty participants completed 6-MWT (mean age 55 years), with 68% blacks, 94% men, and 62% current smokers. Overall, 180 (53%) were HIV-infected and 63 (19%) had spirometry-defined chronic obstructive pulmonary disease. In a multivariable model, age, current smoking, and obesity (body mass index. 30) were independently associated with lower 6-MWT performance, but HIV infection was not; there was a significant interaction between HIV and chronic cough, such that distance walked among HIV-infected participants with chronic cough was 51.76 m less (P = 0.04) compared with those without cough or HIV. Among HIV-infected participants, the forced expiratory volume in 1 second (FEV1, percent predicted), to a greater extent than total lung capacity or diffusing capacity, attenuated the association with chronic cough; decreased FEV1 was independently associated with lower 6-MWT performance in those with HIV.
   Conclusions: Older age, current smoking, and airflow limitation were important determinants of 6-MWT performance in the HIV-infected participants. These findings suggest that potential interventions to improve physical function may include early management of respiratory symptoms and airflow limitation.
C1 [Campo, Monica; Au, David; Shahrir, Shahida; Crothers, Kristina] Univ Washington, Dept Pulm & Crit Care Med, Seattle, WA 98104 USA.
   [Oursler, Krisann K.] Baltimore Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Baltimore, MD USA.
   [Oursler, Krisann K.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
   [Huang, Laurence] Univ Calif San Francisco, Div Pulm & Crit Care Med, San Francisco, CA 94143 USA.
   [Huang, Laurence] Univ Calif San Francisco, Dept Med, Div HIV AIDS, San Francisco, CA USA.
   [Goetz, Matthew Bidwell] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
   [Goetz, Matthew Bidwell] Univ Calif Los Angeles, David Geffen Sch Med, Infect Dis Sect, Dept Med, Los Angeles, CA 90095 USA.
   [Rimland, David] Atlanta Vet Affairs Med Ctr, Div Infect Dis, Atlanta, GA USA.
   [Rimland, David] Emory Univ, Sch Med, Dept Med, Atlanta, GA USA.
   [Hoo, Guy Soo] Vet Affairs Greater Los Angeles Healthcare Syst, West Los Angeles Healthcare Ctr, Pulm & Crit Care Sect, Los Angeles, CA USA.
   [Brown, Sheldon T.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
   [Brown, Sheldon T.] Icahn Sch Med Mt Sinai, Dept Med & Infect Dis, Bronx, NY USA.
   [Rodriguez-Barradas, Maria C.] Michael E DeBakey VAMC, Infect Dis Sect, Houston, TX USA.
   [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
   [Akguen, Kathleen M.] Vet Affairs Connecticut Healthcare Syst, Dept Internal Med, West Haven, CT USA.
   [Akguen, Kathleen M.] Yale Univ, Sch Med, New Haven, CT USA.
RP Campo, M (reprint author), Univ Washington, Harborview Med Ctr, Dept Pulm & Crit Care Med, 325 9th Ave Box 359762, Seattle, WA 98104 USA.
EM mcampo@u.washington.edu
OI Goetz, Matthew/0000-0003-4542-992X; Crothers,
   Kristina/0000-0001-9702-0371
FU National Institutes of Health (NIH) [HL090342]; Firland Foundation;
   Department of Veterans Affairs (VA), Health Services Research and
   Development; Department of Veterans Affairs; Veterans Health
   Administration, VISN 1 Career Development Award; Association of
   Subspecialty Physicians; CHEST Foundation of the American College of
   Chest Physicians;  [NIH R01 HL095136];  [K23 AG02489];  [NIH HL 087713]
FX Supported in part by a grant from the National Institutes of Health
   (NIH) HL090342 (to K.C.); M.C. was supported by the Firland Foundation.
   K.A.O. was supported by grant NIH R01 HL095136 and K23 AG02489. L. H.
   was supported by grant NIH HL 087713. Dr D. A. was supported through the
   Department of Veterans Affairs (VA), Health Services Research and
   Development. KMA was supported by the Department of Veterans Affairs,
   Veterans Health Administration, VISN 1 Career Development Award and the
   Association of Subspecialty Physicians and the CHEST Foundation of the
   American College of Chest Physicians.
NR 38
TC 12
Z9 12
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD APR 15
PY 2014
VL 65
IS 5
BP 557
EP 563
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA AJ4XX
UT WOS:000337684400011
PM 24346638
ER

PT J
AU Spring, B
   Sohn, MW
   Locatelli, SM
   Hadi, S
   Kahwati, L
   Weaver, FM
AF Spring, Bonnie
   Sohn, Min-Woong
   Locatelli, Sara M.
   Hadi, Sattar
   Kahwati, Leila
   Weaver, Frances M.
TI Individual, facility, and program factors affecting retention in a
   national weight management program
SO BMC PUBLIC HEALTH
LA English
DT Article
DE Overweight; Obesity; Veterans; Veterans health; Health education; Weight
   loss
ID RANDOMIZED CONTROLLED-TRIAL; HEALTH-CARE; VETERANS; INTERNET;
   TECHNOLOGY; PREDICTORS; ATTRITION; OBESITY; ADULTS
AB Background: High attrition is a common problem for weight loss programs and directly affects program effectiveness. Since 2006, the Veterans Health Administration (VHA) has offered obesity treatment to its beneficiaries through the MOVE! Weight Management Program for Veterans (MOVE!). An early evaluation of this program showed that attrition rate was high. The present study examines how individual, facility, and program factors relate to retention for participants in the on-site MOVE! group program.
   Methods: Data for all visits to MOVE! group treatment sessions were extracted from the VHA outpatient database. Participants were classified into three groups by their frequency of visits to the group program during a six month period after enrollment: early dropouts (1 - 3 visits), late dropouts (4 - 5 visits), and completers (6 or more visits). A generalized ordered logit model was used to examine individual, facility, and program factors associated with retention.
   Results: More than 60% of participants were early dropouts and 11% were late dropouts. Factors associated with retention were older age, presence of one or more comorbidities, higher body mass index at baseline, lack of co-payment requirement, geographic proximity to VA facility, addition of individual consultation to group treatment, greater program staffing, and regular, on-site physical activity programming. A non-completion rate of 74% for on-site group obesity treatment poses a major challenge to reducing the population prevalence of obesity within the VHA.
   Conclusions: Greater attention to individualized consultation, accessibility to the program, and facility factors including staffing and physical activity resources may improve retention.
C1 [Spring, Bonnie] Northwestern Univ, Dept Prevent Med, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Sohn, Min-Woong; Locatelli, Sara M.; Weaver, Frances M.] Edward Hines Jr VA Hosp, Ctr Innovat Complex Chron Healthcare, Hines, IL 60141 USA.
   [Sohn, Min-Woong] Northwestern Univ, Ctr Healthcare Studies, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Hadi, Sattar] Edward Hines Jr VA Hosp, Patient Care Serv, Hines, IL 60141 USA.
   [Kahwati, Leila] US Dept Vet Affairs, Natl Ctr Hlth Promot & Dis Prevent, Off Patient Care Serv, Vet Hlth Adm, Durham, NC USA.
   [Weaver, Frances M.] Loyola Univ Chicago, Stritch Sch Med, Hlth Serv Res Program, Maywood, IL USA.
RP Sohn, MW (reprint author), Edward Hines Jr VA Hosp, Ctr Innovat Complex Chron Healthcare, Hines, IL 60141 USA.
EM msohn@northwestern.edu
RI Sohn, Min-Woong/C-3560-2015
OI Sohn, Min-Woong/0000-0002-9474-2907
FU US Department of Veterans Affairs Health Services Research and
   Development Service [PPO 10-100-1]; National Institutes of Health
   [RC1DK087126, R01 HL075451]
FX The authors gratefully acknowledge the financial support of the US
   Department of Veterans Affairs Health Services Research and Development
   Service (PPO 10-100-1; Min-Woong Sohn, Ph.D., Principal Investigator)
   and the National Institutes of Health (RC1DK087126 and R01 HL075451;
   Bonnie Spring, Ph.D., Principal Investigator). The paper presents the
   findings and conclusions of the authors; it does not necessarily
   represent the Department of Veterans Affairs or Health Services Research
   and Development Service nor the NIH. The corresponding author had full
   access to all of the data in the study and takes responsibility for the
   integrity of the data and the accuracy of the data analysis.
NR 30
TC 3
Z9 3
U1 2
U2 11
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2458
J9 BMC PUBLIC HEALTH
JI BMC Public Health
PD APR 15
PY 2014
VL 14
AR 363
DI 10.1186/1471-2458-14-363
PG 11
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AH5NO
UT WOS:000336177200001
PM 24735508
ER

PT J
AU Eubank, KJ
   Covinsky, KE
AF Eubank, Kathryn J.
   Covinsky, Kenneth E.
TI Delirium Severity in the Hospitalized Patient: Time to Pay Attention
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Editorial Material
C1 Univ Calif San Francisco, San Francisco, CA 94143 USA.
   San Francisco VA Med Ctr, San Francisco, CA USA.
RP Eubank, KJ (reprint author), 4150 Clement St,Bldg 203,Room 1B-77, San Francisco, CA 94121 USA.
EM kathryn.eubank@ucsf.edu
FU NIA NIH HHS [P30 AG044281, K24 AG029812, P30AG044281, K24AG029812]
NR 7
TC 1
Z9 1
U1 0
U2 5
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD APR 15
PY 2014
VL 160
IS 8
BP 574
EP +
DI 10.7326/M14-0553
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA AG0ZE
UT WOS:000335143700011
PM 24733202
ER

PT J
AU Yaffe, K
   Vittinghoff, E
   Pletcher, MJ
   Hoang, TD
   Launer, LJ
   Whitmer, R
   Coker, LH
   Sidney, S
AF Yaffe, Kristine
   Vittinghoff, Eric
   Pletcher, Mark J.
   Hoang, Tina D.
   Launer, Lenore J.
   Whitmer, Rachel
   Coker, Laura H.
   Sidney, Stephen
TI Early Adult to Midlife Cardiovascular Risk Factors and Cognitive
   Function
SO CIRCULATION
LA English
DT Article
DE blood pressure; cholesterol; cognition; glucose; risk factors
ID CORONARY CALCIUM LATER; LATE-LIFE; ALZHEIMERS-DISEASE; BLOOD-PRESSURE;
   YOUNG-ADULTS; TEST-PERFORMANCE; DEMENTIA; CHOLESTEROL; HEALTH; AGE
AB Background Studies have linked midlife and late-life cardiovascular risk factors (CVRFs) to cognitive function, yet little is known about CVRF exposure in early adulthood and subsequent cognitive function. In addition, most studies rely on single assessments of CVRFs, which may not accurately reflect long-term exposure. We sought to determine the association between cumulative exposure to CVRFs from early to middle adulthood and cognitive function at midlife.
   Methods and Results In a prospective study of 3381 adults (age, 18-30 years at baseline) with 25 years of follow-up, we assessed cognitive function at year 25 (2010-2011) with the Digit Symbol Substitution Test, Stroop Test, and Rey Auditory Verbal Learning Test analyzed with standardized z scores. The primary predictor was 25-year cumulative exposure estimated by areas under the curve for resting systolic and diastolic blood pressures, fasting blood glucose, and total cholesterol. Higher cumulative systolic and diastolic blood pressures and fasting blood glucose were consistently associated with worse cognition on all 3 tests. These associations were significant primarily for exposures above recommended guidelines; cognitive test z scores were between 0.06 and 0.30 points less, on average, for each 1-SD increase in risk factor area under the curve after adjustment for age, race, sex, and education (P<0.05 for all). Fewer significant associations were observed for cholesterol.
   Conclusions Cumulative exposure to CVRFs from early to middle adulthood, especially above recommended guidelines, was associated with worse cognition in midlife. The meaning of this association and whether it warrants more aggressive treatment of CVRFs earlier in life require further investigation.
C1 [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA.
   [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA.
   [Yaffe, Kristine; Vittinghoff, Eric; Pletcher, Mark J.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94121 USA.
   [Pletcher, Mark J.] Univ Calif San Francisco, Dept Med, Div Gen Internal Med, San Francisco, CA 94121 USA.
   [Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA.
   [Hoang, Tina D.] Northern Calif Inst Res & Educ, San Francisco, CA USA.
   [Launer, Lenore J.] NIA, Lab Epidemiol Demog & Biometry, Bethesda, MD 20892 USA.
   [Whitmer, Rachel; Sidney, Stephen] Kaiser Permanente No Calif, Div Res, Oakland, CA USA.
   [Coker, Laura H.] Wake Forest Sch Med, Div Publ Hlth Sci, Winston Salem, NC USA.
RP Yaffe, K (reprint author), Univ Calif San Francisco, Box 181,4150 Clement St, San Francisco, CA 94121 USA.
EM kristine.yaffe@ucsf.edu
FU National Heart, Lung, and Blood Institute (NHLBI) in collaboration with
   the University of Alabama at Birmingham [HHSN268201300025C,
   HHSN268201300026C]; Northwestern University [HHSN268201300027C];
   University of Minnesota [HHSN268201300028C]; Kaiser Foundation Research
   Institute [HHSN268201300029C]; Johns Hopkins University School of
   Medicine [HHSN268200900041C]; Intramural Research Program of the
   National Institute on Aging (NIA); NIA; NHLBI [AG0005]
FX The Coronary Artery Risk Development in Young Adults Study (CARDIA) is
   conducted and supported by the National Heart, Lung, and Blood Institute
   (NHLBI) in collaboration with the University of Alabama at Birmingham
   (HHSN268201300025C & HHSN268201300026C), Northwestern University
   (HHSN268201300027C), University of Minnesota (HHSN268201300028C), Kaiser
   Foundation Research Institute (HHSN268201300029C), and Johns Hopkins
   University School of Medicine (HHSN268200900041C). CARDIA is also
   partially supported by the Intramural Research Program of the National
   Institute on Aging (NIA) and an intra-agency agreement between NIA and
   NHLBI (AG0005). This manuscript has been reviewed by CARDIA for
   scientific content.
NR 50
TC 39
Z9 41
U1 0
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
EI 1524-4539
J9 CIRCULATION
JI Circulation
PD APR 15
PY 2014
VL 129
IS 15
BP 1560
EP 1567
DI 10.1161/CIRCULATIONAHA.113.004798
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA AE9II
UT WOS:000334321100009
PM 24687777
ER

PT J
AU Guridi, J
   Borgatello, C
   Scremin, OU
AF Guridi, Jorge
   Borgatello, Conrado
   Scremin, Oscar U.
TI Arginine NO-dependent and NO-independent effects on hemodynamics
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE L-NAME; Nitric oxide synthase; Arterial blood pressure; Cardiac output;
   Systemic vascular resistance
ID NITRIC-OXIDE SYNTHASE; IN-VITRO; INDUCED HYPERTENSION; INDUCED
   HYPOTENSION; BLOOD-PRESSURE; HEART-RATE; ACTIVATION; RATS; SEX;
   VASODILATION
AB L-arginine administration decreases mean arterial blood pressure (MABP), presumably by excess nitric oxide (NO) synthesis. However, some reports indicate that D-arginine, not a substrate of NO synthase (NOS), also induces hypotension. To clarify this phenomenon, the hemodynamic effects of L- and D-arginine and their modification by NOS inhibition with L-nitroarginine methyl ester (L-NAME) were assessed. MABP, cardiac output, stroke volume, heart rate and systemic vascular resistance were recorded in Sprague-Dawley rats under urethane or ketamine/diazepam anesthesia, with or without blockade of NO synthesis by L-NAME. Both stereoisomers of arginine induced a close-related drop in MABP of similar magnitude and time course, but recovery from hypotension was slower in L-arginine than in D-arginine. The hypotension induced by both stereoisomers was clue to a decrease in systemic vascular resistance (SVR) with increase in cardiac output (CO) and stroke volume (SV). Administration of L-NAME induced a pronounced increase in MABP and SVR, with decreases in CO and heart rate (HR). Infusion of l-arginine after I-NAME significantly decreased MABP and SVR at the highest dose while D-arginine failed to do so. After I-NAME, MABP was significantly lower under L-arginine than under D-arginine at all doses. These experiments suggest a dual mechanism in the hypotensive effect of L-arginine: a NO independent action on vascular resistance shared with D-arginine, and a NO dependent mechanism that becomes evident in the presence of NOS inhibition with L-NAME. Cardiac effects of NO do not appear to play a role in L-arginine hypotension. Published by Elsevier B.V.
C1 [Guridi, Jorge] Univ Nacl Rosario, Fac Ciencias Med, Dept Ciencias Fisiol, RA-2000 Rosario, Santa Fe, Argentina.
   [Guridi, Jorge; Borgatello, Conrado; Scremin, Oscar U.] Univ Nacl Rosario, PROFISIO, RA-2000 Rosario, Santa Fe, Argentina.
   [Scremin, Oscar U.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
   [Scremin, Oscar U.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA.
   [Scremin, Oscar U.] Consejo Nacl Invest Cient & Tecn, Buenos Aires, DF, Argentina.
RP Scremin, OU (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM oscremin@ucla.edu
FU Capacitacion e Investigacion para la Medicina Argentina-Asociacion Civil
FX This work was supported with donations of equipment and supply funds
   from Capacitacion e Investigacion para la Medicina Argentina-Asociacion
   Civil, a non-profit academic organization. The authors wish to express
   their gratitude for the technical help provided by Manuel Chasco,
   Nicolas Turchi and Elisabet Bernaba,
NR 29
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014-2999
EI 1879-0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD APR 15
PY 2014
VL 729
BP 138
EP 143
DI 10.1016/j.ejphar.2014.01.070
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA AE1WO
UT WOS:000333763200019
PM 24530418
ER

PT J
AU Goldman, JG
   Williams-Gray, C
   Barker, RA
   Duda, JE
   Galvin, JE
AF Goldman, Jennifer G.
   Williams-Gray, Caroline
   Barker, Roger A.
   Duda, John E.
   Galvin, James E.
TI The spectrum of cognitive impairment in Lewy body diseases
SO MOVEMENT DISORDERS
LA English
DT Review
DE dementia; Parkinson's disease; cognition; executive function; mild
   cognitive impairment
ID SOCIETY TASK-FORCE; NEWLY-DIAGNOSED PATIENTS; SLEEP BEHAVIOR DISORDER;
   POPULATION-BASED COHORT; MINI-MENTAL-STATE; 5-YEAR FOLLOW-UP;
   PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; DELUSIONAL MISIDENTIFICATION;
   NEURODEGENERATIVE DISEASE
AB Cognitive impairment represents an important and often defining component of the clinical syndromes of Lewy body disorders: Parkinson's disease and dementia with Lewy bodies. The spectrum of cognitive deficits in these Lewy body diseases encompasses a broad range of clinical features, severity of impairment, and timing of presentation. It is now recognized that cognitive dysfunction occurs not only in more advanced Parkinson's disease but also in early, untreated patients and even in those patients with pre-motor syndromes, such as rapid eye movement behavior disorder and hyposmia. In recent years, the concept of mild cognitive impairment as a transitional or pre-dementia state in Parkinson's disease has emerged. This has led to much research regarding the diagnosis, prognosis, and underlying neurobiology of mild cognitive impairment in Parkinson's disease, but has also raised questions regarding the usefulness of this concept and its application in clinical and research settings. In addition, the conundrum of whether Parkinson's disease dementia and dementia with Lewy bodies represent the same or different entities remains unresolved. Although these disorders overlap in many aspects of their presentations and pathophysiology, they differ in other elements, such as timing of cognitive, behavioral, and motor symptoms; medication responses; and neuropathological contributions. This article examines the spectrum and evolution of cognitive impairment in Lewy body disorders and debates these controversial issues in the field using point-counterpoint approaches. (c) 2014 International Parkinson and Movement Disorder Society
C1 [Goldman, Jennifer G.] Rush Univ Med Ctr, Sect Parkinson Dis & Movement Disorders, Dept Neurol Sci, Chicago, IL 60612 USA.
   [Williams-Gray, Caroline; Barker, Roger A.] Univ Cambridge, Dept Clin Neurosci, John Van Geest Ctr Brain Repair, Cambridge, England.
   [Duda, John E.] Univ Penn Perelman Sch Med, Dept Neurol, Philadelphia, PA USA.
   [Duda, John E.] Philadelphia Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA USA.
   [Galvin, James E.] New York Univ Sch Med, Dept Neurol, New York, NY USA.
   [Galvin, James E.] New York Univ Sch Med, Dept Psychiat, New York, NY USA.
   [Galvin, James E.] New York Univ Sch Med, Dept Populat Hlth, New York, NY USA.
RP Goldman, JG (reprint author), Rush Univ Med Ctr, Sect Parkinson Dis & Movement Disorders, Dept Neurol Sci, 1725 W Harrison St,Suite 755, Chicago, IL 60612 USA.
EM jennifer_g_goldman@rush.edu
FU NINDS NIH HHS [K23 NS060949]
NR 128
TC 25
Z9 25
U1 3
U2 24
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0885-3185
EI 1531-8257
J9 MOVEMENT DISORD
JI Mov. Disord.
PD APR 15
PY 2014
VL 29
IS 5
SI SI
BP 608
EP 621
DI 10.1002/mds.25866
PG 14
WC Clinical Neurology
SC Neurosciences & Neurology
GA AF5DA
UT WOS:000334733000004
PM 24757110
ER

PT J
AU Aarsland, D
   Taylor, JP
   Weintraub, D
AF Aarsland, Dag
   Taylor, John-Paul
   Weintraub, Daniel
TI Psychiatric issues in cognitive impairment
SO MOVEMENT DISORDERS
LA English
DT Review
DE Neuropsychiatric symptoms, Parkinson's disease, cognitive impairment,
   depression, psychosis, anxiety, apathy
ID SLEEP BEHAVIOR DISORDER; PARKINSONS-DISEASE PATIENTS; PROGRESSIVE
   SUPRANUCLEAR PALSY; PLACEBO-CONTROLLED TRIAL; IMPULSE CONTROL DISORDERS;
   MULTIPLE SYSTEM ATROPHY; EXCESSIVE DAYTIME SLEEPINESS; CORTICOBASAL
   DEGENERATION; VISUAL HALLUCINATIONS; REM-SLEEP
AB Neuropsychiatric symptoms (NPS) such as depression, hallucinations and apathy commonly occur in Parkinson's disease (PD) and have major clinical consequences including a negative impact on quality of life. This review discusses the epidemiology, clinical features, diagnostic procedures and treatment issues of NPS in PD and related disorders in the perspective of cognitive impairment, focusing on depression, anxiety, visual hallucinations, apathy, sleep disturbances, impulse control disorder and non-motor fluctuations. The majority of NPS are more common in PD patients with dementia, possibly related to shared underlying pathologies. Recent studies also suggest that NPS are associated with mild cognitive impairment in PD, in particular with the amnestic type. Accurate diagnosis of NPS is important but can be difficult, due to overlapping symptoms and similar appearance of symptoms of motor symptoms of parkinsonism, cognitive impairment, mood disorders and apathy. There are few systematic studies focusing on the management of NPS in PD with cognitive impairment. (c) 2014 International Parkinson and Movement Disorder Society
C1 [Aarsland, Dag] Karolinska Inst, Dept Neurobiol Care Sci & Soc, Alzheimers Dis Res Ctr, Stockholm, Sweden.
   [Aarsland, Dag] Stavanger Univ Hosp, Ctr Age Related Med, Stavanger, Norway.
   [Aarsland, Dag] Akershus Univ Hosp, Dept Geriatr Psychiat, Oslo, Norway.
   [Taylor, John-Paul] Inst Ageing & Hlth, Newcastle Upon Tyne, Tyne & Wear, England.
   [Taylor, John-Paul] Tyne & Wear NHS Trust, Newcastle Upon Tyne, Tyne & Wear, England.
   [Weintraub, Daniel] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Weintraub, Daniel] Educ & Clin Ctr PADRECC, Parkinsons Dis Res, Philadelphia, PA USA.
   [Weintraub, Daniel] MIRECC, Philadelphia, PA USA.
   [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
RP Aarsland, D (reprint author), Karolinska Inst, Dept Neurobiol Care Sci & Soc, Alzheimers Dis Res Ctr, Stockholm, Sweden.
EM daarsland@gmail.com
OI Aarsland, Dag/0000-0001-6314-216X
FU NINDS NIH HHS [P50 NS053488]
NR 167
TC 23
Z9 23
U1 2
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0885-3185
EI 1531-8257
J9 MOVEMENT DISORD
JI Mov. Disord.
PD APR 15
PY 2014
VL 29
IS 5
SI SI
BP 651
EP 662
DI 10.1002/mds.25873
PG 12
WC Clinical Neurology
SC Neurosciences & Neurology
GA AF5DA
UT WOS:000334733000007
PM 24757113
ER

PT J
AU Bihorac, A
   Chawla, LS
   Shaw, AD
   Al-Khafaji, A
   Davison, DL
   DeMuth, GE
   Fitzgerald, R
   Gong, MN
   Graham, DD
   Gunnerson, K
   Heung, M
   Jortani, S
   Kleerup, E
   Koyner, JL
   Krell, K
   LeTourneau, J
   Lissauer, M
   Miner, J
   Nguyen, HB
   Ortega, LM
   Self, WH
   Sellman, R
   Shi, J
   Straseski, J
   Szalados, JE
   Wilber, ST
   Walker, MG
   Wilson, J
   Wunderink, R
   Zimmerman, J
   Kellum, JA
AF Bihorac, Azra
   Chawla, Lakhmir S.
   Shaw, Andrew D.
   Al-Khafaji, Ali
   Davison, Danielle L.
   DeMuth, George E.
   Fitzgerald, Robert
   Gong, Michelle Ng
   Graham, Derrel D.
   Gunnerson, Kyle
   Heung, Michael
   Jortani, Saeed
   Kleerup, Eric
   Koyner, Jay L.
   Krell, Kenneth
   LeTourneau, Jennifer
   Lissauer, Matthew
   Miner, James
   Nguyen, H. Bryant
   Ortega, Luis M.
   Self, Wesley H.
   Sellman, Richard
   Shi, Jing
   Straseski, Joely
   Szalados, James E.
   Wilber, Scott T.
   Walker, Michael G.
   Wilson, Jason
   Wunderink, Richard
   Zimmerman, Janice
   Kellum, John A.
TI Validation of Cell-Cycle Arrest Biomarkers for Acute Kidney Injury Using
   Clinical Adjudication
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Article
DE acute kidney injury; biomarkers; cell-cycle arrest; tissue inhibitor of
   metalloproteinases-2; insulin-like growth factor binding protein 7
ID CORONARY-HEART-DISEASE; INTERMEDIATE-RISK PATIENTS;
   MYOCARDIAL-INFARCTION; NIDDK WORKSHOP; GUIDELINES; CARE; MORTALITY;
   SURGERY; SEPSIS; DESIGN
AB Rationale: We recently reported two novel biomarkers for acute kidney injury (AKI), tissue inhibitor of metalloproteinases (TIMP)-2 and insulin-like growth factor binding protein 7 (IGFBP7), both related to G1 cell cycle arrest.
   Objectives: We now validate a clinical test for urinary [TIMP-2].[IGFBP7] at a high-sensitivity cutoff greater than 0.3 for AKI risk stratification in a diverse population of critically ill patients.
   Methods: We conducted a prospective multicenter study of 420 critically ill patients. The primary analysis was the ability of urinary [TIMP-2].[IGFBP7] to predict moderate to severe AKI within 12 hours. AKI was adjudicated by a committee of three independent expert nephrologists who were masked to the results of the test.
   Measurements and Main Results: Urinary TIMP-2 and IGFBP7 were measured using a clinical immunoassay platform. The primary endpoint was reached in 17% of patients. For a single urinary [TIMP-2].[IGFBP7] test, sensitivity at the prespecified high-sensitivity cutoff of 0.3 (ng/ml)(2)/1,000 was 92% (95% confidence interval [CI], 85-98%) with a negative likelihood ratio of 0.18 (95% CI, 0.06-0.33). Critically ill patients with urinary [TIMP-2].[IGFBP7] greater than 0.3 had seven times the risk for AKI (95% CI, 4-22) compared with critically ill patients with a test result below 0.3. In a multivariate model including clinical information, urinary [TIMP-2].[IGFBP7] remained statistically significant and a strong predictor of AKI (area under the curve, 0.70, 95% CI, 0.63-0.76 for clinical variables alone, vs. area under the curve, 0.86, 95% CI, 0.80-0.90 for clinical variables plus [TIMP-2].[IGFBP7]).
   Conclusions: Urinary [TIMP-2].[IGFBP7] greater than 0.3 (ng/ml) (2)/1,000 identifies patients at risk for imminent AKI. Clinical trial registered with www.clinicaltrials.gov (NCT 01573962).
C1 Univ Florida, Dept Anesthesiol, Gainesville, FL USA.
   [Chawla, Lakhmir S.; Davison, Danielle L.] George Washington Univ, Med Ctr, Dept Anesthesiol & Crit Care Med, Washington, DC 20037 USA.
   [Shaw, Andrew D.] Vanderbilt Univ, Ctr Med, Dept Anesthesiol, Nashville, TN 37232 USA.
   [Al-Khafaji, Ali] Univ Pittsburgh, Med Ctr, Dept Crit Care Med, Pittsburgh, PA USA.
   [DeMuth, George E.] Stat Tech Serv LLC, Chapel Hill, NC USA.
   [Fitzgerald, Robert] Univ Calif San Diego, San Diego, CA 92103 USA.
   [Gong, Michelle Ng] Montefiore Med Ctr, Dept Med, Bronx, NY 10467 USA.
   [Graham, Derrel D.] Louisiana State Univ, Shreveport, LA 71105 USA.
   [Gunnerson, Kyle] Virginia Commonwealth Univ, Dept Anesthesiol, Richmond, VA USA.
   [Gunnerson, Kyle] Virginia Commonwealth Univ, Dept Emergency Med, Richmond, VA USA.
   [Heung, Michael] Univ Michigan, Div Nephrol, Ann Arbor, MI 48109 USA.
   [Jortani, Saeed] Univ Louisville, Dept Pathol, Louisville, KY 40292 USA.
   [Kleerup, Eric] Univ Calif Los Angeles, Div Pulm & Crit Care, Los Angeles, CA USA.
   [Koyner, Jay L.] Univ Chicago, Dept Med, Chicago, IL 60637 USA.
   [Krell, Kenneth] Eastern Idaho Med Consultants LLC, Idaho Falls, ID USA.
   [LeTourneau, Jennifer] Portland VA Med Ctr, Portland, OR USA.
   [Lissauer, Matthew] Univ Maryland, Sch Med, Dept Surg, Baltimore, MD 21201 USA.
   [Miner, James] Hennepin Cty Med Ctr, Dept Emergency Med, Minneapolis, MN 55415 USA.
   [Nguyen, H. Bryant] Loma Linda Univ, Loma Linda, CA 92350 USA.
   [Ortega, Luis M.] AGH Nephrol Associates, Dept Nephrol, Pittsburgh, PA USA.
   [Self, Wesley H.] Vanderbilt Univ, Sch Med, Dept Emergency Med, Nashville, TN 37212 USA.
   [Sellman, Richard] Int Heart Inst Montana, Missoula, MT USA.
   [Shi, Jing; Walker, Michael G.] Stat Consultant, Carlsbad, CA USA.
   [Straseski, Joely] Univ Utah, Salt Lake City, UT USA.
   [Straseski, Joely] ARUP Labs, Salt Lake City, UT USA.
   [Szalados, James E.] Rochester Gen Med, Rochester, NY USA.
   [Wilber, Scott T.] Summa Hlth Syst Akron City Hosp, Dept Emergency Med, Akron, OH USA.
   [Wilson, Jason] Tampa Gen Hosp, Tampa, FL 33606 USA.
   [Wunderink, Richard] Northwestern Univ, Div Pulm & Crit Care Med, Chicago, IL 60611 USA.
   [Zimmerman, Janice] Methodist Hosp, Houston, TX 77030 USA.
   [Kellum, John A.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15261 USA.
RP Kellum, JA (reprint author), Univ Pittsburgh, Sch Med, CRISMA Ctr, Ctr Crit Care Nephrol,Dept Crit Care Med, Room 604 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.
EM kellumja@ccm.upmc.edu
OI Lissauer, Matthew/0000-0002-6008-9778; Wunderink,
   Richard/0000-0002-8527-4195
FU Astute Medical, San Diego, CA
FX Supported by Astute Medical, San Diego, CA.
NR 38
TC 110
Z9 111
U1 1
U2 9
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD APR 15
PY 2014
VL 189
IS 8
BP 932
EP 939
DI 10.1164/rccm.201401-0077OC
PG 8
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA AF0KQ
UT WOS:000334403100010
PM 24559465
ER

PT J
AU Barnett, LG
   Simkins, HMA
   Barnett, BE
   Korn, LL
   Johnson, AL
   Wherry, EJ
   Wu, GF
   Laufer, TM
AF Barnett, Lisa G.
   Simkins, Helen M. A.
   Barnett, Burton E.
   Korn, Lisa L.
   Johnson, Andy L.
   Wherry, E. John
   Wu, Gregory F.
   Laufer, Terri M.
TI B Cell Antigen Presentation in the Initiation of Follicular Helper T
   Cell and Germinal Center Differentiation
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID CXC CHEMOKINE RECEPTOR-5; CLASS-II EXPRESSION; MEMORY CD4 CELLS;
   PRESENTING CELLS; IN-VIVO; DENDRITIC CELLS; DEFICIENT MICE; BCL6
   EXPRESSION; RESPONSES; ACTIVATION
AB High-affinity class-switched Abs and memory B cells are products of the germinal center (GC). The CD4(+) T cell help required for the development and maintenance of the GC is delivered by follicular Th cells (T-FH), a CD4(+) Th cell subset characterized by expression of Bcl-6 and secretion of IL-21. The cellular interactions that mediate differentiation of T-FH and GC B cells remain an important area of investigation. We previously showed that MHC class II (MHCII)-dependent dendritic cell Ag presentation is sufficient for the differentiation of a T-FH intermediate (termed pre-T-FH), characterized by Bcl-6 expression but lacking IL-21 secretion. In this article, we examine the contributions of MHCII Ag presentation by B cells to T-FH differentiation and GC responses in several contexts. B cells alone do not efficiently prime naive CD4(+) T cells or induce T-FH after protein immunization; however, during lymphocytic choriomeningitis virus infection, B cells induce T-FH differentiation despite the lack of effector CD4(+) T cell generation. Still, MHCII+ dendritic cells and B cells cooperate for optimal T-FH and GC B cell differentiation in response to both model Ags and viral infection. This study highlights the roles for B cells in both CD4(+) T cell priming and T-FH differentiation, and demonstrates that different APC subsets work in tandem to mediate the GC response.
C1 [Barnett, Lisa G.; Simkins, Helen M. A.; Korn, Lisa L.; Laufer, Terri M.] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA.
   [Barnett, Lisa G.; Simkins, Helen M. A.; Barnett, Burton E.; Korn, Lisa L.; Johnson, Andy L.; Wherry, E. John; Laufer, Terri M.] Univ Penn, Perelman Sch Med, Inst Immunol, Philadelphia, PA 19104 USA.
   [Barnett, Burton E.; Johnson, Andy L.; Wherry, E. John] Univ Penn, Perelman Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA.
   [Wu, Gregory F.] Washington Univ, Dept Neurol, St Louis, MO 63110 USA.
   [Laufer, Terri M.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
RP Laufer, TM (reprint author), Univ Penn, Sch Med, 753 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.
EM tlaufer@mail.med.upenn.edu
FU Target Identification in Lupus award from the Alliance for Lupus;
   Veteran's Affairs Merit Award [1I01BX000435-01]; National Institute of
   Neurological Disorders and Stroke Grant [5K08NS062138]; Dana Foundation;
   National Institutes of Health [AI083005, AI095776, AI083022, AI095608,
   AI082630, AI045008, HHSN266200500030C, T32 AR 0077442]; Brody Family
   Medical Trust
FX This work was supported by a Target Identification in Lupus award from
   the Alliance for Lupus (to T. M. L.), Veteran's Affairs Merit Award
   1I01BX000435-01 (to T. M. L.), National Institute of Neurological
   Disorders and Stroke Grant 5K08NS062138, grants from the Dana Foundation
   (to G. F. W.), National Institutes of Health Grants AI083005, AI095776,
   AI083022, AI095608, AI082630, AI045008, and HHSN266200500030C (all to
   E.J.W.) and Training Grant T32 AR 0077442 (to L. L. K.), and a
   fellowship from the Brody Family Medical Trust (to A.L.J.).
NR 68
TC 23
Z9 24
U1 1
U2 11
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD APR 15
PY 2014
VL 192
IS 8
BP 3607
EP 3617
DI 10.4049/jimmunol.1301284
PG 11
WC Immunology
SC Immunology
GA AE9GB
UT WOS:000334312900016
PM 24646739
ER

PT J
AU Cao, H
   Yu, F
   Zhao, Y
   Scianmarello, N
   Lee, J
   Dai, WD
   Jen, N
   Beebe, T
   Li, RS
   Ebrahimi, R
   Chang, DS
   Mody, FV
   Pacella, J
   Tai, YC
   Hsiai, T
AF Cao, Hung
   Yu, Fei
   Zhao, Yu
   Scianmarello, Nick
   Lee, Juhyun
   Dai, Wangde
   Jen, Nelson
   Beebe, Tyler
   Li, Rongsong
   Ebrahimi, Ramin
   Chang, Donald S.
   Mody, Freny V.
   Pacella, John
   Tai, Yu-Chong
   Hsiai, Tzung
TI Stretchable electrochemical impedance sensors for intravascular
   detection of lipid-rich lesions in New Zealand White rabbits
SO BIOSENSORS & BIOELECTRONICS
LA English
DT Article
DE Stretchable micro-sensor; Electrochemical impedance spectroscopy;
   Balloon inflation; Atherosclerotic lesions; New Zealand White rabbits
ID ACUTE CORONARY SYNDROMES; SHEAR-STRESS; ATHEROSCLEROTIC LESIONS;
   ARTERY-DISEASE; OXIDIZED LDL; SPECTROSCOPY; NITRATION; CATHETER;
   CLASSIFICATION; INFLAMMATION
AB Flexible electronics have enabled catheter-based intravascular sensing. However, real-time interrogation of unstable plaque remains an unmet clinical challenge. Here, we demonstrate the feasibility of stretchable electrochemical impedance spectroscopy (EIS) sensors for endoluminal investigations in New Zealand White (NZW) rabbits on diet-induced hyperlipidemia. A parylene C (PAC)-based EIS sensor mounted on the surface of an inflatable silicone balloon affixed to the, tip of an interrogating catheter was deployed (1) on the explants of NZW rabbit aorta for detection of lipid-rich atherosclerotic lesions, and (2) on live animals for demonstration of balloon inflation and EIS measurements. An input peak-to-peak AC voltage of 10 mV and sweeping-frequency from 300 kHz to 100 Hz were delivered to the endoluminal sites. Balloon inflation allowed EIS sensors to be in contact with endoluminal surface. In the oxidized low-density-lipoprotein (oxLDL)-rich lesions from explants of fat-fed rabbits, impedance magnitude increased significantly by 1.5-fold across the entire frequency band, and phase shifted similar to 5 degrees at frequencies below 10 kHz. In the lesion-free sites of the normal diet-fed rabbits, impedance magnitude increased by 1.2-fold and phase shifted similar to 5 degrees at frequencies above 30 kHz. Thus, we demonstrate the feasibility of stretchable intravascular EIS sensors for identification of lipid rich lesions, with a translational implication for detecting unstable lesions. Crown Copyright (C) 2013 Published by Elsevier B.V. All rights reserved.
C1 [Cao, Hung; Yu, Fei; Lee, Juhyun; Jen, Nelson; Beebe, Tyler; Li, Rongsong; Hsiai, Tzung] Univ So Calif, Dept Biomed Engn, Los Angeles, CA 90089 USA.
   [Zhao, Yu; Scianmarello, Nick; Tai, Yu-Chong] CALTECH, Dept Elect Engn, Pasadena, CA 91125 USA.
   [Cao, Hung; Lee, Juhyun; Jen, Nelson; Beebe, Tyler; Li, Rongsong; Ebrahimi, Ramin; Chang, Donald S.; Mody, Freny V.; Hsiai, Tzung] Univ Calif Los Angeles, Sch Med, VA Greater Los Angeles Healthcare Syst, Div Cardiol,Dept Med, Los Angeles, CA USA.
   [Dai, Wangde] Good Samaritan Hosp, Inst Heart, Los Angeles, CA USA.
   [Pacella, John] Univ Pittsburgh, Sch Med, Div Cardiol, Pittsburgh, PA USA.
RP Hsiai, T (reprint author), Univ Calif Los Angeles, Henry Samueli Sch Engn & Appl Sci, Los Angeles, CA 90073 USA.
EM THsiai@mednet.ucla.edu
FU National Institutes of Health [HL083015, HL111437]
FX The authors would like to express gratitude for technical advice from
   Dr. David Shavelle in the Division of Cardiovascular Medicine at USC,
   and technical support for animal studies from Sharon Hale and Dr. Robert
   Klonner in the Heart Institute at Good Samaritan Medical Center, Los
   Angeles. This project was supported by National Institutes of Health,
   HL083015 (T.K.H.) and HL111437 (T.K.H. and Y.C.T.).
NR 31
TC 5
Z9 5
U1 2
U2 21
PU ELSEVIER ADVANCED TECHNOLOGY
PI OXFORD
PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
   OXFORD OX5 1GB, OXON, ENGLAND
SN 0956-5663
EI 1873-4235
J9 BIOSENS BIOELECTRON
JI Biosens. Bioelectron.
PD APR 15
PY 2014
VL 54
BP 610
EP 616
DI 10.1016/j.bios.2013.11.059
PG 7
WC Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical;
   Electrochemistry; Nanoscience & Nanotechnology
SC Biophysics; Biotechnology & Applied Microbiology; Chemistry;
   Electrochemistry; Science & Technology - Other Topics
GA AD2ND
UT WOS:000333071500091
PM 24333932
ER

PT J
AU Rodriguez, AR
   Muller, LPD
   Brecha, NC
AF Rodriguez, Allen R.
   Mueller, Luis Perez de Sevilla
   Brecha, Nicholas C.
TI The RNA binding protein RBPMS is a selective marker of ganglion cells in
   the mammalian retina
SO JOURNAL OF COMPARATIVE NEUROLOGY
LA English
DT Review
DE RNA-binding protein; transcription factor; amacrine cell; melanopsin;
   SMI-32; ganglion cell
ID DISPLACED AMACRINE CELLS; OPTIC-NERVE REGENERATION; MOUSE RETINA; RAT
   RETINA; MORPHOLOGICAL CLASSIFICATION; QUANTITATIVE-ANALYSIS; MACAQUE
   MONKEY; RABBIT RETINA; CAT RETINA; ALBINO-RAT
AB There are few neurochemical markers that reliably identify retinal ganglion cells (RGCs), which are a heterogeneous population of cells that integrate and transmit the visual signal from the retina to the central visual nuclei. We have developed and characterized a new set of affinity-purified guinea pig and rabbit antibodies against RNA-binding protein with multiple splicing (RBPMS). On western blots these antibodies recognize a single band at similar to 24 kDa, corresponding to RBPMS, and they strongly label RGC and displaced RGC (dRGC) somata in mouse, rat, guinea pig, rabbit, and monkey retina. RBPMS-immunoreactive cells and RGCs identified by other techniques have a similar range of somal diameters and areas. The density of RBPMS cells in mouse and rat retina is comparable to earlier semiquantitative estimates of RGCs. RBPMS is mainly expressed in medium and large DAPI-, DRAQ5-, NeuroTrace- and NeuN-stained cells in the ganglion cell layer (GCL), and RBPMS is not expressed in syntaxin (HPC-1)-immunoreactive cells in the inner nuclear layer (INL) and GCL, consistent with their identity as RGCs, and not displaced amacrine cells. In mouse and rat retina, most RBPMS cells are lost following optic nerve crush or transection at 3 weeks, and all Brn3a-, SMI-32-, and melanopsin-immunoreactive RGCs also express RBPMS immunoreactivity. RBPMS immunoreactivity is localized to cyan fluorescent protein (CFP)-fluorescent RGCs in the B6.Cg-Tg(Thy1-CFP)23Jrs/J mouse line. These findings show that antibodies against RBPMS are robust reagents that exclusively identify RGCs and dRGCs in multiple mammalian species, and they will be especially useful for quantification of RGCs. J. Comp. Neurol. 522:1411-1443, 2014. (c) 2013 Wiley Periodicals, Inc.
C1 [Rodriguez, Allen R.; Mueller, Luis Perez de Sevilla; Brecha, Nicholas C.] Univ Calif Los Angeles, David Geffen Sch Med Los Angeles, Dept Neurobiol, Los Angeles, CA 90095 USA.
   [Brecha, Nicholas C.] Univ Calif Los Angeles, David Geffen Sch Med Los Angeles, Dept Med, Los Angeles, CA 90095 USA.
   [Brecha, Nicholas C.] Univ Calif Los Angeles, David Geffen Sch Med Los Angeles, Jules Stein Eye Inst, Los Angeles, CA 90095 USA.
   [Brecha, Nicholas C.] Univ Calif Los Angeles, David Geffen Sch Med Los Angeles, CURE Digest Dis Res Ctr, Los Angeles, CA 90095 USA.
   [Brecha, Nicholas C.] Vet Adm Greater Los Angeles Hlth Syst, Los Angeles, CA 90073 USA.
RP Brecha, NC (reprint author), Univ Calif Los Angeles, David Geffen Sch Med Los Angeles, Dept Neurobiol, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.
EM nbrecha@ucla.edu
FU U.S. Army Medical Research & Materiel Command (USAMRMC); Telemedicine &
   Advanced Technology Research Center (TATRC) at Fort Detrick, MD
   [W81XWH-10-2-0077]; National Institutes of Health [EY04067]; National
   Institute of Diabetes and Digestive and Kidney Disease, National
   Institutes of Health [P30 DK41301]; VA Merit Review
FX Grant sponsor: This research and development project was conducted by
   the authors at the David Geffen School of Medicine at the University of
   California at Los Angeles and is made possible by a contract agreement
   that was awarded and administered by the U.S. Army Medical Research &
   Materiel Command (USAMRMC) and the Telemedicine & Advanced Technology
   Research Center (TATRC) at Fort Detrick, MD; Grant number:
   W81XWH-10-2-0077; Grant sponsor: National Institutes of Health; Grant
   sponsor: EY04067; Grant sponsor: National Institute of Diabetes and
   Digestive and Kidney Disease, National Institutes of Health; Grant
   number: P30 DK41301 (UCLA Cure Center Core); Grant sponsor: VA Merit
   Review (to N.C.B., who is a VA Career Research Scientist).
NR 128
TC 43
Z9 44
U1 3
U2 17
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9967
EI 1096-9861
J9 J COMP NEUROL
JI J. Comp. Neurol.
PD APR 15
PY 2014
VL 522
IS 6
BP 1411
EP 1443
DI 10.1002/cne.23521
PG 33
WC Neurosciences; Zoology
SC Neurosciences & Neurology; Zoology
GA AC8BB
UT WOS:000332756900013
PM 24318667
ER

PT J
AU Goetzman, ES
   Alcorn, JF
   Bharathi, SS
   Uppala, R
   McHugh, KJ
   Kosmider, B
   Chen, RM
   Zuo, YY
   Beck, ME
   McKinney, RW
   Skilling, H
   Suhrie, KR
   Karunanidhi, A
   Yeasted, R
   Otsubo, C
   Ellis, B
   Tyurina, YY
   Kagan, VE
   Mallampalli, RK
   Vockley, J
AF Goetzman, Eric S.
   Alcorn, John F.
   Bharathi, Sivakama S.
   Uppala, Radha
   McHugh, Kevin J.
   Kosmider, Beata
   Chen, Rimei
   Zuo, Yi Y.
   Beck, Megan E.
   McKinney, Richard W.
   Skilling, Helen
   Suhrie, Kristen R.
   Karunanidhi, Anuradha
   Yeasted, Renita
   Otsubo, Chikara
   Ellis, Bryon
   Tyurina, Yulia Y.
   Kagan, Valerian E.
   Mallampalli, Rama K.
   Vockley, Jerry
TI Long-chain Acyl-CoA Dehydrogenase Deficiency as a Cause of Pulmonary
   Surfactant Dysfunction
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE Fatty Acid Oxidation; Genetic Diseases; Lung; Mitochondrial Metabolism;
   Pulmonary Surfactant; Acyl-CoA Dehydrogenase
ID ACID BETA-OXIDATION; ORGANIC CATION/CARNITINE TRANSPORTER;
   RESPIRATORY-DISTRESS-SYNDROME; ALVEOLAR EPITHELIAL-CELLS; CAPTIVE BUBBLE
   METHOD; FREE CARNITINE LEVELS; INFLUENZA-A VIRUS; LUNG SURFACTANT;
   IN-VITRO; COMPLEX I
AB Background: The contribution of long-chain acyl-CoA dehydrogenase (LCAD) to human fatty acid oxidation is not understood. Results: LCAD localizes to lung alveolar type II cells, which produce pulmonary surfactant; LCAD-deficient mice have surfactant dysfunction. Conclusion: LCAD is important for lung energy metabolism and lung function. Significance: LCAD may play a role in human lung disease and unexplained sudden infant death.
   Long-chain acyl-CoA dehydrogenase (LCAD) is a mitochondrial fatty acid oxidation enzyme whose expression in humans is low or absent in organs known to utilize fatty acids for energy such as heart, muscle, and liver. This study demonstrates localization of LCAD to human alveolar type II pneumocytes, which synthesize and secrete pulmonary surfactant. The physiological role of LCAD and the fatty acid oxidation pathway in lung was subsequently studied using LCAD knock-out mice. Lung fatty acid oxidation was reduced in LCAD(-/-) mice. LCAD(-/-) mice demonstrated reduced pulmonary compliance, but histological examination of lung tissue revealed no obvious signs of inflammation or pathology. The changes in lung mechanics were found to be due to pulmonary surfactant dysfunction. Large aggregate surfactant isolated from LCAD(-/-) mouse lavage fluid had significantly reduced phospholipid content as well as alterations in the acyl chain composition of phosphatidylcholine and phosphatidylglycerol. LCAD(-/-) surfactant demonstrated functional abnormalities when subjected to dynamic compression-expansion cycling on a constrained drop surfactometer. Serum albumin, which has been shown to degrade and inactivate pulmonary surfactant, was significantly increased in LCAD(-/-) lavage fluid, suggesting increased epithelial permeability. Finally, we identified two cases of sudden unexplained infant death where no lung LCAD antigen was detectable. Both infants were homozygous for an amino acid changing polymorphism (K333Q). These findings for the first time identify the fatty acid oxidation pathway and LCAD in particular as factors contributing to the pathophysiology of pulmonary disease.
C1 [Goetzman, Eric S.; Alcorn, John F.; Bharathi, Sivakama S.; Uppala, Radha; McHugh, Kevin J.; McKinney, Richard W.; Skilling, Helen; Suhrie, Kristen R.; Karunanidhi, Anuradha; Yeasted, Renita; Otsubo, Chikara; Vockley, Jerry] Univ Pittsburgh Sch Med, Childrens Hosp Pittsburgh, Dept Pediat, Pittsburgh, PA 15224 USA.
   [Goetzman, Eric S.; Beck, Megan E.; Vockley, Jerry] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15213 USA.
   [Kosmider, Beata] Natl Jewish Hlth, Dept Med, Denver, CO 80206 USA.
   [Chen, Rimei; Zuo, Yi Y.] Univ Hawaii Manoa, Dept Mech Engn, Honolulu, HI 96822 USA.
   [Ellis, Bryon; Mallampalli, Rama K.] Univ Pittsburgh, Dept Med, Acute Lung Injury Ctr Excellence, Pittsburgh, PA 15213 USA.
   [Tyurina, Yulia Y.; Kagan, Valerian E.] Univ Pittsburgh, Ctr Free Radical & Antioxidant Hlth, Pittsburgh, PA 15260 USA.
   [Tyurina, Yulia Y.; Kagan, Valerian E.] Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA 15260 USA.
   [Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA 15213 USA.
RP Goetzman, ES (reprint author), 4401 Penn Ave,Rangos 5117, Pittsburgh, PA 15224 USA.
EM eric.goetzman@chp.edu
OI Vockley, Jerry/0000-0002-8180-6457; Zuo, Yi/0000-0002-3992-3238
FU National Institutes of Health [DK090242]; NIDDK [DK78775]; NHLBI
   [HL107380, HL096376, HL097376, HL098174, P01 HL114453]
FX This work was supported, in whole or in part, by National Institutes of
   Health Grants DK090242 (to E. S. G.) and DK78775 (to J. V.) from NIDDK
   and Grants HL107380 (to J. F. A.), HL096376, HL097376, and HL098174 (to
   R. K. M.), P01 HL114453 (to R. K. M. and V. E. K.) from NHLBI.
NR 69
TC 8
Z9 8
U1 1
U2 7
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD APR 11
PY 2014
VL 289
IS 15
BP 10668
EP 10679
DI 10.1074/jbc.M113.540260
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AE8CI
UT WOS:000334226400037
PM 24591516
ER

PT J
AU Singh, JA
   Lewallen, DG
AF Singh, Jasvinder A.
   Lewallen, David G.
TI Depression in primary TKA and higher medical comorbidities in revision
   TKA are associated with suboptimal subjective improvement in knee
   function
SO BMC MUSCULOSKELETAL DISORDERS
LA English
DT Article
DE Total knee arthroplasty; Knee function; Functional limitation; Primary;
   Arthroplasty; Joint replacement; Outcomes; Patient-reported outcomes
ID QUALITY-OF-LIFE; TOTAL HIP; REPLACEMENT SURGERY; JOINT REPLACEMENT; PAIN
   MEDICATIONS; UNITED-STATES; POOR PAIN; ARTHROPLASTY; OUTCOMES;
   PREDICTORS
AB Background: To characterize whether medical comorbidities, depression and anxiety predict patient-reported functional improvement after total knee arthroplasty (TKA).
   Methods: We analyzed the prospectively collected data from the Mayo Clinic Total Joint Registry for patients who underwent primary or revision TKA between 1993-2005. Using multivariable-adjusted logistic regression analyses, we examined whether medical comorbidities, depression and anxiety were associated with patient-reported subjective improvement in knee function 2- or 5-years after primary or revision TKA. Odds ratios (OR), along with 95% confidence intervals (CI) and p-value are presented.
   Results: We studied 7,139 primary TKAs at 2- and 4,234 at 5-years; and, 1,533 revision TKAs at 2-years and 881 at 5-years. In multivariable-adjusted analyses, we found that depression was associated with significantly lower odds of 0.5 (95% confidence interval [CI]: 0.3 to 0.9; p = 0.02) of 'much better' knee functional status (relative to same or worse status) 2 years after primary TKA. Higher Deyo-Charlson index was significantly associated with lower odds of 0.5 (95% CI: 0.2 to 1.0; p = 0.05) of 'much better' knee functional status after revision TKA for every 5-point increase in score.
   Conclusions: Depression in primary TKA and higher medical comorbidity in revision TKA cohorts were associated with suboptimal improvement in index knee function. It remains to be seen whether strategies focused at optimization of medical comorbidities and depression pre- and peri-operatively may help to improve TKA outcomes. Study limitations include non-response bias and the use of diagnostic codes, which may be associated with under-diagnosis of conditions.
C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL 35233 USA.
   [Singh, Jasvinder A.] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit C SMART, Birmingham, AL USA.
   [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL USA.
   [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA.
   [Singh, Jasvinder A.; Lewallen, David G.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA.
   [Singh, Jasvinder A.] Univ Alabama Birmingham, Birmingham, AL 35294 USA.
RP Singh, JA (reprint author), Birmingham VA Med Ctr, Med Serv, Birmingham, AL 35233 USA.
EM Jasvinder.md@gmail.coml
FU Mayo Clinic Orthopedic Surgery; Agency for Health Quality and Research
   Center for Education and Research on Therapeutics (CERTs); National
   Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS);
   National Institute of Aging (NIA); National Cancer Institute (NCI)
FX This material is the result of work supported with research grants from
   the Mayo Clinic Orthopedic Surgery research funds and the resources and
   use of facilities at the Birmingham VA Medical Center, Alabama, USA.
   J.A.S. is also supported by grants from the Agency for Health Quality
   and Research Center for Education and Research on Therapeutics (CERTs),
   National Institute of Arthritis, Musculoskeletal and Skin Diseases
   (NIAMS), National Institute of Aging (NIA) and National Cancer Institute
   (NCI).
NR 51
TC 16
Z9 16
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2474
J9 BMC MUSCULOSKEL DIS
JI BMC Musculoskelet. Disord.
PD APR 11
PY 2014
VL 15
AR 127
DI 10.1186/1471-2474-15-127
PG 11
WC Orthopedics; Rheumatology
SC Orthopedics; Rheumatology
GA AG1PZ
UT WOS:000335189300004
PM 24725511
ER

PT J
AU Schnell, E
   Long, TH
   Bensen, AL
   Washbum, EK
   Westbrook, GL
AF Schnell, Eric
   Long, Thomas H.
   Bensen, AeSoon L.
   Washbum, Eric K.
   Westbrook, Gary L.
TI Neuroligin-1 knockdown reduces survival of adult-generated newborn
   hippocampal neurons
SO FRONTIERS IN NEUROSCIENCE
LA English
DT Article
DE adult neurogenesis; neuroligin-1; cell survival; dendritic spine;
   synaptogenesis; dendritic growth
ID TERM SYNAPTIC PLASTICITY; DENTATE GYRUS; NEUROGENESIS; SYNAPTOGENESIS;
   INTEGRATION; MATURATION; DOMAIN; CELLS; RAC1; MICE
AB Survival of adult-born hippocampal granule cells is modulated by neural activity, and thought to be enhanced by excitatory synaptic signaling. Here, we report that a reduction in the synaptogenic protein neuroligin-1 in adult-born neurons in vivo decreased their survival, but surprisingly, this effect was independent of changes in excitatory synaptic function. Instead, the decreased survival was associated with unexpected changes in dendrite and spine morphology during granule cell maturation, suggesting a link between cell growth and survival.
C1 [Schnell, Eric] Portland VA Med Ctr, Portland, OR 97239 USA.
   [Schnell, Eric] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97201 USA.
   [Long, Thomas H.] Oregon Hlth & Sci Univ, Sch Med, Portland, OR 97201 USA.
   [Bensen, AeSoon L.; Washbum, Eric K.; Westbrook, Gary L.] Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97201 USA.
RP Schnell, E (reprint author), Portland VA Med Ctr, P3ANES,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM schneler@ohsu.edu
FU Department of Veterans Affairs, Veterans Health Administration, Office
   of Research and Development, Biomedical Laboratory Research and
   Development CDA-2 award [NIH NS26494, MH046613, UL1TR000128,
   P30NS061800]
FX We thank Stefanie Kaech-Petrie for imaging assistance, Ken Tovar for
   comments on the manuscript, Bryan Luikart for his work in constructing
   and optimizing viral vectors, and Laura Villasana for assistance in
   blinding. This material was supported in part by a Department of
   Veterans Affairs, Veterans Health Administration, Office of Research and
   Development, Biomedical Laboratory Research and Development CDA-2 award
   (Eric Schnell) and NIH NS26494 (Gary L. Westbrook), MH046613 (Gary L.
   Westbrook), UL1TR000128 (Thomas H. Long), and P30NS061800 (OHSU) awards.
NR 36
TC 6
Z9 6
U1 1
U2 5
PU FRONTIERS RESEARCH FOUNDATION
PI LAUSANNE
PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND
SN 1662-453X
J9 FRONT NEUROSCI-SWITZ
JI Front. Neurosci.
PD APR 10
PY 2014
VL 8
AR 71
DI 10.3389/fnins.2014.00071
PG 7
WC Neurosciences
SC Neurosciences & Neurology
GA AW7SD
UT WOS:000346463800001
PM 24782702
ER

PT J
AU Goldkorn, A
   Ely, B
   Quinn, DI
   Tangen, CM
   Fink, LM
   Xu, T
   Twardowski, P
   Van Veldhuizen, PJ
   Agarwal, N
   Carducci, MA
   Monk, JP
   Datar, RH
   Garzotto, M
   Mack, PC
   Lara, P
   Higano, CS
   Hussain, M
   Thompson, IM
   Cote, RJ
   Vogelzang, NJ
AF Goldkorn, Amir
   Ely, Benjamin
   Quinn, David I.
   Tangen, Catherine M.
   Fink, Louis M.
   Xu, Tong
   Twardowski, Przemyslaw
   Van Veldhuizen, Peter J.
   Agarwal, Neeraj
   Carducci, Michael A.
   Monk, J. Paul, III
   Datar, Ram H.
   Garzotto, Mark
   Mack, Philip C.
   Lara, Primo, Jr.
   Higano, Celestia S.
   Hussain, Maha
   Thompson, Ian Murchie, Jr.
   Cote, Richard J.
   Vogelzang, Nicholas J.
TI Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG
   S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for
   Metastatic Castration-Resistant Prostate Cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID PREDICTIVE BIOMARKER; PROGRESSION; MEN; CHEMOTHERAPY; ABIRATERONE
AB Purpose Circulating tumor cell (CTC) enumeration has not been prospectively validated in standard first-line docetaxel treatment for metastatic castration-resistant prostate cancer. We assessed the prognostic value of CTCs for overall survival (OS) and disease response in S0421, a phase III trial of docetaxel plus prednisone with or without atrasentan.
   Patients and Methods CTCs were enumerated at baseline (day 0) and before cycle two (day 21) using CellSearch. Baseline counts and changes in counts from day 0 to 21 were evaluated for association with OS, prostate-specific antigen (PSA), and RECIST response using Cox regression as well as receiver operator characteristic (ROC) curves, integrated discrimination improvement (IDI) analysis, and regression trees.
   Results Median day-0 CTC count was five cells per 7.5 mL, and CTCs < versus five per 7.5 mL were significantly associated with baseline PSA, bone pain, liver disease, hemoglobin, alkaline phosphatase, and subsequent PSA and RECIST response. Median OS was 26 months for < five versus 13 months for five CTCs per 7.5 mL at day 0 (hazard ratio [HR], 2.74 [adjusting for covariates]). ROC curves had higher areas under the curve for day-0 CTCs than for PSA, and IDI analysis showed that adding day-0 CTCs to baseline PSA and other covariates increased predictive accuracy for survival by 8% to 10%. Regression trees yielded new prognostic subgroups, and rising CTC count from day 0 to 21 was associated with shorter OS (HR, 2.55).
   Conclusion These data validate the prognostic utility of CTC enumeration in a large docetaxel-based prospective cohort. Baseline CTC counts were prognostic, and rising CTCs at 3 weeks heralded significantly worse OS, potentially serving as an early metric to help redirect and optimize therapy in this clinical setting. J Clin Oncol 32:1136-1142. (C) 2014 by American Society of Clinical Oncology
C1 [Goldkorn, Amir; Quinn, David I.; Xu, Tong] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA.
   [Goldkorn, Amir; Quinn, David I.; Xu, Tong] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA.
   [Twardowski, Przemyslaw] City Hope Natl Med Ctr, Duarte, CA USA.
   [Mack, Philip C.; Lara, Primo, Jr.] Univ Calif Davis, Sacramento, CA 95817 USA.
   [Ely, Benjamin; Tangen, Catherine M.] SW Oncol Grp, Ctr Stat, Seattle, WA USA.
   [Higano, Celestia S.] Seattle Canc Care Alliance, Puget Sound Oncol Consortium, Seattle, WA USA.
   [Higano, Celestia S.] Univ Washington, Seattle, WA 98195 USA.
   [Fink, Louis M.] Nevada Canc Inst, Las Vegas, NV USA.
   [Vogelzang, Nicholas J.] Comprehens Canc Ctr Nevada, Las Vegas, NV USA.
   [Vogelzang, Nicholas J.] US Oncol Res, Las Vegas, NV USA.
   [Van Veldhuizen, Peter J.] Univ Kansas, Ctr Canc, Westwood, KS USA.
   [Agarwal, Neeraj] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA.
   [Carducci, Michael A.] Johns Hopkins Kimmel Canc Ctr, Baltimore, MD USA.
   [Carducci, Michael A.] Eastern Cooperat Oncol Grp, Baltimore, MD USA.
   [Monk, J. Paul, III] Ohio State Univ, Columbus, OH 43210 USA.
   [Monk, J. Paul, III] Canc & Leukemia Grp B, Columbus, OH USA.
   [Datar, Ram H.; Cote, Richard J.] Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
   [Garzotto, Mark] Portland VA Med Ctr, Portland, OR USA.
   [Hussain, Maha] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
   [Thompson, Ian Murchie, Jr.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
RP Goldkorn, A (reprint author), USC Keck Sch Med, Dept Internal Med, Div Med Oncol, Los Angeles, CA 90033 USA.
EM agoldkor@med.usc.edu
RI Quinn, David/F-4343-2015
OI Quinn, David/0000-0002-1411-0417
FU NCI NIH HHS [CA45808, CA014089-38, CA11083, CA12644, CA128567, CA14028,
   CA16116, CA16385, CA20319, CA21115, CA22433, CA31946, CA31949, CA35090,
   CA35128, CA35176,, CA35192, CA35281, CA35421, CA37981, CA42777, CA45377,
   CA45450, CA46282, CA46368, CA58416, CA58723, CA58861, CA58882, CA63845,
   CA63848, CA68183, CA74647, CA76429, CA76447, CA76448, N01 CA004919, N01
   CA013612, N01 CA027057, N01 CA032102, N01 CA035119, N01 CA035176, N01
   CA035178, N01 CA035431, N01 CA038926, N01 CA045560, N01 CA045807, N01
   CA046441, N01 CA063844, N01 CA067575, P30 CA006973, P30 CA014089, P30
   CA093373, R01 CA141077, R01 CA141077-03, U10 CA004919, U10 CA011083, U10
   CA013612, U10 CA014028, U10 CA016116, U10 CA020319, U10 CA021115, U10
   CA027057, U10 CA031946, U10 CA032102, U10 CA035090, U10 CA035119, U10
   CA035128, U10 CA035176, U10 CA035178, U10 CA035192, U10 CA035281, U10
   CA035421, U10 CA035431, U10 CA038926, U10 CA042777, U10 CA045377, U10
   CA045450, U10 CA045560, U10 CA045807, U10 CA045808, U10 CA046282, U10
   CA046368, U10 CA046441, U10 CA058861, U10 CA058882, U10 CA063844, U10
   CA063845, U10 CA063848, U10 CA067575, U10 CA074647, U10 CA128567, U10
   CA180819, U10 CA180888]
NR 32
TC 75
Z9 80
U1 0
U2 10
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD APR 10
PY 2014
VL 32
IS 11
BP 1136
EP +
DI 10.1200/JCO.2013.51.7417
PG 8
WC Oncology
SC Oncology
GA AG3KG
UT WOS:000335314300011
PM 24616308
ER

PT J
AU Pugh, MJ
   Leykum, LK
   Lanham, HJ
   Finley, EP
   Noel, PH
   McMillan, KK
   Pugh, JA
AF Pugh, Mary Jo
   Leykum, Luci K.
   Lanham, Holly J.
   Finley, Erin P.
   Noel, Polly H.
   McMillan, Katharine K.
   Pugh, Jacqueline A.
TI Implementation of the epilepsy center of excellence to improve access to
   and quality of care - protocol for a mixed methods study
SO IMPLEMENTATION SCIENCE
LA English
DT Article
DE Epilepsy; Relational Coordination; Veterans Health Administration (VA)
ID HEALTH-CARE; RELATIONAL COORDINATION; ANTIEPILEPTIC DRUG;
   SURGICAL-PATIENTS; IMPACT; OUTCOMES; ORGANIZATIONS; MECHANISMS;
   VETERANS; SERVICES
AB Background: To address the growing problem of epilepsy among aging Veterans and younger Veterans who have experienced a traumatic brain injury (TBI), the Veterans Health Administration (VA) has implemented 16 Epilepsy Centers of Excellence (ECOE) to assure increased access to high quality of care for Veterans with epilepsy. Each ECOE consists of a network of regional hubs to which spoke facilities refer Veterans for subspecialty treatment. The ECOEs are expected to improve access to and quality of epilepsy care through patient care, consultation and education. This study aims to: evaluate the effectiveness of the ECOE structure by describing changes in the quality of and access to care for epilepsy before and after the ECOE initiative using QUality Indicators in Epilepsy Treatment (QUIET Indicators); describe associations between changes in the structure and processes of care and Relational Coordination (RC), a model of task-oriented communication that has been shown to play a role in implementation science; and determine if variations in care are related to levels of RC.
   Methods: This four-year comparative case study uses a mixed-methods approach. We will use VA inpatient, outpatient, pharmacy, and chart abstraction data to identify changes in the quality of and access to epilepsy care in the VA between Fiscal Year 2008 and Fiscal Year 2014. Qualitative and survey methods will be used to identify changes in the structure and processes of epilepsy care and RC over the course of the study. We will then link data from the first two objectives to determine the extent to which quality of and access to epilepsy care is associated with RC using multivariable models.
   Discussion: This innovative study has the potential to improve understanding of hub-and-spoke model effectiveness, VA epilepsy care, and models of epilepsy specialty care more globally. Moreover, it contributes to implementation science by advancing understanding of the role of RC in the context of a major transformation in the structure of care delivery in a national integrated healthcare system.
C1 [Pugh, Mary Jo; Leykum, Luci K.; Lanham, Holly J.; Finley, Erin P.; Noel, Polly H.; McMillan, Katharine K.; Pugh, Jacqueline A.] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
   [Pugh, Mary Jo] VA Epilepsy Ctr Excellence, San Antonio, TX 78229 USA.
RP Pugh, MJ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, 7400 Merton Minter BLVD, San Antonio, TX 78229 USA.
EM Maryjo.Pugh2@va.gov
OI Pugh, Jacqueline/0000-0003-4933-141X; Pugh, Mary Jo/0000-0003-4196-7763;
   Finley, Erin/0000-0003-4497-7721
FU Department of Veterans Affairs, VA Health Services Research and
   Development Service [IIR-062]; National Institute of Mental Health [R25
   MH080916-01A2]; Department of Veterans Affairs, Health Services Research
   & Development Service, Quality Enhancement Research Initiative (QUERI)
FX This project was funded by the Department of Veterans Affairs, VA Health
   Services Research and Development Service (IIR-062; MJ Pugh PI). Dr.
   Finley is an investigator with the Implementation Research Institute
   (IRI), at the George Warren Brown School of Social Work, Washington
   University in St. Louis; through an award from the National Institute of
   Mental Health (R25 MH080916-01A2) and the Department of Veterans
   Affairs, Health Services Research & Development Service, Quality
   Enhancement Research Initiative (QUERI).
NR 38
TC 4
Z9 4
U1 3
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1748-5908
J9 IMPLEMENT SCI
JI Implement. Sci.
PD APR 9
PY 2014
VL 9
AR 44
DI 10.1186/1748-5908-9-44
PG 10
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA AF7KI
UT WOS:000334893300001
PM 24712733
ER

PT J
AU Hecker, L
   Logsdon, NJ
   Kurundkar, D
   Kurundkar, A
   Bernard, K
   Hock, T
   Meldrum, E
   Sanders, YY
   Thannickal, VJ
AF Hecker, Louise
   Logsdon, Naomi J.
   Kurundkar, Deepali
   Kurundkar, Ashish
   Bernard, Karen
   Hock, Thomas
   Meldrum, Eric
   Sanders, Yan Y.
   Thannickal, Victor J.
TI Reversal of Persistent Fibrosis in Aging by Targeting Nox4-Nrf2 Redox
   Imbalance
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID IDIOPATHIC PULMONARY-FIBROSIS; GROWTH-FACTOR-BETA; HUMAN FIBROBLASTS;
   KIDNEY-DISEASE; LUNG FIBROSIS; MYOFIBROBLAST; SENESCENCE; TISSUE;
   DIFFERENTIATION; BLEOMYCIN
AB The incidence and prevalence of pathological fibrosis increase with advancing age, although mechanisms for this association are unclear. We assessed the capacity for repair of lung injury in young ( 2 months) and aged ( 18 months) mice. Whereas the severity of fibrosis was not different between these groups, aged mice demonstrated an impaired capacity for fibrosis resolution. Persistent fibrosis in lungs of aged mice was characterized by the accumulation of senescent and apoptosis-resistant myofibroblasts. These cellular phenotypes were sustained by alterations in cellular redox homeostasis resulting from elevated expression of the reactive oxygen species-generating enzyme Nox4 [ NADPH ( reduced form of nicotinamide adenine dinucleotide phosphate) oxidase-4] and an impaired capacity to induce the Nrf2 ( NFE2-related factor 2) antioxidant response. Lung tissues from human subjects with idiopathic pulmonary fibrosis ( IPF), a progressive and fatal lung disease, also demonstrated this Nox4-Nrf2 imbalance. Nox4 mediated senescence and apoptosis resistance in IPF fibroblasts. Genetic and pharmacological targeting of Nox4 in aged mice with established fibrosis attenuated the senescent, antiapoptotic myofibroblast phenotype and led to a reversal of persistent fibrosis. These studies suggest that loss of cellular redox homeostasis promotes profibrotic myofibroblast phenotypes that result in persistent fibrosis associated with aging. Our studies suggest that restoration of Nox4-Nrf2 redox balance in myofibroblasts may be a therapeutic strategy in age-associated fibrotic disorders, potentially able to resolve persistent fibrosis or even reverse its progression.
C1 [Hecker, Louise; Logsdon, Naomi J.; Kurundkar, Deepali; Kurundkar, Ashish; Bernard, Karen; Hock, Thomas; Sanders, Yan Y.; Thannickal, Victor J.] Univ Alabama Birmingham, Dept Med, Div Pulm Allergy & Crit Care Med, Birmingham, AL 35294 USA.
   [Hecker, Louise] Birmingham VA Med Ctr, Birmingham, AL 35233 USA.
   [Meldrum, Eric] Genkyotex, CH-1228 Geneva, Switzerland.
RP Hecker, L (reprint author), Univ Alabama Birmingham, Dept Med, Div Pulm Allergy & Crit Care Med, Birmingham, AL 35294 USA.
EM lhecker@uab.edu; vjthan@uab.edu
FU Veterans Administration Health System [1IK2BX001477]; NIH [P01 HL
   114470, R01 HL094230, P50 HL107181]
FX Supported by Veterans Administration Health System grant 1IK2BX001477
   (L.H.) and NIH grants P01 HL 114470, R01 HL094230, and P50 HL107181
   (V.J.T.)
NR 45
TC 68
Z9 69
U1 2
U2 20
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
EI 1946-6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD APR 9
PY 2014
VL 6
IS 231
AR 231ra47
DI 10.1126/scitranslmed.3008182
PG 12
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA AE9QR
UT WOS:000334343900003
PM 24718857
ER

PT J
AU Dehmer, GJ
   Drozda, JP
   Brindis, RG
   Masoudi, FA
   Rumsfeld, JS
   Slattery, LE
   Oetgen, WJ
AF Dehmer, Gregory J.
   Drozda, Joseph P., Jr.
   Brindis, Ralph G.
   Masoudi, Frederick A.
   Rumsfeld, John S.
   Slattery, Lara E.
   Oetgen, William J.
TI Public Reporting of Clinical Quality Data An Update for Cardiovascular
   Specialists
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Article
DE healthcare reform; outcomes; public reporting; quality
ID PERCUTANEOUS CORONARY INTERVENTION; ACUTE MYOCARDIAL-INFARCTION;
   WISCONSIN PHYSICIAN GROUPS; ADMINISTRATIVE DATA; PERFORMANCE REPORTS;
   CARDIAC-SURGERY; CLAIMS DATA; OF-CARE; OUTCOMES; MORTALITY
AB Public reporting of hospital and individual provider quality of care measures is not a new concept. In the United States, the first national public reports of hospital mortality data occurred in 1986, and detailed physician-level data for cardiac surgery are now reported in 4 states. The development of the "Hospital Compare," and more recently, the " Physician Compare" websites has further expanded public reporting for hospitals and providers. Several professional organizations, including the American Medical Association, Society of Thoracic Surgeons, and the American College of Cardiology, have published policy statements articulating key principles to guide the public reporting process. Despite the rapid proliferation of public reporting efforts, more research is needed to better define meaningful measures to report and fully understand the impact of public reporting on healthcare delivery. (C) 2014 by the American College of Cardiology Foundation
C1 [Dehmer, Gregory J.] Baylor Scott & White Hlth, Div Cardiol, Texas A&M Hlth Sci Ctr, Temple, TX 76508 USA.
   [Drozda, Joseph P., Jr.] Mercy Hlth, Chesterfield, MO USA.
   [Brindis, Ralph G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
   [Brindis, Ralph G.] Univ Calif San Francisco, Philip R Lee Inst Hlth Policy Studies, San Francisco, CA USA.
   [Masoudi, Frederick A.] Univ Colorado, Div Cardiol, Aurora, CO USA.
   [Rumsfeld, John S.] Denver VA Med Ctr, Denver, CO USA.
   [Slattery, Lara E.; Oetgen, William J.] Amer Coll Cardiol, Washington, DC USA.
   [Oetgen, William J.] Georgetown Univ, Dept Med, Washington, DC USA.
RP Dehmer, GJ (reprint author), Baylor Scott & White Hlth, Cardiol Div MS 33 ST156, 2401 South 31st St, Temple, TX 76508 USA.
EM gdehmer@sw.org
NR 56
TC 20
Z9 22
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
EI 1558-3597
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD APR 8
PY 2014
VL 63
IS 13
BP 1239
EP 1245
DI 10.1016/j.jacc.2013.11.050
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AE2LK
UT WOS:000333804300003
PM 24509280
ER

PT J
AU Palevsky, PM
AF Palevsky, Paul M.
TI Renal Angina: Right Concept... Wrong Name?
SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Editorial Material
DE AKI; biomarkers; diagnosis
ID ACUTE KIDNEY INJURY; BIOMARKERS
C1 [Palevsky, Paul M.] VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA 15240 USA.
   [Palevsky, Paul M.] Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Pittsburgh, PA USA.
RP Palevsky, PM (reprint author), VA Pittsburgh Healthcare Syst, Renal Sect, Univ Dr,Room 7E123,111F-U, Pittsburgh, PA 15240 USA.
EM palevsky@pitt.edu
OI Palevsky, Paul/0000-0002-7334-5400
NR 12
TC 1
Z9 1
U1 0
U2 1
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1555-9041
EI 1555-905X
J9 CLIN J AM SOC NEPHRO
JI Clin. J. Am. Soc. Nephrol.
PD APR 7
PY 2014
VL 9
IS 4
BP 633
EP 634
DI 10.2215/CJN.01520214
PG 2
WC Urology & Nephrology
SC Urology & Nephrology
GA AE2XM
UT WOS:000333836600001
PM 24677556
ER

PT J
AU Clarkson, BDS
   Ling, CY
   Shi, YJ
   Harris, MG
   Rayasam, A
   Sun, DD
   Salamat, MS
   Kuchroo, V
   Lambris, JD
   Sandor, M
   Fabry, Z
AF Clarkson, Benjamin D. S.
   Ling, Changying
   Shi, Yejie
   Harris, Melissa G.
   Rayasam, Aditya
   Sun, Dandan
   Salamat, M. Shahriar
   Kuchroo, Vijay
   Lambris, John D.
   Sandor, Matyas
   Fabry, Zsuzsanna
TI T cell-derived interleukin (IL)-21 promotes brain injury following
   stroke in mice
SO JOURNAL OF EXPERIMENTAL MEDICINE
LA English
DT Article
ID ISCHEMIC-STROKE; CEREBRAL-ISCHEMIA; IL-21; LYMPHOCYTES; REJECTION;
   COUNTERACTS; DYSFUNCTION; EXPRESSION; AUTOIMMUNE; DISEASE
AB T lymphocytes are key contributors to the acute phase of cerebral ischemia reperfusion injury, but the relevant T cell-derived mediators of tissue injury remain unknown. Using a mouse model of transient focal brain ischemia, we report that IL-21 is highly up-regulated in the injured mouse brain after cerebral ischemia. IL-21-deficient mice have smaller infarcts, improved neurological function, and reduced lymphocyte accumulation in the brain within 24 h of reperfusion. Intracellular cytokine staining and adoptive transfer experiments revealed that brain-infiltrating CD4(+) T cells are the predominant IL-21 source. Mice treated with decoy IL-21 receptor Fc fusion protein are protected from reperfusion injury. In postmortem human brain tissue, IL-21 localized to perivascular CD4(+) T cells in the area surrounding acute stroke lesions, suggesting that IL-21-mediated brain injury may be relevant to human stroke.
C1 [Clarkson, Benjamin D. S.; Ling, Changying; Harris, Melissa G.; Salamat, M. Shahriar; Sandor, Matyas; Fabry, Zsuzsanna] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol & Lab Med, Madison, WI 53792 USA.
   [Shi, Yejie; Sun, Dandan] Univ Wisconsin, Sch Med & Publ Hlth, Dept Neurol Surg, Madison, WI 53792 USA.
   [Clarkson, Benjamin D. S.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Cellular & Mol Pathol, Madison, WI 53792 USA.
   [Harris, Melissa G.; Rayasam, Aditya] Univ Wisconsin, Sch Med & Publ Hlth, Neurosci Training Program, Madison, WI 53792 USA.
   [Sun, Dandan] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15213 USA.
   [Kuchroo, Vijay] Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA.
   [Kuchroo, Vijay] Harvard Univ, Sch Med, Boston, MA 02115 USA.
   [Lambris, John D.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
RP Fabry, Z (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol & Lab Med, Madison, WI 53792 USA.
EM zfabry@facstaff.wisc.edu
OI Lambris, John/0000-0002-9370-5776; Shi, Yejie/0000-0001-7502-9201
FU American Heart Association [12PRE12060020]; National Institutes of
   Health [NS037570, NS076946, AI048087, AI068730]
FX This work was supported by awards from the American Heart Association
   (pre-doctoral fellowship # 12PRE12060020 to B. D. S. Clarkson) and the
   National Institutes of Health (NS037570 and NS076946 to ZF, AI048087 to
   M. S. Salamat, and AI068730 to J.D. Lambris).
NR 30
TC 18
Z9 18
U1 5
U2 15
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA
SN 0022-1007
EI 1540-9538
J9 J EXP MED
JI J. Exp. Med.
PD APR 7
PY 2014
VL 211
IS 4
BP 595
EP 604
DI 10.1084/jem.20131377
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA AF7TJ
UT WOS:000334917400002
PM 24616379
ER

PT J
AU Robertson, DJ
   Dominitz, JA
AF Robertson, Douglas J.
   Dominitz, Jason A.
TI Stool DNA and Colorectal-Cancer Screening
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Editorial Material
ID FECAL DNA
C1 [Robertson, Douglas J.] White River Junct Vet Affairs VA Med Ctr, White River Jct, VT 05009 USA.
   [Robertson, Douglas J.] Geisel Sch Med Dartmouth, Hanover, NH USA.
   [Dominitz, Jason A.] Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, Seattle, WA USA.
RP Robertson, DJ (reprint author), White River Junct Vet Affairs VA Med Ctr, White River Jct, VT 05009 USA.
OI Dominitz, Jason/0000-0002-8070-7086
NR 14
TC 6
Z9 7
U1 0
U2 8
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD APR 3
PY 2014
VL 370
IS 14
BP 1350
EP 1351
DI 10.1056/NEJMe1400092
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA AE2VA
UT WOS:000333830000015
PM 24645801
ER

PT J
AU Giacobbi, PR
   Buman, MP
   Dzierzewski, JM
   Aiken-Morgan, AT
   Roberts, BL
   Marsiske, M
   Knutson, N
   McCrae, CS
AF Giacobbi, Peter R., Jr.
   Buman, Matthew P.
   Dzierzewski, Joseph M.
   Aiken-Morgan, Adrienne T.
   Roberts, Beverly L.
   Marsiske, Michael
   Knutson, Nicholas
   McCrae, Christina S.
TI Content and Perceived Utility of Mental Imagery by Older Adults in a
   Peer-Delivered Physical Activity Intervention
SO JOURNAL OF APPLIED SPORT PSYCHOLOGY
LA English
DT Article
ID EXERCISE IMAGERY; COMPLEMENTARY; MEDICINE; PROGRAM
AB Imagery interventions intended to increase exercise behavior are rare. The Active Adult Mentoring Program (AAMP) was a randomized controlled trial with imagery content. The purposes of this study were to examine the content and perceived utility of mental imagery with 24 AAMP participants (M-age = 65.00, SD = 8.79years). Digital recordings of AAMP sessions and post-intervention interviews were content-analyzed. Emergent themes included images of the physical activity context and negative impressions about imagery. Post-intervention interviews revealed that 13 participants reported positive experiences using mental imagery while 9 would not engage in further use. Important implications are discussed.
C1 [Giacobbi, Peter R., Jr.] W Virginia Univ, Morgantown, WV 26506 USA.
   [Buman, Matthew P.] Arizona State Univ, Tempe, AZ 85287 USA.
   [Dzierzewski, Joseph M.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
   [Dzierzewski, Joseph M.] Univ Calif Los Angeles, Los Angeles, CA USA.
   [Aiken-Morgan, Adrienne T.] Duke Univ, Med Ctr, Durham, NC 27706 USA.
   [Roberts, Beverly L.; Marsiske, Michael; McCrae, Christina S.] Univ Florida, Gainesville, FL 32611 USA.
   [Knutson, Nicholas] Univ Arizona, Tucson, AZ 85721 USA.
RP Giacobbi, PR (reprint author), W Virginia Univ, Morgantown, WV 26506 USA.
EM peter.giacobbi@mail.wvu.edu
OI Marsiske, Michael/0000-0001-5973-2116; McCrae,
   Christina/0000-0003-4313-6867
FU National Institute on Aging [1R36AG029664-01, F31-AG-032802,
   T32-AG000029]; University of Florida (Age Network research award);
   Research Opportunity Fund in the College of Health and Human Performance
   at the University of Florida; Department of Veterans Affairs Advanced
   Geriatrics Fellowship Program, an Institutional Training Grant
   [T32-AG-020499]; Public Health Service Training Grant from the National
   Heart, Lung, and Blood Institute [5-T32-HL-007034]
FX This work was supported by the National Institute on Aging
   (1R36AG029664-01, PI: Aiken-Morgan) and University of Florida (Age
   Network research award, PI: McCrae). This work was also supported, in
   part, by a Research Opportunity Fund in the College of Health and Human
   Performance at the University of Florida. Joseph M. Dzierzewski was
   supported by the Department of Veterans Affairs Advanced Geriatrics
   Fellowship Program, an Institutional Training Grant, T32-AG-020499,
   awarded to the University of Florida by the National Institute on Aging,
   and an Individual Training Grant, F31-AG-032802, awarded by the National
   Institute on Aging. Matthew P. Buman was supported by Public Health
   Service Training Grant, 5-T32-HL-007034, from the National Heart, Lung,
   and Blood Institute. Adrienne T. Aiken-Morgan was supported by an
   Institutional Training Grant, T32-AG000029, to Duke University by the
   National Institute on Aging. None of the authors have declared a
   conflict of interest. The content is solely the responsibility of the
   authors and does not necessarily represent the official views of the
   funding sources, nor were funding sources responsible for the design,
   methods, subject recruitment, data collection, analysis or preparation
   of paper.
NR 25
TC 2
Z9 2
U1 0
U2 5
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1041-3200
EI 1533-1571
J9 J APPL SPORT PSYCHOL
JI J. Appl. Sport Psychol.
PD APR 3
PY 2014
VL 26
IS 2
BP 129
EP 143
DI 10.1080/10413200.2013.803502
PG 15
WC Hospitality, Leisure, Sport & Tourism; Psychology, Applied; Psychology;
   Sport Sciences
SC Social Sciences - Other Topics; Psychology; Sport Sciences
GA AE4WD
UT WOS:000333986100001
PM 25067894
ER

PT J
AU Young, KA
   Franklin, TR
   Roberts, DCS
   Jagannathan, K
   Suh, JJ
   Wetherill, RR
   Wang, Z
   Kampman, KM
   O'Brien, CP
   Childress, AR
AF Young, Kimberly A.
   Franklin, Teresa R.
   Roberts, David C. S.
   Jagannathan, Kanchana
   Suh, Jesse J.
   Wetherill, Reagan R.
   Wang, Ze
   Kampman, Kyle M.
   O'Brien, Charles P.
   Childress, Anna Rose
TI Nipping Cue Reactivity in the Bud: Baclofen Prevents Limbic Activation
   Elicited by Subliminal Drug Cues
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
DE addiction; baclofen; cocaine; cues; fMRI; subliminal
ID COCAINE-SEEKING BEHAVIOR; CONDITIONED DOPAMINE RELEASE;
   NUCLEUS-ACCUMBENS; DEPENDENT INDIVIDUALS; INTRATHECAL BACLOFEN; RATS;
   ADDICTION; AMYGDALA; MOTIVATION; METAANALYSIS
AB Relapse is a widely recognized and difficult to treat feature of the addictions. Substantial evidence implicates cue-triggered activation of the mesolimbic dopamine system as an important contributing factor. Even drug cues presented outside of conscious awareness (i.e., subliminally) produce robust activation within this circuitry, indicating the sensitivity and vulnerability of the brain to potentially problematic reward signals. Because pharmacological agents that prevent these early cue-induced responses could play an important role in relapse prevention, we examined whether baclofen-a GABA(B) receptor agonist that reduces mesolimbic dopamine release and conditioned drug responses in laboratory animals-could inhibit mesolimbic activation elicited by subliminal cocaine cues in cocaine-dependent individuals. Twenty cocaine-dependent participants were randomized to receive baclofen (60 mg/d; 20 mg t.i.d.) or placebo. Event-related BOLD fMRI and a backward-masking paradigm were used to examine the effects of baclofen on subliminal cocaine (vs neutral) cues. Sexual and aversive cues were included to examine specificity. We observed that baclofen-treated participants displayed significantly less activation in response to subliminal cocaine (vs neutral) cues, but not sexual or aversive (vs neutral) cues, than placebo-treated participants in a large interconnected bilateral cluster spanning the ventral striatum, ventral pallidum, amygdala, midbrain, and orbitofrontal cortex (voxel threshold p < 0.005; cluster corrected at p < 0.05). These results suggest that baclofen may inhibit the earliest type of drug cue-induced motivational processing-that which occurs outside of awareness-before it evolves into a less manageable state.
C1 [Young, Kimberly A.; Franklin, Teresa R.; Jagannathan, Kanchana; Suh, Jesse J.; Wetherill, Reagan R.; Wang, Ze; Kampman, Kyle M.; O'Brien, Charles P.; Childress, Anna Rose] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA.
   [Roberts, David C. S.] Wake Forest Univ, Bowman Gray Sch Med, Dept Physiol & Pharmacol, Winston Salem, NC 27157 USA.
   [Suh, Jesse J.; O'Brien, Charles P.; Childress, Anna Rose] Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA.
RP Childress, AR (reprint author), Univ Penn, Perelman Sch Med, Dept Psychiat, 3900 Chestnut St, Philadelphia, PA 19104 USA.
EM childres@mail.med.upenn.edu
OI Roberts, David/0000-0001-7040-0155
FU National Institutes of Health [T32 DA029974, R01 DA010241, P50 DA12756];
   Commonwealth of Pennsylvania CURE Addiction Center of Excellence
FX This work was supported by National Institutes of Health Grants T32
   DA029974, R01 DA010241, and P50 DA12756, and the Commonwealth of
   Pennsylvania CURE Addiction Center of Excellence. We thank the research
   and clinical staff and nurses at the Center for Studies of Addictions,
   for their expert assistance throughout the study, the technical staff at
   the University of Pennsylvania Center for Functional Neuroimaging, and
   Yin Li, for assistance with image processing. We also thank the National
   Institute on Drug Abuse for providing the study medication.
NR 40
TC 14
Z9 14
U1 2
U2 14
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD APR 2
PY 2014
VL 34
IS 14
BP 5038
EP 5043
DI 10.1523/JNEUROSCI.4977-13.2014
PG 6
WC Neurosciences
SC Neurosciences & Neurology
GA AE6CL
UT WOS:000334076000027
PM 24695721
ER

PT J
AU Walter, LC
   Schonberg, MA
AF Walter, Louise C.
   Schonberg, Mara A.
TI Screening Mammography in Older Women A Review
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Review
ID BREAST-CANCER RISK; CARCINOMA IN-SITU; ESTROGEN PLUS PROGESTIN;
   HORMONE-RECEPTOR STATUS; REPLACEMENT THERAPY USE; SERVICES TASK-FORCE;
   AGE 80 YEARS; POSTMENOPAUSAL WOMEN; DECISION-MAKING; UNITED-STATES
AB IMPORTANCE Guidelines recommend individualizing screening mammography decisions for women aged 75 years and older. However, little pragmatic guidance is available to help counsel patients.
   OBJECTIVE To provide an evidence-based approach for individualizing decision-making about screening mammography in older women. E
   EVIDENCE ACQUISITION We searched PubMed for English-language studies in peer-reviewed journals published from January 1,1990, to February 1, 2014, to identify risk factors for late-life breast cancer in women aged 65 years and older and to quantify the benefits and harms of screening mammography for women aged 75 years and older.
   FINDINGS Age is the major risk factor for developing and dying from breast cancer. Breast cancer risk factors that reflect hormonal exposures in the distant past, such as age at first birth or age at menarche, are less predictive of late-life breast cancer than factors indicating recent hormonal exposures such as high bone mass or obesity. Randomized trials of the benefits of screening mammography did not include women older than 74 years. Thus it is not known if screening mammography benefits older women. Observational studies favor extending screening mammography to older women who have a life expectancy of more than 10 years. Modeling studies estimate 2 fewer breast cancer deaths/1000 women who in their 70s continue biennial screening for 10 years instead of stopping screening at age 69. Potential harms of continued screening over 10 years include false-positive mammograms in approximately 200/1000 women screened and overdiagnosis (ie, finding breast cancer that would not have clinically surfaced otherwise) in approximately 13/1000 women screened. Providing information about life expectancy along with potential benefits and harms of screening may help older women's decision-making about screening mammography.
   CONCLUSIONS AND RELEVANCE For women with less than a 10-year life expectancy, recommendations to stop screening mammography should emphasize increased potential harms from screening and highlight health promotion measures likely to be beneficial over the short term. For women with a life expectancy of more than 10 years, deciding whether potential benefits of screening outweigh harms becomes a value judgment for patients, requiring a realistic understanding of screening outcomes.
C1 [Walter, Louise C.] Univ Calif San Francisco, San Francisco, CA 94121 USA.
   [Walter, Louise C.] San Francisco VA Med Ctr, San Francisco, CA USA.
   [Schonberg, Mara A.] Harvard Univ, Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Dept Med,Med Sch, Boston, MA 02215 USA.
RP Walter, LC (reprint author), Univ Calif San Francisco, Div Geriatr, San Francisco VA Med Ctr 181G, 4150 Clement St, San Francisco, CA 94121 USA.
EM Louise.Walter@ucsf.edu
FU National Cancer Institute [RO1 CA134425]; National Institute on Aging
   [K24AG041180]; Paul B. Beeson Career Development Award in Aging
   [K23AG028584]; John A. Hartford Foundation; Atlantic Philanthropies;
   Starr Foundation; American Federation for Aging Research
FX This work was supported by the National Cancer Institute (grant RO1
   CA134425) and the National Institute on Aging (grant K24AG041180) (Dr
   Walter); the Paul B. Beeson Career Development Award in Aging (grant
   K23AG028584) (Dr Schonberg); as well as support from the John A.
   Hartford Foundation, the Atlantic Philanthropies, the Starr Foundation,
   and the American Federation for Aging Research.
NR 98
TC 44
Z9 44
U1 1
U2 18
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD APR 2
PY 2014
VL 311
IS 13
BP 1336
EP 1347
DI 10.1001/jama.2014.2834
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA AE0HU
UT WOS:000333645400017
PM 24691609
ER

PT J
AU Li, ZP
   Heber, D
AF Li, Zhaoping
   Heber, David
TI Managing Weight Loss Expectations The Challenge and the Opportunity
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
ID GASTRIC BYPASS-SURGERY; BARIATRIC SURGERY; MORTALITY; OUTCOMES; RISK
AB IMPORTANCE: Weight loss surgery (WLS) has been shown to produce long-term weight loss but is not risk free or universally effective. The weight loss expectations and willingness to undergo perioperative risk among patients seeking WLS remain unknown.
   OBJECTIVES: To examine the expectations and motivations of WLS patients and the mortality risks they are willing to undertake and to explore the demographic characteristics, clinical factors, and patient perceptions associated with high weight loss expectations and willingness to assume high surgical risk.
   DESIGN: We interviewed patients seeking WLS and conducted multivariable analyses to examine the characteristics associated with high weight loss expectations and the acceptance of mortality risks of 10% or higher. SETTING: Two WLS centers in Boston.
   PARTICIPANTS: Six hundred fifty-four patients.
   MAIN OUTCOME MEASURES: Disappointment with a sustained weight loss of 20% and willingness to accept a mortality risk of 10% or higher with WLS.
   RESULTS: On average, patients expected to lose as much as 38% of their weight after WLS and expressed disappointment if they did not lose at least 26%. Most patients (84.8%) accepted some risk of dying to undergo WLS, but only 57.5% were willing to undergo a hypothetical treatment that produced a 20% weight loss. The mean acceptable mortality risk to undergo WLS was 6.7%, but the median risk was only 0.1%; 19.5% of all patients were willing to accept a risk of at least 10%. Women were more likely than men to be disappointed with a 20% weight loss but were less likely to accept high mortality risk. After initial adjustment, white patients appeared more likely than African American patients to have high weight loss expectations and to be willing to accept high risk. Patients with lower quality-of-life scores and those who perceived needing to lose more than 10% and 20% of weight to achieve "any" health benefits were more likely to have unrealistic weight loss expectations. Low quality-of-life scores were also associated with willingness to accept high risk.
   CONCLUSIONS AND RELEVANCE: Most patients seeking WLS have high weight loss expectations and believe they need to lose substantial weight to derive any health benefits. Educational efforts may be necessary to align expectations with clinical reality.
C1 [Li, Zhaoping; Heber, David] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Human Nutr, Los Angeles, CA 90095 USA.
   [Li, Zhaoping] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Heber, D (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Ctr Human Nutr, 900 Vet Ave, Los Angeles, CA 90095 USA.
EM dheber@mednet.ucla.edu
NR 10
TC 0
Z9 0
U1 2
U2 8
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD APR 2
PY 2014
VL 311
IS 13
BP 1348
EP 1349
DI 10.1001/jamasurg.2013.1048
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA AE0HU
UT WOS:000333645400018
PM 24691610
ER

PT J
AU Anderson, TS
   Dave, S
   Good, CB
   Gellad, WF
AF Anderson, Timothy S.
   Dave, Shravan
   Good, Chester B.
   Gellad, Walid F.
TI Academic Medical Center Leadership on Pharmaceutical Company Boards of
   Directors
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Letter
C1 [Anderson, Timothy S.] Univ Pittsburgh, Med Ctr, Dept Internal Med, Pittsburgh, PA USA.
   [Dave, Shravan] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
   [Good, Chester B.; Gellad, Walid F.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA.
RP Gellad, WF (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 151C Univ Dr, Pittsburgh, PA 15240 USA.
EM wfg3@pitt.edu
NR 6
TC 6
Z9 6
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD APR 2
PY 2014
VL 311
IS 13
BP 1353
EP 1355
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA AE0HU
UT WOS:000333645400020
PM 24691612
ER

PT J
AU McClintock, TR
   Chen, Y
   Parvez, F
   Makarov, DV
   Ge, WZ
   Islam, T
   Ahmed, A
   Rakibuz-Zaman, M
   Hasan, R
   Sarwar, G
   Slavkovich, V
   Bjurlin, MA
   Graziano, JH
   Ahsan, H
AF McClintock, Tyler R.
   Chen, Yu
   Parvez, Faruque
   Makarov, Danil V.
   Ge, Wenzhen
   Islam, Tariqul
   Ahmed, Alauddin
   Rakibuz-Zaman, Muhammad
   Hasan, Rabiul
   Sarwar, Golam
   Slavkovich, Vesna
   Bjurlin, Marc A.
   Graziano, Joseph H.
   Ahsan, Habibul
TI Association between arsenic exposure from drinking water and hematuria:
   Results from the Health Effects of Arsenic Longitudinal Study
SO TOXICOLOGY AND APPLIED PHARMACOLOGY
LA English
DT Article
DE Arsenic; Bangladesh; Environmental epidemiology; Hematuria; Mass
   screening; Urologic neoplasms
ID ASYMPTOMATIC MICROSCOPIC HEMATURIA; DISEASE ENDEMIC AREA; KIDNEY CANCER;
   BLADDER-CANCER; MALIGNANT NEOPLASMS; WELL WATER; MORTALITY; RISK;
   BANGLADESH; TAIWAN
AB Arsenic (As) exposure has been associated with both urologic malignancy and renal dysfunction; however, its association with hematuria is unknown. We evaluated the association between drinking water As exposure and hematuria in 7843 men enrolled in the Health Effects of Arsenic Longitudinal Study (HEALS). Cross-sectional analysis of baseline data was conducted with As exposure assessed in both well water and urinary As measurements, while hematuria was measured using urine dipstick. Prospective analyses with Cox proportional regression models were based on urinary As and dipstick measurements obtained biannually since baseline up to six years. At baseline, urinary As was significantly related to prevalence of hematuria (P-trend < 0.01), with increasing quintiles of exposure corresponding with respective prevalence odds ratios of 1.00 (reference), 1.29 (95% CI: 1.04-1.59), 1.41 (95% CI: 1.15-1.74), 1.46 (95% CI: 1.19-1.79), and 1.56 (95% CI: 1.27-1.91). Compared to those with relatively little absolute urinary As change during follow-up (-10.40 to 41.17 mu g/l), hazard ratios for hematuria were 0.99 (95% CI: 0.80-1.22) and 0.80(95% CI: 0.65-0.99) for those whose urinary As decreased by >47.49 mu g/l and 10.87 to 47.49 mu g/l since last visit, respectively, and 1.17 (95% CI: 0.94-1.45) and 1.36(95% CI: 1.10-1.66) for those with between-visit increases of 10.40 to 41.17 mu g/l and >41.17 mu g/l, respectively. These data indicate a positive association of As exposure with both prevalence and incidence of dipstick hematuria. This exposure effect appears modifiable by relatively short-term changes in drinking water As. (C) 2014 Elsevier Inc. All rights reserved.
C1 [McClintock, Tyler R.; Chen, Yu; Ge, Wenzhen] NYU, Sch Med, Dept Populat Hlth, New York, NY 10016 USA.
   [McClintock, Tyler R.; Chen, Yu; Ge, Wenzhen] NYU, Sch Med, Dept Environm Med, New York, NY 10016 USA.
   [McClintock, Tyler R.; Makarov, Danil V.; Bjurlin, Marc A.] NYU, Sch Med, Dept Urol, New York, NY 10016 USA.
   [Parvez, Faruque; Slavkovich, Vesna; Graziano, Joseph H.] Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY USA.
   [Makarov, Danil V.] NYU, Robert F Wagner Grad Sch Publ Serv, New York, NY 10016 USA.
   [Makarov, Danil V.] US Dept Vet Affairs, Harbor Healthcare Syst, New York, NY USA.
   [Makarov, Danil V.] NYU, Inst Canc, New York, NY 10016 USA.
   [Islam, Tariqul; Ahmed, Alauddin; Rakibuz-Zaman, Muhammad; Hasan, Rabiul; Sarwar, Golam] U Chicago Res Bangladesh Ltd, Dhaka, Bangladesh.
   [Ahsan, Habibul] Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA.
   [Ahsan, Habibul] Univ Chicago, Dept Med, Chicago, IL 60637 USA.
   [Ahsan, Habibul] Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA.
   [Ahsan, Habibul] Univ Chicago, Ctr Comprehens Canc, Chicago, IL 60637 USA.
RP Chen, Y (reprint author), NYU, Sch Med, Dept Populat Hlth, 650 First Ave, New York, NY 10016 USA.
EM yu.chen@nyumc.org; habib@uchicago.edu
OI Makarov, Danil/0000-0002-0565-9272
FU National Institutes of Health [R01 ES017541, R01 CA107431, P42 ES010349,
   P30 ES000260]; National Center for the Advancement of Translational
   Science (NCATS), National Institutes of Health [UL1 TR000038]
FX This work was supported by the National Institutes of Health (grants R01
   ES017541, R01 CA107431, P42 ES010349, and P30 ES000260) and in part by
   grant UL1 TR000038 from the National Center for the Advancement of
   Translational Science (NCATS), National Institutes of Health.
NR 37
TC 4
Z9 5
U1 0
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0041-008X
EI 1096-0333
J9 TOXICOL APPL PHARM
JI Toxicol. Appl. Pharmacol.
PD APR 1
PY 2014
VL 276
IS 1
BP 21
EP 27
DI 10.1016/j.taap.2014.01.015
PG 7
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA CA9XS
UT WOS:000349278700002
PM 24486435
ER

PT J
AU Won, J
   Kim, J
   Singh, A
   Sharma, A
   Singh, I
AF Won, Jeseong
   Kim, Jinsu
   Singh, Avtar
   Sharma, Anand
   Singh, Inderjit
TI STAT3 regulation by S-nitrosylation: implication for inflammatory
   disease
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Experimental Biology Meeting
CY APR 26-30, 2014
CL San Diego, CA
SP Cenveo, LI COR, Wiley, Mead Johnson Pediat Nutr Inst, IPRECIO, F1000 Res, Amer Assoc Anatomists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, Amer Soc Investigat Pathol, Amer Soc Nutr, Amer Soc Pharmacol & Expt Therapeut
C1 [Won, Jeseong; Kim, Jinsu; Singh, Avtar; Sharma, Anand; Singh, Inderjit] Med Univ S Carolina, Charleston, SC 29425 USA.
   [Singh, Avtar] Ralph H Johnson Vet Adm Med Ctr, Pathol & Lab Med Serv, Charleston, SC USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD APR
PY 2014
VL 28
IS 1
SU S
MA 555.8
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA AX0MP
UT WOS:000346646701390
ER

PT J
AU Davies, G
   Birtwistle, M
   Pope, M
   Perry, V
   Sacks, H
   Budge, H
   Symonds, M
AF Davies, Graeme
   Birtwistle, Mark
   Pope, Mark
   Perry, Vivienne
   Sacks, Harold
   Budge, Helen
   Symonds, Michael
TI The developmental transition of epicardial, paracardial and omental
   adipose tissue during early life in the sheep
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 [Davies, Graeme; Birtwistle, Mark; Pope, Mark; Budge, Helen; Symonds, Michael] Univ Nottingham, Nottingham NG7 2RD, England.
   [Perry, Vivienne] Univ Nottingham, Sch Vet Med & Sci, Loughborough, Leics, England.
   [Sacks, Harold] VA Greater Los Angeles Healthcare, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD APR
PY 2014
VL 28
IS 1
SU S
MA 1160.7
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA AX0OG
UT WOS:000346651002192
ER

PT J
AU Mendoza, D
   Xu, Y
   Rodriguez-Barradas, M
   Tweardy, D
   Orson, F
   Corry, D
AF Mendoza, Daniel
   Xu, Yi
   Rodriguez-Barradas, Maria
   Tweardy, David
   Orson, Frank
   Corry, David
TI Human dendritic cells induce B-cell responses to polysaccharide antigens
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 [Mendoza, Daniel; Xu, Yi; Rodriguez-Barradas, Maria; Tweardy, David; Orson, Frank; Corry, David] Baylor Coll Med, Houston, TX 77030 USA.
   [Mendoza, Daniel; Rodriguez-Barradas, Maria; Orson, Frank; Corry, David] VA Med Ctr, Houston, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD APR
PY 2014
VL 28
IS 1
SU S
MA 1004.2
PG 2
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA AX0OG
UT WOS:000346651000027
ER

PT J
AU Toba, H
   Bras, LD
   Weintraub, S
   Jin, YF
   Bradshaw, A
   Lindsey, M
AF Toba, Hiroe
   Bras, Lisandra de Castro
   Weintraub, Susan
   Jin, Yu-Fang
   Bradshaw, Amy
   Lindsey, Merry
TI Age and SPARC dependent cardiac collagen changes
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 [Lindsey, Merry] GV Sonny Montgomery Vet Affairs Med Ctr, Jackson, MS USA.
   [Bradshaw, Amy] MUSC, Med Gazes Cardiac Res Instit, Charleston, SC USA.
   [Toba, Hiroe] Kyoto Pharmaceut Univ, Kyoto 607, Japan.
   [Bradshaw, Amy] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
   [Toba, Hiroe; Bras, Lisandra de Castro; Weintraub, Susan; Jin, Yu-Fang; Lindsey, Merry] San Antonio CV Prote Ctr, San Antonio, TX USA.
   [Toba, Hiroe; Bras, Lisandra de Castro; Lindsey, Merry] UMMC, Mississippi Ctr Heart Res, Jackson, MS USA.
   [Weintraub, Susan] UTHSCSA, San Antonio, TX USA.
   [Jin, Yu-Fang] UTSA, San Antonio, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD APR
PY 2014
VL 28
IS 1
SU S
MA 1120.7
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA AX0OG
UT WOS:000346651001397
ER

PT J
AU Bakaeen, FG
   Chu, D
   Kelly, RF
   Holman, WL
   Jessen, ME
   Ward, HB
AF Bakaeen, Faisal G.
   Chu, Danny
   Kelly, Rosemary F.
   Holman, William L.
   Jessen, Michael E.
   Ward, Herbert B.
TI Perioperative Outcomes after On-and Off-Pump Coronary Artery Bypass
   Grafting
SO TEXAS HEART INSTITUTE JOURNAL
LA English
DT Article
DE Cardiac surgical procedures/adverse effects/methods/mortality; coronary
   artery bypass/adverse effects/methods/mortality; morbidity; mortality;
   outcome assessment
ID REDUCE MORBIDITY; RANDOMIZED-TRIAL; SURGERY; MORTALITY;
   REVASCULARIZATION; STROKE; METAANALYSIS; SURVIVAL; PATENCY; IMPROVEMENT
AB Although numerous reports describe the results of off-pump coronary artery bypass grafting (CABG) at specialized centers and in select patient populations, it remains unclear how off-pump CABG affects real-world patient outcomes. We conducted a large, multicenter observational cohort study of perioperative death and morbidity in on-pump (ON) versus off-pump (OFF) CABG.
   We reviewed Veterans Affairs Surgical Quality Improvement Program data for all patients (N=65,097) who underwent isolated CABG from October 1997 through April 2011 (intention-to-treat data were available from 2005 onward). The primary outcome was perioperative (30-day or in-hospital) death; the secondary outcomes were perioperative stroke, dialysis dependence, reoperation for bleeding, mechanical circulatory support, myocardial infarction, ventilator support >= 48 hr, and mediastinitis. Propensity scores calculated from age, 17 preoperative risk factors, and year of surgery were used to match 8,911 OFF with 26,733 ON patients.
   In the complete cohort, compared with the ON patients (n=53,468), the OFF patients (n=11,629) had less perioperative death (2.02% vs 2.53%, P=0.0012) and lower incidences of all morbidities except perioperative myocardial infarction. In the matched cohort, perioperative death did not differ significantly between OFF and ON patients (1.94% vs 2.28%, P=0.06), but the OFF group had lower incidences of all morbidities except for perioperative myocardial infarction and mediastinitis. A subgroup intention-to-treat analysis yielded similar but smaller outcome differences between the ON and OFF groups.
   Off-pump CABG might be associated with decreased operative morbidity but did not affect operative death, compared with on-pump CABG. Future studies should examine the effect of off-pump CABG on long-term outcomes.
C1 [Bakaeen, Faisal G.; Chu, Danny] Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA.
   [Bakaeen, Faisal G.; Chu, Danny] St Lukes Episcopal Hosp, Texas Heart Inst, Houston, TX 77030 USA.
   [Kelly, Rosemary F.; Ward, Herbert B.] Univ Minnesota, Minneapolis VAMC, Div Cardiothorac Surg, Minneapolis, MN 55417 USA.
   [Holman, William L.] Univ Alabama Birmingham, Dept Cardiothorac Surg, Birmingham, AL 35233 USA.
   Birmingham VAMC, Birmingham, AL 35233 USA.
   [Jessen, Michael E.] Univ Texas SW Med Ctr Dallas, Div Cardiothorac Surg, Dallas, TX 75390 USA.
RP Bakaeen, FG (reprint author), Michael E DeBakey VA Med Ctr, OCL 112,2002 Holcombe Blvd, Houston, TX 77030 USA.
EM fbakaeen@bcm.edu
FU VA Health Services Research and Development Grant [IHY 99214-1]; Office
   of Research at the Northport and Eastern Colorado Health Care System
   Denver Veterans Affairs Medical Centers; Office of Development at the
   Northport and Eastern Colorado Health Care System Denver Veterans
   Affairs Medical Centers
FX The CICSP-X study was initially funded by VA Health Services Research
   and Development Grant #IHY 99214-1 (Dr. Shroyer, Principal
   Investigator), with ongoing support from the Office of Patient Care
   Services, VA Central Office, Washington, DC. This project was supported
   in part by the Offices of Research and Development at the Northport and
   Eastern Colorado Health Care System Denver Veterans Affairs Medical
   Centers.
NR 32
TC 5
Z9 6
U1 0
U2 2
PU TEXAS HEART INST
PI HOUSTON
PA PO BOX 20345, HOUSTON, TX 77225-0345 USA
SN 0730-2347
EI 1526-6702
J9 TEX HEART I J
JI Tex. Heart Inst. J.
PD APR
PY 2014
VL 41
IS 2
BP 144
EP 151
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AQ1MN
UT WOS:000342545600012
PM 24808773
ER

PT J
AU Abu Shehab, M
   Damerill, I
   Shen, T
   Rosario, FJ
   Nijland, M
   Nathanielsz, PW
   Kamat, A
   Jansson, T
   Gupta, MB
AF Abu Shehab, Majida
   Damerill, Ian
   Shen, Tong
   Rosario, Fredrick J.
   Nijland, Mark
   Nathanielsz, Peter W.
   Kamat, Amrita
   Jansson, Thomas
   Gupta, Madhulika B.
TI Liver mTOR Controls IGF-I Bioavailability by Regulation of Protein
   Kinase CK2 and IGFBP-1 Phosphorylation in Fetal Growth Restriction
SO ENDOCRINOLOGY
LA English
DT Article
ID FACTOR-BINDING PROTEIN-1; AMINO-ACID-CONCENTRATIONS; MAMMALIAN TARGET;
   INTRAUTERINE GROWTH; GENE-EXPRESSION; INSULIN REGULATION; TROPHOBLAST
   CELLS; CASEIN KINASE-2; HUMAN FETUS; RAPAMYCIN
AB Fetal growth restriction (FGR) increases the risk for perinatal complications and predisposes the infant to diabetes and cardiovascular disease later in life. No treatment for FGR is available, and the underlying pathophysiology remains poorly understood. Increased IGFBP-1 phosphorylation has been implicated as an important mechanism by which fetal growth is reduced. However, to what extent circulating IGFBP-1 is phosphorylated in FGR is unknown, and the molecular mechanisms linking FGR to IGFBP-1 phosphorylation have not been established. We used umbilical cord plasma of appropriate for gestational age (AGA) and growth-restricted human fetuses and determined IGFBP-1 and IGF-I concentrations (ELISA) and site-specific IGFBP-1 phosphorylation (Western blotting using IGFBP-1 phospho-site specific antibodies). In addition, we used a baboon model of FGR produced by 30% maternal nutrient restriction and determined mammalian target of rapamycin (mTOR) C1 activity, CK2 expression/activity, IGFBP-1 expression and phosphorylation, and IGF-I levels in baboon fetal liver by Western blot, enzymatic assay, and ELISA. HepG2 cells and primary fetal baboon hepatocytes were used to explore mechanistic links between mTORC1 signaling and IGFBP-1 phosphorylation. IGFBP-1 was hyperphosphorylated at Ser101, Ser119, and Ser169 in umbilical plasma of human FGR fetuses. IGFBP-1 was also hyperphosphorylated at Ser101, Ser119, and Ser169 in the liver of growth-restricted baboon fetus. mTOR signaling was markedly inhibited, whereas expression and activity of CK2 was increased in growth-restricted baboon fetal liver in vivo. Using HepG2 cells and primary fetal baboon hepatocytes, we established a mechanistic link between mTOR inhibition, CK2 activation, IGFBP-1 hyperphosphorylation, and decreased IGF-I-induced IGF-I receptor autophosphorylation. We provide clear evidence for IGFBP-1 hyperphosphorylation in FGR and identified an mTOR and CK2-mediated mechanism for regulation of IGF-I bioavailability. Our findings are consistent with the model that inhibition of mTOR in the fetal liver, resulting in increased CK2 activity and IGFBP-1 hyperphosphorylation, constitutes a novel mechanistic link between nutrient deprivation and restricted fetal growth.
C1 [Abu Shehab, Majida; Gupta, Madhulika B.] Univ Western Ontario, Dept Pediat, London, ON N6C 2V5, Canada.
   [Damerill, Ian; Shen, Tong; Gupta, Madhulika B.] Univ Western Ontario, Dept Biochem, London, ON N6C 2V5, Canada.
   [Gupta, Madhulika B.] Univ Western Ontario, Childrens Hlth Res Inst, London, ON N6C 2V5, Canada.
   [Rosario, Fredrick J.; Nijland, Mark; Nathanielsz, Peter W.; Jansson, Thomas] Univ Texas Hlth Sci Ctr San Antonio, Ctr Pregnancy & Newborn Res, San Antonio, TX 78229 USA.
   [Kamat, Amrita] Univ Texas Hlth Sci Ctr San Antonio, Dept Obstet & Gynecol, San Antonio, TX 78229 USA.
   [Kamat, Amrita] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
   [Kamat, Amrita] South Texas Vet Hlth Care Syst, Geriatr Res Educ Ctr, San Antonio, TX 78229 USA.
   [Kamat, Amrita] South Texas Vet Hlth Care Syst, Ctr Clin, San Antonio, TX 78229 USA.
RP Gupta, MB (reprint author), Univ Western Ontario, Childrens Hlth Res Inst, Dept Pediat, VRL Room A5-136 WC,800 Commissioners Rd East, London, ON N6C 2V5, Canada.
EM mbgupta@uwo.ca
OI Nathanielsz, Peter/0000-0001-8410-6280
FU Lawson Health Research Institute and Children's Health Research
   Institute; National Institutes of Health [HD 078313, HD 21350]; VA
   (Merit Review Award) [1I01BX001744-01A1]
FX This work was supported by the Lawson Health Research Institute and
   Children's Health Research Institute (grants to M.B.G.), National
   Institutes of Health (Grants HD 078313 to M.B.G. and T.J. and HD 21350
   to P.W.N.), and the VA (Merit Review Award 1I01BX001744-01A1 to A.K.).
NR 38
TC 6
Z9 6
U1 0
U2 5
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0013-7227
EI 1945-7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD APR
PY 2014
VL 155
IS 4
BP 1327
EP 1339
DI 10.1210/en.2013-1759
PG 13
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA AP8PW
UT WOS:000342342000017
PM 24437487
ER

PT J
AU Anderson, T
   Donohue, JM
   Morden, NE
   Zhao, XH
   Mor, M
   Thorpe, C
   Good, C
   Fine, MJ
   Gellad, WF
AF Anderson, Timothy
   Donohue, Julie M.
   Morden, Nancy E.
   Zhao, Xinhua
   Mor, Maria
   Thorpe, Carolyn
   Good, Chester
   Fine, Michael J.
   Gellad, Walid F.
TI REGIONAL CORRELATION IN BRAND-NAME PRESCRIPTION DRUG USE AMONG VA AND
   MEDICARE PART D PATIENTS WITH DIABETES
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 37th Annual Meeting of the Society-General-Internal-Medicine
CY APR 23-26, 2014
CL San Diego, CA
SP Soc Gen Internal Med
C1 [Anderson, Timothy] UPMC, Pittsburgh, PA USA.
   [Donohue, Julie M.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA.
   [Morden, Nancy E.] Geisel Sch Med Dartmouth, Hanover, NH USA.
   [Zhao, Xinhua; Mor, Maria; Thorpe, Carolyn; Good, Chester; Fine, Michael J.; Gellad, Walid F.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
   [Thorpe, Carolyn] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA USA.
   [Good, Chester; Fine, Michael J.; Gellad, Walid F.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD APR
PY 2014
VL 29
SU 1
BP S196
EP S197
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AO0JZ
UT WOS:000340996201096
ER

PT J
AU Ando, N
   Taki, N
   Kumabe, A
   Nishimura, Y
   Kudo, M
   Kenzaka, T
   Dhaliwal, G
   Matsumura, M
AF Ando, Naokatsu
   Taki, Naoya
   Kumabe, Ayako
   Nishimura, Yoshioki
   Kudo, Michiko
   Kenzaka, Tsuneaki
   Dhaliwal, Gurpreet
   Matsumura, Masami
TI PSEUDORENAL FAILURE CAUSED BY SPONTANEOUS RUPTURE OF THE URINARY BLADDER
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 37th Annual Meeting of the Society-General-Internal-Medicine
CY APR 23-26, 2014
CL San Diego, CA
SP Soc Gen Internal Med
C1 [Ando, Naokatsu; Taki, Naoya; Kumabe, Ayako; Nishimura, Yoshioki; Kudo, Michiko; Kenzaka, Tsuneaki; Matsumura, Masami] Jichi Med Univ, Shimotsuke, Japan.
   [Dhaliwal, Gurpreet] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Dhaliwal, Gurpreet] San Francisco VA Med Ctr, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD APR
PY 2014
VL 29
SU 1
BP S415
EP S415
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AO0JZ
UT WOS:000340996202290
ER

PT J
AU Azari, S
   Hurstak, EE
   Julian, K
   Dulay, MH
   Patel, S
AF Azari, Soraya
   Hurstak, Emily E.
   Julian, Katherine
   Dulay, Maya H.
   Patel, Shalini
TI CONTINUITY CLINIC IMMERSION FOR INTERNAL MEDICINE INTERNS: IMPROVING
   EFFICACY IN AMBULATORY CARE EARLY IN RESIDENCY TRAINING
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 37th Annual Meeting of the Society-General-Internal-Medicine
CY APR 23-26, 2014
CL San Diego, CA
SP Soc Gen Internal Med
C1 [Azari, Soraya; Hurstak, Emily E.; Julian, Katherine; Dulay, Maya H.; Patel, Shalini] UCSF, San Francisco, CA USA.
   [Hurstak, Emily E.; Dulay, Maya H.; Patel, Shalini] San Francisco VA Med Ctr, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD APR
PY 2014
VL 29
SU 1
BP S512
EP S512
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AO0JZ
UT WOS:000340996203098
ER

EF